<SEC-DOCUMENT>0001571049-15-006633.txt : 20150812
<SEC-HEADER>0001571049-15-006633.hdr.sgml : 20150812
<ACCEPTANCE-DATETIME>20150812161141
ACCESSION NUMBER:		0001571049-15-006633
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20150630
FILED AS OF DATE:		20150812
DATE AS OF CHANGE:		20150812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RITTER PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001460702
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				263474527
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37428
		FILM NUMBER:		151047149

	BUSINESS ADDRESS:	
		STREET 1:		1801 CENTURY PARK EAST, SUITE 1820
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067
		BUSINESS PHONE:		310-203-1000

	MAIL ADDRESS:	
		STREET 1:		1801 CENTURY PARK EAST, SUITE 1820
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>t1501786_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&thorn;</FONT></TD><TD>QUARTERLY REPORT
                                         PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the Quarterly Period Ended June 30,&nbsp;2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">OR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>TRANSITION REPORT
                                         PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the Transition Period from ___ to ___</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number: 001-37428</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of Registrant as specified in its
Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="width: 50%; text-align: center"><B>20-1295171</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">incorporation or organization)</TD>
    <TD STYLE="text-align: center">Identification Number)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>1801 Century Park East #1820</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>Los Angeles, CA 90067</B></TD>
    <TD STYLE="text-align: center"><B>90067</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant's Telephone Number, Including Area
Code:&nbsp;<B>(310) 203-1000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 -0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;Yes
<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;No <FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has submitted electronically
and posted on its corporate Web&nbsp;site, if any, every Interactive Data File required to be submitted and posted pursuant to
Rule 405 of Regulation&nbsp;S-T during the preceding 12 months (or for such shorter period that the registrant was required to
submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.&nbsp;&nbsp;See the
definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act. (Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 27%">Large Accelerated Filer</TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 38%">Accelerated Filer</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>Non-Accelerated Filer</TD>
    <TD><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD>Smaller Reporting Company</TD>
    <TD><FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">(Do not check if a smaller reporting company)</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <FONT STYLE="font-family: Wingdings">&uml;</FONT> No <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of August 4, 2015, there were 7,792,433
shares of the issuer&rsquo;s common stock, par value $0.001 per share, outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="toc"></A><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 12%"></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 76%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_001"><B>Part I.</B></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_001"><B>Financial Information</B></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">2</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt"><A HREF="#a_002">Item 1.</A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_002">Unaudited Condensed Financial Statements -</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">2</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.2in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.2in; text-indent: -0.1in"><A HREF="#a_003">Condensed Balance Sheets as of
    June 30, 2015 (unaudited) and December 31, 2014</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD>
    <TD STYLE="padding-left: 0.2in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.2in; text-indent: -0.1in"><A HREF="#a_004">Condensed Statements of Operations for the Three and
    Six Months Ended June 30, 2015 and 2014</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD>
    <TD STYLE="padding-left: 0.2in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.2in; text-indent: -0.1in"><A HREF="#a_005">Condensed Statements of Cash Flows for the Six Months
    Ended June 30, 2015 and 2014</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.2in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.2in; text-indent: -0.1in"><A HREF="#a_006">Notes to Unaudited Condensed Financial
    Statements</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">5</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt"><A HREF="#a_007">Item 2.</A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_007">Management&rsquo;s Discussion and Analysis of Financial Condition and Results
    of Operations</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">22</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt"><A HREF="#a_008">Item 3.</A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_008">Quantitative and Qualitative Disclosures about Market Risk</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">40</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt"><A HREF="#a_009">Item 4.</A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_009">Controls and Procedures</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">40</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_010"><B>Part II.</B></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_010"><B>Other Information</B></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">41</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt"><A HREF="#a_011">Item 1.</A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_011">Legal Proceedings</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">41</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt"><A HREF="#a_012">Item 1A.</A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_012">Risk Factors</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">41</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt"><A HREF="#a_013">Item 2.</A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_013">Unregistered Sales of Equity Securities and Use of Proceeds</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">68</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt"><A HREF="#a_014">Item 6.</A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_014">Exhibits</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">69</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_001"></A><B>PART I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_002"></A><B>ITEM 1. FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_003"></A><B>RITTER PHARMACEUTICALS,
INC.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">CONDENSED
BALANCE SHEETS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>June 30,</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>December 31,</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>2015</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>2014</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>(unaudited)</B></FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-weight: bold">ASSETS</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 9pt">Cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">19,658,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,747,248</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0pt; padding-left: 9pt">Prepaid expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">42,079</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">57,115</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt; padding-left: 9pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,701,073</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,804,363</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,331</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,331</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">143,454</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,566</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,172</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">19,715,970</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,963,320</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 9pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,389,443</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,083,597</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 9pt">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">972,992</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">168,635</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 9pt">Other liablities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,022</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,518</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 10pt; padding-left: 9pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,363,457</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,254,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Preferred stock subject to redemption, $0.001 par value, no shares authorized, issued and outstanding
    as of June 30, 2015; 16,378,646 shares authorized, 13,399,668 shares issued and outstanding as of December 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,203,612</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders&rsquo; equity (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of June 30, 2015;
    8,887,500 shares authorized, issued and outstanding as of December 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,888</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Common stock, $0.001 par value; 25,000,000 shares authorized, 7,788,028 shares issued and outstanding as of June 30, 2015;
    50,000,000 shares authorized, 465,378 shares issued and outstanding as of December 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,788</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">465</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,124,630</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,399,924</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(21,779,905</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(17,904,319</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt; padding-left: 9pt">Total stockholders&rsquo; equity (deficit)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,352,513</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(14,495,042</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&rsquo; Equity (Deficit)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">19,715,970</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,963,320</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to unaudited condensed
financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_004"></A><B>RITTER PHARMACEUTICALS,
INC.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">CONDENSED
STATEMENTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>For
    the Three Months Ended June 30,</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>For
    the Six Months Ended June 30,</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>2015</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>2014</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>2015</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>2014</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-weight: bold; text-align: left">Operating costs and expenses:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 9pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">47,977</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,315</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">79,555</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,416</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 9pt">Patent costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,148</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,382</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,423</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,164</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 9pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,001,706</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">352,431</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,304,152</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">597,087</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt; padding-left: 9pt">Total operating costs and expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,099,831</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">386,128</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,496,130</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">672,667</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,099,831</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(386,128</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,496,130</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(672,667</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 9pt">Interest income (expense), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,101</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,944</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,305</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,739</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 9pt">Other income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,091</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt; padding-left: 9pt">Total other income (expense)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,101</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,944</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,396</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,739</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,097,730</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(391,072</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(3,484,734</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(677,406</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cumulative preferred stock dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">178,286</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">147,337</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">327,569</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">294,785</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accretion of discount on Series C preferred stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31,465</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">63,283</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss applicable to common stockholders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,307,481</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(538,409</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,875,586</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(972,191</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss per common share &ndash; basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7.62</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2.14</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding &ndash; basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">551,912</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">456,408</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">508,645</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">453,901</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to unaudited condensed
financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_005"></A><B>RITTER PHARMACEUTICALS,
INC.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">CONDENSED
STATEMENTS OF CASH FLOWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>For the Six Months Ended
    June 30,</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>2015</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>2014</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-weight: bold; text-align: left">Cash flows from operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,484,734</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(677,406</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 20pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">606</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,534</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,680,247</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,916</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt">Accretion of debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,822</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 30pt">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,036</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(41,061</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 30pt">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,033</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 30pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">305,846</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,454</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 30pt">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">590,796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,012</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 30pt">Other liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,676</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(773</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net cash used in operating activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(893,879</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(584,469</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,166</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net cash used in investing activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,166</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Commissions and issuance costs of initial public offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,194,375</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Proceeds from issuance of shares upon closing of initial public offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Proceeds of borrowing under notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">375,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net cash provided by financing activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">17,805,625</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">375,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net increase (decrease) in cash</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">16,911,746</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(210,635</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Cash at beginning of period</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,747,248</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">448,226</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Cash at end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">19,658,994</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">237,591</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Non-cash financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Accrual of commissions and issuance costs of the initial public offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">213,561</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Deferred offering costs reclassified to additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">665,603</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Conversion of all oustanding preferred stock into common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,888</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Conversion of all oustanding preferred stock subject to redemption into common
    stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16,594,464</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Common stock subject to repurchase</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Cumulative preferred stock dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">327,569</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">294,785</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Accretion of discount on Series C preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">63,283</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash paid for interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash paid for taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to unaudited condensed
financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_006"></A><B>RITTER PHARMACEUTICALS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 1&thinsp;&mdash;&thinsp;ORGANIZATION AND PRINCIPAL ACTIVITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ritter Pharmaceuticals, Inc. (&ldquo;Ritter&rdquo;
or the &ldquo;Company&rdquo;) is a Delaware corporation headquartered in Los Angeles, California. The Company was formed as a
Nevada limited liability company on March&nbsp;29, 2004 under the name Ritter Natural Sciences, LLC, and converted into a Delaware
corporation on September&nbsp;16, 2008.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ritter Pharmaceuticals, Inc. develops novel
therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company is advancing human
gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based
therapeutics into applications intended to have a meaningful impact on a patient&rsquo;s health. The Company&rsquo;s lead compound,
RP-G28 is currently under development for the treatment of lactose intolerance. RP-G28 has the potential to become the first FDA-approved
drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 24, 2015, the Company&rsquo;s registration
statement on Form&nbsp;S-1 (File No. 333-202924) relating to its initial public offering of its common stock was declared effective
by the Securities and Exchange Commission (&ldquo;SEC&rdquo;). The shares began trading on the NASDAQ Capital Market on June 24,
2015.&nbsp; The initial public offering closed on June 29, 2015, and 4,000,000 shares of common stock were sold at an initial
public offering price of $5.00 per share, for aggregate gross proceeds to the Company of $20 million.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company paid to the underwriters underwriting
discounts and commissions of approximately $1.6 million in connection with the offering. In addition, the Company incurred expenses
of approximately $1 million in connection with the offering. Thus, the net offering proceeds to the Company, after deducting underwriting
discounts and commissions and offering expenses, were approximately $17.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 2&thinsp;&mdash;&thinsp;BASIS OF PRESENTATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America (&ldquo;GAAP&rdquo;)
and include all adjustments necessary for the fair presentation of the Company&rsquo;s financial position for the periods presented.
All common share amounts and per share amounts have been adjusted to reflect a 1-for-7.15 reverse stock split of the Company&rsquo;s
common stock effected on June 17, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying interim period unaudited
condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States
(&ldquo;GAAP&rdquo;) and applicable rules and regulations of the SEC regarding interim financial reporting.&nbsp;&nbsp;The condensed
balance sheet as of June 30, 2015, the condensed&nbsp;statements of operations for the three and six months ended June 30, 2015
and 2014, and the condensed statements of cash flows for the six months ended June 30, 2015 and 2014, are unaudited, but include
all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation
of its financial position, operating results and cash flows for the periods presented. The condensed balance sheet at December
31, 2014 has been derived from audited financial statements included in Form S-1 filed on June 19, 2015 with the SEC and declared
effective on June 24, 2015. The results for the three and six months ended June 30, 2015 are not&nbsp;necessarily indicative of
the results expected for the full fiscal year or any other period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying interim period unaudited
condensed financial statements and related financial information included in this Quarterly Report on Form 10-Q should be read
in conjunction with the audited financial statements and notes thereto included in the Company&rsquo;s Form S-1, filed with the
SEC on June 19, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently operates in one business
segment focusing on the development and commercialization of RP-G28. The Company is not organized by market and is managed and
operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer,
who comprehensively manages the entire business. The Company does not currently operate any separate lines of business or separate
business entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Liquidity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2015, after&nbsp;consummation
of the Company&rsquo;s initial public offering, the Company had working capital of approximately $17.3 million, an accumulated
deficit of approximately $21.8 million, and cash of approximately $19.7 million.&nbsp; The&nbsp;Company has not
generated any product revenues and has not achieved profitable operations. There is no assurance that profitable&nbsp;operations
will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities,&nbsp;clinical
and pre-clinical testing, and commercialization of the Company&rsquo;s products will require significant additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believes that its existing cash
will be sufficient to enable the Company to continue as a going concern for at least the next twelve months. However, the Company
will need to secure additional funding in the future, from one or more equity or debt financings, collaborations, or other sources,
in order to carry out all of its planned research and development activities. If the Company is unable to obtain additional financing
or generate license or product revenue, the lack of liquidity could have a material adverse effect on the Company&rsquo;s future
prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 3&thinsp;&mdash;&thinsp;SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&rsquo;s significant accounting
policies are disclosed in the audited financial statements for the year ended December 31, 2014 included in the Company&rsquo;s
Form S-1 filed on June 19, 2015 with the SEC. Since the date of such financial statements, there have been no changes to the Company&rsquo;s
significant accounting policies, other than those detailed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Deferred Offering Costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred offering costs, which primarily consist
of direct, incremental banking, legal and accounting fees relating to a planned public offering of the Company&rsquo;s common
stock, are capitalized within long term assets. The deferred offering costs were reclassified to additional paid-in capital upon
the consummation of the offering on June 29, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Net Loss Per Share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines basic loss per share
and diluted loss per share in accordance with the provisions of ASC 260, &ldquo;<I>Earnings per Share</I>.&rdquo; Basic net loss
per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period. Diluted net
loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period using the
treasury stock method or the two-class method, whichever is more dilutive. The potentially dilutive stock options issued under
the 2015 Stock Plan (described in Note 8) and warrants on the Company&rsquo;s common stock (describe in Note 7) were not considered
in the computation of diluted net loss per share because they would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All common share amounts and per share amounts
have been adjusted to reflect a 1-for-7.15 reverse stock split of the Company&rsquo;s common stock effected on June 17, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August&nbsp;2014, the FASB issued ASU No.
2014-15,&nbsp;<I>Presentation of Financial Statements&thinsp;&mdash;&thinsp;Going Concern (Subtopic 205-40)&thinsp;&mdash;&thinsp;Disclosure
of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern</I>, which provides guidance regarding management&rsquo;s
responsibility to assess whether substantial doubt exists regarding the ability to continue as a going concern and requires related
footnote disclosures. In connection with preparing financial statements for each annual and interim reporting period, management
should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&rsquo;s
ability to continue as a going concern within one year after the date that the financial statements are issued (or within one
year after the date that the financial statements
are available to be issued when applicable). This ASU is effective for the annual period ending after December&nbsp;15, 2016,
and for annual periods and interim periods thereafter. Management is currently evaluating the new guidance and has not determined
the impact this standard may have on the Company&rsquo;s financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 4 &ndash; PROPERTY AND EQUIPMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>June 30,</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>December 31,</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Estimated
    Life</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>2015</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>2014</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Computers and equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">5 years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,487</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,487</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Furniture and fixtures</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">7 years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,270</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,270</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total property and equipment</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,757</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,757</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,191</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,585</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total property and equipment, net of accumulated depreciation</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,566</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,172</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense of approximately
$300 and $1,300 was recognized for the three months ended June 30, 2015 and 2014, respectively, and
approximately $600 and $2,500 for the six months ended June 30, 2015 and 2014, respectively and is classified in general
and administrative expense in the accompanying Unaudited Condensed Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 5&thinsp;&mdash;&thinsp;COMMITMENTS
AND CONTINGENCIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Michael Step</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December&nbsp;2, 2014, the Company entered
into a letter agreement (the &ldquo;Step Letter Agreement&rdquo;), with Michael Step, the Company&rsquo;s current Chief Executive
Officer, setting forth the terms of his employment. The Step Letter Agreement provides that Michael Step is entitled to an annual
base salary of $360,000 and a total of three grants of options to purchase the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first two options entitle Michael Step
to purchase 646,537 and 73,777 of the Company&rsquo;s shares, respectively, for an exercise price of&thinsp;$5.86 per share. Each
of these options is immediately exercisable in full as of the date of the grant, with 44/48<FONT STYLE="font-size: 10pt">ths</FONT>&nbsp;of
the total number of shares covered by each option subject to a right of repurchase by the Company upon termination of Michael
Step&rsquo;s employment with the Company for any reason. This right of repurchase will lapse over a period of 44 months, with
1/44<FONT STYLE="font-size: 10pt">th</FONT>&nbsp;of the total number of shares subject to the right of repurchase lapsing on January&nbsp;1,
2015 and on the first day of each month thereafter. In addition, the right of repurchase will lapse in its entirety upon a termination
of the employment under certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The third option became exercisable upon the
closing of the Company&rsquo;s initial public offering on June 29, 2015. Pursuant to the terms of the agreement, the option is
exercisable for a total of 103,025 shares of the Company&rsquo;s common stock, which, together with the shares subject to the
first option, represent 7.5% of the shares of common stock deemed to be outstanding at June 29, 2015 on a fully-diluted basis
after giving effect to the number of shares subject to the third option. Seventy-five percent (75%) of the shares subject to the
third option are subject to a right of repurchase by the Company upon termination of Michael Step&rsquo;s employment for any reason.
This right of repurchase will lapse with respect to 1/36<FONT STYLE="font-size: 10pt">th</FONT>&nbsp;of the total number of shares
subject to the right of repurchase on the first day of each month following the date on which the third option first becomes exercisable.
In addition, the right of repurchase will lapse in its entirety upon Michael Step&rsquo;s termination of employment under certain
circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the agreement, Michael
Step will be entitled to receive certain payments in the event his employment is terminated under certain scenarios.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Andrew Ritter and Ira Ritter</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September&nbsp;25, 2013, the Company&rsquo;s
Board of Directors approved the Executive Compensation Plan (the &ldquo;Compensation Plan&rdquo;), which was later amended in
June 2015, setting forth the compensation to be paid to Andrew Ritter and Ira Ritter, the Company&rsquo;s current President and
also the Company&rsquo;s former Chief Executive Officer, and Chief Strategic Officer (&ldquo;CSO&rdquo;), respectively, for their
contributions to the Company. Pursuant to the amended terms of the Compensation Plan, effective June 29, 2015, the President&rsquo;s
salary increased to $310,000 per year and the CSO&rsquo;s salary is $295,000 per year. The President will also be entitled to
receive up to $180,000 payable over a three year period for tuition reimbursement. As of June 30, 2015, the Company accrued $121,000
in tuition reimbursement for the President and recognized such amount in general and administrative expenses in our Unaudited
Condensed Statements of Operations in the three and six month periods ending June 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the agreement, both the
President and the CSO will be entitled to receive certain payments in the event their employment is terminated under certain scenarios.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each executive received options to purchase
up to 48,951 shares of the Company&rsquo;s common stock (each referred to in this section as &ldquo;Executive Options&rdquo;)
pursuant to the 2008 Stock Plan, which will vest based on specific performance conditions, described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Cash Bonus and Executive Options Performance
Conditions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the amended terms of the Compensation
Plan, the Company will review bonus opportunities annually for the President and the CSO based on achievement of specific performance
as determined by the Company. The initial target bonus opportunities are 40% and 35% of the base salary for the President and
the CSO, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, each covered executive is also
entitled to the following cash payments and vests in Executive Options upon the satisfaction of the events described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>FDA
                                         Meeting Bonus Opportunities</I>.&nbsp;&nbsp;&nbsp;In April&nbsp;2013, each executive
                                         received a one-time cash bonus of&thinsp;$10,000 for a milestone associated with
                                         meeting with the FDA regarding RP-G28&rsquo;s path to FDA approval. In addition, 2,360
                                         shares of the Executive Options vested and became exercisable as of the grant date of
                                         September&nbsp;25, 2013. The balance of 1,136 shares vests ratably on a monthly
                                         basis beginning on September&nbsp;30, 2013.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Clinical
                                         Trial Funding Commitment Bonus Opportunities</I>.&nbsp;&nbsp;&nbsp;Each executive is
                                         entitled to receive a one-time cash bonus of&thinsp; $75,000 upon the Company&rsquo;s
                                         receipt of a commitment by a third party to fund a Phase 2 or later clinical trial; provided,
                                         however, that no such bonus may be paid at any time the Company has less than $2,000,000
                                         in available cash. In addition, upon the satisfaction of this milestone, 35% of 10,489
                                         shares of the Executive Options will vest and become exercisable, with the balance of
                                         the 10,489 shares vesting in 36 equal monthly installments beginning on the last day
                                         of the following month. Each executive satisfied this performance condition on June 29,
                                         2015 and was entitled to receive a bonus of $75,000 accrued and recognized in general
                                         and administrative expenses in the accompanying Unaudited Condensed Statements of Operations
                                         in the three and six month periods ending June 30, 2015. In addition, 3,671 shares of
                                         the Executive Options vested and became exercisable as of June 29, 2015, with the balance
                                         of 6,818 shares vests ratably on a monthly basis beginning July 31, 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Fundraising
                                         Bonus Opportunities</I>.&nbsp;&nbsp;&nbsp;Each executive is entitled to receive (i) a
                                         one-time cash bonus of&thinsp; $50,000 upon the sale of additional equity capital for
                                         cash, in one or more closings after July&nbsp;17, 2012, and/or the actual deployment
                                         of funds by a third party for a clinical trial in an aggregate amount in excess of&thinsp;
                                         $2,000,000 and (ii) a one-time cash bonus of&thinsp; $150,000 upon the sale of additional
                                         equity capital for cash, in one or more closings after July&nbsp;17, 2012 and/or the
                                         actual deployment of funds by a third party for a clinical trial in an aggregate amount
                                         in excess of $10,000,000 (which such bonus will be reduced by any cash bonus paid under
                                         subsection (i)); provided, however, that no bonus under subsection (i) or (ii) may be
                                         paid at any time the Company has less than $2,000,000 in available cash. In addition,
                                         upon the satisfaction of the milestone described in subsection (i), 35% of 6,993 shares
                                         of the Executive Options will vest and become exercisable, with the balance of the 6,993
                                         shares vesting in 36 equal monthly installments beginning on the last day of the following
                                         month, and, upon satisfaction of the milestone described in subsection (ii), 35% of 13,986
                                         shares of the Executive Options will vest and become exercisable, with the balance of
                                         the 13,986 shares vesting in 36 monthly installments beginning on the last day of the
                                         following month. Upon the closing of the initial public offering on June 29, 2015 raising
                                         approximately $17.4 million, net of offering costs, each executive was entitled to receive
                                         a bonus of $150,000 accrued and recognized in general and administrative expenses in
                                         the accompanying Unaudited Condensed Statements of Operations in the three and six month
                                         periods ending June 30, 2015. In addition, 4,895 shares of the Executive Options vested
                                         and became exercisable as of June 29, 2015, with the balance of 9,091 shares vests ratably
                                         on a monthly basis beginning July 31, 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>License
                                         Event Bonus Opportunities</I>.&nbsp;&nbsp;&nbsp;Each executive is entitled to receive
                                         the following bonus payments in connection with the closing of an exclusive license of
                                         RP-G28 and/or any future product candidate developed by the Company from time to time
                                         during the term of the Compensation Plan by an/or any option to exclusively license such
                                         product candidate to a third party (referred to under the Compensation Plan as a &ldquo;License
                                         Event&rdquo;) with a minimum upfront payment to the Company of&thinsp; $2,000,000:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">A
                                         graduated cash bonus equal to (i) 5% of the Initial Period License Payment (as defined
                                         below) up to $5,000,000; (ii) 4% of the Initial Period License Payment in excess of&thinsp;
                                         $5,000,000 up to $10,000,000; and (iii) 3% of the Initial Period License Payment in excess
                                         of $10,000,000. In addition, upon the Company&rsquo;s receipt of an Initial Period License
                                         Payment of more than $2,000,000, 35% of 45,454 shares of their Executive Options will
                                         vest and become exercisable, with the balance of the 45,454 shares vesting in 36 monthly
                                         installments beginning on the last day of the following month.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">A
                                         cash bonus equal to 3% of any Annual Excess Milestone Payments (as defined below); provided,
                                         however that no such bonus may be paid at any time the Company has less than $1,000,000
                                         in available cash. In addition, upon the Company&rsquo;s receipt of an Annual Excess
                                         Milestone Payment, 35% of 6,993 shares of their Executive Options will vest and become
                                         exercisable, with the balance of the 6,993 shares vesting in 36 monthly installments
                                         beginning on the last day of the following month.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding any of the vesting provisions
set forth above, the total potential number of Executive Options that may vest will not exceed 48,951 and the Executive Options
will automatically terminate for any options for which a vesting date or performance condition has not been met by September&nbsp;25,
2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of the Compensation Plan, the
term &ldquo;<I>Initial Period License Payment</I>&rdquo; means the aggregate amount in cash received by the Company (not including
any amount placed in escrow or subject to earn-outs, contingencies or other deferrals or earmarked to pay or reimburse the Company
for research and development activities) in respect of the License Event over a 24 month period beginning on the closing date
of such License Event (which period is referred to therein as the &ldquo;<I>Initial Period</I>&rdquo;). The term &ldquo;<I>Annual
Excess Milestone Payments</I>&rdquo; means the amount in cash in excess of&thinsp; $2,000,000 (not including any amounts placed
in escrow or subject to earn-outs, contingencies or other deferrals) that is received by the Company in respect of any Post-Closing
Milestones (as defined below) in each 12-month period beginning on the expiration of the Initial Period. The term &ldquo;<I>Post-Closing
Milestones</I>&rdquo; means any post-closing payouts set forth in the definitive transaction documentation executed in connection
with a License Event; provided, however, that such amounts will not include any amounts that are determined by the Board of Directors
to comprise all or any portion of any upfront
payment made in connection with a License Event and any royalty payment based on product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Plan provides that in the
event that the Company enters into more than one License Event with respect to a single product candidate (i.e., for a separate
field of use), then the proceeds of any such additional License Event will be included with the proceeds of the original License
Event for purposes of meeting any of the financial thresholds set forth above. Under the terms of the Compensation Plan, receipt
by the Company of more than one&nbsp;<I>bona fide</I>&nbsp;term sheet for a proposed License Event with respect to RP-G28 will
result in the payment of an additional 10% of any cash bonus earned as Clinical Trial and Fundraising Bonus or a License Event
Bonus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the Compensation Plan,
each executive is entitled to receive certain payments in the event their employment is terminated under certain scenarios.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December&nbsp;2, 2014, pursuant to the
2008 stock plan, the Company granted an aggregate of 453,413 options to the President and the CSO to purchase the Company&rsquo;s
common stock listed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">20,979 fully vested options with
                                         an exercise price of&thinsp; $5.86; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">432,434 options which vest 25%
                                         upon the first anniversary of the vesting commencement date with the remaining options
                                         vesting monthly in equal amounts over 36 months with an exercise price equal to $5.86
                                         for the first 152,347 options covered thereby, $9.30 for the next 140,044 options covered
                                         thereby, and $13.23 for the remaining balance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;In addition, all non-employee directors
will each be initially entitled to receive an option to acquire 1,398 shares of the Company&rsquo;s common stock, which will vest
annually over a three-year term from the grant date, and annually thereafter be entitled to receive an option to acquire 979 shares
of the Company&rsquo;s common stock, each of which will vest one year from the grant date. As of June 30, 2015, no stock based
compensation or cash compensation has been granted to the directors under this program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Leases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: black">The Company leases
office and storage space for its headquarters in California pursuant to a two-year agreement ending September&nbsp;30, 2015 which
calls for a minimum monthly rent of approximately $5,000 and an annual increase of 3%. Rent expense, recognized on a straight-line
basis, was approximately $15,000 for each of the three months ended June 30, 2015 and 2014. </FONT>The Company recognized approximately
$30,000 in each of the six months ended June 30, 2015 and 2014 in rent expense. Rent expense is recorded in general and administrative
expenses in the Unaudited Condensed Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2015, the Company entered into a new
five-year lease agreement for new corporate office space, projected to be effective October 1, 2015, which calls for a minimum
lease payment of approximately $107,000 annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Legal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is not currently involved in any
legal matters arising in the normal course of business. From time to time, the Company could become involved in disputes and various
litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual
property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant
matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered
probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject
to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information
available at the time. As additional information becomes available, the Company reassesses the potential liability related to
pending claims and litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 6&thinsp;&mdash;&thinsp;STOCKHOLDERS&rsquo;
EQUITY (DEFICIT) AND PREFERRED STOCK SUBJECT TO REDEMPTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2014, the Company was authorized
to issue 50,000,000 shares of common stock with a par value of&thinsp;$0.001 per share. The Company amended and restated its Certificate
of Incorporation in June 2015 (&ldquo;the Amended Certificate&rdquo;) and reduced the authorized shares of the Company&rsquo;s
common stock to 25,000,000 with a par value of $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective June 17, 2015, all common share
amounts and per share amounts have been adjusted to reflect a 1-for-7.15 reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&rsquo;s Board of Directors is
authorized, subject to any limitations prescribed by law, to provide for the&nbsp;issuance of the authorized shares of preferred
stock in series and to&nbsp;establish the number of shares to be included in each such series, and to fix the designation, powers,
preferences and&nbsp;rights of the shares of each such series and any qualifications, limitations or restrictions thereon.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: black">Pursuant to the
Amended Certificate, as of June 30, 2015, the Company is authorized to issue 5,000,000 shares of preferred stock, $0.001 par value
per share.</FONT><B><I> </I></B><FONT STYLE="color: black">Prior to the Amended Certificate and as of December 31, 2014, the Company
was authorized to issue 7,200,000 shares, 1,687,500 shares, 4,220,464 shares, 7,658,182 shares, and 4,500,000 shares of Series
A-1, Series A-2, Series A-3, Series B, and Series C preferred stock, respectively, with a par value of&thinsp;$0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: black">Upon the closing
of the Company&rsquo;s initial public offering, all outstanding shares of convertible preferred stock and preferred stock subject
to redemption were converted into an aggregate of 3,322,650 shares of common stock. The following provides material terms and
certain historical information regarding the </FONT>Series A-1, Series A-2, Series A-3, Series B and Series C Preferred Stock
prior to their conversion to common stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Redemption.
                                         </I><FONT STYLE="color: black">At any time after five years following the date of the
                                         initial issuance of the Series A-3, Series B, or Series C preferred stock, as applicable,
                                         and at the option of the holders of a majority of the then outstanding shares of Series
                                         A-3, Series B, and Series C preferred stock, voting together as a single class, the Company
                                         was required to redeem any outstanding shares that have not been converted by paying
                                         cash in an amount per share equal to the liquidation preference of&thinsp; $0.62 and
                                         $1.30 for the Series A-3 and Series C preferred stock, respectively, and $1.19 per share,
                                         plus any accrued but unpaid dividends, for the Series B preferred stock. Given the holders&rsquo;
                                         redemption option, the Series A-3, Series B, and Series C preferred stock is classified
                                         as preferred stock subject to redemption in the accompanying Condensed Balance Sheets.
                                         </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Dividends.
                                         </I><FONT STYLE="color: black">The holders of outstanding shares of preferred stock were
                                         entitled to receive dividends, when, as and if declared by the Company&rsquo;s Board
                                         of Directors. The annual dividend rate was $0.00556 per share for the Series A-1 preferred
                                         stock, $0.032 per share for the Series A-2 preferred stock, $0.04957 per share for the
                                         Series A-3 preferred stock, $0.09524 per share for the Series B preferred stock, and
                                         $0.104 for Series C preferred stock (subject to adjustment). The right to receive dividends
                                         on shares of Series B preferred stock was cumulative and the dividends accrue to holders
                                         of Series B preferred stock whether or not dividends are declared or paid in a calendar
                                         year. Undeclared dividends in arrears for the Series B preferred stock was approximately
                                         $2 million and $1.7 million as of June 30, 2015 and December 31, 2014, respectively.
                                         The right to receive dividends on shares of Series A and Series C preferred stock was
                                         not cumulative and no right to such dividends accrued to holders of Series A or Series
                                         C preferred stock.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Liquidations.
                                         </I><FONT STYLE="color: black">In the event of any liquidation, dissolution or winding
                                         up of the Company, either voluntary or involuntary, Series B and Series C preferred stockholders
                                         receive an amount per share equal to the sum of the original purchase price of&thinsp;$1.19
                                         plus all cumulative but unpaid dividends for Series B, and $1.30 for Series C. If upon
                                         the liquidation, the available assets are insufficient to permit payments to Series B
                                         and Series C holders, the entire assets legally available will be distributed in a pro
                                         rata basis among the holders in proportion to the full amounts they would otherwise be
                                         entitled to receive. Upon the completion of the distribution to the holders of the Series
                                         B and Series C preferred stock, the holders of the Series A preferred stock shall be
                                         entitled to receive, prior and in preference to any distribution of any of the assets
                                         of the Company to the holders of all other capital stock by reason of their ownership
                                         of such stock, an amount per share equal to the sum of the original issue price per share
                                         of&thinsp; $0.07, $0.4, and $0.62 for Series A-1, Series A-2, and Series A-3 preferred
                                         stock, respectively, plus any accrued but unpaid dividends on the preferred stock. Any
                                         remaining assets are distributed pro rata among the preferred and common shareholders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stock Transactions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Initial Public Offering</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 29, 2015, the Company closed its initial
public offering, selling 4,000,000 shares of the Company&rsquo;s common stock at an initial public offering price of $5.00 per
share, for aggregate gross proceeds to the Company of $20 million.&nbsp; The Company paid to the underwriters underwriting discounts
and commissions of approximately $1.6 million in connection with the offering, and approximately $1 million of other expenses
in connection with the offering. Effectively prior to the closing of the initial public offering, the Company converted all of
its outstanding shares of Series A-1, Series A-2, Series A-3, Series B, and Series C preferred into an aggregate of 3,322,650
shares of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Series C Financing</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: black">In December&nbsp;2014,
the Company issued an aggregate of </FONT><FONT STYLE="color: #231F20">2,369,228 </FONT><FONT STYLE="color: black">shares of Series
C preferred stock, which was later converted into an aggregate of 331,358 shares of the Company&rsquo;s common stock, and warrants
to purchase an aggregate of 331,358 shares of the Company&rsquo;s common stock (the &ldquo;Warrants&rdquo;), for aggregate gross
proceeds of&thinsp; $3,081,893 (the &ldquo;Series C Financing&rdquo;). Each Warrant has a term of seven (7) years and provides
for the holder to purchase one share of the Company&rsquo;s common stock at a purchase price of&thinsp;$9.30 per share of common
stock. The Warrants are indexed to the Company&rsquo;s own stock and classified within stockholders&rsquo; equity pursuant to
ASC 815-40. The gross proceeds were allocated to the Series C preferred stock and Warrants on a relative fair value basis, resulting
in a value of&thinsp;$7.83 for the Series C preferred stock. The allocation of proceeds to the Warrants creates a discount of&thinsp;$1.47
in the initial carrying value of the Series C preferred stock, which was recognized as accretion, similar to preferred stock dividends,
over the five-year period prior to optional redemption by the holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Series C Financing,
all of the 2014 Notes were converted into shares of Series C preferred stock and Warrants as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">$535,000
                                         unpaid principal plus accrued interest of&thinsp; $18,342 on convertible notes converted
                                         into </FONT>567,529 <FONT STYLE="color: black">shares of Series C preferred stock, which
                                         was later converted into 79,374 shares of the Company&rsquo;s common stock, and 79,374
                                         Warrants</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">$70,000
                                         unpaid principal plus accrued interest of&thinsp; $537 on note payable extinguished and
                                         converted into </FONT>54,259 <FONT STYLE="color: black">shares of Series C preferred
                                         stock, which was later converted into 7,589 shares of the Company&rsquo;s common stock
                                         and 7,589 Warrants</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notes with an unpaid principal balance of
$535,000 were converted into shares of Series C preferred stock and warrants to purchase shares of common stock at 75% of the
price paid by other purchasers of the Series C Financing. The Company recognized additional interest expense of&thinsp;$184,445
upon conversion, calculated as the fair value of incremental shares and warrants received by the holders compared to converting
the outstanding debt and accrued interest at 100% of the price paid by purchasers of the Series&nbsp;C Financing. The note with
an unpaid principal balance of&thinsp;$70,000 was exchanged for shares of Series C preferred stock and warrants to purchase shares
of common stock at a price per share equal to the price per share paid by purchasers of the Series C Financing. As such, there
was no gain recognized or loss incurred upon extinguishment of the note in 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Prepaid Forward Sale of Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November&nbsp;30, 2010, the Company concurrently
entered into a Research and Development Agreement &amp; License (&ldquo;R&amp;D Agreement&rdquo;) and a Put and Call Option Agreement
(&ldquo;Put/Call&rdquo;) with two commonly controlled entities, Kolu Pohaku Technologies, LLC (&ldquo;KPT&rdquo;) and Kolu Pohaku
Management, LLC (&ldquo;KPM&rdquo;). The agreement was subsequently amended on July&nbsp;6, 2011, September&nbsp;30, 2011, February&nbsp;6,
2012 and November&nbsp;4, 2013 to increase the funding received by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Research and Development Agreement &amp;
License</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The R&amp;D Agreement between the Company
and KPM and KPT, a Qualified High Technology Business within the meaning of Hawaii Revised Statutes, called for KPT to make a
series of payments to the Company totaling $1,750,000 in exchange for the Company performing research and development activities
in Hawaii for the benefit of KPT (referred to herein as the KP Research). The KP Research consisted of the initial phase of research,
including the conduct of Phase II clinical trials in Hawaii for RP-G28. Pursuant to the terms of the R&amp;D Agreement, the Company
maintained ownership of the results of the Company&rsquo;s ongoing research related to RP-G28, but KPT maintained ownership of
the results of the KP Research. Inventions, developments and improvements arising out of the KP Research were owned by KPT. Under
the terms of the R&amp;D Agreement, the Company would bear any costs involved in obtaining patents for any inventions, developments
or improvements resulting from the Research Project. In exchange for the irrevocable, perpetual, exclusive, worldwide right and
license to the results of the KP Research, as they are generated under this R&amp;D Agreement, the Company agreed to pay a quarterly
royalty payment to KPT of $32,000 commencing March&nbsp;31, 2015 and continuing through December&nbsp;31, 2035 or until such time
as the KPM Option (as described below) was exercised. On March&nbsp;26, 2015, the Company exercised the right to put the KPM Option
and issued 1,469,994 shares of Series B preferred stock to KPM, resulting in the full satisfaction of the Company&rsquo;s obligation
to make royalty payments to KPT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Put and Call Option Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms of the KPM Option Agreement,
the Company had the right to put 1,469,994 shares of the Company&rsquo;s Series B Preferred Stock (&ldquo;Series B&rdquo;) to
KPM and KPM has the option to call the same amount of shares of Series B from the Company at any time after December&nbsp;31,
2014. The number of shares was determined by dividing the $1,750,000 of payments made by KPT to the Company under the R&amp;D
Agreement by the Series B original issue price of&thinsp;$1.19. Exercise of the Put/Call results in full satisfaction of the Company&rsquo;s
obligation to make royalty payments to KPT under the R&amp;D Agreement and KPT&rsquo;s right, title and interest in the research
conducted pursuant to the R&amp;D Agreement becomes the property of the Company. On March&nbsp;26, 2015, the Company exercised the right to put the KPM Option
and issued 1,469,994 shares of Series B preferred stock to KPM, or the KPM Shares. Pursuant to the terms of the KPM Option Agreement,
this resulted in the full satisfaction of the Company&rsquo;s obligation to make royalty payments to KPT under the R&amp;D Agreement
and also resulted in the termination of the R&amp;D Agreement and all of KPT&rsquo;s right, title and interest in and to the KP
Research, which rights now belong to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The R&amp;D Agreement and the Put/Call have
been recognized on a combined basis, pursuant to ASC 815-10-15-9, as a fully prepaid forward sale contract on the Company&rsquo;s
Series B preferred stock. The fully prepaid forward sale contract is a hybrid instrument comprising (1) a debt host instrument
and (2) an embedded forward sale contract, requiring the Company to issue 1,469,994 shares of the Company&rsquo;s Series&nbsp;B
for no further consideration. Payments received by the Company, totaling $1,750,000, are recognized as preferred stock subject
to redemption in the Condensed Balance Sheet as of December 31, 2014. The Company converted these shares into an aggregate of
205,593 shares of the Company&rsquo;s common stock upon the closing of the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 7&thinsp;&mdash;&thinsp;WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As described in Note 6, in 2014, the Company
issued seven-year warrants (&ldquo;the Warrants&rdquo;) to investors for the purchase of 418,321 shares of the Company&rsquo;s
common stock at an exercise price of&thinsp;$9.30 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company analyzed the Warrants in accordance
with ASC Topic 815 to determine whether the Warrants meet the definition of a derivative and, if so, whether the Warrants meet
the scope exception that provides for equity classification of derivative instruments issued or held by the reporting entity that
are both (1) indexed to its own stock and (2) classified in stockholders&rsquo; equity. The Company concluded these Warrants should
be classified as equity since they contain no provisions, which would require recognition as a liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following represents a summary of the
warrants outstanding at June 30, 2015 and changes during the period then ended:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>Weighted Average</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Warrants</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Exercise
    Price</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%">Outstanding at December 31, 2014</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">418,321</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">9.30</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 10pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Exercised/Expired/ Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Outstanding at June 30, 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">418,321</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9.30</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Exercisable at June 30, 2015</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">418,321</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9.30</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 8&thinsp;&mdash;&thinsp;STOCK-BASED
COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Terms of the Company&rsquo;s share-based compensation
are governed by the Company&rsquo;s 2015 Stock Plan, 2009 Stock Plan and 2008 Stock Plan (collectively the &ldquo;Plans&rdquo;.)
The Plans permit the Company to grant non-statutory stock options, incentive stock options and stock purchase rights to the Company&rsquo;s
employees, outside directors and consultants; however, incentive stock options may only be granted to the Company&rsquo;s employees.
Beginning June 29, 2015, no awards may be granted under the 2009 Stock Plan or 2008 Stock Plan. &nbsp;As of&nbsp;June 30, 2015,
the maximum aggregate number of shares of common stock that may be issued is 328,289 under the 2015 Stock Plan. The exercise price
for each option is determined by the Board of Directors, but will be (i) in the case of an incentive stock option (A) granted
to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per
share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share on the
date of grant; and (ii) in the case of a nonstatutory stock option, no less than 100% of the fair market value per share on the date
of grant. The options awarded under the Plans shall vest as determined by the Board of Directors but shall not exceed a ten-year
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Options Issued to Directors and Employees
as Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms of the Plans, from inception
to December 31, 2013, the Company has issued options to purchase an aggregate of 206,172 shares to its executive officers and
employees of the Company. Of these, 26,163 options were forfeited and 180,009 options remain outstanding as of December 31, 2013.
No additional options were granted or forfeited during the six months ended June 30, 2014. The exercise prices of these option
grants, as determined by the Company&rsquo;s Board of Directors, range from $0.79 to $1.27 per share, and a portion of these vest
subject to certain performance conditions described in Note 5. The Company&rsquo;s management initially assessed the likelihood
of the performance conditions for the options granted to its executive officers to be probable of achievement. In April 2015,
certain performance conditions providing for options to purchase an aggregate of 41,958 shares of the Company&rsquo;s common stock
were no longer considered to be probable of achievement by September&nbsp;25, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2014, the Company granted additional
non-qualified 10-year term options to its executive officers to purchase an aggregate of 1,729,766 shares of the Company&rsquo;s
common stock. Also in 2014, an aggregate of 41,958 options expired and 13,985 options were exercised. The exercise prices of these
option grants, as determined by the Company&rsquo;s Board of Directors, range from $5.86 to $13.23 per share. No additional options
were granted in the six month period ended June 30, 2015. As of June 30, 2015, 1,853,831 options remain outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized stock based compensation
expense for these services within general and administrative expense in the accompanying Unaudited Condensed Statements of Operations
of approximately $1.7 million and $88,000 for the six months ended June 30, 2015 and 2014, respectively, and approximately $880,000
and $87,000 for the three months ended June 30, 2015 and 2014, respectively. As of June 30, 2015, there was approximately $2.9
million of total unrecognized compensation cost related to non-vested share-based compensation arrangements. This cost is expected
to be recognized over a weighted average period of 1.6 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Options Issued to Nonemployees for Services
Received</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From inception to June 30, 2015, the Company
has issued options to its consultants to purchase an aggregate of 106,573 shares of the Company&rsquo;s common stock under the
Plans. Of these, 69,580 options were forfeited or exercised, and 36,993 options remain outstanding as of June 30, 2015. The exercise
prices of the outstanding options, as determined by the Company&rsquo;s Board of Directors, range from $0.72 to $1.14 per share.
These outstanding options, with the exception of an option to purchase an aggregate of 7,271 shares granted to a consultant, vest
25% upon the first anniversary of the vesting commencement date with the remaining options vesting monthly in equal amounts over
36 months. In March&nbsp;2011, the Company granted an option to a consultant to purchase an aggregate of 7,271 shares with an
exercise price of&thinsp;$1.00 which vests 25% on the date of grant with the remaining options vesting monthly in equal amounts
over 36 months. The Company recognized stock based compensation expense for these services of approximately $700 and $3,500 for
the six months ended June 30, 2015 and 2014, respectively, and approximately $600 and $4,000 for the three months ended June 30,
2015 and 2014, respectively, within research and development expense in the accompanying Unaudited Condensed Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Options Valuation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company calculates the fair value of stock-based
compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. If the Company determines
that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair
value calculated for the Company&rsquo;s stock options could change significantly. Higher volatility and longer expected lives
would result in an increase to stock-based compensation expense to non-employees determined at the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock-based compensation expense to non-employees
affects the Company&rsquo;s general and administrative expenses and research and development expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Black-Scholes option-pricing model requires
the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards. The assumptions used
in the Black-Scholes option-pricing method for the three months and six months ended June 30, 2015 and 2014 are set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Three
    months ended June 30,</B></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Six
    months ended June 30,</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 28%; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 16%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>2015</B></FONT></TD>
    <TD NOWRAP STYLE="width: 2%; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 16%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>2014</B></FONT></TD>
    <TD NOWRAP STYLE="width: 2%; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 17%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>2015</B></FONT></TD>
    <TD NOWRAP STYLE="width: 2%; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 17%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>2014</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt">Expected dividend yield</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">0.00%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">0.00%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">0.00%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">0.00%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font-size: 10pt">Expected stock-price volatility</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">65.06% - 67.08%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">55.32% - 62.09%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">51.45% - 67.08%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">55.32% - 62.09%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt">Risk-free interest rate</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">1.79% - 2.07%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">1.54% - 2.67%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">0.77% - 2.07%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">1.49% - 3.04%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font-size: 10pt">Term of options</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">10</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">10</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">10</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">10</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt">Stock price</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">$5.86</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">$1.17</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">$5.86</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">$1.17</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Expected
                                         dividend.</I>&nbsp;&nbsp;&nbsp;The expected dividend is assumed to be zero as the Company
                                         has never paid dividends and has no current plans to pay any dividends on the Company&rsquo;s
                                         common stock.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Expected
                                         volatility.</I>&nbsp;&nbsp;&nbsp;As the Company&rsquo;s common stock only recently became
                                         publicly traded, the expected volatility is derived from the average historical volatilities
                                         of publicly traded companies within the Company&rsquo;s industry that the Company considers
                                         to be comparable to the Company&rsquo;s business over a period approximately equal to
                                         the expected term.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Risk-free
                                         interest rate.</I>&nbsp;&nbsp;&nbsp;The risk-free interest rate is based on the U.S.
                                         Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with
                                         maturities approximately equal to the expected term.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Expected
                                         term.</I>&nbsp;&nbsp;&nbsp;The expected term represents the period that the stock-based
                                         awards are expected to be outstanding. The Company&rsquo;s historical share option exercise
                                         experience does not provide a reasonable basis upon which to estimate an expected term
                                         because of a lack of sufficient data. Therefore, the Company estimates the expected term
                                         by using the simplified method provided by the SEC. The simplified method calculates
                                         the expected term as the average of the time-to-vesting and the contractual life of the
                                         options.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the assumptions used in the
Black-Scholes option-pricing model, the Company also estimates a forfeiture rate to calculate the stock-based compensation for
the Company&rsquo;s equity awards. The Company will continue to use judgment in evaluating the expected volatility, expected terms
and forfeiture rates utilized for the Company&rsquo;s stock-based compensation calculations on a prospective basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Significant factors, assumptions and methodologies
used in determining the estimated fair value of the Company&rsquo;s common stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is also required to estimate the
fair value of the common stock underlying the Company&rsquo;s stock-based awards when performing the fair value calculations using
the Black-Scholes option-pricing model. The Company&rsquo;s Board of Directors, with the assistance of management, determined
the fair value of the Company&rsquo;s common stock on each grant date. Option grants are based on the estimated fair value of
the Company&rsquo;s common stock on the date of grant, which is determined by taking into account several factors, including the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         prices at which the Company sold the Company&rsquo;s convertible preferred stock and
                                         the rights, preferences, and privileges of the convertible preferred stock relative to
                                         those of the Company&rsquo;s common stock, including the liquidation preferences of the
                                         convertible preferred stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">important
                                         developments in the Company&rsquo;s operations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         Company&rsquo;s actual operating results and financial performance;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">conditions
                                         in the Company&rsquo;s industry and the economy in general;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">stock
                                         price performance of comparable public companies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         estimated likelihood of achieving a liquidity event, such as an IPO or an acquisition
                                         of the Company, given prevailing market conditions; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         illiquidity of the common stock underlying stock options.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below presents the prices received
from sales to third parties of the Company&rsquo;s common stock and various classes of the Company&rsquo;s preferred stock from
inception to date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD NOWRAP STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share Class</TD><TD NOWRAP STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price per Share</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; text-align: center">2005</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; text-align: center">Common Stock (a)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: center">$1.79</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2006</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Series A-2 Preferred Stock (a)(b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.40</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">2008 - 2009</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Series A-3 Preferred Stock (b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.62</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2010 - 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Series B Preferred Stock (b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.19</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Series C Preferred Stock (b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.30</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$5.00</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">After giving effect to the Company&rsquo;s
                                         conversion from a LLC to a corporation.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Shares of preferred stock were
                                         converted into an aggregate of 3,322,650 shares of the Company&rsquo;s common
                                         stock effective June 29, 2015, after giving effect to the 1-for-7.15 reverse stock of
                                         shares of the Company&rsquo;s common stock effective June 17, 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For options issued from inception to November&nbsp;7,
2013, in determining the estimated fair value of the Company&rsquo;s common stock, the Company&rsquo;s Board of Directors, with
the assistance of management, used the market approach to estimate the enterprise value of the Company in accordance with the
American Institute of Certified Public Accountants (&ldquo;AICPA&rdquo;) Accounting and Valuation Guide, Valuation of Privately-Held
Company Equity Securities Issued as Compensation (the &ldquo;AICPA Guide&rdquo;) for the three valuation dates of November&nbsp;7,
2013, July&nbsp;31, 2012, and December&nbsp;31, 2010. The Market Approach is one of the three approaches (along with the Income
Approach and Asset Approach) used to estimate enterprise and equity value. The market approach employs analysis using comparable
companies in determining the value of the entity. Both public and private companies, if publicly available information exists,
are considered in the market approach. Two information points commonly available &mdash; company valuation and transaction value
&mdash; are used for their respective methodologies. There are a number of different methods within the Market Approach that may
be used: the three main methods utilized are: the Guideline Pubic Companies Method; the Guideline Transactions Method; and the
Backsolve Method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Given the early stage of the Company, the
Backsolve Method was used to estimate the fair value of the Company&rsquo;s securities. This method derives an implied market
value of invested capital from a transaction involving a company&rsquo;s own securities. The price of a company&rsquo;s security
that was involved in a recent arms-length transaction is used as a reference point in an allocation of value. The Company first
raised additional capital through the sales of the Company&rsquo;s LLC units. These units later converted into common shares and
preferred shares upon the Company&rsquo;s conversion to a corporation. Subsequent to the Company&rsquo;s corporation conversion,
the Company raised additional capital through the sales of the Company&rsquo;s Series A-1, Series A-2, Series A-3, Series B, and
Series C preferred shares at the price of&thinsp;$0.07, $0.40, $0.62, $1.19, and $1.30, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company valued LLC units and common stock
(after converting to a corporation) from inception through 2009 by reference to the Company&rsquo;s sales of units and/or common
stock &amp; preferred stock over the period. Beginning in 2010, the Company valued the Company&rsquo;s common stock using the
Backsolve Method. The Backsolve Method requires considering the rights and preferences of each class of equity and solving for
the total market value of invested capital that is consistent with a recent transaction in the Company&rsquo;s own securities,
considering the rights and preferences of each class of equity. However, management has decided that the liquidation preferences
between the Company&rsquo;s preferred shares and common shares are immaterial for a pre-revenue company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Per the AICPA Guide, the Backsolve Method
is generally the most reliable indicator of value of early-stage enterprises with no product revenue or cash flow, if relevant
and reliable transactions have occurred in the Company&rsquo;s equity securities. This methodology is also prescribed by the AICPA
when a valuation is conducted in close proximity to the date of a financing transaction, and when other methodologies are deemed
less reliable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The stage of development of the Company&rsquo;s
compound was reflected in the Company&rsquo;s selection of the term and volatility estimates used in the analysis. The estimate
of the term considers the Company&rsquo;s existing cash runway and the time to the next potential financing or liquidity event,
while the volatility estimate reflects the relative riskiness of the Company&rsquo;s equity securities (or asset base) relative
to the general stock market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management estimated the implied market value
of invested capital of the Company by backsolving for the purchase price of the Company&rsquo;s preferred shares for one common
share through the option-pricing method. The premise of this method is that the transaction implied a market price for a share
which in turn implied values for the other classes of equity based on relative claims on equity value, such as liquidation preferences
and conversion rights. The application of the backsolve method considering the Company&rsquo;s capital structure yielded a total
market value of invested capital of approximately $15.5 million, $14.4 million, and $8.9 million, of which approximately $819,000,
$870,000, and $670,000 were allocated to the total value of common stock as of the Company&rsquo;s three valuation dates of November&nbsp;7,
2013, July&nbsp;31, 2012, and December&nbsp;31, 2010, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On the three valuation dates of November&nbsp;7,
2013, July&nbsp;31, 2012, and December&nbsp;31, 2010, after estimating the market value of invested capital, the Company allocated
it to the various equity classes comprising the subject company&rsquo;s capitalization table. This process ultimately results
in creating a final estimate of value for the subject company&rsquo;s underlying equity interests. While there are many different
value allocation methods, these various methods can be grouped into three general categories as defined by the AICPA Guide, one
of which is the Option-Pricing Method (OPM).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company used the OPM to allocate market
value of invested capital to the various equity classes and debt comprising the Company&rsquo;s capitalization structure. The
Company chose the OPM over other acceptable methods due to the complex capital structure, the uncertainty related to market conditions,
and the lack of visibility on an imminent exit event. Under the OPM, each equity class is modeled as a call option with a distinct
claim on the equity of the Company. The option&rsquo;s exercise price is based on the Company&rsquo;s total equity value available
for each participating equity holder. The characteristics of each equity class determine the equity class&rsquo; claim on the
total equity value. By constructing a series of options in which the exercise price is set at incremental levels of value, which
correspond to the equity value necessary for each level of equity to participate, the Company determined the incremental option
value of each series. When multiplied by the percentage of ownership of each equity class participating under that series, the
result is the incremental value allocated to each class under that series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The OPM relies on the Black-Scholes option-pricing
model to value the call options on the Company&rsquo;s invested capital. The following inputs were applied in the Black-Scholes
calculations of the OPM:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 65%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="5" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Valuation
    Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 28%"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 2%"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 24%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>November
    7, 2013</B></FONT></TD>
    <TD NOWRAP STYLE="width: 2%"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 18%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>July 31,
    2012</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 25%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>December
    31, 2010</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP>Volatility</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">58.00%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">61.00%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">61.00%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP>Risk-free interest rate</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">0.55%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">0.57%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">2.01%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP>Maturity (years)</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">3</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">4</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">5</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Discounts ranging from 35.8% to 40% were applied
for lack of control and lack of marketability for the common stock. The calculation resulted in a fair value for the common stock
of&thinsp;$1.17, $1.19, and $1.03 per share as of the Company&rsquo;s three valuation dates of November&nbsp;7, 2013, July&nbsp;31,
2012, and December&nbsp;31, 2010, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For options issued in 2014, given the Company&rsquo;s
distinct possible exit scenarios of an initial public offering, the Company used the probability weighted expected return method
(PWERM) to estimate the fair value of the Company&rsquo;s common equity. Under this method, an analysis of future values of a
company is performed for several likely liquidity scenarios. The value of the common stock is determined for each scenario at
the time of each future liquidity event and discounted back to the present using a risk-adjusted discount rate. The present values
of the common stock under each scenario are then weighted based on the probability of each scenario occurring to determine the
value for the common stock. The Company&rsquo;s management determined the probability weighting of potential liquidity events
to be 45% for an initial public offering and 55% for other scenarios, which represents all other likely outcomes for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management estimated the implied market value
of invested capital of the Company by backsolving for the purchase price of the Company&rsquo;s preferred shares for one common
share through the use of OPM. The application of the backsolve method considering the Company&rsquo;s capital structure yielded
a total market value of invested capital of approximately $25.2 million, of which approximately $1.4 million was allocated to
the total value of common stock as of the Company&rsquo;s valuation date of October&nbsp;31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Given the lack of marketability for the common
stock, the Company applied a discount of 21.4% for using the average strike put option approach. This resulted in a probability
weighted common share value, after adjustment, of&thinsp;$5.86 per share as of valuation date of October&nbsp;31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Stock-based Compensation Summary Tables</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Information regarding the Company&rsquo;s
stock option grants to the Company&rsquo;s employees and non-employees, along with the estimated fair value per share of the underlying
common stock, for stock options granted since 2005 is summarized as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 28%; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 8pt"><B>Number of Common</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 8pt"><B>Exercise Price</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 8pt"><B>Estimated Fair Value</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 17%; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>Shares Underlying</B></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>per Common</B></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>per Share of</B></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>Intrinsic Value</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Grant Date</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Options Granted</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Share</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Common Stock</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Option</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">2005</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">58,321</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">$0.07</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.79</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.72</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2009</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">60,559</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">$0.72 - $0.79</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD STYLE="text-align: center">$4.43</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD STYLE="text-align: center">$3.71 - $3.64</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">2011</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">33,846</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">$1.00</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">$1.00</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.00</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2012</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">60,019</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">$1.14</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.14</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.00</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">2013</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">100,000</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">$1.14 - $1.30</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.14</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.00</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2014</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">1,626,740</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">$5.86- $13.23</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD STYLE="text-align: center">$5.86</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.00</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following represents a summary of the
options granted to employees and non-employees outstanding at June 30, 2015 and changes during the period then ended:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Options</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Weighted
    Average</B></FONT><BR><FONT STYLE="font-size: 8pt"><B> Exercise Price</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Outstanding at December 31, 2014</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">1,788,717</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">7.059</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 10pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103,025</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.863</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Exercised/ Expired/ Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(918</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1.158</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Outstanding at June 30, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,890,824</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.062</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Exercisable at June 30, 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">298,437</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.563</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Expected to be vested</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,592,387</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4.563</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 9&thinsp;&mdash;&thinsp;RELATED PARTY
TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A director of the Company is a managing director
of Javelin Venture Partners GP, LLC, the general partner of Javelin Venture Partners GP, L.P., which held a significant investment
in the Company&rsquo;s Series A-1, Series A-2, Series A-3, Series B, and Series C preferred stock that was converted to common
stock prior to the Company&rsquo;s initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to and during his employment with the
Company, Mr. Ira Ritter served as CEO of Andela Group Inc., (&ldquo;Andela&rdquo;) a company he founded in 1987, which is involved
in corporate management, strategic and financial consulting. The Company incurred no expenses for services received from Andela
during the three months and six months ended June 30, 2015, and approximately $49,000 and $99,000, respectively, during the three
months and six months ended June 30, 2014, all of which were classified in general and administrative expenses in the Unaudited
Condensed Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than disclosed, the Company has not
entered into or been a participant in any transaction in which a related party had or will have a direct or indirect material
interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 10&thinsp;&mdash;&thinsp;SUBSEQUENT
EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 9, 2015, the Company entered into
a lease with Century Park, a California limited partnership, pursuant to which Ritter will lease approximately 2,780 square feet
of office space in Los Angeles, California. The lease provides for a term of sixty-one (61) months, commencing on the later of
October 1, 2015 or the date of substantial completion of certain tenant improvements provided for under the lease. The Company
will pay no rent for the first month of the term and base rent of $9,174 per month for months 2 through 13 of the term, with increasing
base rent for each twelve month period thereafter under the term of the lease to a maximum of $10,325.42 per month for months
50 through 61. The base rent payments do not include the Company&rsquo;s proportionate share of any operating expenses, including
real estate taxes. The Company has the option to extend the term of the lease for one five-year term, provided that the rent would
be subject to market adjustment at the beginning of the renewal term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective July 24, 2015, the Company entered
into an <FONT STYLE="color: black">amended Clinical Supply and Cooperation Agreement (the &ldquo;Amended Supply Agreement&rdquo;)
with Ricerche Sperimentali Montale SpA (&ldquo;Ricerche&rdquo;) and Inalco SpA (collectively, &ldquo;RSM&rdquo;). The Amended
Supply Agreement amends certain terms of the Clinical Supply and Cooperation Agreement, dated December 16, 2009, amended on September
25, 2010 (the &ldquo;Existing Supply Agreement&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Existing Supply Agreement, RSM granted
Ritter an exclusive worldwide option in a specified field and territory to assignment of all right, title and interest to a purified&nbsp;Galacto-oligosaccharides
product (&ldquo;Improved GOS&rdquo;), the composition of matter of the Improved GOS and any information relating to the Improved
GOS, including certain specified technical information and other intellectual property rights (the &ldquo;Improved GOS IP&rdquo;).
Pursuant to the amended terms, the Company may exercise the option by paying RSM $800,000 within ten days after the effective
date of the Amended Supply Agreement. The Company exercised the option on July 30, 2015 and RSM is transferring the Improved GOS
IP to the Company. Under the terms of the existing agreement, if a further option payment due in the future is not made, the Company
may be required to return the Improved GOS IP to RSM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Amended Supply Agreement also provides
that&nbsp;the Company must pay RSM $400,000 within 10 days following FDA approval of a new drug application for the first product
owned or controlled by the Company using Improved GOS as its active pharmaceutical ingredient. In addition, the Company agreed
to purchase 350 kilos of Improved GOS for the sum of $250 per kilo for clinical supply of Improved GOS instead of $2,000 per kilo
as under the Existing Supply Agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RITTER PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for RSM entering into the
Amended Supply Agreement, the Company will issue 100,000 shares of the Company&rsquo;s common stock, par value $0.001 per share
(the &ldquo;Shares&rdquo;), to RSM. The Shares are to be issued within 90 days of the effective date of the Amended Supply Agreement
pursuant to a stock purchase agreement to be negotiated by the parties in good faith. The stock purchase agreement is to include
a lock-up agreement by RSM in favor of the Company pursuant to which RSM will not be able to sell the Shares for a period ending
on the earlier of (i) the public release by the Company of the final results of its Phase 2b/3 clinical trial of RP-G28 and (ii)
the filing of its Form 10-Q with the Securities and Exchange Commission for the fiscal quarter in which the Company receives the
results of its Phase 2b/3 clinical trial of RP-G28. The Company has not issued the shares to RSM as of August 4, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_007"></A><B>ITEM 2. MANAGEMENT&rsquo;S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF</B> <B>OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>The following discussion and analysis of
our financial condition and results of operations should be read in conjunction with our interim unaudited condensed financial
statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto
as of and for the year ended December 31, 2014 and the related Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations, both of which are contained in our final prospectus dated June 24, 2015 filed pursuant to Rule 424(b)(4)
of the Securities Act with the SEC on June 26, 2015. As used in this report, unless the context suggests otherwise, &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our,&rdquo; or &ldquo;Ritter&rdquo; refer to Ritter Pharmaceuticals, Inc.</I> <I>All common share amounts
and per share amounts have been adjusted to reflect a 7.15-to-1 reverse stock split of our common stock.</I>&nbsp; <I>In addition
to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties
and assumptions.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Cautionary Note Regarding Forward-Looking
Statements and Industry Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This quarterly report contains forward-looking
statements. All statements other than statements of historical facts contained in this quarterly report, including statements
regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties
and other important factors that may cause our actual results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo;
&ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo; &ldquo;will,&rdquo;
&ldquo;would&rdquo; and similar expressions are intended to identify forward- looking statements, although not all forward-looking
statements contain these identifying words. These forward- looking statements include, among other things, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to obtain additional financing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         use of the net proceeds from our initial public offering;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         accuracy of our estimates regarding expenses, future revenues and capital requirements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         success and timing of our preclinical studies and clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to obtain and maintain regulatory approval of RP-G28 and any other product candidates
                                         we may develop, and the labeling under any approval we may obtain;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory
                                         developments in the United States and other countries;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         performance of third-party manufacturers;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         plans to develop and commercialize our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to obtain and maintain intellectual property protection for our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         successful development of our sales and marketing capabilities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         potential markets for our product candidates and our ability to serve those markets;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         rate and degree of market acceptance of any future products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         success of competing drugs that are or become available; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         loss of key scientific or management personnel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These forward-looking statements are only
predictions and we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements,
so you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in the forward-looking statements we make. We have based these forward-looking
statements largely on our current expectations and projections about future events and trends that we believe may affect our business,
financial condition and operating results. We have included important factors in the cautionary statements included in this quarterly
report, particularly in the &ldquo;Risk Factors&rdquo; section, that could cause actual future results or events to differ materially
from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future
acquisitions, mergers, dispositions, joint ventures or investments we may make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The forward-looking statements in this quarterly
report represent our views as of the date of this quarterly report. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future,
we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date subsequent to the date of this quarterly report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This quarterly report contains estimates made,
and other statistical data published, by independent parties and by us relating to market size and growth and other data about
our industry. We obtained the industry and market data in this quarterly report from our own research as well as from industry
and general publications, surveys and studies conducted by third parties. This data involves a number of assumptions and limitations
and contains projections and estimates of the future performance of the industries in which we operate that are subject to a high
degree of uncertainty. We caution you not to give undue weight to such projections, assumptions and estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ritter Pharmaceuticals, Inc. develops novel
therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. We are advancing human gut health
research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics
into applications intended to have a meaningful impact on a patient&rsquo;s health. We have completed a Phase 2a clinical trial
of our leading product candidate, RP-G28, an orally administered, high purity oligosaccharide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have devoted substantially all of our resources
to development efforts relating to RP-G28, including conducting clinical trials of RP-G28, providing general and administrative
support for these operations and protecting our intellectual property. We currently do not have any products approved for sale
and we have not generated any revenue from product sales since our inception. From our inception through June 28, 2015, we have
funded our operations primarily through the private placement of preferred stock, common stock and promissory notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 24, 2015, our registration statement
on Form&nbsp;S-1 (File No. 333-202924) relating to our initial public offering of our common stock was declared effective by the
Securities and Exchange Commission (the &ldquo;SEC&rdquo;). The shares began trading on the NASDAQ Capital Market on June 24,
2015.&nbsp; The initial public offering closed on June 29, 2015, and 4,000,000 shares of common stock were sold at an initial
public offering price of $5.00 per share, for aggregate gross proceeds to us of $20 million.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We paid to the underwriters underwriting discounts
and commissions of approximately $1.6 million in connection with the offering. In addition, we incurred expenses of approximately
$1 million in connection with the offering. Thus, the net offering proceeds to us, after deducting underwriting discounts and
commissions and offering expenses, were approximately $17.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have incurred net losses in each year since
our inception, including net losses of approximately $2.1 million and $3.5 million for the three and six months ended June 30,
2015. We had an accumulated deficit of approximately $21.8 million as of June 30, 2015. Substantially all our net losses resulted
from costs incurred in connection with our research and development programs, stock-based compensation, and from general and administrative
costs associated with our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect to continue to incur significant
expenses and increasing operating losses for at least the next several years. We anticipate that our expenses will increase substantially
as we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">complete
                                         the development of our lead product candidate, RP-G28, for the reduction of symptoms
                                         associated with lactose intolerance in patients;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">seek
                                         to obtain regulatory approvals for RP-G28;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">outsource
                                         the commercial manufacturing of RP-G28 for any indications for which we receive regulatory
                                         approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.35pt; text-align: justify; text-indent: -9.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27.35pt; text-align: justify; text-indent: -9.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">contract
                                         with third parties for the sales, marketing and distribution of RP-G28 for any indications
                                         for which we receive regulatory approval;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">maintain,
                                         expand and protect our intellectual property portfolio;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">continue
                                         our research and development efforts;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">add
                                         operational, financial and management information systems and personnel, including personnel
                                         to support our product development and commercialization efforts; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">operate
                                         as a public company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not expect to generate revenue from
product sales unless and until we successfully complete development and obtain marketing approval for one or more of our product
candidates, which we expect will take a number of years and is subject to significant uncertainty. Accordingly, we anticipate
that we will need to raise additional capital in addition to the net proceeds received in our initial public offering prior to
the commercialization of RP-G28 or any other product candidate. Until such time, if ever, as we can generate substantial revenue
from product sales, we expect to finance our operating activities through a combination of equity offerings, debt financings,
government or other third-party funding, commercialization, marketing and distribution arrangements and other collaborations,
strategic alliances and licensing arrangements. However, we may be unable to raise additional funds or enter into such other arrangements
when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed
would have a negative impact on our financial condition and our ability to develop our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Financial Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not generated any revenue since our
inception. Our ability to generate revenue in the future will depend almost entirely on our ability to successfully develop, obtain
regulatory approval for and then successfully commercialize RP-G28 in the United States. In the event we choose to pursue a partnering
arrangement to commercialize RP-G28 or other products outside the United States, we would expect to initiate additional research
and development and clinical trial activities in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since our inception, we have focused our resources
on our research and development activities, including conducting nonclinical studies and clinical trials, manufacturing development
efforts and activities related to regulatory filings for RP-G28. Our research and development expenses consist primarily of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">fees
                                         paid to consultants and CROs, including in connection with our nonclinical and clinical
                                         trials, and other related clinical trial fees, such as for investigator grants, patient
                                         screening, laboratory work, clinical trial database management, clinical trial material
                                         management and statistical compilation and analysis;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">costs
                                         related to acquiring and manufacturing clinical trial materials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">depreciation
                                         of leasehold improvements, laboratory equipment and computers;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">costs
                                         related to compliance with regulatory requirements; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">overhead
                                         expenses for personnel in research and development functions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From inception through June 30, 2015, we have
incurred approximately $4.2 million in research and development expenses. We plan to increase our research and development expenses
for the foreseeable future as we continue the development of RP-G28 for the reduction of symptoms associated with lactose intolerance
in patients and other indications, subject to the availability of additional funding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The successful development of our clinical
and preclinical product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs
of the efforts that will be necessary to complete the remainder of the development of any of our clinical or preclinical product
candidates or the period, if any, in which material net cash inflows from these product candidates
may commence. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty
of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         scope, rate of progress and expense of our ongoing, as well as any additional, clinical
                                         trials and other research and development activities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">future
                                         clinical trial results; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         timing and receipt of any regulatory approvals.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A change in the outcome of any of these variables
with respect to the development of a product candidate could mean a significant change in the costs and timing associated with
the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct
clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a product
candidate or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant
additional financial resources and time on the completion of clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>RP-G28</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The majority of our research and development
resources are focused on the Phase 2b and Phase 3 RP-G28 trials and our other planned clinical and nonclinical studies and other
work needed to submit RP-G28 for the reduction of symptoms associated with lactose intolerance in patients for regulatory approval
in the United States and Europe. We have incurred and expect to continue to incur expenses in connection with these efforts, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">conduct
                                         our Phase 2b/3 clinical trials as an adaptive design Phase 2b/3 clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">working
                                         with our CRO to prepare for launch of the Phase 2b/3 and Phase 3 trials; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">working
                                         with our third-party drug formulator to produce sufficient drug product for the adaptive
                                         design Phase 2b/3 clinical trials and other contemplated trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Patent Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patent costs consist primarily of professional
fees for legal services to prosecute patents and maintain patent rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses include
allocation of facilities costs, salaries, benefits, and stock-based compensation for employees, professional fees for directors,
fees for independent contractors and accounting and legal services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect that our general and administrative
expenses will increase as we operate as a public company and due to the potential commercialization of RP-G28. We believe that
these increases will likely include increased costs for director and officer liability insurance, and increased fees for outside
consultants, lawyers and accountants. We also expect to incur increased costs to comply with corporate governance, internal controls
and similar requirements applicable to public companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Interest Income and Interest Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interest income consists of interest earned
on our cash. We expect our interest income to increase due to the receipt of net proceeds from our initial public offering as
we invest the net proceeds from the offering pending their use in our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interest expense pertains to interest accrued
on our promissory notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Critical Accounting Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This management&rsquo;s discussion and analysis
of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance
with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported
amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial
statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to fair value of financial instruments,
research and development costs, accrued expenses and stock-based compensation. We base our estimates on historical experience,
known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other
sources. Actual results may differ from these estimates under different assumptions or conditions. We believe there have been
no significant changes in our critical accounting policies as discussed in our Form S-1 filed on June19, 2015 with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August&nbsp;2014, the FASB issued ASU No.
2014-15,&nbsp;<I>Presentation of Financial Statements &mdash; Going Concern (Subtopic 205-40) &mdash; Disclosure of Uncertainties
about an Entity&rsquo;s Ability to Continue as a Going Concern</I>, which provides guidance regarding management&rsquo;s responsibility
to assess whether substantial doubt exists regarding the ability to continue as a going concern and requires related footnote
disclosures. In connection with preparing financial statements for each annual and interim reporting period, management should
evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to
continue as a going concern within one year after the date that the financial statements are issued (or within one year after
the date that the financial statements are available to be issued when applicable). This ASU is effective for the annual period
ending after December&nbsp;15, 2016, and for annual periods and interim periods thereafter. Management is currently evaluating
the new guidance and has not determined the impact this standard may have on our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stock-based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2015, we adopted a new equity incentive
plan (&ldquo;2015 Stock Plan&rdquo;) to replace our prior 2008 and 2009 Stock Plans (collectively, &ldquo;Plans&rdquo;). Terms
of our share-based compensation are governed by the 2015 Stock Plan, 2009 Stock Plan and 2008 Stock Plan (collectively the &ldquo;Plans&rdquo;).
The Plans permit us to grant non-statutory stock options, incentive stock options and stock purchase rights to our employees,
outside directors and consultants; however, incentive stock options may only be granted to our employees. Beginning June 29, 2015,
no awards may be granted under the 2009 Stock Plan or 2008 Stock Plan. &nbsp;As of&nbsp;June 30, 2015, the maximum aggregate number
of shares of common stock that may be issued is 328,289 under the 2015 Stock Plan. The exercise price for each option is determined
by our Board of Directors, but will be (i) in the case of an incentive stock option (A) granted to an employee who, at the time
of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per share on the date of grant; or (B)
granted to any other employee, no less than 100% of the fair market value per share on the date of grant; and (ii) in the case
of a nonstatutory stock option, no less than 100% of the fair market value per share on the date of grant. The options awarded
under the Plans shall vest as determined by our Board of Directors but shall not exceed a ten-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Options Issued to Directors and Employees
as Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize compensation costs related to
stock options granted to employees based on the estimated fair value of the awards on the date of grant, net of estimated forfeitures.
We estimate the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing
model. The grant date fair value of stock-based awards is expensed on a straight-line basis over the vesting period of the respective
award. Performance-based awards vest and are expensed over the performance period when the related performance goal is probable
of being achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms of the Plans, from inception
to December 31, 2013, we have issued options to purchase an aggregate of 206,172 shares to our executive officers and employees.
Of these, 26,163 options were forfeited and 180,009 options
remain outstanding as of December 31, 2013. No additional options were granted or forfeited during the six months ended June 30,
2014. The exercise prices of these option grants, as determined by our Board of Directors, range from $0.79 to $1.27 per share,
and a portion of these vest subject to certain performance conditions. Our management initially assessed the likelihood
of the performance conditions for the options granted to our executive officers to be probable of achievement. In April 2015,
certain performance conditions providing for options to purchase an aggregate of 41,958 shares of our common stock were no longer
considered to be probable of achievement by September&nbsp;25, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2014, we granted additional non-qualified
10-year term options to our executive officers to purchase an aggregate of 1,729,766 of our common stock. Also in 2014, an aggregate
of 41,958 options expired and 13,985 options were exercised. The exercise prices of these option grants, as determined by our
Board of Directors, range from $5.86 to $13.23 per share. No additional options were granted for the six months ended June 30,
2015. As of June 30, 2015, 1,853,831 options remain outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognized stock based compensation expense
for these services within general and administrative expense in the accompanying Unaudited Condensed Statements of Operations
of approximately $1.7million and $88,000 for the six months ended June 30, 2015 and 2014, respectively, and approximately $880,000
and $87,000 for the three months ended June 30, 2015 and 2014, respectively. As of June 30, 2015, there was approximately $2.9
million of total unrecognized compensation cost related to non-vested share-based compensation arrangements. This cost is expected
to be recognized over a weighted average period of 1.6 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Options Issued to Non-Employees for Service
Received</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for stock-based compensation arrangements
with non-employees using a fair value approach. The fair value of these options is measured using the Black-Scholes option-pricing
model reflecting the same assumptions as applied to employee options in each of the reported periods, other than the expected
life, which is assumed to be the remaining contractual life of the option. The compensation costs of these arrangements are subject
to re-measurement over the vesting terms as earned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From inception to June 30, 2015, we have issued
options to our consultants to purchase an aggregate of 106,573 shares of our common stock under the Plans. Of these, 69,580 options
were forfeited or exercised, and 36,993 options remain outstanding as of June 30, 2015. The exercise prices of the outstanding
options, as determined by our Board of Directors, range from $0.72 to $1.14 per share. These outstanding options, with the exception
of an option to purchase an aggregate of 7,271 shares granted to a consultant, vest 25% upon the first anniversary of the vesting
commencement date with the remaining options vesting monthly in equal amounts over 36 months. In March&nbsp;2011, we granted an
option to a consultant to purchase an aggregate of 7,271 shares with an exercise price of&thinsp;$1.00 which vests 25% on the
date of grant with the remaining options vesting monthly in equal amounts over 36 months. We recognized stock based compensation
expense for these services of approximately $700 and $4,000 for the three months ended June 30, 2015 and 2014, respectively, within
research and development expense in the accompanying Unaudited Condensed Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Option Valuation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We calculate the fair value of stock-based
compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. If we determine that
other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value
calculated for our stock options could change significantly. Higher volatility and longer expected lives would result in an increase
to stock-based compensation expense to non-employees determined at the date of grant. Stock-based compensation expense to non-employees
affects our general and administrative expenses and research and development expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Black-Scholes option-pricing model requires
the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards. The assumptions used
in the Black-Scholes option-pricing method for the three months and six months ended June 30, 2015 and 2014 are set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Three months
    ended June 30,</B></FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Six months
    ended June 30,</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 28%"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 16%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>2015</B></FONT></TD>
    <TD NOWRAP STYLE="width: 2%"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 16%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>2014</B></FONT></TD>
    <TD NOWRAP STYLE="width: 2%"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 17%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>2015</B></FONT></TD>
    <TD NOWRAP STYLE="width: 2%"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 17%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>2014</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP>Expected dividend yield</TD>
    <TD NOWRAP STYLE="text-align: center">0.00%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">0.00%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">0.00%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">0.00%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP>Expected stock-price volatility</TD>
    <TD NOWRAP STYLE="text-align: center">65.06% - 67.08%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">55.32% - 62.09%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">51.45% - 67.08%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">55.32% - 62.09%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP>Risk-free interest rate</TD>
    <TD NOWRAP STYLE="text-align: center">1.79% - 2.07%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">1.54% - 2.67%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">0.77% - 2.07%</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">1.49% - 3.04%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP>Term of options</TD>
    <TD NOWRAP STYLE="text-align: center">10</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">10</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">10</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">10</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP>Stock price</TD>
    <TD NOWRAP STYLE="text-align: center">$5.86</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">$1.17</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">$5.86</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">$1.17</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Expected
                                         dividend.</I>&nbsp;&nbsp;&nbsp;The expected dividend is assumed to be zero as we have
                                         never paid dividends and have no current plans to pay any dividends on our common stock.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Expected
                                         volatility.</I>&nbsp;&nbsp;&nbsp;As our common stock only recently became publicly traded,
                                         the expected volatility is derived from the average historical volatilities of publicly
                                         traded companies within our industry that we consider to be comparable to our business
                                         over a period approximately equal to the expected term.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Risk-free
                                         interest rate.</I>&nbsp;&nbsp;&nbsp;The risk-free interest rate is based on the U.S.
                                         Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with
                                         maturities approximately equal to the expected term.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Expected
                                         term.</I>&nbsp;&nbsp;&nbsp;The expected term represents the period that the stock-based
                                         awards are expected to be outstanding. Our historical share option exercise experience
                                         does not provide a reasonable basis upon which to estimate an expected term because of
                                         a lack of sufficient data. Therefore we estimate the expected term by using the simplified
                                         method provided by the SEC. The simplified method calculates the expected term as the
                                         average of the time-to-vesting and the contractual life of the options.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the assumptions used in the
Black-Scholes option-pricing model, we also estimate a forfeiture rate to calculate the stock-based compensation for our equity
awards. We will continue to use judgment in evaluating the expected volatility, expected terms and forfeiture rates utilized for
our stock-based compensation calculations on a prospective basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Significant factors, assumptions and methodologies
used in determining the estimated fair value of our common stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are also required to estimate the fair
value of the common stock underlying our stock-based awards when performing the fair value calculations using the Black-Scholes
option-pricing model. Our Board of Directors, with the assistance of management, determined the fair value of our common stock
on each grant date. Option grants are based on the estimated fair value of our common stock on the date of grant, which is determined
by taking into account several factors, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         prices at which we sold our convertible preferred stock and the rights, preferences,
                                         and privileges of the convertible preferred stock relative to those of our common stock,
                                         including the liquidation preferences of the convertible preferred stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">important
                                         developments in our operations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         actual operating results and financial performance;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">conditions
                                         in our industry and the economy in general;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">stock
                                         price performance of comparable public companies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         estimated likelihood of achieving a liquidity event, such as an IPO or an acquisition,
                                         given prevailing market conditions; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         illiquidity of the common stock underlying stock options.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>



<P STYLE="margin: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below presents the prices received
from sales to third parties of our common stock and various classes of our preferred stock from inception to date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD NOWRAP STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share&nbsp;Class</TD><TD NOWRAP STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price&nbsp;per&nbsp;Share</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; text-align: center">2005</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; text-align: center">Common Stock (a)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: center">$1.79</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2006</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Series A-2 Preferred Stock (a)(b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.40</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">2008 - 2009</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Series A-3 Preferred Stock (b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.62</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2010 - 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Series B Preferred Stock (b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.19</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Series C Preferred Stock (b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.30</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$5.00</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">After giving effect to our conversion
                                         from a LLC to a corporation.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Each share of preferred stock
                                         was converted into our common stock on a 7.15 to 1 basis effective June 29, 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For options issued from inception to November&nbsp;7,
2013, in determining the estimated fair value of our common stock, our Board of Directors, with the assistance of management,
used the market approach to estimate our enterprise value in accordance with the American Institute of Certified Public Accountants
(&ldquo;AICPA&rdquo;) Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation
(the &ldquo;AICPA Guide&rdquo;) for the three valuation dates of November&nbsp;7, 2013, July&nbsp;31, 2012, and December&nbsp;31,
2010. The Market Approach is one of the three approaches (along with the Income Approach and Asset Approach) used to estimate
enterprise and equity value. The market approach employs analysis using comparable companies in determining the value of the entity.
Both public and private companies, if publicly available information exists, are considered in the market approach. Two information
points commonly available &mdash; company valuation and transaction value &mdash; are used for their respective methodologies.
There are a number of different methods within the Market Approach that may be used: the three main methods utilized are: the
Guideline Pubic Companies Method; the Guideline Transactions Method; and the Backsolve Method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Given the early stage of our company, the
Backsolve Method was used to estimate the fair value of our securities. This method derives an implied market value of invested
capital from a transaction involving a company&rsquo;s own securities. The price of a company&rsquo;s security that was involved
in a recent arms-length transaction is used as a reference point in an allocation of value. We first raised additional capital
through the sales of our LLC units. These units later converted into common shares and preferred shares upon the conversion to
a corporation. Subsequent to the corporation conversion, we raised additional capital through the sales of our Series A-1, Series
A-2, Series A-3, Series B, and Series C preferred shares at the price of&thinsp;$0.07, $0.40, $0.62, $1.19, and $1.30, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We valued LLC units and common stock (after
converting to a corporation) from inception through 2009 by reference to our sales of units and/or common stock &amp; preferred
stock over the period. Beginning in 2010, we valued our common stock using the Backsolve Method. The Backsolve Method requires
considering the rights and preferences of each class of equity and solving for the total market value of invested capital that
is consistent with a recent transaction in our own securities, considering the rights and preferences of each class of equity.
However, our management has decided that the liquidation preferences between our preferred shares and common shares are immaterial
for a pre-revenue company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Per the AICPA Guide, the Backsolve Method
is generally the most reliable indicator of value of early-stage enterprises with no product revenue or cash flow, if relevant
and reliable transactions have occurred in our equity securities. This methodology is also prescribed by the AICPA when a valuation
is conducted in close proximity to the date of a financing transaction, and when other methodologies are deemed less reliable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The stage of development of our compound was
reflected in our selection of the term and volatility estimates used in the analysis. The estimate of the term considers our existing
cash runway and the time to the next potential financing or liquidity event, while the volatility estimate reflects the relative
riskiness of our equity securities (or asset base) relative to the general stock market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our management estimated the implied market
value of invested capital of our company by backsolving for the purchase price of our preferred shares for one common share through
the option-pricing method. The premise of this method is that the transaction implied a market price for a share which in turn
implied values for the other classes of equity based on relative claims on equity value, such as liquidation preferences and conversion
rights. The application of the backsolve method considering our capital structure yielded a total market value of invested capital
of approximately $15.5 million, $14.4 million, and $8.9 million, of which approximately $819,000, $870,000, and $670,000 were
allocated to the total value of common stock as of our three valuation dates of November&nbsp;7, 2013, July&nbsp;31, 2012, and
December&nbsp;31, 2010, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On the three valuation dates of November&nbsp;7,
2013, July&nbsp;31, 2012, and December&nbsp;31, 2010, after estimating the market value of invested capital, we allocated it to
the various equity classes comprising our capitalization table. This process ultimately results in creating a final estimate of
value for the subject company&rsquo;s underlying equity interests. While there are many different value allocation methods, these
various methods can be grouped into three general categories as defined by the AICPA Guide, one of which is the Option-Pricing
Method (OPM).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We used the OPM to allocate market value of
invested capital to the various equity classes and debt comprising our capitalization structure.&nbsp;&nbsp;We chose the OPM over
other acceptable methods due to the complex capital structure, the uncertainty related to market conditions, and the lack of visibility
on an imminent exit event. Under the OPM, each equity class is modeled as a call option with a distinct claim on the equity of
our company. The option&rsquo;s exercise price is based on our total equity value available for each participating equity holder.
The characteristics of each equity class determine the equity class&rsquo; claim on the total equity value. By constructing a
series of options in which the exercise price is set at incremental levels of value, which correspond to the equity value necessary
for each level of equity to participate, we determined the incremental option value of each series. When multiplied by the percentage
of ownership of each equity class participating under that series, the result is the incremental value allocated to each class
under that series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The OPM relies on the Black-Scholes option-pricing
model to value the call options on our invested capital. The following inputs were applied in the Black-Scholes calculations of
the OPM:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Valuation&nbsp;Date</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">November&nbsp;7,&nbsp;2013</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">July&nbsp;31,&nbsp;2012</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">December&nbsp;31,&nbsp;2010</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%">Volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: center">58.00%</TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: center">61.00%</TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 23%; text-align: center">61.00%</TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">0.55%</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">0.57%</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2.01%</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Maturity (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Discounts ranging from 35.8% to 40% were applied
for lack of control and lack of marketability for the common stock. The calculation resulted in a fair value for the common stock
of&thinsp;$1.17, $1.19, and $1.03 per share as of our three valuation dates of November&nbsp;7, 2013, July&nbsp;31, 2012, and
December&nbsp;31, 2010, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For options issued in 2014, given our distinct
possible exit scenarios of an initial public offering, we used the probability weighted expected return method (PWERM) to estimate
the fair value of our common equity. Under this method, an analysis of future values of a company is performed for several likely
liquidity scenarios. The value of the common stock is determined for each scenario at the time of each future liquidity event
and discounted back to the present using a risk-adjusted discount rate. The present values of the common stock under each scenario
are then weighted based on the probability of each scenario occurring to determine the value for the common stock. Our management determined the probability weighting
of potential liquidity events to be 45% for an initial public offering and 55% for other scenarios, which represents all other
likely outcomes for our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management estimated the implied market value
of invested capital of our company by backsolving for the purchase price of our preferred shares for one common share through
the use of OPM. The application of the backsolve method considering our capital structure yielded a total market value of invested
capital of approximately $25.2 million, of which approximately $1.4 million was allocated to the total value of common stock as
of our valuation date of October&nbsp;31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Given the lack of marketability for the common
stock, we applied a discount of 21.4% for using the average strike put option approach. This resulted in a probability weighted
common share value, after adjustment, of&thinsp;$5.86 per share as of valuation date of October&nbsp;31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Stock-based Compensation Summary Tables</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Information regarding our stock option grants
to our employees and non-employees, along with the estimated fair value per share of the underlying common stock, for stock options
granted since 2005 is summarized as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Number&nbsp;of&nbsp;Common</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Exercise&nbsp;Price</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Estimated&nbsp;Fair&nbsp;Value</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Shares&nbsp;Underlying</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">per&nbsp;Common</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">per&nbsp;Share&nbsp;of</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Intrinsic&nbsp;Value</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Grant&nbsp;Date</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Options&nbsp;Granted</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Share</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Common&nbsp;Stock</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Option</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: center">2005</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: center">58,321</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: center">$0.07</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: center">$1.79</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: center">$1.72</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2009</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">60,559</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.72 - $0.79</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$4.43</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$3.71 - $3.64</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">33,846</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.00</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.00</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.00</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">60,019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.14</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.14</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.00</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">100,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.14 - $1.30</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.14</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.00</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1,626,740</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$5.86- $13.23</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$5.86</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.00</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following represents a summary of the
options granted to employees and non-employees outstanding at June 30, 2015 and changes during the period then ended:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Weighted&nbsp;Average</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Options</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Exercise&nbsp;Price</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Outstanding at December 31, 2014</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">1,891,742</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">7.059</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Exercised/ Expired/ Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(918</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1.158</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Outstanding at June 30, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,890,824</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.062</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Exercisable at June 30, 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">291,095</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.646</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Expected to be vested</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,599,729</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4.646</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>JOBS Act</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April&nbsp;5, 2012, the JOBS Act was enacted.
Section 107 of the JOBS Act provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition
period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the Securities Act), for complying with new or
revised accounting standards. In other words, an &ldquo;emerging growth company&rdquo; can delay the adoption of certain accounting
standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period
for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us to delay
the adoption of new or revised accounting standards that have different effective dates for public and private companies until
those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies
that comply with public company effective dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are in the process of evaluating the benefits
of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set
forth in the JOBS Act, as an &ldquo;emerging growth company,&rdquo; we intend to rely on certain of these exemptions, including
without limitation, (i) providing an auditor&rsquo;s attestation report on our system of internal controls over financial reporting
pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the PCAOB
regarding mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing additional information about the
audit and the financial statements, known as the auditor discussion and analysis. We will remain an &ldquo;emerging growth company&rdquo;
until the earliest of&thinsp; (i) the last day of the fiscal year in which we have total annual gross revenues of&thinsp; $1 billion
or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public
offering; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years;
or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Comparison of the Three Months Ended
June 30, 2015 and 2014</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes our results
of operations for the three months ended June 30, 2015 and 2014, together with the changes in those items in dollars and as a
percentage:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">For
    the Three Months Ended June 30,</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Dollar</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Percentage</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2015</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Change</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Change</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Statement of Operations Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left">Operating costs and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">47,977</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">6,315</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">41,662</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">660</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Patent costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,148</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,382</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,766</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,001,706</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">352,431</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,649,275</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">468</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total operating costs and expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,099,831</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">386,128</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,713,703</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">444</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,099,831</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(386,128</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,713,703</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">444</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Interest income (expense)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,101</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,944</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,045</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">142</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(2,097,729</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(391,072</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,706,657</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">436</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses were approximately
$48,000 and $6,000 for the three months ended June 30, 2015 and 2014, respectively. The increase in research and development expenses
of approximately $42,000, or 660%, primarily reflects our manufacturing ramp-up costs to prepare product for clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Patent Costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patent costs were approximately $50,000 and
$27,000 for the three months ended June 30, 2015 and 2014, respectively, representing an increase of&thinsp;$23,000, or 83%. This
increase was primarily due to our transition to a new service provider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses were approximately
$2 million and $352,000<B>&nbsp;</B>for the three months ended June 30, 2015 and 2014, respectively. The increase in general and
administrative expenses is approximately $1.6 million, or 468%. This increase in general and administrative expenses was
primarily due to the increase in stock based</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">compensation related to the options granted
to our executives and employees in December&nbsp;2014, increase in salary for our officers in 2015, and the increase in expenses
related to the closing of our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Other Income (Expense)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other income (expenses) was approximately
$2,000<B>&nbsp;</B>and ($5,000)<B>&nbsp;</B>for the three months ended June 30, 2015 and 2014, respectively. The increase of&thinsp;approximately
$7,000, or 142%, was primarily a result of interest expense incurred on our outstanding promissory notes in the three months ended
June 30, 2014 and, to a lesser extent, on interest earned from the proceeds of our initial public offering in the three months
ended June 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Comparison of the Six Months Ended June
30, 2015 and 2014</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes our results
of operations for the six months ended June 30, 2015 and 2014, together with the changes in those items in dollars and as a percentage:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">For
    the Six Months Ended June 30,</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Dollar</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Percentage</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2015</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Change</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Change</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Statement of Operations Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left">Operating costs and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">79,555</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">11,416</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">68,139</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">597</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Patent costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,423</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,164</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,259</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,304,152</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">597,087</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,707,065</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">453</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total operating costs and expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,496,130</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">672,667</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,823,463</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">420</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,496,130</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(672,667</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,823,463</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">420</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income (expense), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,305</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,739</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,044</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">191</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,091</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,091</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total other income (expense)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,396</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,739</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,135</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">340</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,484,734</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(677,406</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(2,807,328</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">414</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses were approximately
$80,000 and $11,000 for the six months ended June 30, 2015 and 2014, respectively. The increase in research and development expenses
of approximately $68,000, or 597%, primarily reflects our manufacturing ramp-up costs to prepare product for clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Patent Costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patent costs were approximately in $112,000
and $64,000 for the six months ended June 30, 2015 and 2014, respectively, representing an increase of $48,000, or 75%. This increase
was primarily due to our transition to a new service provider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses were approximately
$3.3 million and $600,000 for the six months ended June 30, 2015 and 2014, respectively. The increase in general and administrative
expenses is $2.7million, or 453%. This increase in general and administrative expenses was primarily due to the increase in stock
based compensation related to the options granted to our executives and employees in December&nbsp;2014, increase in salary for
our officers in 2015, and the increase in expenses related to the closing of our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Other Income (Expense)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The increase in net interest income was approximately
$9,000, or 191%.&nbsp;&nbsp;Net interest income for the six months ended June 30, 2015 was approximately $4,000, which was primarily
a result of increased cash in June 2015 resulting from the net proceeds of our initial public offering.&nbsp;&nbsp;Net interest
expense for the six months ended June 30, 2014 was approximately $5,000, which primarily represented interest costs associated
with our outstanding promissory notes.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other income was $7,091 and $0 for the six
months ended June 30, 2015 and 2014, respectively.&nbsp;&nbsp;The increase of $7,091 was a result of a gain on the settlement
of accounts payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Sources of Liquidity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since our inception, we have incurred net
losses and negative cash flows from operations.&nbsp;&nbsp;We incurred net losses of approximately $2.1 million and $3.5 million
for the three and six months ended June 30, 2015. Net cash used in operating activities was approximately $894,000 for the six
months ended June 30, 2015.&nbsp;&nbsp;We had an accumulated deficit of approximately $21.8 million as of June 30, 2015. Substantially
all our net losses resulted from costs incurred in connection with our research and development programs, stock-based compensation,
and from general and administrative costs associated with our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2015, after&nbsp;consummation
of our initial public offering, we had working capital of $17.3 million, and cash of $19.7 million.&nbsp;We have not generated
any product revenues and have not achieved profitable operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Cash Flows</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the significant
sources and uses of cash for the periods set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">For
    the Six Months Ended June 30,</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2015</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2014</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided by (used in):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">Operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(893,879</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(584,469</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,166</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Financing acitivities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,805,625</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">375,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">16,911,746</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(210,635</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Operating Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities of approximately
$894,000 during the six months ended June 30, 2015 was primarily a result of our net loss of approximately $3.5 million, offset
by stock based compensation of approximately $1.7 million and an increase in accounts payable and accrued expenses of approximately
$880,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities of approximately
$584,000 during the six months ended June 30, 2014 was primarily a result of our net loss of approximately $677,000 and an increase
of approximately $40,000 in prepaid assets, offset by stock based compensation of approximately $92,000 and an increase in accounts
payable of approximately $30,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Financing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash provided by financing activities
of approximately $17.8 million during the six months ended June 30, 2015 was resulted from net proceeds received upon closing
of our initial public offering, selling 4,000,000 shares of our common stock offset partially by commissions and issuance costs
of approximately $2.2 million.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash provided by financing activities
during the six months ended June 30, 2014 of $375,000 resulted from proceeds borrowed under notes payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Future Funding Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, we have not generated any revenue.
We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate significant revenue
from product sales unless and until we obtain regulatory approval of and commercialize RP-G28 or any of our other product candidates.
At the same time, we expect our expenses to increase in connection with our ongoing development activities, particularly as we
continue the research, development and clinical trials of, and seek regulatory approval for, our product candidates. Additionally,
we expect to incur additional costs associated with operating as a public company. In addition, subject to obtaining regulatory
approval of any of our product candidates, we expect to incur significant commercialization expenses for product sales, marketing,
manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based upon our current operating plan, we
believe that the net proceeds from our initial public offering will enable us to fund our operating expenses and capital expenditure
requirements through the first quarter of 2017. We intend to devote our existing financial resources to fund the continued clinical
development of RP-G28 for the reduction of symptoms associated with lactose intolerance, including our anticipated Phase 2b/3
trials; to fund expenses associated with the manufacture and product development of RP-G28; to explore potential orphan indications;
and for general corporate purposes, general and administrative expenses, capital expenditures, working capital and prosecution
and maintenance of our intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our future capital requirements will depend
on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         progress, costs, results of and timing of implementing a Phase 2b/3 clinical trials for
                                         the reduction of symptoms associated with lactose intolerance in patients;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         willingness of the EMA or other regulatory agencies outside the United States to accept
                                         our Phase 2b/3 and any Phase 3 trials of RP-G28, as well as our other completed and planned
                                         clinical and nonclinical studies and other work, as the basis for review and approval
                                         of RP-G28 in the European Union for the reduction of symptoms associated with lactose
                                         intolerance in patients;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         outcome, costs and timing of seeking and obtaining FDA, EMA and any other regulatory
                                         approvals;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         number and characteristics of product candidates that we pursue, including our product
                                         candidates in preclinical development;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         ability of our product candidates to progress through clinical development successfully;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         need to expand our research and development activities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         costs associated with securing and establishing commercialization and manufacturing capabilities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">market
                                         acceptance of our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         costs of acquiring, licensing or investing in businesses, products, product candidates
                                         and technologies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to maintain, expand and defend the scope of our intellectual property portfolio,
                                         including the amount and timing of any payments we may be required to make, or that we
                                         may receive, in connection with the licensing, filing, prosecution, defense and enforcement
                                         of any patents or other intellectual property rights;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         need and ability to hire additional management and scientific and medical personnel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         effect of competing technological and market developments;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         need to implement additional internal systems and infrastructure, including financial
                                         and reporting systems;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         economic and other terms, timing of and success of our existing licensing arrangements
                                         and any collaboration, licensing or other arrangements into which we may enter in the
                                         future; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         costs of operating as a public company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Until such time, if ever, as we can generate
substantial revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings,
government or other third-party funding, commercialization, marketing and distribution arrangements and other collaborations,
strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible
debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include
liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may
involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional
debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party
funding, commercialization, marketing and distribution arrangements or other collaborations, strategic alliances or licensing
arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research
programs or product candidates or to grant licenses on terms that may not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Contractual Obligations and Commitments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Lease Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: black">We lease office
and storage space for its headquarters in California pursuant to a two-year agreement ending September&nbsp;30, 2015 which calls
for a minimum monthly rent of approximately $5,000 and an annual increase of 3%.&nbsp;&nbsp;Rent expense, recognized on a straight-line
basis, was approximately $15,000 for each of the three months ended June 30, 2015 and 2014.&nbsp;&nbsp;</FONT>We recognized approximately
$30,000 in each of the six months ended June 30, 2015 and 2014 in rent expense.&nbsp;&nbsp;Rent expense is recorded in salaries,
general and administrative expenses in the Unaudited Condensed Statements of Operations.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2015, we entered into a new five-year
lease agreement for new corporate office space, projected to be effective October 1, 2015, which calls for a minimum lease payment
of approximately $107,000 annually.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Employment Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Michael Step</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December&nbsp;2, 2014, we entered into
a letter agreement (the &ldquo;Step Letter Agreement&rdquo;), with Michael Step, our current Chief Executive Officer, setting
forth the terms of his employment. The Step Letter Agreement provides that Michael Step is entitled to an annual base salary of
$360,000 and a total of three grants of options to purchase our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first two options entitle Michael Step
to purchase 646,537 and 73,777 of our shares, respectively, for an exercise price of&thinsp;$5.86 per share. Each of these options
is immediately exercisable in full as of the date of the grant, with 44/48ths&nbsp;of the total number of shares covered by each
option subject to a right of repurchase by us upon termination of Michael Step&rsquo;s employment with us for any of the reasons
specified in those options. This right of repurchase will lapse over a period of 44 months, with 1/44th&nbsp;of the total number
of shares subject to the right of repurchase lapsing on January&nbsp;1, 2015 and on the first day of each month thereafter. In
addition, the right of repurchase will lapse in its entirety upon a termination of the employment under certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The third option became exercisable upon the
closing of our initial public offering on June 29, 2015.&nbsp;&nbsp;Pursuant to the terms of the agreement, the option is exercisable
for a total of 103,025 shares of our common stock, which, together with the shares subject to the first option, represent 7.5%
of the shares of common stock deemed to be outstanding at June 29, 2015 on a fully-diluted basis after giving effect to the number
of shares subject to the third option.&nbsp;&nbsp;Seventy-five percent (75%) of the shares subject to the third option are subject
to a right of repurchase by us upon termination of Michael Step&rsquo;s employment for any reason. This right of repurchase will
lapse with respect to 1/36th&nbsp;of the total number of shares subject to the right of repurchase on the first day of each month
following the date on which the third option first becomes
exercisable. In addition, the right of repurchase will lapse in its entirety upon Michael Step&rsquo;s termination of employment
under certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the agreement, Michael
Step will be entitled to receive certain payments in the event his employment is terminated under certain scenarios.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Andrew Ritter and Ira Ritter</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September&nbsp;25, 2013, our Board of Directors
approved the Executive Compensation Plan (the &ldquo;Compensation Plan&rdquo;), which was later amended in June 2015, setting
forth the compensation to be paid to Andrew Ritter and Ira Ritter, our current President and also our former Chief Executive Officer,
and Chief Strategic Officer (&ldquo;CSO&rdquo;), respectively, for their contributions to our company.&nbsp;&nbsp;Pursuant to
the amended terms of the Compensation Plan, effective June 29, 2015, the President&rsquo;s salary increased to $310,000 per year
and the CSO&rsquo;s salary is $295,000 per year.&nbsp;&nbsp;The President will also be entitled to receive up to $180,000 payable
over a three year period for tuition reimbursement.&nbsp;&nbsp;As of June 30, 2015, we accrued $121,000 for tuition reimbursement
for our President.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the agreement, both the
President and the CSO will be entitled to receive certain payments in the event their employment is terminated under certain scenarios.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each executive received options to purchase
up to 48,951 shares of our common stock (each referred to in this section as &ldquo;Executive Options&rdquo;) pursuant to the
2008 Stock Plan, which will vest based on specific performance conditions, described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Cash Bonus and Executive Options Performance
Conditions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the amended terms of the Compensation
Plan, we will review bonus opportunities annually for the President and the CSO based on achievement of specific performance as
determined by us.&nbsp;&nbsp;The initial target bonus opportunities are 40% and 35% of the base salary for the President and the
CSO, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Compensation Plan, each covered
executive is entitled to the following cash payments and vests in Executive Options upon the satisfaction of the events described
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>FDA
                                         Meeting Bonus Opportunities</I>.&nbsp;&nbsp;&nbsp;In April&nbsp;2013, each executive
                                         received a one-time cash bonus of&thinsp; $10,000 for a milestone associated with
                                         meeting with the FDA regarding RP-G28&rsquo;s path to FDA approval. In addition,
                                         2,360 shares of the Executive Options vested and became exercisable as of the grant date
                                         of September&nbsp;25, 2013. The balance of 1,136 shares vests ratably on a monthly
                                         basis beginning on September&nbsp;30, 2013.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Clinical
                                         Trial Funding Commitment Bonus Opportunities</I>.&nbsp;&nbsp;&nbsp;Each executive is
                                         entitled to receive a one-time cash bonus of&thinsp; $75,000 upon our receipt of a commitment
                                         by a third party to fund a Phase 2 or later clinical trial; provided, however, that no
                                         such bonus may be paid at any time we have less than $2,000,000 in available cash. In
                                         addition, upon the satisfaction of this milestone, 35% of 10,489 shares of the Executive
                                         Options will vest and become exercisable, with the balance of the 10,489 shares vesting
                                         in 36 equal monthly installments beginning on the last day of the following month. Each
                                         executive satisfied this performance condition on June 29, 2015 and was entitled to receive
                                         a bonus of $75,000.&nbsp;&nbsp;In addition, 3,671 shares of the Executive Options vested
                                         and became exercisable as of June 29, 2015, with the balance of 6,818 shares vests ratably
                                         on a monthly basis beginning July 31, 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Fundraising
                                         Bonus Opportunities</I>.&nbsp;&nbsp;&nbsp;Each executive is entitled to receive (i) a
                                         one-time cash bonus of&thinsp; $50,000 upon the sale of additional equity capital for
                                         cash, in one or more closings after July&nbsp;17, 2012, and/or the actual deployment
                                         of funds by a third party for a clinical trial in an aggregate amount in excess of&thinsp;
                                         $2,000,000 and (ii) a one-time cash bonus of&thinsp; $150,000 upon the sale of additional
                                         equity capital for cash, in one or more closings after July&nbsp;17, 2012 and/or the
                                         actual deployment of funds by a third party for a clinical trial in an aggregate amount
                                         in excess of $10,000,000 (which such bonus will be reduced by any cash bonus paid under
                                         subsection (i)); provided, however, that no bonus under subsection (i) or (ii) may be
                                         paid at any time we have less than $2,000,000 in available cash. In addition, upon the
                                         satisfaction of the milestone described in subsection (i), 35% of 6,993 shares of the
                                         Executive Options will vest and become exercisable, with the balance of the 6,993 shares
                                         vesting in 36 equal monthly installments beginning on the last day of the following month,
                                         and, upon satisfaction of the milestone described in subsection (ii), 35% of 13,986 shares
                                         of the Executive Options will vest and become exercisable, with the balance of the 13,986
                                         shares vesting in 36 monthly installments beginning on the last day of the following
                                         month.&nbsp;&nbsp;Upon the closing of the initial public offering on June 29, 2015 raising
                                         approximately $17.4 million, net of offering costs, each executive was entitled to receive
                                         a bonus of $150,000.&nbsp;&nbsp;In addition, 4,895 shares of the Executive Options vested
                                         and became exercisable as of June 29, 2015, with the balance of 9,091 shares vests ratably
                                         on a monthly basis beginning July 31, 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>License
                                         Event Bonus Opportunities</I>.&nbsp;&nbsp;&nbsp;Each executive is entitled to receive
                                         the following bonus payments in connection with the closing of an exclusive license of
                                         RP-G28 and/or any future product candidate developed by our company from time to time
                                         during the term of the Compensation Plan by an/or any option to exclusively license such
                                         product candidate to a third party (referred to under the Compensation Plan as a &ldquo;License
                                         Event&rdquo;) with a minimum upfront payment to us of&thinsp; $2,000,000:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">A
                                         graduated cash bonus equal to (i) 5% of the Initial Period License Payment (as defined
                                         below) up to $5,000,000; (ii) 4% of the Initial Period License Payment in excess of&thinsp;$5,000,000
                                         up to $10,000,000; and (iii) 3% of the Initial Period License Payment in excess of $10,000,000.
                                         In addition, upon our receipt of an Initial Period License Payment of more than $2,000,000,
                                         35% of 45,454 shares of their Executive Options will vest and become exercisable, with
                                         the balance of the 45,454 shares vesting in 36 monthly installments beginning on the
                                         last day of the following month.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">A
                                         cash bonus equal to 3% of any Annual Excess Milestone Payments (as defined below); provided,
                                         however that no such bonus may be paid at any time we have less than $1,000,000 in available
                                         cash. In addition, upon our receipt of an Annual Excess Milestone Payment, 35% of 6,993
                                         shares of their Executive Options will vest and become exercisable, with the balance
                                         of the 6,993 shares vesting in 36 monthly installments beginning on the last day of the
                                         following month.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding any of the vesting provisions
set forth above, the total potential number of Executive Options that may vest will not exceed 48,951 and the Executive Options
will automatically terminate for any options for which a vesting date or performance condition has not been met by September&nbsp;25,
2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of the Compensation Plan, the
term &ldquo;<I>Initial Period License Payment</I>&rdquo; means the aggregate amount in cash received by us (not including any
amount placed in escrow or subject to earn-outs, contingencies or other deferrals or earmarked to pay or reimburse us for research
and development activities) in respect of the License Event over a 24 month period beginning on the closing date of such License
Event (which period is referred to therein as the &ldquo;<I>Initial Period</I>&rdquo;). The term &ldquo;<I>Annual Excess Milestone
Payments</I>&rdquo; means the amount in cash in excess of&thinsp; $2,000,000 (not including any amounts placed in escrow or subject
to earn-outs, contingencies or other deferrals) that is received by us in respect of any Post-Closing Milestones (as defined below)
in each 12-month period beginning on the expiration of the Initial Period. The term &ldquo;<I>Post-Closing Milestones</I>&rdquo;
means any post-closing payouts set forth in the definitive transaction documentation executed in connection with a License Event;
provided, however, that such amounts will not include any amounts that are determined by the Board of Directors to comprise all
or any portion of any upfront payment made in connection with a License Event and any royalty payment based on product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Plan provides that in the
event that we enter into more than one License Event with respect to a single product candidate (i.e., for a separate field of
use), then the proceeds of any such additional License Event will be included with the proceeds of the original License Event
for purposes of meeting any of the financial</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">thresholds set forth above. Under the terms
of the Compensation Plan, receipt by the Company of more than one&nbsp;<I>bona fide</I>&nbsp;term sheet for a proposed License
Event with respect to RP-G28 will result in the payment of an additional 10% of any cash bonus earned as Clinical Trial and Fundraising
Bonus or a License Event Bonus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the Compensation Plan,
each executive is entitled to receive certain payments in the event their employment is terminated under certain scenarios.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December&nbsp;2, 2014, pursuant to the
2008 plan, we granted an aggregate of 453,413 options to the President and the CSO to purchase our common stock listed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">20,979 fully vested options with
                                         an exercise price of&thinsp; $5.86; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">432,434 options which vest 25%
                                         upon the first anniversary of the vesting commencement date with the remaining options
                                         vesting monthly in equal amounts over 36 months with an exercise price equal to $5.86
                                         for the first 152,347 options covered thereby, $9.30 for the next 140,044 options covered
                                         thereby, and $13.23 for the remaining balance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, all non-employee directors will
each be initially entitled to receive an option to acquire 1,398 shares of our common stock, which will vest annually over a three-year
term from the grant date, and annually thereafter be entitled to receive an option to acquire 979 shares of our common stock,
each of which will vest one year from the grant date.&nbsp;&nbsp;As of June 30, 2015, no stock based compensation or cash compensation
has been granted to the directors under this program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Research and Development Arrangement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective July 24, 2015, we entered into an
<FONT STYLE="color: black">amended Clinical Supply and Cooperation Agreement (the &ldquo;Amended Supply Agreement&rdquo;) with
Ricerche Sperimentali Montale SpA (&ldquo;Ricerche&rdquo;) and Inalco SpA (collectively, &ldquo;RSM&rdquo;). The Amended Supply
Agreement amends certain terms of the Clinical Supply and Cooperation Agreement, dated December 16, 2009, amended on September
25, 2010 (the &ldquo;Existing Supply Agreement&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Existing Supply Agreement, RSM granted
us an exclusive worldwide option in a specified field and territory to assignment of all right, title and interest to a purified&nbsp;Galacto-oligosaccharides
product (&ldquo;Improved GOS&rdquo;), the composition of matter of the Improved GOS and any information relating to the Improved
GOS, including certain specified technical information and other intellectual property rights (the &ldquo;Improved GOS IP&rdquo;).&nbsp;&nbsp;Pursuant
to the amended terms, we may exercise the option by paying RSM $800,000 within ten days after the effective date of the Amended
Supply Agreement. We exercised the option on July 30, 2015 and RSM is transferring the Improved GOS IP to us. Under the terms
of the existing agreement, if a further option payment due in the future is not made, we may be required to return the Improved
GOS IP to RSM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Amended Supply Agreement also provides
that&nbsp;we must pay RSM $400,000 within 10 days following FDA approval of a new drug application for the first product owned
or controlled by us using Improved GOS as its active pharmaceutical ingredient.&nbsp;&nbsp;In addition,
we agreed to purchase 350 kilos of Improved GOS for the sum of $250 per kilo for clinical supply of Improved GOS instead of $2,000
per kilo as under the Existing Supply Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for RSM entering into the
Amended Supply Agreement, we will issue 100,000 shares of our common stock, par value $0.001 per share (the &ldquo;Shares&rdquo;),
to RSM. The Shares are to be issued within 90 days of the effective date of the Amended Supply Agreement pursuant to a stock purchase
agreement to be negotiated by the parties in good faith. The stock purchase agreement is to include a lock-up agreement by RSM
in favor of us pursuant to which RSM will not be able to sell the Shares for a period ending on the earlier of (i) the public
release by us of the final results of our Phase 2b/3 clinical trial of RP-G28 and (ii) the filing of our Form 10-Q with the Securities
and Exchange Commission for the fiscal quarter in which we receive the results of our Phase 2b/3 clinical trial of RP-G28.&nbsp;&nbsp;We
have not issued the shares to RSM as of August 4, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through June 30, 2015, we do not have any
off-balance sheet arrangements, as defined by applicable under Securities and Exchange Commission regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_008"></A><B>ITEM 3. QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a &ldquo;smaller reporting company&rdquo;
as defined by Item 10 of Regulation S-K, we are not required to provide the information required by Item 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_009"></A><B>ITEM 4. CONTROLS AND
PROCEDURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our management, with the participation of
our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures
as of June 30, 2015, the end of the period covered by this Quarterly Report on Form 10-Q.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on our evaluation, we believe that
our disclosure controls and procedures as of June 30, 2015 were effective to provide reasonable assurance that the
information required to be disclosed by us in reports filed under the Exchange Act is recorded, processed, summarized and
reported within the time periods specified in the SEC&rsquo;s rules and forms, and that such information is accumulated and
communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow
timely decisions regarding required disclosure. We believe that a controls system, no matter how well designed and operated,
cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can
provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Changes in Internal Control over Financial
Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no changes in our internal control
over financial reporting that occurred during our second fiscal quarter ended June 30, 2015 that have materially affected, or
are reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_010"></A><B>PART II &mdash; OTHER
INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_011"></A><B>Item&nbsp;1. Legal
Proceedings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is not currently involved in any
legal matters arising in the normal course of business. From time to time, the Company could become involved in disputes and various
litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual
property, licensing, contract law and employee relations matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_012"></A><B>Item 1A. Risk Factors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This section discusses risk factors that may affect our business,
operations, and financial condition. If any of these risks, as well as other risks and uncertainties that we have not yet identified
or that we currently think are not material, actually occur, we could be materially adversely affected and the value of our common
stock could decline. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Relating to Our Financial Position
and Need for Additional Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have incurred net losses in each
year since our inception. Currently, we have no products approved for commercial sale. As a result, our ability to reduce our
losses and reach profitability is unknown, and we may never achieve or sustain profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have incurred net losses in each year since
our inception. The accompanying financial statements have been prepared assuming that we will continue as a going concern, which
contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business.
We had net losses of approximately $3.5 million and $677,000 for the six months ended June 30, 2015 and 2014, respectively, and
had net cash used in operating activities of approximately $894,000 and $584,000 for the six months ended June 30, 2015 and 2014,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, we have devoted most of our financial
resources to our corporate overhead and research and development, including our drug discovery research, preclinical development
activities and clinical trials. We currently have no products that are approved for commercial sale. We expect to continue to
incur net losses and negative operating cash flow for the foreseeable future, and we expect these losses to increase as we continue
our development of, and seek regulatory approvals for, RP-G28, and other product candidates, prepare for and begin the commercialization
of any approved products, and add infrastructure and personnel to support our product development efforts and operations as a
public company. We anticipate that any such losses could be significant for the next several years as we begin our Phase 2b/3
and any Phase 3 clinical trials for RP-G28 for the reduction of symptoms associated with lactose intolerance and related activities
required for regulatory approval of RP- G28. If RP-G28 or any of our other product candidates fails in clinical trials or does
not gain regulatory approval, or if our product candidates do not achieve market acceptance, we may never become profitable. These
net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&rsquo; equity and
working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because of the numerous risks and uncertainties
associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses
or when, or if, we will be able to achieve profitability. In addition, our expenses could increase if we are required by the FDA
or the EMA, to perform studies or trials in addition to those currently expected, or if there are any delays in completing our
clinical trials or the development of our product candidates. The amount of future net losses will depend, in part, on the rate
of future growth of our expenses and our ability to generate revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will require substantial additional
funding, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit,
reduce or cease our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are currently advancing RP-G28 through
clinical development. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive.
As of June 30, 2015, we have a total of approximately $19.7 million in cash. In addition to our currently available funds, we
will need to secure additional financing following our initial public offering in order
to complete clinical development and commercialize RP-G28 and to fund our operations generally. For instance, to complete the
work necessary to file a new drug application, or NDA, and a Marketing Authorization Application, or MAA, for RP-G28 as a treatment
for patients with lactose intolerance, which is currently anticipated to occur in 2019, we estimate that our RP-G28 clinical trials,
and our planned clinical and nonclinical studies, as well as other work needed to submit RP-G28 for regulatory approval in the
United States, Europe and other countries, will cost approximately $85 million, including the internal resources needed to manage
the program. If the FDA or EMA requires that we perform additional nonclinical studies or clinical trials, our expenses would
further increase beyond what we currently expect and the anticipated timing of any potential NDA or MAA would likely be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to use substantially all of the
net proceeds from our recent initial public offering to fund (i) the continued clinical development of RP-G28 for the reduction
of symptoms associated with lactose intolerance in patients, including implementing a Phase 2b/3 clinical trial and non-clinical
development, (ii) expenses associated with the manufacture and product development of RP-G28, and (iii) the exploration of potential
therapeutic indications and orphan indications. Any remaining amounts will be used for general corporate purposes, general and
administrative expenses, capital expenditures, working capital and prosecution and maintenance of our intellectual property. As
such, the expected net proceeds from our initial public offering will not be sufficient to complete the clinical development of
RP-G28, or any product candidates we may develop in the future. Accordingly, we will continue to require substantial additional
capital beyond the expected proceeds of our initial public offering to continue our clinical development and commercialization
activities. Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds
we will require to complete research and development and commercialize RP-G28, and any other product candidates we may develop
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amount and timing of our future funding
requirements will depend on many factors, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         progress, costs, results of and timing of implementing a Phase 2b/3 clinical trial for
                                         RP-G28 for the reduction of symptoms associated with lactose intolerance in patients;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         willingness of the EMA or other regulatory agencies outside the United States to accept
                                         our Phase 2b/3 and any Phase 3 trials of RP-G28, as well as our other completed and planned
                                         clinical and nonclinical studies and other work, as the basis for review and approval
                                         of RP-G28 in the European Union for the reduction of symptoms associated with lactose
                                         intolerance in patients;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         outcome, costs and timing of seeking and obtaining FDA, EMA and any other regulatory
                                         approvals;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         number and characteristics of product candidates that we pursue, including our product
                                         candidates in preclinical development;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         ability of our product candidates to progress through clinical development successfully;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         need to expand our research and development activities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         costs associated with securing and establishing commercialization and manufacturing capabilities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">market
                                         acceptance of our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         costs of acquiring, licensing or investing in businesses, products, product candidates
                                         and technologies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to maintain, expand and defend the scope of our intellectual property portfolio,
                                         including the amount and timing of any payments we may be required to make, or that we
                                         may receive, in connection with the licensing, filing, prosecution, defense and enforcement
                                         of any patents or other intellectual property rights;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         need and ability to hire additional management and scientific and medical personnel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         effect of competing technological and market developments;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         need to implement additional internal systems and infrastructure, including financial
                                         and reporting systems; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         economic and other terms, timing of and success of our existing licensing arrangements
                                         and any collaboration, licensing or other arrangements into which we may enter in the
                                         future.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Some of these factors are outside of our control.
Based upon our currently expected level of operating expenditures, we believe that we will be able to fund our operations through
at least through the first quarter of 2017. This period could be shortened if there are any significant
increases in planned spending on development programs or more rapid progress of development programs than anticipated. We do not
expect our existing capital resources along with the intended net proceeds from our initial public offering, to be sufficient
to enable us to complete the commercialization of RP-G28, if approved, or to initiate any clinical trials or additional development
work for other product candidates, other than as described above. See also &ldquo;Use of Proceeds.&rdquo; Accordingly, we expect
that we will need to raise additional funds in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may seek additional funding through a combination
of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements
and other collaborations, strategic alliances and licensing arrangements. Additional funding may not be available to us on acceptable
terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the extent that the Company raises additional
funds by issuing equity securities, the Company&rsquo;s stockholders may experience significant dilution. Any debt financing,
if available, may involve restrictive covenants that impact the Company&rsquo;s ability to conduct business. If the Company is
not able to raise additional capital when required or on acceptable terms, the Company may have to (i) significantly delay, scale
back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product
candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be
available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that the Company
would otherwise seek to develop or commercialize. In addition, the terms of any financing may adversely affect the holdings or
the rights of our stockholders and the issuance of additional shares by us, or the possibility of such issuance, may cause the
market price of our shares to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we are unable to obtain funding on a timely
basis, we may be required to significantly curtail one or more of our research or development programs. We also could be required
to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to some of
our technologies or product candidates or otherwise agree to terms unfavorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our financial condition and operating
results have varied significantly since our formation and are expected to continue to fluctuate significantly from quarter-to-quarter
or year-to-year due to a variety of factors, many of which are beyond our control.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operations since 2010 have been limited
to developing our technology and undertaking preclinical studies and clinical trials of our lead product candidate, RP-G28. We
have not yet obtained regulatory approvals for RP-G28, or any other product candidate. Consequently, any predictions made about
our future success or viability may not be as accurate as they could be if we had approved products on the market. Our financial
condition and operating results have varied significantly since our formation and are expected to continue to significantly fluctuate
from quarter-to-quarter or year-to-year due to a variety of factors, many of which are beyond our control. Factors relating to
our business that may contribute to these fluctuations include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any
                                         delays in regulatory review and approval of our product candidates in clinical development,
                                         including our ability to receive approval from the FDA and the EMA for RP-G28 for the
                                         reduction of symptoms associated with lactose intolerance in patients based on our Phase
                                         2b/3 and any Phase 3 trials of RP-G28, and our other completed and planned clinical and
                                         nonclinical studies and other work, as the basis for review and approval of RP-G28 for
                                         the reduction of symptoms associated with lactose intolerance in patients;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">delays
                                         in the commencement, enrollment and timing of clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">difficulties
                                         in identifying and treating patients suffering from our target indications;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         success of our clinical trials through all phases of clinical development, including
                                         our Phase 2b/3 and any Phase 3 trials of RP-G28 for the reduction of symptoms associated
                                         with lactose intolerance in patients;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">potential
                                         side effects of our product candidates that could delay or prevent approval or cause
                                         an approved drug to be taken off the market;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to obtain additional funding to develop our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to identify and develop additional product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">market
                                         acceptance of our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to establish an effective sales and marketing infrastructure directly or through
                                         collaborations with third parties;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">competition
                                         from existing products or new products that may emerge;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         ability of patients or healthcare providers to obtain coverage or sufficient reimbursement
                                         for our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to adhere to clinical study requirements directly or with third parties such
                                         as contract research organizations, or CROs;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         dependency on third-party manufacturers to manufacture our products and key ingredients;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to establish or maintain collaborations, licensing or other arrangements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         costs to us, and our ability and our third-party collaborators&rsquo; ability to obtain,
                                         maintain and protect our intellectual property rights;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">costs
                                         related to and outcomes of potential intellectual property litigation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to adequately support future growth;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to attract and retain key personnel to manage our business effectively; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">potential
                                         product liability claims.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accordingly, the results of any quarterly
or annual periods should not be relied upon as indications of future operating performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Relating to Regulatory Review and
Approval of Our Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are substantially dependent on the
success of our current product candidate, RP-G28.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have no products approved for
sale and we cannot guarantee that we will ever have marketable products. We currently invest nearly all of our efforts and financial
resources in the research and development of RP-G28, which is currently our only product candidate. Our business currently depends
entirely on the successful development and commercialization of RP-G28.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We cannot be certain that RP-G28 will
receive regulatory approval, and without regulatory approval we will not be able to market RP-G28 as a prescription drug.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The development of a product candidate and
issues relating to its approval and marketing are subject to extensive regulation by the FDA in the United States, the EMA in
Europe, and regulatory authorities in other countries, with regulations differing from country to country. We are not permitted
to market our product candidates in the United States or Europe until we receive approval of a NDA from the FDA or a MAA from
the EMA, respectively. We have not submitted any marketing applications for RP-G28.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NDAs and MAAs must include extensive preclinical
and clinical data and supporting information to establish the product candidate&rsquo;s safety and effectiveness for each desired
indication. NDAs and MAAs must also include significant information regarding the chemistry, manufacturing and controls for the
product. Obtaining approval of a NDA or a MAA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining
approval. The FDA and the EMA review processes can take years to complete and approval is never guaranteed. If we submit a NDA
to the FDA, the FDA must decide whether to accept or reject the submission for filing. We cannot be certain that any submissions
will be accepted for filing and review by the FDA. Regulators of other jurisdictions, such as the EMA, have their own procedures
for approval of product candidates. Even if a product is approved, the FDA or the EMA, as the case may be, may limit the indications
for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming
clinical trials or reporting as conditions of approval. Regulatory authorities in countries outside of the United States and Europe
also have requirements for approval of drug candidates with which we must comply prior to marketing in those countries. Obtaining
regulatory approval for marketing of a product candidate in one country does not ensure that we will be able to obtain regulatory
approval in any other country. In addition, delays in approvals or rejections of marketing applications in the United States,
Europe or other countries may be based upon many factors, including regulatory requests for</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">additional analyses, reports, data, preclinical
studies and clinical trials, regulatory questions regarding different interpretations of data and results, changes in regulatory
policy during the period of product development and the emergence of new information regarding our product candidates or other
products. Also, regulatory approval for any of our product candidates may be withdrawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have completed one Phase 2a trial for RP-G28.
Before we submit a NDA to the FDA or a MAA to the EMA for RP-G28 for the treatment of pain and the reduction in the frequency
of symptomatic episodes of lactose intolerance, we must successfully complete a Phase 2b/3 trial and Phase 3 trials. Following
analysis of the Phase 2a clinical trial, discussions with the FDA during the Type C meeting in 2013 about our clinical development
plan, and further discussions with our regulatory consultants, we intend to conduct our planned Phase 2b clinical trial as an
adaptive design Phase 2b/3 clinical trial. A trial that is designed as an adaptive seamless clinical trial refers to a trial that
combines the objectives of what are typically separate trials into a single uninterrupted trial with multiple objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Neither the FDA nor any other comparable governmental
agency has considered this Phase 2b/3 study or our current development plan for RP-G28, and we do not intend to request a meeting
with the FDA to discuss these matters. Regulatory authorities in the United States and Europe have both published guidance documents
on the use and implementation of adaptive design trials. These documents include description of adaptive trials and include a
requirement for prospectively written standard operating procedures and working processes for executing adaptive trials and a
recommendation that sponsor companies engage with CROs that have the necessary experience in running such trials. In addition,
the regulations governing INDs are extensive and involve numerous notification requirements including that, generally, an IND
supplement must be submitted to and cleared by the FDA before a sponsor or an investigator may make any change to the investigational
plan that may affect its scientific soundness or the rights, safety or welfare of human subjects. We intend to comply with these
requirements and believe we will need to submit an IND supplement containing amended protocols for the Phase 2b/3 adaptive trial.
There can be no assurance that the FDA will provide clearance for an amended IND for a Phase 2b/3 trial in a timely manner, if
at all, and that this trial and other trials will not be delayed or disrupted as a result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, guidelines adopted by the FDA
and established by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals
for Human Use (ICH) require nonclinical studies that specifically address female fertility to be completed before the inclusion
of women of child bearing potential in large-scale or long-duration clinical trials (e.g., Phase 3 trials). In the United States,
such assessments of embryo-fetal development can be deferred until before Phase 3 using precautions to prevent pregnancy in clinical
trials. As the FDA recommended in their June 28, 2010 advice letter, we will continue to evaluate females of child-bearing potential
who are willing to use appropriate contraception throughout the duration of any study. To support any Phase 3 study, we plan to
perform ICH-compliant embryo- fetal developmental toxicology studies (in two species) and the ICH-recommended standard battery
of genotoxicity tests using RP-G28. We also intend to perform work on the characterization of compounds and analytical specifications
for RP-G28. The design of our Phase 2b/3 trial will need to account for these FDA and ICH requirements, and we may need to complete
all nonclinical studies that specifically address female fertility before we complete a Phase 2b/3 clinical trial. We cannot predict
whether our future trials and studies will be successful or whether regulators will agree with our conclusions regarding the preclinical
studies and clinical trials we have conducted to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we are unable to obtain approval from the
FDA, the EMA or other regulatory agencies for RP-G28, or if, subsequent to approval, we are unable to successfully commercialize
RP-G28, we will not be able to generate sufficient revenue to become profitable or to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any statements in this document indicating
that RP-G28 has demonstrated preliminary evidence of efficacy are our own and are not based on the FDA&rsquo;s or any other comparable
governmental agency&rsquo;s assessment of RP- G28 and do not indicate that RP-G28 will achieve favorable efficacy results in any
later stage trials or that the FDA or any comparable agency will ultimately determine that RP-G28 is effective for purposes of
granting marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The FDA and other regulatory agencies
outside the United States, such as the EMA, may not agree to our proposed endpoint for approval of RP-G28 for the reduction of
symptoms associated with lactose intolerance in patients, in which case we would need to complete an additional clinical trial
in order to seek approval outside the United States.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During our Type C Meeting with the FDA in
February 2013, we had proposed that future studies with RP- G28 in subjects with lactose intolerance would utilize a total lactose
intolerance symptom score, measured by a patient reporting instrument that we were going to develop, as the primary, stand-alone
endpoint. However, based on RP-G28&rsquo;s mechanism of action, data from the Phase 2a clinical study, further research conducted
after the Type C Meeting with the FDA along with FDA guidance and products under the review of the Division of Gastroenterology
and Inborn Errors Products, we now intend to use abdominal pain, measured by an 11-point validated scale, as the primary endpoint
for the Phase 2b/Phase 3 study that assesses RP-G28 for the management of lactose intolerant patients with moderate to severe
abdominal pain associated with lactose intake. We believe that evaluation of abdominal pain is a reliable clinical assessment
of treatment response and treatment benefit in a lactose intolerant patient. Although no FDA-approved product exists for lactose
intolerance, the use of a pain scale as a primary endpoint has been used as a validated primary measurement in many approved products,
including other gastrointestinal products used to treat diseases such as Irritable Bowel Syndrome (IBS). We have not consulted
with the FDA about our intent to use abdominal pain as a primary endpoint or our plan to convert our Phase 2b clinical trial into
an adaptive design Phase 2b/3 pivotal clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not know if the FDA, the EMA or regulatory
authorities in other countries will agree with our final primary endpoint for approval of RP-G28. The FDA, the EMA and regulatory
authorities in other countries in which we may seek approval for and market RP-G28, may require additional nonclinical studies
and/or clinical trials prior to granting approval. It may be expensive and time consuming to conduct and complete additional nonclinical
studies and clinical trials that the EMA and other regulatory authorities may require us to perform. As such, any requirement
by the EMA or other regulatory authorities that we conduct additional nonclinical studies or clinical trials could materially
and adversely affect our business, financial condition and results of operations. Furthermore, even if we receive regulatory approval
of RP-G28 for the reduction of symptoms associated with lactose intolerance in patients, the labeling for RP-G28 in the United
States, Europe or other countries in which we seek approval may include limitations that could impact the commercial success of
RP-G28.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The results from our planned Phase 2b/3
trial with adaptive design may not be sufficiently robust to support the submission of marketing approval for RP-G28.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to conduct our planned Phase 2b
clinical trial as an adaptive design seamless Phase 2b/3 clinical trial. We do not intend to meet with the FDA to discuss the
Phase 2b/3 study design or current development plan for RP-G28. The FDA standard for traditional approval of a drug generally
requires two well-controlled Phase 3 studies. If the FDA disagrees with our choice of primary endpoint for our Phase 2b/3 trial
or the results for the primary endpoint are not robust or significant relative to control, are subject to confounding factors,
or are not adequately supported by other study endpoints, the FDA may not recognize the Phase 2b/3 trial as one of the required
pivotal trials required for FDA approval. If the FDA or other regulatory authorities do not recognize this trial as a pivotal
trial, we would incur increased costs and delays in the marketing approval process, which would require us to expend more resources
than we have available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Delays in the commencement, enrollment
and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval
for RP-G28 or our other product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Delays in the commencement, enrollment and
completion of clinical trials could increase our product development costs or limit the regulatory approval of RP-G28 or other
product candidates we may develop in the future. Although we anticipate that the net proceeds from our initial public offering,
together with existing cash, and interest on our cash balances, will be sufficient to fund our projected operating requirements
through the completion of the Phase 2b/3 and any Phase 3 trials of RP-G28, we may not be able to complete these trials on time
or we may be required to conduct additional clinical trials or nonclinical studies not currently planned to receive approval for
RP-G28 as a treatment for lactose intolerance. The commencement, enrollment and completion of clinical trials may be delayed or
suspended for a variety of reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">inability
                                         to obtain sufficient funds required for a clinical trial;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">inability
                                         to reach agreements on acceptable terms with prospective CROs and trial sites, the terms
                                         of which can be subject to extensive negotiation and may vary significantly among different
                                         CROs and trial sites;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">clinical
                                         holds, other regulatory objections to commencing or continuing a clinical trial or the
                                         inability to obtain regulatory approval to commence a clinical trial in countries that
                                         require such approvals;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">discussions
                                         with the FDA or non-U.S. regulators regarding the scope or design of our clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">inability
                                         to identify and maintain a sufficient number of trial sites, many of which may already
                                         be engaged in other clinical trial programs, including some that may be for the same
                                         indications targeted by our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">inability
                                         to obtain approval from institutional review boards, or IRBs, to conduct a clinical trial
                                         at their respective sites;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">severe
                                         or unexpected drug-related adverse effects experienced by patients;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">inability
                                         to timely manufacture sufficient quantities of the product candidate required for a clinical
                                         trial;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">difficulty
                                         recruiting and enrolling patients to participate in clinical trials for a variety of
                                         reasons, including meeting the enrollment criteria for our study and competition from
                                         other clinical trial programs for the same indications as our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">inability
                                         to get FDA approval of our end points; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">inability
                                         to retain enrolled patients after a clinical trial is underway.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Changes in regulatory requirements and guidance
may also occur and we may need to amend clinical trial protocols to reflect these changes with appropriate regulatory authorities.
Amendments may require us to resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing
or successful completion of a clinical trial. In addition, a clinical trial may be suspended or terminated at any time by us,
our future collaborators, the FDA or other regulatory authorities due to a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         failure or the failure of our potential future collaborators to conduct the clinical
                                         trial in accordance with regulatory requirements or our clinical protocols;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">unforeseen
                                         safety issues or any determination that a clinical trial presents unacceptable health
                                         risks;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">lack
                                         of adequate funding to continue the clinical trial due to unforeseen costs or other business
                                         decisions; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a
                                         breach of the terms of any agreement with, or for any other reason by, future collaborators
                                         who have responsibility for the clinical development of our product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, if we or any of our potential
future collaborators are required to conduct additional clinical trials or other nonclinical studies of our product candidates
beyond those contemplated, our ability to obtain regulatory approval of these product candidates and to generate revenue from
their sales would be similarly harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Clinical failure can occur at any stage
of clinical development. The results of earlier clinical trials are not necessarily predictive of future results and any product
candidate we or our potential future collaborators advance through clinical trials may not have favorable results in later clinical
trials or receive regulatory approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Clinical failure can occur at any stage of
our clinical development. Clinical trials may produce negative or inconclusive results, and we or our collaborators may decide,
or regulators may require us, to conduct additional clinical trials or nonclinical studies. In addition, data obtained from trials
and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which
may delay, limit or prevent regulatory approval. Success in preclinical studies and early clinical trials does not ensure that
subsequent clinical trials will generate the same or similar results or otherwise provide adequate data to demonstrate the efficacy
and safety of a product candidate. A number of companies in the pharmaceutical industry, including those with greater resources
and experience than us, have suffered significant setbacks in Phase 2b and/or Phase 3 clinical trials, including adaptive seamless
clinical trials even after seeing promising results in earlier clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the design of a clinical trial
can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become
apparent until the clinical trial is well-advanced. We may be unable to design and execute a clinical trial to support regulatory
approval. Further, clinical trials of potential products often reveal that it is not practical or feasible to continue development
efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If RP-G28, or any of our other product candidates,
is found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for it and our business would be harmed.
For example, if the results of our Phase 2b/3 and any Phase 3 trials of RP-G28 do not achieve the primary efficacy endpoints or
demonstrate expected safety, the prospects for approval of RP-G28 would be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In some instances, there can be significant
variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors,
including changes in trial protocols, differences in composition of the patient populations, adherence to the dosing regimen and
other trial protocols and the rate of dropout among clinical trial participants. We do not know whether any Phase 2, Phase 3 or
other clinical trials we or any of our potential future collaborators may conduct will demonstrate the consistent or adequate
efficacy and safety that would be required to obtain regulatory approval and market RP-G28. The adaptive Phase 2b/3 clinical trial
for RP-G28 that we intend to conduct may not be deemed to be a pivotal trial by the FDA or may not provide sufficient support
for NDA approval. The FDA may require us to make changes to the proposed study design for this adaptive trial or may require us
to conduct one or more additional clinical trials, possibly involving a larger sample size or a different clinical trial design,
or may require longer follow-up periods, particularly if the FDA does not find the results from an adaptive Phase 2b/3 clinical
trial to be sufficiently persuasive as one of the required pivotal trials required for FDA approval. If we are unable to bring
RP-G28 to market, our ability to create long-term stockholder value will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our product candidates may have undesirable
side effects which may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market,
require them to include safety warnings or otherwise limit their sales.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unforeseen side effects from RP-G28, or other
product candidates we may develop in the future, could arise either during clinical development or, if approved, after the approved
product has been marketed. The most common side effects observed in clinical trials of RP-G28 were headache (nine out of 57),
nausea (three out of 57), upper respiratory tract infection, nasal congestion, and pain (two out of 57). No patients were withdrawn
from the study for these side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The results of future clinical trials may
show that RP-G28 causes undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result
in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval
from the FDA and other regulatory authorities with restrictive label warnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If RP-G28, or any other product candidate
we develop in the future, receives marketing approval and we or others later identify undesirable or unacceptable side effects
caused by such product:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory
                                         authorities may require the addition of labeling statements, specific warnings, a contraindication
                                         or field alerts to physicians and pharmacies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                         may be required to change instructions regarding the way the product is administered,
                                         conduct additional clinical trials or change the labeling of the product;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                         may be subject to limitations on how we may promote the product;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">sales
                                         of the product may decrease significantly;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory
                                         authorities may require us to take our approved product off the market;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                         may be subject to litigation or product liability claims; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         reputation may suffer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any of these events could prevent us or our
potential future collaborators from achieving or maintaining market acceptance of the affected product or could substantially
increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from
the sale of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Reimbursement decisions by third-party
payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products,
it is less likely that they will be widely used.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Market acceptance and sales of RP-G28, or
any other product candidates we develop in the future, if approved, will depend on reimbursement policies and may be affected
by, among other things, future healthcare reform measures. Government authorities and third-party payors, such as private health
insurers and health maintenance organizations, decide which drugs they will cover and establish payment levels. We cannot be certain
that reimbursement will be available for RP-G28 or any other product candidates that we may develop. Also, we cannot be certain
that reimbursement policies will not reduce the demand for, or the price paid for, our products. If reimbursement is not available
or is available on a limited basis, we may not be able to successfully commercialize RP-G28, or other product candidates that
we develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, the Medicare Prescription
Drug, Improvement, and Modernization Act of 2003, or MMA, changed the way Medicare covers and pays for pharmaceutical products.
The legislation established Medicare Part D, which expanded Medicare coverage for outpatient prescription drug purchases by the
elderly but provided authority for limiting the number of drugs that will be covered in any therapeutic class. The MMA also introduced
a new reimbursement methodology based on average sales prices for physician-administered drugs. Any negotiated prices for our
products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain in the United
States. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare
coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA
may result in a similar reduction in payments from non-governmental payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The United States and several other jurisdictions
are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in
ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere,
there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs,
improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular
focus of these efforts and has been significantly affected by major legislative initiatives. We expect to experience pricing pressures
in connection with the sale of RP-G28, and any other product candidates that we develop, due to the trend toward managed healthcare,
the increasing influence of health maintenance organizations and additional legislative proposals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2010, the Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or, collectively, the ACA,
became law in the United States. The goal of the ACA is to reduce the cost of health care and substantially change the way health
care is financed by both governmental and private insurers. While we cannot predict what impact on federal reimbursement policies
this legislation will have in general or on our business specifically, the ACA may result in downward pressure on pharmaceutical
reimbursement, which could negatively affect market acceptance of RP-G28 or any other product candidates that we may develop.
In addition, some members of the U.S. Congress have been seeking to overturn at least portions of the legislation and we expect
they will continue to review and assess this legislation and alternative health care reform proposals. We cannot predict whether
new proposals will be made or adopted, when they may be adopted or what impact they may have on us if they are adopted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we do not obtain protection under
the Hatch-Waxman Act and similar legislation outside of the United States by extending the patent terms and obtaining data exclusivity
for our product candidates, our business may be materially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depending upon the timing, duration and specifics
of FDA marketing approval of RP-G28, one of our U.S. patents may be eligible for a limited Patent Term Extension under the Drug
Price Competition and Patent Term Restoration Act of 1984 (which is sometimes referred to
as the &ldquo;Hatch-Waxman Act&rdquo;), provided our U.S. patent claims a method of treating lactose intolerance that is approved
by the FDA. The Hatch-Waxman Act, 35 U.S.C. &sect;156, permits a patent extension of up to five years as compensation for patent
term lost during the FDA regulatory review process. The scope of protection afforded by the patent during the extended term is
not commensurate with the scope of the unextended portion of the patent; for example, the &ldquo;rights derived&rdquo; from a
method of use patent during the extended period are &ldquo;limited to any use claimed by the patent and approved for the product.&rdquo;
35 U.S.C. &sect;156(b)(2). We may not be granted an extension because of, for example, failing to apply for the extension within
applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable statutory
and/or regulatory requirements including, for example, the requirement that the patent to be extended &ldquo;claim&rdquo; the
approved product or a method of using the approved product. Moreover, the applicable period of extension could be less than we
request. If we are unable to obtain patent term extension or if the term of any such extension is shorter than we request, the
period during which we will be able to exclude others from marketing their versions of our product will be shortened and our competitors
may obtain approval of generic products following our patent expiration, and our revenue could be reduced, possibly materially.
Similar concerns are associated with obtaining Supplemental Protection Certificates (SPCs) of certain patents issued in Europe
and owned by Inalco, to which we have an exclusive options of assignment, based upon patent terms lost during European regulatory
review processes. In the event that we are unable to obtain any patent term extension, the issued patents for RP-G28 are expected
to expire in 2030, assuming they withstand any challenge toothier validity and/or patentability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we market products in a manner that
violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal
penalties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to FDA restrictions on marketing
of pharmaceutical products, several other types of state and federal healthcare laws, commonly referred to as &ldquo;fraud and
abuse&rdquo; laws, have been applied in recent years to restrict certain marketing practices in the pharmaceutical industry. Other
jurisdictions such as Europe have similar laws. These laws include false claims and anti-kickback statutes. If we market our products
and our products are paid for by governmental programs, it is possible that some of our business activities could be subject to
challenge under one or more of these laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Federal false claims laws prohibit any person
from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making,
or causing to be made, a false statement to get a false claim paid. The federal healthcare program anti-kickback statute prohibits,
among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for,
purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service covered by Medicare,
Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical
manufacturers on the one hand and prescribers, purchasers or formulary managers on the other. Although there are several statutory
exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors
are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be
subject to scrutiny if they do not qualify for an exemption or safe harbor. Most states also have statutes or regulations similar
to the federal anti-kickback law and federal false claims laws, which apply to items and services covered by Medicaid and other
state programs, or, in several states, apply regardless of the payor. Administrative, civil and criminal sanctions may be imposed
under these federal and state laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Over the past few years, a number of pharmaceutical
and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such
as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting inflated
average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion;
and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Any delay or disruption in the manufacture
and supply of RP-G28 may negatively impact our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not intend to manufacture the pharmaceutical
products that we plan to sell. We currently have agreements with contract manufacturers for the production of the active pharmaceutical
ingredients and the formulation of sufficient quantities of drug product for
our Phase 2b/3 and any Phase 3 trials of RP-G28 and the other trials and nonclinical studies that we believe we will need to conduct
prior to seeking regulatory approval. However, we do not have agreements for commercial supplies of RP-G28 and we may not be able
to reach agreements with these or other contract manufacturers for sufficient supplies to commercialize RP-G28 if it is approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reliance on third-party manufacturers entails
risks, to which we would not be subject if we manufactured the product candidates ourselves, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         possibility that we are unable to enter into a manufacturing agreement with a third party
                                         to manufacture our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         possible breach of the manufacturing agreements by the third parties because of factors
                                         beyond our control; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         possibility of termination or nonrenewal of the agreements by the third parties before
                                         we are able to arrange for a qualified replacement third-party manufacturer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any of these factors could cause the delay
of approval or commercialization of our product candidates, cause us to incur higher costs or prevent us from commercializing
our product candidates successfully. Furthermore, if RP-G28 or other product candidates are approved and contract manufacturers
fail to deliver the required commercial quantities of finished product on a timely basis and at commercially reasonable prices
and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially
equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose
potential revenue. It may take several years to establish an alternative source of supply for our product candidates and to have
any such new source approved by the government agencies that regulate our products. In the event we do need to identify alternative
manufacturing partners, we may have to secure licenses to manufacturing and/or purification technologies, including third-party
patent licenses, to allow us to manufacture RP-G28 that is suitable for the late-stage regulatory review process and/or adequate
to manufacture commercial quantities of RP-G28.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If the FDA and EMA and other regulatory
agencies do not approve the manufacturing facilities of our future contract manufacturers for commercial production, we may not
be able to commercialize any of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The facilities used by any contract manufacturer
to manufacture RP-G28, or other product candidates we may develop in the future, must be the subject of a satisfactory inspection
before the FDA or the regulators in other jurisdictions approve the product candidate manufactured at that facility. We are completely
dependent on these third-party manufacturers for compliance with the requirements of U.S. and non-U.S. regulators for the manufacture
of our finished products. If our manufacturers cannot successfully manufacture material that conform to our specifications and
current good manufacturing practice requirements of any governmental agency whose jurisdiction to which we are subject, our product
candidates will not be approved or, if already approved, may be subject to recalls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Even if our product candidates receive
regulatory approval, we may still face future development and regulatory difficulties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RP-G28 and any other product candidates
we develop in the future, if approved, will be subject to ongoing regulatory requirements for labeling, packaging, storage,
advertising, promotion, record-keeping and submission of safety and other post-market information. In addition, approved
products, manufacturers and manufacturers&rsquo; facilities are required to comply with extensive FDA and EMA requirements
and requirements of other similar agencies, including ensuring that quality control and manufacturing procedures conform to
current Good Manufacturing Practices, or cGMPs. As such, we and our contract manufacturers are subject to continual review
and periodic inspections to assess compliance with cGMPs. Accordingly, we and others with whom we work must continue to
expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.
We will also be required to report certain adverse reactions and production problems, if any, to the FDA and EMA and other
similar agencies and to comply with certain requirements concerning advertising and promotion for our products.
Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and
must be consistent with the information in the product&rsquo;s approved label. Accordingly, we may not promote our approved products,
if any, for indications or uses for which they are not approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a regulatory agency discovers previously
unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility
where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, it may impose restrictions
on that product or us, including requiring withdrawal of the product from the market. If our product candidates fail to comply
with applicable regulatory requirements, a regulatory agency may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">issue
                                         warning letters;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">mandate
                                         modifications to promotional materials or require us to provide corrective information
                                         to healthcare practitioners;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require
                                         us or our potential future collaborators to enter into a consent decree or permanent
                                         injunction, which can include imposition of various fines, reimbursements for inspection
                                         costs, required due dates for specific actions and penalties for noncompliance;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">impose
                                         other administrative or judicial civil or criminal penalties;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">withdraw
                                         regulatory approval;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">refuse
                                         to approve pending applications or supplements to approved applications filed by us or
                                         our potential future collaborators;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">impose
                                         restrictions on operations, including costly new manufacturing requirements; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">detain,
                                         seize and/or condemn and destroy products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Relating to the Commercialization
of Our Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Even if approved, our product candidates
may not achieve broad market acceptance among physicians, patients and healthcare payors, and as a result our revenues generated
from their sales may be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The commercial success of RP-G28, if approved,
will depend upon its acceptance among the medical community, including physicians, health care payors and patients. The degree
of market acceptance of RP-G28, or other product candidates we may develop in the future, will depend on a number of factors,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">limitations
                                         or warnings contained in our product candidates&rsquo; FDA-approved labeling;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">changes
                                         in the standard of care or availability of alternative therapies at similar or lower
                                         costs for the targeted indications for such product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">limitations
                                         in the approved clinical indications for such product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">demonstrated
                                         clinical safety and efficacy compared to other products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">lack
                                         of significant adverse side effects;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">sales,
                                         marketing and distribution support;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">availability
                                         of reimbursement from managed care plans and other third-party payors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">timing
                                         of market introduction and perceived effectiveness of competitive products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         degree of cost-effectiveness;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">availability
                                         of alternative therapies at similar or lower cost, including generics and over-the-counter
                                         products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">enforcement
                                         by the FDA and EMA of laws and rulings that prohibit the illegal sale of RP-G28 (or any
                                         other product candidate) as a dietary supplement;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         extent to which our product candidates are approved for inclusion on formularies of hospitals
                                         and managed care organizations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether
                                         our product candidates are designated under physician treatment guidelines for the treatment
                                         of or reduction of symptoms associated with the indications for which we have received
                                         regulatory approval;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">adverse
                                         publicity about our product candidates or favorable publicity about competitive products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">convenience
                                         and ease of administration of our product candidates; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">potential
                                         product liability claims.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If our product candidates are approved, but
do not achieve an adequate level of acceptance by physicians, patients, the medical community and healthcare payors, sufficient
revenue may not be generated from these products and we may not become or remain profitable. In addition, efforts to educate the
medical community and third-party payors on the benefits of our product candidates may require significant resources and may never
be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have no internal sales, distribution
and/or marketing capabilities at this time and we will have to invest significant resources to develop those capabilities or enter
into acceptable third-party sales and marketing arrangements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have no internal sales, distribution and/or
marketing capabilities at this time. To develop these capabilities, we will have to invest significant amounts of financial and
management resources, some of which will be committed prior to any confirmation that RP-G28 will be approved. For product candidates
for which we decide to perform sales, marketing and distribution functions ourselves or through third parties, we could face a
number of additional risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                         or our third-party sales collaborators may not be able to attract and build an effective
                                         marketing or sales force;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         cost of securing or establishing a marketing or sales force may exceed the revenues generated
                                         by any products; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         direct sales and marketing efforts may not be successful.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may have limited or no control over the
sales, marketing and distribution activities of these third parties. Our future revenues may depend heavily on the success of
the efforts of these third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may not be successful in establishing
and maintaining development and commercialization collaborations, which could adversely affect our ability to develop RP-G28 or
other product candidates and our financial condition and operating results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because developing pharmaceutical products,
conducting clinical trials, obtaining regulatory approval, establishing manufacturing capabilities and marketing approved products
are expensive, we may seek to enter into collaborations with companies that have more experience. Additionally, if RP-G28, or
any other product candidate we develop in the future, receives marketing approval, we may enter into sales and marketing arrangements
with third parties with respect to our unlicensed territories. If we are unable to enter into arrangements on acceptable terms,
we may be unable to effectively market and sell our products in our target markets. We expect to face competition in seeking appropriate
collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate, document and implement and they
may require substantial resources to maintain. We may not be successful in our efforts to establish and implement collaborations
or other alternative arrangements for the development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When we collaborate with a third party for
the development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the
future success of that product candidate to the third party. For example, we may relinquish the rights to RP-G28 in jurisdictions
outside of the United States. Our collaboration partner may not devote sufficient resources to the commercialization of our product
candidates or may otherwise fail in their commercialization. The terms of any collaboration or other arrangement that we establish
may not be favorable to us. In addition, any collaboration that we enter into may be unsuccessful in the development and commercialization
of our product candidates. In some cases, we may be responsible for continuing preclinical and initial clinical development of
a product candidate or research program under a collaboration arrangement, and the payment we receive from our collaboration partner
may be insufficient to cover the cost of this development. If we are unable to reach agreements with suitable collaborators for
our product candidates, we would face increased costs, we may be forced to limit the number of our product candidates we can commercially
develop or the territories in which we commercialize them and we might fail to commercialize products or programs for which a suitable collaborator cannot be found. If
we fail to achieve successful collaborations, our operating results and financial condition will be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The Company&rsquo;s pipeline of product
candidates beyond RP-G28 is limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to develop and commercialize drug
candidates in addition to RP-G28 through our research program. Even if we are successful in completing preclinical and clinical
development and receiving regulatory approval for one commercially viable drug for the treatment of one disease, we cannot be
certain that we will be able to develop and receive regulatory approval for other drug candidates for the treatment of other forms
of that disease or other diseases. If we fail to develop and commercialize RP-G28 for the reduction of symptoms associated with
lactose intolerance, we will not be successful in developing a pipeline of potential drug candidates to follow RP-G28, and our
business prospects could be significantly limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Relating to Our Business and Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may face competition from other biotechnology
and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although we know of no other drug candidates
in advanced clinical trials for treating lactose intolerance, the biotechnology and pharmaceutical industries are intensely competitive
and subject to rapid and significant technological change. We have potential competitors in the United States, Europe and other
jurisdictions, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical
and generic drug companies and universities and other research institutions. Many of these potential competitors have greater
financial and other resources, such as larger research and development staff and more experienced marketing and manufacturing
organizations. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory
approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research,
sales and marketing capabilities and collaborative arrangements in our target markets with leading companies and research institutions.
Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to
in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors,
these potential competitors may succeed in obtaining patent protection and/or FDA approval or discovering, developing and commercializing
drugs for the diseases that we are targeting before we do. Smaller or early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large, established companies. Some of the pharmaceutical and biotechnology
companies we expect to compete with include microbiome based development companies: Second Genome, Inc., Seres Health, Inc., Enterome
SA, Vedanta Biosciences, Inc., and Microbiome Therapeutics, LLC. In addition, many universities and private and public research
institutes may become active in our target disease areas. These potential competitors may succeed in developing, acquiring or
licensing on an exclusive basis, technologies and drug products that are more effective or less costly than RP-G28 or any other
product candidates that we are currently developing or that we may develop, which could render our products obsolete and noncompetitive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that our ability to successfully
compete will depend on, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         results of our and our potential strategic collaborators&rsquo; clinical trials and preclinical
                                         studies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to recruit and enroll patients for our clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         efficacy, safety and reliability of our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         speed at which we develop our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to design and successfully execute appropriate clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to maintain a good relationship with regulatory authorities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         ability to get FDA approval of our end points;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         timing and scope of regulatory approvals, if any;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to commercialize and market any of our product candidates that receive regulatory
                                         approval;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         price of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">adequate
                                         levels of reimbursement under private and governmental health insurance plans, including
                                         Medicare;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to protect intellectual property rights related to our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         ability to manufacture and sell commercial quantities of any approved products to the
                                         market; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">acceptance
                                         of our product candidates by physicians and other health care providers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If our competitors market products that are
more effective, safer or less expensive than ours, or that reach the market sooner than ours, we may not achieve commercial success.
In addition, the biopharmaceutical industry is characterized by rapid technological change. Because our research approach integrates
many technologies, it may be difficult for us to stay abreast of the rapid changes in each technology. If we fail to stay at the
forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our
competitors may render our technologies or product candidates obsolete, less competitive or not economical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We depend on third-party contractors
for a substantial portion of our operations and may not be able to control their work as effectively as if we performed these
functions ourselves.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We outsource substantial portions of our operations
to third-party service providers, including the conduct of preclinical studies and clinical trials, collection and analysis of
data, and manufacturing. Our agreements with third-party service providers and CROs are on a study-by-study and project-by-project
basis. Typically, we may terminate the agreements with notice and are responsible for the supplier&rsquo;s previously incurred
costs. In addition, any CRO that we retain will be subject to the FDA&rsquo;s and EMA&rsquo;s regulatory requirements and similar
standards outside of the United States and Europe and we do not have control over compliance with these regulations by these providers.
Consequently, if these providers do not adhere to applicable governing practices and standards, the development and commercialization
of our product candidates could be delayed or stopped, which could severely harm our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because we have relied on third parties, our
internal capacity to perform these functions is limited to management oversight. Outsourcing these functions involves the risk
that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all.
Although we have not experienced any significant difficulties with our third-party contractors, it is possible that we could experience
difficulties in the future. In addition, the use of third-party service providers requires us to disclose our proprietary information
to these parties, which could increase the risk that this information will be misappropriated. There are a limited number of third-party
service providers that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and
managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs.
We currently have a small number of employees, which limits the internal resources we have available to identify and monitor third-party
service providers. To the extent we are unable to identify, retain and successfully manage the performance of third-party service
providers in the future, our business may be adversely affected, and we may be subject to the imposition of civil or criminal
penalties if their conduct of clinical trials violates applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>A variety of risks associated with our
possible international business relationships could materially adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may enter into agreements with other third
parties for the development and commercialization of RP- G28, or other product candidates we develop in the future, in international
markets. International business relationships subject us to additional risks that may materially adversely affect our ability
to attain or sustain profitable operations, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">differing
                                         regulatory requirements for drug approvals internationally;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">potentially
                                         reduced protection for intellectual property rights;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">potential
                                         third-party patent rights in the United States and/or in countries outside of the United
                                         States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         potential for so-called &ldquo;parallel importing,&rdquo; which is what occurs when a
                                         local seller, faced with relatively high local prices, opts to import goods from another
                                         jurisdiction with relatively low prices, rather than buying them locally;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">unexpected
                                         changes in tariffs, trade barriers and regulatory requirements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">economic
                                         weakness, including inflation, or political instability, particularly in non-U.S. economies
                                         and markets, including several countries in Europe;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">compliance
                                         with tax, employment, immigration and labor laws for employees traveling abroad;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">taxes
                                         in other countries;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">foreign
                                         currency fluctuations, which could result in increased operating expenses and reduced
                                         revenue, and other obligations incident to doing business in another country;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">workforce
                                         uncertainty in countries where labor unrest is more common than in the United States;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">production
                                         shortages resulting from any events affecting raw material supply or manufacturing capabilities
                                         abroad; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">business
                                         interruptions resulting from geo-political actions, including war and terrorism, or natural
                                         disasters, including earthquakes, volcanoes, typhoons, floods, hurricanes and fires.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will need to expand our operations
and increase the size of our company, and we may experience difficulties in managing growth.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As we increase the number of ongoing product
development programs and advance our product candidates through preclinical studies and clinical trials, we will need to increase
our product development, scientific and administrative headcount to manage these programs. In addition, to meet our obligations
as a public company, we will need to increase our general and administrative capabilities. Our management, personnel and systems
currently in place may not be adequate to support this future growth. Our need to effectively manage our operations, growth and
various projects requires that we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">successfully
                                         attract and recruit new employees or consultants with the expertise and experience we
                                         will require;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">manage
                                         our clinical programs effectively, which we anticipate being conducted at numerous clinical
                                         sites;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">develop
                                         a marketing and sales infrastructure; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">continue
                                         to improve our operational, financial and management controls, reporting systems and
                                         procedures.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we are unable to successfully manage this
growth and increased complexity of operations, our business may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may not be able to manage our business
effectively if we are unable to attract and retain key personnel and consultants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may not be able to attract or retain qualified
management, finance, scientific and clinical personnel and consultants due to the intense competition for qualified personnel
and consultants among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel
and consultants to accomplish our business objectives, we may experience constraints that will significantly impede the achievement
of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are highly dependent on the development,
regulatory, commercialization and business development expertise of Michael D. Step, our Chief Executive Officer, Andrew J. Ritter,
our Founder and President, and Ira E. Ritter, our Executive Chairman and Chief Strategic Officer. If we were to lose one or more
of these key employees, our ability to implement our business strategy successfully could be seriously harmed. Any of our executive
officers may terminate their employment at any time. Replacing any of these persons would be difficult and could take an extended
period of time because of the limited number of individuals in our industry with the breadth of skills and experience required
to develop, gain regulatory approval of and commercialize products successfully.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is also a risk that other obligations
could distract our officers and employees, including any of our other part-time employees, from our business, which could have
negative impact on our ability to effectuate our business plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, we have scientific and clinical
advisors and consultants who assist us in formulating our research, development and clinical strategies. Competition to hire and
retain consultants from a limited pool is intense. Further, because these advisors are not our employees, they may have commitments
to, or consulting or advisory contracts with, other entities that may limit their availability to us, and typically they will
not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another
entity, we may lose their services. In addition, our advisors may have arrangements with other companies to assist those companies
in developing products or technologies that may compete with ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Failure to build our finance infrastructure
and improve our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls
requirements for publicly traded companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a public company, we will operate in an
increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act, and the related rules
and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules.
Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control
over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable
financial reports and are important to help prevent financial fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have begun implementing our system of internal
controls over financial reporting and preparing the documentation necessary to perform the evaluation needed to comply with Section
404(a) of the Sarbanes-Oxley Act. However, we anticipate that we will need to retain additional finance capabilities and build
our financial infrastructure as we transition to operating as a public company, including complying with the requirements of Section
404 of the Sarbanes-Oxley Act. As we begin operating as a public company following our initial public offering, we will continue
improving our financial infrastructure with the retention of additional financial and accounting capabilities, the enhancement
of internal controls and additional training for our financial and accounting staff.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 404(a) of the Sarbanes-Oxley Act requires
annual management assessments of the effectiveness of our internal control over financial reporting, starting with the second
annual report that we would expect to file with the SEC. However, for as long as we remain an &ldquo;emerging growth company&rdquo;
as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not &ldquo;emerging growth companies&rdquo; including, but not limited to, not being required
to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act. We may take advantage of these
reporting exemptions until we are no longer an &ldquo;emerging growth company.&rdquo; We will remain an &ldquo;emerging growth
company&rdquo; until the earliest of&thinsp; (i) the last day of the fiscal year in which we have total annual gross revenues
of&thinsp; $1 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion
of our initial public offering; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the
previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Until we are able to expand our finance and
administrative capabilities and establish necessary financial reporting infrastructure, we may not be able to prepare and disclose,
in a timely manner, our financial statements and other required disclosures or comply with the Sarbanes-Oxley Act or existing
or new reporting requirements. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations
could be harmed and investors could lose confidence in our reported financial information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our employees may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could
significantly harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are exposed to the risk of employee fraud
or other misconduct. Misconduct by employees could include intentional failures to comply with the regulations of the FDA and
non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with health care fraud and abuse
laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized
activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive
laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and
regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer
incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained
in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted
an employee handbook, but it is not always possible to identify and deter employee misconduct, and the precautions we take to
detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us
from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.
If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those
actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We face potential product liability
exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and may
have to limit its commercialization.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The use of our product candidates in clinical
trials and the sale of any products for which we may obtain marketing approval expose us to the risk of product liability claims.
Product liability claims may be brought against us or our potential future collaborators by participants enrolled in our clinical
trials, patients, health care providers or others using, administering or selling our products. If we cannot successfully defend
ourselves against any such claims, we would incur substantial liabilities. Regardless of merit or eventual outcome, product liability
claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">withdrawal
                                         of clinical trial participants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">termination
                                         of clinical trial sites or entire trial programs;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">costs
                                         of related litigation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">substantial
                                         monetary awards to patients or other claimants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">decreased
                                         demand for our product candidates and loss of revenues;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">impairment
                                         of our business reputation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">diversion
                                         of management and scientific resources from our business operations; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         inability to commercialize our product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect to obtain product liability insurance
coverage for our clinical trials in the United States and in selected other jurisdictions where we intend to conduct clinical
trials at levels we believe are sufficient and consistent with industry standards for companies at our stage of development. However,
our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer.
Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance
coverage at a reasonable cost or in sufficient amounts to protect us against losses due to product liability. We intend to expand
our insurance coverage for products to include the sale of commercial products if we obtain marketing approval for our product
candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products
approved for marketing. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side
effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance
coverage, could decrease our cash resources and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our insurance policies are expensive
and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not carry insurance for all categories
of risk that our business may encounter. Some of the policies we currently maintain include general liability ($2 million coverage),
employment practices liability, workers&rsquo; compensation, and directors&rsquo; and officers&rsquo;
insurance at levels we believe are typical for a company in our industry and at our stage of development. We do not currently
carry clinical trial liability insurance or products liability insurance, but we are currently seeking to purchase such insurance
and we expect to obtain such insurance prior to the beginning our clinical trials at levels we believe are sufficient and
consistent with industry standards for companies at our stage of development. We do not know, however, if we will be able to maintain
insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which
would adversely affect our financial position and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we engage in an acquisition, reorganization
or business combination, we will incur a variety of risks that could adversely affect our business operations or our stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time we have considered, and
we will continue to consider in the future, strategic business initiatives intended to further the expansion and development of
our business. These initiatives may include acquiring businesses, technologies or products or entering into a business combination
with another company. If we pursue such a strategy, we could, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">issue
                                         equity securities that would dilute our current stockholders&rsquo; percentage ownership;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">incur
                                         substantial debt that may place strains on our operations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">spend
                                         substantial operational, financial and management resources to integrate new businesses,
                                         technologies and products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">assume
                                         substantial actual or contingent liabilities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">reprioritize
                                         our development programs and even cease development and commercialization of our product
                                         candidates; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">merge
                                         with, or otherwise enter into a business combination with, another company in which our
                                         stockholders would receive cash and/or shares of the other company on terms that certain
                                         of our stockholders may not deem desirable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although we intend to evaluate and consider
acquisitions, reorganizations and business combinations in the future, we have no agreements or understandings with respect to
any acquisition, reorganization or business combination at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Relating to Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>It is difficult and costly to protect
our proprietary rights, and we may not be able to ensure their protection. If our patent position does not adequately protect
our product candidates, others could compete against us more directly, which would harm our business, possibly materially.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our commercial success will depend in part
on obtaining, maintaining and enforcing patent protection and on developing, preserving and enforcing current trade secret protection.
In particular, it will depend in part on our ability to obtain, maintain and enforce patents, especially those related to methods
of using our current product, RP-G28, and other future drug candidates, and those related to the methods used to develop and manufacture
our products, as well as successfully defending these patents against third-party challenges. Our ability to stop third parties
from making, using, selling, offering to sell or importing our products depends on the extent to which we have rights under valid
and enforceable patents (and/or trade secrets) that cover these activities. We cannot be sure that patents will be granted with
respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can
we be sure that any of our existing patents or any patents that may be granted to us in the future will withstand subsequent challenges
to their validity and or patentability, or if they will be commercially useful in protecting our product candidates, discovery
programs and processes. Furthermore, we cannot be sure that our existing patents and patent applications will embrace (or &ldquo;claim&rdquo;)
the particular uses for RP-G28 that will be approved by FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The patent positions of biotechnology
and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal
principles remain unresolved.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No consistent policy regarding the patentability
and/or validity of patent claims related to pharmaceutical patents has emerged, to date, in the United States or in most jurisdictions
outside of the United States. Changes in either the patent laws (be they substantive or procedural) or in the interpretations
of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot
predict the breadth of claims that will issue or will be enforceable in the patents that have or may be issued from the patents
and applications we currently own or may in the future own or license from third parties. Further, if any patents we obtain, or
to which we obtain licenses, are deemed invalid, unpatentable and unenforceable, our ability to commercialize or license our technology
could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the future others may file patent applications
covering products, uses for products, and manufacturing techniques and related technologies that are similar, identical or competitive
to ours or important to our business. We cannot be certain that any patent application owned by a third party will not have priority
over patent applications filed or in-licensed by us in the future, or that we or our licensors will not be involved in interference,
opposition, inter partes review or invalidity proceedings before U.S. or non-U.S. patent offices or courts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The degree of future protection for our proprietary
rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us
to gain or keep our competitive advantage. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">others
                                         may be able to develop a platform similar to, or better than, ours in a way that is not
                                         covered by the claims of our patents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">others
                                         may be able to make compounds that are similar to our product candidates but that are
                                         not covered by the claims of our patents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">others
                                         may be able to manufacture compounds that are similar or identical to our product candidates
                                         using processes that are not covered by the claims of our method of making patents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">others
                                         may obtain regulatory approval for uses of compounds, similar or identical to our product,
                                         that are not covered by the claims of our method of use patents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                         may not be able to obtain licenses for patents that are essential to the process of making
                                         the product;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                         might not have been the first to make the inventions covered by our pending patent applications;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                         might not have been the first to file patent applications for these inventions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">others
                                         may independently develop similar or alternative technologies or duplicate any of our
                                         technologies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any
                                         patents that we obtain may not provide us with any competitive advantages;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we
                                         may not develop additional proprietary technologies that are patentable; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         patents of others may have an adverse effect on our business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patents covering methods of using RP-G28 expire
in 2030 if the appropriate maintenance fee renewal, annuity, or other government fees are paid, unless a patent term extension
based on regulatory delay is obtained. We expect that expiration in 2030 of some of our method-of-use patents covering use of
RP-G28 for treating lactose intolerance will have a limited impact on our ability to protect our intellectual property in the
United States, where we have additional issued patents covering this use that extend until 2030. In other countries, our pending
patent applications covering use of RP-G28 for treating other indications, if issued, would expire in 2030. We will attempt to
mitigate the effect of patent expiration by seeking data exclusivity, or the foreign equivalent thereof, in conjunction with product
approval, as well as by filing additional patent applications covering improvements in our intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect that the other patent applications
for the RP-G28 portfolio, if issued, and if the appropriate maintenance, renewal, annuity or other governmental fees are paid,
would expire in 2030. We own pending applications in the United States and Europe covering RP-G28 analogs, and uses of such analogs
as therapeutics to treat a variety of disorders, including lactose intolerance. Patent protection, to the extent it issues, would
be expected to extend to 2030, unless a patent term extension based on regulatory delay is obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to the patent laws of a country, or the
decisions of a patent examiner in a country, or our own filing strategies, we may not obtain patent coverage for all of our product
candidates or methods involving these candidates in the parent patent application. We plan to pursue divisional patent applications
or continuation patent applications in the United States and other countries to obtain claim coverage for inventions which were
disclosed but not claimed in the parent patent application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may also rely on trade secrets to protect
our technology, especially where we do not believe patent protection is appropriate or feasible. However, trade secrets are difficult
to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside
scientific collaborators and other advisors may unintentionally or willfully disclose our information to competitors. Enforcing
a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome
is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover,
our competitors may independently develop equivalent knowledge, methods and know-how.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>RP-G28 does not have composition of
matter patent protection.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although we own certain patents and patent
applications with claims directed to specific methods of using RP-G28 to treat lactose intolerance, RP-G28 has no composition
of matter patent protection in the United States or elsewhere. As a result, we may be limited in our ability to list our patents
in the FDA&rsquo;s Orange Book if the use of our product, consistent with its FDA-approved label, would not fall within the scope
of our patent claims. Also, our competitors may be able to offer and sell products so long as these competitors do not infringe
any other patents that we (or third parties) hold, including patents with claims directed to the manufacture of RP-G28 and/or
method of use patents. In general, method of use patents are more difficult to enforce than composition of matter patents because,
for example, of the risks that FDA may approve alternative uses of the subject compounds not covered by the method of use patents,
and others may engage in off-label sale or use of the subject compounds. Physicians are permitted to prescribe an approved product
for uses that are not described in the product&rsquo;s labeling. Although off-label prescriptions may infringe our method of use
patents, the practice is common across medical specialties and such infringement is difficult to prevent or prosecute. FDA approval
of uses that are not covered by our patents would limit our ability to generate revenue from the sale of RP-G28, if approved for
commercial sale. Off-label sales would limit our ability to generate revenue from the sale of RP- G28, if approved for commercial
sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may incur substantial costs as a
result of litigation or other proceedings relating to patent and other intellectual property rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we choose to go to court to stop another
party from using the inventions claimed in any patents we obtain, that individual or company may seek a post grant review (including
inter parte review) of our patents, and has the right to ask the court to rule that such patents are invalid or should not be
enforced against that third party. These lawsuits and administrative proceedings are expensive and would consume time and resources
and divert the attention of managerial and scientific personnel even if we were successful in stopping the infringement of such
patents. In addition, there is a risk that the court or administrative body will decide that such patents are not valid or unpatentable
and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the
validity/patentability of such patents is upheld, the court will refuse to stop the other party on the ground that such other
party&rsquo;s activities do not infringe our rights to such patents. In addition, the U.S. Supreme Court and the Court of Appeals
for the Federal Circuit have recently articulated and/or modified certain tests used by the U.S. Patent and Trademark Office,
or USPTO, in assessing patentability and by the courts in assessing validity and claim scope, which may decrease the likelihood
that we will be able to obtain patents and increase the likelihood that others may succeed in challenging any patents we obtain
or license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may infringe the intellectual property
rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the
costs of commercializing our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success will depend in part on our ability
to operate without infringing the proprietary rights of third parties. We cannot guarantee that our products, our methods of manufacture,
or our uses of RP-G28 (or our other product candidates), will not infringe third-party
patents. Furthermore, a third party may claim that we or our manufacturing or commercialization collaborators are using inventions
covered by the third party&rsquo;s patent rights and may go to court to stop us from engaging in our normal operations and activities,
including making or selling our product candidates. These lawsuits are costly and could affect our results of operations and divert
the attention of managerial and scientific personnel. There is a risk that a court would decide that we or our commercialization
collaborators are infringing the third party&rsquo;s patents and would order us or our collaborators to stop the activities covered
by the patents. In that event, we or our commercialization collaborators may not have a viable way around the patent and may need
to halt commercialization of the relevant product. In addition, there is a risk that a court will order us or our collaborators
to pay the other party damages for having violated the other party&rsquo;s patents. In the future, we may agree to indemnify our
commercial collaborators against certain intellectual property infringement claims brought by third parties. The pharmaceutical
and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including
us, which patents cover various types of products or methods of use. The scope of coverage of a patent is subject to interpretation
by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, the patentee would need to
demonstrate, by a preponderance of the evidence that our products or methods infringe the patent claims of the relevant patent,
and we would need to demonstrate either that we do not infringe or, by clear and convincing evidence, that the patent claims are
invalid; we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity
requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if
we are successful in these proceedings, we may incur substantial costs and divert management&rsquo;s time and attention in pursuing
these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of
others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity
of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions
to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend
an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter
significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We cannot be certain that others have not
filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology,
because:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">some
                                         patent applications in the United States may be maintained in secrecy until the patents
                                         are issued;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">patent
                                         applications in the United States are typically not published until at least 18 months
                                         after the earliest asserted priority date; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">publications
                                         in the scientific literature often lag behind actual discoveries.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competitors may have filed, and may in
the future file, patent applications covering technology similar to ours. Any such patent application may have priority over our
patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another
party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding
declared by the USPTO to determine priority of invention in the United States. The costs of these proceedings could be substantial,
and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at
the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such
inventions. Other countries have similar laws that permit secrecy of patent applications, and may be entitled to priority over
our applications in such jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Some of our competitors may be able to sustain
the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition,
any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our
ability to raise the funds necessary to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Obtaining and maintaining our patent
protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental
patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Periodic maintenance fees, renewal fees, annuity
fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental
patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We employ
an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies and this outside firm has systems
in place to ensure compliance on payment of fees. The USPTO and various non-U.S. governmental patent agencies require compliance
with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ
reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment
of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance
can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights
in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would
have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be subject to claims that our
employees have wrongfully used or disclosed alleged trade secrets of their former employers. If we are not able to adequately
prevent disclosure of trade secrets and other proprietary information, the value of our technology and products could be significantly
diminished.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As is common in the biotechnology and pharmaceutical
industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our
competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise
used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend
against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs
and be a distraction to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We rely on trade secrets to protect our proprietary
technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult
to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored
researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively
prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure
of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For
example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly
available on a routine basis, including information that we may consider to be trade secrets or other proprietary information,
and it is not clear at the present time how the FDA&rsquo;s disclosure policies may change in the future, if at all. Costly and
time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain
or maintain trade secret protection could adversely affect our competitive business position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Failure to secure trademark registrations
could adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not developed a trademark for our
RP-G28 product. Hence, we do not currently own any actual or potential trademark rights associated with our RP-G28 product. If
we seek to register additional trademarks, including trademarks associated with our RP-G28 product, our trademark applications
may not be allowed for registration or our registered trademarks may not be maintained or enforced. During trademark registration
proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable
to overcome such rejections. In addition, in the USPTO and in comparable agencies in many other jurisdictions, third parties are
given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation
proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations
for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Relating to Our Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>An active trading market may not develop
or be sustained following our initial public offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to our initial public offering, there
was no public market for our common stock. An active trading market may not develop as a result of our initial public offering
or, if developed, may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you
wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value
of your shares. An inactive market may also impair our ability to raise capital to continue to fund operations by selling shares
and may impair our ability to acquire other companies or technologies by using our shares as consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our share price may be volatile, which
could subject us to securities class action litigation and prevent you from being able to sell your shares at or above your purchase
price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The market price of shares of our common stock
could be subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our control,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">results
                                         of our clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">results
                                         of clinical trials of our competitors&rsquo; products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory
                                         actions with respect to our products or our competitors&rsquo; products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">actual
                                         or anticipated fluctuations in our financial condition and operating results;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">actual
                                         or anticipated changes in our growth rate relative to our competitors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">actual
                                         or anticipated fluctuations in our competitors&rsquo; operating results or changes in
                                         their growth rate;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">competition
                                         from existing products or new products that may emerge;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">announcements
                                         by us, our potential future collaborators or our competitors of significant acquisitions,
                                         strategic collaborations, joint ventures, or capital commitments;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">issuance
                                         of new or updated research or reports by securities analysts;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">fluctuations
                                         in the valuation of companies perceived by investors to be comparable to us;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">share
                                         price and volume fluctuations attributable to inconsistent trading volume levels of our
                                         shares;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">additions
                                         or departures of key management or scientific personnel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">disputes
                                         or other developments related to proprietary rights, including patents, litigation matters
                                         and our ability to obtain patent protection for our technologies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">announcement
                                         or expectation of additional financing efforts;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">sales
                                         of our common stock by us, our insiders or our other stockholders;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">market
                                         conditions for biopharmaceutical stocks in general; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">general
                                         economic and market conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Furthermore, the stock markets have experienced
extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many
companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These
broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest
rate changes or international currency fluctuations, may negatively impact the market price of shares of our common stock. In
addition, such fluctuations could subject us to securities class action litigation, which could result in substantial costs and
divert our management&rsquo;s attention from other business concerns, which could seriously harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have three significant stockholders,
which will limit your ability to influence corporate matters and may give rise to conflicts of interest.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Javelin Venture Partners I SPV I, LLC, or
Javelin I, Javelin Venture Partners, L.P., or Javelin, and Stonehenge Partners LLC, or Stonehenge, are our largest stockholders.
Javelin I is beneficially own shares representing approximately [8.0%] of our common stock, Javelin beneficially own shares representing
approximately [27.4%] of our common stock, and Stonehenge beneficially own shares representing 10.5% of our common stock. Accordingly,
Javelin I, Javelin and Stonehenge may exert significant influence over us and any action requiring the approval of the holders
of our common stock, including the election of directors and the approval of significant corporate transactions. This concentration
of voting power makes it less likely that any other holder of our common stock or our directors will be able to affect the way
we are managed and could delay or prevent an acquisition of us on terms that other stockholders may desire.&nbsp;&nbsp;Furthermore,
the interests of Javelin I, Javelin and Stonehenge may not always coincide with your interests or the interests of other stockholders
and Javelin I, Javelin and Stonehenge may act in a manner that advances their best interests and not necessarily those of other
stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Being a public company will increase
our expenses and administrative burden.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a public company, we will incur significant
legal, insurance, accounting and other expenses that we did not incur as a private company. In addition, our administrative staff
will be required to perform additional tasks. For example, as a public company, we will bear all of the internal and external
costs of preparing and distributing periodic public reports in compliance with our obligations under the securities laws.&nbsp;&nbsp;In
addition, laws, regulations and standards applicable to public companies relating to corporate governance and public disclosure,
including the Sarbanes-Oxley Act and related regulations implemented by the SEC and NASDAQ, are creating uncertainty for public
companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations
and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their
application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result
in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance
practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment will result
in increased general and administrative expenses and may divert management&rsquo;s time and attention from product development
activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory
or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and
our business may be harmed. In the future, it may be more expensive for us to obtain director and officer liability insurance,
and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could
also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on
our audit committee and compensation committee, and qualified executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are an &ldquo;emerging growth company&rdquo;
and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make
our common stock less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an &ldquo;emerging growth company,&rdquo;
as defined in the JOBS Act and we intend to take advantage of certain exemptions from various reporting requirements that are
applicable to other public companies that are not &ldquo;emerging growth companies&rdquo; including not being required to comply
with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding
executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We
cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors
find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock
price may be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may take advantage of these reporting exemptions
until we are no longer an &ldquo;emerging growth company.&rdquo; We will remain an &ldquo;emerging growth company&rdquo; until
the earliest of&thinsp; (i) the last day of the fiscal year in which we have total annual gross revenues of&thinsp; $1 billion
or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public
offering; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years;
or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>A significant portion of our total outstanding
shares of common stock is restricted from immediate resale but may be sold into the market in the near future. This could cause
the market price of our common stock to drop significantly, even if our business is doing well.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales of a substantial number of shares of
our common stock in the public market could occur in the future. These sales, or the perception in the market that the holders
of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. We had 7,788,028
outstanding shares of common stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">based on the number of shares outstanding
as of June 30, 2015. Of these shares, 4,000,000 shares may be resold in the public market immediately and the remaining 3,788,028
shares are currently restricted under securities laws or as a result of lock-up agreements. We also intend to register all shares
of common stock that we may issue under our equity compensation plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Future sales and issuances of our common
stock or rights to purchase common stock pursuant to our equity incentive plans could result in additional dilution of the percentage
ownership of our stockholders and could cause our share price to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect that significant additional capital
will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities,
our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities
in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities
or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales may
also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We cannot predict what effect, if any, market
sales of shares held by any stockholder or the availability of shares for future sale will have on the market price of our common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2015, we had options to purchase
1,890,824 shares outstanding under our stock plans. Sales of shares granted under our equity incentive plans may result in material
dilution to our existing stockholders, which could cause our share price to fall.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If securities or industry analysts do
not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could
decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trading market for our common stock will
depend on the research and reports that securities or industry analysts publish about us or our business. We do not have any control
over these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the
analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or
more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the
financial markets, which could cause our share price or trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our failure to meet the continued listing
requirements of NASDAQ could result in a de-listing of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we fail to satisfy the continued listing
requirements of NASDAQ, such as the corporate governance requirements or the minimum closing bid price requirement, NASDAQ may
take steps to de-list our common stock. Such a de-listing would likely have a negative effect on the price of our common stock
and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a de-listing, we would
take actions to restore our compliance with NASDAQ&rsquo;s listing requirements, but we can provide no assurance that any such
action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of
our common stock, prevent our common stock from dropping below the NASDAQ minimum bid price requirement or prevent future non-compliance
with NASDAQ&rsquo;s listing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Provisions in our corporate charter
documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult
and may prevent attempts by our stockholders to replace or remove our current management.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Provisions in our amended and restated certificate
of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in
control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a
premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for
shares of our common stock, thereby depressing the market price
of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team,
these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making
it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions provide
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         authorized number of directors can be changed only by resolution of our board of directors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         bylaws may be amended or repealed by our board of directors or our stockholders;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">stockholders
                                         may not call special meetings of the stockholders or fill vacancies on the board of directors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         board of directors is authorized to issue, without stockholder approval, preferred stock,
                                         the rights of which will be determined at the discretion of the board of directors and
                                         that, if issued, could operate as a &ldquo;poison pill&rdquo; to dilute the stock ownership
                                         of a potential hostile acquirer to prevent an acquisition that our board of directors
                                         does not approve;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         stockholders do not have cumulative voting rights, and therefore our stockholders holding
                                         a majority of the shares of common stock outstanding will be able to elect all of our
                                         directors; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                         stockholders must comply with advance notice provisions to bring business before or nominate
                                         directors for election at a stockholder meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, because we are incorporated in Delaware,
we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which prohibits a person who
owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the
date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination
is approved in a prescribed manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Claims for indemnification by our directors
and officers may reduce our available funds to satisfy successful stockholder claims against us and may reduce the amount of money
available to us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As permitted by Section 102(b)(7) of the DGCL,
our amended and restated certificate of incorporation limits the liability of our directors to the fullest extent permitted by
law. In addition, as permitted by Section 145 of the DGCL, our restated certificate of incorporation and our amended and restated
bylaws provide that we shall indemnify, to the fullest extent authorized by the DGCL, each person who is involved in any litigation
or other proceeding because such person is or was a director or officer of our company or is or was serving as an officer or director
of another entity at our request, against all expense, loss or liability reasonably incurred or suffered in connection therewith.
Our amended and restated certificate of incorporation provides that the right to indemnification includes the right to be paid
expenses incurred in defending any proceeding in advance of its final disposition, provided, however, that such advance payment
will only be made upon delivery to us of an undertaking, by or on behalf of the director or officer, to repay all amounts so advanced
if it is ultimately determined that such director is not entitled to indemnification. If we do not pay a proper claim for indemnification
in full within 60 days after we receive a written claim for such indemnification, except in the case of a claim for an advancement
of expenses, in which case such period is 20 days, our restated certificate of incorporation and our restated bylaws authorize
the claimant to bring an action against us and prescribe what constitutes a defense to such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 145 of the DGCL permits a corporation
to indemnify any director or officer of the corporation against expenses (including attorney&rsquo;s fees), judgments, fines and
amounts paid in settlement actually and reasonably incurred in connection with any action, suit or proceeding brought by reason
of the fact that such person is or was a director or officer of the corporation, if such person acted in good faith and in a manner
that he reasonably believed to be in, or not opposed to, the best interests of the corporation, and, with respect to any criminal
action or proceeding, if he or she had no reason to believe his or her conduct was unlawful. In a derivative action, (i.e., one
brought by or on behalf of the corporation), indemnification may be provided only for expenses actually and reasonably incurred
by any director or officer in connection with the defense or settlement of such an action or suit if such person acted in good
faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best interests of the corporation, except
that no indemnification shall be provided if such person shall have been adjudged to be liable to the corporation, unless and
only to the extent that the court in which the action or suit was brought shall determine that the defendant
is fairly and reasonably entitled to indemnity for such expenses despite such adjudication of liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The rights conferred in the restated certificate
of incorporation and the restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with
our directors, officers, employees and agents and to obtain insurance to indemnify such persons. We have entered into or plan
to enter into indemnification agreements with each of our officers and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The above limitations on liability and our
indemnification obligations limit the personal liability of our directors and officers for monetary damages for breach of their
fiduciary duty as directors by shifting the burden of such losses and expenses to us. Although we plan to increase the coverage
under our directors&rsquo; and officers&rsquo; liability insurance, certain liabilities or expenses covered by our indemnification
obligations may not be covered by such insurance or the coverage limitation amounts may be exceeded. As a result, we may need
to use a significant amount of our funds to satisfy our indemnification obligations, which could severely harm our business and
financial condition and limit the funds available to stockholders who may choose to bring a claim against our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We do not anticipate paying cash dividends,
and accordingly, stockholders must rely on stock appreciation for any return on their investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not anticipate paying cash dividends
in the future. As a result, only appreciation of the market price of our common stock, which may never occur, will provide a return
to stockholders. Investors seeking cash dividends should not invest in our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our ability to use our net operating
loss carryforwards and certain other tax attributes may be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2014, we had federal net
operating loss carryforwards, or NOLs, of approximately $9.7 million which begin to expire in 2028. Our ability to utilize our
NOLs may be limited under Section 382 and 383 of the Internal Revenue Code. The limitations apply if an ownership change, as defined
by Section 382, occurs. Generally, an ownership change occurs when certain shareholders increase their aggregate ownership by
more than 50 percentage points over their lowest ownership percentage in a testing period (typically three years). Although we
have not undergone a Section 382 analysis, it is possible that the utilization of the NOLs, could be substantially limited. Additionally,
U.S. tax laws limit the time during which these carryforwards may be utilized against future taxes. As a result, we may not be
able to take full advantage of these carryforwards for federal and state tax purposes. Future changes in stock ownership may also
trigger an ownership change and, consequently, a Section 382 limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_013"></A><B>Item 2. Unregistered
Sales of Equity Securities and Use of Proceeds.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 24, 2015, the Company&rsquo;s registration
statement on Form S-1 (File No. 333-202924) relating to its initial public offering of its common stock was declared effective
by the SEC. The initial public offering closed on June 29, 2015, and 4,000,000 shares of common stock were sold at an initial
public offering price of $5.00 per share, for aggregate gross proceeds to the Company of $20 million and net proceeds to the Company,
after deducting underwriting discounts and commissions and offering expenses, were approximately $17.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There has been no material change in the planned
use of proceeds as described in the registration statement for our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_014"></A><B>Item 6. Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="7" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Incorporated
    by Reference</B></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Description</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Form</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>File No.</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Exhibit</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Filing Date</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Certificate of Incorporation of Ritter Pharmaceuticals, Inc.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">8-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">001-37428</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">3.1</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">7/1/2015</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Bylaws of Ritter Pharmaceuticals, Inc.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">8-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">001-37428</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">3.2</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">7/1/2015</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Offer Letter, by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Offer Letter, by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Executive Severance &amp; Change in Control Agreement, by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Executive Severance &amp; Change in Control Agreement, by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">31.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: #231F20">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
    of 2002</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">31.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: #231F20">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
    of 2002</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">32</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: #231F20">Certifications pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the
    Sarbanes-Oxley Act of 2002</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">101.INS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>XBRL Instance Document.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">101.SCH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>XBRL Taxonomy Schema Linkbase Document.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">101.CAL</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>XBRL Taxonomy Calculation Linkbase Document.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">101.DEF</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>XBRL Taxonomy Definition Linkbase Document.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">101.LAB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>XBRL Taxonomy Labels Linkbase Document.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">101.PRE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>XBRL Taxonomy Presentation Linkbase Document.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>August 12, 2015</TD>
    <TD COLSPAN="2"><B>RITTER PHARMACEUTICALS, INC.</B>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify">By:</TD>
    <TD STYLE="width: 46%; border-bottom: black 1pt solid; text-align: justify">/s/ Michael D. Step</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>Name: Michael D. Step</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>Title: Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>t1501786_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #020202"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202">June 29, 2015</P>

<P STYLE="color: #020202; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="color: #020202; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Andrew J. Ritter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1260 So. Beverly Glen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No. 301<BR>
Los Angeles, CA 90024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #020202">Dear</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif; color: #020202">Mr. Ritter: </FONT></P>

<P STYLE="color: #020202; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #020202">This letter
sets forth the terms of your continued employment with Ritter Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) as of the date
of this letter (the &ldquo;Effective Date&rdquo;). Except as otherwise provided for specifically, this letter shall supersede and
replace any previous letters or agreements with respect to the matters set forth herein. For the avoidance of doubt, the fundraising
bonus opportunities provided for in the Executive Compensation Plan, dated September 25, 2013, will remain in effect. You shall
continue to remain employed with the Company as the President with all of your current dut</FONT><FONT STYLE="color: #1B1B1B">i</FONT><FONT STYLE="color: #020202">es,
authorities and responsibilities as of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202"><B><U>Compensation</U>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202"><B>&nbsp;</B></P>

<P STYLE="color: #020202; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I><U>Base
Salary</U></I>:&nbsp;&nbsp;You will receive an annual base salary of $310,000, paid semi-monthly in accordance with the Company&rsquo;s
payroll practice.</P>

<P STYLE="color: #020202; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #020202"><I><U>Bonus
Compensation</U></I>:&nbsp;&nbsp;You will have the opportunity to earn an annual bonus based upon a percentage of your base salary
and the achievement of specific performance measures as determined by the Company. Your initial target bonus opportunity percentage
equals 40%. The Company will review your base salary and bonus opportunities at least annually for adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #020202">&nbsp;</P>

<P STYLE="color: #020202; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I><U>Severance</U>:</I>&nbsp;&nbsp;You
will be eligible for severance benefits under the Company&rsquo;s policy for employees in positions comparable to yours or pursuant
to the terms, if any, of a separate agreement with the Company.</P>

<P STYLE="color: #020202; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202"><B><U>Benefits</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202">You will be entitled to
continue to receive all employee benefits that the Company customarily makes available to employees in positions comparable to
yours. Additionally, you will be eligible to receive equity award grants pursuant to the terms of the Company&rsquo;s equity compensation
plans. Additionally, you will also be entitled to receive up to $180,000, payable over a three-year period, as reimbursement for
tuition-related expenses incurred by you in connection with your attending the University of Pennsylvania Wharton School of Business
to pursue an MBA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Governing Law</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity, interpretation, construction
and performance of the provisions of this letter shall be governed by the laws of the State of California without reference to
principles of conflicts of laws that would direct the application of the law of any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Severability</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The invalidity or unenforceability of any
provision of this letter will not affect the validity or enforceability of the other provisions of this offer letter, which will
remain in full force and effect. Moreover, if any provision is found to be excessively broad in duration, scope or covered activity,
the provision will be construed, and to the extent necessary
will be deemed to be amended, so as to be enforceable to the maximum extent compatible with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Employment Relationship; Modification
of Terms of Offer</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please be advised that neither this letter
nor any statement made by the Company or its parent, subsidiaries or affiliates is intended to be a contract of employment for
a definite period of time. That means that the employment relationship established by this letter is &ldquo;at will&rdquo; and
either you or the Company may terminate the employment relationship at any time and for any reason, with or without cause or notice.
The Company may from time to time and in its own discretion, change the terms and conditions of your employment with or without
notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To indicate your acceptance, please sign
and return the enclosed copy of this letter to me by June 29, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sincerely,<B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ritter Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/MICHAEL D. STEP</FONT></TD>
    <TD STYLE="width: 58%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Michael D. Step,</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ACCEPTED</B>: </FONT></TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">/S/ANDREW J. RITTER</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Andrew J. Ritter</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date June 29, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>t1501786_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #020202"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202">June 29, 2015</P>

<P STYLE="color: #020202; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="color: #020202; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ira E. Ritter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">226 Wikil Place</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Palm Desert, CA 92260</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #020202">Dear</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif; color: #020202">Mr. Ritter: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #020202">This letter
sets forth the terms of your continued employment with Ritter Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) as of the date
of this letter (the &ldquo;Effective Date&rdquo;). Except as otherwise provided for specifically, this letter shall supersede and
replace any previous letters or agreements with respect to the matters set forth herein. For the avoidance of doubt, the fundraising
bonus opportunities provided for in the Executive Compensation Plan, dated September 25, 2013, will remain in effect. You shall
continue to remain employed with the Company as the Executive Chairman and Chief Strategic Officer with all of your current dut</FONT><FONT STYLE="color: #1B1B1B">i</FONT><FONT STYLE="color: #020202">es,
authorities and responsibilities as of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202"><B><U>Compensation</U>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202"><B>&nbsp;</B></P>

<P STYLE="color: #020202; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I><U>Base
Salary</U></I>:&nbsp;&nbsp;You will receive an annual base salary of $295,000, paid semi-monthly in accordance with the Company&rsquo;s
payroll practice.</P>

<P STYLE="color: #020202; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #020202"><I><U>Bonus
Compensation</U></I>:&nbsp;&nbsp;You will have the opportunity to earn an annual bonus based upon a percentage of your base salary
and the achievement of specific performance measures as determined by the Company. Your initial target bonus opportunity percentage
equals 35%. The Company will review your base salary and bonus opportunities at least annually for adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #020202">&nbsp;</P>

<P STYLE="color: #020202; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I><U>Severance</U>:</I>&nbsp;&nbsp;You
will be eligible for severance benefits under the Company&rsquo;s policy for employees in positions comparable to yours or pursuant
to the terms, if any, of a separate agreement with the Company.</P>

<P STYLE="color: #020202; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202"><B><U>Benefits</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202">You will be entitled to
continue to receive all employee benefits that the Company customarily makes available to employees in positions comparable to
yours. Additionally, you will be eligible to receive equity award grants pursuant to the terms of the Company&rsquo;s equity compensation
plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #020202">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Governing Law</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity, interpretation, construction
and performance of the provisions of this letter shall be governed by the laws of the State of California without reference to
principles of conflicts of laws that would direct the application of the law of any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Severability</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The invalidity or unenforceability of any
provision of this letter will not affect the validity or enforceability of the other provisions of this offer letter, which will
remain in full force and effect. Moreover, if any provision is found to be excessively broad in duration, scope or covered activity,
the provision will be construed, and to the extent necessary will be deemed to be amended, so as to be enforceable to the maximum
extent compatible with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Employment Relationship; Modification
of Terms of Offer</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please be advised that neither this letter
nor any statement made by the Company or its parent, subsidiaries or affiliates is intended to be a contract of employment for
a definite period of time. That means that the employment relationship established by this letter is &ldquo;at will&rdquo; and
either you or the Company may terminate the employment relationship at any time and for any reason, with or without cause or notice.
The Company may from time to time and in its own discretion, change the terms and conditions of your employment with or without
notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To indicate your acceptance, please sign
and return the enclosed copy of this letter to me by June 29, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sincerely,<B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ritter Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">/S/MICHAEL D. STEP</FONT></TD>
    <TD STYLE="width: 58%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Michael D. Step,</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ACCEPTED</B>: </FONT></TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">/S/IRA E. RITTER</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ira E. Ritter</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date 6/29/15</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>t1501786_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXECUTIVE SEVERANCE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&amp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHANGE IN CONTROL AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS EXECUTIVE SEVERANCE
AND CHANGE IN CONTROL AGREEMENT</B> (the &ldquo;<U>Agreement</U>&rdquo;) is made by and between Ritter Pharmaceuticals, Inc. (the
&ldquo;<U>Company</U>&rdquo;), and Andrew J. Ritter (&ldquo;<U>Executive</U>&rdquo;) as of June 29, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration of
the mutual promises, covenants and obligations contained herein, the Company and Executive agree as follows:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>At-Will
Employment</U>.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-weight: normal">The Company and Executive acknowledge that Executive&rsquo;s
employment is and shall continue to be at-will, as defined under applicable law. If Executive&rsquo;s employment terminates for
any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided by
this Agreement, or as may otherwise be available in accordance with the Company&rsquo;s established employee plans and practices
in accordance with other agreements between the Company and Executive.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U><FONT STYLE="font-weight: normal">.</FONT>&nbsp;&nbsp;<FONT STYLE="font-weight: normal">For
purposes of this Agreement, the following terms have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Accrued
Obligations</U>&rdquo; means (i) Executive&rsquo;s earned but unpaid Base Salary through the Termination Date; (ii) payment of
any annual, long-term, or other incentive award which relates to a completed fiscal year or performance period, as applicable,
and is payable (but not yet paid) on or before the Termination Date; (iii) a lump-sum payment in respect of accrued but unused
vacation days at Executive&rsquo;s per-business-day Base Salary rate in effect as of the Termination Date; and (iv) any unpaid
expense or other reimbursements due pursuant to Company expense reimbursement policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Affiliate(s)</U>&rdquo;
means, with respect to any specified Person (as such term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended),
any other Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common
control with, such specified Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Annual
Bonus</U>&rdquo; means Executive&rsquo;s target annual bonus for the year in which the Change in Control occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Base
Salary</U>&rdquo; means Executive&rsquo;s base rate of pay as of a specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Cause</U>&rdquo;
means a finding by the Company that Executive has (i) been convicted of a felony or crime involving moral turpitude; (ii) disclosed
trade secrets or confidential information of the Company (or any Parent or Subsidiary) to persons not entitled to receive such
information; (iii) engaged in conduct in connection with Executive&rsquo;s employment or service to the Company (or any Parent
or Subsidiary), that has, or could reasonably be expected to result in, material injury to the business or reputation of the Company
(or any Parent or Subsidiary), including, without limitation, act(s) of fraud, embezzlement, misappropriation and breach of fiduciary duty;
(iv) violated the operating and ethics policies of the Company (or any Parent or Subsidiary) in any material way, including, but
not limited to those relating to sexual harassment and the disclosure or misuse of confidential information; (v) engaged in willful
and continued negligence in the performance of the duties assigned to Executive by the Company, after Executive has received notice
of and failed to cure such negligence; or (vi) breached any material provision of any agreement between Executive and the Company
(or any Parent or Subsidiary), including, without limitation, any confidentiality agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Change
in Control</U>&rdquo; means the occurrence of any of the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Any &ldquo;person&rdquo; (as such term is used in sections 13(d) and 14(d) of the Exchange Act)
becomes a &ldquo;beneficial owner&rdquo; (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities
of the Company representing more than 50% of the voting power of the then outstanding securities of the Company; provided that
a Change of Control shall not be deemed to occur as a result of a change of ownership resulting from the death of a shareholder,
and a Change of Control shall not be deemed to occur as a result of a transaction in which the Company becomes a subsidiary of
another corporation and in which the shareholders of the Company, immediately prior to the transaction, will beneficially own,
immediately after the transaction, shares entitling such shareholders to more than 50% of all votes to which all shareholders of
the parent corporation would be entitled in the election of directors (without consideration of the rights of any class of stock
to elect directors by a separate class vote)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">A change in the effective control of the Company which occurs on the date that a majority of members
of the Board is replaced during any twelve (12)&nbsp;month period by Directors whose appointment or election is not endorsed by
a majority of the members of the Board prior to the date of the appointment or election; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">The consummation of (A) a merger or consolidation of the Company with another corporation where
the shareholders of the Company, immediately prior to the merger or consolidation, will not beneficially own, immediately after
the merger or consolidation, shares entitling such shareholders to more than 50% of all votes to which all shareholders of the
surviving corporation would be entitled in the election of directors (without consideration of the rights of any class of stock
to elect directors by a separate class vote); (B) a sale or other disposition of all or substantially all of the assets of the
Company; or (C) a liquidation or dissolution of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Disability</U>&rdquo;
means total and permanent disability as defined in Section 22(e)(3) of the Code or in the Company&rsquo;s long-term disability
plan. A termination of Executive&rsquo;s employment due to a Disability
shall be effective only if the party terminating Executive&rsquo;s employment first gives at least 15 days&rsquo; written notice
of such termination to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Good
Reason</U>&rdquo; means, without Executive&rsquo;s express written consent, the occurrence of any one or more of the following:
(i) a substantial and material diminution in Executive&rsquo;s duties or responsibilities; (ii) a material reduction in Executive&rsquo;s
Base Salary; or (iii) the relocation of Executive&rsquo;s principal place of employment to a location more than 50 miles from Executive&rsquo;s
principal work location to a location that is more than 50 miles from the prior location. A termination of employment by Executive
for Good Reason shall be effectuated by giving the Company written notice (&ldquo;<U>Notice of Termination for Good Reason</U>&rdquo;),
not later than 90 days following the occurrence of the circumstance that constitutes Good Reason, setting forth in reasonable detail
the specific conduct of the Company that constitutes Good Reason and the specific provision(s) of this Agreement on which Executive
relied. The Company shall be entitled, during the 30-day period following receipt of a Notice of Termination for Good Reason, to
cure the circumstances that gave rise to Good Reason, provided that the Company shall be entitled to waive its right to cure or
reduce the cure period by delivery of written notice to that effect to Executive (such 30-day or shorter period, the &ldquo;<U>Cure
Period</U>&rdquo;). If, during the Cure Period, such circumstance is remedied, Executive will not be permitted to terminate employment
for Good Reason as a result of such circumstance. If, at the end of the Cure Period, the circumstance that constitutes Good Reason
has not been remedied, Executive shall terminate employment for Good Reason on the date of expiration of the Cure Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Termination
Date</U>&rdquo; means the date on which Executive&rsquo;s employment hereunder terminates.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
Without Cause or by Executive With Good Reason</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;Subject to Section 6 below, if
the Company terminates Executive&rsquo;s employment without Cause, or the Executive terminates for Good Reason, Executive shall
be entitled to: (a) the Accrued Obligations; (b) an amount equal to twelve (12) months of the Base Salary as in effect immediately
prior to the Termination Date, paid in a lump sum on the sixtieth (60<SUP>th</SUP>) day following the Termination Date; (c) medical,
dental benefits provided by the Company to Executive and Executive&rsquo;s spouse and dependents (in each case, as provided in
any applicable plan) at least equal to the levels of benefits provided to other similarly situated active employees of the Company
and its subsidiaries until the earlier of (i) the twelve (12) month anniversary of the Termination Date or (ii) the date that Executive
becomes covered under a subsequent employer&rsquo;s medical and dental plans; and (d) acceleration of vesting of all equity and
equity-based awards.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Change
in Control Termination</U>. <FONT STYLE="font-weight: normal">Subject to Section 6 below,</FONT> <FONT STYLE="font-weight: normal">in
the event that within the one (1) month prior to or the twelve (12) months following a Change in Control the Company terminates
Executive&rsquo;s employment without Cause, or the Executive terminates for Good Reason, then, in lieu of the payments and benefits
otherwise due to Executive under Section 3 above, Executive shall be entitled to: (a) the Accrued Obligations; (b) an amount equal
to the sum of (twelve (12) months of the Base Salary as in effect on the Termination Date or the date of the Change in Control,
whichever is greater; (c) medical, dental benefits provided by the Company to Executive and Executive&rsquo;s spouse and dependents
(in each case, as provided in any applicable plan) at least equal to the levels of benefits provided to other similarly situated
active employees
of the Company and its subsidiaries until the earlier of (i) the twelve (12) month anniversary of the Termination Date or (ii)
the date that Executive becomes covered under a subsequent employer&rsquo;s medical and dental plans; and (d) acceleration of vesting
of all equity and equity-based awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Terminations</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;If Executive&rsquo;s employment hereunder is terminated (a) by Executive
without Good Reason; (b) by the Company for Cause; or (c) due to Executive&rsquo;s death or Executive&rsquo;s Disability, Executive
and/or Executive&rsquo;s estate or beneficiaries shall be entitled to the Accrued Obligations. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Release</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;&nbsp;Executive&rsquo;s
entitlement to the payments (other than the Accrued Obligations) and benefits described in Sections 3 and 4 above is expressly
contingent upon Executive providing the Company with a signed release satisfactory to the Company (the &ldquo;<U>Release</U>&rdquo;).
To be effective, such Release must be delivered by Executive to the Company no later than 45 days following the Termination Date
and must not be revoked during the seven (7) days following such delivery. If such Release is not executed in a timely manner or
is revoked, all such payments and benefits shall immediately cease and the Executive shall be required to repay to the Company
any such payments that have already been paid to the Executive.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;The
Company shall withhold all applicable federal, state and local taxes, social security and workers&rsquo; compensation contributions
and other amounts as may be required by law with respect to compensation payable to Executive. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Modification
of Payments</U><FONT STYLE="font-weight: normal">.&nbsp;In the event it shall be determined that any payment, right or distribution
by the Company or any other person or entity to or for the benefit of Executive pursuant to the terms of this Agreement or otherwise,
in connection with, or arising out of, his employment with the Company or a change in ownership or effective control of the Company
or a substantial portion of its assets (a &ldquo;<U>Payment</U>&rdquo;) is a &ldquo;parachute payment&rdquo; within the meaning
of Section&nbsp;280G of the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;) on account of the aggregate
value of the Payments due to Executive being equal to or greater than three times the &ldquo;base amount,&rdquo; as defined in
Section 280G(b)(3) of the Code, (the &ldquo;<U>Parachute Threshold</U>&rdquo;) so that Executive would be subject to the excise
tax imposed by Section&nbsp;4999 of the Code (the &ldquo;<U>Excise Tax</U>&rdquo;) and the net after-tax benefit that Executive
would receive by reducing the Payments to the Parachute Threshold is greater than the net after-tax benefit Executive would receive
if the full amount of the Payments were paid to Executive, then the Payments payable to Executive shall be reduced (but not below
zero) so that the Payments due to Executive do not exceed the amount of the Parachute Threshold, reducing first any Payments under
Section&nbsp;4(d) above. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Section
409A</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;(a)&nbsp;&nbsp;Notwithstanding anything herein to the contrary, this Agreement
is intended to be interpreted and applied so that the payment of the benefits set forth herein either shall either be exempt from
the requirements of Section 409A of the Code (&ldquo;<U>Section&nbsp;409A</U>&rdquo;) or shall comply with the requirements of
such provision. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
any provision of this Agreement to the contrary, if Executive is a &ldquo;specified employee&rdquo; within the meaning of Section
409A, any payments or arrangements due upon a termination of Executive&rsquo;s employment under any arrangement that constitutes a &ldquo;nonqualified
deferral of compensation&rdquo; within the meaning of Section 409A and which do not otherwise qualify under the exemptions under
Treas. Regs. Section 1.409A-1 (including without limitation, the short-term deferral exemption or the permitted payments under
Treas. Regs. Section 1.409A-1(b)(9)(iii)(A)), shall be delayed and paid or provided, without interest, on the earlier of (i) the
date which is six months after Executive&rsquo;s &ldquo;separation from service&rdquo; (as such term is defined in Section 409A
and the regulations and other published guidance thereunder) for any reason other than death, and (ii) the date of Executive&rsquo;s
death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
any Termination Date, Executive shall have no duties or responsibilities that are inconsistent with having a &ldquo;separation
from service&rdquo; within the meaning of Section 409A and, notwithstanding anything in the Agreement to the contrary, distributions
upon termination of employment of nonqualified deferred compensation may only be made upon a &ldquo;separation from service&rdquo;
as determined under Section 409A and such date shall be the Termination Date for purposes of this Agreement. Each payment under
this Agreement or otherwise shall be treated as a separate payment for purposes of Section 409A. In no event may Executive, directly
or indirectly, designate the calendar year of any payment to be made under this Agreement which constitutes a &ldquo;nonqualified
deferral of compensation&rdquo; within the meaning of Section 409A and to the extent an amount is payable within a time period,
the time during which such amount is paid shall be in the discretion of the Company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Merger
Clause</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;Effective as of the Effective Date, this Agreement contains the complete,
full, and exclusive understanding of Executive and the Company as to its subject matter and shall, on such date, and supersede
any prior agreement between Executive and the Company</FONT> <FONT STYLE="font-weight: normal">regarding severance benefits. Any
amendments to this Agreement shall be effective and binding on Executive and the Company only if any such amendments are in writing
and signed by both Parties. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;(a)&nbsp;&nbsp;This
Agreement is personal to Executive and, without the prior written consent of the Company, shall not be assigned by Executive otherwise
than by will or the laws of descent and distribution, and any assignment in violation of this Agreement shall be void.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement and all rights of Executive hereunder shall inure to the benefit of, and be enforceable by, Executive&rsquo;s personal
or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If Executive should
die while any amounts would still be payable to him or her hereunder if he or she had continued to live, all such amounts, unless
otherwise provided herein, shall be paid in accordance with the terms of this Agreement to Executive&rsquo;s devisee, legatee or
other designee or, should there be no such designee, to Executive&rsquo;s estate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially
all of the business or assets of the Company (a &ldquo;<U>Successor</U>&rdquo;) to assume and agree to perform this Agreement in
the same manner and to the same extent that the Company would have been required to perform it if no such succession had taken
place. As used in this Agreement, (i) the term &ldquo;<U>Company</U>&rdquo; shall mean the Company as hereinbefore defined and
any Successor and any permitted assignee to which this Agreement is assigned and (ii) the term &ldquo;<U>Board</U>&rdquo; shall
mean the Board as hereinbefore defined and the board
of directors or equivalent governing body of any Successor and any permitted assignee to which this Agreement is assigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Dispute
Resolution</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;The parties agree that any dispute arising out of or relating to this
Agreement or the formation, breach, termination or validity thereof, will be settled by binding arbitration by a panel of three
arbitrators in accordance with the commercial arbitration rules of the American Arbitration Association. The arbitration proceedings
will be located in Los Angeles County, California. The arbitrators are not empowered to award damages in excess of compensatory
damages and each party irrevocably waives any damages in excess of compensatory damages. Judgment upon any arbitration award may
be entered into any court having jurisdiction thereof and the parties consent to the jurisdiction of any court of competent jurisdiction
located in the State of California.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>GOVERNING
LAW</U>.&nbsp;&nbsp;THIS AGREEMENT SHALL BE DEEMED TO BE MADE IN THE STATE OF CALIFORNIA, AND THE VALIDITY, INTERPRETATION, CONSTRUCTION
AND PERFORMANCE OF THIS AGREEMENT IN ALL RESPECT SHALL BE GOVERNED BY THE LAWS OF THE STATE OF CALIFORNIA WITHOUT REGARD TO ITS
PRINCIPLES OF CONFLICTS OF LAW.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment;
No Waiver</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;No provision of this Agreement may be amended, modified, waived or
discharged except by a written document signed by Executive and duly authorized officer of the Company. The failure of a party
to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered as a waiver of such party&rsquo;s
rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement.
No failure or delay by any party in exercising any right or power hereunder will operate as a waiver thereof, nor will any single
or partial exercise of any other right or power. No agreements or representations, oral or otherwise, express or implied, with
respect to the subject matter hereof have been made by any party, which are not set forth expressly in this Agreement.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;If
any term or provision of this Agreement is invalid, illegal or incapable of being enforced by any applicable law or public policy,
all other conditions and provisions of this Agreement shall nonetheless remain in full force and effect so long as the economic
and legal substance of the transactions contemplated by this Agreement is not affected in any manner materially adverse to any
party. Upon any such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties
hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as
possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated
to the fullest extent possible.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;The
rights and obligations of the parties under the provisions of this Agreement that relate to post-termination obligations shall
survive and remain binding and enforceable, notwithstanding the expiration of the term of this Agreement, the termination of Executive&rsquo;s
employment with the Company for any reason or any settlement of the financial rights and obligations arising from Executive&rsquo;s
employment hereunder, to the extent necessary to preserve the intended benefits of such provisions.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;All
notices and other communications required or permitted by this Agreement will be made in writing and all such notices and communications
will be deemed to have been duly given when delivered or (unless otherwise specified) mailed by United States certified or registered
mail, return receipt requested, postage prepaid, addressed to the Company at its headquarters, and addressed to Executive at his
last address on file with the Company, or to such other address as any party may have furnished to the other in writing in accordance
herewith, except that notices of change of address shall be effective only upon receipt.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings
and References</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;The headings of this Agreement are inserted for convenience only
and neither constitute a part of this Agreement nor affect in any way the meaning or interpretation of this Agreement. When a reference
in this Agreement is made to a Section, such reference shall be to a Section of this Agreement unless otherwise indicated.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;This
Agreement may be executed in one or more counterparts (including via facsimile), each of which shall be deemed to be an original,
but all of which together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, this Agreement
has been executed by the parties as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>RITTER PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD>/S/MICHAEL D. STEP</TD></TR>
</TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%">Name:</TD>
    <TD STYLE="width: 44%">Michael D. Step</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Executive</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>/S/ANDREW J. RITTER</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Andrew J. Ritter</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>t1501786_ex10-4.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXECUTIVE SEVERANCE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&amp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHANGE IN CONTROL AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS EXECUTIVE SEVERANCE
AND CHANGE IN CONTROL AGREEMENT</B> (the &ldquo;<U>Agreement</U>&rdquo;) is made by and between Ritter Pharmaceuticals, Inc. (the
&ldquo;<U>Company</U>&rdquo;), and Ira E. Ritter (&ldquo;<U>Executive</U>&rdquo;) as of June 29, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration of
the mutual promises, covenants and obligations contained herein, the Company and Executive agree as follows:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>At-Will
Employment</U>.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-weight: normal">The Company and Executive acknowledge that Executive&rsquo;s
employment is and shall continue to be at-will, as defined under applicable law. If Executive&rsquo;s employment terminates for
any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided by
this Agreement, or as may otherwise be available in accordance with the Company&rsquo;s established employee plans and practices
in accordance with other agreements between the Company and Executive.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U><FONT STYLE="font-weight: normal">.</FONT>&nbsp;&nbsp;&nbsp;<FONT STYLE="font-weight: normal">For
purposes of this Agreement, the following terms have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Accrued
Obligations</U>&rdquo; means (i) Executive&rsquo;s earned but unpaid Base Salary through the Termination Date; (ii) payment of
any annual, long-term, or other incentive award which relates to a completed fiscal year or performance period, as applicable,
and is payable (but not yet paid) on or before the Termination Date; (iii) a lump-sum payment in respect of accrued but unused
vacation days at Executive&rsquo;s per-business-day Base Salary rate in effect as of the Termination Date; and (iv) any unpaid
expense or other reimbursements due pursuant to Company expense reimbursement policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Affiliate(s)</U>&rdquo;
means, with respect to any specified Person (as such term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended),
any other Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common
control with, such specified Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Annual
Bonus</U>&rdquo; means Executive&rsquo;s target annual bonus for the year in which the Change in Control occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Base
Salary</U>&rdquo; means Executive&rsquo;s base rate of pay as of a specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Cause</U>&rdquo;
means a finding by the Company that Executive has (i) been convicted of a felony or crime involving moral turpitude; (ii) disclosed
trade secrets or confidential information of the Company (or any Parent or Subsidiary) to persons not entitled to receive such
information; (iii) engaged in conduct in connection with Executive&rsquo;s employment or service to the Company (or any Parent
or Subsidiary), that has, or could reasonably be expected to result in, material injury to the business or reputation of the Company
(or any Parent or Subsidiary), including, without limitation, act(s) of fraud, embezzlement, misappropriation and breach of fiduciary duty;
(iv) violated the operating and ethics policies of the Company (or any Parent or Subsidiary) in any material way, including, but
not limited to those relating to sexual harassment and the disclosure or misuse of confidential information; (v) engaged in willful
and continued negligence in the performance of the duties assigned to Executive by the Company, after Executive has received notice
of and failed to cure such negligence; or (vi) breached any material provision of any agreement between Executive and the Company
(or any Parent or Subsidiary), including, without limitation, any confidentiality agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Change
in Control</U>&rdquo; means the occurrence of any of the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">Any &ldquo;person&rdquo; (as such term is used in sections
13(d) and 14(d) of the Exchange Act) becomes a &ldquo;beneficial owner&rdquo; (as defined in Rule 13d-3 under the Exchange Act),
directly or indirectly, of securities of the Company representing more than 50% of the voting power of the then outstanding securities
of the Company; provided that a Change of Control shall not be deemed to occur as a result of a change of ownership resulting
from the death of a shareholder, and a Change of Control shall not be deemed to occur as a result of a transaction in which the
Company becomes a subsidiary of another corporation and in which the shareholders of the Company, immediately prior to the transaction,
will beneficially own, immediately after the transaction, shares entitling such shareholders to more than 50% of all votes to
which all shareholders of the parent corporation would be entitled in the election of directors (without consideration of the
rights of any class of stock to elect directors by a separate class vote)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">A change in the effective control of the Company which
occurs on the date that a majority of members of the Board is replaced during any twelve (12)&nbsp;month period by Directors whose
appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election;
or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">The consummation of (A) a merger or consolidation of the
Company with another corporation where the shareholders of the Company, immediately prior to the merger or consolidation, will
not beneficially own, immediately after the merger or consolidation, shares entitling such shareholders to more than 50% of all
votes to which all shareholders of the surviving corporation would be entitled in the election of directors (without consideration
of the rights of any class of stock to elect directors by a separate class vote); (B) a sale or other disposition of all or substantially
all of the assets of the Company; or (C) a liquidation or dissolution of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Disability</U>&rdquo;
means total and permanent disability as defined in Section 22(e)(3) of the Code or in the Company&rsquo;s long-term disability
plan. A termination of Executive&rsquo;s employment due to a Disability
shall be effective only if the party terminating Executive&rsquo;s employment first gives at least 15 days&rsquo; written notice
of such termination to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Good
Reason</U>&rdquo; means, without Executive&rsquo;s express written consent, the occurrence of any one or more of the following:
(i) a substantial and material diminution in Executive&rsquo;s duties or responsibilities; (ii) a material reduction in Executive&rsquo;s
Base Salary; or (iii) the relocation of Executive&rsquo;s principal place of employment to a location more than 50 miles from Executive&rsquo;s
principal work location to a location that is more than 50 miles from the prior location. A termination of employment by Executive
for Good Reason shall be effectuated by giving the Company written notice (&ldquo;<U>Notice of Termination for Good Reason</U>&rdquo;),
not later than 90 days following the occurrence of the circumstance that constitutes Good Reason, setting forth in reasonable detail
the specific conduct of the Company that constitutes Good Reason and the specific provision(s) of this Agreement on which Executive
relied. The Company shall be entitled, during the 30-day period following receipt of a Notice of Termination for Good Reason, to
cure the circumstances that gave rise to Good Reason, provided that the Company shall be entitled to waive its right to cure or
reduce the cure period by delivery of written notice to that effect to Executive (such 30-day or shorter period, the &ldquo;<U>Cure
Period</U>&rdquo;). If, during the Cure Period, such circumstance is remedied, Executive will not be permitted to terminate employment
for Good Reason as a result of such circumstance. If, at the end of the Cure Period, the circumstance that constitutes Good Reason
has not been remedied, Executive shall terminate employment for Good Reason on the date of expiration of the Cure Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Termination
Date</U>&rdquo; means the date on which Executive&rsquo;s employment hereunder terminates.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
Without Cause or by Executive With Good Reason</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;Subject to Section 6 below, if
the Company terminates Executive&rsquo;s employment without Cause, or the Executive terminates for Good Reason, Executive shall
be entitled to: (a) the Accrued Obligations; (b) an amount equal to twelve (12) months of the Base Salary as in effect immediately
prior to the Termination Date, paid in a lump sum on the sixtieth (60<SUP>th</SUP>) day following the Termination Date; (c) medical,
dental benefits provided by the Company to Executive and Executive&rsquo;s spouse and dependents (in each case, as provided in
any applicable plan) at least equal to the levels of benefits provided to other similarly situated active employees of the Company
and its subsidiaries until the earlier of (i) the twelve (12) month anniversary of the Termination Date or (ii) the date that Executive
becomes covered under a subsequent employer&rsquo;s medical and dental plans; and (d) acceleration of vesting of all equity and
equity-based awards.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Change
in Control Termination</U>.&nbsp;<FONT STYLE="font-weight: normal">Subject to Section 6 below,</FONT> <FONT STYLE="font-weight: normal">in
the event that within the one (1) month prior to or the twelve (12) months following a Change in Control the Company terminates
Executive&rsquo;s employment without Cause, or the Executive terminates for Good Reason, then, in lieu of the payments and benefits
otherwise due to Executive under Section 3 above, Executive shall be entitled to: (a) the Accrued Obligations; (b) an amount equal
to the sum of (twelve (12) months of the Base Salary as in effect on the Termination Date or the date of the Change in Control,
whichever is greater; (c) medical, dental benefits provided by the Company to Executive and Executive&rsquo;s spouse and dependents
(in each case, as provided in any applicable plan) at least equal to the levels of benefits provided to other similarly situated
active </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">employees
of the Company and its subsidiaries until the earlier of (i) the twelve (12) month anniversary of the Termination Date or (ii)
the date that Executive becomes covered under a subsequent employer&rsquo;s medical and dental plans; and (d) acceleration of vesting
of all equity and equity-based awards.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Terminations</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;If Executive&rsquo;s employment hereunder is terminated (a) by Executive
without Good Reason; (b) by the Company for Cause; or (c) due to Executive&rsquo;s death or Executive&rsquo;s Disability, Executive
and/or Executive&rsquo;s estate or beneficiaries shall be entitled to the Accrued Obligations. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Release</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;Executive&rsquo;s
entitlement to the payments (other than the Accrued Obligations) and benefits described in Sections 3 and 4 above is expressly
contingent upon Executive providing the Company with a signed release satisfactory to the Company (the &ldquo;<U>Release</U>&rdquo;).
To be effective, such Release must be delivered by Executive to the Company no later than 45 days following the Termination Date
and must not be revoked during the seven (7) days following such delivery. If such Release is not executed in a timely manner or
is revoked, all such payments and benefits shall immediately cease and the Executive shall be required to repay to the Company
any such payments that have already been paid to the Executive.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;The
Company shall withhold all applicable federal, state and local taxes, social security and workers&rsquo; compensation contributions
and other amounts as may be required by law with respect to compensation payable to Executive. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Modification
of Payments</U><FONT STYLE="font-weight: normal">.&nbsp;In the event it shall be determined that any payment, right or distribution
by the Company or any other person or entity to or for the benefit of Executive pursuant to the terms of this Agreement or otherwise,
in connection with, or arising out of, his employment with the Company or a change in ownership or effective control of the Company
or a substantial portion of its assets (a &ldquo;<U>Payment</U>&rdquo;) is a &ldquo;parachute payment&rdquo; within the meaning
of Section&nbsp;280G of the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;) on account of the aggregate
value of the Payments due to Executive being equal to or greater than three times the &ldquo;base amount,&rdquo; as defined in
Section 280G(b)(3) of the Code, (the &ldquo;<U>Parachute Threshold</U>&rdquo;) so that Executive would be subject to the excise
tax imposed by Section&nbsp;4999 of the Code (the &ldquo;<U>Excise Tax</U>&rdquo;) and the net after-tax benefit that Executive
would receive by reducing the Payments to the Parachute Threshold is greater than the net after-tax benefit Executive would receive
if the full amount of the Payments were paid to Executive, then the Payments payable to Executive shall be reduced (but not below
zero) so that the Payments due to Executive do not exceed the amount of the Parachute Threshold, reducing first any Payments under
Section&nbsp;4(d) above. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Section
409A</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;(a)&nbsp;&nbsp;Notwithstanding anything herein to the contrary, this Agreement
is intended to be interpreted and applied so that the payment of the benefits set forth herein either shall either be exempt from
the requirements of Section 409A of the Code (&ldquo;<U>Section&nbsp;409A</U>&rdquo;) or shall comply with the requirements of
such provision. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
any provision of this Agreement to the contrary, if Executive is a &ldquo;specified employee&rdquo; within the meaning of Section
409A, any payments or arrangements due upon a termination of Executive&rsquo;s employment under any arrangement that constitutes a &ldquo;nonqualified
deferral of compensation&rdquo; within the meaning of Section 409A and which do not otherwise qualify under the exemptions under
Treas. Regs. Section 1.409A-1 (including without limitation, the short-term deferral exemption or the permitted payments under
Treas. Regs. Section 1.409A-1(b)(9)(iii)(A)), shall be delayed and paid or provided, without interest, on the earlier of (i) the
date which is six months after Executive&rsquo;s &ldquo;separation from service&rdquo; (as such term is defined in Section 409A
and the regulations and other published guidance thereunder) for any reason other than death, and (ii) the date of Executive&rsquo;s
death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
any Termination Date, Executive shall have no duties or responsibilities that are inconsistent with having a &ldquo;separation
from service&rdquo; within the meaning of Section 409A and, notwithstanding anything in the Agreement to the contrary, distributions
upon termination of employment of nonqualified deferred compensation may only be made upon a &ldquo;separation from service&rdquo;
as determined under Section 409A and such date shall be the Termination Date for purposes of this Agreement. Each payment under
this Agreement or otherwise shall be treated as a separate payment for purposes of Section 409A. In no event may Executive, directly
or indirectly, designate the calendar year of any payment to be made under this Agreement which constitutes a &ldquo;nonqualified
deferral of compensation&rdquo; within the meaning of Section 409A and to the extent an amount is payable within a time period,
the time during which such amount is paid shall be in the discretion of the Company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Merger
Clause</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;Effective as of the Effective Date, this Agreement contains the complete,
full, and exclusive understanding of Executive and the Company as to its subject matter and shall, on such date, and supersede
any prior agreement between Executive and the Company</FONT> <FONT STYLE="font-weight: normal">regarding severance benefits. Any
amendments to this Agreement shall be effective and binding on Executive and the Company only if any such amendments are in writing
and signed by both Parties. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;(a)&nbsp;&nbsp;This
Agreement is personal to Executive and, without the prior written consent of the Company, shall not be assigned by Executive otherwise
than by will or the laws of descent and distribution, and any assignment in violation of this Agreement shall be void.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement and all rights of Executive hereunder shall inure to the benefit of, and be enforceable by, Executive&rsquo;s personal
or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If Executive should
die while any amounts would still be payable to him or her hereunder if he or she had continued to live, all such amounts, unless
otherwise provided herein, shall be paid in accordance with the terms of this Agreement to Executive&rsquo;s devisee, legatee or
other designee or, should there be no such designee, to Executive&rsquo;s estate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially
all of the business or assets of the Company (a &ldquo;<U>Successor</U>&rdquo;) to assume and agree to perform this Agreement in
the same manner and to the same extent that the Company would have been required to perform it if no such succession had taken
place. As used in this Agreement, (i) the term &ldquo;<U>Company</U>&rdquo; shall mean the Company as hereinbefore defined and
any Successor and any permitted assignee to which this Agreement is assigned and (ii) the term &ldquo;<U>Board</U>&rdquo; shall
mean the Board as hereinbefore defined and the board
of directors or equivalent governing body of any Successor and any permitted assignee to which this Agreement is assigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Dispute
Resolution</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;The parties agree that any dispute arising out of or relating to this
Agreement or the formation, breach, termination or validity thereof, will be settled by binding arbitration by a panel of three
arbitrators in accordance with the commercial arbitration rules of the American Arbitration Association. The arbitration proceedings
will be located in Los Angeles County, California. The arbitrators are not empowered to award damages in excess of compensatory
damages and each party irrevocably waives any damages in excess of compensatory damages. Judgment upon any arbitration award may
be entered into any court having jurisdiction thereof and the parties consent to the jurisdiction of any court of competent jurisdiction
located in the State of California.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>GOVERNING
LAW</U>.&nbsp;&nbsp;THIS AGREEMENT SHALL BE DEEMED TO BE MADE IN THE STATE OF CALIFORNIA, AND THE VALIDITY, INTERPRETATION, CONSTRUCTION
AND PERFORMANCE OF THIS AGREEMENT IN ALL RESPECT SHALL BE GOVERNED BY THE LAWS OF THE STATE OF CALIFORNIA WITHOUT REGARD TO ITS
PRINCIPLES OF CONFLICTS OF LAW.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment;
No Waiver</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;No provision of this Agreement may be amended, modified, waived or
discharged except by a written document signed by Executive and duly authorized officer of the Company. The failure of a party
to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered as a waiver of such party&rsquo;s
rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement.
No failure or delay by any party in exercising any right or power hereunder will operate as a waiver thereof, nor will any single
or partial exercise of any other right or power. No agreements or representations, oral or otherwise, express or implied, with
respect to the subject matter hereof have been made by any party, which are not set forth expressly in this Agreement.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;If
any term or provision of this Agreement is invalid, illegal or incapable of being enforced by any applicable law or public policy,
all other conditions and provisions of this Agreement shall nonetheless remain in full force and effect so long as the economic
and legal substance of the transactions contemplated by this Agreement is not affected in any manner materially adverse to any
party. Upon any such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties
hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as
possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated
to the fullest extent possible.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;The
rights and obligations of the parties under the provisions of this Agreement that relate to post-termination obligations shall
survive and remain binding and enforceable, notwithstanding the expiration of the term of this Agreement, the termination of Executive&rsquo;s
employment with the Company for any reason or any settlement of the financial rights and obligations arising from Executive&rsquo;s
employment hereunder, to the extent necessary to preserve the intended benefits of such provisions.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;All
notices and other communications required or permitted by this Agreement will be made in writing and all such notices and communications
will be deemed to have been duly given when delivered or (unless otherwise specified) mailed by United States certified or registered
mail, return receipt requested, postage prepaid, addressed to the Company at its headquarters, and addressed to Executive at his
last address on file with the Company, or to such other address as any party may have furnished to the other in writing in accordance
herewith, except that notices of change of address shall be effective only upon receipt.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings
and References</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;The headings of this Agreement are inserted for convenience only
and neither constitute a part of this Agreement nor affect in any way the meaning or interpretation of this Agreement. When a reference
in this Agreement is made to a Section, such reference shall be to a Section of this Agreement unless otherwise indicated.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U><FONT STYLE="font-weight: normal">.&nbsp;&nbsp;This
Agreement may be executed in one or more counterparts (including via facsimile), each of which shall be deemed to be an original,
but all of which together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, this Agreement
has been executed by the parties as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>RITTER PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="padding-bottom: 1pt">/S/MICHAEL D. STEP</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%">Name:</TD>
    <TD STYLE="width: 44%">Michael D. Step</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Executive</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>/S/IRA E. RITTER</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Ira E. Ritter</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>t1501786_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Certification
of Chief EXECUTIVE Officer pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Section
302 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Michael D. Step, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have reviewed this quarterly report on Form 10-Q of Ritter Pharmaceuticals, Inc., a Delaware corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b) Evaluated the effectiveness
of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c) Disclosed in this report
any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal
quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant's internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the
equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant's ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b) Any fraud, whether or
not material, that involves management or other employees who have a significant role in the registrant's internal control over
financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>August 12, 2015</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify">By:</TD>
    <TD STYLE="width: 46%; border-bottom: black 1pt solid; text-align: justify">/s/ Michael D. Step</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>Name:&nbsp;&nbsp;Michael D. Step</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer (Principal Executive Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>t1501786_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Certification
of Chief Financial Officer pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Section
302 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Samuel O. Lynn, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have reviewed this quarterly report on Form 10-Q of Ritter Pharmaceuticals, Inc., a Delaware corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b) Evaluated the effectiveness
of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c) Disclosed in this report
any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal
quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant's internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the
equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant's ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b) Any fraud, whether or
not material, that involves management or other employees who have a significant role in the registrant's internal control over
financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>August 12, 2015</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify">By:</TD>
    <TD STYLE="width: 46%; border-bottom: black 1pt solid; text-align: justify">/s/ Samuel O. Lynn</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>Name:&nbsp;&nbsp;Samuel O. Lynn</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>Title:&nbsp;&nbsp;&nbsp;Chief Financial Officer (Principal Financial Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>t1501786_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Certifications
pursuant to 18 U.S.C. Section 1350 as adopted pursuant to </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Section
906 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of the undersigned, Michael D. Step, Chief
Executive Officer of Ritter Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), and Samuel O. Lynn, Chief
Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that, to his knowledge (1) the quarterly report on Form 10-Q of the Company for the three months ended
June 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (2) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>August 12, 2015</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify">By:</TD>
    <TD STYLE="width: 46%; border-bottom: black 1pt solid; text-align: justify">/s/ Michael D. Step</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>Name:&nbsp;&nbsp;Michael D. Step </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer (Principal Executive Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>August 12, 2015</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">/s/ Samuel O. Lynn</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>Name:&nbsp;&nbsp;Samuel O. Lynn</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>Title:&nbsp;&nbsp;&nbsp;Chief Financial Officer (Principal Financial Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>These certifications accompanying and being
&ldquo;furnished&rdquo; with this Report, shall not be deemed &ldquo;filed&rdquo; by the Company for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section and shall not be deemed to
be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange
Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language
contained in such filing.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>rttr-20150630.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 7.3.0.6 [08/07/2015 03:51:48 PM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.3.0.4 on Thursday, August 13, 2015 12:14:30 AM -->
<xbrli:xbrl xmlns:rttr="http://www.ritterpharmaceuticals.com/20150630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="rttr-20150630.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_As_Of_30_Nov_2010T00_00_00_TO_30_Nov_2010T00_00_00_AgreementAxis_PutAndCallOptionAgreementMember_AgreementPartiesAxis_KoluPohakuManagementLlcMember_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:PutAndCallOptionAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:AgreementPartiesAxis">rttr:KoluPohakuManagementLlcMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2010T00_00_00_TO_30_Nov_2010T00_00_00_AgreementAxis_ResearchAndDevelopmentAgreementLicenseMember_AgreementPartiesAxis_KoluPohakuTechnologiesLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:ResearchAndDevelopmentAgreementLicenseMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:AgreementPartiesAxis">rttr:KoluPohakuTechnologiesLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-11-01
</xbrli:startDate>
<xbrli:endDate>
2010-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2010T00_00_00_TO_30_Nov_2010T00_00_00_AgreementAxis_PutAndCallOptionAgreementMember_AgreementPartiesAxis_KoluPohakuTechnologiesLlcMember_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:PutAndCallOptionAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:AgreementPartiesAxis">rttr:KoluPohakuTechnologiesLlcMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-11-01
</xbrli:startDate>
<xbrli:endDate>
2010-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2010T00_00_00_TO_31_Dec_2010T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2010T00_00_00_TO_31_Dec_2010T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-12-01
</xbrli:startDate>
<xbrli:endDate>
2010-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-07-17
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-07-17
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-07-17
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-07-17
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-01
</xbrli:startDate>
<xbrli:endDate>
2012-07-17
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-01
</xbrli:startDate>
<xbrli:endDate>
2012-07-17
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-01
</xbrli:startDate>
<xbrli:endDate>
2012-07-17
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_0ME_01-Jul-2012T00_00_00_TO_17-Jul-2012T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-01
</xbrli:startDate>
<xbrli:endDate>
2012-07-17
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-07-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-01
</xbrli:startDate>
<xbrli:endDate>
2012-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_29-Jun-2015T00_00_00_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:ClinicalTrialFundingCommitmentBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2015-06-29</xbrli:instant>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_0ME_01-Jun-2015T00_00_00_TO_29-Jun-2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:ClinicalTrialFundingCommitmentBonusOpportunitiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2015-06-01</xbrli:startDate>
<xbrli:endDate>2015-06-29</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_As_Of_25-Sep-2013T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FdaMeetingBonusOpportunitiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FdaMeetingBonusOpportunitiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-25
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Sep-2013T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_StockPlan2008Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rttr:StockPlan2008Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Sep-2013T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_StockPlan2008Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rttr:StockPlan2008Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Sep-2013T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FdaMeetingBonusOpportunitiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FdaMeetingBonusOpportunitiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_07_Nov_2013T00_00_00_TO_07_Nov_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-11-07
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2013T00_00_00_TO_07_Nov_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-11-01
</xbrli:startDate>
<xbrli:endDate>
2013-11-07
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2005T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2005-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2005T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2005-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2005T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2005-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01-Apr-2014T00_00_00_TO_30-Jun-2014T00_00_00_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">rttr:ConsultantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_12ME_01-Jan-2014T00_00_00_TO_31-Dec-2014T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>2014-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01-Jan-2014T00_00_00_TO_30-Jun-2014T00_00_00_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">rttr:ConsultantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_ValuationTechniqueAxis_AverageStrikePutOptionApproachMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">rttr:AverageStrikePutOptionApproachMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-10-01
</xbrli:startDate>
<xbrli:endDate>
2014-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_02_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:StepLetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-02
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_02_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:StepLetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rttr:EmployeeStockOptionTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-02
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_02_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndCsoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-02
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_02_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember_VestingAxis_ShareBasedCompensationAwardTrancheTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndCsoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-02
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_02_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember_VestingAxis_ShareBasedCompensationAwardTrancheThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndCsoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-02
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_02_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndCsoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-02
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:StepLetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-12-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-02
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:StepLetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-12-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-02
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:StepLetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rttr:EmployeeStockOptionTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-12-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-02
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndCsoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-12-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-02
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember_VestingAxis_ShareBasedCompensationAwardTrancheTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndCsoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-12-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-02
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndCsoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-12-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-02
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_DirectorMember_VestingAxis_VestingPeriodThreeYearsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">rttr:VestingPeriodThreeYearsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-12-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-02
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_DirectorMember_VestingAxis_VestingPeriodOneYearMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">rttr:VestingPeriodOneYearMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-12-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-02
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesA1PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rttr:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesA2PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rttr:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesA3PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rttr:SeriesAThreePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ExecutiveOfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-12-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember_TitleOfIndividualAxis_ExecutiveOfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-12-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember_TitleOfIndividualAxis_ExecutiveOfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-12-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2015T00_00_00_TO_26_Mar_2015T00_00_00_AgreementAxis_ResearchAndDevelopmentAgreementLicenseMember_AgreementPartiesAxis_KoluPohakuManagementLlcMember_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:ResearchAndDevelopmentAgreementLicenseMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:AgreementPartiesAxis">rttr:KoluPohakuManagementLlcMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-03-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-26
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2015T00_00_00_TO_26_Mar_2015T00_00_00_AgreementAxis_PutAndCallOptionAgreementMember_AgreementPartiesAxis_KoluPohakuManagementLlcMember_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:PutAndCallOptionAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:AgreementPartiesAxis">rttr:KoluPohakuManagementLlcMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-03-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-26
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2015T00_00_00_TO_17_Jun_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-06-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-17
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_As_Of_29_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-29
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_29_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:StepLetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rttr:EmployeeStockOptionThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-29
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_29_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_PlanNameAxis_ExecutiveCompensationPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rttr:ExecutiveCompensationPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-29
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_29-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:ClinicalTrialFundingCommitmentBonusOpportunitiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-29
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_29-Jun-2015T00_00_00_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>


<xbrli:segment><xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-29
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-06-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:StepLetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rttr:EmployeeStockOptionThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-06-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_PlanNameAxis_ExecutiveCompensationPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rttr:ExecutiveCompensationPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-06-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PlanNameAxis_ExecutiveCompensationPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rttr:ExecutiveCompensationPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-06-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-06-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01-Apr-2015T00_00_00_TO_30-Jun-2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:ClinicalTrialFundingCommitmentBonusOpportunitiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AndelaGroupIncMember_RelatedPartyTransactionAxis_CorporateManagementStrategicAndFinancialConsultingMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rttr:AndelaGroupIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rttr:CorporateManagementStrategicAndFinancialConsultingMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01-Apr-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01-Apr-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">rttr:ConsultantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:ClinicalTrialFundingCommitmentBonusOpportunitiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AndelaGroupIncMember_RelatedPartyTransactionAxis_CorporateManagementStrategicAndFinancialConsultingMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rttr:AndelaGroupIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rttr:CorporateManagementStrategicAndFinancialConsultingMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember_TypeOfBonusAwardAxis_GraduatedCashBonusMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:TypeOfBonusAwardAxis">rttr:GraduatedCashBonusMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA1PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rttr:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA2PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rttr:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA3PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rttr:SeriesAThreePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember_DebtInstrumentAxis_TwoThousandFourteenNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rttr:TwoThousandFourteenNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember_DebtInstrumentAxis_TwoThousandFourteenNotesOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rttr:TwoThousandFourteenNotesOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_DebtInstrumentAxis_TwoThousandFourteenNotesOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rttr:TwoThousandFourteenNotesOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_DebtInstrumentAxis_TwoThousandFourteenNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rttr:TwoThousandFourteenNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_DebtInstrumentAxis_TwoThousandFourteenNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rttr:TwoThousandFourteenNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_DebtInstrumentAxis_TwoThousandFourteenNotesOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rttr:TwoThousandFourteenNotesOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandFiveMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">rttr:GrantYearTwoThousandFiveMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandNineMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">rttr:GrantYearTwoThousandNineMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandElevenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">rttr:GrantYearTwoThousandElevenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandTwelveMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">rttr:GrantYearTwoThousandTwelveMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandThirteenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">rttr:GrantYearTwoThousandThirteenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandFourteenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">rttr:GrantYearTwoThousandFourteenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandNineMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">rttr:GrantYearTwoThousandNineMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandNineMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">rttr:GrantYearTwoThousandNineMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandThirteenMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">rttr:GrantYearTwoThousandThirteenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandThirteenMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">rttr:GrantYearTwoThousandThirteenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandFourteenMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">rttr:GrantYearTwoThousandFourteenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandFourteenMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">rttr:GrantYearTwoThousandFourteenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_PlanNameAxis_StockPlan2015Member_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rttr:StockPlan2015Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_PlanNameAxis_StockPlan2015Member_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rttr:StockPlan2015Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">rttr:ConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">rttr:ConsultantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">rttr:ConsultantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_PlanNameAxis_ExecutiveCompensationPlanMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rttr:ExecutiveCompensationPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_ClassOfWarrantOrRightAxis_SevenYearWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rttr:SevenYearWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember_TypeOfBonusAwardAxis_GraduatedCashBonusMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:TypeOfBonusAwardAxis">rttr:GraduatedCashBonusMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA1PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rttr:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA2PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rttr:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA3PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rttr:SeriesAThreePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_DebtInstrumentAxis_TwoThousandFourteenNotesOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rttr:TwoThousandFourteenNotesOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_DebtInstrumentAxis_TwoThousandFourteenNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rttr:TwoThousandFourteenNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_CommonStockMember_PeriodOfShareIssueAxis_YearTwoThousandFiveMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PeriodOfShareIssueAxis">rttr:YearTwoThousandFiveMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA2PreferredStockMember_PeriodOfShareIssueAxis_YearTwoThousandSixMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rttr:SeriesATwoPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PeriodOfShareIssueAxis">rttr:YearTwoThousandSixMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA3PreferredStockMember_PeriodOfShareIssueAxis_YearTwoThousandEightToYearTwoThousandNineMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rttr:SeriesAThreePreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PeriodOfShareIssueAxis">rttr:YearTwoThousandEightToYearTwoThousandNineMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember_PeriodOfShareIssueAxis_YearTwoThousandTenToYearTwoThousandThirteenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PeriodOfShareIssueAxis">rttr:YearTwoThousandTenToYearTwoThousandThirteenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember_PeriodOfShareIssueAxis_YearTwoThousandFourteenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PeriodOfShareIssueAxis">rttr:YearTwoThousandFourteenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_PlanNameAxis_StockPlan2015Member_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rttr:StockPlan2015Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_PlanNameAxis_StockPlan2015Member_AwardTypeAxis_IncentiveStockOptionMember_TitleOfIndividualAxis_EmployeeHoldTenPercentOwnershipInterestMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rttr:StockPlan2015Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rttr:IncentiveStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:EmployeeHoldTenPercentOwnershipInterestMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_PlanNameAxis_StockPlan2015Member_AwardTypeAxis_IncentiveStockOptionMember_TitleOfIndividualAxis_OtherEmployeeMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rttr:StockPlan2015Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rttr:IncentiveStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:OtherEmployeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_PlanNameAxis_StockPlan2015Member_AwardTypeAxis_NonstatutoryStockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rttr:StockPlan2015Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rttr:NonstatutoryStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ExecutiveOfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">rttr:ConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">rttr:ConsultantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">rttr:ConsultantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2005T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">rttr:ConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2005-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_0ME_01-Oct-2015T00_00_00_TO_01-Oct-2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_CenturyParkMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">rttr:CenturyParkMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2015-10-01</xbrli:startDate>
<xbrli:endDate>2015-10-01</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_0ME_01-Oct-2015T00_00_00_TO_01-Oct-2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_CenturyParkMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">rttr:CenturyParkMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2015-10-01</xbrli:startDate>
<xbrli:endDate>2015-10-01</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_24_Jul_2015T00_00_00_TO_24_Jul_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_RicercheSperimentaliMontaleSpaAndInalcoSpaMember_AgreementAxis_AmendedClinicalSupplyAndCooperationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">rttr:RicercheSperimentaliMontaleSpaAndInalcoSpaMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:AmendedClinicalSupplyAndCooperationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-07-24
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_24_Jul_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_RicercheSperimentaliMontaleSpaAndInalcoSpaMember_AgreementAxis_AmendedClinicalSupplyAndCooperationAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">rttr:RicercheSperimentaliMontaleSpaAndInalcoSpaMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:AmendedClinicalSupplyAndCooperationAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-07-24
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_30_Jul_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_RicercheSperimentaliMontaleSpaAndInalcoSpaMember_AgreementAxis_AmendedClinicalSupplyAndCooperationAgreementMember_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">rttr:RicercheSperimentaliMontaleSpaAndInalcoSpaMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:AmendedClinicalSupplyAndCooperationAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-07-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_29-Jun-2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>


<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:ClinicalTrialFundingCommitmentBonusOpportunitiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2015-06-29</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-07-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_04_Aug_2015T00_00_00_TO_04_Aug_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-08-04
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2014T00_00_00_TO_31_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2015T00_00_00_TO_31_Dec_2014T00_00_00_ClassOfWarrantOrRightAxis_SevenYearWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rttr:SevenYearWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>MrlsywiI~\FVP6459c444c555cT{h>EF847:;;1665818J981=E=H17<86=<G=F4=: -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Segment"><xbrli:measure>rttr:Segment</xbrli:measure></xbrli:unit>
<xbrli:unit id="Option"><xbrli:measure>rttr:Option</xbrli:measure></xbrli:unit>
<xbrli:unit id="SquareFoot"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>


<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">RITTER PHARMACEUTICALS INC</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">0001460702</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_04_Aug_2015T00_00_00_TO_04_Aug_2015T00_00_00" unitRef="shares" decimals="INF">7792433</dei:EntityCommonStockSharesOutstanding>
<dei:DocumentType contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">2015-06-30</dei:DocumentPeriodEndDate>
<dei:AmendmentFlag contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">false</dei:AmendmentFlag>
<dei:DocumentFiscalYearFocus contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">2015</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">Q2</dei:DocumentFiscalPeriodFocus>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">237591</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2747248</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">19658994</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_01_Jan_2014T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">448226</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">57115</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">42079</us-gaap:PrepaidExpenseCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2804363</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">19701073</us-gaap:AssetsCurrent>
<us-gaap:OtherAssetsNoncurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">10331</us-gaap:OtherAssetsNoncurrent>
<us-gaap:OtherAssetsNoncurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">10331</us-gaap:OtherAssetsNoncurrent>
<us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">143454</us-gaap:DeferredFinanceCostsNoncurrentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">5172</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">4566</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2963320</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">19715970</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1083597</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">1389443</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">168635</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">972992</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:OtherLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2518</us-gaap:OtherLiabilitiesCurrent>
<us-gaap:OtherLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">1022</us-gaap:OtherLiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1254750</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">2363457</us-gaap:LiabilitiesCurrent>

<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">8888</us-gaap:PreferredStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">465</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">7788</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3399924</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">39124630</us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-17904319</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-21779905</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-14495042</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">17352513</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2963320</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">19715970</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesA1PreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesA2PreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesA3PreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">8887500</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">7658182</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesA1PreferredStockMember" unitRef="shares" decimals="INF">7200000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesA2PreferredStockMember" unitRef="shares" decimals="INF">1687500</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesA3PreferredStockMember" unitRef="shares" decimals="INF">4220464</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="shares" decimals="INF">4500000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">8887500</us-gaap:PreferredStockSharesIssued>

<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">8887500</us-gaap:PreferredStockSharesOutstanding>

<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_24_Jul_2015T00_00_00_TO_24_Jul_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_RicercheSperimentaliMontaleSpaAndInalcoSpaMember_AgreementAxis_AmendedClinicalSupplyAndCooperationAgreementMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="INF">25000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">465378</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="INF">7788028</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">465378</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="INF">7788028</us-gaap:CommonStockSharesOutstanding>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">6315</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">11416</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">47977</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">79555</us-gaap:ResearchAndDevelopmentExpense>
<rttr:PatentCosts contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">27382</rttr:PatentCosts>
<rttr:PatentCosts contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">64164</rttr:PatentCosts>
<rttr:PatentCosts contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">50148</rttr:PatentCosts>
<rttr:PatentCosts contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">112423</rttr:PatentCosts>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">352431</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">597087</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">2001706</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">3304152</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">386128</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">672667</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">2099831</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">3496130</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-386128</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-672667</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-2099831</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="2">-3496130</us-gaap:OperatingIncomeLoss>
<us-gaap:InvestmentIncomeInterest contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-4944</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-4739</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">2101</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">4305</us-gaap:InvestmentIncomeInterest>
<us-gaap:OtherNonoperatingIncome contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">7091</us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherIncome contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-4944</us-gaap:OtherIncome>
<us-gaap:OtherIncome contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-4739</us-gaap:OtherIncome>
<us-gaap:OtherIncome contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">2101</us-gaap:OtherIncome>
<us-gaap:OtherIncome contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">11396</us-gaap:OtherIncome>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-391072</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-677406</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-2097730</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-3484734</us-gaap:NetIncomeLoss>
<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">147337</us-gaap:PreferredStockDividendsIncomeStatementImpact>
<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">294785</us-gaap:PreferredStockDividendsIncomeStatementImpact>
<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">178286</us-gaap:PreferredStockDividendsIncomeStatementImpact>
<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">327569</us-gaap:PreferredStockDividendsIncomeStatementImpact>
<us-gaap:PreferredStockRedemptionDiscount contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">31465</us-gaap:PreferredStockRedemptionDiscount>
<us-gaap:PreferredStockRedemptionDiscount contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">63283</us-gaap:PreferredStockRedemptionDiscount>
<rttr:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-538409</rttr:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
<rttr:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-972191</rttr:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
<rttr:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-2307481</rttr:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
<rttr:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-3875586</rttr:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-1.18</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-2.14</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD_per_Share" decimals="2">-4.18</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD_per_Share" decimals="2">-7.62</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">456408</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">453901</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="0">551912</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="0">508645</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:Depreciation contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">1300</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">2534</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">300</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">606</us-gaap:Depreciation>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01-Apr-2014T00_00_00_TO_30-Jun-2014T00_00_00_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">87000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">91916</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01-Jan-2014T00_00_00_TO_30-Jun-2014T00_00_00_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">88000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01-Apr-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">880000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">1680247</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-5">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">41061</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-15036</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">32454</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">305846</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">1012</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">590796</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-773</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-1676</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-584469</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">-893879</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">1166</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-1166</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">375000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">17805625</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-210635</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">16911746</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:DividendsPreferredStockStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">294785</us-gaap:DividendsPreferredStockStock>
<us-gaap:DividendsPreferredStockStock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">327569</us-gaap:DividendsPreferredStockStock>
<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">63283</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
<us-gaap:NatureOfOperations contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 1&amp;#8201;&amp;#8212;&amp;#8201;ORGANIZATION AND PRINCIPAL ACTIVITIES&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Ritter Pharmaceuticals, Inc. (&amp;#8220;Ritter&amp;#8221; or the &amp;#8220;Company&amp;#8221;) is a Delaware corporation headquartered in Los Angeles, California. The Company was formed as a Nevada limited liability company on March&amp;#160;29, 2004 under the name Ritter Natural Sciences, LLC, and converted into a Delaware corporation on September&amp;#160;16, 2008.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company is advancing human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have a meaningful impact on a patient&amp;#8217;s health. The Company&amp;#8217;s lead compound, RP-G28 is currently under development for the treatment of lactose intolerance. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On June 24, 2015, the Company&amp;#8217;s registration statement on Form&amp;#160;S-1 (File No. 333-202924) relating to its initial public offering of its common stock was declared effective by the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;). The shares began trading on the NASDAQ Capital Market on June 24, 2015.&amp;#160; The initial public offering closed on June 29, 2015, and 4,000,000 shares of common stock were sold at an initial public offering price of $5.00 per share, for aggregate gross proceeds to the Company of $20 million.&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company paid to the underwriters underwriting discounts and commissions of approximately $1.6 million in connection with the offering. In addition, the Company incurred expenses of approximately $1 million in connection with the offering. Thus, the net offering proceeds to the Company, after deducting underwriting discounts and commissions and offering expenses, were approximately $17.4 million.&lt;/p&gt;</us-gaap:NatureOfOperations>
<us-gaap:BasisOfAccounting contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 2&amp;#8201;&amp;#8212;&amp;#8201;BASIS OF PRESENTATION&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) and include all adjustments necessary for the fair presentation of the Company&amp;#8217;s financial position for the periods presented. All common share amounts and per share amounts have been adjusted to reflect a 1-for-7.15 reverse stock split of the Company&amp;#8217;s common stock effected on June 17, 2015.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The accompanying interim period unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;GAAP&amp;#8221;) and applicable rules and regulations of the SEC regarding interim financial reporting.&amp;#160;&amp;#160;The condensed balance sheet as of June 30, 2015, the condensed&amp;#160;statements of operations for the three and six months ended June 30, 2015 and 2014, and the condensed statements of cash flows for the six months ended June 30, 2015 and 2014, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of its financial position, operating results and cash flows for the periods presented. The condensed balance sheet at December 31, 2014 has been derived from audited financial statements included in Form S-1 filed on June 19, 2015 with the SEC and declared effective on June 24, 2015. The results for the three and six months ended June 30, 2015 are not&amp;#160;necessarily indicative of the results expected for the full fiscal year or any other period.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The accompanying interim period unaudited condensed financial statements and related financial information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company&amp;#8217;s Form S-1, filed with the SEC on June 19, 2015.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company currently operates in one business segment focusing on the development and commercialization of RP-G28. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of business or separate business entities.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;At June 30, 2015, after&amp;#160;consummation of the Company&amp;#8217;s initial public offering, the Company had working capital of&amp;#160;approximately $17.3 million, an accumulated deficit of&amp;#160;approximately&amp;#160;$21.8 million, and cash of&amp;#160;approximately&amp;#160;$19.7 million.&amp;#160; The&amp;#160;Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable&amp;#160;operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities,&amp;#160;clinical and pre-clinical testing, and commercialization of the Company&amp;#8217;s products will require significant additional financing.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company believes that its existing cash will be sufficient to enable the Company to continue as a going concern for at least the next twelve months. However, the Company will need to secure additional funding in the future, from one or more equity or debt financings, collaborations, or other sources, in order to carry out all of its planned research and development activities. If the Company is unable to obtain additional financing or generate license or product revenue, the lack of liquidity could have a material adverse effect on the Company&amp;#8217;s future prospects.&lt;/p&gt;</us-gaap:BasisOfAccounting>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 3&amp;#8201;&amp;#8212;&amp;#8201;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2014 included in the Company&amp;#8217;s Form S-1 filed on June 19, 2015 with the SEC. Since the date of such financial statements, there have been no changes to the Company&amp;#8217;s significant accounting policies, other than those detailed below.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Deferred Offering Costs&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Deferred offering costs, which primarily consist of direct, incremental banking, legal and accounting fees relating to a planned public offering of the Company&amp;#8217;s common stock, are capitalized within long term assets. The deferred offering costs were reclassified to additional paid-in capital upon the consummation of the offering on June 29, 2015.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company determines basic loss per share and diluted loss per share in accordance with the provisions of ASC 260, &amp;#8220;&lt;i&gt;Earnings per Share&lt;/i&gt;.&amp;#8221; Basic net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period. Diluted net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The potentially dilutive stock options issued under the 2015 Stock Plan (described in Note 8) and warrants on the Company&amp;#8217;s common stock (describe in Note 7) were not considered in the computation of diluted net loss per share because they would be anti-dilutive.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;All common share amounts and per share amounts have been adjusted to reflect a 1-for-7.15 reverse stock split of the Company&amp;#8217;s common stock effected on June 17, 2015.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In August&amp;#160;2014, the FASB issued ASU No. 2014-15,&amp;#160;&lt;i&gt;Presentation of Financial Statements&amp;#8201;&amp;#8212;&amp;#8201;Going Concern (Subtopic 205-40)&amp;#8201;&amp;#8212;&amp;#8201;Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern&lt;/i&gt;, which provides guidance regarding management&amp;#8217;s responsibility to assess whether substantial doubt exists regarding the ability to continue as a going concern and requires related footnote disclosures. In connection with preparing financial statements for each annual and interim reporting period, management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). This ASU is effective for the annual period ending after December&amp;#160;15, 2016, and for annual periods and interim periods thereafter. Management is currently evaluating the new guidance and has not determined the impact this standard may have on the Company&amp;#8217;s financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 4 &amp;#8211; PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Property and equipment consists of the following:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Estimated Life&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 861px;"&gt;Computers and equipment&lt;/td&gt;
&lt;td style="width: 14px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 169px;"&gt;5 years&lt;/td&gt;
&lt;td style="width: 14px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 14px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 141px;"&gt;5,487&lt;/td&gt;
&lt;td style="text-align: left; width: 14px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 14px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 141px;"&gt;5,487&lt;/td&gt;
&lt;td style="text-align: left; width: 14px;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Furniture and fixtures&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;"&gt;7 years&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;4,270&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;4,270&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Total property and equipment&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9,757&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9,757&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Accumulated depreciation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(5,191&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(4,585&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Total property and equipment, net of accumulated depreciation&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,566&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;5,172&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: center; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Depreciation expense of approximately $300&amp;#160;and $1,300&amp;#160;was recognized for the three months ended June 30, 2015 and 2014, respectively,&amp;#160;and approximately $600 and $2,500 for the six months ended June 30, 2015 and 2014, respectively&amp;#160;and is classified in general and administrative expense in the accompanying Unaudited Condensed Statements of Operations.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 5&amp;#8201;&amp;#8212;&amp;#8201;COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Employment Agreements&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Michael Step&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On December&amp;#160;2, 2014, the Company entered into a letter agreement (the &amp;#8220;Step Letter Agreement&amp;#8221;), with Michael Step, the Company&amp;#8217;s current Chief Executive Officer, setting forth the terms of his employment. The Step Letter Agreement provides that Michael Step is entitled to an annual base salary of $360,000 and a total of three grants of options to purchase the Company&amp;#8217;s common stock.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The first two options entitle Michael Step to purchase 646,537 and 73,777 of the Company&amp;#8217;s shares, respectively, for an exercise price of&amp;#8201;$5.86 per share. Each of these options is immediately exercisable in full as of the date of the grant, with 44/48&lt;font style="font-size: 10pt;"&gt;ths&lt;/font&gt;&amp;#160;of the total number of shares covered by each option subject to a right of repurchase by the Company upon termination of Michael Step&amp;#8217;s employment with the Company for any reason. This right of repurchase will lapse over a period of 44 months, with 1/44&lt;font style="font-size: 10pt;"&gt;th&lt;/font&gt;&amp;#160;of the total number of shares subject to the right of repurchase lapsing on January&amp;#160;1, 2015 and on the first day of each month thereafter. In addition, the right of repurchase will lapse in its entirety upon a termination of the employment under certain circumstances.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The third option became exercisable upon the closing of the Company&amp;#8217;s initial public offering on June 29, 2015. Pursuant to the terms of the agreement, the option is exercisable for a total of 103,025 shares of the Company&amp;#8217;s common stock, which, together with the shares subject to the first option, represent 7.5% of the shares of common stock deemed to be outstanding at June 29, 2015 on a fully-diluted basis after giving effect to the number of shares subject to the third option. Seventy-five percent (75%) of the shares subject to the third option are subject to a right of repurchase by the Company upon termination of Michael Step&amp;#8217;s employment for any reason. This right of repurchase will lapse with respect to 1/36&lt;font style="font-size: 10pt;"&gt;th&lt;/font&gt;&amp;#160;of the total number of shares subject to the right of repurchase on the first day of each month following the date on which the third option first becomes exercisable. In addition, the right of repurchase will lapse in its entirety upon Michael Step&amp;#8217;s termination of employment under certain circumstances.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Under the terms of the agreement, Michael Step will be entitled to receive certain payments in the event his employment is terminated under certain scenarios.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Andrew Ritter and Ira Ritter&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On September&amp;#160;25, 2013, the Company&amp;#8217;s Board of Directors approved the Executive Compensation Plan (the &amp;#8220;Compensation Plan&amp;#8221;), which was later amended in June 2015, setting forth the compensation to be paid to Andrew Ritter and Ira Ritter, the Company&amp;#8217;s current President and also the Company&amp;#8217;s former Chief Executive Officer, and Chief Strategic Officer (&amp;#8220;CSO&amp;#8221;), respectively, for their contributions to the Company. Pursuant to the amended terms of the Compensation Plan, effective June 29, 2015, the President&amp;#8217;s salary increased to $310,000 per year and the CSO&amp;#8217;s salary is $295,000 per year. The President will also be entitled to receive up to $180,000 payable over a three year period for tuition reimbursement. As of June 30, 2015, the Company accrued $121,000 in tuition reimbursement for the President and recognized such amount in general and administrative expenses in our Unaudited Condensed Statements of Operations in the three and six month periods ending June 30, 2015.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Under the terms of the agreement, both the President and the CSO will be entitled to receive certain payments in the event their employment is terminated under certain scenarios.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Each executive received options to purchase up to 48,951 shares of the Company&amp;#8217;s common stock (each referred to in this section as &amp;#8220;Executive Options&amp;#8221;) pursuant to the 2008 Stock Plan, which will vest based on specific performance conditions, described below.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Cash Bonus and Executive Options Performance Conditions&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Pursuant to the amended terms of the Compensation Plan, the Company will review bonus opportunities annually for the President and the CSO based on achievement of specific performance as determined by the Company. The initial target bonus opportunities are 40% and 35% of the base salary for the President and the CSO, respectively.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In addition, each covered executive is also entitled to the following cash payments and vests in Executive Options upon the satisfaction of the events described below:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;i&gt;FDA Meeting Bonus Opportunities&lt;/i&gt;.&amp;#160;&amp;#160;&amp;#160;In April&amp;#160;2013, each executive received a one-time cash bonus of&amp;#8201;$10,000 for&amp;#160;a milestone associated with&amp;#160;meeting with the FDA regarding RP-G28&amp;#8217;s path to FDA approval. In addition, 2,360 shares of the Executive Options vested and became exercisable as of the grant date of September&amp;#160;25, 2013. The balance of&amp;#160;1,136&amp;#160;shares vests ratably on a monthly basis beginning on September&amp;#160;30, 2013.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px 0px 0px 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;i&gt;Clinical Trial Funding Commitment Bonus Opportunities&lt;/i&gt;.&amp;#160;&amp;#160;&amp;#160;Each executive is entitled to receive a one-time cash bonus of&amp;#8201; $75,000 upon the Company&amp;#8217;s receipt of a commitment by a third party to fund a Phase 2 or later clinical trial; provided, however, that no such bonus may be paid at any time the Company has less than $2,000,000 in available cash. In addition, upon the satisfaction of this milestone, 35% of 10,489 shares of the Executive Options will vest and become exercisable, with the balance of the 10,489 shares vesting in 36 equal monthly installments beginning on the last day of the following month. Each executive satisfied this performance condition on June 29, 2015 and was entitled to receive a bonus of $75,000 accrued and recognized in general and administrative expenses in the accompanying Unaudited Condensed Statements of Operations in the three and six month periods ending June 30, 2015. In addition, 3,671 shares of the Executive Options vested and became exercisable as of June 29, 2015, with the balance of 6,818 shares vests ratably on a monthly basis beginning July 31, 2015.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px 0px 0px 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;i&gt;Fundraising Bonus Opportunities&lt;/i&gt;.&amp;#160;&amp;#160;&amp;#160;Each executive is entitled to receive (i) a one-time cash bonus of&amp;#8201; $50,000 upon the sale of additional equity capital for cash, in one or more closings after July&amp;#160;17, 2012, and/or the actual deployment of funds by a third party for a clinical trial in an aggregate amount in excess&amp;#160;of&amp;#8201; $2,000,000 and (ii) a one-time cash bonus of&amp;#8201; $150,000 upon the sale of additional equity capital for cash, in one or more closings after July&amp;#160;17, 2012 and/or the actual deployment of funds by a third party for a clinical trial in an aggregate amount in excess of $10,000,000 (which such bonus will be reduced by any cash bonus paid under subsection (i)); provided, however, that no bonus under subsection (i) or (ii) may be paid at any time the Company has less than $2,000,000 in available cash. In addition, upon the satisfaction of the milestone described in subsection (i), 35% of 6,993 shares of the Executive Options will vest and become exercisable, with the balance of the 6,993 shares vesting in 36 equal monthly installments beginning on the last day of the following month, and, upon satisfaction of the milestone described in subsection (ii), 35% of 13,986 shares of the Executive Options will vest and become exercisable, with the balance of the 13,986 shares vesting in 36 monthly installments beginning on the last day of the following month. Upon the closing of the initial public offering on June 29, 2015 raising approximately $17.4 million, net of offering costs, each executive was entitled to receive a bonus of $150,000 accrued and recognized in general and administrative expenses in the accompanying Unaudited Condensed Statements of Operations in the three and six month periods ending June 30, 2015. In addition, 4,895 shares of the Executive Options vested and became exercisable as of June 29, 2015, with the balance of 9,091 shares vests ratably on a monthly basis beginning July 31, 2015.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: -0.25in; margin: 0px 0px 0px 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;i&gt;License Event Bonus Opportunities&lt;/i&gt;.&amp;#160;&amp;#160;&amp;#160;Each executive is entitled to receive the following bonus payments in connection with the closing of an exclusive license of RP-G28 and/or any future product candidate developed by the Company from time to time during the term of the Compensation Plan by an/or any option to exclusively license such product candidate to a third party (referred to under the Compensation Plan as a &amp;#8220;License Event&amp;#8221;) with a minimum upfront payment to the Company of&amp;#8201; $2,000,000:&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;o&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;A graduated cash bonus equal to (i) 5% of the Initial Period License Payment (as defined below) up to $5,000,000; (ii) 4% of the Initial Period License Payment in excess of&amp;#8201; $5,000,000 up to $10,000,000; and (iii) 3% of the Initial Period License Payment in excess of $10,000,000. In addition, upon the Company&amp;#8217;s receipt of an Initial Period License Payment of more than $2,000,000, 35% of 45,454 shares of their Executive Options will vest and become exercisable, with the balance of the 45,454 shares vesting in 36 monthly installments beginning on the last day of the following month.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px 0px 0px 0.75in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;o&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;A cash bonus equal to 3% of any Annual Excess Milestone Payments (as defined below); provided, however that no such bonus may be paid at any time the Company has less than $1,000,000 in available cash. In addition, upon the Company&amp;#8217;s receipt of an Annual Excess Milestone Payment, 35% of 6,993 shares of their Executive Options will vest and become exercisable, with the balance of the 6,993 shares vesting in 36 monthly installments beginning on the last day of the following month.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Notwithstanding any of the vesting provisions set forth above, the total potential number of Executive Options that may vest will not exceed 48,951 and the Executive Options will automatically terminate for any options for which a vesting date or performance condition has not been met by September&amp;#160;25, 2015.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;For purposes of the Compensation Plan, the term &amp;#8220;&lt;i&gt;Initial Period License Payment&lt;/i&gt;&amp;#8221; means the aggregate amount in cash received by the Company (not including any amount placed in escrow or subject to earn-outs, contingencies or other deferrals or earmarked to pay or reimburse the Company for research and development activities) in respect of the License Event over a 24 month period beginning on the closing date of such License Event (which period is referred to therein as the &amp;#8220;&lt;i&gt;Initial Period&lt;/i&gt;&amp;#8221;). The term &amp;#8220;&lt;i&gt;Annual Excess Milestone Payments&lt;/i&gt;&amp;#8221; means the amount in cash in excess of&amp;#8201; $2,000,000 (not including any amounts placed in escrow or subject to earn-outs, contingencies or other deferrals) that is received by the Company in respect of any Post-Closing Milestones (as defined below) in each 12-month period beginning on the expiration of the Initial Period. The term &amp;#8220;&lt;i&gt;Post-Closing Milestones&lt;/i&gt;&amp;#8221; means any post-closing payouts set forth in the definitive transaction documentation executed in connection with a License Event; provided, however, that such amounts will not include any amounts that are determined by the Board of Directors to comprise all or any portion of any upfront payment made in connection with a License Event and any royalty payment based on product sales.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Compensation Plan provides that in the event that the Company enters into more than one License Event with respect to a single product candidate (i.e., for a separate field of use), then the proceeds of any such additional License Event will be included with the proceeds of the original License Event for purposes of meeting any of the financial thresholds set forth above. Under the terms of the Compensation Plan, receipt by the Company of more than one&amp;#160;&lt;i&gt;bona fide&lt;/i&gt;&amp;#160;term sheet for a proposed License Event with respect to RP-G28 will result in the payment of an additional 10% of any cash bonus earned as Clinical Trial and Fundraising Bonus or a License Event Bonus.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Under the terms of the Compensation Plan, each executive is entitled to receive certain payments in the event their employment is terminated under certain scenarios.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On December&amp;#160;2, 2014, pursuant to the 2008 stock plan, the Company granted an aggregate of 453,413 options to the President and the CSO to purchase the Company&amp;#8217;s common stock listed as follows:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;(i)&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;20,979 fully vested options with an exercise price of&amp;#8201; $5.86; and&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;(ii)&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;432,434 options which vest 25% upon the first anniversary of the vesting commencement date with the remaining options vesting monthly in equal amounts over 36 months with an exercise price equal to $5.86 for the first 152,347 options covered thereby, $9.30 for the next 140,044 options covered thereby, and $13.23 for the remaining balance.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;In addition, all non-employee directors will each be initially entitled to receive an option to acquire 1,398 shares of the Company&amp;#8217;s common stock, which will vest annually over a three-year term from the grant date, and annually thereafter be entitled to receive an option to acquire 979 shares of the Company&amp;#8217;s common stock, each of which will vest one year from the grant date. As of June 30, 2015, no stock based compensation or cash compensation has been granted to the directors under this program.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="color: black;"&gt;The Company leases office and storage space for its headquarters in California pursuant to a two-year agreement ending September&amp;#160;30, 2015 which calls for a minimum monthly rent of approximately $5,000 and an annual increase of 3%. Rent expense, recognized on a straight-line basis, was approximately $15,000 for each of the three months ended June 30, 2015 and 2014.&amp;#160;&lt;/font&gt;The Company recognized approximately $30,000 in each of the six months ended June 30, 2015 and 2014 in rent expense. Rent expense is recorded in general and administrative expenses in the Unaudited Condensed Statements of Operations.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In July 2015, the Company entered into a new five-year lease agreement for new corporate office space, projected to be effective October 1, 2015, which calls for a minimum lease payment of approximately $107,000 annually.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Legal&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company is not currently involved in any legal matters arising in the normal course of business. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 6&amp;#8201;&amp;#8212;&amp;#8201;STOCKHOLDERS&amp;#8217; EQUITY (DEFICIT) AND PREFERRED STOCK SUBJECT TO REDEMPTION&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;As of December 31, 2014, the Company was authorized to issue 50,000,000 shares of common stock with a par value of&amp;#8201;$0.001 per share. The Company amended and restated its Certificate of Incorporation in June 2015 (&amp;#8220;the Amended Certificate&amp;#8221;) and reduced the authorized shares of the Company&amp;#8217;s common stock to 25,000,000 with a par value of $0.001 per share.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Effective June 17, 2015, all common share amounts and per share amounts have been adjusted to reflect a 1-for-7.15 reverse stock split.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s Board of Directors is authorized, subject to any limitations prescribed by law, to provide for the&amp;#160;issuance of the authorized shares of preferred stock in series and to&amp;#160;establish the number of shares to be included in each such series, and to fix the designation, powers, preferences and&amp;#160;rights of the shares of each such series and any qualifications, limitations or restrictions thereon.&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="color: black;"&gt;Pursuant to the Amended Certificate, as of June 30, 2015, the Company is authorized to issue 5,000,000 shares of preferred stock, $0.001 par value per share.&lt;/font&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;font style="color: black;"&gt;Prior to the Amended Certificate and as of December 31, 2014, the Company was authorized to issue 7,200,000 shares, 1,687,500 shares, 4,220,464 shares, 7,658,182 shares, and 4,500,000 shares of Series A-1, Series A-2, Series A-3, Series B, and Series C preferred stock, respectively, with a par value of&amp;#8201;$0.001 per share.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="color: black;"&gt;Upon the closing of the Company&amp;#8217;s initial public offering, all outstanding shares of convertible preferred stock and preferred stock subject to redemption were converted into an aggregate of 3,322,650 shares of common stock. The following provides material terms and certain historical information regarding the&amp;#160;&lt;/font&gt;Series A-1, Series A-2, Series A-3, Series B and Series C Preferred Stock prior to their conversion to common stock:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; font-size-adjust: none;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;i&gt;Redemption.&amp;#160;&lt;/i&gt;&lt;font style="color: black;"&gt;At any time after five years following the date of the initial issuance of the Series A-3, Series B, or Series C preferred stock, as applicable, and at the option of the holders of a majority of the then outstanding shares of Series A-3, Series B, and Series C preferred stock, voting together as a single class, the Company was required to redeem any outstanding shares that have not been converted by paying cash in an amount per share equal to the liquidation preference of&amp;#8201; $0.62 and $1.30 for the Series A-3 and Series C preferred stock, respectively, and $1.19 per share, plus any accrued but unpaid dividends, for the Series B preferred stock. Given the holders&amp;#8217; redemption option, the Series A-3, Series B, and Series C preferred stock is classified as preferred stock subject to redemption in the accompanying Condensed Balance Sheets.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: -0.25in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;/b&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; font-size-adjust: none;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;i&gt;Dividends.&amp;#160;&lt;/i&gt;&lt;font style="color: black;"&gt;The holders of outstanding shares of preferred stock were entitled to receive dividends, when, as and if declared by the Company&amp;#8217;s Board of Directors. The annual dividend rate was $0.00556 per share for the Series A-1 preferred stock, $0.032 per share for the Series A-2 preferred stock, $0.04957 per share for the Series A-3 preferred stock, $0.09524 per share for the Series B preferred stock, and $0.104 for Series C preferred stock (subject to adjustment). The right to receive dividends on shares of Series B preferred stock was cumulative and the dividends accrue to holders of Series B preferred stock whether or not dividends are declared or paid in a calendar year. Undeclared dividends in arrears for the Series B preferred stock was approximately $2 million and $1.7 million as of June 30, 2015 and December 31, 2014, respectively. The right to receive dividends on shares of Series A and Series C preferred stock was not cumulative and no right to such dividends accrued to holders of Series A or Series C preferred stock.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table align="center" style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; font-size-adjust: none;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;i&gt;Liquidations.&amp;#160;&lt;/i&gt;&lt;font style="color: black;"&gt;In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series B and Series C preferred stockholders receive an amount per share equal to the sum of the original purchase price of&amp;#8201;$1.19 plus all cumulative but unpaid dividends for Series B, and $1.30 for Series C. If upon the liquidation, the available assets are insufficient to permit payments to Series B and Series C holders, the entire assets legally available will be distributed in a pro rata basis among the holders in proportion to the full amounts they would otherwise be entitled to receive. Upon the completion of the distribution to the holders of the Series B and Series C preferred stock, the holders of the Series A preferred stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the Company to the holders of all other capital stock by reason of their ownership of such stock, an amount per share equal to the sum of the original issue price per share of&amp;#8201; $0.07, $0.4, and $0.62 for Series A-1, Series A-2, and Series A-3 preferred stock, respectively, plus any accrued but unpaid dividends on the preferred stock. Any remaining assets are distributed pro rata among the preferred and common shareholders.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Stock Transactions&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Initial Public Offering&lt;/u&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On June 29, 2015, the Company closed its initial public offering, selling 4,000,000 shares of the Company&amp;#8217;s common stock at an initial public offering price of $5.00 per share, for aggregate gross proceeds to the Company of $20 million.&amp;#160; The Company paid to the underwriters underwriting discounts and commissions of approximately $1.6 million in connection with the offering, and approximately $1 million of other expenses in connection with the offering. Effectively prior to the closing of the initial public offering, the Company converted all of its outstanding shares of Series A-1, Series A-2, Series A-3, Series B, and Series C preferred into an aggregate of 3,322,650 shares of the Company&amp;#8217;s common stock.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Series C Financing&lt;/u&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="color: black;"&gt;In December&amp;#160;2014, the Company issued an aggregate of&amp;#160;&lt;/font&gt;&lt;font style="color: #231f20;"&gt;2,369,228&amp;#160;&lt;/font&gt;&lt;font style="color: black;"&gt;shares of Series C preferred stock, which was later converted into an aggregate of 331,358 shares of the Company&amp;#8217;s common stock, and warrants to purchase an aggregate of 331,358 shares of the Company&amp;#8217;s common stock (the &amp;#8220;Warrants&amp;#8221;), for aggregate gross proceeds of&amp;#8201; $3,081,893 (the &amp;#8220;Series C Financing&amp;#8221;). Each Warrant has a term of seven (7) years and provides for the holder to purchase one share of the Company&amp;#8217;s common stock at a purchase price of&amp;#8201;$9.30 per share of common stock. The Warrants are indexed to the Company&amp;#8217;s own stock and classified within stockholders&amp;#8217; equity pursuant to ASC 815-40. The gross proceeds were allocated to the Series C preferred stock and Warrants on a relative fair value basis, resulting in a value of&amp;#8201;$7.83 for the Series C preferred stock. The allocation of proceeds to the Warrants creates a discount of&amp;#8201;$1.47 in the initial carrying value of the Series C preferred stock, which was recognized as accretion, similar to preferred stock dividends, over the five-year period prior to optional redemption by the holders.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In connection with the Series C Financing, all of the 2014 Notes were converted into shares of Series C preferred stock and Warrants as follows:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; font-size-adjust: none;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="color: black; font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="color: black;"&gt;$535,000 unpaid principal plus accrued interest of&amp;#8201; $18,342 on convertible notes converted into&amp;#160;&lt;/font&gt;567,529&amp;#160;&lt;font style="color: black;"&gt;shares of Series C preferred stock, which was later converted into 79,374 shares of the Company&amp;#8217;s common stock, and 79,374 Warrants&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; font-size-adjust: none;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="color: black; font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="color: black;"&gt;$70,000 unpaid principal plus accrued interest of&amp;#8201; $537 on note payable extinguished and converted into&amp;#160;&lt;/font&gt;54,259&amp;#160;&lt;font style="color: black;"&gt;shares of Series C preferred stock, which was later converted into 7,589 shares of the Company&amp;#8217;s common stock and 7,589 Warrants&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Notes with an unpaid principal balance of $535,000 were converted into shares of Series C preferred stock and warrants to purchase shares of common stock at 75% of the price paid by other purchasers of the Series C Financing. The Company recognized additional interest expense of&amp;#8201;$184,445 upon conversion, calculated as the fair value of incremental shares and warrants received by the holders compared to converting the outstanding debt and accrued interest at 100% of the price paid by purchasers of the Series&amp;#160;C Financing. The note with an unpaid principal balance of&amp;#8201;$70,000 was exchanged for shares of Series C preferred stock and warrants to purchase shares of common stock at a price per share equal to the price per share paid by purchasers of the Series C Financing. As such, there was no gain recognized or loss incurred upon extinguishment of the note in 2014.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Prepaid Forward Sale of Preferred Stock&lt;/u&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On November&amp;#160;30, 2010, the Company concurrently entered into a Research and Development Agreement &amp;amp; License (&amp;#8220;R&amp;amp;D Agreement&amp;#8221;) and a Put and Call Option Agreement (&amp;#8220;Put/Call&amp;#8221;) with two commonly controlled entities, Kolu Pohaku Technologies, LLC (&amp;#8220;KPT&amp;#8221;) and Kolu Pohaku Management, LLC (&amp;#8220;KPM&amp;#8221;). The agreement was subsequently amended on July&amp;#160;6, 2011, September&amp;#160;30, 2011, February&amp;#160;6, 2012 and November&amp;#160;4, 2013 to increase the funding received by the Company.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Research and Development Agreement &amp;amp; License&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The R&amp;amp;D Agreement between the Company and KPM and KPT, a Qualified High Technology Business within the meaning of Hawaii Revised Statutes, called for KPT to make a series of payments to the Company totaling $1,750,000 in exchange for the Company performing research and development activities in Hawaii for the benefit of KPT (referred to herein as the KP Research). The KP Research consisted of the initial phase of research, including the conduct of Phase II clinical trials in Hawaii for RP-G28. Pursuant to the terms of the R&amp;amp;D Agreement, the Company maintained ownership of the results of the Company&amp;#8217;s ongoing research related to RP-G28, but KPT maintained ownership of the results of the KP Research. Inventions, developments and improvements arising out of the KP Research were owned by KPT. Under the terms of the R&amp;amp;D Agreement, the Company would bear any costs involved in obtaining patents for any inventions, developments or improvements resulting from the Research Project. In exchange for the irrevocable, perpetual, exclusive, worldwide right and license to the results of the KP Research, as they are generated under this R&amp;amp;D Agreement, the Company agreed to pay a quarterly royalty payment to KPT of $32,000 commencing March&amp;#160;31, 2015 and continuing through December&amp;#160;31, 2035 or until such time as the KPM Option (as described below) was exercised. On March&amp;#160;26, 2015, the Company exercised the right to put the KPM Option and issued 1,469,994 shares of Series B preferred stock to KPM, resulting in the full satisfaction of the Company&amp;#8217;s obligation to make royalty payments to KPT.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Put and Call Option Agreement&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Pursuant to the terms of the KPM Option Agreement, the Company had the right to put 1,469,994 shares of the Company&amp;#8217;s Series B Preferred Stock (&amp;#8220;Series B&amp;#8221;) to KPM and KPM has the option to call the same amount of shares of Series B from the Company at any time after December&amp;#160;31, 2014. The number of shares was determined by dividing the $1,750,000 of payments made by KPT to the Company under the R&amp;amp;D Agreement by the Series B original issue price of&amp;#8201;$1.19. Exercise of the Put/Call results in full satisfaction of the Company&amp;#8217;s obligation to make royalty payments to KPT under the R&amp;amp;D Agreement and KPT&amp;#8217;s right, title and interest in the research conducted pursuant to the R&amp;amp;D Agreement becomes the property of the Company. On March&amp;#160;26, 2015, the Company exercised the right to put the KPM Option and issued 1,469,994 shares of Series B preferred stock to KPM, or the KPM Shares. Pursuant to the terms of the KPM Option Agreement, this resulted in the full satisfaction of the Company&amp;#8217;s obligation to make royalty payments to KPT under the R&amp;amp;D Agreement and also resulted in the termination of the R&amp;amp;D Agreement and all of KPT&amp;#8217;s right, title and interest in and to the KP Research, which rights now belong to the Company.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The R&amp;amp;D Agreement and the Put/Call have been recognized on a combined basis, pursuant to ASC 815-10-15-9, as a fully prepaid forward sale contract on the Company&amp;#8217;s Series B preferred stock. The fully prepaid forward sale contract is a hybrid instrument comprising (1) a debt host instrument and (2) an embedded forward sale contract, requiring the Company to issue 1,469,994 shares of the Company&amp;#8217;s Series&amp;#160;B for no further consideration. Payments received by the Company, totaling $1,750,000, are recognized as preferred stock subject to redemption in the Condensed Balance Sheet as of December 31, 2014. The Company converted these shares into an aggregate of 205,593 shares of the Company&amp;#8217;s common stock upon the closing of the IPO.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<rttr:WarrantsTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 7&amp;#8201;&amp;#8212;&amp;#8201;WARRANTS&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;As described in Note 6, in 2014, the Company issued seven-year warrants (&amp;#8220;the Warrants&amp;#8221;) to investors for the purchase of 418,321 shares of the Company&amp;#8217;s common stock at an exercise price of&amp;#8201;$9.30 per share.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company analyzed the Warrants in accordance with ASC Topic 815 to determine whether the Warrants meet the definition of a derivative and, if so, whether the Warrants meet the scope exception that provides for equity classification of derivative instruments issued or held by the reporting entity that are both (1) indexed to its own stock and (2) classified in stockholders&amp;#8217; equity. The Company concluded these Warrants should be classified as equity since they contain no provisions, which would require recognition as a liability.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The following represents a summary of the warrants outstanding at June 30, 2015 and changes during the period then ended:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 928px;"&gt;Outstanding at December 31, 2014&lt;/td&gt;
&lt;td style="width: 13px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 13px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 126px; text-align: right;"&gt;418,321&lt;/td&gt;
&lt;td style="width: 12px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 125px; text-align: right;"&gt;9.30&lt;/td&gt;
&lt;td style="width: 12px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 10pt;"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 10pt; padding-bottom: 1pt;"&gt;Exercised/Expired/ Forfeited&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style:
 solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Outstanding at June 30, 2015&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;418,321&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;9.30&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Exercisable at June 30, 2015&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;418,321&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;9.30&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</rttr:WarrantsTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 8&amp;#8201;&amp;#8212;&amp;#8201;STOCK-BASED COMPENSATION&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Terms of the Company&amp;#8217;s share-based compensation are governed by the Company&amp;#8217;s 2015 Stock Plan, 2009 Stock Plan and 2008 Stock Plan (collectively the &amp;#8220;Plans&amp;#8221;.) The Plans permit the Company to grant non-statutory stock options, incentive stock options and stock purchase rights to the Company&amp;#8217;s employees, outside directors and consultants; however, incentive stock options may only be granted to the Company&amp;#8217;s employees. Beginning June 29, 2015, no awards may be granted under the 2009 Stock Plan or 2008 Stock Plan. &amp;#160;As of&amp;#160;June 30, 2015, the maximum aggregate number of shares of common stock that may be issued is 328,289 under the 2015 Stock Plan. The exercise price for each option is determined by the Board of Directors, but will be (i) in the case of an incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share on the date of grant; and (ii) in the case of a nonstatutory stock option, no less than 100% of the fair market value per share on the date of grant. The options awarded under the Plans shall vest as determined by the Board of Directors but shall not exceed a ten-year period.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Options Issued to Directors and Employees as Compensation&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Pursuant to the terms of the Plans, from inception to December 31, 2013, the Company has issued options to purchase an aggregate of 206,172 shares to its executive officers and employees of the Company. Of these, 26,163 options were forfeited and 180,009 options remain outstanding as of December 31, 2013. No additional options were granted or forfeited during the six months ended June 30, 2014. The exercise prices of these option grants, as determined by the Company&amp;#8217;s Board of Directors, range from $0.79 to $1.27 per share, and a portion of these vest subject to certain performance conditions described in Note 5. The Company&amp;#8217;s management initially assessed the likelihood of the performance conditions for the options granted to its executive officers to be probable of achievement. In April 2015, certain performance conditions providing for options to purchase an aggregate of 41,958 shares of the Company&amp;#8217;s common stock were no longer considered to be probable of achievement by September&amp;#160;25, 2015.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In December 2014, the Company granted additional non-qualified 10-year term options to its executive officers to purchase an aggregate of 1,729,766 shares of the Company&amp;#8217;s common stock. Also in 2014, an aggregate of 41,958 options expired and 13,985 options were exercised. The exercise prices of these option grants, as determined by the Company&amp;#8217;s Board of Directors, range from $5.86 to $13.23 per share. No additional options were granted in the six month period ended June 30, 2015. As of June 30, 2015, 1,853,831 options remain outstanding.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company recognized stock based compensation expense for these services within general and administrative expense in the accompanying Unaudited Condensed Statements of Operations of approximately $1.7 million and $88,000 for the six months ended June 30, 2015 and 2014, respectively, and approximately $880,000 and $87,000 for the three months ended June 30, 2015 and 2014, respectively. As of June 30, 2015, there was approximately $2.9 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements. This cost is expected to be recognized over a weighted average period of 1.6 years.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Options Issued to Nonemployees for Services Received&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;From inception to June 30, 2015, the Company has issued options to its consultants to purchase an aggregate of 106,573 shares of the Company&amp;#8217;s common stock under the Plans. Of these, 69,580 options were forfeited or exercised, and 36,993 options remain outstanding as of June 30, 2015. The exercise prices of the outstanding options, as determined by the Company&amp;#8217;s Board of Directors, range from $0.72 to $1.14 per share. These outstanding options, with the exception of an option to purchase an aggregate of 7,271 shares granted to a consultant, vest 25% upon the first anniversary of the vesting commencement date with the remaining options vesting monthly in equal amounts over 36 months. In March&amp;#160;2011, the Company granted an option to a consultant to purchase an aggregate of 7,271 shares with an exercise price of&amp;#8201;$1.00 which vests 25% on the date of grant with the remaining options vesting monthly in equal amounts over 36 months. The Company recognized stock based compensation expense for these services of approximately $700 and $3,500 for the six months ended June 30, 2015 and 2014, respectively, and approximately $600 and $4,000 for the three months ended June 30, 2015 and 2014, respectively, within research and development expense in the accompanying Unaudited Condensed Statements of Operations.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Options Valuation&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. If the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company&amp;#8217;s stock options could change significantly. Higher volatility and longer expected lives would result in an increase to stock-based compensation expense to non-employees determined at the date of grant.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Stock-based compensation expense to non-employees affects the Company&amp;#8217;s general and administrative expenses and research and development expenses.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Black-Scholes option-pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards. The assumptions used in the Black-Scholes option-pricing method for the three months and six months ended June 30, 2015 and 2014 are set forth below:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="3" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Three months ended June 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="3" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Six months ended June 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; width: 439px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 251px; font-size: 10pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 32px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 251px; font-size: 10pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 31px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 266px; font-size: 10pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 31px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 266px; font-size: 10pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;" nowrap="nowrap"&gt;Expected dividend yield&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;0.00%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;0.00%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;0.00%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;0.00%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;" nowrap="nowrap"&gt;Expected stock-price volatility&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;65.06% - 67.08%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;55.32% - 62.09%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;51.45% - 67.08%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;55.32% - 62.09%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;" nowrap="nowrap"&gt;Risk-free interest rate&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;1.79% - 2.07%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;1.54% - 2.67%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;0.77% - 2.07%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;1.49% - 3.04%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;" nowrap="nowrap"&gt;Term of options&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;10&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;10&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;10&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;10&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;" nowrap="nowrap"&gt;Stock price&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;$5.86&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;$1.17&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;$5.86&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;$1.17&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;i&gt;Expected dividend.&lt;/i&gt;&amp;#160;&amp;#160;&amp;#160;The expected dividend is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on the Company&amp;#8217;s common stock.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;i&gt;Expected volatility.&lt;/i&gt;&amp;#160;&amp;#160;&amp;#160;As the Company&amp;#8217;s common stock only recently became publicly traded, the expected volatility is derived from the average historical volatilities of publicly traded companies within the Company&amp;#8217;s industry that the Company considers to be comparable to the Company&amp;#8217;s business over a period approximately equal to the expected term.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;i&gt;Risk-free interest rate.&lt;/i&gt;&amp;#160;&amp;#160;&amp;#160;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;i&gt;Expected term.&lt;/i&gt;&amp;#160;&amp;#160;&amp;#160;The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&amp;#8217;s historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by the SEC. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In addition to the assumptions used in the Black-Scholes option-pricing model, the Company also estimates a forfeiture rate to calculate the stock-based compensation for the Company&amp;#8217;s equity awards. The Company will continue to use judgment in evaluating the expected volatility, expected terms and forfeiture rates utilized for the Company&amp;#8217;s stock-based compensation calculations on a prospective basis.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Significant factors, assumptions and methodologies used in determining the estimated fair value of the Company&amp;#8217;s common stock&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company is also required to estimate the fair value of the common stock underlying the Company&amp;#8217;s stock-based awards when performing the fair value calculations using the Black-Scholes option-pricing model. The Company&amp;#8217;s Board of Directors, with the assistance of management, determined the fair value of the Company&amp;#8217;s common stock on each grant date. Option grants are based on the estimated fair value of the Company&amp;#8217;s common stock on the date of grant, which is determined by taking into account several factors, including the following:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;the prices at which the Company sold the Company&amp;#8217;s convertible preferred stock and the rights, preferences, and privileges of the convertible preferred stock relative to those of the Company&amp;#8217;s common stock, including the liquidation preferences of the convertible preferred stock;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;important developments in the Company&amp;#8217;s operations;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;the Company&amp;#8217;s actual operating results and financial performance;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;conditions in the Company&amp;#8217;s industry and the economy in general;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px 0px 0px 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;stock price performance of comparable public companies;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;the estimated likelihood of achieving a liquidity event, such as an IPO or an acquisition of the Company, given prevailing market conditions; and&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;the illiquidity of the common stock underlying stock options.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The table below presents the prices received from sales to third parties of the Company&amp;#8217;s common stock and various classes of the Company&amp;#8217;s preferred stock from inception to date:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 940px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold;" nowrap="nowrap"&gt;Year&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold;" nowrap="nowrap"&gt;Share Class&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold;" nowrap="nowrap"&gt;Price per Share&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; width: 320px;"&gt;2005&lt;/td&gt;
&lt;td style="width: 10px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 413px;"&gt;Common Stock (a)&lt;/td&gt;
&lt;td style="width: 9px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 188px;"&gt;$1.79&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2006&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Series A-2 Preferred Stock (a)(b)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.40&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2008 - 2009&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Series A-3 Preferred Stock (b)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.62&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2010 - 2013&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Series B Preferred Stock (b)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$1.19&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2014&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Series C Preferred Stock (b)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$1.30&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2015&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Common Stock&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$5.00&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;(a)&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;After giving effect to the Company&amp;#8217;s conversion from a LLC to a corporation.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;(b)&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;Shares of preferred stock were converted into an aggregate of 3,322,650 shares of the Company&amp;#8217;s common stock effective June 29, 2015, after giving effect to the 1-for-7.15 reverse stock of shares of the Company&amp;#8217;s common stock effective June 17, 2015.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;For options issued from inception to November&amp;#160;7, 2013, in determining the estimated fair value of the Company&amp;#8217;s common stock, the Company&amp;#8217;s Board of Directors, with the assistance of management, used the market approach to estimate the enterprise value of the Company in accordance with the American Institute of Certified Public Accountants (&amp;#8220;AICPA&amp;#8221;) Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the &amp;#8220;AICPA Guide&amp;#8221;) for the three valuation dates of November&amp;#160;7, 2013, July&amp;#160;31, 2012, and December&amp;#160;31, 2010. The Market Approach is one of the three approaches (along with the Income Approach and Asset Approach) used to estimate enterprise and equity value. The market approach employs analysis using comparable companies in determining the value of the entity. Both public and private companies, if publicly available information exists, are considered in the market approach. Two information points commonly available &amp;#8212; company valuation and transaction value &amp;#8212; are used for their respective methodologies. There are a number of different methods within the Market Approach that may be used: the three main methods utilized are: the Guideline Pubic Companies Method; the Guideline Transactions Method; and the Backsolve Method.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Given the early stage of the Company, the Backsolve Method was used to estimate the fair value of the Company&amp;#8217;s securities. This method derives an implied market value of invested capital from a transaction involving a company&amp;#8217;s own securities. The price of a company&amp;#8217;s security that was involved in a recent arms-length transaction is used as a reference point in an allocation of value. The Company first raised additional capital through the sales of the Company&amp;#8217;s LLC units. These units later converted into common shares and preferred shares upon the Company&amp;#8217;s conversion to a corporation. Subsequent to the Company&amp;#8217;s corporation conversion, the Company raised additional capital through the sales of the Company&amp;#8217;s Series A-1, Series A-2, Series A-3, Series B, and Series C preferred shares at the price of&amp;#8201;$0.07, $0.40, $0.62, $1.19, and $1.30, respectively.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company valued LLC units and common stock (after converting to a corporation) from inception through 2009 by reference to the Company&amp;#8217;s sales of units and/or common stock &amp;amp; preferred stock over the period. Beginning in 2010, the Company valued the Company&amp;#8217;s common stock using the Backsolve Method. The Backsolve Method requires considering the rights and preferences of each class of equity and solving for the total market value of invested capital that is consistent with a recent transaction in the Company&amp;#8217;s own securities, considering the rights and preferences of each class of equity. However, management has decided that the liquidation preferences between the Company&amp;#8217;s preferred shares and common shares are immaterial for a pre-revenue company.&lt;/p&gt;
&lt;p&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Per the AICPA Guide, the Backsolve Method is generally the most reliable indicator of value of early-stage enterprises with no product revenue or cash flow, if relevant and reliable transactions have occurred in the Company&amp;#8217;s equity securities. This methodology is also prescribed by the AICPA when a valuation is conducted in close proximity to the date of a financing transaction, and when other methodologies are deemed less reliable.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The stage of development of the Company&amp;#8217;s compound was reflected in the Company&amp;#8217;s selection of the term and volatility estimates used in the analysis. The estimate of the term considers the Company&amp;#8217;s existing cash runway and the time to the next potential financing or liquidity event, while the volatility estimate reflects the relative riskiness of the Company&amp;#8217;s equity securities (or asset base) relative to the general stock market.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Management estimated the implied market value of invested capital of the Company by backsolving for the purchase price of the Company&amp;#8217;s preferred shares for one common share through the option-pricing method. The premise of this method is that the transaction implied a market price for a share which in turn implied values for the other classes of equity based on relative claims on equity value, such as liquidation preferences and conversion rights. The application of the backsolve method considering the Company&amp;#8217;s capital structure yielded a total market value of invested capital of approximately $15.5 million, $14.4 million, and $8.9 million, of which approximately $819,000, $870,000, and $670,000 were allocated to the total value of common stock as of the Company&amp;#8217;s three valuation dates of November&amp;#160;7, 2013, July&amp;#160;31, 2012, and December&amp;#160;31, 2010, respectively.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On the three valuation dates of November&amp;#160;7, 2013, July&amp;#160;31, 2012, and December&amp;#160;31, 2010, after estimating the market value of invested capital, the Company allocated it to the various equity classes comprising the subject company&amp;#8217;s capitalization table. This process ultimately results in creating a final estimate of value for the subject company&amp;#8217;s underlying equity interests. While there are many different value allocation methods, these various methods can be grouped into three general categories as defined by the AICPA Guide, one of which is the Option-Pricing Method (OPM).&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company used the OPM to allocate market value of invested capital to the various equity classes and debt comprising the Company&amp;#8217;s capitalization structure. The Company chose the OPM over other acceptable methods due to the complex capital structure, the uncertainty related to market conditions, and the lack of visibility on an imminent exit event. Under the OPM, each equity class is modeled as a call option with a distinct claim on the equity of the Company. The option&amp;#8217;s exercise price is based on the Company&amp;#8217;s total equity value available for each participating equity holder. The characteristics of each equity class determine the equity class&amp;#8217; claim on the total equity value. By constructing a series of options in which the exercise price is set at incremental levels of value, which correspond to the equity value necessary for each level of equity to participate, the Company determined the incremental option value of each series. When multiplied by the percentage of ownership of each equity class participating under that series, the result is the incremental value allocated to each class under that series.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The OPM relies on the Black-Scholes option-pricing model to value the call options on the Company&amp;#8217;s invested capital. The following inputs were applied in the Black-Scholes calculations of the OPM:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="5" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Valuation Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="width: 286px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 21px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 244px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;November 7, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 20px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 183px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;July 31, 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 10px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 254px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;December 31, 2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;Volatility&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;58.00%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;61.00%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;61.00%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;Risk-free interest rate&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;0.55%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;0.57%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;2.01%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;Maturity (years)&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;3&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;4&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;5&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Discounts ranging from 35.8% to 40% were applied for lack of control and lack of marketability for the common stock. The calculation resulted in a fair value for the common stock of&amp;#8201;$1.17, $1.19, and $1.03 per share as of the Company&amp;#8217;s three valuation dates of November&amp;#160;7, 2013, July&amp;#160;31, 2012, and December&amp;#160;31, 2010, respectively.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;For options issued in 2014, given the Company&amp;#8217;s distinct possible exit scenarios of an initial public offering, the Company used the probability weighted expected return method (PWERM) to estimate the fair value of the Company&amp;#8217;s common equity. Under this method, an analysis of future values of a company is performed for several likely liquidity scenarios. The value of the common stock is determined for each scenario at the time of each future liquidity event and discounted back to the present using a risk-adjusted discount rate. The present values of the common stock under each scenario are then weighted based on the probability of each scenario occurring to determine the value for the common stock. The Company&amp;#8217;s management determined the probability weighting of potential liquidity events to be 45% for an initial public offering and 55% for other scenarios, which represents all other likely outcomes for the Company.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Management estimated the implied market value of invested capital of the Company by backsolving for the purchase price of the Company&amp;#8217;s preferred shares for one common share through the use of OPM. The application of the backsolve method considering the Company&amp;#8217;s capital structure yielded a total market value of invested capital of approximately $25.2 million, of which approximately $1.4 million was allocated to the total value of common stock as of the Company&amp;#8217;s valuation date of October&amp;#160;31, 2014.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Given the lack of marketability for the common stock, the Company applied a discount of 21.4% for using the average strike put option approach. This resulted in a probability weighted common share value, after adjustment, of&amp;#8201;$5.86 per share as of valuation date of October&amp;#160;31, 2014.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Stock-based Compensation Summary Tables&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Information regarding the Company&amp;#8217;s stock option grants to the Company&amp;#8217;s employees and non-employees, along with the estimated fair value per share of the underlying common stock, for stock options granted since 2005 is summarized as follows:&lt;/p&gt;
&lt;p style="widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; width: 395px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 15px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 240px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Number of Common&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 15px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 239px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 14px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 239px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Estimated Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 14px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 239px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Shares Underlying&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;per Common&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;per Share of&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Intrinsic Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Grant Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Options Granted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Option&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2005&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;58,321&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$0.07&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$1.79&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$1.72&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2009&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;60,559&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$0.72 - $0.79&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$4.43&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$3.71 - $3.64&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2011&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;33,846&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$1.00&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$1.00&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.00&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2012&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;60,019&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$1.14&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$1.14&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.00&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2013&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;100,000&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$1.14 - $1.30&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$1.14&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.00&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2014&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;1,626,740&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$5.86- $13.23&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$5.86&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.00&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The following represents a summary of the options granted to employees and non-employees outstanding at June 30, 2015 and changes during the period then ended:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/font&gt;&lt;br  /&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="width: 802px;"&gt;Outstanding at December 31, 2014&lt;/td&gt;
&lt;td style="width: 13px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 13px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 188px;"&gt;1,788,717&lt;/td&gt;
&lt;td style="text-align: left; width: 13px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 13px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 12px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 187px;"&gt;7.059&lt;/td&gt;
&lt;td style="text-align: left; width: 12px;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-indent: 10pt;"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;103,025&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5.863&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt;"&gt;Exercised/ Expired/ Forfeited&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(918&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(1.158&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;Outstanding at June 30, 2015&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,890,824&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;7.062&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Exercisable at June 30, 2015&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;298,437&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;4.563&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Expected to be vested&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,592,387&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4.563&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 9&amp;#8201;&amp;#8212;&amp;#8201;RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;A director of the Company is a managing director of Javelin Venture Partners GP, LLC, the general partner of Javelin Venture Partners GP, L.P., which held a significant investment in the Company&amp;#8217;s Series A-1, Series A-2, Series A-3, Series B, and Series C preferred stock that was converted to common stock prior to the Company&amp;#8217;s initial public offering.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Prior to and during his employment with the Company, Mr. Ira Ritter served as CEO of Andela Group Inc., (&amp;#8220;Andela&amp;#8221;) a company he founded in 1987, which is involved in corporate management, strategic and financial consulting. The Company incurred no expenses for services received from Andela during the three months and six months ended June 30, 2015, and approximately $49,000 and $99,000, respectively, during the three months and six months ended June 30, 2014, all of which were classified in general and administrative expenses in the Unaudited Condensed Statements of Operations.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Other than disclosed, the Company has not entered into or been a participant in any transaction in which a related party had or will have a direct or indirect material interest.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;NOTE 10&amp;#8201;&amp;#8212;&amp;#8201;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;On July 9, 2015, the Company entered into a lease with Century Park, a California limited partnership, pursuant to which Ritter will lease approximately 2,780 square feet of office space in Los Angeles, California. The lease provides for a term of sixty-one (61) months, commencing on the later of October 1, 2015 or the date of substantial completion of certain tenant improvements provided for under the lease. The Company will pay no rent for the first month of the term and base rent of $9,174 per month for months 2 through 13 of the term, with increasing base rent for each twelve month period thereafter under the term of the lease to a maximum of $10,325.42 per month for months 50 through 61. The base rent payments do not include the Company&amp;#8217;s proportionate share of any operating expenses, including real estate taxes. The Company has the option to extend the term of the lease for one five-year term, provided that the rent would be subject to market adjustment at the beginning of the renewal term.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Effective July 24, 2015, the Company entered into an&amp;#160;&lt;font style="color: black;"&gt;amended Clinical Supply and Cooperation Agreement (the &amp;#8220;Amended Supply Agreement&amp;#8221;) with Ricerche Sperimentali Montale SpA (&amp;#8220;Ricerche&amp;#8221;) and Inalco SpA (collectively, &amp;#8220;RSM&amp;#8221;). The Amended Supply Agreement amends certain terms of the Clinical Supply and Cooperation Agreement, dated December 16, 2009, amended on September 25, 2010 (the &amp;#8220;Existing Supply Agreement&amp;#8221;).&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Under the Existing Supply Agreement, RSM granted Ritter an exclusive worldwide option in a specified field and territory to assignment of all right, title and interest to a purified&amp;#160;Galacto-oligosaccharides product (&amp;#8220;Improved GOS&amp;#8221;), the composition of matter of the Improved GOS and any information relating to the Improved GOS, including certain specified technical information and other intellectual property rights (the &amp;#8220;Improved GOS IP&amp;#8221;). Pursuant to the amended terms, the Company may exercise the option by paying RSM $800,000 within ten days after the effective date of the Amended Supply Agreement. The Company exercised the option on July 30, 2015 and RSM is transferring the Improved GOS IP to the Company. Under the terms of the existing agreement, if a further option payment due in the future is not made, the Company may be required to return the Improved GOS IP to RSM.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;The Amended Supply Agreement also provides that&amp;#160;the Company must pay RSM $400,000 within 10 days following FDA approval of a new drug application for the first product owned or controlled by the Company using Improved GOS as its active pharmaceutical ingredient. In addition, the Company agreed to purchase 350 kilos of Improved GOS for the sum of $250 per kilo for clinical supply of Improved GOS instead of $2,000 per kilo as under the Existing Supply Agreement.&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;In consideration for RSM entering into the Amended Supply Agreement, the Company will issue 100,000 shares of the Company&amp;#8217;s common stock, par value $0.001 per share (the &amp;#8220;Shares&amp;#8221;), to RSM. The Shares are to be issued within 90 days of the effective date of the Amended Supply Agreement pursuant to a stock purchase agreement to be negotiated by the parties in good faith. The stock purchase agreement is to include a lock-up agreement by RSM in favor of the
 Company pursuant to which RSM will not be able to sell the Shares for a period ending on the earlier of (i) the public release by the Company of the final results of its Phase 2b/3 clinical trial of RP-G28 and (ii) the filing of its Form 10-Q with the Securities and Exchange Commission for the fiscal quarter in which the Company receives the results of its Phase 2b/3 clinical trial of RP-G28. The Company has not issued the shares to RSM as of August&amp;#160;&lt;/font&gt;4&lt;font style="font-family: times new roman,times;" size="2"&gt;, 2015.&lt;/font&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:DeferredChargesPolicyTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Deferred Offering Costs&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Deferred offering costs, which primarily consist of direct, incremental banking, legal and accounting fees relating to a planned public offering of the Company&amp;#8217;s common stock, are capitalized within long term assets. The deferred offering costs were reclassified to additional paid-in capital upon the consummation of the offering on June 29, 2015.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company determines basic loss per share and diluted loss per share in accordance with the provisions of ASC 260, &amp;#8220;&lt;i&gt;Earnings per Share&lt;/i&gt;.&amp;#8221; Basic net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period. Diluted net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The potentially dilutive stock options issued under the 2015 Stock Plan (described in Note 8) and warrants on the Company&amp;#8217;s common stock (describe in Note 7) were not considered in the computation of diluted net loss per share because they would be anti-dilutive.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;All common share amounts and per share amounts have been adjusted to reflect a 1-for-7.15 reverse stock split of the Company&amp;#8217;s common stock effected on June 17, 2015.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In August&amp;#160;2014, the FASB issued ASU No. 2014-15,&amp;#160;&lt;i&gt;Presentation of Financial Statements&amp;#8201;&amp;#8212;&amp;#8201;Going Concern (Subtopic 205-40)&amp;#8201;&amp;#8212;&amp;#8201;Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern&lt;/i&gt;, which provides guidance regarding management&amp;#8217;s responsibility to assess whether substantial doubt exists regarding the ability to continue as a going concern and requires related footnote disclosures. In connection with preparing financial statements for each annual and interim reporting period, management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). This ASU is effective for the annual period ending after December&amp;#160;15, 2016, and for annual periods and interim periods thereafter. Management is currently evaluating the new guidance and has not determined the impact this standard may have on the Company&amp;#8217;s financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Estimated Life&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 861px; text-align: left;"&gt;Computers and equipment&lt;/td&gt;
&lt;td style="width: 14px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 169px; text-align: center;"&gt;5 years&lt;/td&gt;
&lt;td style="width: 14px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;5,487&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;5,487&lt;/td&gt;
&lt;td style="width: 14px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Furniture and fixtures&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;"&gt;7 years&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;4,270&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;4,270&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;Total property and equipment&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9,757&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9,757&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Accumulated depreciation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(5,191&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;(4,585&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Total property and equipment, net of accumulated depreciation&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;4,566&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;5,172&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 928px;"&gt;Outstanding at December 31, 2014&lt;/td&gt;
&lt;td style="width: 13px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 13px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 126px; text-align: right;"&gt;418,321&lt;/td&gt;
&lt;td style="width: 12px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 125px; text-align: right;"&gt;9.30&lt;/td&gt;
&lt;td style="width: 12px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 10pt;"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 10pt; padding-bottom: 1pt;"&gt;Exercised/Expired/ Forfeited&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Outstanding at June 30, 2015&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;418,321&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;9.30&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Exercisable at June 30, 2015&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;418,321&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;9.30&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="3" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Three months ended June 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="3" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Six months ended June 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="width: 439px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 251px; text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 32px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 251px; text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 31px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 266px; text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 31px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 266px; text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-size: 10pt;" nowrap="nowrap"&gt;Expected dividend yield&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;0.00%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;0.00%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;0.00%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;0.00%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-size: 10pt;" nowrap="nowrap"&gt;Expected stock-price volatility&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;65.06% - 67.08%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;55.32% - 62.09%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;51.45% - 67.08%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;55.32% - 62.09%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-size: 10pt;" nowrap="nowrap"&gt;Risk-free interest rate&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;1.79% - 2.07%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;1.54% - 2.67%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;0.77% - 2.07%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;1.49% - 3.04%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-size: 10pt;" nowrap="nowrap"&gt;Term of options&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;10&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;10&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;10&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;10&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-size: 10pt;" nowrap="nowrap"&gt;Stock price&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;$5.86&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;$1.17&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;$5.86&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" nowrap="nowrap"&gt;$1.17&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<rttr:ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 940px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold;" nowrap="nowrap"&gt;Year&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold;" nowrap="nowrap"&gt;Share Class&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold;" nowrap="nowrap"&gt;Price per Share&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; width: 320px;"&gt;2005&lt;/td&gt;
&lt;td style="width: 10px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 413px;"&gt;Common Stock (a)&lt;/td&gt;
&lt;td style="width: 9px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 188px;"&gt;$1.79&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2006&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Series A-2 Preferred Stock (a)(b)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.40&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2008 - 2009&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Series A-3 Preferred Stock (b)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.62&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2010 - 2013&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Series B Preferred Stock (b)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$1.19&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2014&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Series C Preferred Stock (b)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$1.30&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;2015&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;Common Stock&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$5.00&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;(a)&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;After giving effect to the Company&amp;#8217;s conversion from a LLC to a corporation.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;(b)&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;Shares of preferred stock were converted into an aggregate of 3,322,650 shares of the Company&amp;#8217;s common stock effective June 29, 2015, after giving effect to the 1-for-7.15 reverse stock of shares of the Company&amp;#8217;s common stock effective June 17, 2015.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</rttr:ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock>
<us-gaap:FairValueInputsInstrumentsClassifiedInShareholdersEquityQuantitativeInformationTableTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&lt;br class="apple-interchange-newline" /&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="5" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Valuation Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="width: 286px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 21px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 244px; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;November 7, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 20px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 183px; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;July 31, 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 10px;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 254px; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;December 31, 2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td nowrap="nowrap"&gt;Volatility&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;58.00%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;61.00%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;61.00%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td nowrap="nowrap"&gt;Risk-free interest rate&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;0.55%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;0.57%&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;2.01%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td nowrap="nowrap"&gt;Maturity (years)&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;3&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;4&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;5&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueInputsInstrumentsClassifiedInShareholdersEquityQuantitativeInformationTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="width: 395px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 240px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Number of Common&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 239px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 14px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 239px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Estimated Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 14px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 239px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Shares Underlying&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;per Common&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;per Share of&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Intrinsic Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Grant Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Options Granted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Option&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: center;"&gt;2005&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;58,321&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$0.07&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$1.79&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$1.72&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: center;"&gt;2009&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;60,559&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$0.72 - $0.79&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$4.43&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$3.71 - $3.64&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: center;"&gt;2011&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;33,846&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$1.00&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$1.00&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.00&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: center;"&gt;2012&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;60,019&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$1.14&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$1.14&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.00&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: center;"&gt;2013&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;100,000&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$1.14 - $1.30&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$1.14&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.00&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: center;"&gt;2014&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;1,626,740&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;$5.86- $13.23&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$5.86&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.00&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">&lt;table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 1253px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/font&gt;&lt;br  /&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="width: 802px;"&gt;Outstanding at December 31, 2014&lt;/td&gt;
&lt;td style="width: 13px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 13px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 188px;"&gt;1,788,717&lt;/td&gt;
&lt;td style="text-align: left; width: 13px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 13px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 12px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 187px;"&gt;7.059&lt;/td&gt;
&lt;td style="text-align: left; width: 12px;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-indent: 10pt;"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;103,025&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5.863&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt;"&gt;Exercised/ Expired/ Forfeited&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(918&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(1.158&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;Outstanding at June 30, 2015&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,890,824&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;7.062&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Exercisable at June 30, 2015&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;298,437&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;4.563&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Expected to be vested&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,592,387&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4.563&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="shares" decimals="INF">2369228</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="shares" decimals="INF">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_29_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD_per_Share" decimals="2">5.00</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">1.19</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA1PreferredStockMember" unitRef="USD_per_Share" decimals="2">0.07</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA2PreferredStockMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA3PreferredStockMember" unitRef="USD_per_Share" decimals="2">0.62</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="2">1.30</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_CommonStockMember_PeriodOfShareIssueAxis_YearTwoThousandFiveMember" unitRef="USD_per_Share" decimals="2" id="Footnote-1_1">1.79</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA2PreferredStockMember_PeriodOfShareIssueAxis_YearTwoThousandSixMember" unitRef="USD_per_Share" decimals="2" id="Footnote-2_1">0.40</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA3PreferredStockMember_PeriodOfShareIssueAxis_YearTwoThousandEightToYearTwoThousandNineMember" unitRef="USD_per_Share" decimals="2" id="Footnote-2_2">0.62</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember_PeriodOfShareIssueAxis_YearTwoThousandTenToYearTwoThousandThirteenMember" unitRef="USD_per_Share" decimals="2" id="Footnote-2_3">1.19</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember_PeriodOfShareIssueAxis_YearTwoThousandFourteenMember" unitRef="USD_per_Share" decimals="2" id="Footnote-2_4">1.30</us-gaap:SharesIssuedPricePerShare>

<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD" decimals="-6">20000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<rttr:PaymentsOfUnderwritingDiscountsAndCommissions contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD" decimals="-5">1600000</rttr:PaymentsOfUnderwritingDiscountsAndCommissions>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD" decimals="-6">1000000</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD" decimals="-5">17400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD" decimals="-5">17400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_17_Jun_2015T00_00_00" unitRef="pure" decimals="2">7.15</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
<us-gaap:NumberOfOperatingSegments contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_17_Jun_2015T00_00_00" unitRef="Segment" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
<rttr:WorkingCapital contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="-5">17300000</rttr:WorkingCapital>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">9757</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember" unitRef="USD" decimals="0">5487</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="USD" decimals="0">4270</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">9757</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember" unitRef="USD" decimals="0">5487</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="USD" decimals="0">4270</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">4585</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">5191</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:OfficersCompensation contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="USD" decimals="0">360000</us-gaap:OfficersCompensation>
<us-gaap:OfficersCompensation contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_PlanNameAxis_ExecutiveCompensationPlanMember" unitRef="USD" decimals="0">310000</us-gaap:OfficersCompensation>
<us-gaap:OfficersCompensation contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PlanNameAxis_ExecutiveCompensationPlanMember" unitRef="USD" decimals="0">295000</us-gaap:OfficersCompensation>
<rttr:NumberOfOptionGranted contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" unitRef="Option" decimals="INF">3</rttr:NumberOfOptionGranted>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember" unitRef="shares" decimals="INF">6993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember" unitRef="shares" decimals="INF">13986</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_30-Sep-2013T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_StockPlan2008Member" unitRef="shares" decimals="INF">48951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_30-Sep-2013T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_StockPlan2008Member" unitRef="shares" decimals="INF">48951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_02_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">646537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_02_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionTwoMember" unitRef="shares" decimals="INF">73777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_29_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionThreeMember" unitRef="shares" decimals="INF">103025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember_TypeOfBonusAwardAxis_GraduatedCashBonusMember" unitRef="shares" decimals="INF">45454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_30-Jun-2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="shares" decimals="INF">6993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_PlanNameAxis_StockPlan2015Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">328289</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01_Jan_2005T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember" unitRef="USD_per_Share" decimals="2">0.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01_Jan_2005T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember" unitRef="USD_per_Share" decimals="2">1.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">5.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionTwoMember" unitRef="USD_per_Share" decimals="2">5.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="USD_per_Share" decimals="2">5.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="USD_per_Share" decimals="2">13.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD_per_Share" decimals="3">5.863</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandFiveMember" unitRef="USD_per_Share" decimals="2">0.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandElevenMember" unitRef="USD_per_Share" decimals="2">1.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandTwelveMember" unitRef="USD_per_Share" decimals="2">1.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandNineMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandNineMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandThirteenMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">1.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandThirteenMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">1.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandFourteenMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">5.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandFourteenMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">13.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

<rttr:PercentageSharesOfCommonStockDeemedToBeOutstanding contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionThreeMember" unitRef="pure" decimals="3">0.075</rttr:PercentageSharesOfCommonStockDeemedToBeOutstanding>
<rttr:PercentageOfSharesSubjectToRightOfRepurchase contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionThreeMember" unitRef="pure" decimals="2">0.75</rttr:PercentageOfSharesSubjectToRightOfRepurchase>
<rttr:DescriptionOfRightToRepurchaseLapse contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionThreeMember">1/36th of the total number of shares subject to the right of repurchase</rttr:DescriptionOfRightToRepurchaseLapse>
<rttr:TuitionReimbursementAuthorizedAmount contextRef="Context_As_Of_29_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_PlanNameAxis_ExecutiveCompensationPlanMember" unitRef="USD" decimals="0">180000</rttr:TuitionReimbursementAuthorizedAmount>
<rttr:PeriodOfTuitionReimbursement contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_PlanNameAxis_ExecutiveCompensationPlanMember">P3Y</rttr:PeriodOfTuitionReimbursement>
<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_PlanNameAxis_ExecutiveCompensationPlanMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">121000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
<rttr:BonusPercentageOfSalary contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_PlanNameAxis_ExecutiveCompensationPlanMember" unitRef="pure" decimals="2">0.40</rttr:BonusPercentageOfSalary>
<rttr:BonusPercentageOfSalary contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_29_Jun_2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PlanNameAxis_ExecutiveCompensationPlanMember" unitRef="pure" decimals="2">0.35</rttr:BonusPercentageOfSalary>
<rttr:ExecutiveCompensation contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember" unitRef="USD" decimals="0">50000</rttr:ExecutiveCompensation>
<rttr:ExecutiveCompensation contextRef="Context_0ME_01-Jul-2012T00_00_00_TO_17-Jul-2012T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember" unitRef="USD" decimals="0">150000</rttr:ExecutiveCompensation>
<rttr:ExecutiveCompensation contextRef="Context_1ME_01-Apr-2013T00_00_00_TO_30-Apr-2013T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FdaMeetingBonusOpportunitiesMember" unitRef="USD" decimals="0">10000</rttr:ExecutiveCompensation>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="Context_As_Of_25-Sep-2013T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FdaMeetingBonusOpportunitiesMember" unitRef="shares" decimals="INF">2360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="Context_As_Of_30-Sep-2013T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FdaMeetingBonusOpportunitiesMember" unitRef="shares" decimals="INF">1136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="Context_As_Of_29-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" unitRef="shares" decimals="INF">3671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="Context_As_Of_29-Jun-2015T00_00_00_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember" unitRef="shares" decimals="INF">4895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="Context_As_Of_31_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">9091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:Cash contextRef="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember_RangeAxis_MinimumMember" unitRef="USD" decimals="0">2000000</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_RangeAxis_MinimumMember" unitRef="USD" decimals="0">2000000</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_29-Jun-2015T00_00_00_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember_RangeAxis_MinimumMember" unitRef="USD" decimals="0">2000000</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_RangeAxis_MinimumMember" unitRef="USD" decimals="0">1000000</us-gaap:Cash>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember" unitRef="pure" decimals="2">0.35</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember" unitRef="pure" decimals="2">0.35</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Context_0ME_01-Jun-2015T00_00_00_TO_29-Jun-2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" unitRef="pure" decimals="2">0.35</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember" unitRef="pure" decimals="2">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember_TypeOfBonusAwardAxis_GraduatedCashBonusMember" unitRef="pure" decimals="2">0.35</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.35</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember" unitRef="pure" decimals="2">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember" unitRef="shares" decimals="INF">6993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember" unitRef="shares" decimals="INF">13986</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_0ME_01-Jun-2015T00_00_00_TO_29-Jun-2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" unitRef="shares" decimals="INF">10489</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_Jan_2005T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember" unitRef="shares" decimals="0">206172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_0ME_01-Dec-2014T00_00_00_TO_02-Dec-2014T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">453413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_DirectorMember_VestingAxis_VestingPeriodThreeYearsMember" unitRef="shares" decimals="INF">1398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_DirectorMember_VestingAxis_VestingPeriodOneYearMember" unitRef="shares" decimals="INF">979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="shares" decimals="0">1729766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="0">103025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember_TypeOfBonusAwardAxis_GraduatedCashBonusMember" unitRef="shares" decimals="INF">45454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">6993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandFiveMember" unitRef="shares" decimals="0">58321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandNineMember" unitRef="shares" decimals="0">60559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandElevenMember" unitRef="shares" decimals="0">33846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandTwelveMember" unitRef="shares" decimals="0">60019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandThirteenMember" unitRef="shares" decimals="0">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandFourteenMember" unitRef="shares" decimals="0">1626740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_Jan_2005T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember" unitRef="shares" decimals="0">106573</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_0ME_01-Jun-2015T00_00_00_TO_29-Jun-2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_DirectorMember_VestingAxis_VestingPeriodThreeYearsMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_DirectorMember_VestingAxis_VestingPeriodOneYearMember">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember_TypeOfBonusAwardAxis_GraduatedCashBonusMember">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_PlanNameAxis_StockPlan2015Member_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<rttr:AccruedBonusToExecutive contextRef="Context_3ME_01-Apr-2015T00_00_00_TO_30-Jun-2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" unitRef="USD" decimals="0">75000</rttr:AccruedBonusToExecutive>
<rttr:AccruedBonusToExecutive contextRef="Context_3ME_01-Apr-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">150000</rttr:AccruedBonusToExecutive>
<rttr:AccruedBonusToExecutive contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" unitRef="USD" decimals="0">75000</rttr:AccruedBonusToExecutive>
<rttr:AccruedBonusToExecutive contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">150000</rttr:AccruedBonusToExecutive>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember" unitRef="shares" decimals="INF">152347</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember_VestingAxis_ShareBasedCompensationAwardTrancheTwoMember" unitRef="shares" decimals="INF">140044</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember" unitRef="shares" decimals="INF">20979</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<rttr:MinimumActualDeploymentOfFundsByThirdParty contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember" unitRef="USD" decimals="0">2000000</rttr:MinimumActualDeploymentOfFundsByThirdParty>


<rttr:ClassOfWarrantOrRightGranted contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_ClassOfWarrantOrRightAxis_SevenYearWarrantsMember" unitRef="shares" xsi:nil="true"/>

<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_ClassOfWarrantOrRightAxis_SevenYearWarrantsMember" unitRef="shares" decimals="0">418321</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_01_Jan_2015T00_00_00_TO_31_Dec_2014T00_00_00_ClassOfWarrantOrRightAxis_SevenYearWarrantsMember" unitRef="shares" decimals="0">418321</us-gaap:ClassOfWarrantOrRightOutstanding>
<rttr:ClassOfWarrantOrRightExercisable contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_ClassOfWarrantOrRightAxis_SevenYearWarrantsMember" unitRef="shares" decimals="0">418321</rttr:ClassOfWarrantOrRightExercisable>


<rttr:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_ClassOfWarrantOrRightAxis_SevenYearWarrantsMember" unitRef="USD_per_Share" decimals="2">9.30</rttr:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">9.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_ClassOfWarrantOrRightAxis_SevenYearWarrantsMember" unitRef="USD_per_Share" decimals="2">9.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_01_Jan_2015T00_00_00_TO_31_Dec_2014T00_00_00_ClassOfWarrantOrRightAxis_SevenYearWarrantsMember" unitRef="USD_per_Share" decimals="2">9.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">331358</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_ClassOfWarrantOrRightAxis_SevenYearWarrantsMember" unitRef="shares" decimals="0">418321</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AndelaGroupIncMember_RelatedPartyTransactionAxis_CorporateManagementStrategicAndFinancialConsultingMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">49000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_AndelaGroupIncMember_RelatedPartyTransactionAxis_CorporateManagementStrategicAndFinancialConsultingMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">99000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>




<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">1822</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-5033</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">20000000</us-gaap:ProceedsFromIssuanceOfCommonStock>

<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">2194375</us-gaap:PaymentsOfStockIssuanceCosts>

<us-gaap:ProceedsFromNotesPayable contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">375000</us-gaap:ProceedsFromNotesPayable>


<rttr:AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">213561</rttr:AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering>
<rttr:CommonStockSubjectToRepurchase contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">180</rttr:CommonStockSubjectToRepurchase>
<rttr:DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">665603</rttr:DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital>
<rttr:PercentageOfInitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember" unitRef="pure" decimals="2">0.05</rttr:PercentageOfInitialPeriodLicensePayment>
<rttr:PercentageOfInitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember" unitRef="pure" decimals="2">0.04</rttr:PercentageOfInitialPeriodLicensePayment>
<rttr:PercentageOfInitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionThreeMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="pure" decimals="2">0.03</rttr:PercentageOfInitialPeriodLicensePayment>
<rttr:InitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember" unitRef="USD" decimals="0">5000000</rttr:InitialPeriodLicensePayment>
<rttr:InitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionThreeMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="USD" decimals="0">10000000</rttr:InitialPeriodLicensePayment>
<rttr:InitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_RangeAxis_MinimumMember" unitRef="USD" decimals="0">5000000</rttr:InitialPeriodLicensePayment>
<rttr:InitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_RangeAxis_MaximumMember" unitRef="USD" decimals="0">10000000</rttr:InitialPeriodLicensePayment>
<rttr:ReceiptOfInitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember_RangeAxis_MinimumMember" unitRef="USD" decimals="0">2000000</rttr:ReceiptOfInitialPeriodLicensePayment>
<rttr:PercentageOfCashBonusExcessOfMilestonePayments contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="pure" decimals="2">0.03</rttr:PercentageOfCashBonusExcessOfMilestonePayments>
<rttr:InitialPeriod contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">P24M</rttr:InitialPeriod>
<rttr:AnnualExcessMilestonePayments contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_RangeAxis_MinimumMember" unitRef="USD" decimals="0">2000000</rttr:AnnualExcessMilestonePayments>
<rttr:PercentageOfAdditionalCashBonus contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="pure" decimals="2">0.10</rttr:PercentageOfAdditionalCashBonus>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_02_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember" unitRef="USD_per_Share" decimals="2">5.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_02_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember_VestingAxis_ShareBasedCompensationAwardTrancheTwoMember" unitRef="USD_per_Share" decimals="2">9.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_02_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember_VestingAxis_ShareBasedCompensationAwardTrancheThreeMember" unitRef="USD_per_Share" decimals="2">13.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_02_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember" unitRef="USD_per_Share" decimals="2">5.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD_per_Share" decimals="3">4.563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember" unitRef="shares" decimals="0">180009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_02_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndCsoMember" unitRef="shares" decimals="INF">432434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="0">1788717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="0">1890824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="shares" decimals="0">1853831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember" unitRef="shares" decimals="0">36993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD_per_Share" decimals="3">7.059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD_per_Share" decimals="3">7.062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<rttr:PercentageOfIncreaseInAnnualRent contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="pure" decimals="2">0.03</rttr:PercentageOfIncreaseInAnnualRent>
<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">P2Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="Context_0ME_01-Oct-2015T00_00_00_TO_01-Oct-2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_CenturyParkMember">P61M</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>

<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="Context_0ME_01-Oct-2015T00_00_00_TO_01-Oct-2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_CenturyParkMember" unitRef="USD" decimals="0">9174</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">107000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
<us-gaap:LeaseAndRentalExpense contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">15000</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">30000</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">15000</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">30000</us-gaap:LeaseAndRentalExpense>

<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="INF">3322650</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
<us-gaap:PreferredStockLiquidationPreference contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">1.19</us-gaap:PreferredStockLiquidationPreference>
<us-gaap:PreferredStockLiquidationPreference contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA3PreferredStockMember" unitRef="USD_per_Share" decimals="2">0.62</us-gaap:PreferredStockLiquidationPreference>
<us-gaap:PreferredStockLiquidationPreference contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="2">1.30</us-gaap:PreferredStockLiquidationPreference>
<rttr:PurchasePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">1.19</rttr:PurchasePrice>
<rttr:PurchasePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="2">1.30</rttr:PurchasePrice>
<us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="5">0.09524</us-gaap:PreferredStockDividendRatePerDollarAmount>
<us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA1PreferredStockMember" unitRef="USD_per_Share" decimals="5">0.00556</us-gaap:PreferredStockDividendRatePerDollarAmount>
<us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA2PreferredStockMember" unitRef="USD_per_Share" decimals="3">0.032</us-gaap:PreferredStockDividendRatePerDollarAmount>
<us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA3PreferredStockMember" unitRef="USD_per_Share" decimals="5">0.04957</us-gaap:PreferredStockDividendRatePerDollarAmount>
<us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="3">0.104</us-gaap:PreferredStockDividendRatePerDollarAmount>
<us-gaap:PreferredStockAmountOfPreferredDividendsInArrears contextRef="Context_12ME_01-Jan-2014T00_00_00_TO_31-Dec-2014T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="-5">1700000</us-gaap:PreferredStockAmountOfPreferredDividendsInArrears>
<us-gaap:PreferredStockAmountOfPreferredDividendsInArrears contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="-6">2000000</us-gaap:PreferredStockAmountOfPreferredDividendsInArrears>

<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2010T00_00_00_TO_31_Dec_2010T00_00_00" unitRef="USD_per_Share" decimals="2">1.03</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00" unitRef="USD_per_Share" decimals="2">1.19</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_07_Nov_2013T00_00_00_TO_07_Nov_2013T00_00_00" unitRef="USD_per_Share" decimals="2">1.17</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">1.17</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00" unitRef="USD_per_Share" decimals="2">5.86</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD_per_Share" decimals="2">5.86</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA1PreferredStockMember" unitRef="USD_per_Share" decimals="2">0.07</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA2PreferredStockMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesA3PreferredStockMember" unitRef="USD_per_Share" decimals="2">0.62</us-gaap:SharePrice>
<rttr:TermOfWarrantIssued contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember">P7Y</rttr:TermOfWarrantIssued>
<rttr:FairValuePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="2">7.83</rttr:FairValuePerShare>
<rttr:DiscountOnInitialCarryingValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD" decimals="2">1.47</rttr:DiscountOnInitialCarryingValue>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD" decimals="0">3081893</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_DebtInstrumentAxis_TwoThousandFourteenNotesOneMember" unitRef="USD" decimals="0">70000</us-gaap:ConvertibleNotesPayable>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_DebtInstrumentAxis_TwoThousandFourteenNotesMember" unitRef="USD" decimals="0">535000</us-gaap:ConvertibleNotesPayable>
<rttr:PercentageOfPricePerShare contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">0.75</rttr:PercentageOfPricePerShare>
<rttr:PercentageOfConvertingOutstandingDebtAndAccruedInterest contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">1.00</rttr:PercentageOfConvertingOutstandingDebtAndAccruedInterest>
<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_DebtInstrumentAxis_TwoThousandFourteenNotesOneMember" unitRef="USD" decimals="0">537</us-gaap:InterestPayableCurrentAndNoncurrent>
<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_DebtInstrumentAxis_TwoThousandFourteenNotesMember" unitRef="USD" decimals="0">18342</us-gaap:InterestPayableCurrentAndNoncurrent>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember_DebtInstrumentAxis_TwoThousandFourteenNotesMember" unitRef="shares" decimals="INF">567529</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember_DebtInstrumentAxis_TwoThousandFourteenNotesOneMember" unitRef="shares" decimals="INF">54259</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_DebtInstrumentAxis_TwoThousandFourteenNotesMember" unitRef="shares" decimals="INF">79374</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_DebtInstrumentAxis_TwoThousandFourteenNotesOneMember" unitRef="shares" decimals="INF">7589</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_DebtInstrumentAxis_TwoThousandFourteenNotesOneMember" unitRef="shares" decimals="INF">7589</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
<us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_DebtInstrumentAxis_TwoThousandFourteenNotesMember" unitRef="shares" decimals="INF">79374</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">70000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:InterestExpenseDebt contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">184445</us-gaap:InterestExpenseDebt>
<us-gaap:DebtConversionOriginalDebtAmount1 contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">535000</us-gaap:DebtConversionOriginalDebtAmount1>
<us-gaap:RoyaltyExpense contextRef="Context_Custom_01_Nov_2010T00_00_00_TO_30_Nov_2010T00_00_00_AgreementAxis_ResearchAndDevelopmentAgreementLicenseMember_AgreementPartiesAxis_KoluPohakuTechnologiesLlcMember" unitRef="USD" decimals="0">32000</us-gaap:RoyaltyExpense>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_01_Mar_2015T00_00_00_TO_26_Mar_2015T00_00_00_AgreementAxis_ResearchAndDevelopmentAgreementLicenseMember_AgreementPartiesAxis_KoluPohakuManagementLlcMember_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">1469994</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_01_Mar_2015T00_00_00_TO_26_Mar_2015T00_00_00_AgreementAxis_PutAndCallOptionAgreementMember_AgreementPartiesAxis_KoluPohakuManagementLlcMember_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">1469994</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_24_Jul_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_RicercheSperimentaliMontaleSpaAndInalcoSpaMember_AgreementAxis_AmendedClinicalSupplyAndCooperationAgreementMember" unitRef="shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="Context_Custom_01_Nov_2010T00_00_00_TO_30_Nov_2010T00_00_00_AgreementAxis_ResearchAndDevelopmentAgreementLicenseMember_AgreementPartiesAxis_KoluPohakuTechnologiesLlcMember" unitRef="USD" decimals="0">1750000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="Context_Custom_01_Nov_2010T00_00_00_TO_30_Nov_2010T00_00_00_AgreementAxis_PutAndCallOptionAgreementMember_AgreementPartiesAxis_KoluPohakuTechnologiesLlcMember_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="0">1750000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
<rttr:AreaOfLease contextRef="Context_0ME_01-Oct-2015T00_00_00_TO_01-Oct-2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_CenturyParkMember" unitRef="SquareFoot" decimals="INF">2780</rttr:AreaOfLease>
<rttr:PaymentToExerciseOptionUnderAgreement contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_30_Jul_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_RicercheSperimentaliMontaleSpaAndInalcoSpaMember_AgreementAxis_AmendedClinicalSupplyAndCooperationAgreementMember_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember" unitRef="USD" decimals="0">800000</rttr:PaymentToExerciseOptionUnderAgreement>

<rttr:PaymentRequiredFollowingFdaApproval contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_30_Jul_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_RicercheSperimentaliMontaleSpaAndInalcoSpaMember_AgreementAxis_AmendedClinicalSupplyAndCooperationAgreementMember_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember" unitRef="USD" decimals="0">400000</rttr:PaymentRequiredFollowingFdaApproval>
<rttr:PurchaseOfImprovedGosInKilos contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_30_Jul_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_RicercheSperimentaliMontaleSpaAndInalcoSpaMember_AgreementAxis_AmendedClinicalSupplyAndCooperationAgreementMember_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember" unitRef="kg" decimals="INF">350</rttr:PurchaseOfImprovedGosInKilos>
<rttr:GosPricePerKilo contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_30_Jul_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_RicercheSperimentaliMontaleSpaAndInalcoSpaMember_AgreementAxis_AmendedClinicalSupplyAndCooperationAgreementMember_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember" unitRef="USD_per_kg" decimals="0">250</rttr:GosPricePerKilo>
<rttr:GosPricePerKiloUnderExistingSupplyAgreement contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_30_Jul_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_RicercheSperimentaliMontaleSpaAndInalcoSpaMember_AgreementAxis_AmendedClinicalSupplyAndCooperationAgreementMember_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ContractualRightsMember" unitRef="USD_per_kg" decimals="0">2000</rttr:GosPricePerKiloUnderExistingSupplyAgreement>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_0ME_01-Oct-2015T00_00_00_TO_01-Oct-2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_CenturyParkMember_RangeAxis_MaximumMember" unitRef="USD" decimals="2">10325.42</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm contextRef="Context_0ME_01-Oct-2015T00_00_00_TO_01-Oct-2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_CenturyParkMember">P5M</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="pure" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="pure" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="4">0.5532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="4">0.5532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="pure" decimals="4">0.6506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="pure" decimals="4">0.5145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="4">0.6209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="4">0.6209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="pure" decimals="4">0.6708</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="pure" decimals="4">0.6708</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="4">0.0154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="4">0.0149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="pure" decimals="4">0.0179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="pure" decimals="4">0.0077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="4">0.0267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="4">0.0304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="pure" decimals="4">0.0207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="pure" decimals="4">0.0207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00">P10M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">P10M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00">P10M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00">P10M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01_Dec_2010T00_00_00_TO_31_Dec_2010T00_00_00" unitRef="pure" decimals="4">0.0201</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00" unitRef="pure" decimals="4">0.0057</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_07_Nov_2013T00_00_00" unitRef="pure" decimals="4">0.0055</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_01_Dec_2010T00_00_00_TO_31_Dec_2010T00_00_00" unitRef="pure" decimals="4">0.6100</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00" unitRef="pure" decimals="4">0.6100</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_07_Nov_2013T00_00_00" unitRef="pure" decimals="4">0.5800</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_Custom_01_Dec_2010T00_00_00_TO_31_Dec_2010T00_00_00">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00">P4Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_07_Nov_2013T00_00_00">P3Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandFiveMember" unitRef="USD_per_Share" decimals="2">1.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandNineMember" unitRef="USD_per_Share" decimals="2">4.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandElevenMember" unitRef="USD_per_Share" decimals="2">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandTwelveMember" unitRef="USD_per_Share" decimals="2">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandThirteenMember" unitRef="USD_per_Share" decimals="2">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandFourteenMember" unitRef="USD_per_Share" decimals="2">5.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandFiveMember" unitRef="USD_per_Share" decimals="2">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandElevenMember" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandTwelveMember" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandThirteenMember" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandFourteenMember" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandNineMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">3.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_AwardDateAxis_GrantYearTwoThousandNineMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">3.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
<rttr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="0">918</rttr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="0">298437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" decimals="0">1592387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<rttr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD_per_Share" decimals="3">1.158</rttr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD_per_Share" decimals="3">4.563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<rttr:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_PlanNameAxis_StockPlan2015Member_AwardTypeAxis_EmployeeStockOptionMember">&lt;div style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"&gt;The exercise price for each option is determined by the Board of Directors, but will be (i) in the case of an incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share on the date of grant; and (ii) in the case of a nonstatutory stock option, no less than 100% of the fair market value per share on the date of grant. The options awarded under the Plans shall vest as determined by the Board of Directors but shall not exceed a ten-year period.&lt;/div&gt;</rttr:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription>
<rttr:ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_PlanNameAxis_StockPlan2015Member_AwardTypeAxis_IncentiveStockOptionMember_TitleOfIndividualAxis_EmployeeHoldTenPercentOwnershipInterestMember_RangeAxis_MinimumMember" unitRef="pure" decimals="2">1.10</rttr:ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice>
<rttr:ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_PlanNameAxis_StockPlan2015Member_AwardTypeAxis_IncentiveStockOptionMember_TitleOfIndividualAxis_OtherEmployeeMember_RangeAxis_MinimumMember" unitRef="pure" decimals="0">1</rttr:ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice>
<rttr:ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_PlanNameAxis_StockPlan2015Member_AwardTypeAxis_NonstatutoryStockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="0">1</rttr:ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember" unitRef="shares" decimals="0">41958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="shares" decimals="0">41958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>

<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="-5">2900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<rttr:TermOfShareBaseCompensationArrangement contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ExecutiveOfficerMember">P10Y</rttr:TermOfShareBaseCompensationArrangement>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="shares" decimals="0">13985</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

<rttr:ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost contextRef="Context_3ME_01_Apr_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">4000</rttr:ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost>
<rttr:ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">3500</rttr:ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost>
<rttr:ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost contextRef="Context_3ME_01_Apr_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">600</rttr:ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost>
<rttr:ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">700</rttr:ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost>
<us-gaap:PreferredStockConversionBasis contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_17_Jun_2015T00_00_00">1-for-7.15</us-gaap:PreferredStockConversionBasis>
<rttr:CapitalStructureYieldedTotalMarketValueOfInvestedCapital contextRef="Context_As_Of_31_Dec_2010T00_00_00_TO_31_Dec_2010T00_00_00" unitRef="USD" decimals="-5">8900000</rttr:CapitalStructureYieldedTotalMarketValueOfInvestedCapital>
<rttr:CapitalStructureYieldedTotalMarketValueOfInvestedCapital contextRef="Context_As_Of_31_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00" unitRef="USD" decimals="-5">14400000</rttr:CapitalStructureYieldedTotalMarketValueOfInvestedCapital>
<rttr:CapitalStructureYieldedTotalMarketValueOfInvestedCapital contextRef="Context_As_Of_07_Nov_2013T00_00_00_TO_07_Nov_2013T00_00_00" unitRef="USD" decimals="-5">15500000</rttr:CapitalStructureYieldedTotalMarketValueOfInvestedCapital>
<rttr:CapitalStructureYieldedTotalMarketValueOfInvestedCapital contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00" unitRef="USD" decimals="-5">25200000</rttr:CapitalStructureYieldedTotalMarketValueOfInvestedCapital>
<rttr:ValueOfCommonStock contextRef="Context_As_Of_31_Dec_2010T00_00_00_TO_31_Dec_2010T00_00_00" unitRef="USD" decimals="0">670000</rttr:ValueOfCommonStock>
<rttr:ValueOfCommonStock contextRef="Context_As_Of_31_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00" unitRef="USD" decimals="0">870000</rttr:ValueOfCommonStock>
<rttr:ValueOfCommonStock contextRef="Context_As_Of_07_Nov_2013T00_00_00_TO_07_Nov_2013T00_00_00" unitRef="USD" decimals="0">819000</rttr:ValueOfCommonStock>
<rttr:ValueOfCommonStock contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00" unitRef="USD" decimals="-5">1400000</rttr:ValueOfCommonStock>
<us-gaap:FairValueInputsDiscountForLackOfMarketability contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_ValuationTechniqueAxis_AverageStrikePutOptionApproachMember" unitRef="pure" decimals="3">0.214</us-gaap:FairValueInputsDiscountForLackOfMarketability>
<us-gaap:FairValueInputsDiscountForLackOfMarketability contextRef="Context_0ME_01-Nov-2013T00_00_00_TO_07-Nov-2013T00_00_00_RangeAxis_MinimumMember" unitRef="pure" decimals="3">0.358</us-gaap:FairValueInputsDiscountForLackOfMarketability>
<us-gaap:FairValueInputsDiscountForLackOfMarketability contextRef="Context_0ME_01-Nov-2013T00_00_00_TO_07-Nov-2013T00_00_00_RangeAxis_MaximumMember" unitRef="pure" decimals="2">0.40</us-gaap:FairValueInputsDiscountForLackOfMarketability>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Footnote-1_1" xlink:label="lab_Footnote-1_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_1" xlink:label="lab_Footnote-2_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-2_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="2.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_2" xlink:label="lab_Footnote-2_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_3" xlink:label="lab_Footnote-2_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_4" xlink:label="lab_Footnote-2_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_4"/>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-1">After giving effect to the Company's conversion from a LLC to a corporation.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-2">Shares of preferred stock were converted into an aggregate of 3,322,676 shares of the Company's common stock effective June 29, 2015, after giving effect to the 1-for-7.15 reverse stock of shares of the Company's common stock effective June 17, 2015.</link:footnote>
</link:footnoteLink>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_ClassOfWarrantOrRightAxis_SevenYearWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rttr:SevenYearWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:ClassOfWarrantOrRightExercisedExpiredForfeited contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_ClassOfWarrantOrRightAxis_SevenYearWarrantsMember" unitRef="shares" xsi:nil="true"/>
<rttr:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_ClassOfWarrantOrRightAxis_SevenYearWarrantsMember" unitRef="USD_per_Share" xsi:nil="true"/>
<rttr:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_ClassOfWarrantOrRightAxis_SevenYearWarrantsMember" unitRef="USD_per_Share" xsi:nil="true"/>

	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="Context_Custom_01_Jan_2005T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember" unitRef="shares" decimals="0">69580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_Custom_01_Jan_2005T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_ExecutiveOfficersAndEmployeesMember" unitRef="shares" decimals="0">26163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<xbrli:unit id="kg"><xbrli:measure>utr:kg</xbrli:measure></xbrli:unit>

	<xbrli:unit id="USD_per_kg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>utr:kg</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
	<us-gaap:InterestPaid contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaid contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_AgreementAxis_PutAndCallOptionAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rttr:AgreementAxis">rttr:PutAndCallOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_AgreementAxis_PutAndCallOptionAgreementMember" unitRef="shares" decimals="INF">205593</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

<xbrli:context id="Context_As_Of_30-Jun-2015T00_00_00_StatementClassOfStockAxis_RedeemablePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2014T00_00_00_StatementClassOfStockAxis_RedeemablePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2014T00_00_00_StatementClassOfStockAxis_RedeemablePreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="Context_As_Of_30-Jun-2015T00_00_00_StatementClassOfStockAxis_RedeemablePreferredStockMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:TemporaryEquitySharesAuthorized contextRef="Context_As_Of_30-Jun-2015T00_00_00_StatementClassOfStockAxis_RedeemablePreferredStockMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:TemporaryEquitySharesIssued contextRef="Context_As_Of_30-Jun-2015T00_00_00_StatementClassOfStockAxis_RedeemablePreferredStockMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:TemporaryEquitySharesOutstanding contextRef="Context_As_Of_30-Jun-2015T00_00_00_StatementClassOfStockAxis_RedeemablePreferredStockMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:TemporaryEquitySharesAuthorized contextRef="Context_As_Of_31-Dec-2014T00_00_00_StatementClassOfStockAxis_RedeemablePreferredStockMember" unitRef="shares" decimals="INF">16378646</us-gaap:TemporaryEquitySharesAuthorized>
<us-gaap:TemporaryEquitySharesIssued contextRef="Context_As_Of_31-Dec-2014T00_00_00_StatementClassOfStockAxis_RedeemablePreferredStockMember" unitRef="shares" decimals="INF">13399668</us-gaap:TemporaryEquitySharesIssued>
<us-gaap:TemporaryEquitySharesOutstanding contextRef="Context_As_Of_31-Dec-2014T00_00_00_StatementClassOfStockAxis_RedeemablePreferredStockMember" unitRef="shares" decimals="INF">13399668</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="Context_As_Of_31-Dec-2014T00_00_00_StatementClassOfStockAxis_RedeemablePreferredStockMember" unitRef="USD" decimals="0">16203612</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="Context_As_Of_30-Jun-2015T00_00_00_StatementClassOfStockAxis_RedeemablePreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="shares" xsi:nil="true"/>
<xbrli:context id="Context_1ME_01-Apr-2013T00_00_00_TO_30-Apr-2013T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FdaMeetingBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FdaMeetingBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-04-01</xbrli:startDate><xbrli:endDate>2013-04-30</xbrli:endDate></xbrli:period></xbrli:context>
	<xbrli:context id="Context_1ME_01-Apr-2013T00_00_00_TO_30-Apr-2013T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FdaMeetingBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FdaMeetingBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-04-01</xbrli:startDate><xbrli:endDate>2013-04-30</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:ExecutiveCompensation contextRef="Context_1ME_01-Apr-2013T00_00_00_TO_30-Apr-2013T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FdaMeetingBonusOpportunitiesMember" unitRef="USD" decimals="0">10000</rttr:ExecutiveCompensation>


<xbrli:context id="Context_3ME_01-Apr-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:ClinicalTrialFundingCommitmentBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-04-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:AccruedBonusToExecutive contextRef="Context_3ME_01-Apr-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" unitRef="USD" decimals="0">75000</rttr:AccruedBonusToExecutive>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:ClinicalTrialFundingCommitmentBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:AccruedBonusToExecutive contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" unitRef="USD" decimals="0">75000</rttr:AccruedBonusToExecutive>
<xbrli:context id="Context_3ME_01-Apr-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-04-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:AccruedBonusToExecutive contextRef="Context_3ME_01-Apr-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember" unitRef="USD" decimals="0">150000</rttr:AccruedBonusToExecutive>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:AccruedBonusToExecutive contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember" unitRef="USD" decimals="0">150000</rttr:AccruedBonusToExecutive>
<xbrli:context id="Context_0ME_01-Dec-2014T00_00_00_TO_02-Dec-2014T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-01</xbrli:startDate><xbrli:endDate>2014-12-02</xbrli:endDate></xbrli:period></xbrli:context>
	<xbrli:context id="Context_0ME_01-Dec-2014T00_00_00_TO_02-Dec-2014T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-01</xbrli:startDate><xbrli:endDate>2014-12-02</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_0ME_01-Dec-2014T00_00_00_TO_02-Dec-2014T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">453413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<rttr:OperatingLeaseRentExpenseMinimumMonthlyRentals contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00" unitRef="USD" decimals="0">5000</rttr:OperatingLeaseRentExpenseMinimumMonthlyRentals>
<xbrli:context id="Context_0ME_01-Nov-2013T00_00_00_TO_07-Nov-2013T00_00_00_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-11-01</xbrli:startDate><xbrli:endDate>2013-11-07</xbrli:endDate></xbrli:period></xbrli:context>
	<xbrli:context id="Context_1ME_01-Jul-2012T00_00_00_TO_31-Jul-2012T00_00_00_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-07-01</xbrli:startDate><xbrli:endDate>2012-07-31</xbrli:endDate></xbrli:period></xbrli:context>
	<xbrli:context id="Context_1ME_01-Jul-2012T00_00_00_TO_31-Jul-2012T00_00_00_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-07-01</xbrli:startDate><xbrli:endDate>2012-07-31</xbrli:endDate></xbrli:period></xbrli:context>
	<xbrli:context id="Context_1ME_01-Dec-2010T00_00_00_TO_31-Dec-2010T00_00_00_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-12-01</xbrli:startDate><xbrli:endDate>2010-12-31</xbrli:endDate></xbrli:period></xbrli:context>
	<xbrli:context id="Context_1ME_01-Dec-2010T00_00_00_TO_31-Dec-2010T00_00_00_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-12-01</xbrli:startDate><xbrli:endDate>2010-12-31</xbrli:endDate></xbrli:period></xbrli:context>
	<xbrli:context id="Context_0ME_01-Nov-2013T00_00_00_TO_07-Nov-2013T00_00_00_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-11-01</xbrli:startDate><xbrli:endDate>2013-11-07</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:FairValueInputsDiscountForLackOfMarketability contextRef="Context_1ME_01-Jul-2012T00_00_00_TO_31-Jul-2012T00_00_00_RangeAxis_MinimumMember" unitRef="pure" decimals="3">0.358</us-gaap:FairValueInputsDiscountForLackOfMarketability>
<us-gaap:FairValueInputsDiscountForLackOfMarketability contextRef="Context_1ME_01-Jul-2012T00_00_00_TO_31-Jul-2012T00_00_00_RangeAxis_MaximumMember" unitRef="pure" decimals="2">0.40</us-gaap:FairValueInputsDiscountForLackOfMarketability>
<us-gaap:FairValueInputsDiscountForLackOfMarketability contextRef="Context_1ME_01-Dec-2010T00_00_00_TO_31-Dec-2010T00_00_00_RangeAxis_MinimumMember" unitRef="pure" decimals="3">0.358</us-gaap:FairValueInputsDiscountForLackOfMarketability>
<us-gaap:FairValueInputsDiscountForLackOfMarketability contextRef="Context_1ME_01-Dec-2010T00_00_00_TO_31-Dec-2010T00_00_00_RangeAxis_MaximumMember" unitRef="pure" decimals="2">0.40</us-gaap:FairValueInputsDiscountForLackOfMarketability>
<us-gaap:Depreciation contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">600</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">2500</us-gaap:Depreciation>
<rttr:PercentageOfSharesSubjectToRightOfRepurchase contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="3">0.916</rttr:PercentageOfSharesSubjectToRightOfRepurchase>
<rttr:PercentageOfSharesSubjectToRightOfRepurchase contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionTwoMember" unitRef="pure" decimals="3">0.916</rttr:PercentageOfSharesSubjectToRightOfRepurchase>
<rttr:DescriptionOfRightToRepurchaseLapse contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionMember">1/44th of the total number of shares subject to the right of repurchase</rttr:DescriptionOfRightToRepurchaseLapse>
<rttr:DescriptionOfRightToRepurchaseLapse contextRef="Context_Custom_01_Dec_2014T00_00_00_TO_02_Dec_2014T00_00_00_AgreementAxis_StepLetterAgreementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_AwardTypeAxis_EmployeeStockOptionTwoMember">1/44th of the total number of shares subject to the right of repurchase</rttr:DescriptionOfRightToRepurchaseLapse>
<rttr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber contextRef="Context_6ME_01_Jan_2015T00_00_00_TO_30_Jun_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ConsultantsMember" unitRef="shares" decimals="INF">7271</rttr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber>



<xbrli:context id="Context_As_Of_29-Jun-2015T00_00_00_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity><xbrli:period><xbrli:instant>2015-06-29</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="Context_As_Of_29-Jun-2015T00_00_00_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">4895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<xbrli:context id="Context_As_Of_29-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:ClinicalTrialFundingCommitmentBonusOpportunitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-29</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="Context_As_Of_29-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">3671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<rttr:StockOptionsToVestRatablyOnMonthlyBasis contextRef="Context_As_Of_29-Jun-2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" unitRef="shares" decimals="INF">6818</rttr:StockOptionsToVestRatablyOnMonthlyBasis>
<xbrli:context id="Context_As_Of_30-Sep-2013T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FdaMeetingBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FdaMeetingBonusOpportunitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-09-30</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="Context_As_Of_30-Sep-2013T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FdaMeetingBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<xbrli:context id="Context_As_Of_25-Sep-2013T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FdaMeetingBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FdaMeetingBonusOpportunitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-09-25</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="Context_As_Of_25-Sep-2013T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FdaMeetingBonusOpportunitiesMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:MinimumActualDeploymentOfFundsByThirdParty contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="USD" decimals="0">2000000</rttr:MinimumActualDeploymentOfFundsByThirdParty>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:MinimumActualDeploymentOfFundsByThirdParty contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="USD" decimals="0">2000000</rttr:MinimumActualDeploymentOfFundsByThirdParty>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionThreeMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionThreeMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:PercentageOfInitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionThreeMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="pure" decimals="2">0.03</rttr:PercentageOfInitialPeriodLicensePayment>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:PercentageOfInitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="pure" decimals="2">0.05</rttr:PercentageOfInitialPeriodLicensePayment>
<rttr:InitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionOneMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="USD" decimals="0">5000000</rttr:InitialPeriodLicensePayment>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_RangeAxis_MinimumMember_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:PercentageOfInitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="pure" decimals="2">0.04</rttr:PercentageOfInitialPeriodLicensePayment>
<rttr:PercentageOfCashBonusExcessOfMilestonePayments contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="pure" decimals="2">0.03</rttr:PercentageOfCashBonusExcessOfMilestonePayments>
<rttr:InitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionThreeMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="USD" decimals="0">10000000</rttr:InitialPeriodLicensePayment>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_RangeAxis_MaximumMember_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:InitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_RangeAxis_MaximumMember_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="USD" decimals="0">10000000</rttr:InitialPeriodLicensePayment>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_TypeOfBonusAwardAxis_GraduatedCashBonusMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:TypeOfBonusAwardAxis">rttr:GraduatedCashBonusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_TypeOfBonusAwardAxis_GraduatedCashBonusMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="pure" decimals="2">0.35</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_TypeOfBonusAwardAxis_GraduatedCashBonusMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="shares" decimals="INF">45454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_TypeOfBonusAwardAxis_GraduatedCashBonusMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<xbrli:context id="Context_As_Of_30-Jun-2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context>
	<xbrli:context id="Context_As_Of_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_TypeOfBonusAwardAxis_GraduatedCashBonusMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:TypeOfBonusAwardAxis">rttr:GraduatedCashBonusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_TypeOfBonusAwardAxis_GraduatedCashBonusMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="shares" decimals="INF">45454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="pure" decimals="2">0.35</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="shares" decimals="INF">6993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<xbrli:context id="Context_As_Of_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_AwardTypeAxis_EmployeeStockOptionMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="shares" decimals="INF">6993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_RangeAxis_MinimumMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:ReceiptOfInitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_RangeAxis_MinimumMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="USD" decimals="0">2000000</rttr:ReceiptOfInitialPeriodLicensePayment>
<rttr:InitialPeriodLicensePayment contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_RangeAxis_MinimumMember_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="USD" decimals="0">5000000</rttr:InitialPeriodLicensePayment>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<xbrli:context id="Context_As_Of_30-Jun-2015T00_00_00_RangeAxis_MinimumMember_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:LicenseEventBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:Cash contextRef="Context_As_Of_30-Jun-2015T00_00_00_RangeAxis_MinimumMember_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_LicenseEventBonusOpportunitiesMember" unitRef="USD" decimals="0">1000000</us-gaap:Cash>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_ConversionOfStockByUniqueDescriptionAxis_ConversionOfPreferredToCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">rttr:ConversionOfPreferredToCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_ConversionOfStockByUniqueDescriptionAxis_ConversionOfPreferredToCommonStockMember" unitRef="USD" decimals="0">8888</us-gaap:ConversionOfStockAmountConverted1>
<xbrli:context id="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_ConversionOfStockByUniqueDescriptionAxis_ConversionOfRedeemablePreferredStockToCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">rttr:ConversionOfRedeemablePreferredStockToCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="Context_6ME_01-Jan-2015T00_00_00_TO_30-Jun-2015T00_00_00_ConversionOfStockByUniqueDescriptionAxis_ConversionOfRedeemablePreferredStockToCommonStockMember" unitRef="USD" decimals="0">16594464</us-gaap:ConversionOfStockAmountConverted1>
<rttr:PreferredStockOriginalIssuePrice contextRef="Context_As_Of_30_Nov_2010T00_00_00_TO_30_Nov_2010T00_00_00_AgreementAxis_PutAndCallOptionAgreementMember_AgreementPartiesAxis_KoluPohakuManagementLlcMember_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">1.19</rttr:PreferredStockOriginalIssuePrice>
<xbrli:context id="Context_0ME_01-Jun-2015T00_00_00_TO_29-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:PresidentAndFormerChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:ClinicalTrialFundingCommitmentBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-29</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:ExecutiveCompensation contextRef="Context_0ME_01-Jun-2015T00_00_00_TO_29-Jun-2015T00_00_00_TitleOfIndividualAxis_PresidentAndFormerChiefExecutiveOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" unitRef="USD" decimals="0">75000</rttr:ExecutiveCompensation>
<xbrli:context id="Context_0ME_01-Jun-2015T00_00_00_TO_29-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:ClinicalTrialFundingCommitmentBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-29</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:ExecutiveCompensation contextRef="Context_0ME_01-Jun-2015T00_00_00_TO_29-Jun-2015T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" unitRef="USD" decimals="0">75000</rttr:ExecutiveCompensation>
<xbrli:context id="Context_0ME_01-Jul-2012T00_00_00_TO_17-Jul-2012T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rttr:ChiefStrategicOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-07-01</xbrli:startDate><xbrli:endDate>2012-07-17</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:ExecutiveCompensation contextRef="Context_0ME_01-Jul-2012T00_00_00_TO_17-Jul-2012T00_00_00_TitleOfIndividualAxis_ChiefStrategicOfficerMember_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember" unitRef="USD" decimals="0">150000</rttr:ExecutiveCompensation>
<xbrli:context id="Context_0ME_01-Jul-2012T00_00_00_TO_17-Jul-2012T00_00_00_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rttr:PerformanceMilestoneTypeAxis">rttr:PerformanceMilestoneConditionTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rttr:CashBonusAndExecutiveOptionsPerformanceConditionsAxis">rttr:FundraisingBonusOpportunitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-07-01</xbrli:startDate><xbrli:endDate>2012-07-17</xbrli:endDate></xbrli:period></xbrli:context>
	<rttr:MinimumActualDeploymentOfFundsByThirdParty contextRef="Context_0ME_01-Jul-2012T00_00_00_TO_17-Jul-2012T00_00_00_PerformanceMilestoneTypeAxis_PerformanceMilestoneConditionTwoMember_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_FundraisingBonusOpportunitiesMember" unitRef="USD" decimals="0">10000000</rttr:MinimumActualDeploymentOfFundsByThirdParty>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>rttr-20150630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.3.0.4 on Thursday, August 13, 2015 12:14:30 AM -->
<schema targetNamespace="http://www.ritterpharmaceuticals.com/20150630" elementFormDefault="qualified" xmlns:rttr="http://www.ritterpharmaceuticals.com/20150630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation><appinfo>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/CONDENSEDBALANCESHEETS" id="CONDENSEDBALANCESHEETS">
<link:definition>002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/CONDENSEDBALANCESHEETSParentheticals" id="CONDENSEDBALANCESHEETSParentheticals">
<link:definition>003 - Statement - CONDENSED BALANCE SHEETS (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/CONDENSEDSTATEMENTSOFOPERATIONSUnaudited" id="CONDENSEDSTATEMENTSOFOPERATIONSUnaudited">
<link:definition>004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited" id="CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited">
<link:definition>005 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureOrganizationAndPrincipalActivities" id="DisclosureOrganizationAndPrincipalActivities">
<link:definition>006 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
<link:definition>007 - Disclosure - BASIS OF PRESENTATION</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
<link:definition>008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
<link:definition>009 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
<link:definition>010 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureStockholdersDeficitAndPreferredStockSubjectToRedemption" id="DisclosureStockholdersDeficitAndPreferredStockSubjectToRedemption">
<link:definition>011 - Disclosure - STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureWarrants" id="DisclosureWarrants">
<link:definition>012 - Disclosure - WARRANTS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
<link:definition>013 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS" id="RELATEDPARTYTRANSACTIONS">
<link:definition>014 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
<link:definition>015 - Disclosure - SUBSEQUENT EVENTS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
<link:definition>016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/PROPERTYANDEQUIPMENTTables" id="PROPERTYANDEQUIPMENTTables">
<link:definition>017 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/WARRANTSTables" id="WARRANTSTables">
<link:definition>018 - Disclosure - WARRANTS (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables" id="STOCKBASEDCOMPENSATIONTables">
<link:definition>019 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/OrganizationAndPrincipalActivitiesDetailTextuals" id="OrganizationAndPrincipalActivitiesDetailTextuals">
<link:definition>020 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/BasisOfPresentationDetailTextuals" id="BasisOfPresentationDetailTextuals">
<link:definition>021 - Disclosure - BASIS OF PRESENTATION (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesDetailTextuals" id="SummaryOfSignificantAccountingPoliciesDetailTextuals">
<link:definition>022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/PROPERTYANDEQUIPMENTDetails" id="PROPERTYANDEQUIPMENTDetails">
<link:definition>023 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/PropertyAndEquipmentdetailTextuals" id="PropertyAndEquipmentdetailTextuals">
<link:definition>024 - Disclosure - PROPERTY AND EQUIPMENT(Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals" id="CommitmentsAndContingenciesDetailTextuals">
<link:definition>025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals1" id="CommitmentsAndContingenciesDetailTextuals1">
<link:definition>026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals2" id="CommitmentsAndContingenciesDetailTextuals2">
<link:definition>027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals3" id="CommitmentsAndContingenciesDetailTextuals3">
<link:definition>028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals4" id="CommitmentsAndContingenciesDetailTextuals4">
<link:definition>029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals 4)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals" id="StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals">
<link:definition>030 - Disclosure - STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1" id="StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1">
<link:definition>031 - Disclosure - STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals2" id="StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals2">
<link:definition>032 - Disclosure - STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals3" id="StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals3">
<link:definition>033 - Disclosure - STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals4" id="StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals4">
<link:definition>034 - Disclosure - STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 4)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/WARRANTSDetails" id="WARRANTSDetails">
<link:definition>035 - Disclosure - WARRANTS (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/WarrantsDetailTextuals" id="WarrantsDetailTextuals">
<link:definition>036 - Disclosure - WARRANTS (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetails" id="StockBasedCompensationDetails">
<link:definition>037 - Disclosure - STOCK-BASED COMPENSATION (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails1" id="STOCKBASEDCOMPENSATIONDetails1">
<link:definition>038 - Disclosure - STOCK-BASED COMPENSATION (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationParentheticalsDetails1" id="StockBasedCompensationParentheticalsDetails1">
<link:definition>039 - Disclosure - STOCK-BASED COMPENSATION (Parentheticals) (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails2" id="STOCKBASEDCOMPENSATIONDetails2">
<link:definition>040 - Disclosure - STOCK-BASED COMPENSATION (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails3" id="STOCKBASEDCOMPENSATIONDetails3">
<link:definition>041 - Disclosure - STOCK-BASED COMPENSATION (Details 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails4" id="STOCKBASEDCOMPENSATIONDetails4">
<link:definition>042 - Disclosure - STOCK-BASED COMPENSATION (Details 4)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals" id="StockBasedCompensationDetailTextuals">
<link:definition>043 - Disclosure - STOCK-BASED COMPENSATION (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals1" id="StockBasedCompensationDetailTextuals1">
<link:definition>044 - Disclosure - STOCK-BASED COMPENSATION (Detail Textuals 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals2" id="StockBasedCompensationDetailTextuals2">
<link:definition>045 - Disclosure - STOCK-BASED COMPENSATION (Detail Textuals 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals3" id="StockBasedCompensationDetailTextuals3">
<link:definition>046 - Disclosure - STOCK-BASED COMPENSATION (Detail Textuals 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetailTextuals" id="RELATEDPARTYTRANSACTIONSDetailTextuals">
<link:definition>047 - Disclosure - RELATED PARTY TRANSACTIONS (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ritterpharmaceuticals.com/role/SubsequentEventsDetailTextuals" id="SubsequentEventsDetailTextuals">
<link:definition>048 - Disclosure - SUBSEQUENT EVENTS (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="rttr-20150630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="rttr-20150630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="rttr-20150630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="rttr-20150630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2015-01-31" schemaLocation="http://xbrl.sec.gov/exch/2015/exch-2015-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="rttr_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PatentCosts" id="rttr_PatentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" id="rttr_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering" id="rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>

<element name="CommonStockSubjectToRepurchase" id="rttr_CommonStockSubjectToRepurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BasisOfPresentationAbstract" id="rttr_BasisOfPresentationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsTextBlock" id="rttr_WarrantsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock" id="rttr_ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OrganizationAndPrincipalActivitiesTable" id="rttr_OrganizationAndPrincipalActivitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="OrganizationAndPrincipalActivitiesLineItems" id="rttr_OrganizationAndPrincipalActivitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentsOfUnderwritingDiscountsAndCommissions" id="rttr_PaymentsOfUnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WorkingCapital" id="rttr_WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentsAndContingenciesTable" id="rttr_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="AgreementAxis" id="rttr_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="AgreementDomain" id="rttr_AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StepLetterAgreementMember" id="rttr_StepLetterAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PresidentAndFormerChiefExecutiveOfficerMember" id="rttr_PresidentAndFormerChiefExecutiveOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ChiefStrategicOfficerMember" id="rttr_ChiefStrategicOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmployeeStockOptionTwoMember" id="rttr_EmployeeStockOptionTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmployeeStockOptionThreeMember" id="rttr_EmployeeStockOptionThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExecutiveCompensationPlanMember" id="rttr_ExecutiveCompensationPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>

<element name="CommitmentsAndContingenciesLineItems" id="rttr_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TuitionReimbursementAuthorizedAmount" id="rttr_TuitionReimbursementAuthorizedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodOfTuitionReimbursement" id="rttr_PeriodOfTuitionReimbursement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfOptionGranted" id="rttr_NumberOfOptionGranted" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageSharesOfCommonStockDeemedToBeOutstanding" id="rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfSharesSubjectToRightOfRepurchase" id="rttr_PercentageOfSharesSubjectToRightOfRepurchase" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfRightToRepurchaseLapse" id="rttr_DescriptionOfRightToRepurchaseLapse" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BonusPercentageOfSalary" id="rttr_BonusPercentageOfSalary" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CashBonusAndExecutiveOptionsPerformanceConditionsAxis" id="rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="CashBonusAndExecutiveOptionsPerformanceConditionsDomain" id="rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FdaMeetingBonusOpportunitiesMember" id="rttr_FdaMeetingBonusOpportunitiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClinicalTrialFundingCommitmentBonusOpportunitiesMember" id="rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FundraisingBonusOpportunitiesMember" id="rttr_FundraisingBonusOpportunitiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PerformanceMilestoneTypeAxis" id="rttr_PerformanceMilestoneTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="PerformanceMilestoneTypeDomain" id="rttr_PerformanceMilestoneTypeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PerformanceMilestoneConditionOneMember" id="rttr_PerformanceMilestoneConditionOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PerformanceMilestoneConditionTwoMember" id="rttr_PerformanceMilestoneConditionTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExecutiveCompensation" id="rttr_ExecutiveCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MinimumActualDeploymentOfFundsByThirdParty" id="rttr_MinimumActualDeploymentOfFundsByThirdParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedBonusToExecutive" id="rttr_AccruedBonusToExecutive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseEventBonusOpportunitiesMember" id="rttr_LicenseEventBonusOpportunitiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PerformanceMilestoneConditionThreeMember" id="rttr_PerformanceMilestoneConditionThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TypeOfBonusAwardAxis" id="rttr_TypeOfBonusAwardAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="TypeOfBonusAwardDomain" id="rttr_TypeOfBonusAwardDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GraduatedCashBonusMember" id="rttr_GraduatedCashBonusMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfInitialPeriodLicensePayment" id="rttr_PercentageOfInitialPeriodLicensePayment" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InitialPeriodLicensePayment" id="rttr_InitialPeriodLicensePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReceiptOfInitialPeriodLicensePayment" id="rttr_ReceiptOfInitialPeriodLicensePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfCashBonusExcessOfMilestonePayments" id="rttr_PercentageOfCashBonusExcessOfMilestonePayments" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PresidentAndCsoMember" id="rttr_PresidentAndCsoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="VestingPeriodThreeYearsMember" id="rttr_VestingPeriodThreeYearsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="VestingPeriodOneYearMember" id="rttr_VestingPeriodOneYearMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>

<element name="InitialPeriod" id="rttr_InitialPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AnnualExcessMilestonePayments" id="rttr_AnnualExcessMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfAdditionalCashBonus" id="rttr_PercentageOfAdditionalCashBonus" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfIncreaseInAnnualRent" id="rttr_PercentageOfIncreaseInAnnualRent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesAOnePreferredStockMember" id="rttr_SeriesAOnePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesATwoPreferredStockMember" id="rttr_SeriesATwoPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesAThreePreferredStockMember" id="rttr_SeriesAThreePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PurchasePrice" id="rttr_PurchasePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandFourteenNotesMember" id="rttr_TwoThousandFourteenNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandFourteenNotesOneMember" id="rttr_TwoThousandFourteenNotesOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TermOfWarrantIssued" id="rttr_TermOfWarrantIssued" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValuePerShare" id="rttr_FairValuePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DiscountOnInitialCarryingValue" id="rttr_DiscountOnInitialCarryingValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfPricePerShare" id="rttr_PercentageOfPricePerShare" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfConvertingOutstandingDebtAndAccruedInterest" id="rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockholdersDeficitAndPreferredStockSubjectToRedemptionTable" id="rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="ResearchAndDevelopmentAgreementLicenseMember" id="rttr_ResearchAndDevelopmentAgreementLicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PutAndCallOptionAgreementMember" id="rttr_PutAndCallOptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgreementPartiesAxis" id="rttr_AgreementPartiesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="AgreementPartiesDomain" id="rttr_AgreementPartiesDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="KoluPohakuTechnologiesLlcMember" id="rttr_KoluPohakuTechnologiesLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="KoluPohakuManagementLlcMember" id="rttr_KoluPohakuManagementLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems" id="rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SevenYearWarrantsMember" id="rttr_SevenYearWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightGranted" id="rttr_ClassOfWarrantOrRightGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightExercisedExpiredForfeited" id="rttr_ClassOfWarrantOrRightExercisedExpiredForfeited" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightExercisable" id="rttr_ClassOfWarrantOrRightExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" id="rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited" id="rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" id="rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodOfShareIssueAxis" id="rttr_PeriodOfShareIssueAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="PeriodOfShareIssueDomain" id="rttr_PeriodOfShareIssueDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="YearTwoThousandFiveMember" id="rttr_YearTwoThousandFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="YearTwoThousandSixMember" id="rttr_YearTwoThousandSixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="YearTwoThousandEightToYearTwoThousandNineMember" id="rttr_YearTwoThousandEightToYearTwoThousandNineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="YearTwoThousandTenToYearTwoThousandThirteenMember" id="rttr_YearTwoThousandTenToYearTwoThousandThirteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="YearTwoThousandFourteenMember" id="rttr_YearTwoThousandFourteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrantYearTwoThousandFiveMember" id="rttr_GrantYearTwoThousandFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrantYearTwoThousandNineMember" id="rttr_GrantYearTwoThousandNineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrantYearTwoThousandElevenMember" id="rttr_GrantYearTwoThousandElevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrantYearTwoThousandTwelveMember" id="rttr_GrantYearTwoThousandTwelveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrantYearTwoThousandThirteenMember" id="rttr_GrantYearTwoThousandThirteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GrantYearTwoThousandFourteenMember" id="rttr_GrantYearTwoThousandFourteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod" id="rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice" id="rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockPlan2015Member" id="rttr_StockPlan2015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncentiveStockOptionMember" id="rttr_IncentiveStockOptionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NonstatutoryStockOptionMember" id="rttr_NonstatutoryStockOptionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmployeeHoldTenPercentOwnershipInterestMember" id="rttr_EmployeeHoldTenPercentOwnershipInterestMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OtherEmployeeMember" id="rttr_OtherEmployeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription" id="rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice" id="rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>

<element name="ExecutiveOfficersAndEmployeesMember" id="rttr_ExecutiveOfficersAndEmployeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TermOfShareBaseCompensationArrangement" id="rttr_TermOfShareBaseCompensationArrangement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultantsMember" id="rttr_ConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost" id="rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AverageStrikePutOptionApproachMember" id="rttr_AverageStrikePutOptionApproachMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CapitalStructureYieldedTotalMarketValueOfInvestedCapital" id="rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ValueOfCommonStock" id="rttr_ValueOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>


<element name="AndelaGroupIncMember" id="rttr_AndelaGroupIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CorporateManagementStrategicAndFinancialConsultingMember" id="rttr_CorporateManagementStrategicAndFinancialConsultingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CenturyParkMember" id="rttr_CenturyParkMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RicercheSperimentaliMontaleSpaAndInalcoSpaMember" id="rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmendedClinicalSupplyAndCooperationAgreementMember" id="rttr_AmendedClinicalSupplyAndCooperationAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AreaOfLease" id="rttr_AreaOfLease" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentToExerciseOptionUnderAgreement" id="rttr_PaymentToExerciseOptionUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentRequiredFollowingFdaApproval" id="rttr_PaymentRequiredFollowingFdaApproval" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PurchaseOfImprovedGosInKilos" id="rttr_PurchaseOfImprovedGosInKilos" type="num:massItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GosPricePerKilo" id="rttr_GosPricePerKilo" type="us-types:perUnitItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GosPricePerKiloUnderExistingSupplyAgreement" id="rttr_GosPricePerKiloUnderExistingSupplyAgreement" type="us-types:perUnitItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockPlan2008Member" id="rttr_StockPlan2008Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true"/>
<element name="ClassOfWarrantOrRightNumberOfWarrantsRollForward" id="rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true"/>
<element name="ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" id="rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true"/>
<element name="DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" id="rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true" xbrli:balance="credit"/>
<element name="OperatingLeaseRentExpenseMinimumMonthlyRentals" id="rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true" xbrli:balance="debit"/>

<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber" id="rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true"/>
<element name="StockOptionsToVestRatablyOnMonthlyBasis" id="rttr_StockOptionsToVestRatablyOnMonthlyBasis" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" abstract="false" nillable="true"/>
<element name="ConversionOfPreferredToCommonStockMember" id="rttr_ConversionOfPreferredToCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true"/>
<element name="ConversionOfRedeemablePreferredStockToCommonStockMember" id="rttr_ConversionOfRedeemablePreferredStockToCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true"/>
<element name="PreferredStockOriginalIssuePrice" id="rttr_PreferredStockOriginalIssuePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" abstract="false" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>rttr-20150630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.3.0.4 on Thursday, August 13, 2015 12:14:30 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" roleURI="http://www.ritterpharmaceuticals.com/role/CONDENSEDBALANCESHEETS" xlink:href="rttr-20150630.xsd#CONDENSEDBALANCESHEETS"/>
<calculationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CONDENSEDBALANCESHEETS">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="30" use="optional" weight="1"/></calculationLink>




<roleRef xlink:type="simple" roleURI="http://www.ritterpharmaceuticals.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:href="rttr-20150630.xsd#CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_Depreciation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" order="50" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="60" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="70" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="80" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="90" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromNotesPayable" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="30" use="optional" weight="1"/></calculationLink>



<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#PROPERTYANDEQUIPMENTDetails" roleURI="http://www.ritterpharmaceuticals.com/role/PROPERTYANDEQUIPMENTDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/PROPERTYANDEQUIPMENTDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="20" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#CONDENSEDSTATEMENTSOFOPERATIONSUnaudited" roleURI="http://www.ritterpharmaceuticals.com/role/CONDENSEDSTATEMENTSOFOPERATIONSUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CONDENSEDSTATEMENTSOFOPERATIONSUnaudited"><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="0" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="0" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="0" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PatentCosts" xlink:label="loc_rttr_PatentCosts"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_rttr_PatentCosts" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OtherIncome" order="1" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherIncome" xlink:to="loc_us-gaap_InvestmentIncomeInterest" order="0" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherIncome" xlink:to="loc_us-gaap_OtherNonoperatingIncome" order="1" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>rttr-20150630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.3.0.4 on Thursday, August 13, 2015 12:14:30 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" roleURI="http://www.ritterpharmaceuticals.com/role/CONDENSEDBALANCESHEETSParentheticals" xlink:href="rttr-20150630.xsd#CONDENSEDBALANCESHEETSParentheticals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#OrganizationAndPrincipalActivitiesDetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/OrganizationAndPrincipalActivitiesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#PROPERTYANDEQUIPMENTDetails" roleURI="http://www.ritterpharmaceuticals.com/role/PROPERTYANDEQUIPMENTDetails"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#PropertyAndEquipmentdetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/PropertyAndEquipmentdetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#CommitmentsAndContingenciesDetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#CommitmentsAndContingenciesDetailTextuals1" roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals1"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#CommitmentsAndContingenciesDetailTextuals2" roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals2"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#CommitmentsAndContingenciesDetailTextuals3" roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals3"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#CommitmentsAndContingenciesDetailTextuals4" roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals4"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1" roleURI="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals2" roleURI="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals2"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals3" roleURI="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals3"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals4" roleURI="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals4"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#WARRANTSDetails" roleURI="http://www.ritterpharmaceuticals.com/role/WARRANTSDetails"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#WarrantsDetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/WarrantsDetailTextuals"/>

<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#STOCKBASEDCOMPENSATIONDetails1" roleURI="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails1"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#STOCKBASEDCOMPENSATIONDetails3" roleURI="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails3"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockBasedCompensationDetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockBasedCompensationDetailTextuals1" roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals1"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockBasedCompensationDetailTextuals2" roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals2"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockBasedCompensationDetailTextuals3" roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals3"/>
<roleRef xlink:type="simple" roleURI="http://www.ritterpharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetailTextuals" xlink:href="rttr-20150630.xsd#RELATEDPARTYTRANSACTIONSDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#SubsequentEventsDetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/SubsequentEventsDetailTextuals"/>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CONDENSEDBALANCESHEETSParentheticals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_8" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_9" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_10" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_11" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_12" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_13" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_14" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_15" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_16" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_17" order="120" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/OrganizationAndPrincipalActivitiesDetailTextuals">
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_OrganizationAndPrincipalActivitiesLineItems" xlink:label="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_OrganizationAndPrincipalActivitiesTable" xlink:label="loc_rttr_OrganizationAndPrincipalActivitiesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_0" xlink:to="loc_rttr_OrganizationAndPrincipalActivitiesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3" xlink:to="loc_us-gaap_IPOMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="loc_rttr_PaymentsOfUnderwritingDiscountsAndCommissions_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_0" xlink:to="loc_rttr_PaymentsOfUnderwritingDiscountsAndCommissions_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10" order="60" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/PROPERTYANDEQUIPMENTDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ComputerEquipmentMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/PropertyAndEquipmentdetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_Depreciation_5" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals">
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesLineItems" xlink:label="loc_rttr_CommitmentsAndContingenciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesTable" xlink:label="loc_rttr_CommitmentsAndContingenciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_CommitmentsAndContingenciesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementAxis" xlink:label="loc_rttr_AgreementAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_AgreementAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementDomain" xlink:label="loc_rttr_AgreementDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rttr_AgreementAxis_2" xlink:to="loc_rttr_AgreementDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementDomain" xlink:label="loc_rttr_AgreementDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rttr_AgreementAxis_2" xlink:to="loc_rttr_AgreementDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StepLetterAgreementMember" xlink:label="loc_rttr_StepLetterAgreementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_AgreementDomain_3" xlink:to="loc_rttr_StepLetterAgreementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PresidentAndFormerChiefExecutiveOfficerMember" xlink:label="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ChiefStrategicOfficerMember" xlink:label="loc_rttr_ChiefStrategicOfficerMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_rttr_ChiefStrategicOfficerMember_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_EmployeeStockOptionTwoMember" xlink:label="loc_rttr_EmployeeStockOptionTwoMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_rttr_EmployeeStockOptionTwoMember_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_EmployeeStockOptionThreeMember" xlink:label="loc_rttr_EmployeeStockOptionThreeMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_rttr_EmployeeStockOptionThreeMember_14" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_PlanNameAxis_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_15" xlink:to="loc_us-gaap_PlanNameDomain_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_16_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_15" xlink:to="loc_us-gaap_PlanNameDomain_16_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ExecutiveCompensationPlanMember" xlink:label="loc_rttr_ExecutiveCompensationPlanMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_16" xlink:to="loc_rttr_ExecutiveCompensationPlanMember_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockPlan2008Member" xlink:label="loc_rttr_StockPlan2008Member_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_16" xlink:to="loc_rttr_StockPlan2008Member_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_19" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_20_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_20_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_20" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_OfficersCompensation_22" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TuitionReimbursementAuthorizedAmount" xlink:label="loc_rttr_TuitionReimbursementAuthorizedAmount_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_TuitionReimbursementAuthorizedAmount_23" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PeriodOfTuitionReimbursement" xlink:label="loc_rttr_PeriodOfTuitionReimbursement_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_PeriodOfTuitionReimbursement_24" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_25" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_NumberOfOptionGranted" xlink:label="loc_rttr_NumberOfOptionGranted_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_NumberOfOptionGranted_26" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_27" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_28" order="70" use="optional"/>


<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding" xlink:label="loc_rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding_30" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfSharesSubjectToRightOfRepurchase" xlink:label="loc_rttr_PercentageOfSharesSubjectToRightOfRepurchase_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_PercentageOfSharesSubjectToRightOfRepurchase_31" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_DescriptionOfRightToRepurchaseLapse" xlink:label="loc_rttr_DescriptionOfRightToRepurchaseLapse_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_DescriptionOfRightToRepurchaseLapse_32" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_BonusPercentageOfSalary" xlink:label="loc_rttr_BonusPercentageOfSalary_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_BonusPercentageOfSalary_33" order="120" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals1">
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesLineItems" xlink:label="loc_rttr_CommitmentsAndContingenciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesTable" xlink:label="loc_rttr_CommitmentsAndContingenciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_CommitmentsAndContingenciesTable_1" order="10" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis" xlink:label="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain" xlink:label="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_5" xlink:to="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain" xlink:label="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_5" xlink:to="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_FdaMeetingBonusOpportunitiesMember" xlink:label="loc_rttr_FdaMeetingBonusOpportunitiesMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_6" xlink:to="loc_rttr_FdaMeetingBonusOpportunitiesMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" xlink:label="loc_rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_6" xlink:to="loc_rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_FundraisingBonusOpportunitiesMember" xlink:label="loc_rttr_FundraisingBonusOpportunitiesMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_6" xlink:to="loc_rttr_FundraisingBonusOpportunitiesMember_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneTypeAxis" xlink:label="loc_rttr_PerformanceMilestoneTypeAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_PerformanceMilestoneTypeAxis_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneTypeDomain" xlink:label="loc_rttr_PerformanceMilestoneTypeDomain_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rttr_PerformanceMilestoneTypeAxis_10" xlink:to="loc_rttr_PerformanceMilestoneTypeDomain_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneTypeDomain" xlink:label="loc_rttr_PerformanceMilestoneTypeDomain_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rttr_PerformanceMilestoneTypeAxis_10" xlink:to="loc_rttr_PerformanceMilestoneTypeDomain_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneConditionOneMember" xlink:label="loc_rttr_PerformanceMilestoneConditionOneMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_PerformanceMilestoneTypeDomain_11" xlink:to="loc_rttr_PerformanceMilestoneConditionOneMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneConditionTwoMember" xlink:label="loc_rttr_PerformanceMilestoneConditionTwoMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_PerformanceMilestoneTypeDomain_11" xlink:to="loc_rttr_PerformanceMilestoneConditionTwoMember_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RangeAxis_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_14" xlink:to="loc_us-gaap_RangeMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_15_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_14" xlink:to="loc_us-gaap_RangeMember_15_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_15" xlink:to="loc_us-gaap_MinimumMember_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_17" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_18_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_17" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_18_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_18" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_20" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_20" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_21_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_20" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_21_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_21" xlink:to="loc_us-gaap_SubsequentEventMember_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_23" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_23" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_23" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24" xlink:to="loc_us-gaap_IPOMember_25" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ExecutiveCompensation" xlink:label="loc_rttr_ExecutiveCompensation_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_ExecutiveCompensation_26" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_MinimumActualDeploymentOfFundsByThirdParty" xlink:label="loc_rttr_MinimumActualDeploymentOfFundsByThirdParty_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_MinimumActualDeploymentOfFundsByThirdParty_27" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_28" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_Cash_29" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_30" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_31" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_33" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AccruedBonusToExecutive" xlink:label="loc_rttr_AccruedBonusToExecutive_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_AccruedBonusToExecutive_34" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_35" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PresidentAndFormerChiefExecutiveOfficerMember" xlink:label="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ChiefStrategicOfficerMember" xlink:label="loc_rttr_ChiefStrategicOfficerMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_rttr_ChiefStrategicOfficerMember" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="1"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockOptionsToVestRatablyOnMonthlyBasis" xlink:label="loc_rttr_StockOptionsToVestRatablyOnMonthlyBasis"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_StockOptionsToVestRatablyOnMonthlyBasis" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals2">
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesLineItems" xlink:label="loc_rttr_CommitmentsAndContingenciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesTable" xlink:label="loc_rttr_CommitmentsAndContingenciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_CommitmentsAndContingenciesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis" xlink:label="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain" xlink:label="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_2" xlink:to="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain" xlink:label="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_2" xlink:to="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_LicenseEventBonusOpportunitiesMember" xlink:label="loc_rttr_LicenseEventBonusOpportunitiesMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_3" xlink:to="loc_rttr_LicenseEventBonusOpportunitiesMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneTypeAxis" xlink:label="loc_rttr_PerformanceMilestoneTypeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_PerformanceMilestoneTypeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneTypeDomain" xlink:label="loc_rttr_PerformanceMilestoneTypeDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rttr_PerformanceMilestoneTypeAxis_5" xlink:to="loc_rttr_PerformanceMilestoneTypeDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneTypeDomain" xlink:label="loc_rttr_PerformanceMilestoneTypeDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rttr_PerformanceMilestoneTypeAxis_5" xlink:to="loc_rttr_PerformanceMilestoneTypeDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneConditionOneMember" xlink:label="loc_rttr_PerformanceMilestoneConditionOneMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_PerformanceMilestoneTypeDomain_6" xlink:to="loc_rttr_PerformanceMilestoneConditionOneMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneConditionTwoMember" xlink:label="loc_rttr_PerformanceMilestoneConditionTwoMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_PerformanceMilestoneTypeDomain_6" xlink:to="loc_rttr_PerformanceMilestoneConditionTwoMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneConditionThreeMember" xlink:label="loc_rttr_PerformanceMilestoneConditionThreeMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_PerformanceMilestoneTypeDomain_6" xlink:to="loc_rttr_PerformanceMilestoneConditionThreeMember_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RangeAxis_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_13" xlink:to="loc_us-gaap_RangeMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_13" xlink:to="loc_us-gaap_RangeMember_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_14" xlink:to="loc_us-gaap_MinimumMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_14" xlink:to="loc_us-gaap_MaximumMember_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TypeOfBonusAwardAxis" xlink:label="loc_rttr_TypeOfBonusAwardAxis_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_TypeOfBonusAwardAxis_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TypeOfBonusAwardDomain" xlink:label="loc_rttr_TypeOfBonusAwardDomain_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rttr_TypeOfBonusAwardAxis_17" xlink:to="loc_rttr_TypeOfBonusAwardDomain_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TypeOfBonusAwardDomain" xlink:label="loc_rttr_TypeOfBonusAwardDomain_18_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rttr_TypeOfBonusAwardAxis_17" xlink:to="loc_rttr_TypeOfBonusAwardDomain_18_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GraduatedCashBonusMember" xlink:label="loc_rttr_GraduatedCashBonusMember_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_TypeOfBonusAwardDomain_18" xlink:to="loc_rttr_GraduatedCashBonusMember_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_MinimumActualDeploymentOfFundsByThirdParty" xlink:label="loc_rttr_MinimumActualDeploymentOfFundsByThirdParty_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_MinimumActualDeploymentOfFundsByThirdParty_20" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfInitialPeriodLicensePayment" xlink:label="loc_rttr_PercentageOfInitialPeriodLicensePayment_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_PercentageOfInitialPeriodLicensePayment_21" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_InitialPeriodLicensePayment" xlink:label="loc_rttr_InitialPeriodLicensePayment_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_InitialPeriodLicensePayment_22" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ReceiptOfInitialPeriodLicensePayment" xlink:label="loc_rttr_ReceiptOfInitialPeriodLicensePayment_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_ReceiptOfInitialPeriodLicensePayment_23" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_24" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_25" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_26" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_27" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfCashBonusExcessOfMilestonePayments" xlink:label="loc_rttr_PercentageOfCashBonusExcessOfMilestonePayments_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_PercentageOfCashBonusExcessOfMilestonePayments_28" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_Cash_29" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PresidentAndFormerChiefExecutiveOfficerMember" xlink:label="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ChiefStrategicOfficerMember" xlink:label="loc_rttr_ChiefStrategicOfficerMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_rttr_ChiefStrategicOfficerMember" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="1"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals3">
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesLineItems" xlink:label="loc_rttr_CommitmentsAndContingenciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesTable" xlink:label="loc_rttr_CommitmentsAndContingenciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_CommitmentsAndContingenciesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_9" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_9" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PresidentAndCsoMember" xlink:label="loc_rttr_PresidentAndCsoMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_10" xlink:to="loc_rttr_PresidentAndCsoMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_10" xlink:to="loc_us-gaap_DirectorMember_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_VestingAxis_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_13" xlink:to="loc_us-gaap_VestingDomain_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_13" xlink:to="loc_us-gaap_VestingDomain_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_14" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_14" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_14" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_VestingPeriodThreeYearsMember" xlink:label="loc_rttr_VestingPeriodThreeYearsMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_14" xlink:to="loc_rttr_VestingPeriodThreeYearsMember_18" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_VestingPeriodOneYearMember" xlink:label="loc_rttr_VestingPeriodOneYearMember_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_14" xlink:to="loc_rttr_VestingPeriodOneYearMember_19" order="40" use="optional"/>


<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_InitialPeriod" xlink:label="loc_rttr_InitialPeriod_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_InitialPeriod_21" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AnnualExcessMilestonePayments" xlink:label="loc_rttr_AnnualExcessMilestonePayments_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_AnnualExcessMilestonePayments_22" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfAdditionalCashBonus" xlink:label="loc_rttr_PercentageOfAdditionalCashBonus_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_PercentageOfAdditionalCashBonus_23" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_24" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_25" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_26" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_27" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_28" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_29" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PresidentAndFormerChiefExecutiveOfficerMember" xlink:label="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_10" xlink:to="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ChiefStrategicOfficerMember" xlink:label="loc_rttr_ChiefStrategicOfficerMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_10" xlink:to="loc_rttr_ChiefStrategicOfficerMember" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals4">
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesLineItems" xlink:label="loc_rttr_CommitmentsAndContingenciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesTable" xlink:label="loc_rttr_CommitmentsAndContingenciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_CommitmentsAndContingenciesTable_1" order="10" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6" xlink:to="loc_us-gaap_SubsequentEventMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_9" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfIncreaseInAnnualRent" xlink:label="loc_rttr_PercentageOfIncreaseInAnnualRent_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_PercentageOfIncreaseInAnnualRent_10" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_us-gaap_LeaseAndRentalExpense_11" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals" xlink:label="loc_rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesAOnePreferredStockMember" xlink:label="loc_rttr_SeriesAOnePreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesAOnePreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesATwoPreferredStockMember" xlink:label="loc_rttr_SeriesATwoPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesATwoPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesAThreePreferredStockMember" xlink:label="loc_rttr_SeriesAThreePreferredStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesAThreePreferredStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_13" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:label="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_14" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PurchasePrice" xlink:label="loc_rttr_PurchasePrice_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_rttr_PurchasePrice_15" order="70" use="optional"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare" order="90" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3" xlink:to="loc_us-gaap_IPOMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="loc_rttr_PaymentsOfUnderwritingDiscountsAndCommissions_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_rttr_PaymentsOfUnderwritingDiscountsAndCommissions_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_10" order="60" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_CommonStockMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_9" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_9" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_10" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_12" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_12" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TwoThousandFourteenNotesMember" xlink:label="loc_rttr_TwoThousandFourteenNotesMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13" xlink:to="loc_rttr_TwoThousandFourteenNotesMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TwoThousandFourteenNotesOneMember" xlink:label="loc_rttr_TwoThousandFourteenNotesOneMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13" xlink:to="loc_rttr_TwoThousandFourteenNotesOneMember_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_18" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TermOfWarrantIssued" xlink:label="loc_rttr_TermOfWarrantIssued_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_rttr_TermOfWarrantIssued_19" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_FairValuePerShare" xlink:label="loc_rttr_FairValuePerShare_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_rttr_FairValuePerShare_21" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_DiscountOnInitialCarryingValue" xlink:label="loc_rttr_DiscountOnInitialCarryingValue_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_rttr_DiscountOnInitialCarryingValue_22" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ConvertibleNotesPayable_23" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_24" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_25" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_26" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_27" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfPricePerShare" xlink:label="loc_rttr_PercentageOfPricePerShare_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_rttr_PercentageOfPricePerShare_28" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_InterestExpenseDebt_29" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest" xlink:label="loc_rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest_30" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_31" order="160" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals4">
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems" xlink:label="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable" xlink:label="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems_0" xlink:to="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementAxis" xlink:label="loc_rttr_AgreementAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable_1" xlink:to="loc_rttr_AgreementAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementDomain" xlink:label="loc_rttr_AgreementDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rttr_AgreementAxis_2" xlink:to="loc_rttr_AgreementDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementDomain" xlink:label="loc_rttr_AgreementDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rttr_AgreementAxis_2" xlink:to="loc_rttr_AgreementDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ResearchAndDevelopmentAgreementLicenseMember" xlink:label="loc_rttr_ResearchAndDevelopmentAgreementLicenseMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_AgreementDomain_3" xlink:to="loc_rttr_ResearchAndDevelopmentAgreementLicenseMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PutAndCallOptionAgreementMember" xlink:label="loc_rttr_PutAndCallOptionAgreementMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_AgreementDomain_3" xlink:to="loc_rttr_PutAndCallOptionAgreementMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementPartiesAxis" xlink:label="loc_rttr_AgreementPartiesAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable_1" xlink:to="loc_rttr_AgreementPartiesAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementPartiesDomain" xlink:label="loc_rttr_AgreementPartiesDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rttr_AgreementPartiesAxis_6" xlink:to="loc_rttr_AgreementPartiesDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementPartiesDomain" xlink:label="loc_rttr_AgreementPartiesDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rttr_AgreementPartiesAxis_6" xlink:to="loc_rttr_AgreementPartiesDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_KoluPohakuTechnologiesLlcMember" xlink:label="loc_rttr_KoluPohakuTechnologiesLlcMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_AgreementPartiesDomain_7" xlink:to="loc_rttr_KoluPohakuTechnologiesLlcMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_KoluPohakuManagementLlcMember" xlink:label="loc_rttr_KoluPohakuManagementLlcMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_AgreementPartiesDomain_7" xlink:to="loc_rttr_KoluPohakuManagementLlcMember_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10" xlink:to="loc_us-gaap_ClassOfStockDomain_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10" xlink:to="loc_us-gaap_ClassOfStockDomain_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_11" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems_0" xlink:to="loc_us-gaap_RoyaltyExpense_14" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_15" order="30" use="optional"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PreferredStockOriginalIssuePrice" xlink:label="loc_rttr_PreferredStockOriginalIssuePrice"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems_0" xlink:to="loc_rttr_PreferredStockOriginalIssuePrice" order="60" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/WARRANTSDetails">































<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:label="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightGranted" xlink:label="loc_rttr_ClassOfWarrantOrRightGranted"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:to="loc_rttr_ClassOfWarrantOrRightGranted" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisedExpiredForfeited" xlink:label="loc_rttr_ClassOfWarrantOrRightExercisedExpiredForfeited"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:to="loc_rttr_ClassOfWarrantOrRightExercisedExpiredForfeited" order="2" use="optional"/>


<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisable" xlink:label="loc_rttr_ClassOfWarrantOrRightExercisable"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:to="loc_rttr_ClassOfWarrantOrRightExercisable" order="4" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:label="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" xlink:label="loc_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="loc_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited" xlink:label="loc_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="loc_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited" order="2" use="optional"/>


<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" xlink:label="loc_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="loc_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" order="4" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable" order="10" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SevenYearWarrantsMember" xlink:label="loc_rttr_SevenYearWarrantsMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="loc_rttr_SevenYearWarrantsMember" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="1"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/WarrantsDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SevenYearWarrantsMember" xlink:label="loc_rttr_SevenYearWarrantsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_rttr_SevenYearWarrantsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6" order="20" use="optional"/>
</definitionLink>

<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesATwoPreferredStockMember" xlink:label="loc_rttr_SeriesATwoPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesATwoPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesAThreePreferredStockMember" xlink:label="loc_rttr_SeriesAThreePreferredStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesAThreePreferredStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PeriodOfShareIssueAxis" xlink:label="loc_rttr_PeriodOfShareIssueAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_rttr_PeriodOfShareIssueAxis_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PeriodOfShareIssueDomain" xlink:label="loc_rttr_PeriodOfShareIssueDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rttr_PeriodOfShareIssueAxis_9" xlink:to="loc_rttr_PeriodOfShareIssueDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PeriodOfShareIssueDomain" xlink:label="loc_rttr_PeriodOfShareIssueDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rttr_PeriodOfShareIssueAxis_9" xlink:to="loc_rttr_PeriodOfShareIssueDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandFiveMember" xlink:label="loc_rttr_YearTwoThousandFiveMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_PeriodOfShareIssueDomain_10" xlink:to="loc_rttr_YearTwoThousandFiveMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandSixMember" xlink:label="loc_rttr_YearTwoThousandSixMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_PeriodOfShareIssueDomain_10" xlink:to="loc_rttr_YearTwoThousandSixMember_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandEightToYearTwoThousandNineMember" xlink:label="loc_rttr_YearTwoThousandEightToYearTwoThousandNineMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_PeriodOfShareIssueDomain_10" xlink:to="loc_rttr_YearTwoThousandEightToYearTwoThousandNineMember_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandTenToYearTwoThousandThirteenMember" xlink:label="loc_rttr_YearTwoThousandTenToYearTwoThousandThirteenMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_PeriodOfShareIssueDomain_10" xlink:to="loc_rttr_YearTwoThousandTenToYearTwoThousandThirteenMember_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandFourteenMember" xlink:label="loc_rttr_YearTwoThousandFourteenMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_PeriodOfShareIssueDomain_10" xlink:to="loc_rttr_YearTwoThousandFourteenMember_15" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_16" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_AwardDateAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_5" xlink:to="loc_us-gaap_AwardDateDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_5" xlink:to="loc_us-gaap_AwardDateDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandFiveMember" xlink:label="loc_rttr_GrantYearTwoThousandFiveMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_6" xlink:to="loc_rttr_GrantYearTwoThousandFiveMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandNineMember" xlink:label="loc_rttr_GrantYearTwoThousandNineMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_6" xlink:to="loc_rttr_GrantYearTwoThousandNineMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandElevenMember" xlink:label="loc_rttr_GrantYearTwoThousandElevenMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_6" xlink:to="loc_rttr_GrantYearTwoThousandElevenMember_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandTwelveMember" xlink:label="loc_rttr_GrantYearTwoThousandTwelveMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_6" xlink:to="loc_rttr_GrantYearTwoThousandTwelveMember_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandThirteenMember" xlink:label="loc_rttr_GrantYearTwoThousandThirteenMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_6" xlink:to="loc_rttr_GrantYearTwoThousandThirteenMember_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandFourteenMember" xlink:label="loc_rttr_GrantYearTwoThousandFourteenMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_6" xlink:to="loc_rttr_GrantYearTwoThousandFourteenMember_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_RangeAxis_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_13" xlink:to="loc_us-gaap_RangeMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_13" xlink:to="loc_us-gaap_RangeMember_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_14" xlink:to="loc_us-gaap_MinimumMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_14" xlink:to="loc_us-gaap_MaximumMember_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_19" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_20" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockPlan2015Member" xlink:label="loc_rttr_StockPlan2015Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_rttr_StockPlan2015Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_IncentiveStockOptionMember" xlink:label="loc_rttr_IncentiveStockOptionMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOptionMember_7" xlink:to="loc_rttr_IncentiveStockOptionMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_NonstatutoryStockOptionMember" xlink:label="loc_rttr_NonstatutoryStockOptionMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOptionMember_7" xlink:to="loc_rttr_NonstatutoryStockOptionMember_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_10" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_10" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_EmployeeHoldTenPercentOwnershipInterestMember" xlink:label="loc_rttr_EmployeeHoldTenPercentOwnershipInterestMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11" xlink:to="loc_rttr_EmployeeHoldTenPercentOwnershipInterestMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_OtherEmployeeMember" xlink:label="loc_rttr_OtherEmployeeMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11" xlink:to="loc_rttr_OtherEmployeeMember_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_14" xlink:to="loc_us-gaap_RangeMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_15_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_14" xlink:to="loc_us-gaap_RangeMember_15_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_15" xlink:to="loc_us-gaap_MinimumMember_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_15" xlink:to="loc_us-gaap_MaximumMember_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription" xlink:label="loc_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice" xlink:label="loc_rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice_20" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_21" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_10" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_10" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ExecutiveOfficersAndEmployeesMember" xlink:label="loc_rttr_ExecutiveOfficersAndEmployeesMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11" xlink:to="loc_rttr_ExecutiveOfficersAndEmployeesMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11" xlink:to="loc_us-gaap_ExecutiveOfficerMember_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_14" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_15_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_14" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_15_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_15" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_21" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TermOfShareBaseCompensationArrangement" xlink:label="loc_rttr_TermOfShareBaseCompensationArrangement_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_rttr_TermOfShareBaseCompensationArrangement_22" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_23" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_24" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_25" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27" order="110" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" order="10" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_5" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_5" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ConsultantsMember" xlink:label="loc_rttr_ConsultantsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_6" xlink:to="loc_rttr_ConsultantsMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MinimumMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_VestingAxis_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_12" xlink:to="loc_us-gaap_VestingDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_12" xlink:to="loc_us-gaap_VestingDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_13" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_15" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_15" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_16_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_15" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_16_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_16" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_19" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost" xlink:label="loc_rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0" xlink:to="loc_rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost_24" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber" xlink:label="loc_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_0" xlink:to="loc_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesAOnePreferredStockMember" xlink:label="loc_rttr_SeriesAOnePreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesAOnePreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesATwoPreferredStockMember" xlink:label="loc_rttr_SeriesATwoPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesATwoPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesAThreePreferredStockMember" xlink:label="loc_rttr_SeriesAThreePreferredStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesAThreePreferredStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MinimumMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MaximumMember_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ValuationTechniqueAxis_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_13" xlink:to="loc_us-gaap_ValuationTechniqueDomain_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_13" xlink:to="loc_us-gaap_ValuationTechniqueDomain_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AverageStrikePutOptionApproachMember" xlink:label="loc_rttr_AverageStrikePutOptionApproachMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_14" xlink:to="loc_rttr_AverageStrikePutOptionApproachMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital" xlink:label="loc_rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ValueOfCommonStock" xlink:label="loc_rttr_ValueOfCommonStock_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_rttr_ValueOfCommonStock_18" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountForLackOfMarketability" xlink:label="loc_us-gaap_FairValueInputsDiscountForLackOfMarketability_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_FairValueInputsDiscountForLackOfMarketability_19" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharePrice_20" order="50" use="optional"/>




</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AndelaGroupIncMember" xlink:label="loc_rttr_AndelaGroupIncMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_rttr_AndelaGroupIncMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CorporateManagementStrategicAndFinancialConsultingMember" xlink:label="loc_rttr_CorporateManagementStrategicAndFinancialConsultingMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6" xlink:to="loc_rttr_CorporateManagementStrategicAndFinancialConsultingMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_11" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/SubsequentEventsDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CenturyParkMember" xlink:label="loc_rttr_CenturyParkMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_rttr_CenturyParkMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember" xlink:label="loc_rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_RangeAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MaximumMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementAxis" xlink:label="loc_rttr_AgreementAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_rttr_AgreementAxis_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementDomain" xlink:label="loc_rttr_AgreementDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rttr_AgreementAxis_12" xlink:to="loc_rttr_AgreementDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementDomain" xlink:label="loc_rttr_AgreementDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rttr_AgreementAxis_12" xlink:to="loc_rttr_AgreementDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AmendedClinicalSupplyAndCooperationAgreementMember" xlink:label="loc_rttr_AmendedClinicalSupplyAndCooperationAgreementMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rttr_AgreementDomain_13" xlink:to="loc_rttr_AmendedClinicalSupplyAndCooperationAgreementMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualRightsMember" xlink:label="loc_us-gaap_ContractualRightsMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16" xlink:to="loc_us-gaap_ContractualRightsMember_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AreaOfLease" xlink:label="loc_rttr_AreaOfLease_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_rttr_AreaOfLease_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_20" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_21" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_22" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PaymentToExerciseOptionUnderAgreement" xlink:label="loc_rttr_PaymentToExerciseOptionUnderAgreement_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_rttr_PaymentToExerciseOptionUnderAgreement_23" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PaymentRequiredFollowingFdaApproval" xlink:label="loc_rttr_PaymentRequiredFollowingFdaApproval_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_rttr_PaymentRequiredFollowingFdaApproval_24" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PurchaseOfImprovedGosInKilos" xlink:label="loc_rttr_PurchaseOfImprovedGosInKilos_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_rttr_PurchaseOfImprovedGosInKilos_25" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GosPricePerKilo" xlink:label="loc_rttr_GosPricePerKilo_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_rttr_GosPricePerKilo_26" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GosPricePerKiloUnderExistingSupplyAgreement" xlink:label="loc_rttr_GosPricePerKiloUnderExistingSupplyAgreement_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_rttr_GosPricePerKiloUnderExistingSupplyAgreement_27" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_28" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_29" order="120" use="optional"/>
</definitionLink>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#CONDENSEDBALANCESHEETS" roleURI="http://www.ritterpharmaceuticals.com/role/CONDENSEDBALANCESHEETS"/>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CONDENSEDBALANCESHEETS"><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_AssetsAbstract" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_AssetsCurrentAbstract" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="loc_us-gaap_AssetsCurrent" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="3" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_Assets" order="4" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="3" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaap_StockholdersEquityAbstract" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="loc_us-gaap_PreferredStockValue" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="loc_us-gaap_CommonStockValue" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="3" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="loc_us-gaap_StockholdersEquity" order="4" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity" order="3" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_StatementTable" order="10" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable" xlink:to="loc_us-gaap_StatementClassOfStockAxis" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="loc_us-gaap_ClassOfStockDomain" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_us-gaap_RedeemablePreferredStockMember" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="1"/>
</definitionLink>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited" roleURI="http://www.ritterpharmaceuticals.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited"/>
<definitionLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited"><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_StatementTable" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="loc_us-gaap_ConversionOfStockNameDomain" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_Default" order="1"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ConversionOfPreferredToCommonStockMember" xlink:label="loc_rttr_ConversionOfPreferredToCommonStockMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="loc_rttr_ConversionOfPreferredToCommonStockMember" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ConversionOfRedeemablePreferredStockToCommonStockMember" xlink:label="loc_rttr_ConversionOfRedeemablePreferredStockToCommonStockMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="loc_rttr_ConversionOfRedeemablePreferredStockToCommonStockMember" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_NetIncomeLoss" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaap_Depreciation" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="3" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="4" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="3" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="3" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_ProceedsFromNotesPayable" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="3" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="4" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="5" use="optional"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering" xlink:label="loc_rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" xlink:label="loc_rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" order="1" use="optional"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1" order="3" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommonStockSubjectToRepurchase" xlink:label="loc_rttr_CommonStockSubjectToRepurchase"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_rttr_CommonStockSubjectToRepurchase" order="4" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="loc_us-gaap_DividendsPreferredStockStock"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaap_DividendsPreferredStockStock" order="5" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount" order="6" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaap_InterestPaid" order="7" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaap_IncomeTaxesPaid" order="8" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>rttr-20150630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.3.0.4 on Thursday, August 13, 2015 12:14:30 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_DocumentAndEntityInformationAbstract" xlink:label="loc_839743H4G541_rttr_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_DocumentAndEntityInformationAbstract" xlink:to="lab_051965J6I763_rttr_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_FG95812277699K094F4I_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_dei_EntityRegistrantName" xlink:to="lab_HI17034499811M216H6K_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_839743H4G541_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_dei_EntityCentralIndexKey" xlink:to="lab_051965J6I763_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_FG95812277699K094F4I_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_dei_CurrentFiscalYearEndDate" xlink:to="lab_HI17034499811M216H6K_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_839743H4G541_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_dei_EntityFilerCategory" xlink:to="lab_051965J6I763_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_FG95812277699K094F4I_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_HI17034499811M216H6K_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_839743H4G541_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_dei_DocumentType" xlink:to="lab_051965J6I763_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_FG95812277699K094F4I_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_dei_DocumentPeriodEndDate" xlink:to="lab_HI17034499811M216H6K_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_839743H4G541_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_dei_AmendmentFlag" xlink:to="lab_051965J6I763_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_FG95812277699K094F4I_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_dei_DocumentFiscalYearFocus" xlink:to="lab_HI17034499811M216H6K_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_839743H4G541_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_dei_DocumentFiscalPeriodFocus" xlink:to="lab_051965J6I763_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_FG95812277699K094F4I_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_HI17034499811M216H6K_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_839743H4G541_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AssetsAbstract" xlink:to="lab_051965J6I763_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_FG95812277699K094F4I_us-gaap_AssetsCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_AssetsCurrentAbstract" xlink:to="lab_HI17034499811M216H6K_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_839743H4G541_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_051965J6I763_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_051965J6I763_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_051965J6I763_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_FG95812277699K094F4I_us-gaap_PrepaidExpenseCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_HI17034499811M216H6K_us-gaap_PrepaidExpenseCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_839743H4G541_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AssetsCurrent" xlink:to="lab_051965J6I763_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_FG95812277699K094F4I_us-gaap_OtherAssetsNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_HI17034499811M216H6K_us-gaap_OtherAssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_839743H4G541_us-gaap_DeferredFinanceCostsNoncurrentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_DeferredFinanceCostsNoncurrentNet" xml:lang="en-US">Deferred Finance Costs, Noncurrent, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_DeferredFinanceCostsNoncurrentNet" xml:lang="en-US">Deferred offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_051965J6I763_us-gaap_DeferredFinanceCostsNoncurrentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Total property and equipment, net of accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_839743H4G541_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_Assets" xlink:to="lab_051965J6I763_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_FG95812277699K094F4I_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_HI17034499811M216H6K_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_839743H4G541_us-gaap_LiabilitiesCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_051965J6I763_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_FG95812277699K094F4I_us-gaap_AccountsPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_AccountsPayableCurrent" xlink:to="lab_HI17034499811M216H6K_us-gaap_AccountsPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_839743H4G541_us-gaap_AccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_051965J6I763_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_FG95812277699K094F4I_us-gaap_OtherLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other liablities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_HI17034499811M216H6K_us-gaap_OtherLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_839743H4G541_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_LiabilitiesCurrent" xlink:to="lab_051965J6I763_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_FG95812277699K094F4I_us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Preferred stock subject to redemption, $0.001 par value, no shares authorized, issued and outstanding as of June 30, 2015; 16,378,646 shares authorized, 13,399,668 shares issued and outstanding as of December 31, 2014</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_HI17034499811M216H6K_us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_839743H4G541_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StockholdersEquityAbstract" xlink:to="lab_051965J6I763_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_FG95812277699K094F4I_us-gaap_PreferredStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of June 30, 2015; 8,887,500 shares authorized, issued and outstanding as of December 31, 2014</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PreferredStockValue" xlink:to="lab_HI17034499811M216H6K_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_839743H4G541_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 25,000,000 shares authorized, 7,788,028 shares issued and outstanding as of June 30, 2015; 50,000,000 shares authorized, 465,378 shares issued and outstanding as of December 31, 2014</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_CommonStockValue" xlink:to="lab_051965J6I763_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_FG95812277699K094F4I_us-gaap_AdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_AdditionalPaidInCapital" xlink:to="lab_HI17034499811M216H6K_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_839743H4G541_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_051965J6I763_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_FG95812277699K094F4I_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_StockholdersEquity" xlink:to="lab_HI17034499811M216H6K_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_839743H4G541_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_051965J6I763_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_FG95812277699K094F4I_us-gaap_StatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_StatementTable" xlink:to="lab_HI17034499811M216H6K_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_839743H4G541_us-gaap_StatementClassOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StatementClassOfStockAxis" xlink:to="lab_051965J6I763_us-gaap_StatementClassOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_ClassOfStockDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ClassOfStockDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_ClassOfStockDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_839743H4G541_us-gaap_SeriesBPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B cumulative preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_051965J6I763_us-gaap_SeriesBPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_RedeemablePreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_RedeemablePreferredStockMember" xml:lang="en-US">Redeemable Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:label="lab_HI17034499811M216H6K_us-gaap_RedeemablePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Preferred stock subject to redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_RedeemablePreferredStockMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_RedeemablePreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_839743H4G541_us-gaap_StatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StatementLineItems" xlink:to="lab_051965J6I763_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_FG95812277699K094F4I_us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:label="lab_HI17034499811M216H6K_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Preferred stock subject to redemption, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_HI17034499811M216H6K_us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_839743H4G541_us-gaap_TemporaryEquitySharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
<label xlink:type="resource" xlink:label="lab_051965J6I763_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Preferred stock subject to redemption, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_051965J6I763_us-gaap_TemporaryEquitySharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_FG95812277699K094F4I_us-gaap_TemporaryEquitySharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Temporary Equity, Shares Issued</label>
<label xlink:type="resource" xlink:label="lab_HI17034499811M216H6K_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Preferred stock subject to redemption, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_HI17034499811M216H6K_us-gaap_TemporaryEquitySharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_839743H4G541_us-gaap_TemporaryEquitySharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:label="lab_051965J6I763_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Preferred stock subject to redemption, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_051965J6I763_us-gaap_TemporaryEquitySharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_FG95812277699K094F4I_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_HI17034499811M216H6K_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_839743H4G541_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_051965J6I763_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_FG95812277699K094F4I_us-gaap_PreferredStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PreferredStockSharesIssued" xlink:to="lab_HI17034499811M216H6K_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_839743H4G541_us-gaap_PreferredStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_051965J6I763_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_FG95812277699K094F4I_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common shares issued, par value per share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_HI17034499811M216H6K_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_839743H4G541_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_051965J6I763_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_FG95812277699K094F4I_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_CommonStockSharesIssued" xlink:to="lab_HI17034499811M216H6K_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_839743H4G541_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_051965J6I763_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncomeStatementAbstract" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_839743H4G541_us-gaap_OperatingCostsAndExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_OperatingCostsAndExpensesAbstract" xml:lang="en-US">Operating Costs and Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_OperatingCostsAndExpensesAbstract" xml:lang="en-US">Operating costs and expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_051965J6I763_us-gaap_OperatingCostsAndExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_FG95812277699K094F4I_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_HI17034499811M216H6K_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PatentCosts" xlink:label="loc_839743H4G541_rttr_PatentCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_PatentCosts" xml:lang="en-US">Patent Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_rttr_PatentCosts" xml:lang="en-US">Patent costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_PatentCosts" xml:lang="en-US">Represents costs incurred and are directly related to patent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_PatentCosts" xlink:to="lab_051965J6I763_rttr_PatentCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_FG95812277699K094F4I_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_HI17034499811M216H6K_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_839743H4G541_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating costs and expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_OperatingExpenses" xlink:to="lab_051965J6I763_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_FG95812277699K094F4I_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_OperatingIncomeLoss" xlink:to="lab_HI17034499811M216H6K_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_839743H4G541_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_051965J6I763_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_FG95812277699K094F4I_us-gaap_InvestmentIncomeInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income (expense), net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_InvestmentIncomeInterest" xlink:to="lab_HI17034499811M216H6K_us-gaap_InvestmentIncomeInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_839743H4G541_us-gaap_OtherNonoperatingIncome"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other Nonoperating Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_OtherNonoperatingIncome" xlink:to="lab_051965J6I763_us-gaap_OtherNonoperatingIncome"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_FG95812277699K094F4I_us-gaap_OtherIncome"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_OtherIncome" xml:lang="en-US">Other Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OtherIncome" xml:lang="en-US">Total other income (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_OtherIncome" xlink:to="lab_HI17034499811M216H6K_us-gaap_OtherIncome"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_839743H4G541_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_NetIncomeLoss" xml:lang="en-US">Net losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_us-gaap_NetIncomeLoss" xml:lang="en-US">Net losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_NetIncomeLoss" xlink:to="lab_051965J6I763_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_FG95812277699K094F4I_us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockDividendsIncomeStatementImpact" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockDividendsIncomeStatementImpact" xml:lang="en-US">Cumulative preferred stock dividends</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockDividendsIncomeStatementImpact" xml:lang="en-US">Cumulative preferred stock dividends</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="lab_HI17034499811M216H6K_us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockRedemptionDiscount" xlink:label="loc_839743H4G541_us-gaap_PreferredStockRedemptionDiscount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PreferredStockRedemptionDiscount" xml:lang="en-US">Preferred Stock Redemption Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_PreferredStockRedemptionDiscount" xml:lang="en-US">Accretion of discount on Series C preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_us-gaap_PreferredStockRedemptionDiscount" xml:lang="en-US">Accretion of discount on Series C preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PreferredStockRedemptionDiscount" xlink:to="lab_051965J6I763_us-gaap_PreferredStockRedemptionDiscount"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="loc_FG95812277699K094F4I_rttr_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_1_1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xml:lang="en-US">Net Income Loss Available To Common Stockholders Basic And Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_rttr_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xml:lang="en-US">Net loss applicable to common stockholders</label>

<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_1_1" xlink:to="lab_HI17034499811M216H6K_rttr_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xml:lang="en-US">Represents net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period) and accretion of discount on preferred stock.</label>



<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_839743H4G541_us-gaap_EarningsPerShareBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share - basic and diluted (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_051965J6I763_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_FG95812277699K094F4I_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_HI17034499811M216H6K_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_839743H4G541_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_051965J6I763_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_FG95812277699K094F4I_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_839743H4G541_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_051965J6I763_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_FG95812277699K094F4I_us-gaap_Depreciation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_Depreciation" xlink:to="lab_HI17034499811M216H6K_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_839743H4G541_us-gaap_AllocatedShareBasedCompensationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_051965J6I763_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_FG95812277699K094F4I_us-gaap_AmortizationOfDebtDiscountPremium"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Accretion of debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_HI17034499811M216H6K_us-gaap_AmortizationOfDebtDiscountPremium"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_839743H4G541_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_051965J6I763_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_839743H4G541_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Other assets</label>
<label xlink:type="resource" xlink:label="lab_051965J6I763_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_051965J6I763_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_839743H4G541_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_051965J6I763_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_839743H4G541_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_FG95812277699K094F4I_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_839743H4G541_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_051965J6I763_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_FG95812277699K094F4I_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_839743H4G541_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>





<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_839743H4G541_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of shares upon closing of initial public offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_051965J6I763_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_FG95812277699K094F4I_us-gaap_ProceedsFromNotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds of borrowing under notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_HI17034499811M216H6K_us-gaap_ProceedsFromNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_839743H4G541_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_FG95812277699K094F4I_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net decrease in cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_839743H4G541_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Non-cash financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_051965J6I763_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering" xlink:label="loc_FG95812277699K094F4I_rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering" xml:lang="en-US">Accrual of commissions and issuance costs of the initial public offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering" xml:lang="en-US">Represent the value Accrual Of Commissions And Issuance Costs Of The Initial Public Offering in noncash financing activities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering" xlink:to="lab_HI17034499811M216H6K_rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering"/>








<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_839743H4G541_us-gaap_ConversionOfStockAmountConverted1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of all oustanding preferred stock, redeemable preferred stock into common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_051965J6I763_us-gaap_ConversionOfStockAmountConverted1"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommonStockSubjectToRepurchase" xlink:label="loc_FG95812277699K094F4I_rttr_CommonStockSubjectToRepurchase"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_CommonStockSubjectToRepurchase" xml:lang="en-US">Common stock subject to repurchase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_CommonStockSubjectToRepurchase" xml:lang="en-US">Represent the value of Common Stock Subject to repurchase in noncash financing activities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_CommonStockSubjectToRepurchase" xlink:to="lab_HI17034499811M216H6K_rttr_CommonStockSubjectToRepurchase"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="loc_839743H4G541_us-gaap_DividendsPreferredStockStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_DividendsPreferredStockStock" xml:lang="en-US">Dividends, Preferred Stock, Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_DividendsPreferredStockStock" xml:lang="en-US">Cumulative preferred stock dividends</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_DividendsPreferredStockStock" xlink:to="lab_051965J6I763_us-gaap_DividendsPreferredStockStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="loc_FG95812277699K094F4I_us-gaap_PreferredStockAccretionOfRedemptionDiscount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockAccretionOfRedemptionDiscount" xml:lang="en-US">Preferred Stock, Accretion of Redemption Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockAccretionOfRedemptionDiscount" xml:lang="en-US">Accretion of discount on Series C preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:to="lab_HI17034499811M216H6K_us-gaap_PreferredStockAccretionOfRedemptionDiscount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_839743H4G541_us-gaap_InterestPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_InterestPaid" xlink:to="lab_051965J6I763_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncomeTaxesPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncomeTaxesPaid" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_839743H4G541_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_051965J6I763_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_FG95812277699K094F4I_us-gaap_NatureOfOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_NatureOfOperations" xml:lang="en-US">ORGANIZATION AND PRINCIPAL ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_NatureOfOperations" xlink:to="lab_HI17034499811M216H6K_us-gaap_NatureOfOperations"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_BasisOfPresentationAbstract" xlink:label="loc_839743H4G541_rttr_BasisOfPresentationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_BasisOfPresentationAbstract" xml:lang="en-US">Basis of presentation [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_BasisOfPresentationAbstract" xlink:to="lab_051965J6I763_rttr_BasisOfPresentationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_FG95812277699K094F4I_us-gaap_BasisOfAccounting"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_BasisOfAccounting" xml:lang="en-US">Basis of Accounting [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_BasisOfAccounting" xml:lang="en-US">BASIS OF PRESENTATION</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_BasisOfAccounting" xlink:to="lab_HI17034499811M216H6K_us-gaap_BasisOfAccounting"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_839743H4G541_us-gaap_AccountingPoliciesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_051965J6I763_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_839743H4G541_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_839743H4G541_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_051965J6I763_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_839743H4G541_us-gaap_StockholdersEquityNoteAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_051965J6I763_us-gaap_StockholdersEquityNoteAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_839743H4G541_us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="lab_051965J6I763_us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_WarrantsTextBlock" xlink:label="loc_FG95812277699K094F4I_rttr_WarrantsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_WarrantsTextBlock" xml:lang="en-US">Warrants [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_WarrantsTextBlock" xml:lang="en-US">WARRANTS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_WarrantsTextBlock" xml:lang="en-US">Represents disclosure of warrants issued. Warrants outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_WarrantsTextBlock" xlink:to="lab_HI17034499811M216H6K_rttr_WarrantsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_839743H4G541_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Options granted, exercise price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_051965J6I763_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">STOCK-BASED COMPENSATION</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_839743H4G541_us-gaap_RelatedPartyTransactionsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_051965J6I763_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_839743H4G541_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SubsequentEventsAbstract" xlink:to="lab_051965J6I763_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">SUBSEQUENT EVENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_839743H4G541_us-gaap_DeferredChargesPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Deferred Offering Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_051965J6I763_us-gaap_DeferredChargesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_EarningsPerSharePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_839743H4G541_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_051965J6I763_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule Property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_839743H4G541_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule summary of the warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_051965J6I763_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule assumptions used in the Black-Scholes option-pricing method</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock" xlink:label="loc_839743H4G541_rttr_ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock" xml:lang="en-US">Schedule Of Prices Received From Sales Of Various Classes Of Stock Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_rttr_ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock" xml:lang="en-US">Schedule the prices received from sales to third parties</label>

<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock" xlink:to="lab_051965J6I763_rttr_ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock" xml:lang="en-US">Represents schedule of prices received from sales of various classes of stock.</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsInstrumentsClassifiedInShareholdersEquityQuantitativeInformationTableTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_FairValueInputsInstrumentsClassifiedInShareholdersEquityQuantitativeInformationTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_FairValueInputsInstrumentsClassifiedInShareholdersEquityQuantitativeInformationTableTextBlock" xml:lang="en-US">Fair Value Inputs, Instruments Classified in Shareholders' Equity, Quantitative Information [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_FairValueInputsInstrumentsClassifiedInShareholdersEquityQuantitativeInformationTableTextBlock" xml:lang="en-US">Schedule inputs were applied in the Black-Scholes calculations of the OPM</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_FairValueInputsInstrumentsClassifiedInShareholdersEquityQuantitativeInformationTableTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_FairValueInputsInstrumentsClassifiedInShareholdersEquityQuantitativeInformationTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xml:lang="en-US">Schedule regarding the Company's stock option grants to the Company's employees and non-employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule represents a summary of the options granted to employees and non-employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_OrganizationAndPrincipalActivitiesTable" xlink:label="loc_839743H4G541_rttr_OrganizationAndPrincipalActivitiesTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_OrganizationAndPrincipalActivitiesTable" xml:lang="en-US">Organization And Principal Activities [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_OrganizationAndPrincipalActivitiesTable" xml:lang="en-US">Represents tabular disclosure of organization and principal activities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_OrganizationAndPrincipalActivitiesTable" xlink:to="lab_051965J6I763_rttr_OrganizationAndPrincipalActivitiesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_SubsidiarySaleOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_839743H4G541_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_051965J6I763_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_IPOMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_IPOMember" xml:lang="en-US">Initial Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IPOMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_IPOMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_OrganizationAndPrincipalActivitiesLineItems" xlink:label="loc_839743H4G541_rttr_OrganizationAndPrincipalActivitiesLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_OrganizationAndPrincipalActivitiesLineItems" xml:lang="en-US">Organization And Principal Activities [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_OrganizationAndPrincipalActivitiesLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_OrganizationAndPrincipalActivitiesLineItems" xlink:to="lab_051965J6I763_rttr_OrganizationAndPrincipalActivitiesLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_FG95812277699K094F4I_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Agreegate number of shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of common shares sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_839743H4G541_us-gaap_SharesIssuedPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Stock Price per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares of common stock sold, per share (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Sale of stock, price per share</label>
<label xlink:type="resource" xlink:label="lab_051965J6I763_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xml:lang="en-US">Original issue price per share, per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_051965J6I763_us-gaap_SharesIssuedPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_FG95812277699K094F4I_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Aggregate gross proceeds from sale of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_HI17034499811M216H6K_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="loc_839743H4G541_rttr_PaymentsOfUnderwritingDiscountsAndCommissions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_PaymentsOfUnderwritingDiscountsAndCommissions" xml:lang="en-US">Payments Of Underwriting Discounts And Commissions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_rttr_PaymentsOfUnderwritingDiscountsAndCommissions" xml:lang="en-US">Underwriting discounts and commissions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_PaymentsOfUnderwritingDiscountsAndCommissions" xml:lang="en-US">Represents cash outflow from underwriting discounts and commissions.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:to="lab_051965J6I763_rttr_PaymentsOfUnderwritingDiscountsAndCommissions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_FG95812277699K094F4I_us-gaap_PaymentsOfStockIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Offering expenses</label>
<label xlink:type="resource" xlink:label="lab_HI17034499811M216H6K_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US">Commissions and issuance costs of initial public offering</label>
<label xlink:type="resource" xlink:label="lab_HI17034499811M216H6K_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Commissions and issuance costs of initial public offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_HI17034499811M216H6K_us-gaap_PaymentsOfStockIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_839743H4G541_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Net offering proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_FG95812277699K094F4I_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Reverse stock split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stock Split, Conversion Ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_HI17034499811M216H6K_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_839743H4G541_us-gaap_NumberOfOperatingSegments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of operating business segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_NumberOfOperatingSegments" xlink:to="lab_051965J6I763_us-gaap_NumberOfOperatingSegments"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_WorkingCapital" xlink:label="loc_FG95812277699K094F4I_rttr_WorkingCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_WorkingCapital" xml:lang="en-US">Working Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_WorkingCapital" xml:lang="en-US">Working capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_WorkingCapital" xml:lang="en-US">Represents carrying value of working capital as of the balance sheet date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_WorkingCapital" xlink:to="lab_HI17034499811M216H6K_rttr_WorkingCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_839743H4G541_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_051965J6I763_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_839743H4G541_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_ComputerEquipmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computers and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ComputerEquipmentMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_ComputerEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_839743H4G541_us-gaap_FurnitureAndFixturesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and fixtures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_051965J6I763_us-gaap_FurnitureAndFixturesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_839743H4G541_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Estimated Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Total property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_839743H4G541_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_051965J6I763_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncomeStatementLocationAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncomeStatementLocationAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_839743H4G541_us-gaap_IncomeStatementLocationDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_051965J6I763_us-gaap_IncomeStatementLocationDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesTable" xlink:label="loc_839743H4G541_rttr_CommitmentsAndContingenciesTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments And Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_CommitmentsAndContingenciesTable" xml:lang="en-US">Schedule presenting information about commitments and contingencies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_CommitmentsAndContingenciesTable" xlink:to="lab_051965J6I763_rttr_CommitmentsAndContingenciesTable"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementAxis" xlink:label="loc_FG95812277699K094F4I_rttr_AgreementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_AgreementAxis" xml:lang="en-US">Represents a group of agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_AgreementAxis" xlink:to="lab_HI17034499811M216H6K_rttr_AgreementAxis"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementDomain" xlink:label="loc_839743H4G541_rttr_AgreementDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_AgreementDomain" xml:lang="en-US">Represents a categorization of agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_AgreementDomain" xlink:to="lab_051965J6I763_rttr_AgreementDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StepLetterAgreementMember" xlink:label="loc_FG95812277699K094F4I_rttr_StepLetterAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_StepLetterAgreementMember" xml:lang="en-US">Step Letter Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_StepLetterAgreementMember" xml:lang="en-US">Step Letter Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_StepLetterAgreementMember" xml:lang="en-US">Represents information regarding step letter agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_StepLetterAgreementMember" xlink:to="lab_HI17034499811M216H6K_rttr_StepLetterAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_839743H4G541_us-gaap_TitleOfIndividualAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_TitleOfIndividualAxis" xlink:to="lab_051965J6I763_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_839743H4G541_us-gaap_ChiefExecutiveOfficerMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Michael Step</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ChiefExecutiveOfficerMember" xlink:to="lab_051965J6I763_us-gaap_ChiefExecutiveOfficerMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PresidentAndFormerChiefExecutiveOfficerMember" xlink:label="loc_FG95812277699K094F4I_rttr_PresidentAndFormerChiefExecutiveOfficerMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PresidentAndFormerChiefExecutiveOfficerMember" xml:lang="en-US">President And Former Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_PresidentAndFormerChiefExecutiveOfficerMember" xml:lang="en-US">Andrew Ritter</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PresidentAndFormerChiefExecutiveOfficerMember" xml:lang="en-US">Represents Highest ranking former executive officer, who has ultimate managerial responsibility for the entity and who reports to the board of directors. In addition, the former chief executive officer (CEO) may also be the chairman of the board or president.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PresidentAndFormerChiefExecutiveOfficerMember" xlink:to="lab_HI17034499811M216H6K_rttr_PresidentAndFormerChiefExecutiveOfficerMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ChiefStrategicOfficerMember" xlink:label="loc_839743H4G541_rttr_ChiefStrategicOfficerMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ChiefStrategicOfficerMember" xml:lang="en-US">Chief Strategic Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_ChiefStrategicOfficerMember" xml:lang="en-US">Ira Ritter</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ChiefStrategicOfficerMember" xml:lang="en-US">Represents chief strategic officer of the company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ChiefStrategicOfficerMember" xlink:to="lab_051965J6I763_rttr_ChiefStrategicOfficerMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_AwardTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_AwardTypeAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_EmployeeStockOptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Executive Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_EmployeeStockOptionMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_EmployeeStockOptionTwoMember" xlink:label="loc_839743H4G541_rttr_EmployeeStockOptionTwoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_EmployeeStockOptionTwoMember" xml:lang="en-US">Employee Stock Option Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_EmployeeStockOptionTwoMember" xml:lang="en-US">Stock Option 2</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_EmployeeStockOptionTwoMember" xml:lang="en-US">Represents an arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_EmployeeStockOptionTwoMember" xlink:to="lab_051965J6I763_rttr_EmployeeStockOptionTwoMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_EmployeeStockOptionThreeMember" xlink:label="loc_FG95812277699K094F4I_rttr_EmployeeStockOptionThreeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_EmployeeStockOptionThreeMember" xml:lang="en-US">Employee Stock Option Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_EmployeeStockOptionThreeMember" xml:lang="en-US">Stock Option 3</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_EmployeeStockOptionThreeMember" xml:lang="en-US">Represents an arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_EmployeeStockOptionThreeMember" xlink:to="lab_HI17034499811M216H6K_rttr_EmployeeStockOptionThreeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_839743H4G541_us-gaap_PlanNameAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PlanNameAxis" xlink:to="lab_051965J6I763_us-gaap_PlanNameAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_PlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PlanNameDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_PlanNameDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ExecutiveCompensationPlanMember" xlink:label="loc_839743H4G541_rttr_ExecutiveCompensationPlanMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ExecutiveCompensationPlanMember" xml:lang="en-US">Executive Compensation Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_ExecutiveCompensationPlanMember" xml:lang="en-US">Executive Compensation Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ExecutiveCompensationPlanMember" xml:lang="en-US">Represents executive compensation plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ExecutiveCompensationPlanMember" xlink:to="lab_051965J6I763_rttr_ExecutiveCompensationPlanMember"/>





<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesLineItems" xlink:label="loc_839743H4G541_rttr_CommitmentsAndContingenciesLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments And Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_CommitmentsAndContingenciesLineItems" xlink:to="lab_051965J6I763_rttr_CommitmentsAndContingenciesLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_FG95812277699K094F4I_us-gaap_OfficersCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_OfficersCompensation" xml:lang="en-US">Officers' Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OfficersCompensation" xml:lang="en-US">Annual base salary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_OfficersCompensation" xlink:to="lab_HI17034499811M216H6K_us-gaap_OfficersCompensation"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TuitionReimbursementAuthorizedAmount" xlink:label="loc_839743H4G541_rttr_TuitionReimbursementAuthorizedAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_TuitionReimbursementAuthorizedAmount" xml:lang="en-US">Tuition Reimbursement Authorized Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_TuitionReimbursementAuthorizedAmount" xml:lang="en-US">Tuition reimbursement, amount authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_TuitionReimbursementAuthorizedAmount" xml:lang="en-US">Represents authorized amount of tuition reimbursement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_TuitionReimbursementAuthorizedAmount" xlink:to="lab_051965J6I763_rttr_TuitionReimbursementAuthorizedAmount"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PeriodOfTuitionReimbursement" xlink:label="loc_FG95812277699K094F4I_rttr_PeriodOfTuitionReimbursement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PeriodOfTuitionReimbursement" xml:lang="en-US">Period Of Tuition Reimbursement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_PeriodOfTuitionReimbursement" xml:lang="en-US">Tuition reimbursement, payable period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PeriodOfTuitionReimbursement" xml:lang="en-US">Represents period of tuition reimbursement payable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PeriodOfTuitionReimbursement" xlink:to="lab_HI17034499811M216H6K_rttr_PeriodOfTuitionReimbursement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_839743H4G541_us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Accrued tuition reimbursement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_051965J6I763_us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_NumberOfOptionGranted" xlink:label="loc_FG95812277699K094F4I_rttr_NumberOfOptionGranted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_NumberOfOptionGranted" xml:lang="en-US">Number Of Option Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_NumberOfOptionGranted" xml:lang="en-US">Number of option granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_NumberOfOptionGranted" xml:lang="en-US">Represents number of option granted during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_NumberOfOptionGranted" xlink:to="lab_HI17034499811M216H6K_rttr_NumberOfOptionGranted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Number of shares called by options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Maximum aggregate number of shares of common stock authorized to issue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options granted, exercise price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercise Price per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>




<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding" xlink:label="loc_FG95812277699K094F4I_rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding" xml:lang="en-US">Percentage Shares Of Common Stock Deemed To Be Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding" xml:lang="en-US">Percentage shares of common stock deemed to be outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding" xml:lang="en-US">Represents percentage shares of common stock deemed to be outstanding on a fully-diluted basis after giving effect to the issuance of option.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding" xlink:to="lab_HI17034499811M216H6K_rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfSharesSubjectToRightOfRepurchase" xlink:label="loc_839743H4G541_rttr_PercentageOfSharesSubjectToRightOfRepurchase"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_PercentageOfSharesSubjectToRightOfRepurchase" xml:lang="en-US">Percentage Of Shares Subject To Right Of Repurchase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_PercentageOfSharesSubjectToRightOfRepurchase" xml:lang="en-US">Percentage of shares subject to right of repurchase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_PercentageOfSharesSubjectToRightOfRepurchase" xml:lang="en-US">Represents percentage of shares subject to right of repurchase.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_PercentageOfSharesSubjectToRightOfRepurchase" xlink:to="lab_051965J6I763_rttr_PercentageOfSharesSubjectToRightOfRepurchase"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_DescriptionOfRightToRepurchaseLapse" xlink:label="loc_FG95812277699K094F4I_rttr_DescriptionOfRightToRepurchaseLapse"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_DescriptionOfRightToRepurchaseLapse" xml:lang="en-US">Description Of Right To Repurchase Lapse</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_DescriptionOfRightToRepurchaseLapse" xml:lang="en-US">Description of right to repurchase lapse</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_DescriptionOfRightToRepurchaseLapse" xml:lang="en-US">Represents description of right to repurchase lapse.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_DescriptionOfRightToRepurchaseLapse" xlink:to="lab_HI17034499811M216H6K_rttr_DescriptionOfRightToRepurchaseLapse"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_BonusPercentageOfSalary" xlink:label="loc_839743H4G541_rttr_BonusPercentageOfSalary"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_BonusPercentageOfSalary" xml:lang="en-US">Bonus Percentage Of Salary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_BonusPercentageOfSalary" xml:lang="en-US">Bonus percentage of salary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_BonusPercentageOfSalary" xml:lang="en-US">Represents percentage of the base salary targeted for bonus.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_BonusPercentageOfSalary" xlink:to="lab_051965J6I763_rttr_BonusPercentageOfSalary"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis" xlink:label="loc_FG95812277699K094F4I_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis" xml:lang="en-US">Cash Bonus And Executive Options Performance Conditions [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis" xml:lang="en-US">Represents group of cash bonus and executive options performance conditions to be satisfied.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis" xlink:to="lab_HI17034499811M216H6K_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain" xlink:label="loc_839743H4G541_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain" xml:lang="en-US">Cash Bonus And Executive Options Performance Conditions [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain" xml:lang="en-US">FDA Meeting Bonus Opportunities.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain" xml:lang="en-US">Represents categorization of cash bonus and executive options performance conditions to be satisfied.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain" xlink:to="lab_051965J6I763_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_FdaMeetingBonusOpportunitiesMember" xlink:label="loc_FG95812277699K094F4I_rttr_FdaMeetingBonusOpportunitiesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_FdaMeetingBonusOpportunitiesMember" xml:lang="en-US">Fda Meeting Bonus Opportunities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_FdaMeetingBonusOpportunitiesMember" xml:lang="en-US">FDA Meeting Bonus Opportunities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_FdaMeetingBonusOpportunitiesMember" xml:lang="en-US">Represents information about FDA Meeting Bonus Opportunities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_FdaMeetingBonusOpportunitiesMember" xlink:to="lab_HI17034499811M216H6K_rttr_FdaMeetingBonusOpportunitiesMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" xlink:label="loc_839743H4G541_rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" xml:lang="en-US">Clinical Trial Funding Commitment Bonus Opportunities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" xml:lang="en-US">Clinical Trial Funding Commitment Bonus Opportunities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" xml:lang="en-US">Represents information about Clinical Trial Funding Commitment Bonus Opportunities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" xlink:to="lab_051965J6I763_rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_FundraisingBonusOpportunitiesMember" xlink:label="loc_FG95812277699K094F4I_rttr_FundraisingBonusOpportunitiesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_FundraisingBonusOpportunitiesMember" xml:lang="en-US">Fundraising Bonus Opportunities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_FundraisingBonusOpportunitiesMember" xml:lang="en-US">Fundraising Bonus Opportunities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_FundraisingBonusOpportunitiesMember" xml:lang="en-US">Represents information about Fundraising Bonus Opportunities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_FundraisingBonusOpportunitiesMember" xlink:to="lab_HI17034499811M216H6K_rttr_FundraisingBonusOpportunitiesMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneTypeAxis" xlink:label="loc_839743H4G541_rttr_PerformanceMilestoneTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_PerformanceMilestoneTypeAxis" xml:lang="en-US">Performance Milestone Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_PerformanceMilestoneTypeAxis" xml:lang="en-US">Represents group of performance milestone conditions.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_PerformanceMilestoneTypeAxis" xlink:to="lab_051965J6I763_rttr_PerformanceMilestoneTypeAxis"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneTypeDomain" xlink:label="loc_FG95812277699K094F4I_rttr_PerformanceMilestoneTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PerformanceMilestoneTypeDomain" xml:lang="en-US">Performance Milestone Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PerformanceMilestoneTypeDomain" xml:lang="en-US">Represents categorization of performance milestone conditions.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PerformanceMilestoneTypeDomain" xlink:to="lab_HI17034499811M216H6K_rttr_PerformanceMilestoneTypeDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneConditionOneMember" xlink:label="loc_839743H4G541_rttr_PerformanceMilestoneConditionOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_PerformanceMilestoneConditionOneMember" xml:lang="en-US">Performance Milestone Condition One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_PerformanceMilestoneConditionOneMember" xml:lang="en-US">Performance milestone condition one</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_PerformanceMilestoneConditionOneMember" xml:lang="en-US">Represents information about performance milestone one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_PerformanceMilestoneConditionOneMember" xlink:to="lab_051965J6I763_rttr_PerformanceMilestoneConditionOneMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneConditionTwoMember" xlink:label="loc_FG95812277699K094F4I_rttr_PerformanceMilestoneConditionTwoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PerformanceMilestoneConditionTwoMember" xml:lang="en-US">Performance Milestone Condition Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_PerformanceMilestoneConditionTwoMember" xml:lang="en-US">Performance milestone condition two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PerformanceMilestoneConditionTwoMember" xml:lang="en-US">Represents information about performance milestone two.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PerformanceMilestoneConditionTwoMember" xlink:to="lab_HI17034499811M216H6K_rttr_PerformanceMilestoneConditionTwoMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_839743H4G541_us-gaap_RangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_RangeAxis" xlink:to="lab_051965J6I763_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_RangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_RangeMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_839743H4G541_us-gaap_MinimumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_MinimumMember" xlink:to="lab_051965J6I763_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_SubsequentEventTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_839743H4G541_us-gaap_SubsequentEventTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_051965J6I763_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_SubsequentEventMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SubsequentEventMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ExecutiveCompensation" xlink:label="loc_839743H4G541_rttr_ExecutiveCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ExecutiveCompensation" xml:lang="en-US">Executive Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_ExecutiveCompensation" xml:lang="en-US">Cash bonus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ExecutiveCompensation" xml:lang="en-US">Represents executive compensation payable upon satisfaction of condition.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ExecutiveCompensation" xlink:to="lab_051965J6I763_rttr_ExecutiveCompensation"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_MinimumActualDeploymentOfFundsByThirdParty" xlink:label="loc_FG95812277699K094F4I_rttr_MinimumActualDeploymentOfFundsByThirdParty"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_MinimumActualDeploymentOfFundsByThirdParty" xml:lang="en-US">Minimum Actual Deployment Of Funds By Third Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_MinimumActualDeploymentOfFundsByThirdParty" xml:lang="en-US">Minimum actual deployment of funds by third party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_MinimumActualDeploymentOfFundsByThirdParty" xml:lang="en-US">Represents minimum actual deployment of funds by third party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_MinimumActualDeploymentOfFundsByThirdParty" xlink:to="lab_HI17034499811M216H6K_rttr_MinimumActualDeploymentOfFundsByThirdParty"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Number of stock options expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="loc_FG95812277699K094F4I_us-gaap_Cash"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_Cash" xml:lang="en-US">Minimum cash available limit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_Cash" xlink:to="lab_HI17034499811M216H6K_us-gaap_Cash"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_839743H4G541_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Vesting percentage of option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Percentage of option vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_051965J6I763_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Common Shares Underlying Options Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Remaining options vesting monthly in equal amounts, period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Options vesting period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vesting period of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AccruedBonusToExecutive" xlink:label="loc_FG95812277699K094F4I_rttr_AccruedBonusToExecutive"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_AccruedBonusToExecutive" xml:lang="en-US">Accrued Bonus To Executive</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_AccruedBonusToExecutive" xml:lang="en-US">Accrued bonus to executive</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_AccruedBonusToExecutive" xml:lang="en-US">Represents amount of accrued bonus to executive.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_AccruedBonusToExecutive" xlink:to="lab_HI17034499811M216H6K_rttr_AccruedBonusToExecutive"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_LicenseEventBonusOpportunitiesMember" xlink:label="loc_839743H4G541_rttr_LicenseEventBonusOpportunitiesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_LicenseEventBonusOpportunitiesMember" xml:lang="en-US">License Event Bonus Opportunities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_LicenseEventBonusOpportunitiesMember" xml:lang="en-US">Represents information about License Event Bonus Opportunities..</label>
<label xlink:type="resource" xlink:label="lab_051965J6I763_rttr_LicenseEventBonusOpportunitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">License Event Bonus Opportunities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_LicenseEventBonusOpportunitiesMember" xlink:to="lab_051965J6I763_rttr_LicenseEventBonusOpportunitiesMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneConditionThreeMember" xlink:label="loc_FG95812277699K094F4I_rttr_PerformanceMilestoneConditionThreeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PerformanceMilestoneConditionThreeMember" xml:lang="en-US">Performance Milestone Condition Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_PerformanceMilestoneConditionThreeMember" xml:lang="en-US">Performance milestone condition three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PerformanceMilestoneConditionThreeMember" xml:lang="en-US">Represents information about performance milestone three.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PerformanceMilestoneConditionThreeMember" xlink:to="lab_HI17034499811M216H6K_rttr_PerformanceMilestoneConditionThreeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_839743H4G541_us-gaap_MaximumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_MaximumMember" xlink:to="lab_051965J6I763_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TypeOfBonusAwardAxis" xlink:label="loc_FG95812277699K094F4I_rttr_TypeOfBonusAwardAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_TypeOfBonusAwardAxis" xml:lang="en-US">Type Of Bonus Award [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_TypeOfBonusAwardAxis" xml:lang="en-US">Represents type of bonus award.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_TypeOfBonusAwardAxis" xlink:to="lab_HI17034499811M216H6K_rttr_TypeOfBonusAwardAxis"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TypeOfBonusAwardDomain" xlink:label="loc_839743H4G541_rttr_TypeOfBonusAwardDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_TypeOfBonusAwardDomain" xml:lang="en-US">Type Of Bonus Award [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_TypeOfBonusAwardDomain" xml:lang="en-US">Represents categorization of bonus award.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_TypeOfBonusAwardDomain" xlink:to="lab_051965J6I763_rttr_TypeOfBonusAwardDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GraduatedCashBonusMember" xlink:label="loc_FG95812277699K094F4I_rttr_GraduatedCashBonusMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_GraduatedCashBonusMember" xml:lang="en-US">Graduated Cash Bonus [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_GraduatedCashBonusMember" xml:lang="en-US">Graduated Cash Bonus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_GraduatedCashBonusMember" xml:lang="en-US">Represents graduated cash bonus.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_GraduatedCashBonusMember" xlink:to="lab_HI17034499811M216H6K_rttr_GraduatedCashBonusMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfInitialPeriodLicensePayment" xlink:label="loc_839743H4G541_rttr_PercentageOfInitialPeriodLicensePayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_PercentageOfInitialPeriodLicensePayment" xml:lang="en-US">Percentage Of Initial Period License Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_rttr_PercentageOfInitialPeriodLicensePayment" xml:lang="en-US">Percentage of initial period license payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_PercentageOfInitialPeriodLicensePayment" xml:lang="en-US">Represents percentage of initial period license payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_PercentageOfInitialPeriodLicensePayment" xlink:to="lab_051965J6I763_rttr_PercentageOfInitialPeriodLicensePayment"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_InitialPeriodLicensePayment" xlink:label="loc_FG95812277699K094F4I_rttr_InitialPeriodLicensePayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_InitialPeriodLicensePayment" xml:lang="en-US">Initial Period License Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_InitialPeriodLicensePayment" xml:lang="en-US">Initial period license payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_InitialPeriodLicensePayment" xml:lang="en-US">Represents initial period license payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_InitialPeriodLicensePayment" xlink:to="lab_HI17034499811M216H6K_rttr_InitialPeriodLicensePayment"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ReceiptOfInitialPeriodLicensePayment" xlink:label="loc_839743H4G541_rttr_ReceiptOfInitialPeriodLicensePayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ReceiptOfInitialPeriodLicensePayment" xml:lang="en-US">Receipt Of Initial Period License Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_ReceiptOfInitialPeriodLicensePayment" xml:lang="en-US">Receipt of Initial period license payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ReceiptOfInitialPeriodLicensePayment" xml:lang="en-US">Represents receipt of initial period license payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ReceiptOfInitialPeriodLicensePayment" xlink:to="lab_051965J6I763_rttr_ReceiptOfInitialPeriodLicensePayment"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfCashBonusExcessOfMilestonePayments" xlink:label="loc_FG95812277699K094F4I_rttr_PercentageOfCashBonusExcessOfMilestonePayments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageOfCashBonusExcessOfMilestonePayments" xml:lang="en-US">Percentage Of Cash Bonus Excess Of Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageOfCashBonusExcessOfMilestonePayments" xml:lang="en-US">Percentage of annual excess milestone payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageOfCashBonusExcessOfMilestonePayments" xml:lang="en-US">Represents percentage of cash bonus percentage in excess of milestone payments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PercentageOfCashBonusExcessOfMilestonePayments" xlink:to="lab_HI17034499811M216H6K_rttr_PercentageOfCashBonusExcessOfMilestonePayments"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PresidentAndCsoMember" xlink:label="loc_839743H4G541_rttr_PresidentAndCsoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_PresidentAndCsoMember" xml:lang="en-US">President And Cso [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_rttr_PresidentAndCsoMember" xml:lang="en-US">Andrew Ritter and Ira Ritter</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_PresidentAndCsoMember" xml:lang="en-US">Represents information about President and CSO.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_PresidentAndCsoMember" xlink:to="lab_051965J6I763_rttr_PresidentAndCsoMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_DirectorMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_DirectorMember" xml:lang="en-US">Director [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_DirectorMember" xml:lang="en-US">Non-employee directors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_DirectorMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_DirectorMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_839743H4G541_us-gaap_VestingAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_VestingAxis" xlink:to="lab_051965J6I763_us-gaap_VestingAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_VestingDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_VestingDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_VestingDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">First anniversary of the vesting commencement date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Share-based Compensation Award, Tranche One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Share-based Compensation Award, Tranche Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xml:lang="en-US">Share-based Compensation Award, Tranche Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xml:lang="en-US">Share-based Compensation Award, Tranche Three</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_VestingPeriodThreeYearsMember" xlink:label="loc_FG95812277699K094F4I_rttr_VestingPeriodThreeYearsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_VestingPeriodThreeYearsMember" xml:lang="en-US">Vesting Period Three Years [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_VestingPeriodThreeYearsMember" xml:lang="en-US">Three years vesting period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_VestingPeriodThreeYearsMember" xml:lang="en-US">Represents vesting period three years.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_VestingPeriodThreeYearsMember" xlink:to="lab_HI17034499811M216H6K_rttr_VestingPeriodThreeYearsMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_VestingPeriodOneYearMember" xlink:label="loc_839743H4G541_rttr_VestingPeriodOneYearMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_VestingPeriodOneYearMember" xml:lang="en-US">Vesting Period One Year [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_VestingPeriodOneYearMember" xml:lang="en-US">One year vesting period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_VestingPeriodOneYearMember" xml:lang="en-US">Represents vesting period one year.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_VestingPeriodOneYearMember" xlink:to="lab_051965J6I763_rttr_VestingPeriodOneYearMember"/>





<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_InitialPeriod" xlink:label="loc_839743H4G541_rttr_InitialPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_InitialPeriod" xml:lang="en-US">Initial Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_InitialPeriod" xml:lang="en-US">Initial period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_InitialPeriod" xml:lang="en-US">Represent initial period of stated event.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_InitialPeriod" xlink:to="lab_051965J6I763_rttr_InitialPeriod"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AnnualExcessMilestonePayments" xlink:label="loc_FG95812277699K094F4I_rttr_AnnualExcessMilestonePayments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_AnnualExcessMilestonePayments" xml:lang="en-US">Annual Excess Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_AnnualExcessMilestonePayments" xml:lang="en-US">Represents annual excess milestone payments.</label>
<label xlink:type="resource" xlink:label="lab_HI17034499811M216H6K_rttr_AnnualExcessMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Annual excess milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_AnnualExcessMilestonePayments" xlink:to="lab_HI17034499811M216H6K_rttr_AnnualExcessMilestonePayments"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfAdditionalCashBonus" xlink:label="loc_839743H4G541_rttr_PercentageOfAdditionalCashBonus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_PercentageOfAdditionalCashBonus" xml:lang="en-US">Percentage Of Additional Cash Bonus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_rttr_PercentageOfAdditionalCashBonus" xml:lang="en-US">Additional cash bonus earned as Clinical Trial and Fundraising Bonus or a License Event Bonus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_PercentageOfAdditionalCashBonus" xml:lang="en-US">Represents percentage of additional cash bonus.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_PercentageOfAdditionalCashBonus" xlink:to="lab_051965J6I763_rttr_PercentageOfAdditionalCashBonus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_FG95812277699K094F4I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Number of fully vested options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Options vested, balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_HI17034499811M216H6K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Expected to be vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Exercise price of fully vested options (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of options outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding at December 31, 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding at June 30, 2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Exercise price of outstanding options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Exercise price per share of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding at December 31, 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding at June 30, 2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_FG95812277699K094F4I_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Term of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xml:lang="en-US">Period of lease agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="lab_HI17034499811M216H6K_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_839743H4G541_us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_OperatingLeasesRentExpenseMinimumRentals" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_OperatingLeasesRentExpenseMinimumRentals" xml:lang="en-US">Base rent per month for months 2 through 13 of term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_OperatingLeasesRentExpenseMinimumRentals" xml:lang="en-US">Minimum annual rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="lab_051965J6I763_us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfIncreaseInAnnualRent" xlink:label="loc_FG95812277699K094F4I_rttr_PercentageOfIncreaseInAnnualRent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageOfIncreaseInAnnualRent" xml:lang="en-US">Percentage Of Increase In Annual Rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageOfIncreaseInAnnualRent" xml:lang="en-US">Percentage of increase in annual rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageOfIncreaseInAnnualRent" xml:lang="en-US">Represents percentage increase in annual rent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PercentageOfIncreaseInAnnualRent" xlink:to="lab_HI17034499811M216H6K_rttr_PercentageOfIncreaseInAnnualRent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_839743H4G541_us-gaap_LeaseAndRentalExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating Leases, Rent Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Rent expenses incurred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_LeaseAndRentalExpense" xlink:to="lab_051965J6I763_us-gaap_LeaseAndRentalExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_FG95812277699K094F4I_us-gaap_ScheduleOfStockByClassTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_HI17034499811M216H6K_us-gaap_ScheduleOfStockByClassTable"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesAOnePreferredStockMember" xlink:label="loc_839743H4G541_rttr_SeriesAOnePreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_SeriesAOnePreferredStockMember" xml:lang="en-US">Series AOne Preferred Stock Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_rttr_SeriesAOnePreferredStockMember" xml:lang="en-US">Series A-1 Preferred stock</label>

<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_SeriesAOnePreferredStockMember" xlink:to="lab_051965J6I763_rttr_SeriesAOnePreferredStockMember"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_SeriesAOnePreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>

<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesATwoPreferredStockMember" xlink:label="loc_FG95812277699K094F4I_rttr_SeriesATwoPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_SeriesATwoPreferredStockMember" xml:lang="en-US">Series ATwo Preferred Stock Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_SeriesATwoPreferredStockMember" xml:lang="en-US">Series A-2 Preferred Stock</label>

<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_SeriesATwoPreferredStockMember" xlink:to="lab_HI17034499811M216H6K_rttr_SeriesATwoPreferredStockMember"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_SeriesATwoPreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>

<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesAThreePreferredStockMember" xlink:label="loc_839743H4G541_rttr_SeriesAThreePreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_SeriesAThreePreferredStockMember" xml:lang="en-US">Series AThree Preferred Stock Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_SeriesAThreePreferredStockMember" xml:lang="en-US">Series A-3 Preferred Stock</label>

<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_SeriesAThreePreferredStockMember" xlink:to="lab_051965J6I763_rttr_SeriesAThreePreferredStockMember"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_SeriesAThreePreferredStockMember" xml:lang="en-US">Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_SeriesCPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_SeriesCPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_839743H4G541_us-gaap_ClassOfStockLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ClassOfStockLineItems" xlink:to="lab_051965J6I763_us-gaap_ClassOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_FG95812277699K094F4I_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Number of common shares issued upon conversion of preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Number of preferred stock and preferred stock subject to redemption converted into common stock (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_HI17034499811M216H6K_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_839743H4G541_us-gaap_PreferredStockLiquidationPreference"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PreferredStockLiquidationPreference" xml:lang="en-US">Preferred Stock, Liquidation Preference Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_PreferredStockLiquidationPreference" xml:lang="en-US">Liquidation preference, per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PreferredStockLiquidationPreference" xlink:to="lab_051965J6I763_us-gaap_PreferredStockLiquidationPreference"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="loc_FG95812277699K094F4I_us-gaap_PreferredStockDividendRatePerDollarAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockDividendRatePerDollarAmount" xml:lang="en-US">Preferred Stock, Dividend Rate, Per-Dollar-Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockDividendRatePerDollarAmount" xml:lang="en-US">Preferred stock, Annual dividend rate, per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:to="lab_HI17034499811M216H6K_us-gaap_PreferredStockDividendRatePerDollarAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:label="loc_839743H4G541_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xml:lang="en-US">Preferred Stock, Amount of Preferred Dividends in Arrears</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xml:lang="en-US">Preferred stock, undeclared dividends in arrears (in dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:to="lab_051965J6I763_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PurchasePrice" xlink:label="loc_FG95812277699K094F4I_rttr_PurchasePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PurchasePrice" xml:lang="en-US">Purchase Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_PurchasePrice" xml:lang="en-US">Purchase price, per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PurchasePrice" xml:lang="en-US">Represents price of a single shares purchased.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PurchasePrice" xlink:to="lab_HI17034499811M216H6K_rttr_PurchasePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_839743H4G541_us-gaap_SharePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SharePrice" xml:lang="en-US">Common stock value per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_SharePrice" xml:lang="en-US">Common Stock value (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_SharePrice" xml:lang="en-US">Preferred Stock original issue price</label>
<label xlink:type="resource" xlink:label="lab_051965J6I763_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xml:lang="en-US">Stock value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SharePrice" xlink:to="lab_051965J6I763_us-gaap_SharePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_839743H4G541_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_EquityComponentDomain" xlink:to="lab_051965J6I763_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_WarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_WarrantMember" xml:lang="en-US">Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_WarrantMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_839743H4G541_us-gaap_CommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_CommonStockMember" xlink:to="lab_051965J6I763_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShortTermDebtTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShortTermDebtTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_839743H4G541_us-gaap_ShortTermDebtTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_051965J6I763_us-gaap_ShortTermDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_ConvertibleNotesPayableMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_ConvertibleNotesPayableMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_839743H4G541_us-gaap_DebtInstrumentAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_DebtInstrumentAxis" xlink:to="lab_051965J6I763_us-gaap_DebtInstrumentAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_DebtInstrumentNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_DebtInstrumentNameDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TwoThousandFourteenNotesMember" xlink:label="loc_839743H4G541_rttr_TwoThousandFourteenNotesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_TwoThousandFourteenNotesMember" xml:lang="en-US">Two Thousand Fourteen Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_rttr_TwoThousandFourteenNotesMember" xml:lang="en-US">Two Thousand Fourteen Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_TwoThousandFourteenNotesMember" xml:lang="en-US">Represents information related to the 2014 Notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_TwoThousandFourteenNotesMember" xlink:to="lab_051965J6I763_rttr_TwoThousandFourteenNotesMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TwoThousandFourteenNotesOneMember" xlink:label="loc_FG95812277699K094F4I_rttr_TwoThousandFourteenNotesOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_TwoThousandFourteenNotesOneMember" xml:lang="en-US">Two Thousand Fourteen Notes One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_TwoThousandFourteenNotesOneMember" xml:lang="en-US">Two Thousand Fourteen Notes One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_TwoThousandFourteenNotesOneMember" xml:lang="en-US">Represents information related to the 2014 Notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_TwoThousandFourteenNotesOneMember" xlink:to="lab_HI17034499811M216H6K_rttr_TwoThousandFourteenNotesOneMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_839743H4G541_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants to purchase an aggregate of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of common stock called by warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_FG95812277699K094F4I_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Gross proceeds of preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_HI17034499811M216H6K_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TermOfWarrantIssued" xlink:label="loc_839743H4G541_rttr_TermOfWarrantIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_TermOfWarrantIssued" xml:lang="en-US">Term Of Warrant Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_TermOfWarrantIssued" xml:lang="en-US">Term of warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_TermOfWarrantIssued" xml:lang="en-US">Represents term of the warrants issued, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_TermOfWarrantIssued" xlink:to="lab_051965J6I763_rttr_TermOfWarrantIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_FG95812277699K094F4I_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Outstanding at December 31, 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Outstanding at June 30, 2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_FairValuePerShare" xlink:label="loc_839743H4G541_rttr_FairValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_FairValuePerShare" xml:lang="en-US">Fair Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_FairValuePerShare" xml:lang="en-US">Fair value per share (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_FairValuePerShare" xml:lang="en-US">Represents per share value of stock and warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_FairValuePerShare" xlink:to="lab_051965J6I763_rttr_FairValuePerShare"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_DiscountOnInitialCarryingValue" xlink:label="loc_FG95812277699K094F4I_rttr_DiscountOnInitialCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_DiscountOnInitialCarryingValue" xml:lang="en-US">Discount On Initial Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_DiscountOnInitialCarryingValue" xml:lang="en-US">Discount on initial carrying value (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_DiscountOnInitialCarryingValue" xml:lang="en-US">Represents the discount on initial carrying value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_DiscountOnInitialCarryingValue" xlink:to="lab_HI17034499811M216H6K_rttr_DiscountOnInitialCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_839743H4G541_us-gaap_ConvertibleNotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Convertible Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Unpaid principal on convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ConvertibleNotesPayable" xlink:to="lab_051965J6I763_us-gaap_ConvertibleNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_FG95812277699K094F4I_us-gaap_InterestPayableCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_InterestPayableCurrentAndNoncurrent" xml:lang="en-US">Interest Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_InterestPayableCurrentAndNoncurrent" xml:lang="en-US">Accrued interest on convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_HI17034499811M216H6K_us-gaap_InterestPayableCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_839743H4G541_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Convertible notes converted into Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_051965J6I763_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_FG95812277699K094F4I_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants or Options Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xml:lang="en-US">Convertible notes converted into Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="lab_HI17034499811M216H6K_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_839743H4G541_us-gaap_DebtConversionOriginalDebtAmount1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Unpaid principal balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_051965J6I763_us-gaap_DebtConversionOriginalDebtAmount1"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfPricePerShare" xlink:label="loc_FG95812277699K094F4I_rttr_PercentageOfPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageOfPricePerShare" xml:lang="en-US">Percentage Of Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageOfPricePerShare" xml:lang="en-US">Percentage of price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageOfPricePerShare" xml:lang="en-US">Represents percentage of price per share paid by investors for convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PercentageOfPricePerShare" xlink:to="lab_HI17034499811M216H6K_rttr_PercentageOfPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_839743H4G541_us-gaap_InterestExpenseDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_InterestExpenseDebt" xml:lang="en-US">Additional interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_InterestExpenseDebt" xlink:to="lab_051965J6I763_us-gaap_InterestExpenseDebt"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest" xlink:label="loc_FG95812277699K094F4I_rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest" xml:lang="en-US">Percentage Of Converting Outstanding Debt And Accrued Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest" xml:lang="en-US">Percentage of convertible debt and accrued interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest" xml:lang="en-US">Represents percentage of converting the outstanding debt and accrued interest.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest" xlink:to="lab_HI17034499811M216H6K_rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_839743H4G541_us-gaap_DebtInstrumentFaceAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Note unpaid principal balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_051965J6I763_us-gaap_DebtInstrumentFaceAmount"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable" xlink:label="loc_FG95812277699K094F4I_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable" xml:lang="en-US">Stockholders Deficit And Preferred Stock Subject To Redemption [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable" xml:lang="en-US">Schedule of information pertaining to stockholders' deficit and preferred stock subject to redemption.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable" xlink:to="lab_HI17034499811M216H6K_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ResearchAndDevelopmentAgreementLicenseMember" xlink:label="loc_839743H4G541_rttr_ResearchAndDevelopmentAgreementLicenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ResearchAndDevelopmentAgreementLicenseMember" xml:lang="en-US">Research And Development Agreement &amp; License [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ResearchAndDevelopmentAgreementLicenseMember" xml:lang="en-US">Represents information about Research and Development Agreement &amp; License.</label>
<label xlink:type="resource" xlink:label="lab_051965J6I763_rttr_ResearchAndDevelopmentAgreementLicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Research and Development Agreement &amp; License</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ResearchAndDevelopmentAgreementLicenseMember" xlink:to="lab_051965J6I763_rttr_ResearchAndDevelopmentAgreementLicenseMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PutAndCallOptionAgreementMember" xlink:label="loc_FG95812277699K094F4I_rttr_PutAndCallOptionAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PutAndCallOptionAgreementMember" xml:lang="en-US">Put And Call Option Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_PutAndCallOptionAgreementMember" xml:lang="en-US">Put and Call Option Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PutAndCallOptionAgreementMember" xml:lang="en-US">Represents information about put and call option agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PutAndCallOptionAgreementMember" xlink:to="lab_HI17034499811M216H6K_rttr_PutAndCallOptionAgreementMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementPartiesAxis" xlink:label="loc_839743H4G541_rttr_AgreementPartiesAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_AgreementPartiesAxis" xml:lang="en-US">Agreement Parties [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_AgreementPartiesAxis" xml:lang="en-US">Represents information about agreement with different parties.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_AgreementPartiesAxis" xlink:to="lab_051965J6I763_rttr_AgreementPartiesAxis"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementPartiesDomain" xlink:label="loc_FG95812277699K094F4I_rttr_AgreementPartiesDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_AgreementPartiesDomain" xml:lang="en-US">Agreement Parties [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_AgreementPartiesDomain" xml:lang="en-US">Represents information about agreement with different parties.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_AgreementPartiesDomain" xlink:to="lab_HI17034499811M216H6K_rttr_AgreementPartiesDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_KoluPohakuTechnologiesLlcMember" xlink:label="loc_839743H4G541_rttr_KoluPohakuTechnologiesLlcMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_KoluPohakuTechnologiesLlcMember" xml:lang="en-US">Kolu Pohaku Technologies, Llc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_KoluPohakuTechnologiesLlcMember" xml:lang="en-US">Kolu Pohaku Technologies, LLC</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_KoluPohakuTechnologiesLlcMember" xml:lang="en-US">Represents information about Kolu Pohaku Technologies, LLC ("KPT").</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_KoluPohakuTechnologiesLlcMember" xlink:to="lab_051965J6I763_rttr_KoluPohakuTechnologiesLlcMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_KoluPohakuManagementLlcMember" xlink:label="loc_FG95812277699K094F4I_rttr_KoluPohakuManagementLlcMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_KoluPohakuManagementLlcMember" xml:lang="en-US">Kolu Pohaku Management, Llc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_KoluPohakuManagementLlcMember" xml:lang="en-US">Kolu Pohaku Management, LLC</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_KoluPohakuManagementLlcMember" xml:lang="en-US">Represents information about Kolu Pohaku Management, LLC ("KPM").</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_KoluPohakuManagementLlcMember" xlink:to="lab_HI17034499811M216H6K_rttr_KoluPohakuManagementLlcMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems" xlink:label="loc_839743H4G541_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems" xml:lang="en-US">Stockholders Deficit And Preferred Stock Subject To Redemption [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems" xlink:to="lab_051965J6I763_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_FG95812277699K094F4I_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xml:lang="en-US">Payments received for performing research and development activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_HI17034499811M216H6K_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_839743H4G541_us-gaap_RoyaltyExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_RoyaltyExpense" xml:lang="en-US">Payment of quarterly royalty</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_RoyaltyExpense" xlink:to="lab_051965J6I763_us-gaap_RoyaltyExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_FG95812277699K094F4I_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Number of common shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_839743H4G541_us-gaap_ClassOfWarrantOrRightTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_ClassOfWarrantOrRightAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_839743H4G541_us-gaap_ClassOfWarrantOrRightDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SevenYearWarrantsMember" xlink:label="loc_FG95812277699K094F4I_rttr_SevenYearWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_SevenYearWarrantsMember" xml:lang="en-US">Seven Year Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_SevenYearWarrantsMember" xml:lang="en-US">Seven-year warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_SevenYearWarrantsMember" xml:lang="en-US">Represents the seven year warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_SevenYearWarrantsMember" xlink:to="lab_HI17034499811M216H6K_rttr_SevenYearWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_839743H4G541_us-gaap_ClassOfWarrantOrRightLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_FG95812277699K094F4I_us-gaap_ClassOfWarrantOrRightOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Outstanding at December 31, 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Outstanding at June 30, 2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightOutstanding"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightGranted" xlink:label="loc_839743H4G541_rttr_ClassOfWarrantOrRightGranted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ClassOfWarrantOrRightGranted" xml:lang="en-US">Class Of Warrant Or Right Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_ClassOfWarrantOrRightGranted" xml:lang="en-US">Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ClassOfWarrantOrRightGranted" xml:lang="en-US">Represents number of warrants or rights granted.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ClassOfWarrantOrRightGranted" xlink:to="lab_051965J6I763_rttr_ClassOfWarrantOrRightGranted"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisedExpiredForfeited" xlink:label="loc_FG95812277699K094F4I_rttr_ClassOfWarrantOrRightExercisedExpiredForfeited"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_ClassOfWarrantOrRightExercisedExpiredForfeited" xml:lang="en-US">Class Of Warrant Or Right Exercised Expired Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_ClassOfWarrantOrRightExercisedExpiredForfeited" xml:lang="en-US">Exercised/Expired/ Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_ClassOfWarrantOrRightExercisedExpiredForfeited" xml:lang="en-US">Represents number of warrants or rights exercised/expired/forfeited.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_ClassOfWarrantOrRightExercisedExpiredForfeited" xlink:to="lab_HI17034499811M216H6K_rttr_ClassOfWarrantOrRightExercisedExpiredForfeited"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisable" xlink:label="loc_839743H4G541_rttr_ClassOfWarrantOrRightExercisable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ClassOfWarrantOrRightExercisable" xml:lang="en-US">Class Of Warrant Or Right Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_ClassOfWarrantOrRightExercisable" xml:lang="en-US">Exercisable at June 30, 2015</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ClassOfWarrantOrRightExercisable" xml:lang="en-US">Number of warrants or rights exercisable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ClassOfWarrantOrRightExercisable" xlink:to="lab_051965J6I763_rttr_ClassOfWarrantOrRightExercisable"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" xlink:label="loc_FG95812277699K094F4I_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" xml:lang="en-US">Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" xml:lang="en-US">Exercise price per share or per unit of warrants or rights granted.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" xlink:to="lab_HI17034499811M216H6K_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited" xlink:label="loc_839743H4G541_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised Expired Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited" xml:lang="en-US">Exercised/Expired/ Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited" xml:lang="en-US">Exercise price per share or per unit of warrants or rights exercised/expired/forfeited.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited" xlink:to="lab_051965J6I763_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" xlink:label="loc_FG95812277699K094F4I_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" xml:lang="en-US">Exercisable at June 30, 2015</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" xml:lang="en-US">Exercise price per share or per unit of warrants or rights Exercisable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" xlink:to="lab_HI17034499811M216H6K_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_839743H4G541_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_051965J6I763_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Expected stock-price volatility, Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Expected stock-price volatility, Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Risk-free interest rate, Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Risk-free interest rate, Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_839743H4G541_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Term of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_051965J6I763_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PeriodOfShareIssueAxis" xlink:label="loc_FG95812277699K094F4I_rttr_PeriodOfShareIssueAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PeriodOfShareIssueAxis" xml:lang="en-US">Period Of Share Issue [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PeriodOfShareIssueAxis" xml:lang="en-US">Represents period of share issue.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PeriodOfShareIssueAxis" xlink:to="lab_HI17034499811M216H6K_rttr_PeriodOfShareIssueAxis"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PeriodOfShareIssueDomain" xlink:label="loc_839743H4G541_rttr_PeriodOfShareIssueDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_PeriodOfShareIssueDomain" xml:lang="en-US">Period Of Share Issue [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_PeriodOfShareIssueDomain" xml:lang="en-US">Represents period of share issue.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_PeriodOfShareIssueDomain" xlink:to="lab_051965J6I763_rttr_PeriodOfShareIssueDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandFiveMember" xlink:label="loc_FG95812277699K094F4I_rttr_YearTwoThousandFiveMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_YearTwoThousandFiveMember" xml:lang="en-US">Year Two Thousand Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_YearTwoThousandFiveMember" xml:lang="en-US">2005</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_YearTwoThousandFiveMember" xml:lang="en-US">Issue year 2005</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_YearTwoThousandFiveMember" xlink:to="lab_HI17034499811M216H6K_rttr_YearTwoThousandFiveMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandSixMember" xlink:label="loc_839743H4G541_rttr_YearTwoThousandSixMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_YearTwoThousandSixMember" xml:lang="en-US">Year Two Thousand Six [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_YearTwoThousandSixMember" xml:lang="en-US">2006</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_YearTwoThousandSixMember" xml:lang="en-US">Issue year 2006</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_YearTwoThousandSixMember" xlink:to="lab_051965J6I763_rttr_YearTwoThousandSixMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandEightToYearTwoThousandNineMember" xlink:label="loc_FG95812277699K094F4I_rttr_YearTwoThousandEightToYearTwoThousandNineMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_YearTwoThousandEightToYearTwoThousandNineMember" xml:lang="en-US">Year Two Thousand Eight To Year Two Thousand Nine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_YearTwoThousandEightToYearTwoThousandNineMember" xml:lang="en-US">2008 - 2009</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_YearTwoThousandEightToYearTwoThousandNineMember" xml:lang="en-US">Issue year 2008 to 2009</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_YearTwoThousandEightToYearTwoThousandNineMember" xlink:to="lab_HI17034499811M216H6K_rttr_YearTwoThousandEightToYearTwoThousandNineMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandTenToYearTwoThousandThirteenMember" xlink:label="loc_839743H4G541_rttr_YearTwoThousandTenToYearTwoThousandThirteenMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_YearTwoThousandTenToYearTwoThousandThirteenMember" xml:lang="en-US">Year Two Thousand Ten To Year Two Thousand Thirteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_YearTwoThousandTenToYearTwoThousandThirteenMember" xml:lang="en-US">2010 - 2013</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_YearTwoThousandTenToYearTwoThousandThirteenMember" xml:lang="en-US">Issue year 2010 to 2013</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_YearTwoThousandTenToYearTwoThousandThirteenMember" xlink:to="lab_051965J6I763_rttr_YearTwoThousandTenToYearTwoThousandThirteenMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandFourteenMember" xlink:label="loc_FG95812277699K094F4I_rttr_YearTwoThousandFourteenMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_YearTwoThousandFourteenMember" xml:lang="en-US">Year Two Thousand Fourteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_YearTwoThousandFourteenMember" xml:lang="en-US">2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_YearTwoThousandFourteenMember" xml:lang="en-US">Issue year 2014</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_YearTwoThousandFourteenMember" xlink:to="lab_HI17034499811M216H6K_rttr_YearTwoThousandFourteenMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_FG95812277699K094F4I_us-gaap_PreferredStockConversionBasis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockConversionBasis" xml:lang="en-US">Preferred Stock, Conversion Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PreferredStockConversionBasis" xlink:to="lab_HI17034499811M216H6K_us-gaap_PreferredStockConversionBasis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_839743H4G541_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_051965J6I763_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_FG95812277699K094F4I_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_HI17034499811M216H6K_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_839743H4G541_us-gaap_FairValueAssumptionsExpectedTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Maturity (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_051965J6I763_us-gaap_FairValueAssumptionsExpectedTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:label="loc_FG95812277699K094F4I_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xml:lang="en-US">Schedule of Share-based Goods and Nonemployee Services Transaction [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="lab_HI17034499811M216H6K_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_839743H4G541_us-gaap_AwardDateAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AwardDateAxis" xml:lang="en-US">Award Date [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AwardDateAxis" xlink:to="lab_051965J6I763_us-gaap_AwardDateAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_AwardDateDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_AwardDateDomain" xml:lang="en-US">Award Date [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_AwardDateDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_AwardDateDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandFiveMember" xlink:label="loc_839743H4G541_rttr_GrantYearTwoThousandFiveMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_GrantYearTwoThousandFiveMember" xml:lang="en-US">Grant Year Two Thousand Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_GrantYearTwoThousandFiveMember" xml:lang="en-US">Grant year 2005</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_GrantYearTwoThousandFiveMember" xml:lang="en-US">Represents a year of grant, pertaining to equity-based compensation arrangements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_GrantYearTwoThousandFiveMember" xlink:to="lab_051965J6I763_rttr_GrantYearTwoThousandFiveMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandNineMember" xlink:label="loc_FG95812277699K094F4I_rttr_GrantYearTwoThousandNineMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_GrantYearTwoThousandNineMember" xml:lang="en-US">Grant Year Two Thousand Nine [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_GrantYearTwoThousandNineMember" xml:lang="en-US">Grant year 2009</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_GrantYearTwoThousandNineMember" xml:lang="en-US">Represents a year of grant, pertaining to equity-based compensation arrangements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_GrantYearTwoThousandNineMember" xlink:to="lab_HI17034499811M216H6K_rttr_GrantYearTwoThousandNineMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandElevenMember" xlink:label="loc_839743H4G541_rttr_GrantYearTwoThousandElevenMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_GrantYearTwoThousandElevenMember" xml:lang="en-US">Grant Year Two Thousand Eleven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_GrantYearTwoThousandElevenMember" xml:lang="en-US">Grant year 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_GrantYearTwoThousandElevenMember" xml:lang="en-US">Represents a year of grant, pertaining to equity-based compensation arrangements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_GrantYearTwoThousandElevenMember" xlink:to="lab_051965J6I763_rttr_GrantYearTwoThousandElevenMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandTwelveMember" xlink:label="loc_FG95812277699K094F4I_rttr_GrantYearTwoThousandTwelveMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_GrantYearTwoThousandTwelveMember" xml:lang="en-US">Grant Year Two Thousand Twelve [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_GrantYearTwoThousandTwelveMember" xml:lang="en-US">Grant year 2012</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_GrantYearTwoThousandTwelveMember" xml:lang="en-US">Represents a year of grant, pertaining to equity-based compensation arrangements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_GrantYearTwoThousandTwelveMember" xlink:to="lab_HI17034499811M216H6K_rttr_GrantYearTwoThousandTwelveMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandThirteenMember" xlink:label="loc_839743H4G541_rttr_GrantYearTwoThousandThirteenMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_GrantYearTwoThousandThirteenMember" xml:lang="en-US">Grant Year Two Thousand Thirteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_GrantYearTwoThousandThirteenMember" xml:lang="en-US">Grant year 2013</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_GrantYearTwoThousandThirteenMember" xml:lang="en-US">Represents a year of grant, pertaining to equity-based compensation arrangements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_GrantYearTwoThousandThirteenMember" xlink:to="lab_051965J6I763_rttr_GrantYearTwoThousandThirteenMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandFourteenMember" xlink:label="loc_FG95812277699K094F4I_rttr_GrantYearTwoThousandFourteenMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_GrantYearTwoThousandFourteenMember" xml:lang="en-US">Grant Year Two Thousand Fourteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_GrantYearTwoThousandFourteenMember" xml:lang="en-US">Grant year 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_GrantYearTwoThousandFourteenMember" xml:lang="en-US">Represents a year of grant, pertaining to equity-based compensation arrangements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_GrantYearTwoThousandFourteenMember" xlink:to="lab_HI17034499811M216H6K_rttr_GrantYearTwoThousandFourteenMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:label="loc_839743H4G541_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="lab_051965J6I763_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Estimated Fair Value per Share of Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xml:lang="en-US">Intrinsic Value Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Number of Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod" xlink:label="loc_839743H4G541_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Options, Forfeitures Exercises And Expirations In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod" xml:lang="en-US">For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan exercised or that expired.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod" xml:lang="en-US">Exercised/ Expired/ Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod" xlink:to="lab_051965J6I763_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Exercisable at June 30, 2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Expected to be vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_839743H4G541_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Options, Forfeitures Exercises And Expirations In Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average price of options that were either forfeited exercises or expired.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercised/ Expired/ Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_051965J6I763_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Exercisable at June 30, 2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockPlan2015Member" xlink:label="loc_839743H4G541_rttr_StockPlan2015Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_StockPlan2015Member" xml:lang="en-US">Stock Plan 2015 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_StockPlan2015Member" xml:lang="en-US">2015 Stock Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_StockPlan2015Member" xml:lang="en-US">2015 Stock based compensation plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_StockPlan2015Member" xlink:to="lab_051965J6I763_rttr_StockPlan2015Member"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_IncentiveStockOptionMember" xlink:label="loc_FG95812277699K094F4I_rttr_IncentiveStockOptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_IncentiveStockOptionMember" xml:lang="en-US">Incentive Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_IncentiveStockOptionMember" xml:lang="en-US">Incentive stock option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_IncentiveStockOptionMember" xml:lang="en-US">Represents stock option that can be granted only to employees and confer tax benefit. It referred as incentive share options or Qualified Stock Options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_IncentiveStockOptionMember" xlink:to="lab_HI17034499811M216H6K_rttr_IncentiveStockOptionMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_NonstatutoryStockOptionMember" xlink:label="loc_839743H4G541_rttr_NonstatutoryStockOptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_NonstatutoryStockOptionMember" xml:lang="en-US">Nonstatutory Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_NonstatutoryStockOptionMember" xml:lang="en-US">Nonstatutory stock option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_NonstatutoryStockOptionMember" xml:lang="en-US">Represents a type of employee stock option which is less advantageous for the employer from a tax standpoint than an incentive stock option, but which is less restrictive and generally easier to set up and administer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_NonstatutoryStockOptionMember" xlink:to="lab_051965J6I763_rttr_NonstatutoryStockOptionMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_EmployeeHoldTenPercentOwnershipInterestMember" xlink:label="loc_FG95812277699K094F4I_rttr_EmployeeHoldTenPercentOwnershipInterestMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_EmployeeHoldTenPercentOwnershipInterestMember" xml:lang="en-US">Employee Hold Ten Percent Ownership Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_EmployeeHoldTenPercentOwnershipInterestMember" xml:lang="en-US">Employee - 10% stockholder</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_EmployeeHoldTenPercentOwnershipInterestMember" xml:lang="en-US">Represents an employee who hold ten percent ownership interest in the company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_EmployeeHoldTenPercentOwnershipInterestMember" xlink:to="lab_HI17034499811M216H6K_rttr_EmployeeHoldTenPercentOwnershipInterestMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_OtherEmployeeMember" xlink:label="loc_839743H4G541_rttr_OtherEmployeeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_OtherEmployeeMember" xml:lang="en-US">Other Employee [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_OtherEmployeeMember" xml:lang="en-US">Other employee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_OtherEmployeeMember" xml:lang="en-US">Represents an other employee of the organization.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_OtherEmployeeMember" xlink:to="lab_051965J6I763_rttr_OtherEmployeeMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription" xlink:label="loc_FG95812277699K094F4I_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Exercise Price, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription" xml:lang="en-US">Description of exercise price for stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription" xml:lang="en-US">Represents the description related to exercise price of options issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription" xlink:to="lab_HI17034499811M216H6K_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice" xlink:label="loc_839743H4G541_rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice" xml:lang="en-US">Threshold Percentage Of Fair Market Value Per Share On Grant Date As Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice" xml:lang="en-US">Threshold percentage of fair market value per share on grant date as exercise price of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice" xml:lang="en-US">Represents a threshold percentage of fair market value per share on grant date as exercise price of share based awards.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice" xlink:to="lab_051965J6I763_rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice"/>





<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ExecutiveOfficersAndEmployeesMember" xlink:label="loc_839743H4G541_rttr_ExecutiveOfficersAndEmployeesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ExecutiveOfficersAndEmployeesMember" xml:lang="en-US">Executive Officers And Employees [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_ExecutiveOfficersAndEmployeesMember" xml:lang="en-US">Executive officers and employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ExecutiveOfficersAndEmployeesMember" xml:lang="en-US">Represents Executive of the entity that is appointed to the position by the board of directors and employees of the company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ExecutiveOfficersAndEmployeesMember" xlink:to="lab_051965J6I763_rttr_ExecutiveOfficersAndEmployeesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_ExecutiveOfficerMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ExecutiveOfficerMember" xml:lang="en-US">Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ExecutiveOfficerMember" xml:lang="en-US">Executive Officers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ExecutiveOfficerMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_ExecutiveOfficerMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of options forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xml:lang="en-US">Options to purchase an aggregate common stock no longer considered to be probable of achievement by September 25, 2015</label>
<label xlink:type="resource" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Options to purchase an aggregate common stock no longer considered to be probable of achievement by September 25, 2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TermOfShareBaseCompensationArrangement" xlink:label="loc_839743H4G541_rttr_TermOfShareBaseCompensationArrangement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_TermOfShareBaseCompensationArrangement" xml:lang="en-US">Term Of Share Base Compensation Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_TermOfShareBaseCompensationArrangement" xml:lang="en-US">Term of employee share base compensation arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_TermOfShareBaseCompensationArrangement" xml:lang="en-US">Represents term of share base compensation arrangement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_TermOfShareBaseCompensationArrangement" xlink:to="lab_051965J6I763_rttr_TermOfShareBaseCompensationArrangement"/>




<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_839743H4G541_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_FG95812277699K094F4I_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Unrecognized compensation cost of nonvested stock awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_HI17034499811M216H6K_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_839743H4G541_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Weighted average period of compensation cost expected to be recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_051965J6I763_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xml:lang="en-US">Supplier [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_839743H4G541_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Supplier [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="lab_051965J6I763_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ConsultantsMember" xlink:label="loc_FG95812277699K094F4I_rttr_ConsultantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_ConsultantsMember" xml:lang="en-US">Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_ConsultantsMember" xml:lang="en-US">Consultants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_ConsultantsMember" xml:lang="en-US">Represents a party from whom services were or are to be received.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_ConsultantsMember" xlink:to="lab_HI17034499811M216H6K_rttr_ConsultantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_839743H4G541_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_051965J6I763_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Number of options forfeited or exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost" xlink:label="loc_839743H4G541_rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost" xml:lang="en-US">Share Based Goods And Nonemployee Services Transaction, Allocated Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost" xml:lang="en-US">Nonemployee stock based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost" xml:lang="en-US">Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with non-employees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost" xlink:to="lab_051965J6I763_rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_ValuationTechniqueAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ValuationTechniqueAxis" xml:lang="en-US">Valuation Technique [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ValuationTechniqueAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_ValuationTechniqueAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_839743H4G541_us-gaap_ValuationTechniqueDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ValuationTechniqueDomain" xml:lang="en-US">Valuation Technique [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ValuationTechniqueDomain" xlink:to="lab_051965J6I763_us-gaap_ValuationTechniqueDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AverageStrikePutOptionApproachMember" xlink:label="loc_FG95812277699K094F4I_rttr_AverageStrikePutOptionApproachMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_AverageStrikePutOptionApproachMember" xml:lang="en-US">Average Strike Put Option Approach [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_AverageStrikePutOptionApproachMember" xml:lang="en-US">Average strike put option approach</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_AverageStrikePutOptionApproachMember" xml:lang="en-US">Average strike put option approach</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_AverageStrikePutOptionApproachMember" xlink:to="lab_HI17034499811M216H6K_rttr_AverageStrikePutOptionApproachMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital" xlink:label="loc_839743H4G541_rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital" xml:lang="en-US">Capital Structure Yielded Total Market Value Of Invested Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital" xml:lang="en-US">Capital structure yielded total market value of invested capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital" xml:lang="en-US">Represents capital structure yielded total market value of invested capital.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital" xlink:to="lab_051965J6I763_rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ValueOfCommonStock" xlink:label="loc_FG95812277699K094F4I_rttr_ValueOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_ValueOfCommonStock" xml:lang="en-US">Value Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_ValueOfCommonStock" xml:lang="en-US">Total value of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_ValueOfCommonStock" xml:lang="en-US">Represents value of common stock as on specified valuation date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_ValueOfCommonStock" xlink:to="lab_HI17034499811M216H6K_rttr_ValueOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountForLackOfMarketability" xlink:label="loc_839743H4G541_us-gaap_FairValueInputsDiscountForLackOfMarketability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_FairValueInputsDiscountForLackOfMarketability" xml:lang="en-US">Fair Value Inputs, Discount for Lack of Marketability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_FairValueInputsDiscountForLackOfMarketability" xml:lang="en-US">Discounts for lack of control and lack of marketability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_FairValueInputsDiscountForLackOfMarketability" xlink:to="lab_051965J6I763_us-gaap_FairValueInputsDiscountForLackOfMarketability"/>










<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_FG95812277699K094F4I_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_HI17034499811M216H6K_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_839743H4G541_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_051965J6I763_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_RelatedPartyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_RelatedPartyDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AndelaGroupIncMember" xlink:label="loc_839743H4G541_rttr_AndelaGroupIncMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_AndelaGroupIncMember" xml:lang="en-US">Andela Group Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_AndelaGroupIncMember" xml:lang="en-US">Andela Group Inc</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_AndelaGroupIncMember" xml:lang="en-US">Represents information about Andela Group Inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_AndelaGroupIncMember" xlink:to="lab_051965J6I763_rttr_AndelaGroupIncMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_RelatedPartyTransactionAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_RelatedPartyTransactionAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_839743H4G541_us-gaap_RelatedPartyTransactionDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_051965J6I763_us-gaap_RelatedPartyTransactionDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CorporateManagementStrategicAndFinancialConsultingMember" xlink:label="loc_FG95812277699K094F4I_rttr_CorporateManagementStrategicAndFinancialConsultingMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_CorporateManagementStrategicAndFinancialConsultingMember" xml:lang="en-US">Corporate Management Strategic And Financial Consulting [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_CorporateManagementStrategicAndFinancialConsultingMember" xml:lang="en-US">Corporate management, strategic and financial consulting</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_CorporateManagementStrategicAndFinancialConsultingMember" xml:lang="en-US">Represents a corporate management, strategic and financial consulting.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_CorporateManagementStrategicAndFinancialConsultingMember" xlink:to="lab_HI17034499811M216H6K_rttr_CorporateManagementStrategicAndFinancialConsultingMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_839743H4G541_us-gaap_RelatedPartyTransactionLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_051965J6I763_us-gaap_RelatedPartyTransactionLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_FG95812277699K094F4I_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related party transaction expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_HI17034499811M216H6K_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_839743H4G541_us-gaap_SubsequentEventTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SubsequentEventTable" xlink:to="lab_051965J6I763_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_FG95812277699K094F4I_dei_LegalEntityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_dei_LegalEntityAxis" xlink:to="lab_HI17034499811M216H6K_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_839743H4G541_dei_EntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_dei_EntityDomain" xlink:to="lab_051965J6I763_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CenturyParkMember" xlink:label="loc_FG95812277699K094F4I_rttr_CenturyParkMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_CenturyParkMember" xml:lang="en-US">Century Park [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_CenturyParkMember" xml:lang="en-US">Century Park</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_CenturyParkMember" xml:lang="en-US">Represents information about Century Park a legal entity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_CenturyParkMember" xlink:to="lab_HI17034499811M216H6K_rttr_CenturyParkMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember" xlink:label="loc_839743H4G541_rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember" xml:lang="en-US">Ricerche Sperimentali Montale Spa And Inalco Spa [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember" xml:lang="en-US">RSM</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember" xml:lang="en-US">Represents information about Ricerche Sperimentali Montale SpA and Inalco SpA a legal entity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember" xlink:to="lab_051965J6I763_rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AmendedClinicalSupplyAndCooperationAgreementMember" xlink:label="loc_FG95812277699K094F4I_rttr_AmendedClinicalSupplyAndCooperationAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_AmendedClinicalSupplyAndCooperationAgreementMember" xml:lang="en-US">Amended Clinical Supply And Cooperation Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_AmendedClinicalSupplyAndCooperationAgreementMember" xml:lang="en-US">Amended Supply Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_AmendedClinicalSupplyAndCooperationAgreementMember" xml:lang="en-US">Represents information about amended clinical supply and cooperation agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_AmendedClinicalSupplyAndCooperationAgreementMember" xlink:to="lab_HI17034499811M216H6K_rttr_AmendedClinicalSupplyAndCooperationAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_839743H4G541_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_051965J6I763_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualRightsMember" xlink:label="loc_839743H4G541_us-gaap_ContractualRightsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ContractualRightsMember" xml:lang="en-US">Contractual Rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ContractualRightsMember" xml:lang="en-US">Improved GOS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ContractualRightsMember" xlink:to="lab_051965J6I763_us-gaap_ContractualRightsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_FG95812277699K094F4I_us-gaap_SubsequentEventLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SubsequentEventLineItems" xlink:to="lab_HI17034499811M216H6K_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AreaOfLease" xlink:label="loc_839743H4G541_rttr_AreaOfLease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_AreaOfLease" xml:lang="en-US">Area Of Lease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_AreaOfLease" xml:lang="en-US">Area of lease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_AreaOfLease" xml:lang="en-US">Represents area of land subject to lease.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_AreaOfLease" xlink:to="lab_051965J6I763_rttr_AreaOfLease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_FG95812277699K094F4I_us-gaap_OperatingLeasesRentExpenseNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Maximum rent per month for months 50 through 61</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesRentExpenseNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_839743H4G541_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Renewal Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xml:lang="en-US">Term of option to extend lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:to="lab_051965J6I763_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PaymentToExerciseOptionUnderAgreement" xlink:label="loc_FG95812277699K094F4I_rttr_PaymentToExerciseOptionUnderAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PaymentToExerciseOptionUnderAgreement" xml:lang="en-US">Payment To Exercise Option Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_PaymentToExerciseOptionUnderAgreement" xml:lang="en-US">Payment for GOS IP</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PaymentToExerciseOptionUnderAgreement" xml:lang="en-US">Represents cash outflow required to exercise option under agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PaymentToExerciseOptionUnderAgreement" xlink:to="lab_HI17034499811M216H6K_rttr_PaymentToExerciseOptionUnderAgreement"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PaymentRequiredFollowingFdaApproval" xlink:label="loc_839743H4G541_rttr_PaymentRequiredFollowingFdaApproval"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_PaymentRequiredFollowingFdaApproval" xml:lang="en-US">Payment Required Following Fda Approval</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_rttr_PaymentRequiredFollowingFdaApproval" xml:lang="en-US">Payment required following FDA approval to RSM</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_PaymentRequiredFollowingFdaApproval" xml:lang="en-US">Represents cash payment required following FDA approval.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_PaymentRequiredFollowingFdaApproval" xlink:to="lab_051965J6I763_rttr_PaymentRequiredFollowingFdaApproval"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PurchaseOfImprovedGosInKilos" xlink:label="loc_FG95812277699K094F4I_rttr_PurchaseOfImprovedGosInKilos"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_PurchaseOfImprovedGosInKilos" xml:lang="en-US">Purchase Of Improved Gos In Kilos</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_PurchaseOfImprovedGosInKilos" xml:lang="en-US">GOS kilograms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_PurchaseOfImprovedGosInKilos" xml:lang="en-US">Represent purchase of improved GOS in Kilos.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_PurchaseOfImprovedGosInKilos" xlink:to="lab_HI17034499811M216H6K_rttr_PurchaseOfImprovedGosInKilos"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GosPricePerKilo" xlink:label="loc_839743H4G541_rttr_GosPricePerKilo"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_rttr_GosPricePerKilo" xml:lang="en-US">Gos Price Per Kilo</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_rttr_GosPricePerKilo" xml:lang="en-US">GOS price per kilo (in dollars per kilo)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_rttr_GosPricePerKilo" xml:lang="en-US">Represents GOS price per kilo.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_rttr_GosPricePerKilo" xlink:to="lab_051965J6I763_rttr_GosPricePerKilo"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GosPricePerKiloUnderExistingSupplyAgreement" xlink:label="loc_FG95812277699K094F4I_rttr_GosPricePerKiloUnderExistingSupplyAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_rttr_GosPricePerKiloUnderExistingSupplyAgreement" xml:lang="en-US">Gos Price Per Kilo Under Existing Supply Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_rttr_GosPricePerKiloUnderExistingSupplyAgreement" xml:lang="en-US">GOS price per kilo under existing supply agreement (in dollars per kilo)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_rttr_GosPricePerKiloUnderExistingSupplyAgreement" xml:lang="en-US">Represents GOS price per kilo under existing supply agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_rttr_GosPricePerKiloUnderExistingSupplyAgreement" xlink:to="lab_HI17034499811M216H6K_rttr_GosPricePerKiloUnderExistingSupplyAgreement"/>




<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockPlan2008Member" xlink:label="loc_rttr_StockPlan2008Member"/>
<label xlink:type="resource" xlink:label="lab_rttr_StockPlan2008Member" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stock Plan 2008 [Member]</label>
<label xlink:type="resource" xlink:label="lab_rttr_StockPlan2008Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">2008 Stock plan</label>
<label xlink:type="resource" xlink:label="lab_rttr_StockPlan2008Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">2008 Stock Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rttr_StockPlan2008Member" xlink:to="lab_rttr_StockPlan2008Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Number of options expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:label="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward_1"/>
<label xlink:type="resource" xlink:label="lab_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Class Of Warrant Or Right Number Of Warrants [Roll Forward]</label>
<label xlink:type="resource" xlink:label="lab_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward_1" xlink:to="lab_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>

<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:label="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_1"/>
<label xlink:type="resource" xlink:label="lab_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Class Of Warrant Or Right Weighted Average Exercise Price [Roll Forward]</label>
<label xlink:type="resource" xlink:label="lab_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_1" xlink:to="lab_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Aggregate converted shares of the common stock upon the closing of the IPO</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>




<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" xlink:label="loc_rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital_1"/>
<label xlink:type="resource" xlink:label="lab_rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Deferred Offering Costs Reclassified To Additional Paid In Capital</label>

<label xlink:type="resource" xlink:label="lab_rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Deferred offering costs reclassified to additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital_1" xlink:to="lab_rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" xml:lang="en-US">Represents the value of deferred offering costs reclassified to additional paid-in capital in non cash financing activities.</label>

<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals" xlink:label="loc_rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals_1"/>
<label xlink:type="resource" xlink:label="lab_rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Operating Lease Rent Expense Minimum Monthly Rentals</label>
<label xlink:type="resource" xlink:label="lab_rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Minimum monthly rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals_1" xlink:to="lab_rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals" xml:lang="en-US">Represents the amount related to monthly payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease.</label>











<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber" xlink:label="loc_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber_1"/>
<label xlink:type="resource" xlink:label="lab_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Alternate Vesting Schedule Number</label>
<label xlink:type="resource" xlink:label="lab_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Number of options subject to alternate vesting schedule</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber_1" xlink:to="lab_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber" xml:lang="en-US">Represents alternated vesting shares during the period.</label>

<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockOptionsToVestRatablyOnMonthlyBasis" xlink:label="loc_rttr_StockOptionsToVestRatablyOnMonthlyBasis_1"/>
<label xlink:type="resource" xlink:label="lab_rttr_StockOptionsToVestRatablyOnMonthlyBasis" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stock Options To Vest Ratably On Monthly Basis</label>
<label xlink:type="resource" xlink:label="lab_rttr_StockOptionsToVestRatablyOnMonthlyBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Stock options to vest ratably on a monthly basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rttr_StockOptionsToVestRatablyOnMonthlyBasis_1" xlink:to="lab_rttr_StockOptionsToVestRatablyOnMonthlyBasis"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rttr_StockOptionsToVestRatablyOnMonthlyBasis" xml:lang="en-US">Represents number of share options vests ratably on a monthly basis.</label>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stock Conversion Description [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Conversion of Stock, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ConversionOfPreferredToCommonStockMember" xlink:label="loc_rttr_ConversionOfPreferredToCommonStockMember_1"/>
<label xlink:type="resource" xlink:label="lab_rttr_ConversionOfPreferredToCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Conversion Of Preferred To Common Stock [Member]</label>
<label xlink:type="resource" xlink:label="lab_rttr_ConversionOfPreferredToCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Conversion of Preferred Stock to Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rttr_ConversionOfPreferredToCommonStockMember_1" xlink:to="lab_rttr_ConversionOfPreferredToCommonStockMember"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rttr_ConversionOfPreferredToCommonStockMember" xml:lang="en-US">Represents the conversion of preferred stock to common stock.</label>

<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ConversionOfRedeemablePreferredStockToCommonStockMember" xlink:label="loc_rttr_ConversionOfRedeemablePreferredStockToCommonStockMember_1"/>
<label xlink:type="resource" xlink:label="lab_rttr_ConversionOfRedeemablePreferredStockToCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Conversion Of Redeemable Preferred Stock To Common Stock [Member]</label>
<label xlink:type="resource" xlink:label="lab_rttr_ConversionOfRedeemablePreferredStockToCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Conversion of Redeemable Preferred Stock to Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rttr_ConversionOfRedeemablePreferredStockToCommonStockMember_1" xlink:to="lab_rttr_ConversionOfRedeemablePreferredStockToCommonStockMember"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rttr_ConversionOfRedeemablePreferredStockToCommonStockMember" xml:lang="en-US">Represents conversion of Redeemable Preferred Stock to Common Stock.</label>

<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PreferredStockOriginalIssuePrice" xlink:label="loc_rttr_PreferredStockOriginalIssuePrice_1_1_1"/>
<label xlink:type="resource" xlink:label="lab_rttr_PreferredStockOriginalIssuePrice" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Preferred Stock Original Issue Price</label>
<label xlink:type="resource" xlink:label="lab_rttr_PreferredStockOriginalIssuePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Preferred stock original issue price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rttr_PreferredStockOriginalIssuePrice_1_1_1" xlink:to="lab_rttr_PreferredStockOriginalIssuePrice"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rttr_PreferredStockOriginalIssuePrice" xml:lang="en-US">This element represent preferred stock original issue price.</label>



</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>rttr-20150630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.3.0.4 on Thursday, August 13, 2015 12:14:30 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ritterpharmaceuticals.com/role/DocumentDocumentAndEntityInformation"/>
<roleRef xlink:type="simple" roleURI="http://www.ritterpharmaceuticals.com/role/CONDENSEDBALANCESHEETS" xlink:href="rttr-20150630.xsd#CONDENSEDBALANCESHEETS"/>
<roleRef xlink:type="simple" roleURI="http://www.ritterpharmaceuticals.com/role/CONDENSEDBALANCESHEETSParentheticals" xlink:href="rttr-20150630.xsd#CONDENSEDBALANCESHEETSParentheticals"/>
<roleRef xlink:type="simple" roleURI="http://www.ritterpharmaceuticals.com/role/CONDENSEDSTATEMENTSOFOPERATIONSUnaudited" xlink:href="rttr-20150630.xsd#CONDENSEDSTATEMENTSOFOPERATIONSUnaudited"/>
<roleRef xlink:type="simple" roleURI="http://www.ritterpharmaceuticals.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:href="rttr-20150630.xsd#CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#DisclosureOrganizationAndPrincipalActivities" roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureOrganizationAndPrincipalActivities"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#DisclosureBasisOfPresentation" roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureBasisOfPresentation"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureSummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.ritterpharmaceuticals.com/role/DisclosurePropertyAndEquipment"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureCommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#DisclosureStockholdersDeficitAndPreferredStockSubjectToRedemption" roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureStockholdersDeficitAndPreferredStockSubjectToRedemption"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#DisclosureWarrants" roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureWarrants"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#DisclosureStockBasedCompensation" roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureStockBasedCompensation"/>
<roleRef xlink:type="simple" roleURI="http://www.ritterpharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS" xlink:href="rttr-20150630.xsd#RELATEDPARTYTRANSACTIONS"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#DisclosureSubsequentEvents" roleURI="http://www.ritterpharmaceuticals.com/role/DisclosureSubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.ritterpharmaceuticals.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#PROPERTYANDEQUIPMENTTables" roleURI="http://www.ritterpharmaceuticals.com/role/PROPERTYANDEQUIPMENTTables"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#WARRANTSTables" roleURI="http://www.ritterpharmaceuticals.com/role/WARRANTSTables"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#STOCKBASEDCOMPENSATIONTables" roleURI="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#OrganizationAndPrincipalActivitiesDetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/OrganizationAndPrincipalActivitiesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#BasisOfPresentationDetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/BasisOfPresentationDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#SummaryOfSignificantAccountingPoliciesDetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#PROPERTYANDEQUIPMENTDetails" roleURI="http://www.ritterpharmaceuticals.com/role/PROPERTYANDEQUIPMENTDetails"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#PropertyAndEquipmentdetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/PropertyAndEquipmentdetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#CommitmentsAndContingenciesDetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#CommitmentsAndContingenciesDetailTextuals1" roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals1"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#CommitmentsAndContingenciesDetailTextuals2" roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals2"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#CommitmentsAndContingenciesDetailTextuals3" roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals3"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#CommitmentsAndContingenciesDetailTextuals4" roleURI="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals4"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1" roleURI="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals2" roleURI="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals2"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals3" roleURI="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals3"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals4" roleURI="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals4"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#WARRANTSDetails" roleURI="http://www.ritterpharmaceuticals.com/role/WARRANTSDetails"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#WarrantsDetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/WarrantsDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockBasedCompensationDetails" roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetails"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#STOCKBASEDCOMPENSATIONDetails1" roleURI="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails1"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockBasedCompensationParentheticalsDetails1" roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationParentheticalsDetails1"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#STOCKBASEDCOMPENSATIONDetails2" roleURI="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails2"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#STOCKBASEDCOMPENSATIONDetails3" roleURI="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails3"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#STOCKBASEDCOMPENSATIONDetails4" roleURI="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails4"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockBasedCompensationDetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockBasedCompensationDetailTextuals1" roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals1"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockBasedCompensationDetailTextuals2" roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals2"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#StockBasedCompensationDetailTextuals3" roleURI="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals3"/>
<roleRef xlink:type="simple" roleURI="http://www.ritterpharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetailTextuals" xlink:href="rttr-20150630.xsd#RELATEDPARTYTRANSACTIONSDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="rttr-20150630.xsd#SubsequentEventsDetailTextuals" roleURI="http://www.ritterpharmaceuticals.com/role/SubsequentEventsDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/DocumentDocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_DocumentAndEntityInformationAbstract" xlink:label="loc_rttr_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_10" order="90" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CONDENSEDBALANCESHEETS">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11" xlink:to="loc_us-gaap_AccountsPayableCurrent_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11" xlink:to="loc_us-gaap_LiabilitiesCurrent_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_StockholdersEquityAbstract_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_PreferredStockValue_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_CommonStockValue_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_AdditionalPaidInCapital_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_StockholdersEquity_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable" xlink:to="loc_us-gaap_StatementClassOfStockAxis" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="loc_us-gaap_ClassOfStockDomain" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="loc_us-gaap_RedeemablePreferredStockMember" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable" xlink:to="loc_us-gaap_StatementLineItems" order="1" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CONDENSEDBALANCESHEETSParentheticals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesIssued_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_18" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CONDENSEDSTATEMENTSOFOPERATIONSUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PatentCosts" xlink:label="loc_rttr_PatentCosts_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_1" xlink:to="loc_rttr_PatentCosts_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingIncomeLoss_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_OtherNonoperatingIncome_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_OtherIncome_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockRedemptionDiscount" xlink:label="loc_us-gaap_PreferredStockRedemptionDiscount_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_PreferredStockRedemptionDiscount_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="loc_rttr_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_rttr_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_16" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited">


























































































































































































































<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ConversionOfPreferredToCommonStockMember" xlink:label="loc_rttr_ConversionOfPreferredToCommonStockMember_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_1" xlink:to="loc_rttr_ConversionOfPreferredToCommonStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ConversionOfRedeemablePreferredStockToCommonStockMember" xlink:label="loc_rttr_ConversionOfRedeemablePreferredStockToCommonStockMember_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_1" xlink:to="loc_rttr_ConversionOfRedeemablePreferredStockToCommonStockMember_1" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_1" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_NetIncomeLoss" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaap_Depreciation" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_ProceedsFromNotesPayable" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1_2_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1_2_3" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering" xlink:label="loc_rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" xlink:label="loc_rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommonStockSubjectToRepurchase" xlink:label="loc_rttr_CommonStockSubjectToRepurchase"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_rttr_CommonStockSubjectToRepurchase" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="loc_us-gaap_DividendsPreferredStockStock"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaap_DividendsPreferredStockStock" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaap_InterestPaid" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaap_IncomeTaxesPaid" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/DisclosureOrganizationAndPrincipalActivities">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NatureOfOperations_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/DisclosureBasisOfPresentation">
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_BasisOfPresentationAbstract" xlink:label="loc_rttr_BasisOfPresentationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaap_BasisOfAccounting_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_BasisOfPresentationAbstract_0" xlink:to="loc_us-gaap_BasisOfAccounting_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/DisclosureSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/DisclosurePropertyAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/DisclosureCommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/DisclosureStockholdersDeficitAndPreferredStockSubjectToRedemption">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/DisclosureWarrants">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_WarrantsTextBlock" xlink:label="loc_rttr_WarrantsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_rttr_WarrantsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/DisclosureStockBasedCompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/DisclosureSubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/PROPERTYANDEQUIPMENTTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/WARRANTSTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock" xlink:label="loc_rttr_ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_rttr_ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsInstrumentsClassifiedInShareholdersEquityQuantitativeInformationTableTextBlock" xlink:label="loc_us-gaap_FairValueInputsInstrumentsClassifiedInShareholdersEquityQuantitativeInformationTableTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_FairValueInputsInstrumentsClassifiedInShareholdersEquityQuantitativeInformationTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/OrganizationAndPrincipalActivitiesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_OrganizationAndPrincipalActivitiesTable" xlink:label="loc_rttr_OrganizationAndPrincipalActivitiesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_rttr_OrganizationAndPrincipalActivitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3" xlink:to="loc_us-gaap_IPOMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_OrganizationAndPrincipalActivitiesLineItems" xlink:label="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesTable_1" xlink:to="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_5" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_5" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="loc_rttr_PaymentsOfUnderwritingDiscountsAndCommissions_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_5" xlink:to="loc_rttr_PaymentsOfUnderwritingDiscountsAndCommissions_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_OrganizationAndPrincipalActivitiesLineItems_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/BasisOfPresentationDetailTextuals">
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_BasisOfPresentationAbstract" xlink:label="loc_rttr_BasisOfPresentationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_BasisOfPresentationAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_BasisOfPresentationAbstract_0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_WorkingCapital" xlink:label="loc_rttr_WorkingCapital_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_BasisOfPresentationAbstract_0" xlink:to="loc_rttr_WorkingCapital_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_BasisOfPresentationAbstract_0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_BasisOfPresentationAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/PROPERTYANDEQUIPMENTDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ComputerEquipmentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/PropertyAndEquipmentdetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5" xlink:to="loc_us-gaap_Depreciation_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesTable" xlink:label="loc_rttr_CommitmentsAndContingenciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_rttr_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementAxis" xlink:label="loc_rttr_AgreementAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_AgreementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementDomain" xlink:label="loc_rttr_AgreementDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_AgreementAxis_2" xlink:to="loc_rttr_AgreementDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StepLetterAgreementMember" xlink:label="loc_rttr_StepLetterAgreementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_AgreementDomain_3" xlink:to="loc_rttr_StepLetterAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PresidentAndFormerChiefExecutiveOfficerMember" xlink:label="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ChiefStrategicOfficerMember" xlink:label="loc_rttr_ChiefStrategicOfficerMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_rttr_ChiefStrategicOfficerMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_EmployeeStockOptionTwoMember" xlink:label="loc_rttr_EmployeeStockOptionTwoMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_rttr_EmployeeStockOptionTwoMember_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_EmployeeStockOptionThreeMember" xlink:label="loc_rttr_EmployeeStockOptionThreeMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_rttr_EmployeeStockOptionThreeMember_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_PlanNameAxis_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_15" xlink:to="loc_us-gaap_PlanNameDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ExecutiveCompensationPlanMember" xlink:label="loc_rttr_ExecutiveCompensationPlanMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_16" xlink:to="loc_rttr_ExecutiveCompensationPlanMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockPlan2008Member" xlink:label="loc_rttr_StockPlan2008Member_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_16" xlink:to="loc_rttr_StockPlan2008Member_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_20" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesLineItems" xlink:label="loc_rttr_CommitmentsAndContingenciesLineItems_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_CommitmentsAndContingenciesLineItems_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_22" xlink:to="loc_us-gaap_OfficersCompensation_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TuitionReimbursementAuthorizedAmount" xlink:label="loc_rttr_TuitionReimbursementAuthorizedAmount_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_22" xlink:to="loc_rttr_TuitionReimbursementAuthorizedAmount_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PeriodOfTuitionReimbursement" xlink:label="loc_rttr_PeriodOfTuitionReimbursement_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_22" xlink:to="loc_rttr_PeriodOfTuitionReimbursement_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_22" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_NumberOfOptionGranted" xlink:label="loc_rttr_NumberOfOptionGranted_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_22" xlink:to="loc_rttr_NumberOfOptionGranted_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_29" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>


<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding" xlink:label="loc_rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_22" xlink:to="loc_rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding_31" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfSharesSubjectToRightOfRepurchase" xlink:label="loc_rttr_PercentageOfSharesSubjectToRightOfRepurchase_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_22" xlink:to="loc_rttr_PercentageOfSharesSubjectToRightOfRepurchase_32" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_DescriptionOfRightToRepurchaseLapse" xlink:label="loc_rttr_DescriptionOfRightToRepurchaseLapse_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_22" xlink:to="loc_rttr_DescriptionOfRightToRepurchaseLapse_33" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_BonusPercentageOfSalary" xlink:label="loc_rttr_BonusPercentageOfSalary_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_22" xlink:to="loc_rttr_BonusPercentageOfSalary_34" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesTable" xlink:label="loc_rttr_CommitmentsAndContingenciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_rttr_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis" xlink:label="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain" xlink:label="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_5" xlink:to="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_FdaMeetingBonusOpportunitiesMember" xlink:label="loc_rttr_FdaMeetingBonusOpportunitiesMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_6" xlink:to="loc_rttr_FdaMeetingBonusOpportunitiesMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember" xlink:label="loc_rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_6" xlink:to="loc_rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_FundraisingBonusOpportunitiesMember" xlink:label="loc_rttr_FundraisingBonusOpportunitiesMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_6" xlink:to="loc_rttr_FundraisingBonusOpportunitiesMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneTypeAxis" xlink:label="loc_rttr_PerformanceMilestoneTypeAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_PerformanceMilestoneTypeAxis_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneTypeDomain" xlink:label="loc_rttr_PerformanceMilestoneTypeDomain_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_PerformanceMilestoneTypeAxis_10" xlink:to="loc_rttr_PerformanceMilestoneTypeDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneConditionOneMember" xlink:label="loc_rttr_PerformanceMilestoneConditionOneMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_PerformanceMilestoneTypeDomain_11" xlink:to="loc_rttr_PerformanceMilestoneConditionOneMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneConditionTwoMember" xlink:label="loc_rttr_PerformanceMilestoneConditionTwoMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_PerformanceMilestoneTypeDomain_11" xlink:to="loc_rttr_PerformanceMilestoneConditionTwoMember_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RangeAxis_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_14" xlink:to="loc_us-gaap_RangeMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_15" xlink:to="loc_us-gaap_MinimumMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_17" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_18" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_20" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_21" xlink:to="loc_us-gaap_SubsequentEventMember_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_23" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_23" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24" xlink:to="loc_us-gaap_IPOMember_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesLineItems" xlink:label="loc_rttr_CommitmentsAndContingenciesLineItems_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_CommitmentsAndContingenciesLineItems_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ExecutiveCompensation" xlink:label="loc_rttr_ExecutiveCompensation_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_26" xlink:to="loc_rttr_ExecutiveCompensation_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_MinimumActualDeploymentOfFundsByThirdParty" xlink:label="loc_rttr_MinimumActualDeploymentOfFundsByThirdParty_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_26" xlink:to="loc_rttr_MinimumActualDeploymentOfFundsByThirdParty_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_26" xlink:to="loc_us-gaap_Cash_30" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_26" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_31" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_32" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_33" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_34" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AccruedBonusToExecutive" xlink:label="loc_rttr_AccruedBonusToExecutive_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_26" xlink:to="loc_rttr_AccruedBonusToExecutive_35" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_26" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_36" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>


<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PresidentAndFormerChiefExecutiveOfficerMember" xlink:label="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ChiefStrategicOfficerMember" xlink:label="loc_rttr_ChiefStrategicOfficerMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_rttr_ChiefStrategicOfficerMember" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockOptionsToVestRatablyOnMonthlyBasis" xlink:label="loc_rttr_StockOptionsToVestRatablyOnMonthlyBasis"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_26" xlink:to="loc_rttr_StockOptionsToVestRatablyOnMonthlyBasis" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesTable" xlink:label="loc_rttr_CommitmentsAndContingenciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_rttr_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis" xlink:label="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain" xlink:label="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis_2" xlink:to="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_LicenseEventBonusOpportunitiesMember" xlink:label="loc_rttr_LicenseEventBonusOpportunitiesMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsDomain_3" xlink:to="loc_rttr_LicenseEventBonusOpportunitiesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneTypeAxis" xlink:label="loc_rttr_PerformanceMilestoneTypeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_PerformanceMilestoneTypeAxis_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneTypeDomain" xlink:label="loc_rttr_PerformanceMilestoneTypeDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_PerformanceMilestoneTypeAxis_5" xlink:to="loc_rttr_PerformanceMilestoneTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneConditionOneMember" xlink:label="loc_rttr_PerformanceMilestoneConditionOneMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_PerformanceMilestoneTypeDomain_6" xlink:to="loc_rttr_PerformanceMilestoneConditionOneMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneConditionTwoMember" xlink:label="loc_rttr_PerformanceMilestoneConditionTwoMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_PerformanceMilestoneTypeDomain_6" xlink:to="loc_rttr_PerformanceMilestoneConditionTwoMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PerformanceMilestoneConditionThreeMember" xlink:label="loc_rttr_PerformanceMilestoneConditionThreeMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_PerformanceMilestoneTypeDomain_6" xlink:to="loc_rttr_PerformanceMilestoneConditionThreeMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RangeAxis_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_13" xlink:to="loc_us-gaap_RangeMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_14" xlink:to="loc_us-gaap_MinimumMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_14" xlink:to="loc_us-gaap_MaximumMember_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TypeOfBonusAwardAxis" xlink:label="loc_rttr_TypeOfBonusAwardAxis_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_TypeOfBonusAwardAxis_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TypeOfBonusAwardDomain" xlink:label="loc_rttr_TypeOfBonusAwardDomain_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_TypeOfBonusAwardAxis_17" xlink:to="loc_rttr_TypeOfBonusAwardDomain_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GraduatedCashBonusMember" xlink:label="loc_rttr_GraduatedCashBonusMember_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_TypeOfBonusAwardDomain_18" xlink:to="loc_rttr_GraduatedCashBonusMember_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesLineItems" xlink:label="loc_rttr_CommitmentsAndContingenciesLineItems_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_CommitmentsAndContingenciesLineItems_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_MinimumActualDeploymentOfFundsByThirdParty" xlink:label="loc_rttr_MinimumActualDeploymentOfFundsByThirdParty_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_rttr_MinimumActualDeploymentOfFundsByThirdParty_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfInitialPeriodLicensePayment" xlink:label="loc_rttr_PercentageOfInitialPeriodLicensePayment_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_rttr_PercentageOfInitialPeriodLicensePayment_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_InitialPeriodLicensePayment" xlink:label="loc_rttr_InitialPeriodLicensePayment_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_rttr_InitialPeriodLicensePayment_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ReceiptOfInitialPeriodLicensePayment" xlink:label="loc_rttr_ReceiptOfInitialPeriodLicensePayment_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_rttr_ReceiptOfInitialPeriodLicensePayment_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_28" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfCashBonusExcessOfMilestonePayments" xlink:label="loc_rttr_PercentageOfCashBonusExcessOfMilestonePayments_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_rttr_PercentageOfCashBonusExcessOfMilestonePayments_29" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_us-gaap_Cash_30" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PresidentAndFormerChiefExecutiveOfficerMember" xlink:label="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ChiefStrategicOfficerMember" xlink:label="loc_rttr_ChiefStrategicOfficerMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_rttr_ChiefStrategicOfficerMember" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesTable" xlink:label="loc_rttr_CommitmentsAndContingenciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_rttr_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_9" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PresidentAndCsoMember" xlink:label="loc_rttr_PresidentAndCsoMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_10" xlink:to="loc_rttr_PresidentAndCsoMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_10" xlink:to="loc_us-gaap_DirectorMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_VestingAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_13" xlink:to="loc_us-gaap_VestingDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_14" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_14" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_14" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_VestingPeriodThreeYearsMember" xlink:label="loc_rttr_VestingPeriodThreeYearsMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_14" xlink:to="loc_rttr_VestingPeriodThreeYearsMember_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_VestingPeriodOneYearMember" xlink:label="loc_rttr_VestingPeriodOneYearMember_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_14" xlink:to="loc_rttr_VestingPeriodOneYearMember_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesLineItems" xlink:label="loc_rttr_CommitmentsAndContingenciesLineItems_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_CommitmentsAndContingenciesLineItems_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>


<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_InitialPeriod" xlink:label="loc_rttr_InitialPeriod_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_rttr_InitialPeriod_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AnnualExcessMilestonePayments" xlink:label="loc_rttr_AnnualExcessMilestonePayments_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_rttr_AnnualExcessMilestonePayments_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfAdditionalCashBonus" xlink:label="loc_rttr_PercentageOfAdditionalCashBonus_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_rttr_PercentageOfAdditionalCashBonus_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_28" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_29" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_30" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PresidentAndFormerChiefExecutiveOfficerMember" xlink:label="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_10" xlink:to="loc_rttr_PresidentAndFormerChiefExecutiveOfficerMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ChiefStrategicOfficerMember" xlink:label="loc_rttr_ChiefStrategicOfficerMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_10" xlink:to="loc_rttr_ChiefStrategicOfficerMember" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesTable" xlink:label="loc_rttr_CommitmentsAndContingenciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_rttr_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6" xlink:to="loc_us-gaap_SubsequentEventMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CommitmentsAndContingenciesLineItems" xlink:label="loc_rttr_CommitmentsAndContingenciesLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesTable_1" xlink:to="loc_rttr_CommitmentsAndContingenciesLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_8" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_8" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfIncreaseInAnnualRent" xlink:label="loc_rttr_PercentageOfIncreaseInAnnualRent_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_8" xlink:to="loc_rttr_PercentageOfIncreaseInAnnualRent_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_8" xlink:to="loc_us-gaap_LeaseAndRentalExpense_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals" xlink:label="loc_rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_CommitmentsAndContingenciesLineItems_8" xlink:to="loc_rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesAOnePreferredStockMember" xlink:label="loc_rttr_SeriesAOnePreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesAOnePreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesATwoPreferredStockMember" xlink:label="loc_rttr_SeriesATwoPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesATwoPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesAThreePreferredStockMember" xlink:label="loc_rttr_SeriesAThreePreferredStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesAThreePreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9" xlink:to="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:label="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9" xlink:to="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PurchasePrice" xlink:label="loc_rttr_PurchasePrice_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9" xlink:to="loc_rttr_PurchasePrice_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9" xlink:to="loc_us-gaap_SharesIssuedPricePerShare" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3" xlink:to="loc_us-gaap_IPOMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="loc_rttr_PaymentsOfUnderwritingDiscountsAndCommissions_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5" xlink:to="loc_rttr_PaymentsOfUnderwritingDiscountsAndCommissions_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_CommonStockMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_9" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_10" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_12" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TwoThousandFourteenNotesMember" xlink:label="loc_rttr_TwoThousandFourteenNotesMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13" xlink:to="loc_rttr_TwoThousandFourteenNotesMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TwoThousandFourteenNotesOneMember" xlink:label="loc_rttr_TwoThousandFourteenNotesOneMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13" xlink:to="loc_rttr_TwoThousandFourteenNotesOneMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TermOfWarrantIssued" xlink:label="loc_rttr_TermOfWarrantIssued_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_rttr_TermOfWarrantIssued_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_FairValuePerShare" xlink:label="loc_rttr_FairValuePerShare_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_rttr_FairValuePerShare_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_DiscountOnInitialCarryingValue" xlink:label="loc_rttr_DiscountOnInitialCarryingValue_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_rttr_DiscountOnInitialCarryingValue_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_us-gaap_ConvertibleNotesPayable_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_27" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_28" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfPricePerShare" xlink:label="loc_rttr_PercentageOfPricePerShare_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_rttr_PercentageOfPricePerShare_29" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_us-gaap_InterestExpenseDebt_30" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest" xlink:label="loc_rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest_31" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_16" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_32" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable" xlink:label="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementAxis" xlink:label="loc_rttr_AgreementAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable_1" xlink:to="loc_rttr_AgreementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementDomain" xlink:label="loc_rttr_AgreementDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_AgreementAxis_2" xlink:to="loc_rttr_AgreementDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ResearchAndDevelopmentAgreementLicenseMember" xlink:label="loc_rttr_ResearchAndDevelopmentAgreementLicenseMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_AgreementDomain_3" xlink:to="loc_rttr_ResearchAndDevelopmentAgreementLicenseMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PutAndCallOptionAgreementMember" xlink:label="loc_rttr_PutAndCallOptionAgreementMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_AgreementDomain_3" xlink:to="loc_rttr_PutAndCallOptionAgreementMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementPartiesAxis" xlink:label="loc_rttr_AgreementPartiesAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable_1" xlink:to="loc_rttr_AgreementPartiesAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementPartiesDomain" xlink:label="loc_rttr_AgreementPartiesDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_AgreementPartiesAxis_6" xlink:to="loc_rttr_AgreementPartiesDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_KoluPohakuTechnologiesLlcMember" xlink:label="loc_rttr_KoluPohakuTechnologiesLlcMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_AgreementPartiesDomain_7" xlink:to="loc_rttr_KoluPohakuTechnologiesLlcMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_KoluPohakuManagementLlcMember" xlink:label="loc_rttr_KoluPohakuManagementLlcMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_AgreementPartiesDomain_7" xlink:to="loc_rttr_KoluPohakuManagementLlcMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10" xlink:to="loc_us-gaap_ClassOfStockDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_11" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems" xlink:label="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionTable_1" xlink:to="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems_13" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems_13" xlink:to="loc_us-gaap_RoyaltyExpense_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PreferredStockOriginalIssuePrice" xlink:label="loc_rttr_PreferredStockOriginalIssuePrice"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems_13" xlink:to="loc_rttr_PreferredStockOriginalIssuePrice" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/WARRANTSDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SevenYearWarrantsMember" xlink:label="loc_rttr_SevenYearWarrantsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_rttr_SevenYearWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightGranted" xlink:label="loc_rttr_ClassOfWarrantOrRightGranted_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:to="loc_rttr_ClassOfWarrantOrRightGranted_7" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisedExpiredForfeited" xlink:label="loc_rttr_ClassOfWarrantOrRightExercisedExpiredForfeited_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:to="loc_rttr_ClassOfWarrantOrRightExercisedExpiredForfeited_8" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisable" xlink:label="loc_rttr_ClassOfWarrantOrRightExercisable_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:to="loc_rttr_ClassOfWarrantOrRightExercisable_10" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" xlink:label="loc_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="loc_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted_12" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited" xlink:label="loc_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="loc_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited_13" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable" xlink:label="loc_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="loc_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable_15" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:label="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:label="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/WarrantsDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SevenYearWarrantsMember" xlink:label="loc_rttr_SevenYearWarrantsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_rttr_SevenYearWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>










<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_SharePrice_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesATwoPreferredStockMember" xlink:label="loc_rttr_SeriesATwoPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesATwoPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesAThreePreferredStockMember" xlink:label="loc_rttr_SeriesAThreePreferredStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesAThreePreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PeriodOfShareIssueAxis" xlink:label="loc_rttr_PeriodOfShareIssueAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_rttr_PeriodOfShareIssueAxis_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PeriodOfShareIssueDomain" xlink:label="loc_rttr_PeriodOfShareIssueDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_PeriodOfShareIssueAxis_9" xlink:to="loc_rttr_PeriodOfShareIssueDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandFiveMember" xlink:label="loc_rttr_YearTwoThousandFiveMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_PeriodOfShareIssueDomain_10" xlink:to="loc_rttr_YearTwoThousandFiveMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandSixMember" xlink:label="loc_rttr_YearTwoThousandSixMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_PeriodOfShareIssueDomain_10" xlink:to="loc_rttr_YearTwoThousandSixMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandEightToYearTwoThousandNineMember" xlink:label="loc_rttr_YearTwoThousandEightToYearTwoThousandNineMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_PeriodOfShareIssueDomain_10" xlink:to="loc_rttr_YearTwoThousandEightToYearTwoThousandNineMember_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandTenToYearTwoThousandThirteenMember" xlink:label="loc_rttr_YearTwoThousandTenToYearTwoThousandThirteenMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_PeriodOfShareIssueDomain_10" xlink:to="loc_rttr_YearTwoThousandTenToYearTwoThousandThirteenMember_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_YearTwoThousandFourteenMember" xlink:label="loc_rttr_YearTwoThousandFourteenMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_PeriodOfShareIssueDomain_10" xlink:to="loc_rttr_YearTwoThousandFourteenMember_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationParentheticalsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_PreferredStockConversionBasis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_AwardDateAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_5" xlink:to="loc_us-gaap_AwardDateDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandFiveMember" xlink:label="loc_rttr_GrantYearTwoThousandFiveMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_6" xlink:to="loc_rttr_GrantYearTwoThousandFiveMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandNineMember" xlink:label="loc_rttr_GrantYearTwoThousandNineMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_6" xlink:to="loc_rttr_GrantYearTwoThousandNineMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandElevenMember" xlink:label="loc_rttr_GrantYearTwoThousandElevenMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_6" xlink:to="loc_rttr_GrantYearTwoThousandElevenMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandTwelveMember" xlink:label="loc_rttr_GrantYearTwoThousandTwelveMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_6" xlink:to="loc_rttr_GrantYearTwoThousandTwelveMember_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandThirteenMember" xlink:label="loc_rttr_GrantYearTwoThousandThirteenMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_6" xlink:to="loc_rttr_GrantYearTwoThousandThirteenMember_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GrantYearTwoThousandFourteenMember" xlink:label="loc_rttr_GrantYearTwoThousandFourteenMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_6" xlink:to="loc_rttr_GrantYearTwoThousandFourteenMember_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_RangeAxis_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_13" xlink:to="loc_us-gaap_RangeMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_14" xlink:to="loc_us-gaap_MinimumMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_14" xlink:to="loc_us-gaap_MaximumMember_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod" xlink:label="loc_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8" xlink:to="loc_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_StockPlan2015Member" xlink:label="loc_rttr_StockPlan2015Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_rttr_StockPlan2015Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_IncentiveStockOptionMember" xlink:label="loc_rttr_IncentiveStockOptionMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOptionMember_7" xlink:to="loc_rttr_IncentiveStockOptionMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_NonstatutoryStockOptionMember" xlink:label="loc_rttr_NonstatutoryStockOptionMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOptionMember_7" xlink:to="loc_rttr_NonstatutoryStockOptionMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_10" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_EmployeeHoldTenPercentOwnershipInterestMember" xlink:label="loc_rttr_EmployeeHoldTenPercentOwnershipInterestMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11" xlink:to="loc_rttr_EmployeeHoldTenPercentOwnershipInterestMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_OtherEmployeeMember" xlink:label="loc_rttr_OtherEmployeeMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11" xlink:to="loc_rttr_OtherEmployeeMember_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_14" xlink:to="loc_us-gaap_RangeMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_15" xlink:to="loc_us-gaap_MinimumMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_15" xlink:to="loc_us-gaap_MaximumMember_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription" xlink:label="loc_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18" xlink:to="loc_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice" xlink:label="loc_rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18" xlink:to="loc_rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_10" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ExecutiveOfficersAndEmployeesMember" xlink:label="loc_rttr_ExecutiveOfficersAndEmployeesMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11" xlink:to="loc_rttr_ExecutiveOfficersAndEmployeesMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_11" xlink:to="loc_us-gaap_ExecutiveOfficerMember_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_14" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_15" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_TermOfShareBaseCompensationArrangement" xlink:label="loc_rttr_TermOfShareBaseCompensationArrangement_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_rttr_TermOfShareBaseCompensationArrangement_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_25" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_26" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_27" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_28" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_5" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ConsultantsMember" xlink:label="loc_rttr_ConsultantsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_6" xlink:to="loc_rttr_ConsultantsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MinimumMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_VestingAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_12" xlink:to="loc_us-gaap_VestingDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_13" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_15" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_16" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_1" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost" xlink:label="loc_rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_18" xlink:to="loc_rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber" xlink:label="loc_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_18" xlink:to="loc_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesAOnePreferredStockMember" xlink:label="loc_rttr_SeriesAOnePreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesAOnePreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesATwoPreferredStockMember" xlink:label="loc_rttr_SeriesATwoPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesATwoPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_SeriesAThreePreferredStockMember" xlink:label="loc_rttr_SeriesAThreePreferredStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_rttr_SeriesAThreePreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MinimumMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MaximumMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ValuationTechniqueAxis_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_13" xlink:to="loc_us-gaap_ValuationTechniqueDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AverageStrikePutOptionApproachMember" xlink:label="loc_rttr_AverageStrikePutOptionApproachMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_14" xlink:to="loc_rttr_AverageStrikePutOptionApproachMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital" xlink:label="loc_rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_ValueOfCommonStock" xlink:label="loc_rttr_ValueOfCommonStock_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_rttr_ValueOfCommonStock_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountForLackOfMarketability" xlink:label="loc_us-gaap_FairValueInputsDiscountForLackOfMarketability_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_FairValueInputsDiscountForLackOfMarketability_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_SharePrice_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>




</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AndelaGroupIncMember" xlink:label="loc_rttr_AndelaGroupIncMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_rttr_AndelaGroupIncMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CorporateManagementStrategicAndFinancialConsultingMember" xlink:label="loc_rttr_CorporateManagementStrategicAndFinancialConsultingMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6" xlink:to="loc_rttr_CorporateManagementStrategicAndFinancialConsultingMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.ritterpharmaceuticals.com/role/SubsequentEventsDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_CenturyParkMember" xlink:label="loc_rttr_CenturyParkMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_rttr_CenturyParkMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember" xlink:label="loc_rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_RangeAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MaximumMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementAxis" xlink:label="loc_rttr_AgreementAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_rttr_AgreementAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AgreementDomain" xlink:label="loc_rttr_AgreementDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_AgreementAxis_12" xlink:to="loc_rttr_AgreementDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AmendedClinicalSupplyAndCooperationAgreementMember" xlink:label="loc_rttr_AmendedClinicalSupplyAndCooperationAgreementMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rttr_AgreementDomain_13" xlink:to="loc_rttr_AmendedClinicalSupplyAndCooperationAgreementMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualRightsMember" xlink:label="loc_us-gaap_ContractualRightsMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16" xlink:to="loc_us-gaap_ContractualRightsMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_AreaOfLease" xlink:label="loc_rttr_AreaOfLease_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_rttr_AreaOfLease_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PaymentToExerciseOptionUnderAgreement" xlink:label="loc_rttr_PaymentToExerciseOptionUnderAgreement_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_rttr_PaymentToExerciseOptionUnderAgreement_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PaymentRequiredFollowingFdaApproval" xlink:label="loc_rttr_PaymentRequiredFollowingFdaApproval_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_rttr_PaymentRequiredFollowingFdaApproval_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_PurchaseOfImprovedGosInKilos" xlink:label="loc_rttr_PurchaseOfImprovedGosInKilos_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_rttr_PurchaseOfImprovedGosInKilos_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GosPricePerKilo" xlink:label="loc_rttr_GosPricePerKilo_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_rttr_GosPricePerKilo_27" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="rttr-20150630.xsd#rttr_GosPricePerKiloUnderExistingSupplyAgreement" xlink:label="loc_rttr_GosPricePerKiloUnderExistingSupplyAgreement_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_rttr_GosPricePerKiloUnderExistingSupplyAgreement_28" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_29" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_18" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_30" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624473832432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Parentheticals) (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 17, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred Stock, Conversion Basis</a></td>
<td class="text">1-for-7.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of common shares issued upon conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,322,650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624206212448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2015 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2015 </div>
<div>USD ($) </div>
<div>kg </div>
<div>$ / kg</div>
</th>
<th class="th">
<div>Jul. 24, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Period of lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares issued, par value per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Period of lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Base rent per month for months 2 through 13 of term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Century Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AreaOfLease', window );">Area of lease | ft&#178;</a></td>
<td class="nump">2,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Period of lease agreement</a></td>
<td class="text">61 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Base rent per month for months 2 through 13 of term</a></td>
<td class="nump">$ 9,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Term of option to extend lease</a></td>
<td class="text">5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Century Park | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Maximum rent per month for months 50 through 61</a></td>
<td class="nump">$ 10,325.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | RSM | Amended Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares issued, par value per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | RSM | Amended Supply Agreement | Improved GOS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PaymentToExerciseOptionUnderAgreement', window );">Payment for GOS IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PaymentRequiredFollowingFdaApproval', window );">Payment required following FDA approval to RSM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PurchaseOfImprovedGosInKilos', window );">GOS kilograms | kg</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_GosPricePerKilo', window );">GOS price per kilo (in dollars per kilo) | $ / kg</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_GosPricePerKiloUnderExistingSupplyAgreement', window );">GOS price per kilo under existing supply agreement (in dollars per kilo) | $ / kg</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_AreaOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents area of land subject to lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_AreaOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_GosPricePerKilo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents GOS price per kilo.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_GosPricePerKilo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_GosPricePerKiloUnderExistingSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents GOS price per kilo under existing supply agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_GosPricePerKiloUnderExistingSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PaymentRequiredFollowingFdaApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents cash payment required following FDA approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PaymentRequiredFollowingFdaApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PaymentToExerciseOptionUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents cash outflow required to exercise option under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PaymentToExerciseOptionUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PurchaseOfImprovedGosInKilos">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent purchase of improved GOS in Kilos.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PurchaseOfImprovedGosInKilos</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:massItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7661868&amp;loc=d3e34039-112682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rttr_CenturyParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rttr_CenturyParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rttr_RicercheSperimentaliMontaleSpaAndInalcoSpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_AgreementAxis=rttr_AmendedClinicalSupplyAndCooperationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_AgreementAxis=rttr_AmendedClinicalSupplyAndCooperationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(`%2"#$<]SG18X0$```D>```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,V9S4[C,!2%7Z7*%C6N?V`81-D`6T""%_`DMXW5.+9L4\K;8Z>`9JHR
M@ADJG4U^>J[O.<EUODW/'YX]Q<G&]D.<5UU*_HRQV'1D=:R=IR$K"Q>L3ODV
M+)G7S4HOB8G9[(0U;D@TI&DJ/:J+\]LUA6!:FEQNA=)[7FGO>]/H9-S`UD.[
MTW7J%@O34.N:1YN7U"E;TU'6J\F=#NE&V]R";7HV"MLCKXO.OL<P^D"ZC1U1
MLGT=TW-/<9__5GESOJ*%?NS3EXQ?WUT=J!]K8F?\J]7U)G>)^;=YE=7X*8?=
MA7]+9FP9FA^6?ZPH]__X+#LO<6W[JZ"?S([!^F!C*N?::C/L&]63"ZM?SJV^
M<YM0>:J6VJD/N3`DLV>7Y.*[K$:66_^7]]M.:5R@3QF6P@-^%)T.U-ZGD.>[
M_]OXO>!P.<I<Q^N/ACZ*D8VG`T+B2SD$2`X)DD.!Y#@&R7$"DN,'2(Y3D!P_
M07+P&4H0%*)R%*1R%*9R%*AR%*IR%*QR%*YR%+!R%+(*%+(*%+(*%+(*%+(*
M%+(*%+(*%+(*%+(*%+(*%+)*%+)*%+)*%+)*%+)*%+)*%+)*%+)*%+)*%+)*
M%+(J%+(J%+(J%+(J%+(J%+(J%+(J%+(J%+*J=[*R\1_@BQ=02P,$%`````@`
M5((,1TAU!>[%````*P(```L```!?<F5L<R\N<F5L<ZV2RV["0`Q%?R6:?7%*
M)1818<6&'4+\@#OC/)3,>.0Q(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8<4M?'
M5$Q^#*G*_=ITJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.
MU49V[M,41Y26M#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997
M'L=V+YRO+0O]C^AY%.!)T:'B1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C@KN_
MV/P"4$L#!!0````(`%2"#$=@@IJAT@$``(T=```:````>&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'/%V4M.XT`4A>&M1%X`Y?L@0$08,6%*LP$KJ<11$MMR
M5:MA]VTR0.%11PPBG8DMV]*M?_2I5+[O4KUXCH<F[_HNM;LAS5Z/ARXMIO?+
MJLUY6(205FT\-NFJ'V(W?=WTX[')T^.X#4.SVC?;&+2NYV$\GU,]W'^=/7M:
M+ZOQ:2W5[*49MS$OJW_]N$]MC#F%TTVNI@6FSV]#_,WR_6:S6\7'?O7W&+O\
M0T7X6*`*Y2`M!RDER,I!1@GR<I!3@J[+0=>4H'DY:$X)NBD'W5"";LM!MY2@
MNW+0'25(:B!CS4E"6'.T%L"U<+P6`+9PQ!9`MG#,%H"V<-06P+9PW!8`MW#D
M%D"W<.P6@+=P]%:@MW+T5J"WDO;::+/-T5N!WLK16X'>RM%;@=[*T5N!WLK1
M6X'>RM%;@=[*T5N!WLK1VX#>QM';@-[&T=N`WD8Z*T&')1R]#>AM'+T-Z&T<
MO0WH;1R]#>AM'+T-Z&T<O0WH;1R]'>CM'+T=Z.T<O1WH[1R]'>CMI+-N=-C-
MT=N!WL[1VX'>SM';@=[.T=N!WL[1V\_T3FTSQO6?/.ZZ;;ITS:?A\%_.&=XI
MOQWBY5-.4V'#F=9Y6BF&T_7B3I^FOH>$;W]>'_X#4$L#!!0````(`%2"#$?<
M9XOE`@,``+$,```0````9&]C4')O<',O87!P+GAM;+U7T7*B,!3]E8POZSZT
M6.MVNXYEAD*LS"JP$-OIOJ48*U,$AJ1.NU^_%U`76Y(6']:G<#GGWIQS;X8X
M2GAOZ.5IQG(1,8Y>UG'"AQ"\ZJR$R(::QL,56U-^"I`$WB[3?$T%/.:/6KI<
M1B&STO!YS1*A]7N]"XV]")8LV.(DVR?MZ*.BBI%E<112$:6)/HO"/.7I4B#\
M$K)XI+T%E`S('+#P.8_$J]ZK,/50B0E"&C,3:NE+&G-6H?X%2XR9KC.:O&K5
MTS1*GO@\(ZE%!:NS#E]4V5<T9PLH>I!]'RPQDU?0&1=<<T631[:H8]^_W'EQ
MRW)>*#WKG_;@M[=@%Z]R,[J(DD>/1CG71QLQW+!0I/FV31MQ;)<6:5@TG=\2
MV!_OH`?*6;&\ZFQH'M%$=!"/_L!COU.5K:+E.LZXR/6[-'_B*\8$'VG[8+FL
M8^OK:*`/+DL$K`Z1VEZ9OK7M0'<1(9&(&7>7'LW%?[*BU+0S8G#9J:G?I4`T
M62"<"!A'9"=5*6A>W9+]RG0="SL!MM"U,34<$Z-@@C$)6H%1%PQ@'Q4(B$'P
M##N`=\?(];!O$+L5QS2""1I/&SFN?V,X]F](Z3K(<"SD^;9CVIXQ188IJ7-M
M!':9V/-Q`$5*<B,RF,]FAG]?8`/[QK''MFDX!#*;[MR19/?\0B.Y+W>#?\UM
MKQ`B$3R;V:326:#!`&([-Q@$X.96!,0U?T[<J87]X`NR,&S()EO=>(P;.7>&
M[\.N%0E/P!%<E)]YX+_<#A]/H2]0RRCT$<@:%":[CB3W_#H``T`>PK=8N@.5
MQV<7+3Q&74(?X&!^5=J@1LG\V++:SV"_]_D91%V+"1K%J'E<E$[U^ZV<J@KQ
M%ASUWI2CC+KM.?WFSJLYWX_@7![!^='^<)XWSX&:<W8$IWD.U)SS(SB##T[9
M=L(^.HR[J8*[VC.5P>6GLJ2WYYPW=UW.D7_IE'4&BJY+.8JN2SF*KDLYBJY+
M.<U=5W.^'<%I/OWR#U#)^MQ7Z'#FWMT8ZU>_-Q<][?`/BOX74$L#!!0````(
M`%2"#$=\,J7?/P$``&D#```1````9&]C4')O<',O8V]R92YX;6S-DTU/PS`,
MAO\*ZKU+LXDQ15T/@#@Q"8DA$+>0>%M8\Z'$4]=_3Y9U+0,NNW&K:[^/7\=)
M*1P3UL.3MPX\*@A7>UV;P(2;9QM$QP@)8@.:AU&L,#&YLEYSC*%?$\?%EJ^!
MC(MB2C0@EQPY.0!SUQ.SJI2""0\<K>_P4O1XM_-U@DE!H`8-!@.A(TJRZL5L
MC6U,209]54;'-0^XL%*M%,C;=BC[G8J=$;P.1SG(OGWZ^Z>'E"%95[D/JJ]J
MFF;43%)=')B2M\7C<SJ;7)F`W`B(JJ`8M@[FV:GSZ^3N?OF05>."7N?%+*?C
M)9TR.F.3F_?#9&?^!L.Z&^+?.CX93-M%A35<N-NDD6FYZ3.!)`3AE4-ES46X
MA/DF3K"P^_@$@9>#.F&Z;%MH&^MEJ-+]&J+#RXDK6UO?'E,_HK-757T!4$L#
M!!0````(`%2"#$>97)PC$`8``)PG```3````>&PO=&AE;64O=&AE;64Q+GAM
M;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'
M-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D
M$4$P&:>O\,`*I4Q>M5II`,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$
M:6RA&$=D8'U>+&A`T%116F]?(+3E'S/X%<M4C66C`1-702:YB+3R^6S%_-K>
M/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z2?:C
MTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT;+^D
M00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^\4^'
MPZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ=90:
MV1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2TER0
MUL\IM5`:")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CD
MGZ>3UTU"SG"\+`GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E,L_O^0KK3CQG'U:6
ML%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&
MF&I0'`*D"3&6H8;XM,:L$>`3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F
M<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\'1,2S90+!D&&ER0F
M$JDY?DU($_XKI=K^G--`\)0O)/I*D8]ILR.G=";-Z#,:P4:O&W6':-(\>OX%
M^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:<K46@;9QJ81@6A+&
MT7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY`1OQZ&.$J:[:)Q6`3]
MGE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR-`>CFED)O816:I^JAS0^
MJ!XR"@7QN1X^Y7IX"C>6QKQ0KH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VATK<W
M(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?P.S]:#Z>\>WZV22$
MKYI9+2,6D$N!LT$DN/R+RO`JQ`GH9%LE"<M4TV4WBA*>0AMNZ5/U2I77Y:^Y
M*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL<QP3A[+##MG/)(=
MMG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9
M!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T%&UL
MK"0L1K=@N-?Q+!3@9&`MH`>#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2
MX]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,
M$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'<4Y3N!)VM@\",KF[
M.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T
M74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0!A,!S93)1/`"@F2F
M'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L`P%(1=RX^_ODVIWC-?Z+(%M
MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+PWING2TG_]M>U#VT
M%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ`$:MB
MOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\4
M8JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT')$%
M7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%`````@`5((,1S%E=,B``@``
M'@X```T```!X;"]S='EL97,N>&ULS5=M:]LP$/XK0AFCA1';&4G6U3:,0F"P
ME4+S8=^*',N.0"^>+&=.?_TDV;$=CS1-EA;GB^1'=\\]=[Z(LY^K+<6/:XP5
M*!GE>0#72F5?'2=?K3%#^5ADF.N31$B&E'Z4J9-G$J,X-TZ,.A/7G3D,$0Y#
MGQ=LP50.5J+@*H#S!@*5_YV(<0"?KC[^+H2Z_0"J=?1I-'*?KF_[^)4]N(:@
MXO@>!]";3:'S>M*QZQXF-H<]\MF)Y"]Q]ZCGI^H^HOR?`%\.!.@6XF#B-\><
M>^Y]@KE[6GHOI-8C]@RQ4S=6Z">"M_TU@140^ODSV""J[:WY2E`A@=(-K!58
MA".&*XL[1$DDB0$3Q`C=5O#$`+;G:SM&N)`V=A6A'V?LMI%D&@70K7^O#Q>U
M['8QZ1%*]]/30.AG2"DL^4(_@'J_W&8Z.2XXKD1:NR/6J41;;S+M.-A%QXV$
MC+%L(GMP!X4^Q8G2#I*D:[,JD1GI0BG!]"8F*!4<44.Y\Z@WFG:%*7TT-\RO
M9(^[3$!E8]ZQ"X%1L=OJ0M3;M@UL49TN6\7=I9V>Q0O*I`F@O5&6T>TW2E+.
M<"6V@A:B?CI&[QV@#WVT8P5K(<FSMC>-L-(`EA!LL%1DU47^2)0M<:GJ#G;*
MY)#"<U-^2TV7KUJK1K?@>Y?G[.`6NB]8A.7"7HNG2_H\/_[*[+\3]F2^;]><
M(>$"Q3$#P6"ES88K[6UZZA+=?C-496;$&JRTX59M/MR[0P^7_R?-J8>0SJ2S
M-^<T*(@*0A7A.PW(3*;W1C?=&T':&4=SQF4[WMA3A2+]L;8719/%.$$%50]D
M(Y0]#&"[_V'D>[/&:ME0!+#=_\0Q*9C]"'#:+\+P+U!+`P04````"`!4@@Q'
MF8:RA3P$```)$```#P```'AL+W=O<FMB;V]K+GAM;)6777/:.!2&_XK&-YN]
MV`7;@GQ,Z8P#2N)9,*SMI-/>.2"*IL9F+-%D^^M7,J1Y361/<@7^T*.CH\=G
MCC[)JZ>R^O%8EC_(\S8OY%4U<C9*[:YZ/;G<\&TF_RYWO-#/UF6US92^K+[W
MRO5:+/FD7.ZWO%`]K]\?]BJ>9TJ4A=R(G72.-/D>FMQ5/%O)#>=JFQ]@VTP4
MSN=/\FHM<O[`*ZG!)-OMHFS+1\YS[I`\DXJMA.*KD4/U9?G$&S>J_>YZ+W)S
M,>@/G)Z!O2QU49%EN>('6+H1\LOQ@4-6?)WM<Y7J8%_F'3FN1SUO>&"8UQX$
M?Y((-#=(ME3B)T^SQY'3=TBV5^6-R!6O)IGBMU6YWXGBNV8Y9"TJJ1*SW/K-
MK2C$5OPR<>LKN2F?[LI*_"H+E>7)LBKSO!YE'M2#]`SR]QT=HQ++QHLJ>XS-
M3HR<85\#?PHI'D4NU'\CI_Z?<[.2WLE2ZO2__B-%G9R7+299L2*L4)I"PN*P
M>3HU)@;]<KBJ)ZZNA/Y3A2OWD"H$C>?1A$4)FY#K8!I$8T:2.\;2!`@>$+SW
M$\C9(JLXAN(#R.\")6F0LAF+-&1^0^8+%@=I""`*(/I^T#A([LC-%$`#``W>
M@N;Q;1"%W_3D\X@$T80LXC`:AXM@2H)Q(Z(A@(9O0==!$M8A+&*6Z'!J(@P_
MA^'G;X<G][-9$'\U@"2\C<*;<!Q$J8YA/+^/&G%<`.CB+6@1FV2F7^O%L'_O
MPX5)#HR_A/&7MLS.9F%Z2*A!Z$RG873+=%(8*N/VT;J^947I?/S/W7PZ87'R
M!YDPO:(P/::8W3!$-02V&/PEB&.=C<;TJ*QK<;:>_B^]*\RL8;;0MIQNB8NV
MNA9=8S;5<NF``Y/05,>0&"GF42,25-6UN)K<7R=Z(W1&"7M@)\M`/5V+GYU>
MN$-$H:"NQ5"[&>1,%[6<RS\1A;*Z%EM?-L0Z&`5U+8:V[<P1ABATU;7(VOGU
M>GVL<*BK9]'5^OV2LPE7F<@)?D`>ZNI9=.W<,\]#5*/P6BQNV[-#6!)1*+-G
MD=F.LBX0C?:LU;>C1I`S1*'?GL7O3I2'?GOHMV?QNQMUCBCTV[/XW8VZ0!3:
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ME`Y,PV*N9_J(.W+,.50?.?=Y/M;WYL6TS.K3VH'\<H#]_#]02P,$%`````@`
M5((,1U5%)+%'`@``C0<``!@```!X;"]W;W)K<VAE971S+W-H965T,2YX;6R-
ME=V.FS`0A5\%\0"+,022B"`E657M1:757K373N($M#9F;2=LW[[^`6(LVN0&
ML#EGOADSV$7'^(>H,);!%R6-V(25E.TZBL2QPA2)%];B1KTY,TZ15$-^B43+
M,3H9$R41!""+**J;L"S,W!LO"W:5I&[P&P_$E5+$_^PP8=TFC,-AXKV^5%)/
M1&41C;Y337$C:M8$')\WX39>[^-$2XSB5XT[X3P'.OD#8Q]Z\..T"8'.`1-\
ME#H$4K<;WF-"="1%_NR#WIG:Z#X/T;^9<E7Z!R3PGI'?]4E6*EL0!B=\1E<B
MWUGW'?<U+'3`(R/"7(/C54A&!TL84/1E[W5C[IU]DR:];=X`>P,<#3#_KR'I
M#<EHB%-3J<W,U/6*)"H+SKI`M$A_[7BMY%P'49$#8:)QNURJ,J%F;R4HHIL.
MTRN@4>Q<13PJ(A5[%@##J1TZ=C@'V+N*Y#$@&0!VN$T<>_K8G@[VU-I3Q[Z8
MYF<5.U>1/08L/,#"L>=3P,("K**Q*YQF(`?P,2;S,)F#6<[6X2I6CP&Y!\C=
M/@"SA(GDB5Y9>HBEZX=S:[5?.FN5YRN8)D^TS,KCK%Q.,EO*1/)$6\7`8^@M
MY!YAOK.FFB=Z*XY]RN3OS.<I$\WR"0KT*>XO&J]FF[C7V"\#@5/QOSF)SW'_
M9>CU6-9S)AJ_R2)G]Z.87\RI(((CNS;2;G[C['CR;*'9/>_RLFC1!?]$_%(W
M(C@PJ?9@LV&>&9-8)0%>5-&5.AO'`<%GJ1]SO1KVM+`#R=KA\!M/X/(O4$L#
M!!0````(`%2"#$=E\,L69@,``.L-```8````>&PO=V]R:W-H965T<R]S:&5E
M=#(N>&ULE9=-<YLP$(;_"N-[@G8E(91Q/%/3Z;2'SG1R:,\DEF.F@%P@<?OO
M*S[L+!JEICD$A-_5OA*K1V)]LLW/]F!,%_VNRKJ]7QVZ[G@7Q^W3P51Y>VN/
MIG:_[&U3Y9UK-L]Q>VQ,OAN"JC)&QI*XRHMZM5D/S[XUF[5]Z<JB-M^:J'VI
MJKSYLS6E/=VO8'5^\%`\'[K^0;Q9QY>X75&9NBUL'35F?[_Z`'<9BEXR*+X7
MYM22^Z@W_VCMS[[Q97>_8KT'4YJGKN\B=Y=7DYFR['MRF7]-G;[E[`/I_;GW
M3\-PG?W'O#69+7\4N^[@W+)5M#/[_*7L'NSILYG&(/L.GVS9#O^CIY>VL]4Y
M9!55^>_Q6M3#]33^DK(I+!R`4P!>`D#\,X!/`=P+B$=GP[@^YEV^63?V%+7'
MO'_;<.?D3=^)ZSEJA]Z:<;K<R%KW]'6#N(Y?^WXF"0Z2[4P24F0S!;](8I<_
M:`+/)L;F!Z3QXGH\/\>+,9[3>#FWJ,9!C))ZD(!.9*JU"`DS*D0E%(KTNB'A
M&1+44#+/(T=#@N01R)0.J3*JD@I`7O<B/2^2>E%!+W(V.8H!4SQHAPHQ98(G
M"]YVXAE*J*$T:"BAAACG$'3SONI=+\KSHJB7\"M0-(O@0BXHT-1+DY(TG`6'
MG-)ZD$FP:#(JDJ#PNA/M.='427!:MWI>#2!=103=4"'JA'-DUPT!\Q9_S]HW
M2PN&!."-"2A_>+!RMY-F&A5/M1#A$I\+6<K=\!=X0M\391H784](4FF%6F/8
M$M5!DB9\`0;`AR102G(9=C3#)/,WA+.?&2,E+``D^(0$BD@>1B10^J%CC9!!
M?F4S(:`42BZI1.E7(D4E7_+6?;0!91L/LBT#BJW4_2W(XV,+*+=XD%M;H.!2
M*GW'#56)9$EA^7`#2C<1IAM0<G$-*)(P![.YDFNW*!8`%WS.`06="(,.*,!N
M$)32F@471C:7@M)N[P-]W1<RSQ=2VHG@^MI.FJF<%9=NC85A-5/>@!!:,K$`
MH>@C%"E"?3).1RB$I1O#3+EX9T"?H4@9*A94`7)O12/_S[T%?4XAY90(GBTS
MG.$G0<83\'/%Y%A^S)_-U[QY+NHV>K2=.^$/Q_&]M9UQ_;%;-XT']^5U:91F
MW_6WJI_?\5MD;'3V>/ZTNGS?;?X"4$L#!!0````(`%2"#$=>`\XU;`(``/P(
M```8````>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULG9;;CILP$(9?!?$``0/F
ML")(#5757E1:[45[[21.0`N88B=LW[ZV(=F):[II<A&P^6?^SP?&Y",;7GE%
MJ7#>VJ;C:[<2HG_R/+ZK:$OXBO6TDT\.;&B)D,WAZ/%^H&2O@]K&"WP_]EI2
M=VZ1Z[[GH<C9231U1Y\'AY_:E@R_-[1AX]I%[J7CI3Y60G5X1>Y=X_9U2SM>
ML\X9Z&'M?D)/)8J41"M^U'3DX-Y1\%O&7E7CVW[M^HJ!-G0G5`HB+V=:TJ91
MF:3SKSGINZ<*A/>7[%_T<"7^EG!:LN9GO1>5I/5=9T\/Y-2(%S9^I?,8L$JX
M8PW7_\[NQ`5K+R&NTY*WZ5IW^CI.3Y)@#K,'!'-`<`V89F(Q()P#0B/`F\CT
MN#X308I\8*/#>Z)6&SU)^:"2R,P.U]F&:;KDR+CL/1=1G'MGE6>6!%JR@9+`
MIBAO%.%5XDE_*T1P@8@FB`!")+<6Z00Q23HM\5>^CVRJ<EFUR!(:+"%D26]=
M\,02`A?LZY]-5T)=FJ8)!KI%GLC@B2!/9O6)'O'!A@\&/M@^'OR(3VSXQ-#'
MNHJ;^*ZU7E8MLB0&2P)9`NM:)\`E^-=B)W]OBCMF)S6(4D@46HE28)0D:>H'
MUEU:0ET4XS!)/\;)#)P,XD16G.Q.G.P!'.0;/*HNO[\-T1T9D)D!UBJ,K3MK
MUOS7UD)F34.PJ.'8.B<(UBL4RSF)00U>]C)K%H)%"R=V+UB-4!AF61S?LP1F
M/4*P(&'[6J/H8R\/G%,].=+O9#C6'7>V3,@C3Y]/!\8$E?G\E<Q;R4^1:Z.A
M!Z%N$V4X'<Y30[#^\JUQ_>`I_@!02P,$%`````@`5((,1[0.KN[>`P``2A``
M`!@```!X;"]W;W)K<VAE971S+W-H965T-"YX;6R-F-N.HS@0AE\%Y7Z"RV=:
MZ4@38+1[L=)H+G:NZ8YST'#(`.G,OOUR2F);U0DW#3A?E>LOP#_NU:6J?S4'
M8]K@3Y&7S>OBT+:GES!LW@^FR)IE=3)E]\NNJHNL[2[K?=B<:I-MAZ`B#RDA
M,BRR8[E8KX:Q[_5Z59W;_%B:[W70G(LBJ__;F+RZO"Y@<1WX<=P?VGX@7*_"
M6]SV6)BR.59E4)O=Z^(KO*2@>V0@_CV:2V.=!WWQ;U7UJ[_X>_NZ('T-)C?O
M;9\BZPX?)C9YWF?J9OX]);W/V0?:Y]?LWP:Y7?EO66/B*O]YW+:'KEJR"+9F
MEYWS]D=U^<M,&D2?\+W*F^%O\'YNVJJXABR"(OLS'H_E<+R,OZAK&!Y`IP!Z
M"X#'`6P*8/<`_C"`3P%\[@QB"A#>#.&H?>A<DK79>E57EZ`Y9?WS!"\=7O=)
MNLQ!,V2KQQO2]:[I1C_6(EJ%'WV>":$#LK$123`DL1&X$6$W/UH$7;@S4"N<
M8A/$-B$!K>%IDO23))^6R:YELK%7S(ZGS^/Y-9Z/\=R.9VZ):NS$B)0#PE6D
M%$;%-B49"`Q*;$A%0J!4:E,`'.1S6<*3)6Q9W)UEC-@(:Q9!@&N,BFV**J8I
M1B7"J9ARRC`LM3'9Z>+/A4E/F+2%"528M$LF!!21J#2;8X)R!J@V!V.$@T![
MD-J<B!31ZKDZY:E3MCJTZHURU$61QLN.;8YI"12]OXF#\4@"(Z@ZFY.*2CE#
MG?;4:5N=0M5I:YHOC^0YX`-]+O=`H`/.51AYJU%D*]3/XX%X+>IM])XA0GLT
M,=,C``1OD$-]X1%'5X'$P3@CZ"N5>LD4BV9H`U^;[4@*O0O)Q$PK)(EF.`)0
M?Q[;4Q3:G<W$/.LAG==#ZBQ_+$+?W-3+-J^)S!=G&YY"5Z+-Q-S?(J7PASYV
M218!P5,F'LAU5S[:C-0EI5*<S/`O\'T9;&-6J)ULP#%*I:G&%WJ7ZRIGZ.*3
M.!RC2N`O8.IP-.)*BQD*?8L&VZ,5[M%@.R8#CCM>XF"24<UFU.,[*]C6JM`O
MDPU(Y\EB1'$-&!F[I&":DP@#$Q=D6@GAW\;IL\@E(T5AUO+@>RS8)JN\J:))
MIW)>U25H#(M=##[!$A=32TDQ+'4QNH09GT?@>RS8)NM_JEZ?*MOKA.C:B+[T
ML<-Q(3G!/=;-1[3DG[B(FX]%Q+]_H;51*DR]'[:H3?!>G<MV_/:_C=ZVP5]I
MO]'RQC?P$@,RGO3;YF%C=D^_7IVRO?DGJ_?'L@G>JK;;W@U[L5U5M:8KG"P[
M`8=N8W^[R,VN[4]5KVS<ZHX7;76Z[MQO_SY8_P]02P,$%`````@`5((,1STW
M_BPZ!```21,``!@```!X;"]W;W)K<VAE971S+W-H965T-2YX;6R=F,F.VS@0
MAE]%\#TQ6=P;;@-M#X+,88`@AYFSVJ871(M'DMN9MQ\MMKM8H-%,<H@M=2U_
MD:I/92XN=?.C/7C?93_+HFJ?9X>N.SW-Y^WFX,N\_5R??-7_95<W9=[UE\U^
MWIX:GV]'I[*8`V-Z7N;':K9<C/>^-<M%?>Z*8^6_-5E[+LN\^6_EB_KR/..S
MVXWOQ_VA&V[,EXOYW6][+'W5'NLJ:_SN>?;"G]:2#2:CQ=]'?VG1]VP0_UK7
M/X:+/[?/,S9H\(7?=$.(O/]X\VM?%$.D/O._UZ#O.0='_/T6_<M8;B__-6_]
MNB[^.6Z[0Z^6S;*MW^7GHOM>7[[Z:PUJ"+BIBW;\/]N<VZXN;RZSK,Q_3I_'
M:OR\3'^Q[.H6=X"K`]P=[GGB#N+J(-X=Y%CII&RLZX^\RY>+IKYD[2D?=IL_
M]>;-$*2/G+5CM&9:KKZRMK_[MC1V,7\;XEQ-8#1981-^MYCWP:,98!:Z`W*'
M6((UMM`)&<0MPW3Y(G`-[F-_>?.7D[_$_D2BF8J83*K1Y).05AHA8X;KP%`;
M(YG^6)`B!2DDR+*/_34I2&-_'NI44T$:Z=1(([)98QM0J."'0@P18K`0B`HQ
M*`G7EH$T43'8SG''$Y;5$C46JQ'1+!:KL0`?)W%D[QQ.DK!DG!&5`WO>&R:Z
M,ZNKS56G8B*^@8'9)\E92G=Q3@5A`("-9^(H4Z]').0!F@=S0$3W9W6UF?((
MIJQ\4'E@!U*E[(2@@C!8:+_?!`E<N&/&/1"$[3CC"4\6IYSB&%16Q?4$`.+:
M/)`3F!F3LE^*R@DP]>!!53B/=<(B0`>"`L-^7Z5.(#G7I/MX@#Z3$($BBP?,
M>O"TFV"1N4Z`$:<TX@&.'JR*_8U$E$@<(\DEO$Z`(@DPDES\A0(!:X`[*8Q*
MR$5I`Y@V+O[.`$R;?BX=_R7DHL0!3!P7?R-`0!*CTC)1E`!&B8NC!`)$&,N4
MAFB3KP/+9$T4)X!QXN(X`<P)KAWGY@%Q`\M^_YD6*=M/H0(8*G&6K@"S`HPT
M(.-]&AA*V;_/$_H'Z#0%F"DN.IVL`,]*W&EE77R7UX$E])OG4F9J0WH:,*6<
M38A`\0,8/RZ*GQ5@_``7*F5^`$<S8?YP]*@&J1P>2+72+.&5)"BH!`M2Q4DE
M@N$I9;X6%%(B^-D4'U4$AI0`HS19Y.LOAL`.G#0VH6\$19G`*#/1WR8K@5&F
M!=B4):8D$R)8XH0Y1E#P"!F$2%%!,2%4$")ANA-T5!#Z%UM(T%%!F$"$BB\Z
MGA6LM2F):*\*&R1*@)B@0X!POUBMI+TE64*U,N@MK5P_Q]'-F:,3BM(W^_'D
MILTV];GJIN.#^]W[Z=`+#"<<Y/Z*/ZVG,Y[W,,O%*=_[O_)F?ZS:[+7NNKH<
M#SMV==WY7B+[W#\Z!Y]O[Q>%WW7#5S,T[G32,UUT]>EV<'4_/5O^#U!+`P04
M````"`!4@@Q'*ONEDY\!``"Q`P``&````'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;(53VT[C,!#]%<L?@-.T7+9*(U$0@H>5$`^[SVXR22QL3["=AOW[]24)
M+4+P$L],SCESQI=B1/-J.P!'WI74=D<[Y_HM8[;J0'%[@3UH_Z=!H[CSJ6F9
M[0WP.I*49'F673'%A:9E$6O/IBQP<%)H>#;$#DIQ\V\/$L<=7=&Y\"+:SH4"
M*PNV\&JA0%N!FAAH=O1VM=UO`B("_@@8[4E,@O<#XFM(GNH=S8(%D%"YH,#]
M<H0[D#((^<9OD^9'RT`\C6?UASBM=W_@%NY0_A6UZ[S9C)(:&CY(]X+C(TPC
M7`;!"J6-7U(-UJ&:*90H_IY6H>,ZIC\WV43[FI!/A/P3@:5&T>8]=[PL#([$
M]CR<W6KKX2:(>&5BHYI)TWNCUE>/Y2J[+M@Q"$V81-F?818$\^I?MLCI.3T_
MH><_T]<S?9T<KL\<WOPLL)D%-DE@\]V(";,_Q_SZU(2=[*D"T\:K8TF%@W9I
M2Y?J<CMO\W@F'_"RZ'D+O[EIA;;D@,Z?;#R&!M&!-Y%=7%+2^?>S)!(:%\)K
M'YMTI5+BL)\?R/)*R_]02P,$%`````@`5((,1VZ='1VA`0``L0,``!@```!X
M;"]W;W)K<VAE971S+W-H965T-RYX;6R-4\MNVS`0_!6"'Q#JX;2%(0N(4P3M
MH4"00WNFI95$A.0J)&6E?U\^),4.@K87<7<U,SO+1S6C>;8#@".O2FI[H(-S
MXYXQVPR@N+W!$;3_TZ%1W/G4],R.!G@;24JR(LL^,<6%IG45:X^FKG!R4FAX
M-,1.2G'S^P@2YP/-Z5IX$OW@0H'5%=MXK5"@K4!-#'0'>I?OC[N`B("?`F9[
M$9/@_83X')+O[8%FP0)(:%Q0X'XYPSU(&81\XY=%\ZUE(%[&J_I#G-:[/W$+
M]RA_B=8-WFQ&20L=GZ1[POD;+"/<!L$&I8U?TDS6H5HIE"C^FE:AXSJG/V6Y
MT#XF%`NAV`A?LF@\-8HVOW+'Z\K@3.S(P]GE>P\W0<0K$QO53)K>&[6^>J[S
M/*O8.0@MF$0Y7F$V!//J'[8HZ#6]N*`7_Z:7*[U,#LLKA__1?[<*[)+`[F\C
M)LSQ&O/>);O84P6FCU?'D@8G[=*6;M7M=MX5\4S>X'4U\AY^<-,+;<D)G3_9
M>`P=H@-O(KNYI63P[V=+)'0NA)]];-*52HG#<7T@VRNM_P!02P,$%`````@`
M5((,1Z+VT;*A`0``L0,``!@```!X;"]W;W)K<VAE971S+W-H965T."YX;6R%
M4]MNG#`0_17+'Q!SV[9:L4C91%7S$"G*0_OLA0&LV`RUS9+^?7T!LAM%R0N>
M&<XY<\:7<D;]8GH`2UZ5',R!]M:.>\9,W8/BY@9'&-R?%K7BUJ6Z8V;4P)M`
M4I)E2?*-*2X&6I6A]J2K$B<KQ0!/FIA)*:[_'4'B?*`I70O/HNNM+["J9!NO
M$0H&(W`@&MH#O4WWQ\(C`N"W@-E<Q,1[/R&^^.2A.=#$6P`)M?4*W"UGN`,I
MO9!K_'?1?&OIB9?QJOXS3.O<G[B!.Y1_1&-[9S:AI(&63](^X_P+EA%V7K!&
M:<*7U).QJ%8*)8J_QE4,89WCGR)?:!\3LH60;80?23`>&P6;]]SRJM0X$S-R
M?W;IWL&U%W'*Q`0U':=W1HVKGJLTS4MV]D(+)E*.5Y@-P9SZARTR>DW/+NC9
MU_1\I>?187[EL/A:H%@%BBA0?#9BQ!RO,;MW3=C%GBK07;@ZAM0X#39NZ5;=
M;N=M%L[D#5Z5(^_@D>M.#(:<T+J3#<?0(EIP)I*;'26]>S];(J&U/OSN8AVO
M5$PLCNL#V5YI]1]02P,$%`````@`5((,1^ZU+^>B`0``L0,``!@```!X;"]W
M;W)K<VAE971S+W-H965T.2YX;6R%4]MNG#`0_17+'Q`#2RY:L4C95%7[4"G*
M0_OLA0&LV!YJFR7]^_H"9+>*FA<\,YQSYHPOU8SFU0X`CKPIJ>V!#LZ->\9L
M,X#B]@9'T/Y/AT9QYU/3,SL:X&TD*<F*++MCB@M-ZRK6GDU=X>2DT/!LB)V4
MXN;/$23.!YK3M?`B^L&%`JLKMO%:H4!;@9H8Z`[T,=\?RX"(@)\"9GL1D^#]
MA/@:DN_M@6;!`DAH7%#@?CG#$T@9A'SCWXOF>\M`O(Q7]:]Q6N_^Q"T\H?PE
M6C=XLQDE+71\DNX%YV^PC'`;!!N4-GY),UF':J50HOA;6H6.ZYS^E/E"^YA0
M+(1B(SQDT7AJ%&U^X8[7E<&9V)&'L\OW'FZ"B%<F-JJ9-+TW:GWU7.?Y7<7.
M06C!),KQ"K,AF%?_L$5!K^G%!;WXG+Y;Z;OD<'?E\/YS@7(5*)-`^;\1$^9X
MC7GXIPF[V%,%IH]7QY(&)^W2EF[5[78^%O%,WN%U-?(>?G#3"VW)"9T_V7@,
M':(#;R*[N:5D\.]G2R1T+H3W/C;I2J7$X;@^D.V5UG\!4$L#!!0````(`%2"
M#$<K=I^'H@$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;(53
MVVZ<,!#]%<L?$(-WMY<5BY1-5;4/E:(\M,]>&,"*S5#;+.G?UQ<@;!4U+WAF
M..?,&5^*"<VS[0`<>=&JMR?:.3<<&;-5!UK8.QR@]W\:-%HXGYJ6V<&`J"-)
M*\:S[`/30O:T+&+MT90%CD[)'AX-L:/6POPY@\+I1'.Z%)YDV[E08&7!5EXM
M-?168D\,-"=ZGQ_/^X"(@)\2)KN)2?!^07P.R??Z1+-@`114+B@(OUSA`90*
M0K[Q[UGSM64@;N-%_6N<UKN_"`L/J'[)VG7>;$9)#8T8E7O"Z1O,(QR"8(7*
MQB^I1NM0+Q1*M'A)J^SC.J4_!S[3WB;PF<!7PJ<L&D^-HLTOPHFR,#@1.XAP
M=OG1PTT0\<K$1C63IO=&K:]>RSS_7+!K$)HQB7*^P:P(YM7?;,'I+9UOZ/Q]
M^FZA[Y+#W;8[S]X7V"\"^R2P_]^("7.^P?!_AV2;/=5@VGAU+*EP[%W:TK6Z
MWL[[>(CL%5X6@VCAAS"M["VYH/,G&X^A073@361W!THZ_W[61$'C0OC1QR9=
MJ90X')8'LK[2\B]02P,$%`````@`5((,1]=#V/>A`0``L0,``!D```!X;"]W
M;W)K<VAE971S+W-H965T,3$N>&ULA5/;;J,P$/T5RQ]0$T(OB@A2TVJU^[!2
MU8?=9P<&L&I[J&U"^_?U!6BRJK8O>&8XY\P97\H)S8OM`1QY4U+;/>V=&W:,
MV;H'Q>T5#J#]GQ:-XLZGIF-V,,";2%*2Y5EVPQ07FE9EK#V9JL312:'AR1`[
M*L7-^P$D3GNZH4OA672]"P56E6SE-4*!M@(U,=#NZ?UF=R@"(@+^")CL64R"
M]R/B2TA^-7N:!0L@H79!@?OE!`\@91#RC5]GS<^6@7@>+^H_XK3>_9%;>$#Y
M5S2N]V8S2AIH^2C=,TX_81[A.@C6*&W\DGJT#M5"H43QM[0*'=<I_;DI9MK7
MA'PFY"OA+HO&4Z-H\Y$[7I4&)V(''LYNL_-P$T2\,K%1S:3IO5'KJZ=JD^<E
M.P6A&9,HAPO,BF!>_<L6.;VDYV?T_'OZ=J%OD\/MA</M]P+%(E`D@>)_(R;,
MX1)3_-.$G>VI`M/%JV-)C:-V:4O7ZGH[[_-X)I_PJAQX![^YZ82VY(C.GVP\
MAA;1@3>175U3TOOWLR826A?"6Q^;=*52XG!8'LCZ2JL/4$L#!!0````(`%2"
M#$<YMG3^H@$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;(53
MRV[;,!#\%8(?$,JR'!>&+"!.4;2'`D$.[9F65A(1DJN2E)7^??F0%#L(FHNX
MNYJ9G>6CG-"\V![`D5<EM3W2WKGAP)BM>U#<WN$`VO]IT2CN?&HZ9@<#O(DD
M)5F>9?=,<:%I5<;:DZE*')T4&IX,L:-2W/P]@<3I2#=T*3R+KG>AP*J2K;Q&
M*-!6H"8&VB-]V!Q.14!$P"\!D[V*2?!^1GP)R8_F2+-@`234+BAPOUS@$:0,
M0K[QGUGSK64@7L>+^K<XK7=_YA8>4?X6C>N]V8R2!EH^2O>,TW>81]@%P1JE
MC5]2C]:A6BB4*/Z:5J'C.J4_Q7ZF?4S(9T*^$KYDT7AJ%&U^Y8Y7I<&)V(&'
ML]L</-P$$:],;%0S:7IOU/KJI=KDNY)=@M",2933#69%,*_^88N<WM+S*WK^
M.7V[T+?)X?;&X?WG`L4B4"2!XG\C)LSI%K-_UX1=[:D"T\6K8TF-HW9I2]?J
M>CL?\G@F;_"J''@'/[GIA+;DC,Z?;#R&%M&!-Y'=[2CI_?M9$PFM"^'>QR9=
MJ90X')8'LK[2ZA]02P,$%`````@`5((,1_FRA_6C`0``L0,``!D```!X;"]W
M;W)K<VAE971S+W-H965T,3,N>&ULA5/;;IPP$/T5RQ\0LRQITA6+E$U5)0^5
MHCRDSUX8P(KMH;99TK^/+T!VJZAYP3/#.6?.^%).:%YM#^#(FY+:[FGOW+!C
MS-8]*&ZO<`#M_[1H%'<^-1VS@P'>1)*2+,^R;TQQH6E5QMJ3J4H<G10:G@RQ
MHU+<_#V`Q&E/-W0I/(NN=Z'`JI*MO$8HT%:@)@;:/;W;[`Y%0$3`BX#)GL4D
M>#\BOH;DL=G3+%@`";4+"MPO)[@'*8.0;_QGUOQH&8CG\:+^,T[KW1^YA7N4
MOT7C>F\VHZ2!EH_2/>/T`/,(UT&P1FGCE]2C=:@6"B6*OZ55Z+A.Z<]-,=,^
M)^0S(5\)MUDTGAI%FS^XXU5I<")VX.'L-CL/-T'$*Q,;U4R:WANUOGJJ-OEM
MR4Y!:,8DRN$"LR*85_^T14XOZ?D9/?^:OEWHV^1P>^'P^]<"Q2)0)('B?R,F
MS.$"L\W^:<+.]E2!Z>+5L:3&4;NTI6MUO9UW>3R3#WA5#KR#7]QT0EMR1.=/
M-AY#B^C`F\BNKBGI_?M9$PFM"^&-CTVZ4BEQ."P/9'VEU3M02P,$%`````@`
M5((,1^_OQONB`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,30N>&UL
MC5/+;MLP$/P5@A\0ZN&T@2$+B!,4[:%`D$-[IJ651(3D*B1EI7]?/B3%+H*V
M%W%W-3,[RT<UHWFQ`X`C;TIJ>Z"#<^.>,=L,H+B]P1&T_].A4=SYU/3,C@9X
M&TE*LB++/C'%A:9U%6M/IJYP<E)H>#+$3DIQ\^L($N<#S>E:>!;]X$*!U17;
M>*U0H*U`30QT!WJ?[X^[@(B`'P)F>Q&3X/V$^!*2;^V!9L$"2&A<4.!^.<,#
M2!F$?./71?.]92!>QJOZESBM=W_B%AY0_A2M&[S9C)(6.CY)]XSS5UA&N`V"
M#4H;OZ29K$.U4BA1_"VM0L=U3G_*NX7V,:%8",5&N,NB\=0HVGSDCM>5P9G8
MD8>SR_<>;H*(5R8VJIDTO3=J??5<YV5>L7,06C")<KS";`CFU3]L4=!K>G%!
M+_Y-+U=ZF1R65P[_0V"W"NR2P.YO(R;,\1I3_M&$7>RI`M/'JV-)@Y-V:4NW
MZG8[[XMX)N_PNAIY#]^YZ86VY(3.GVP\A@[1@3>1W=Q2,OCWLR42.A?"SSXV
MZ4JEQ.&X/I#ME=:_`5!+`P04````"`!4@@Q'(,@<0Z(!``"Q`P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6R%4\MNVS`0_!6"'Q#*LIRVABP@3A&T
MAP)!#NV9EE82$9*KD)25_GWYD!0[")J+N+N:F9WEHYS0/-L>P)%7);4]T-ZY
M8<^8K7M0W-[@`-K_:=$H[GQJ.F8'`[R))"59GF6W3'&A:57&VJ.I2AR=%!H>
M#;&C4MS\/8+$Z4`W="D\B:YWH<"JDJV\1BC05J`F!MH#O=OLCT5`1,!O`9.]
MB$GP?D)\#LG/YD"S8`$DU"XH<+^<X1ZD#$*^\<NL^=8R$"_C1?TA3NO=G[B%
M>Y1_1.-Z;S:CI(&6C](]X?0#YA%V0;!&:>.7U*-UJ!8*)8J_IE7HN$[I3_YM
MIGU,R&="OA*^9M%X:A1M?N>.5Z7!B=B!A[/;[#W<!!&O3&Q4,VEZ;]3ZZKG:
M;(N2G8/0C$F4XQ5F13"O_F&+G%[3\PMZ_CE]N]"WR>'VRN'N<X%B$2B20/&_
M$1/F>(VY?=>$7>RI`M/%JV-)C:-V:4O7ZGH[[_)X)F_PJAQX![^XZ82VY(3.
MGVP\AA;1@3>1W>PHZ?W[61,)K0OA%Q^;=*52XG!8'LCZ2JM_4$L#!!0````(
M`%2"#$>B/P'OP0$``'L$```9````>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM
M;(U46V^;,!3^*Q8_H.:6M(L(4M-IVAXF57W8GATX@%5?F&U"]^_G"U"((F4O
ML7WX;H<<4XQ2O>L.P*`/SH0^1ITQ_0%C777`B7Z0/0C[I)&*$V./JL6Z5T!J
M3^(,IW&\QYQ0$96%K[VJLI"#853`JT)ZX)RHOR=@<CQ&2307WFC;&5?`98$7
M7DTY"$VE0`J:8_2<'$Y[A_"`7Q1&O=HCE_TLY;L[_*B/4>PB`(/*.`5BEPN\
M`&-.R!K_F30_+1UQO9_5O_EN;?HST?`BV6]:F\Z&C2-40T,&9M[D^!VF%G9.
ML)),^U]4#=I(/E,BQ,E'6*GPZQB>[/*)=IN03H1T(3S%/G@P\C&_$D/*0LD1
MZ9ZX_RXY6+AR(E89::^F0O<VJ+;52YEDCP6^.*$)$RBG#69!8*M^TR*-MO1T
M14_OT[.9GH6$V=H]R>\+Y+-`'@3R38M/VQ8#YK3%?+EOLKLRV:T%\OBFR1;S
M'V]R?V6RWPBD-TVVF.S*!*^F@X-J_270J)*#,&$XENIRSYY3/UV?\++H20L_
MB6JIT.@LC9U1/U"-E`9LB/C!MMK9+\%R8-`8MWVT>Q4N1S@8V<]7??G>E/\`
M4$L#!!0````(`%2"#$?7G[]^I`$``+$#```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;(53VVZ<,!#]%<L?$`/+)M6*1<JFJMJ'2E$>VF<O#&#%9JAM
MEO3OZPL0J"+E!<\,YYPYXTLQH7XU'8`E;TKVYDP[:X<38Z;J0'%SAP/T[D^#
M6G'K4MTR,VC@=2`IR;(DN6>*BYZ61:@]Z[+`T4K1P[,F9E2*Z[\7D#B=:4J7
MPHMH.^L+K"S8RJN%@MX([(F&YDP?T],E]X@`^"5@,IN8>.]7Q%>?_*C/-/$6
M0$)EO0)WRPV>0$HOY!K_F37?6WKB-E[4OX5IG?LK-_"$\K>H;>?,)I34T/!1
MVA><OL,\PM$+5BA-^))J-!;50J%$\;>XBCZL4_R3IS/M8T(V$[*5\"4)QF.C
M8/,KM[PL-$[$#-R?77IR<.U%G#(Q04W'Z9U1XZJW,LWS@MV\T(R)E,L.LR*8
M4_^P14;W]&Q#SSZG'Q;Z(3H\;+NG#Y\+Y(M`'@7RW8C'_8@1<]EC[O]KPC9[
MJD"WX>H84N'8V[BE:W6]G8]9.)-W>%D,O(6?7+>B-^2*UIUL.(8&T8(SD=P=
M*>G<^UD3"8WUX8.+=;Q2,;$X+`]D?:7E/U!+`P04````"`!4@@Q'H*CT]*4!
M``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R%4]MNG#`0_17+
M'Q"S+,FF*Q8IFRIJ'RI%>6B?O3"`%9LAMEG2OZ\O0*"*E!<\,YQSYHPO^8CZ
MU;0`EKPKV9D3;:WMCXR9L@7%S0WVT+D_-6K%K4MUPTRO@5>!I"1+D^2.*2XZ
M6N2A]JR+'`<K10?/FIA!*:[_GD'B>*([.A=>1--:7V!%SA9>)11T1F!'--0G
M^K`[GC./"(#?`D:SBHGW?D%\]<G/ZD03;P$DE-8K<+=<X1&D]$*N\=ND^='2
M$]?QK/X4IG7N+]S`(\H_HK*M,YM04D'-!VE?</P!TPBW7K!$:<*7E(.QJ&8*
M)8J_QU5T81WCG^PPT3XGI!,A70CW23`>&P6;W[GE1:YQ)*;G_NQV1P?77L0I
M$Q/4=)S>&36N>BUVV2%G5R\T82+EO,$L".;4/VV1TBT]7='3K^G[F;Z/#O?K
M[NG=UP+9+)!%@6PSXOUVQ(@Y;S'?_FO"5GNJ0#?AZAA2XM#9N*5+=;F=#VDX
MDP]XD?>\@5]<-Z(SY(+6G6PXAAK1@C.1W-Q2TKKWLR02:NO#@XMUO%(QL=C/
M#V1YI<4_4$L#!!0````(`%2"#$>EKFF<V`$``$4%```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$Y+GAM;(U4RVZC,!3]%8L/J($$DD8$J>FHZBQ&JKJ863O)
MY:':F+%-Z/S]^`$T1DAT@^W+>5W!==9S\2$K`(4^&6WD,:B4:@\8RTL%C,@'
MWD*CWQ1<,*+T4918M@+(U9(8Q7$8IIB1N@GRS-;>1)[Q3M&Z@3>!9,<8$?].
M0'E_#*)@++S79:5,`><9GGC7FD$C:]X@`<4Q>(H.I[U!6,#O&GIYMT<F^YGS
M#W/X>3T&H8D`%"[**!"]W.`9*#5"VOCOH/EE:8CW^U']Q7:KTY^)A&=._]17
M5>FP88"N4)".JG?>O\+00F($+YQ*^T273BK.1DJ`&/ET:]W8M7=O]N%`6R;$
M`R&>$;`SLC%_$$7R3/`>R9:8;Q<=-%P8$:V,I%43KGL=5.KJ+8^2,,,W(S1@
M'.7D828$UNJ+%G'@T^,[>KQ.WXSTC4NXN7>/']<%MJ/`U@ELO18COT6'.?F8
M;Z1,9B:))[!9-/$QVW63=&:2>@+)HHF/2==-=C.3G2>P6S3Q,?MUD_W,9.\)
M/"Z:>)@TG)G@N_^<@2CM.$MTX5VCW&\^5:<;XRFV<_(%S[.6E/"+B+)N)#IS
MI:?-CD;!N0(=(GS0'ZW2=]ITH%`HL]WIO7!C[@Z*M^.E-=V<^7]02P,$%```
M``@`5((,1["UOM@S`@``+`<``!D```!X;"]W;W)K<VAE971S+W-H965T,C`N
M>&ULE97;CMHP$(9?Q<H#K.,<`85(0%6U%Y56>]%>&S`D6L=.;4.V;U\?DFP<
M185R06SGG_^;L6%<=%R\RXH0!3X:RN0VJ)1J-Q#*4T4:+%]X2YA^<^&BP4I/
MQ17*5A!\MD$-A5$89K#!-0O*PJZ]BK+@-T5K1EX%D+>FP>+/GE#>;0,4#`MO
M];529@&6!1SCSG5#F*PY`X)<ML$.;0XH,A*K^%F33D[&P"1_Y/S=3+Z?MT%H
M<B"4G)2QP/IQ)P="J7'2Y-^]Z2?3!$['@_M76ZY._X@E.7#ZJSZK2F<;!N!,
M+OA&U1OOOI&^AM08GCB5]AN<;E+Q9@@)0(,_W+-F]MFY-UG6ART'1'U`-`:,
MG.6`N`^(9P'096;K^H(5+@O!.R!;;$X;;;1<&!/M#*1U$VZ[=&52K]Y+E*$"
MWHU1KXFL9N]KHB7-P=.,"J@S6$PC"GQ$Y"'B1<14$SU&Q`/"37>QAT@>&R2#
M0>(,$L\@]7/,78Y.PUR.:)W$>?H8E,Y`J0?*'AMDLU*S_RTUGV60>P:Y7VKJ
MCBR?E)J$]O,8M)J!5AYHM;2G^]4$],1NKF>(M8=8+R+6TV,+GRT&A3.4:1N?
MK#Q<W+=>Q/J$GF6A.0O]Z^<XL-"4]71=T9SE_3USM+B'O:AGY<D2#$Z:4T/$
MU39M"4[\QI3K3>/J>#'L[+T`/^5ET>(K^8'%M682'+G2+=+VLPOGBNA4PA==
M?J6OKG%"R46986[VQ35S-U&\'>ZF\8(L_P)02P,$%`````@`5((,1WN.AGY2
M`@``2P<``!D```!X;"]W;W)K<VAE971S+W-H965T,C$N>&ULC55-CZ(P&/XK
MA/L*E$+!(,F,CMD];#*9P^ZY:A4R0-FVRNR_W[9\V!*RZD':\GR]K;[-.LH^
M>4&(<+[JJN$;MQ"B77L>/Q:DQGQ%6]+(-V?*:BSDE%T\WC*"3YI45Q[P_=BK
M<=FX>:;7WEF>T:NHRH:\,X=?ZQJSOZ^DHMW&#=QQX:.\%$(M>'GF3;Q369.&
ME[1Q&#EOW)=@O4\40@-^E:3CQMA1V0^4?JK)C]/&]54$4I&C4`I8/FYD2ZI*
M"4GC/X/FW5(1S?&HOM?5RO0'S,F65K_+DRAD6-]U3N2,KY7XH-UW,I00*<$C
MK;C^=HY7+F@]4ERGQE_]LVSTL^O?0#30E@E@((")`(+_$L*!$#Y+@`,!/DN(
M!D+T+"$>"/&,X/6;I;=ZAP7.,T8[A[=8_?Z"M80S)2*5':[56'^"<K.Y7+WE
M`0*9=U-"`P9HS*N%B>\83^HOF@#7%@"62;ADLK4Q<`FSLS'1$N;-QL1+F+V-
M08\+"L>"PG[70E,@"!X+P%$`]@+02I#8*=4?0FU;#VHT"*V"Z+%--+.)+)O4
MMHEZE\AP>:*2>&81FQ:);UN@_FQCTP*%OOH\=D(S)V0XP6"IEBTRC+X!>;1I
MZD=+D7864FZ-#\,@?9PIF65*C$Q@T6F;F,6G<92D*5R,9`(!@@C`9`GW9N%"
M%*7!$FQOPB!,`(AGY7E&IZ@)N^BFSITCO3:B;Q33ZG1OO`#=:>[P/&OQA?S$
M[%(VW#E0(?N5;BYG2@61.?R5/)M"WFS3I")GH89('5K?[/N)H.UX=4WW9_X/
M4$L#!!0````(`%2"#$=^6CP/K0$``+<#```9````>&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;(V3VVZC,!"&7\7R`\1`2%)%!*GI:K6]J%3U8O?:@0&L^L#:
M)G3??GT`2JI*[0VVA_F_^>VQBU'I5],!6/0FN#0GW%G;'PDQ50>"FHWJ0;H_
MC=*"6K?4+3&]!EH'D>`D2Y(]$91)7!8A]JS+0@V6,PG/&IE!"*K_G8&K\813
M/`=>6-M9'R!E019=S01(PY1$&IH3OD^/Y]QGA(3?#$:SFB/O_:+4JU\\UB><
M>`O`H;*>0-UPA0?@W(-<X;\3\[VD%Z[G,_UGV*US?Z$&'A3_PVK;.;,)1C4T
M=.#V18V_8-K"S@,KQ4WXHFHP5HE9@I&@;W%D,HQC_+-/)]GG@FP29(L@UB&Q
M4+#Y@UI:%EJ-R/34]RX]NG3M(8Z,3*#IN'MGU+CHM4SOTH)</6C*B9+S3<X^
M6W*(XW]:),.W@.RFR#<`VQFPC2ZW:T":?PW(9T`>`?D:<+B[W:9OGK<9DV1(
M.FS2W8<R9'6R`G0;+I!!E1JDC0>[1)<[>I^%SKRGET5/6WBBNF72H(NRKK^A
M&8U2%IR+9+/#J'.O:%EP:*R?'MQ<QXL5%U;U\S-9WFKY'U!+`P04````"`!4
M@@Q'$D#DO5\"```W"```&0```'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R5
M5DV/FS`0_2N(>]>8SQ`1I(2J:@^55GMHST[B!+2`6=L)VW]??P#!"$3V$K!Y
M[\V;P<PD:0E]9SG&W/JLRIKM[)SS9@L`.^6X0NR%-+@63RZ$5HB+);T"UE",
MSHI4E<!UG!!4J*CM-%%[KS1-R(V718U?J<5N587HOP,N2;NSH=UOO!77G,L-
MD"9@X)V+"M>L(+5%\65G[^$V@[Z$*,2?`K=L=&])\T="WN7BUWEG.](#+O&)
M2PDD+G><X;*42B+R1R?ZB"F)X_M>_8=*5]@_(H8S4OXMSCP7;AW;.N,+NI7\
MC;0_<9=#(`5/I&3JUSK=&"=53[&M"GWJ:U&K:ZN?A&Y'FR>X'<$="$.<>8+7
M$;P'094.:&<JK^^(HS2AI+58@^3;AEL!IU)$*%M,J5%=+I$9$[OW%&Z\!-RE
M4(=Q%>9@8`8$$.JS(5S;I+LCNCL7(#,0WGH$KX^@EWO/2,)?%_![`5\+^(9`
M8)J,=!H:4RM,'`71'"A;!"U:"296`L-*:$8)M)5@%.5;`&,XA\H,E!^,TEHT
M$T[,A(:9V90/X2B,'X2SCK,Q*("1NVXEFEB)#"N;=8'-Y)!LOGI(XHF#V!"(
MS3PUYF!@8F<]"'0F463K63V+':BKIS]],UW1EU'+=N#4CO'QQT]\_M"=%!ZZ
M7ZT\]*8NO"=J;X+B)\X8G/8!^$PC@../W'<C9[83+*.T'3#JTQ6F5S6_F'4B
MMYKK-CWL#C-RKR8)>,#3I$%7_!O1:U$SZTBXF!:JM5\(X5C8<%[$6<C%%!\6
M);YP>1O)0Z+GFEYPTO1C>OBOD/X'4$L#!!0````(`%2"#$?+GJ$$'@(``'D&
M```9````>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;)55VXZ;,!#]%8L/6'.G
MC0C2AJ1J'RJM]J%]=H(3T-J8VD[8_GU]`6(BLMF^Q/9PSIDS$SSD/>-OHL98
M@G=*6K'V:BF[%83B4&.*Q!/K<*N>'!FG2*HC/T'1<8PJ0Z($AKZ?0HJ:UBMR
M$WOA1<[.DC0M?N%`G"E%_.\&$]:OO<`;`Z_-J98Z`(L<3KRJH;@5#6L!Q\>U
M]QRL=IE&&,"O!O?"V0/M?<_8FS[\J-:>KRU@@@]2*R"U7'")"=%"*O&?0?.:
M4A/=_:C^S52KW.^1P"4COYM*ULJL[X$*']&9R%?6?\=#"8D6/#`BS"\XG(5D
M=*1X@*)WNS:M67O[)/$'VC(A'`CA1)CR+!.B@1!="?&'A'@@Q)_-D`R$Y"8#
MM+6;SFV11$7.60]$A_3K%*P4G&L1I0R$4>/V#U&]$RIZ*8*O40XO6FC`A`:S
M<3&IOP39SF0F!%0&%EV$WCQ#Z-##I02EBTB#10\/179W1.[:C$:;D6U6Y%;Y
M)7XL$(\"L16(9]V.YR8S6X;%M$.WTR7,SL6$2?0))\F-DV3F)'DLD-[T(OW?
M7F0W#K+'O=AD3IV1[R]A2A<3W`%MLUE3%S&[;-94!V1+@L[%HIB?S$@3X,#.
MK;2ORA2=IN9SJ"_F37P3K,I@(;Y54]8.Q:M\D7?HA'\B?FI:`?9,JG%@[NZ1
M,8F5:_])=;=6WX'I0/!1ZFVFVVY'HSU(UHV#?OK:%/\`4$L#!!0````(`%2"
M#$=E`?M6B0,``%02```9````>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;)58
MVW*;,!#]%88/"&@E0&1LS]1..NU#9S)Y:)^)+=M,`+F`X_3ORT5VT(8)RXNY
M^.R>772.)%A<=/E:'96JG?<\*ZJE>ZSKT[WG5=NCRI/J3I]4T?RSUV6>U,UE
M>?"J4ZF271>49Q[X?NCE25JXJT5W[ZE<+?2YSM)"/95.=<[SI/RW5IF^+%WF
M7F\\IX=CW=[P5@OO%K=+<U54J2Z<4NV7[C=V_RA$"^D0OU-UJ0;G3EO\B]:O
M[<7/W=+UVQI4IK9UFR)I#F]JH[*LS=0P_S5)/SC;P.'Y-?OWKMVF_)>D4AN=
M_4EW];&IUG>=G=HGYZQ^UI<?RO00M`FW.JNZ7V=[KFJ=7T-<)T_>^V-:=,=+
M_X_T3=AX`)@`N`5$\&4`-P&<&B!,@+@%</9E0&`"@EL`=#UX?>_=DWM(ZF2U
M*/7%J4Y)JR=VW\#+-DF3V:FZ;&4_(,VSJYJ[;RL6APOOK4UD,-!AUC8F&L-L
M;(P<PSS8F'@,\SC$-)J^8;RFE]&&X-H0[QL"*P&;3L"O"42?@%L)P*Y2]IWT
MF*+#!'<RY-,T`M$(BX:0($"-!G,;#5$%H95`V(U&_;"&@T8Y\WW*B$2()[)X
M@E&>:,##)(U'(AYI\2`I]YB-C8FF26)$$EL)Y"B)C8FG29B/6-H9[B,%(SP,
MQI`\&)NK#P:X"LM+C(V-W(,!F:$#1AHZADW'+-<Q(*00N&$QN^$`5V%YBG&[
MX<#,4,&@82'C@,*$O<<L\S%!2!'A?J/9_6+',$F8`@RH[Q?B@#;`V#>,8AP;
MQ`+"[(^=`[9S0D(*[!R8[1S`S@$@"`E@OI``&P=LXQ!F-,#&@=G&`6P<"*:%
MM(:A<7A(F^0!.P=LY\BQ1[L&:]TBL.`U"RQS,<(<#A(_5CG[L6+30#PMH[4!
M];V&(@PX000<^X9;OL';GKBG,J"/?0^!B&$BRUW@CTT$:P2B[.*P!;EE08!Q
M'AM$4`K_M%VT#`B$F9QC`_+9!N38@)RP<JWYT(`1CR**4+#_>$@12CA?*-B"
M/*(()9HM%+P(<DD1BIPM%&QF;ID9"(N;\)%0A#]7*`+;3[!IH6P,R.SI?.Z3
MJL4.%+:YQC?D"$10I,`.%'Q:*!L$D@2>3V]L8EHH&P3""X<W>#L_)0?U*RD/
M:5$Y+[IN7O2[M_*]UK5J4OEW31U'E>QN%YG:U^UIU!;8?_3H+VI]NG[#N7U(
M6OT'4$L#!!0````(`%2"#$>92'?VRP4``'PF```9````>&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;)V:VV[;.!"&7\7P`]02SRP<`YM3DP`+%+WH7BN)DABU
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MAAU$<!#O#JD:=9#!07(=5'!07`<='#37P00'PW6PP<%R'5QP<%P''QP\UZ&]
MYMV52\!ET5WR_88YS^ILM2R+MUGUG+4<I5];^[*-TP2?5?N`9;<1FSU3-=^^
MKH1,EHO7-E*P$7N;4VJ3#MF<]6U2(X=LSFD<,61S06T&XUP2FR&+;T<MKN@X
M:LCFFMKH(9L;:F/>;1;-X@]?`7&X`K*[`J(?(4D9$>0A@NHB2#('2^>INQ7I
M;';=]4ED(C1C(`4#*7*1.6(UB-718@W,P?3G8&$SVFXSFKY8JY+V'V,H"T-9
MLJZ.$<&!7!<MU\,</)F#'Y)[[LFUY6E-$QBH_?[/2(H5(P6Y:1JM-Q4X#\%0
M'(PB)2,W*0%'L::K4+**EZQQ'GI,L@X'K.Y)MIHI&>E)#9$L.#$L2K;QDAW.
MPW$DNRF2D:"4(*0DYXA.0+)(HB6+%.8A"!Q*#6WLRV`T)+EG]FW$;&1&B)H@
MJ"E.1A`25T;&KPRF%:'&5D:'E5'C*Q/RW(C9R(R02$&(5*RT;G!E3/S*8`82
M!#5E![-=,-J%@;C93B"3@C"I./E.>!3MHT5+S$0R86R'8!0R@$X^VP]C=B-S
M0G@EA==S8F"A)R=4>A]*/<DX1*0\LC;A%!FS&YD3XBL)OIH5`^M"&5\82LQM
MTHSEE$[SA>S7AFS)R*4D7.IT:.M=R&E<2N12$BXU)V=+Y%+&<ZF02Y6,'49!
MM$HFB58(G"+`:4[65@B<B@=.(7!*,JZTHMT57_6'!HNBI#@Q$"45CY)"E-0H
M2@?59LKQH9`E15EB]:789ZGX1DMAG:A&6ZV#9C]%LT:4-$%)LSII;+9T?+.E
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M1F>V7QE*8UDC(;"6`LO9<A:K0AM?%5I,9M9P%)L)BC_<>:<HLC8DUH0VOB:T
MR(_M\_/9KPV6\,/_N<$A0H[085DQL"IT\56APT3EQ/'K?.7Z5:%//&LD9,@1
MAEA[Q6%)Z.)+0H<IR.GC!_(%-6(=R`X1<N;X@7SA^@@9[SE5F$.$'$'(BN&1
M[(21,)LY=_SDOP`CSLGOD$9'LIGE3-9C8>GC"TN/&<BGC-U"C5B[Q2.(7C!V
MBR>_A4GO.&OKD40O&=O%RRE#83KSBK%?P(@U$%+M";"6<S?%8V'IXPM+CRAZ
MR\B;OH]B4X.Q-@RBZ`EEEA4#;Q7Z^%N%[5-1\*-;DC`T'ZP^%;WH/<WRG#WF
M?V?EXWI7S6Z+NBZV^X=8'HJBSIM@R9<FZ%.>W;]_V.0/=?NV+7W*[MFH[D-=
M/)^$9[W>'SA;_0]02P,$%`````@`5((,1U.CFSV;!```B!X``!D```!X;"]W
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M+6]^E)??W1B#ZA2^E'G=_XU>WNJF+*8EJZC(?@V?QU/_>1G^8Y-QV?4%?%S`
M/Q8P>7.!&!<(6!`/GO5Q?<N:;+.NRDM4G[/N:K.'5KSJE+2:H[K75@WI:B.K
MV[/O&V[T.G[O%(TRO)=Y\F0$NR:S]60^).+6@ZMN\,F-X?`KGR]/V'T%8E(@
M!P7"B\/X/JK!QT'FU,NP1"1<W;<CP8Z<VU'FO@(%D:K02#5XH.]'^J1GD4HE
M)!/W[1BP8[Q([7T%%B*UH9&FX$%*B#1=$"E+P%"'^\P2(5;&(%C&0J-E'+WP
M(%#`F1DYX[.`VUMR]T.PA;@PGY?4MR5'6YZ0I=A!7)C'BZ6D!8%AP<0P1(9I
M2F;UHLPB-LQ0,FN",VO1CH>7)=QS68J934,SRY$<[I%CQ=7,CD*!F>4,;7F(
MR>OW^%%HNLE3;2&+W&/12H(*`=GE(CB[2`^7M[([12P795>A+74KN].55(NR
MBSQRCT=+:,/<8'9-<':1(.X1I.554GTA1G$5VQ@G]+$MGS<RG::$-B801N&W
M,7[5D$C"#2&)PB-1JZN9`R%-L(,4"I]"B@JD4`13*)!"(0EUX@M1ZD0@@4(1
MZD2H\,N'^`E-J1,=;@A[H3"4.C'!=8(D"[\7$G;E`GNA".Z%$O&3":%.?"%*
MG4BD3S)"G<AY'Y2J_2580OXD)Q2*Y`LLX7Y4"D*E@!"A4N2GQS>_HQ)V^A+W
MHS)X/RH10*DIE:*#*P7YDX92*6;!]4,"I:54BEU@";NI3"F5DH96BD*:E;^S
M30DJ\)E0!3\3*B10>02FR=5H08AB!_E3'EHI7+]Q]Z?F`Q1%W?TI9%!Y#%(:
MB_HT1`EF4"&#2E,RJX,SBPPJ0\FL6919I%!Y%*8$O!3V017<!S62HQ-"9D&(
M<'?3V`>UAU=*@%SCV%$'SQTUDJ,%)5H1'"U2HWUJ"'L<C=3H\-GCI^&C)E2S
MUDNJ62,YVB>'T*LUCB!U\`Q28[_1Z:V(Q\ZFTR41&R3'^%`0>H[!GF.">X[!
MGF,X(6(SW_6-DP!*R(B/F9,A2"HDABR#0\9'+Z,(96VN##\H_B)#1GLA4_S%
MZ8<)GGX8[!7&$NY;OA!E3FF0'W.3GRFUZ:+46@3()EYJ"4-1BP#98(`L`F0I
MFS9?B)):B^Q8RJ;-BONIC6?O#,_9J_LSJUZ/ISIZ+INF+/IWA?NR;%RK+_G2
M4G!PV>[C('?[IOO:X5$-+TJ'@Z8\3^]]/UX^;_X#4$L#!!0````(`%2"#$?)
MF-4PC0,``/<1```9````>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;)58VW*;
M,!#]%<8?8*1=B4O&\4P<3Z=]Z$RF#^TSL>68"2`72)S^?;G915LF7G@P")_=
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M?R(QF$T;P&``5P.I/C7`P0"Y!FHP4,3`[U/I"K%-ZF2]*NW9JTY)NSSD70,O
M6R>-9Z_JO)5]?9M25,W=]S4*7/GOK:,!`QUF,\8`RBG,HX.90FQ=+U>(WP0Y
M&2E<(L4^4AC;"WG;`5X<],,'=%)5;I`]YM'%Z-LDBI`HQT$P2>)BPMLDFI!H
MQT'DDNB>I,<4'48*%,!()B`\@<,3NSQ1SQ.,>-12!XR9#0E-.*:18C*=<)Q.
M%(L(U!1NZ^#"*`HEH[X1"2AR`I*3>4<CHG`I`IA";0E*Q[>#B4DPL1,,W'8@
M!5%.N_W-DXZ4)`CI[!.2[!/AL`?(4;9-?VD/!A=0+G"X%,,%THQQ=L94R-)1
MJ=13JVTS@"X9QR%C?B55L]2?R2P>F,9ZULLH8!!1.<O@MM`VTA$T@D+.!%!)
M2U?3D_O@AH`80I54J=*5:C3-,P9!P"D=%:%T5<B89J`JA-DJ!*I"D(PU"6,5
M2@VH&(4%*D(`QJ(<0',6)="N#$[+!<:&`8I65LVN+-4@:$YEG9ZJA%`,:0!5
M(7S:52^5':LP7J(8'YP$J2#!T1IP7$2TS-'L,E,90<S)/1Z7&9><AT44A`F%
MDR^C;:(D^:*<FR]2%:&KHLDGM0V"DV\<,8C^>[9%QCZ(;E=D;`M(NR(Z79$U
M,YJ65<\N*Y40!IRR.A+B=&:DHL&04U5768PM`6D70T=9FC,Q,:UJ/+>JBDI&
M"495!]#P>*!12<8:4+21*4=:FK'B%7T=5+/?!Q45C4).PG@K87_TQGU*7LSW
MI'Q)B\I[MG7S\MZ]:1^LK4WC32P;KT>3[*^#S!SJ]C)LZ?KO$OV@MJ?+9Y;K
MMY[U7U!+`P04````"`!4@@Q'-W1ZP7P"``#]"```&0```'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6R55LENHS`8?A7$`Q0O0!81I&;3S&&DJH>9LYLX"2K@
MC.TTG;<?+X38R&WI!6SS+?\"-L65\5=QHE1&[TW=BD5\DO(\3Q*Q.]&&B`=V
MIJUZ<F"\(5)-^3$19T[)WI":.D$`Y$E#JC8N"[/VQ,N"761=M?2)1^+2-(3_
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MY"`$V7@R/2)1008C1;$?!7+H"*?!*)"731["K%U,#H.1>E8AQ/8#D0^3P;=D
ML"T[=AW`"('T)I!:@=3+=.(':3$;'S/]VB0;F&2>P,PWF5@3BVD-)@,`?.V2
M#UQRUP6#8"HN!DU'F$P&)A//9$3!IX..3;_;L=D@@MG7'5NZ&#@;D28$`Q>]
MF3J)HE#/EAW(-@V"R:BV03BT\C[H639"`@V*"M%WJPKQ,`KL)8Q#":\Z4)>P
M]YHZL/4XV,:#8?`!;/L)S*:7.%MU0_G1G*HBVK%+*^V6T:_V)_<CTEO]8'T%
MYVL86-_HD]X<#7?YLCB3(_U%^+%J1?3"I#I@S&EP8$Q2%3=X4)_T2?V+]).:
M'J0>3M28V]/93B0[WWXV^C^>\C]02P,$%`````@`5((,1]`*$!<!`@``@`4`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,S`N>&ULA53=CJ(P%'Z5A@>PI0@:
M@R2.9K-[L<ED+G:OJQZ%3$O9MLKLVV]_@`'#K%Y`6[Z_4]N3MU*]ZQ+`H`_!
M:[V-2F.:#<;Z5()@>B$;J.V7BU2"&3M55ZP;!>SL28)C2DB&!:OJJ,C]VJLJ
M<GDSO*KA52%]$X*IOR_`9;N-XJA?>*NNI7$+N,CQP#M7`FI=R1HIN&RC7;PY
M9`[A`;\J:/5HC%SVHY3O;O+CO(V(BP`<3L8I,/NZPQXX=T+6^$^G^6GIB.-Q
MK_[-5VO3'YF&O>2_J[,I;5@2H3-<V(V;-]E^AZZ$U`F>)-?^B4XW;:3H*1$2
M[".\J]J_V_!E33K:/(%V!#H0!I]Y0M(1DH&0_-]AV1&6#P0<2O$;<6"&%;F2
M+=(-<Z<CWEBX<B)6&6FOIL+^VJW0=O5>),DRQW<GU&&HQ[R,,7%&!PRV^K,F
M-)H*T+'`FLZ9[.DD2#J'.4PQV?,@21\D"=4FXR`T>2ZP[`7"=+<<":0/A:2A
MD`"I/82FQ/_F@(<QL,.1YXG2AT3I9$]64Z=UB)2.G,B"D'@.=?@:]668["%,
M-@FSGMJX6^A.0S;R62WB],$&CPZP`'7UG4"CD[S5)IS?875H-COJ+\`GO,@;
M=H6?3%VK6J.C-/8:^3-_D=*`34$6MMS2ML-APN%BW'#E_I[0(<+$R*;O=T/3
M+?X!4$L#!!0````(`%2"#$=61=2,O@,``.T2```9````>&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;)U8VXZ;,!#]%<0'!'O&YK+*1MJEJMJ'2E4?VF<V<1)4
MP"F0S?;ORS6+1VQBFH=PR<R<&7S.#/'ZHLO?U5&IVGG+LZ)Z=(]U?7KPO&I[
M5'E2K?1)%<TO>UWF2=U<E@>O.I4JV75.>>8!8[Z7)VGA;M;=O>_E9JW/=986
MZGOI5.<\3\J_SRK3ET>7N^.-'^GA6+<WO,W:N_KMTEP55:H+IU3[1_>)/\0"
M6I/.XF>J+M7DW&F3?]'Z=WOQ=??HLC8'E:EMW89(FL.KBE66M9$:Y#]#T'?,
MUG%Z/D;_W)7;I/^25"K6V:]T5Q^;;)GK[-0^.6?U#WWYHH8:9!MPJ[.J^W:V
MYZK6^>CB.GGRUA_3HCM>^E]"-KC-.\#@`%>'*\Z\`PX.^.[@=Y7VF75U?4KJ
M9+,N]<6I3DF[VORA,2_;($UDI^JBE?WC:BJKFKNO&\1H[;VV@08;Z&R>IS9\
MSB(VH@AVM?&:#&;3`->$@$D`F(4P+/`^`HX(_>43&BGR^P'$&$#T`801@"0I
M^S)ZFZ*SD:S[S-G%4[LP#`/)+)Z9)`G)24(B,''"/A\YP6$KQOB<5?RQU8>Y
M^"07WW@X./MP_`D,(H`O+8H."%!@`(G[`4+"@W`I#R*2072?!W$T*34`DP<?
M`G%&D-HN=&>%X\%FT>)Q3H%,_4H3B?.A#7`"):5O`084#`PPGX"Q`0Q,L(`9
M'YLJD0*;+2"P""$(>;A8RAY.5<NE!7_X5)+<MVP0G*J2^Q8$\O^#0%25/+A)
MH'&.!"84@@542*%"*_J$!I1%G^!4Y]P4>F@QU!BA"["E=`$J3>`6=(&I,@4`
M$[Y%Q4"5"7"?+@#+Z0)4B6`J,9I?P\%JA/(MV`)T:(.X24P<D(19E(BD17<`
M*FV0-M0$N;PL*FPPYJW-'(6`<C-8S$TJ10AMN#E58N#+D(<V%5,U0F3!S6@Y
M-Y$.760VW,3IV.4K'ED@46FCU=1%,G4C"6+9($2J<S0FL"0OA<&`.Q4Z65K>
M!XH-&[ZRT`S25H!X2S/1D`LN?]JT$Z#1"22M:%Q7L1R)M@$TVH"T^:_B$W&B
MOU2<2$<R!A;BQ.E$%M+R115I(\#POC@Q_`]QTBZ`D94X(V,1+19`T"X@V$UM
M#B\TPGSYYLQBZ@K:!@2WF1J"+ZZ)RE[`+04,4A-P$\>;["[DJCQTNRZ5L]7G
MHNXW%ZYWKSL[3]W&CO=NOEF?DH/ZEI2'M*B<%UW7.N\V)/9:UZK)@JT:?AY5
MLKM>9&I?MZ=!2]Q^-Z:_J/5IW%RZ[G!M_@%02P,$%`````@`5((,1R5%XS\Y
M`@``*P<``!D```!X;"]W;W)K<VAE971S+W-H965T,S(N>&ULE97;CILP$(9?
M!?$`:S"G)")(2:JJO:BTVHOVVB%.0&ML:CMA^_;U"180$ME<!-O\,]\_!L9Y
MQ_B[J#"6WD=#J-C[E93M#@!15KA!XH6UF*H[5\8;)-64WX!H.487$]00`(,@
M!0VJJ5_D9NV5%SF[2U)3_,H]<6\:Q/\=,6'=W@_]?N&MOE52+X`B!T/<I6XP
M%36C'L?7O7\(=Z<0:HE1_*YQ)T9C3YL_,_:N)S\O>S_0'C#!I=0ID+H\\`D3
MHC,I\E^7]).I`\?C/OMW4ZZR?T8"GQCY4U]DI=P&OG?!5W0G\HUU/["K(=$)
M2T:$^??*NY"LZ4-\KT$?]EI3<^WLG4W@PI8#H`N`0\#`60Z(7$`T"P#6F:GK
M&Y*HR#GK/-$B_;3#G9)SG41E]H3)QNUVJ<J$6GT441+GX*$3.0TTFN-8$Z9P
M27.::`8%4`X6;4!_BH`31+2(&&O@.B+J$79ZB,:5QD]XC/L$L4T03SPF4X^9
M]6@UU'H,MW&4)>N@9`9*)DYGFY%84#("11&$:1*L@](9*)U4E*XGR&9[FGUU
M3S<S!YN)@VRIU.-F5&H<F-\Z:#L#;2>@S=+#.VY'H"<>6QC,&+IKC"#;18@3
MN5<D>+:>,)S#)E]<%BQNG1-1Y^A9%IRSX/JK?W0BQUJL"XQZ4X/YS?1LX97L
M3J5M3</J<"X<S+$`/N5%WJ(;_H7XK:;".S.I.J1I9U?&)%9.@A=5?:5.KF%"
M\%7J8::WQ?9R.Y&L[8^FX7PL_@-02P,$%`````@`5((,1V)X:?S0`P``X!(`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,S,N>&ULE9C;DILX$(9?A>(!C$Y(
M,.5QU8Q3J>S%5J5RL7O-V+)-!9`#>)R\?3C('G6OLA9S,0;<ZE]_HT^2M;Z:
M]GMWTKJ/?M95TSW'I[X_/R5)MSOINNA6YJR;X9N#:>NB'V[;8]*=6UWLIT9U
ME3!"9%(791-OUM.SK^UF;2Y]53;Z:QMUE[HNVE^ONC+7YYC&MP??RN.I'Q\D
MFW5R;[<O:]UTI6FB5A^>XQ?ZM!79&#)%_%/J:^=<1V/GWXSY/M[\M7^.R=@'
M7>E=/Z8HAH]WO=55-68:E'_8I!^:8T/W^I;]\V1WZ/Y;T>FMJ?XM]_UIZ"V)
MH[T^%)>J_V:N7[3UD(X)=Z;JIO_1[M+UIKXUB:.Z^#E_ELWT>9V_R8AMYF_`
M;`-V;W#7\3?@M@'_:"`GIW//)E^?BK[8K%MSC;IS,;YM^C2$MV.2(7/43=G:
MN5R#LVYX^K[A:;I.WL=$-H9-,:]N#/5%;$$60>XQR=`#;S=8#"68DX!Y)4`$
M?ZS`;PIB-LJ!4?DX@;@EF&]?!/!('R=(40]2T`,%7:JY#G-,,\6D/"4DH)82
MZ4B@DT&==-:1C@[-N&"/912244`F?YP@0P7-EA8T1SW(_Z^@UFCN&%4DJ)Z4
M()UQ-OAS1>V;LT&W5Z<"="C6`1C)D*XR5%/*EA:58E`H($4BX(4%W@VB><#P
MH0+K`*`DHCZW.L*I:K[BQ/T+<8<AI(!"&3"14(EK+!?7&+-#`3Q2>(>N#;)C
M-^=*!"AE6`E0)M.`%#GVFR_URS!!C`3X92Y!*LT"IA2&$6(0H8!IGF&$V&*$
M&$:(082\,]/6!LUV.:?NQ/)G*4P1@Q2%I$BQX72Q8;SD,("$S/WO5RX?SPR3
MPP`Y*F2K@=<=MGCA87CE87F(WWSQ>.88'`Z7GI!]#T5V.5UJES/<"X"$HM[Q
M;(,:NT.3.6,!HY'_9Y\&V%',M]AN.6"'9#3+0TJ#X>$`'L6]2Q!WER"URD*$
M\*K#`6)*^(7<S1]=B8`M!,<@<@"B"ICNN<+C12T>+WC1X5D`'C;(;IBD2ED(
M()A$#DA4(?MZ@@P+LM2PP,N.H`&&;9`U+%C(GEE@%`5$,6","([]\L5^,3@"
M@N/?$0L7G-`?,P*C(R`ZJ+3"2KE!0?..P.0(0$Y&_);@[R8A1`!A`J]A`A"6
M>7?8KR@H8(<M,(8"8)AQOR470]\OI,0Y4*AU>YP.6KIH9RY-/Y\GW)_>#W->
MV'0@\1&^69^+H_Z[:(]ETT5OIN]-/9U!'(SI]=`/LAI>X4D7^_M-I0_]>*E&
M?.8#F/FF-^?;>=+]4&OS&U!+`P04````"`!4@@Q'C-G/`X("``!M"0``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6R=5MNNHR`4_17C!U3!*XTUZ263
MF8=)3L[#S#-M:6N.2@=H/?/W`Z)6B#FUTX<*N/9::^^PA:RA[(-?"!'.9U76
M?.5>A+@N/8\?+J3"?$&OI)9O3I156,@I.WO\R@@^MD%5Z4'?C[T*%[6;9^W:
M&\LS>A-E49,WYO!;56'V=T-*VJQ<X/8+[\7Y(M2"EV?>$'<L*E+S@M8.(Z>5
MNP;+'4`*TB)^%:3AH[&CS.\I_5"3'\>5ZRL/I"0'H2BP?-S)EI2E8I+*?SK2
MAZ8*'(][]F]MNM+^'G.RI>7OXB@NTJWO.D=RPK=2O-/F.^ERB!3A@9:\_7<.
M-RYHU8>X3H4_];.HVV>CWZ1^%S8=`+L`.`0,.M,!01<0/`+"+P/"+B"T%#R=
M2EN('18XSQAM''[%:GN`I80S12*9'=ZR,5U?60HN5^]YD(:9=U=$'0:VF,T8
M`V(XA=D9F`'A20>3-J!K2D##1C0EL34Q\:2-,08^MQ'T-O1T'1@2R7."L"<(
M-$%H$*3/"2++0600(#/)1!="8VI=ZR3RY>^Y4&P)Q6,AY)M"D1:*1T(!G"63
M6#*)(3-C9Z161=-7*XHL!\AP`*<2W:!Q1<,8(10^%P*^I:0^,R.I8`8%L+(%
MX-5T`;1=&'V"PJF$=QU(9PS]*)KEUFX78/0+BF90V`T#7NX88+<,F-,SX+^:
M!MA=`\RVB6=0)';&R<L9I[:+=,:>[D"O;FJ[?8#9/XFIA;KJ&@VT`,@2\D:'
M4D78N3W=N7.@MUKHPV!8'6X0:Z@.-6M]`Y9;?0]XT.39%9_)3\S.1<V=/17R
MR&S/MQ.E@DA[_D*6Y"+O/L.D)">AAHFJE;X-Z(F@U_YR,]RP\G]02P,$%```
M``@`5((,1Z(5.00``@``M`8``!D```!X;"]W;W)K<VAE971S+W-H965T,S4N
M>&ULG971CJ,@%(9?A?@`%<1J;:S)=C:;W8M-)G.Q>TTK5C,@+M`Z^_8+HJZ:
MIIVV%Q7PG.__3SA"V@KYKDI*-?C@K%8[K]2ZV?J^.I:4$[42#:W-FT)(3K29
MRI.O&DE)WB5QY@<01CXG5>UE:;?V*K-4G#6K:OHJ@3IS3N3?/66BW7G(&Q;>
MJE.I[8*?I?Z8EU><UJH2-9"TV'E?T':/L`WI(GY5M%63,;#F#T*\V\F/?.=!
MZX$R>M060<SC0E\H8Y9DE/_TT/^:-G$Z'NC?NG*-_0-1]$6PWU6N2^,6>B"G
M!3DS_2;:[[2O86V!1\%4]P^.9Z4%'U(\P,F'>U9U]VS=FQCV:=<3@CXA&!.2
MSK?3Z5Q^)9IDJ10M4`VQ>X>V)EI:A@$#U<&D*][X5&;UDN%DD_H7"^IC7,I^
M'I.,,;[A7Q4)!A'L1((I((+W`7@`A`Z`)X`0PKG+M7/I8FH7@S8X0/=UPH5.
M.-$)<'P?L%X`UC.CGW`0+0#1#!!<K31ZHM)XH1//=/!5G?@)G<UBZS<SG?`^
M(%D836YM?>*,)A.CR0K#Z>\3GA%<:-J/^;$^0&B)0(]V`@J6B.!6+_2E]T'/
MU[[\U!"^U1F#*GY`U9^<2`TYT9]$GJI:@8/0YFSK3J)""$T-&*Y,ZY7F"ADG
MC!;:#F/;D^Y0=1,MFN&.&"^J[!]02P,$%`````@`5((,1T:V^$6V`0``,P0`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,S8N>&ULC53;;J,P$/T5BP^(P9!T
M&Q&DEM5J]V&EJ@_;9R<,P:HOK.V$]N_K"U`21=OE`7N&<\Z<\85R4/K5=``6
MO0DNS2[IK.VW&)M#!X*:E>I!NB^MTH):%^HC-KT&V@22X)BDZ08+RF12E2'W
MI*M2G2QG$IXT,B<AJ'Y_!*Z&79(E4^*9'3OK$[@J\<QKF`!IF))(0[M+'K)M
M77A$`/QA,)C%''GO>Z5>??"KV26IMP`<#M8K4#><H0;.O9`K_'?4_"SIB<OY
MI/XC=.O<[ZF!6O$7UMC.F4T3U$!+3]P^J^$GC"VLO>!!<1/>Z'`R5HF)DB!!
MW^+(9!B'^&5#1MIM`AD)9"9DQ3\)^4C(KP@X.@M]?:>65J56`S(]]9N=;1U<
M>Q&GC$Q0TW&Y7&?&9<]5D:Y+?/9"(X8$S.,20VXAZ@M$/D.P,W#3!9E<Q/"!
M7+C8?"V03P)%%,@O!.XN3:YC&Q$C(R;[EI/LZSK%59UB42??7"W&?:Q3+.K<
MK_)T^62W&/7_,:))O-C?GA[A-]5')@W:*^N.2MC75BD+3C==N<X[=X/G@$-K
M_?3.+TD\U#&PJI^NZ/R?J#X`4$L#!!0````(`%2"#$>BI&X!U0(``$@,```9
M````>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;(V7WW*B,!3&7X7A`>0_B(/,
M5*2M%SO3V8O=ZU2C,@7B)K%VWWX3B)0PAS4W!>+O^W*^),II=B/T@YTQYM97
M4[=L;9\YOZP<A^W/N$%L02ZX%9\<"6T0%X_TY+`+Q>C0B9K:\5TW=AI4M7:>
M=6-O-,_(E==5B]^HQ:Y-@^C?#:[);6U[]GW@9W4Z<SG@Y)DSZ`Y5@UM6D=:B
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M!G\D]Z$)BC$1>V`-#TW*QR;/OK8>*<2\:(P'+LBKSH!S[73&?[QLP7W9@G[S
M@O&J^^EC@_!N$/8&H59!H%?9,QN="2&F,&"V!DPYQ\P&BB:!(LT@`@/I3`P&
MTID$#*0S2S#0G,]LH'@2*-8,4C"0QO@N&$AG/#"0@4\YYS,;*)D$2C0#'PRD
M,^"Q+'0&/G(Z`YZ&4F?BQX&6DT!+S0`\*AN=`8]*H3/@3F\-?$J-"=S'@=))
MH%0S`(_*1F?`72P,F*T!4\XQLX$\=Y)(-CTCB\F!2M5;KH?:#HH6RQBB"HWR
M%M.?AE2]#DV\2B.O9R.O%R.OURF50M1N0KG!9,F=48O18'KJ&E1F[<FUY?U+
M:A@=FN`G7[8HD_&-MRH\8'SKK<J^Q?VVS[,+.N$?B)ZJEEGOA(O&J.MBCH1P
M+,IV%^+']BS:^N&AQD<N;Q-Q3_M&MW_@Y'+OVX=_'O)_4$L#!!0````(`%2"
M#$?V=[MMZ`(``"T-```9````>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;)57
MVXZ;,!#]%<0'!'SA%B5(FU15^U!IM0_M,YLX"5K`J>ULMG]?7X!B-YN8EX"=
M,V?F##-X6%TI>^,G0D3PT38=7X<G(<[+*.*[$VDKOJ!GTLE_#I2UE9!+=HSX
MF9%JKXW:)H)QG$9M57=AN=)[SZQ<T8MHZHX\LX!?VK9B?S:DH==U",)AXZ4^
MGH3:B,I5--KMZY9TO*9=P,AA'3Z!Y19IB$;\K,F53^X#%?PKI6]J\7V_#F,5
M`VG(3BB*2E[>R98TC6*2GG_WI/]\*L/I_<#^5<N5X;]6G&QI\ZO>BY.,-@Z#
M/3E4ET:\T.LWTFM(%.&.-ES_!KL+%[0=3,*@K3[,M>[T]6K^R8K>[+8![`W@
M:)#'=PU0;X!&`XBU4A.9UO6E$E6Y8O0:\'.EGC982CA3))(YX)J-F71)95SN
MOI<8X57TKHAZ#-28K8U)1DPD^6\Z@8,3;)Q`BR!]3(`&`K-\0A9!]I@`.Q%@
MBR"W91K,QL84-J8PJ3"83F/`(BL>1Y(XD203+PA[2$F=7*1S<Y$Y$63W<J$J
M7PG-)D+C!7[L)7>\Y%,O.'Y,4#@ZB[DZ0>R$H+0\?.HV"(/;Z>A1,_(!@!L-
ML)Y\[D$!G90`.#LGR(T"^3S]'C7(3:&')[?E@-5/V(<B<?4FL_6F;A2I3PU8
M((P^24HZ/REN[X%I\Z'$HRU`[B8EGYV4PHVB\"J"PGK9`8^7'71;$-K=Y=$W
M$#AZ(9BK%_YW_D"/(K!!GQ5!CYJ5%+<'(;**`'E08#<I>'92W(,()CY%T*,&
MO3ZQNBT([>[RF1\R5VXV6ZY['L'<IP;R>S70SP`]:$Y*3`-J(Q.,VK@_`;F=
MA.S#K+@9OPW"/I.6>TPA<"\%@Q\;Y#Z/:#*#MH0=]6S.@QV]=,),A^/N./]O
M]+3N[L-BN8%Z?H[^$96K<W4D/RIVK#L>O%(A9V0]T!XH%43&%R]DU9[DM\NX
M:,A!J-M,WC,SS9N%H.?AXV3\0BK_`E!+`P04````"`!4@@Q']LU5DLL!``!Q
M!```&0```'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6R-5-MNFS`8?A6+!ZC!
M0-I&!"G)-&T7DZI>;-<._!Q4&S/;A.[MYP,0Z")U-['_G^_D4[)1R#?5`&CT
MSEFG#D&C=;_'6!4-<*H>1`^=^5()R:DVI:RQZB70TI$XPR0,=YC3M@ORS/5>
M9)Z)0;.V@Q>)U,`YE7].P,1X"*)@;KRV=:-M`^<97GAERZ%3K>B0A.H0'*/]
M.;4(!_C9PJA6<V2S7X1XL\7W\A"$-@(P*+15H&:XPAD8LT+&^/>D>;.TQ/5\
M5O_J5FO27ZB"LV"_VE(W)FP8H!(J.C#]*L9O,"W!)2P$4^X7%8/2@L^4`''Z
M[L>V<^/HOSPF$^T^@4P$LA`6G_N$>"+$-X)SP#Z96]<7JFF>23$BU5-[V-'>
MP*45,<I(.37IM\NL3)GN-4^2IPQ?K="$(0YS6F.B'5DPV.C?-2'!5H"L!9[(
M/9/S&O,?%O%LX<MCO+8@SY\+)+-`X@62S48\;S-ZS&F#2<//3=(/)NE&(-J:
MI'XC/*9SF#@F9/>/$5X=,0=9NZNO4"&&3OL37KK+ZSH2=T5N\#SK:0T_J*S;
M3J&+T.:BN5M1":'!!`D?3)+&O/^E8%!I.WVT2?V3\(46_?S`EW^9_"]02P,$
M%`````@`5((,1^^6!"+9`0``A04``!D```!X;"]W;W)K<VAE971S+W-H965T
M-#`N>&ULC93?;ML@&,5?!?D!BO\F:^18:A)-V\6DJA?;-8D_QZA@/"!Q]_8#
M;*<FHEMO#!_\SN&`,.4@Y*MJ`31ZXZQ3VZC5NM]@K$XM<*(>1`^=F6F$Y$2;
M4IZQZB60VHDXPVD<KS`GM(NJTHT]RZH4%\UH!\\2J0OG1/[9`1/#-DJB>>"%
MGEMM!W!5XINNIAPZ146')#3;Z"G9'`I+..`GA4$M^LAF/PKQ:HOO]3:*;01@
M<-+6@9CF"GM@S!J9A7]/GN]+6N&R/[M_=;LUZ8]$P5ZP7[36K0D;1ZB&AER8
M?A'#-YBVX!*>!%/NBTX7I06?)1'BY&UL:>?:89Q9YY,L+$@G07H3)/\69),@
M^ZP@GP3YG0"/6W$'<2":5*44`U(]L;<CV1A<6A/CC)1SD^/YFJ-09O1:Y45:
MXJLUFIC4,3N/2>(0L_>9),0<?.9]+6QR!L.F<]AL#)LN#)+T\?\&V6PPED^9
MM]O,3SDR.Y_)0\S>9XH0<_B(^3!L?A<V]PQ6P;`^LPZ&]9DOP;`^\XF3+>["
M%DN#51P,NV32.!S6]TF"89=,\AC?A<6+'Z`G9_A!Y)EV"AV%-O^2N_B-$!J,
M4_Q@K%KS)MX*!HVVW;7IR_&9&`LM^OG1N[V\U5]02P,$%`````@`5((,1[6A
M9J??`P``:!4``!D```!X;"]W;W)K<VAE971S+W-H965T-#$N>&ULE9C-;MLX
M$,=?1?`#6"2'%.7`,;#IHM@]+%#TT)Z5F(Z%2J(K*7'W[2OJPR6GJ3+,(;9D
M<OXSP_EQ1.VOMOW6G8WIDQ]UU73WFW/?7^[2M'LZF[KHMO9BFN&7DVWKHA\N
MV^>TN[2F.(Z3ZBH5C&5I793-YK`?[WUJ#WO[TE=E8SZU2?=2UT7[_X.I[/5^
MPS?+C<_E\[EW-]+#/KW-.Y:U:;K2-DEK3O>;O_C=@\K<D''$E])<.^][XIQ_
MM/:;N_CW>+]AS@=3F:?>F2B&CU?SP525LS0H?Y^-_M)T$_WOB_6/8[B#^X]%
M9S[8ZFMY[,^#MVR3',VI>*GZS_;ZCYEC4,[@DZVZ\7_R]-+UMEZF;)*Z^#%]
MELWX>9U^R=D\[>T)8IX@;A/X."&=A$8W_R[ZXK!O[37I+H5;/'XW#&^=D<%R
MTHW6VBGZP=%NN/MZD)G8IZ_.T#QFFO+@CX'=[C8F'>R_*2(6$9A$1"`"[QN`
MQ8"<#(!G0&@=>JDF+Z<QS3B&,V!"O:\CD8X,')6A3C[I2$]';7-*.`K)J$"&
MX&>&$IK%)E0C#S0AH=H/-`?!WY?)D4R^EL_=))-[,FS+-`O^"*([)+H+1+-0
MU('J5'=^M6PUH:@Y0SK.E">DWXQN'G03$@0ACH5"2'.""4P@CT:08P8Y!4+N
M4Y@QI2B)Q11RN;:"2V)]#N564D+"'/(01(JOF$0>C2+'+'*]1LE2L%P'G)`*
M">/(\[6*O2GY1,)6$Q#DF$$>0*@9H6<PE%G!8C,K,#B"4S([C[IEEM+@!%82
MA+U@'K0DUO/GST*80@%!8@EK(R1.K(Q.+`9'*,)>,`^:PX5<9@2E#"ME:TNH
M9Z7,WV0)*AA!H==VG"4>':F"\1.K^"VQ!/V0H(+1$R%ZA'T",'H0C1Y@](`3
M*@1XT"T8)Z`'&#T0:Q4RHP<^>GS+">C!;P^AL%8DRVX"$*^$&R!(0J&`C"L4
MP!!#T/TT995Q]X/H[@<8/:`\BD*`WOA@2)#"_$&^MH!+I>3QZX<1A-W:^BTQ
M[>+63^+G3QE0J@F.2H[63_+8]9,8/[F*WT*%C.=/8OYDV/HHQSO<^F1TZY.8
M&JD(VXU40;@4'=SX9("6)O1.J7&T.CI:C(S,"73*`)E,9%I2ZAE3(U</;DMF
M?6K<\9MP^L;@J-6#VQR48G%X*MP!5<"6E[H_F\"G-A5]:E,8&@44/!7$9Q4W
M+16PI0FG5*5PO"HZ7HR-6GU>G(M(!<^+L!58*?5>HEV*9_-?T3Z739<\VKZW
M]?CR[&1M;P9C;#LX?3;%\791F5/OOFI72=.+P.FBMY?EO>;MY>KA)U!+`P04
M````"`!4@@Q'%7V-)G8"``"""```&0```'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6R-EE&/HR`0Q[^*\?TJH"@VUF2[E\O=PR6;?;A[IBUMS:JX0+=[W_Y`
MJHO&J"\J.//_S>#`F-VY>)-7QI3W696UW/E7I9IM$,CCE554;GC#:OWFS$5%
ME1Z*2R`;P>BI=:K*``$0!Q4M:C_/VKD7D6?\ILJB9B_"D[>JHN+?GI7\OO.A
MWTV\%I>K,A-!G@6]WZFH6"T+7GN"G7?^$]SN86Q,6HL_!;M+Y]DSP1\X?S.#
M7Z>=#TP,K&1'922HOGVP9U:61DF3WQ^B7TSCZ#YWZC_:='7X!RK9,R__%B=U
MU=$"WSNQ,[V5ZI7??[)'#M@('GDIVZMWO$G%J\[%]RKZ:>]%W=[O]@T&#[=I
M!_1P0+V#Y006U(;YG2J:9X+?/=E0\_'@5IL+(Z*5/=FJ"9N]#E3JV8\\2M(L
M^#!"#QOKLG=M8&\1:/5)!/*'[LAQ1\ON8><>V@A#-T("E@6B3B"R`I$K`,`P
M16QCM#:U33$A)('),@B/0-A--$PF0=@%@1`@O,R)1YQXL")PDA,[G&\I),N4
M9$1)!LN&)BF)FPU)`4'1,HB,0&0`"B=!Q`&AE$3ABL^3CCCI8-FF$TK=A'"*
M0K("!,&H9,UIX*2T8DT@'`4+X5S5DL?&A$ZXR0;@=`4)C4EHKFQA=P8@!X4W
M)`Y7H,(Q*IRKW!X5NK4+-Q"OJ%XXWO4PFJO?GA4-5S!><4#!\;Z'>*Z">Y2[
M]:,-7K6"XZT/X[DB[LHB7B`%3H^HF+BTK5!Z1WZKE6T1_6S?;I]0VV.^S/.L
MH1?VFXI+44OOP)7N5&U;.7.NF(X#;'3&5_U#T`]*=E;F,3&[S;9(.U"\Z3I^
M_]N1_P=02P,$%`````@`5((,1Q]G1:X8`@``D@<``!D```!X;"]W;W)K<VAE
M971S+W-H965T-#,N>&ULE57;CJ,@&'X5XP,,@N?&FFQG,]F]V&0R%[O7M&(U
M@^(`K;-OOR"U*Z29VAL1_/[O@/FA&!E_%PTATOOL:"^V?B/EL`%`'!K28?'$
M!M*K+S7C'99JRH]`#)S@:BKJ*$!!D(`.M[U?%M/:*R\+=I*T[<DK]\2IZS#_
MNR.4C5L?^O/"6WMLI%X`90&N=57;D5ZTK/<XJ;?^-[C9P51#)L3OEHQB\>YI
M\WO&WO7D9[7U`^V!4'*0F@*KX4R>":6:22E_7$C_:^K"Y?O,_C+%5?;W6)!G
M1O^TE6R4V\#W*E+C$Y5O;/Q!+AEB37A@5$Q/[W`2DG5SB>]U^-.,;3^-H_F2
M!9>RVP7H4H"<`F"$)IO?L<1EP=GHB0'KGP<W"LXUB6+VQ,3&37IE5*C5<QEE
M80'.FNB",26[)2;,\RL&*/Z;(F@6B8P(LD2B^P3A3!`:@G!)$*;W"2+'0;0@
M0"FR8\8FIL'T)B;*4+8B:>SHQ%;2V-8QF)V-2>Z+)(Y(8A&LV(W4V<[TT>W,
M'`?9<CN3VS$SRV5V7R1W1'*+8,7/@(&34W?E8T$A=$Q`JT'RX&94!P17Z+@M
M`JT>R=$*"K=)X,-=`MTV@=&:M$M0F*VQZK8)M'H@#U=0)&[:Y.&TJ>LB79,V
M_3(M6!RW`SZ27Y@?VUYX>R;5R3T=LS5CDBBJX$FE;M0%>9U04DO]FNH3R%P9
M9B+9,-^`UVNX_`=02P,$%`````@`5((,1ZVU7?L1!```J!,``!D```!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&ULE5A-<^(X$/TK+NZ+I98MRQ2A:@(A[&&K
MIN8P>W9`?-38%FN;,/OOUU\X4J_`(H=@B]?]NB6]9Z/Y516_RJ.4E?<[2_/R
M97*LJO/,]\OM469).55GF=??[%61)55]6QS\\ES(9-<&9:D/A'`_2T[Y9#%O
MQ[X7B[FZ5.DIE]\+K[QD65+\^RI3=7V9T,EMX,?I<*R:`7\Q]X>XW2F3>7E2
MN5?(_<OD&YUM6-Q`6L3/D[R6VK77%/^AU*_FYL_=RX0T-<A4;JLF15)_?,JE
M3-,F4\W\3Y_TB[,)U*]OV==MNW7Y'TDIERK]^[2KCG6U9.+MY#ZYI-4/==W(
MOH>P2;A5:=G^][:7LE+9+63B9<GO[O.4MY_7[AM!^C![`/0!,`0,//8`U@>P
MKX#@84#0!P2N#&$?$+HR\#Z`#P'`'@9$?4#DRB#Z`/$5$+7+VRU'NYBKI$H6
M\T)=O?*<-%N<SFIXT22I,WMEFZWH]DB]G&4]^KD(XF#N?S:)>@RTF%<=0SG8
M,"L=PXD-LC;2V!`;LYAPP/AU(]9N8&)6"D8";B-9ZAA@UF8,B`WQIB.XM9GU
M:)+W\20;LZ%H?$;8;498M[Y,3\`<$@2W!$&7(-`2,"+,*L.NU0Z3=RM+&`&'
MI0L13ZCS4&+C688Z3R1$1",;;F7@1$P$!-:Z'^'N%LY1X=Q8(C1!7<B::T3A
M5'`V3A,AFLB@B4V:J*.)]'ZX(!!$-MR[CHMI3/EX.0*5(_1RA,.TQ6ACQL]N
M3$I0"<V3:4@1$F)K==6#NEXA)LV?=>X>`N\717%1U"@*J3KHN4P0./``Y@$C
MA<.&HM@:Z-/>0+$Y4`=WV%#='H!P&KDTC/V!AD;#5D%OJ*YHX-1%:!0+FO)Q
M*]I0;GA'O5EB!RHL:AH9384VJE>JR_6/@,:A<*#"@J7"H'*0/,62I4]K%K!F
M@8S;V`IT*0IQ3[)O)BZZIVP#1J.[%O#^?UZ'#K$!@*EMETD"-,\`3\\SPU6P
M<6$N>]!M8B".N,.V`&P"$(SK907&.X((F6#4!EP_!-XO"ML%F'8A;#Z\-$"!
M<)`58+,`;O#$]HG6S<)1P("]`@RON/.&!,8K`(N%RTLTM@HPK(*Z3#^V"GC:
M*ABV"F9:!5K!N+-AIDN63",'$V98L<Q0+'5X.#&L6/:T8AE6+&/C[2Z9KMCF
M1=*!",N5!4:[#D](%N)VPZ?;Q;IA#U^;;ZMK/&2GX$*$9<-,V3B\J3*!VQ5/
MMQOC*F*7U8T-\4X!KXVO_;;/9'%H#WI*;ZLN>=7]<AM&A\.D;]"<#:#Q5SI;
M4LOXBL[>;.-K.GOOCI"^:!?S<W*0?R7%X927WH>J*I6UQPI[I2I9]T.F]38Y
MRF0WW*1R7S674>-6W4%2=U.I\^U<;#B<6_P'4$L#!!0````(`%2"#$?X20QB
M6P,``"@/```9````>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;)57VY*B,!#]
M%8H/D"00+I9:->K@[L-63<W#[C.C4:D!XA(<9_]^@41,4E'BBT`\?4YWTNFD
M9Q=:?[(C(8WS7185F[O'ICE-/8]MCZ3,V(2>2-7^LZ=UF37M9WWPV*DFV:XW
M*@L/`1!Z9997[F+6C[W5BQD]-T5>D;?:8>>RS.I_2U+0R]R%[G7@/3\<FV[`
M6\R\P6Z7EZ1B.:V<FNSG[@N<;A#N(#WB=TXN3'IW.N<_*/WL/G[NYB[H?"`%
MV38=1=8^OLB*%$7'U"K_%:0WS<Y0?K^RIWVXK?L?&2,K6OS)=\VQ]1:XSH[L
MLW/1O-/+#R)BZ#W<TH+UO\[VS!I:7DU<I\R^^3.O^N>%_Q,#868V0,(`#0:#
MCMG`%P;^S2!X:!`(@\!6`0L#;*L0"H/P9A`]-(B$0:0I>'QV^[599TVVF-7T
MXK!3UF4LG+;PNB-IF1W6L]5\R=O58>WHUP)#//.^.B*!03UF*6-"8(*L90@T
M(5)5*!PP7NNDT5/DJEX@B0"9)%8R(C1ZL1XE>1TG24=)-@K"'X_5O\;J\U7Q
M)?L@M"`(K@0!)P@D`A_$JI.8SP7'5'S-@`\0'M?!F@Z6=2`PZ2RQK!,G($:!
MT1]+7&J)VRBX*(XC&(T'&&H!ADK:1JI0S`,,):%H`D)D0JVM4*D5:J.A<#(>
M6*0%%BF!Q>,$L9:C\;,YFF@>).,YFB9*CH8XLM"!0!/J3B0IUL28?0(DYA1%
MT$((ZD)*D4/&[9`*$!<*$QP#"R6D*R&+C2=`7,D/D\0W1VX%2Q_`[OOMZW[[
MR@QI]340#LD@%%J<%5"O?S!0=)`%!=;R&^)G$QSJQ0,JU0-I\QJ)59(W<PB`
M";120`$PH]8**C*#7A60CX%-^NG%`RK50ZJ_]RGT\@&?KA]0+R!0J2#2G4))
M)A5D<00@O7X@I7[8'),(:M$B^&RT2-_R"#TZBA)Q29(W*9A$R(1:6Z'2^ZC[
M3NO[':G[W>;:%^A3%SP]=?HM!6&;J5/N"Q,8F*?.!I7>1W&G/>F27I+ZT#=@
MS-G2<]7PV^`P.C1Y+ZB[Y&OC2SA=0</X&DY?>0MWHU_,3MF!_,KJ0UXQYX,V
M;6O1]P%[2AO2N@TFK=O'MFT=/@JR;[K7J#L#>"/'/QIZNO:E0W.\^`]02P,$
M%`````@`5((,1QS7XQ-:`P``N1```!D```!X;"]W;W)K<VAE971S+W-H965T
M-#8N>&ULI5C;;J,P$/T5Q`<$?.%6)9$VEW;W8:6J#[O/-'$25,!93)KNWR_F
MDM@CW!IM'L(E9\[,.3!CR/S*JS=Q8JQV/HJ\%`OW5-?G!\\3NQ,K4C'C9U8V
MOQQX5:1U<U@=/7&N6+IO@XK<P[X?>D6:E>YRWIY[KI9S?JGSK&3/E2,N19%6
M?U<LY]>%B]SAQ$MV/-7RA+><>[>X?5:P4F2\="IV6+C?T,,3P1+2(GYE["J4
M?4<6_\KYFSSXL5^XOJR!Y6Q72XJTV;RS-<MSR=1D_M.3WG/*0'5_8']LY3;E
MOZ:"K7G^.]O7IZ9:WW7V[)!>\OJ%7[^S7D,@"7<\%^VWL[N(FA=#B.L4Z4>W
MS<IV>^U^B9(^;#P`]P'X%H#HIP&D#R"V`;0/H+8!01\0V`:$?4!H&Q#U`1$(
M\#IWVVNS2>MT.:_XU1'G5-ZQZ*&!5Y*D879$RU9UE[RY.J(Y^[X,<#3WWB51
MC\$M9J5B*/+',&L-XR=CF(W.@\8P6QV#QS"/*F84\:0BPGLBKS%DU!4\N$(Z
M5[!:!8F^)B`#`>T(B&9KK!?9A:PZ3-EB4!#X\C,&7*M`'&`C<*,Q4FH$;E5@
MG.@XHT8*-%)-8S*JD:J)4&)22+7"S0(UNL@H3X6%D9VZ`*@+5'4$Y$DZ=8%:
M]@Q%8Z"U"@IF<3@&V@"F9`RTU4$^&0,]VJ1[,A9NM"<$]H2:/18M%H$6BZ:V
M6`PJB+4*P!SH,&L=0[Y.DH`DB4)`E'%D)$`^T"F7PVE"$0)%(/2UU!4`T3'0
MQ@:T-8+,%6-8,=8H`@L*`GTCDWV#`PI1&]]4$(8KU^";!6AK!)DKAD,'J5.'
M4!OK0^A;.-FW"%81:;Z!$2)OZ'85CI0AXL_\=L[>/Q8C`<&61O%G0_>6./[O
MQ+#-D=;GU,(T#/L<3^YS#/L<(QO?>]0@W^(>P;`],;;QN4=-200?@S#1?(TM
M*"CTE4[V%785#JQ\#32YH<6PQW!5Q*&5L>'T3+!'L=JC)+!XP,$Q=#:>["SL
M&YQ8.9N8GF[,S],^R$1\3:_%4DX0T$O05+T$-@[!G^GMG\`(UN3"4CWE!>V<
M'MG/M#IFI7!>>=V\Z[4O9@?.:]90^;/FGCRQ='\[R-FAEKM1LU]U;];=0<W/
MPQ\%MW\KEO\`4$L#!!0````(`%2"#$=)`,J:IP$``/<#```9````>&PO=V]R
M:W-H965T<R]S:&5E=#0W+GAM;(U3VVZC,!#]%<L?4#M`-DU$D%JJ5?NP4M6'
M[K,3AF#5%VH[H?OW]06RI,I>7O#,^)SC,QY<#MJ\V0[`H0\IE-WBSKE^0XC=
M=R"9O=$]*+_3:B.9\ZDY$-L;8$TD24$R2K\1R;C"51EKSZ8J]=$)KN#9('N4
MDIE?]R#TL,4+/!5>^*%SH4"JDIQY#9>@+-<*&6BW^&ZQJ8N`B(!7#H.=Q2AX
MWVG]%I*G9HMIL``"]BXH,+^<H`8A@I`_^'W4_'UD(,[C2?U[[-:[WS$+M18_
M>>,Z;Y9BU$#+CL*]Z.$1QA:607"OA8U?M#]:I^5$P4BRC[1R%=<A[=S2D7:=
MD(V$[$Q8_)V0CX3\"X$D9[&O!^9851H](-NS,.S%QL--$/'*R$8UDZ[+=V9]
M]50M\U5)3D%HQ&01<S_'Y.OU-4S])PSQ'JX:R28C13*271BY_;=`/@FD]"Z_
M$/@/!\47!\5<H*"7;:[2522,BIAB3>E55#U'K2]0R0R9S:AG!_C!S($KBW;:
M^7''V;1:._!:]&:)4>=?X3D1T+H0KGQLTH^9$J?[Z9F=WWKU"5!+`P04````
M"`!4@@Q'NTJ"B10#``#(#0``&0```'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6R55\MRVC`4_16//R"6KBP_,L!,@23MHC.9+-JU`P(\L2UJB9#^?2U;$$M5
M0&SP@_.X]XHC[,F1MV]BQY@,/NJJ$=-P)^7^/HK$:L?J0MSQ/6NZ;S:\K0O9
M7;;;2.Q;5JQ[4EU%@%`2U479A+-)?^^YG4WX059EPY[;0!SJNFC_SEG%C],0
MAZ<;+^5V)]6-:#:)SKQU6;-&E+P)6K:9AM_P_1-D"M(C?I7L*$;G@2K^E?,W
M=?%C/0V1JH%5;"651-$=WMF"5952ZIS_:-%/3T4<GY_4'_MVN_)?"\$6O/I=
MKN6NJQ:%P9IMBD,E7_CQ.],]4"6XXI7H/X/504A>GRAA4!<?P[%L^N-Q^"9#
MFN8F@";`F0#Q10+1!/))P!<)L2;$GX3\(H%J`CT3R.4>$DU(?'M(-2&U"-$P
MW7YMEH4L9I.6'P.Q+]0O%M]W\%:)=,J!Z-7:8<F[U1'=W?<9C?$D>E="&@,]
M9FYBP(59F!CBPBQ-3.S"/)@8ZL(\CC$Q<6*>3)WDC(FZF3@'`Z?!D&$P8`BD
MUP7(22`>!,A(@$!J5CE@'DU,=MTDMDQBH\K,-,D&DP'3]!ATAQ!VH9Z^1GU9
M#+6*H>-NB(=`8LT\N77FJ55!>GWFBS$&Y^BZ26:99$:5N6DR4!;9:)H8I0AY
M^.263S[VH1X"&%GS5%OQ;0/%V"H"&T&BUF^'Z@T"C]J%-/.I%6PCN+YV<P-$
M*7CXV+'$Y/KRS35H:"C':>QA9$<3&]FDQ-V0"?+QL5.'J2%!/23LW.&;@X?M
MY.'4J"(QN\UUMZD1"P+T+O990SN!V(@@]:DWMUO.;VT9D%4%&.FBF2L:#QIT
M:AEY[01@IQ#P]7W^`?#M6SC8,00S8;F'!+%&"^3FT=K9`2,6"7*%=`GCOZS,
M=[1V?,"(3X+=5G1D%?M:);:5$;,$7#^8I08-5L1GVP<[BV!D,2%NGW$6P<O'
MCB$8,4QBM\_XKQ#^'UPT>E[=%UOVLVBW92."5RZ[1]_^.77#N62=%KKK-'?=
M:]7YHF(;J4Y393:\:`P7DN]/[TWGE[?9/U!+`P04````"`!4@@Q'^DJ\_NA2
M``!N7`$`%````'AL+W-H87)E9%-T<FEN9W,N>&UL[7W)<B/9M=C:_(H,1;5%
M1B11&`FR6T\1*!:KFE)Q:(*E#OF%%TD@2:8J@8200+&HZ(6V7ML;1]@_X8WW
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M^U6Z*):K;'X7'1>S13+W7E0++V8S`-AX54P^Q=&83C&Z6*_*%1PU?%X+^>O'
MA;?P3GO_I]H/+M-E5DQK-ZV08><__(<@.L`84QKG79YXJ[I-\M(;4<]LP_P=
M//30M/JF+#7X[D]=[V@OSM^>G(]/WD9O1A]&Y\<GT?C'DY/K,=R*C^.WT>ZK
M/6^^=`)[[1!N]^LP)2G+=.5-?YR4]]5GE\MTD633*/T"=[WT;^%UL8)-31K'
MO5C=`]:$?WN;WJ;P[30J;N$?B%.3HO1?NUP"K5D"3B&12/^ZSA8(TSB:IZOP
MBD;A'<HZ\RRYR?)LE?D;&DTF2*/*:)$\)C>Y=_+P^W*=U@.$-XL3A,=W`=:P
M$+HV]T4^39?E;VG/L/W=:7J;3;*5=^QP3@+(DJ_;JW:KW>[`+I;1YR1?IS]$
M@[C=;N/_"T&-DO7JOEAF?TNG`,A"/<W*$O>'@"[,787C@R.*X":EFJS^$!W&
MAX?#>!`>LG$@0--T=@.0JD55)AZUN^DV;F<8#P\/XW;W\#F[&K2;ANX?#.+>
M<+N!-^YR-)UFR%4`)?":[6?S:)(L,D"1`-ZM9^L<J-LT$B0(HU;Y)+SA;SX8
M-*2=N+AW(F.\W0[WHG)]\Y=TLHI6100/T]D"=_BLC_R#MS%U:V2KG&_G``\P
M/N@?A$;J].+>T5%\</!"1UQ+PG<O$Z0!]^DJ`\90[@%-?Q6]KI%VO/NM(1+M
M`M),BSQ/ED"T8"$TP&8"X6U]VR\8'-N^7=3S>_>*/W5#[M<;=Q-\_32XE>"K
M#?O8$I6_\L3JAGWJ.6X89ZO3W3!&TYGKVS"^'EV?G)V<PTVX>!==7)Y<C:Y/
M+\[A7GR<)VL@B^ETKU[,Z6TM_7L7\@)`GJRTJ,$BA7#S[SUI/2U!M)O<TUO3
M]'.:%R1Z>``"P@S\/"B\O$_G*0KP.$0RG65S4@]6V6=/N&!J7#0LL'XS>5'6
M""/9?%+,`.MDC#UODZ?S50KGMO+>#`I8]J`U&PA.6WWW/%T%%WW,?`[`$RTJ
M:#?-/F=3$-9#4MLR)?4,2/(4)&V4X2)4/D"H!(P\K@Y5MY@H62QRH,<@^2%R
M3RQ2(/RP]DN\R>I]O`>`O#=)F4T8=;)\C:Q[NZO_<YK=W>/KR6<XWKO4&=>Y
M7[63\*L^U:RY?\>C\8_1NP\7/V]Y_U!7B&[SXJ&,;I?%S,)9T(SAE(*B]?0O
MZW*%MZ=DPC$IYA/0.!')&(3P%/\]P<'7)>P$-A(:V</@MRF<[R1+0I(&"3,(
M)1@/X(C(&'S/Q:'T9J41R=O\?3*_0UKIK(XT#CH'2ZKW5FKT@QJY_WP;`&PZ
MCFS^&>YS\S>7:Z!K`!7<[B*H7VU<VC;35)=VF\T3./;F;P#=@1'!63!`D2G!
M1ZD01%@P$-%5AE+S&O2LB=8>`WKC)$VG"BIJ&!A`KM)Z`><]`>3#!3UC7/CD
MIE@NBP?\?@V\:`D"ZBJM51\U"`'B2,NFT<WC5B#!#X&B+E,\,1#G^5][$6D,
MOMY.4$]6T4UZE\WGLKD%V1[J7DU1OJU[Z;R8[].Z0VOUD)R49&0$MT2YFH\2
M+L2V8*^Q%B`IR>'^9;<9_`9$)-E:K;)E/5>J6<CU"(*+;"*W!3(Y9IW-;ZV2
M+R$DA]NS+(7@&`F+Z16LP;:?-7^<Y`#KM>8)BZHLCC):.B.F5F6IL`&7S37/
M=&5&>N**+Z[>C\Y/_Q,)>='H_&UT>75Z?GQZ.?H0C8ZO3_]T>GUZ,O8^6MXE
M\^QO"8N7L)2RR+,I&V(1FV`-)1"J1)'M=XR=<.YC>)@RKZFWV)Y?7)]$G7_\
M_;_\X^__#?Z[U1*CJVP%9QY=`@&9)9-TS>I;')W.)ZUH]Q]__Q_\PC_^_C\C
M/'K`;G@FEE)X"%<6;@+HC7GR@%+"I%@NBB7OX#Y-IG]=)TO$*2*P'XHR&@&O
MR5.8X#C),\"F>9:THFL85L:,'D`31?LTR@LX]'GZ.9DFP&-FR,0UKWDD[H<?
MP$QG)-1VCU!$;O>%<N%:YPG(;++%\V2U1L%U/,E2N+*PA`\?CF,"_(2P8D6K
MQ`L7W@\)8(L5*\B@=N-DAZUF"(J070(=A7_@FI;)@MY!FCE=3U!ZN`=Z-8,_
MT!Y"R[Y?SY)Y=+>&Q]ED6=QD*'K"PE9`)E?170((4.!=16X%.P+.CN2S=`&)
M!S/]+.3-C`BGDJ_NHZ52!8!B@TR;%T2`9NDJN2F0:`&%228(9J%I]F)6"4$-
MO0)ESLP<7[E=SR=,I^0[N)WX=C;99WG%VGTID&;Y=$4$%7>$^@_N]!YD13B'
M69H@N;]=YU$&NYJ0%)P`*0)"/5_]X^__O93].%NGYSE@'^$(R#S3.+JZW'_?
M/42@B+4R?Q0\L?0@)F\P$`&:GL`V<IBW*%-:<0X[`.1IJ?&`IM('BP(U)KRJ
ML/B;E'0%@DFV!$WDW=O1/FP5F"3:NY;KNZTG`OQ$Z0TQG@$M9\U(DP#C0`R"
M<0$C(W@M1T1=I,4"2-I#L<RG#\"66]'%G,U&77$3Q32Y#:ZE^'D(TTM%;A#<
M[^`R1N/]3K2+#I7HO`!EM-?;[[:[1]W^'GRH4*"(LE59Q_Q('(&?;>),=WV*
MW`X)1$J;044)4!*7-T[AJ(P9[^3+A"35R,A31*#&)\=(B!@#1!`"00'0';9#
M'`1>Q/'.1^.WHY^`\!#O1*+Q*:4=.J#A<>IV@<(5<FSUT9&")ZZP7[6TBL1@
M]@N4,`*B/T4))9G7SK)89BS7O1JT8#2M6L6$-\G='9P6THJ[):EJ2GQ#"F$1
M`/R^VX9;2UCA$@=BYO(^78,'@#0P1O.'()OX#YA*&N$'V30B])=L!@N!N_2J
MTSI04Y$85\SG*9&#Z"$#>H,3J?VU@#9JJ<9!110*U\2%E8D@--/V\US?KTN>
M`#4Q"[Y!B,$IWJZ((B!AUC+P9FB0,54-KE8>\W%7%S]L]?615#GXF]'XE!38
MRZN3,2BSQ+N]ET!#+H6\&G%A@UC0U6)!<`["C60B+!5W<:MEC]+('D25;])T
MCG,O$F'K^-UR2F(P'4'"3B=!9!@$B%$9W;'="&``OR,;I6\1^A_GQ-E)QJ&-
MC68`R4E"M_O]:'1)<@:)V_-)OIZF)"$FEOX-&)"69;)\U'3U-LF6+H"$C]DT
MS^QQ`2H3O:6^9[VA5$.DTU8T@DD=BT@R,]B@KZA^:F#%*V6^!E)FCD)Y$G7V
M8:[]8:LS@(<HDZ9*;@>6N`HMUR$E3"TM4M09VO3+.4L2Z[.9;`J06BPB>'FF
MB*O3?[OC]L[8,EDMU[G0?J!W9$43TD/<X>08'R?+J;U%LX^E\NLS0,Q6;Y*<
M%D]A'2&?"A,,\X$%$7A5#!BX$LW$[Y=I2NLLLR\@R9$IET499V!Z!8VXS"Z:
M9IE8=@:99?NQEZDYXSBZ6:_J+DZ,\P,U63&7S(EGS#$X!.&'E)A48_N#A_ML
M<N^0;!H";8F5:YB$+R$*`?[%BRW#$'RPSA65]>$0N)J-![SRO5HDMA%BP[HS
M%,K(HJ*N1?`R"`@)C;5(=`L2D74%11HPG`B1E&WMGI`3ECO4WI^.6G#H\V*E
MSR#+D9E.2;C^G*I+HX9''D740]/+-6#&+0=U/&+X!QX@RA!DX&.0OR!EX3O-
M_E_S0F8%)MG@7MT#P_N)-<G\42)VM&B*L31PUL4:Q*H;W&(R%<'@+Z*0F/-H
M/&%<%)N[<-,IRK/.(EQJK'`@%B1PSKR*$:[P93001GHQOL+[-^LRF\/Y165Z
M)PK)9%U:,JRMK"@I)%WB3L2N0&8-TDT\;1#1HV`3!%OJ9BP!LR$+_IHG=\HS
MS.LB%=Q>%W#!")<#Q)E?IX6LTF0F]%:+5)/[++VU+C7<@(Q$]EGR*5V*T$?O
MG'P!2D-(>G%["W+O$HD,67'@AM\#$L%/^:/,Q]H6JEI+>U7V3J=%RGOUP$P8
M72(GPS]R_)9,G@KH@//Z5_T0YT(=I!5]R/ZZSJ:HVXY658[!@B.2PO5L5BMP
MU,C[K@A\#_@+JMLG4C=$5PD(P<-63\F1R$[P7E9#*@*?=3NM0_LSH;"!\8]:
MP[#J@+03P<L<GI`$%0JV9I`L,U\+VU:O)H@-2&;AK5O8$#)WPT=I>#A.0E'T
M/*Q)]645-_@%7#8@5R@UX8U7H]-^XBB[M9Y,%%DHT:`()SIE"P*<%*#E&F&,
M'J>RHI(XUTQ;AF$X0!HT[[#,MTSW]0,VQMS%];>RB@S:_D.;6:*?`K7#[&Z>
MP>EAP*5E^-6&:O<L;M(<-RHVI(PHN[!S.E<:FG:/5RNCRUH`2K-'T!J(S*8$
MDI3-;G<%&Z3A()8L%L,$>9J4*U&GOL`_'M(<KBUSI5;T8_&`1^)B,ZU@GK+T
M6Z),D3K[6L]%?A,VM%J3FDM>.+AA,.^L@$\D\J=8LB]+@X-$F#Q/;L1(!W_#
M.\RURF*])#L?$M<EF01AE\D2Y),"9"(R,[,\L@"!`5%C6>,?MW``$,4Y2L3:
M]5QY6(L;1++@P>&ZU)4!VC-![HC/*A>'H9<G(.*C14B3'$9D919+D.TB&DY9
M<V"Q0C$)1\<AB.(L);+\TM,YQQ_/SD97?T:-<'SZ_OSTW>GQZ/PZ&AT?7WP\
MOSX]?Q]=7GPX/0Z8LT=&\+]$FR$::C:HH3VMAFX_K6?9<ZZ(I7RH-:`HA+HZ
MFVH$LQHYOY*"2/)AZ<J7&;<1!K81"%O1.&/R!LM$9$#_W7IR'UQ:S+*(I8H!
MB9R(Q]:U7FP#FUBN!I`+W`0:&Z<IH"PN&FA)\="*M%?J0ADTCLDK5>.M4AH!
MJ'XSECI%I>#8!=`B5C&[^G`_L+>;9/Z)"&4.RIN$D9B%WJ9IZ9@4$WTY`P;%
M)@V9]2!AH"3QX"'`V>4%CIS"@;&3FRGJM,891S:<[3UR[((5S<Z3!<S:*_;#
M5H0>T0]HS;N$XZ'H<E>H27'%)+%PA(0.TA"K@Q4P4?DIH+*3&H4N6VW,&XV/
MH^X!B#.@CD<GR1*M[CP(K^7_&>/'%=Q;3'>P:-.RF,._)W+7@<^/UG>P)M&6
M<:)WH_$;%1@Y&G\D&S?^NH^BW39>.4W6WA=\8YAM[H[7-ZMB`<?5;0_V^^T]
M_=Y;ID](FF'(C_@Z<@XV=M\0>YI+O@9M?R1.+W)+VGS:F=!S[%]A)-KUG\G]
M=_+3Q]-+#)&I"T>'K>:)2EU141.;*'H?,.:_1N&)HG"@NZ(0VI1S"QR<8@Z^
MW]%BM4U_=TY`I)F1J/DANTV9I.+Y[""&K,EN[<XP(%)>1J^B0=P_'*K_W7FW
M!LPFAHCOWV9?\-]E-)37^W%WV.;_[G#P5SB4)#J*AX,A_W?'C64VD3O1[B#N
M''6BO6BW'P\.!]%>XYBQF*@K@KPUWBM8V>#@@#;3&78C.TQ(69T#DGROW::9
M7G5B_"?Z7#!8Z8[50-?0L)5]"2"V8"-&_A@KFYT]XX&:L4O1]$\V8-D3*.W4
M(L!`T.YJ@Q`U(!3?M\T5.A8,+XS8)\:.W>W":"5^L-G9V>DUQY@AFA]?D)QR
M<AZ2C<A'M3)V!;ZTL&R24*S;O^%Z#33%:)P^.IDM\N*1,[WNX"1YYC/@S$F*
MA"I=H`]07ZIN;%$_Q6/2N?+4$]_-4_)K)VJX:%>\_S3:!_Y53X;VVYBYBSVK
M[VA4R2*URC_P9!8%BJ6P*F1]=#IH!TKU3IEQ!U>C`I)$,7+@D(E.GPLOQ]B+
M^9HD$V1#28X&3/2=]0[8F4=(!J^*(LXWY0Y3XL0@S#HIC*6B;!JY%R^;'<.K
MAT)_+XMR%VL/>M`_B`>](:UGV(N'PV&(4;+KL7I+28%#*H%J:9EJ#R,@UJM!
MZ_#`\/`6L/_)O8R,!$66!V#+0*N=9GS)9212?."JD?TPT11=R;44.8"0$M3H
M]U_W#R.D`/#'-9&=;#F5.=!OCO$:]M!&G#)1;5M:50)"UN5ZB?%:*R4Y:\0B
M2J&0AW%6UH388JV'#=L:%SKM7MSN#BQ_;[-(2K(RC%_<I22':VE,!K!BMDST
M0"'QZ,M43-[1L#7X3DU6XVK&P"9&<%#_G42/E0L5MH?@^3WN*PF23")BT[H#
MQ1>]FJQARL+F:R(C)O*PLG#[6$'?0=5V];A_2U'0`$RB)L/!=WN5332,0M*\
M]7L2+3&J&`<PT6TJ<D!1-,8>$IRU^&9?+SHA0U#DECRB#;EDLQ>`(30/637R
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M>0HS116Q2^!\U>LP>T3.0883Y=.D_5A?@1C>/1HX[S(/-+`E["?@UER!-;'"
M5YU#F9/CD3GP*1&63(L03Q0!;\T^_66:S6X`2"D+#:,ZCZ^B&HDDQ;[J=#LT
M&UZWT%A:LG61Q)*NR:[#2O%V8BM[@M;+)XFJBAX$G(7:6YHR]7>VW=J"2-T4
M<K/</<HY?P798M1^.N$BZ235MTPFFP;%,,::_F%\-.ALR:.CW10GT-'`Y`5D
M#V0I<49`E.#66A>=9Z8(AD7E,F*(J$04\ZT3PH9@PVP#R>3`V>'JH^4.3XS<
MH!Q6/F=+4XD^B7("5,!8ZB@J^TTQ7ZOXN,J"T)2D1SK6(SV;8'AF_67Z.0.*
M>D-+*!;H_UO/5<`>BM3Y8\T54>BC=R\>&Q4)&00&!0N*&6Q:8?5NU-XJ68*`
M%5X8B!']]G>TBIZ1HFS9OW')+I6NN(T(=29(E"B"39T'RE)(V^Q+XM@])(E"
MW1.<#I&#;HQ_K%HFQM,I;Y.);6*DRU56D>7[G?_SOS$*-3I+4^*8C#87-FCP
ME6/ESKHF]\([\<X8;;;N0WQSF61EP]@?Q.=Q\KEN'.#1J"U,UT0!""9\A.E?
MUQQ9NYOM1>;03N6XI0J%FN"2X1CM$L+<,K8@%/84&]'9]C_`B#!D?]LA,U2A
M)N0K1M7)&DESJ+89&\\1QH<)>L^9P!ZL@F@:!=P07B"%"[8AS3=-!"^18XT\
M`:^Z:IY878K^(.X/^B[1!'KM8Z,A9;A="7VV5*;8*#DJ,$=`X4ZA<J\``B!`
M$_.B$!907/*<[X65_C,7-QE,.TUTD+JY4/1]BS`JA$=\'DC(1JS[GS#0S[(<
MEH&.QTMU&7TL^D&G.\71/?L\V<R`R?S(\'FR6?*HQ4\*]P6"E<U<MRLZR'.<
MF(^AH[$)C?:?DRPG*0=W\'0$V+`S?=('\=%1[YL>M#/#MSCGZ+Q8X>1&R9WK
M=]5\EK\#U`91&9(;(-;,V5BG-W'\1L7U0<$9&[`>`@>[N(L5W5S`$I$W%-.H
M@62R7A7H'9H0F]22C]9!E3R#?[/0D.B]L'EE&185=-0%^5]FR`<??74.A+]W
M.,)ZN2C*=!/;)W<9NH8V4)7*SQLOUV51KO:/Q;2C?R^UZ\O5&5VC7D6:3%:^
M,5.R3`RAP\E=/E15WQ,5WZ3\\A-$*0+X;M9*6V)*,X%"MUF:DQ*\IA1S6,-<
M^==T4B7%'9$J8!R'U66P'*V=S+:?3H]#=JEE=I?Y`]Q6#G,FC-ZZ"<:_C(I"
MB1G@WEVH50D"B*'(3<7HXG`6"AZ#_<+DT_0)8Z>NE%^QV7Y;#2-H*`\*]JPQ
M+#SIF$R>%!AE)6L04^W%_4[/UE7J9>-M[<E1GI42JL=TL?Q^!^6D;CL^&AZQ
M98\HAZ4D<>!VV!X<D4&8I)<=EHYZW;C?ZYN/B1H1Z>L""]&LB*V5(/EGZ-$5
M*[I-@BDL2ARQ3,,TEB]3+*Q')%]F41\9#B'L6_F82?=7+*1V2YKELYE;Q[O2
M6CN#;MSK#_6<2G2GF(N;QSAZ==3J&0<6!3UU^L"A^_WZ;]C7UFMU>_I#LSOA
MC!5NGA`#F>\SKJ:I!$Z@08TCW?`VW&C])G\,W@:\;@ME^$HF'$_6B7M'AT^S
M3SN<7M0XV]"R3X868@D4IZ6-_'2FXA%4'Q)8V))<8R8(+ALQ=]M%I^*OJ"X>
M:0\M-;#*&C,02G`U!1:0WY(HZ3S4@>3JRLN5-@>HDE$SBOB#UV:MZ`.E:SH!
M'CD_*L@NR#8<^!RK992+9,)B`8:J64FU1.Y,&JU#HA)T+?%!&0>>V(",+*!]
MKPPZ%$5*X6]HG)JM9_KZ+45IJ+AZ!\9#IOUH.K$?7N]]AR$9.#?;MV+;.D:>
M![2`H85]'^-QV?,0D^&W&I#*4^'J4N.@BK;V6].5^\,:AO(M?A7/YSQ]B-!7
MP?"CD[&@B"O`-U1J<*H.C0XJQE/^"T>GL/W9V%DO`",H=UBA6SW8>=*%4=:J
MT&@/!?)\SQ"G,)S*1JFL&@:=S3\7^6?)XB&<PT]@2(Z@6++Z+CQ4TD`F!5H[
M[3!I$!SI/F62DPS_ZT)3Q=R2@F#/.<U*C-80`P=R6U"3L&[('5\FM1+.;5UF
MQHO?L)AK\E*B,*Z27)QI\N2A7&>K4J<;D$$/@(B12&LK&B.6H$R*32.+.Z8;
MP^<<IJ$H,\>F(>&7U;9$V&5!WH4$&\@X9AUC^M9$<^P8/1F$HY81$S%\5TAH
M"02!+,(8H:KU$B/%P96B&`(=DFI>HA`PSFG!`\F3;(;TBP^<_\28"LG<X<#L
M&](UE00B1FM8).&P"L`)6<HQ#,FDY2N>IS^AQ2C\%&F6HLLJ'KVU'01E,J2*
M]0H1285UXE5;Y_3!`A:>35:MZ$TZ2=:E":2LCL3U.W@$;7$D/97+1)FL$Z-S
MBSJ!V$V\PI+<[0\8RTOS814!]"E6#DC#R\++A1!H.B!5?$?=#C]P]_KB^(\_
M7GQX>W(U_FWT]N3=Z?'IM11Z.'EW<G5%99'@G6C\\<T?3HZOH^N+"!Z>G%V&
MTDJ#51)!K]X8HG)@8GJM%0&?ID"PZS]'N[*VO>T7Y]3>$%;M1>16+-*)73:.
MKCD&]`7J7WI9V20Y6A7M."Q":C6:N`B;MBJ;.?M[*%YW2A?U&#"/+C=+_*=S
MNX*$[;TDUQ]N8"1#65_J9,@E9B*+-]7:W):N#("!55@TL,W(W^2)ZQ54@94L
MH_YJ$:`MKQ[+=66C`=]SYI:^M(,%D-EA`1$AW1A'H<SCCTCC8Z8G9%[0%,PN
ML%1[`'X%&E"IEZIF`29;E)B]DI6LYWB!$RPCV+'E)-T0'>.!8C72;?:%9<L4
M.8A4D5D4#\0_>!U4V(0Q!V4JC2)FO=71179[C%!/8O1C=Y,-+P`((CDH5,K^
M!5-A@$35E13`Y;@^Q=:N5!*ZN8&+ZQ4#JI94M7'Y$OCRLF%IPF:_@K@,XZZS
MQ!ADNP.GB'",X:2@BO</^OK),#X8',:=PZY^PM4C!MYVI>#?"-,,];^[UK][
M^M]O>)2Z$H'5Z()MB=['YP=@Q5+)R<0>V028*NYDH2).DENUN40G!^=7B_=4
M;"Z]N-?M`L#KR+^$XVF+LC8RZB0;ME517I<8BT"9`XI#CC);&##IZ``A='E=
MZ:6V,&=0NP!8'Z9P*`X\-M/3!;>BYQ1LJ\0HC`&`[O4(D-CU($7&9"E']&\9
M6H0`TCH`"G^!G9HZ0&3?#)_I<Y#R<R&)'A(01S'M8H&ED%__'DJFW%3A0LI"
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M3$@M)PZ\#)U*9%6/O:U=!D%X8NKO*HW2#,/7B.J-&=2I'^Z>:51!53'M85`S
M56B!?AB\CQFE&2<YO)&HH#?T?\AKYFM\$69A-M`,V)!=K*NK(0G)&)H'ON!%
M+P6$'3>HY1G0'S53A(=$&:.<XY@79AX22JMG,PT?SJB)T[4XVD33:D[N-GXA
M<<A9U#Q&FU%9Y&MEZ'W(F'2L%Q5Y)X[2C)#@,[P]7Y&38\E&+O[3T,A&@*@M
M64;P9MY3KF>>!U"[A^QH?N89Q"A08S/P#O$*^W:^B2O<2ZV=[$O:R^.`C<BU
ML9E(T6!*.G13SA?H=UL91QT\"L-)`,-#2YT'&9>L5Y@1I"=47M,IQE%B@*S8
M-E&(0R*;J$CV62&BE8)[1MYDJA#$C@=R"E$2@RBP\`#D#3)E4L[L`YHCPRX,
M6TH&-,E36YK2:[,FLA#:N>[-`D+]ER.?P=XGM8&9J"QF!<?K9HXD(ZJRLV2Y
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MLU<VF2A`#NL-MO?2(\@>0&9,A)-J.>#K!M8Y.3_+V)R5TGB[A+#VXO9A)SX\
MZIDD40_P7*25PO=E`O*>)QQ)@+0?Q;-H=[@G1A&V`XDU1HG&3-*<7:.?7Y'Y
MS00F+#51G(?-+P(V(@46$7"FZ1?C[[>G!(9F6;(L15@*4-@"(.K=4MO&=M]C
M.8;##I8,X*DK4.?"HGE>3!(KYJ!6^,9EZ,63TYV]F)^E3B8;`,7USB7BQ!&<
M.,;!8>NP5]51?.F;-5Y>G%"N*C'6B\%``?+46FU.1(KM#Y4]0-$G*MV#"]/N
MBZ9UV+?0BCE(6+-(I<5/!O0U68HW,=R=)>;@%Q(0=5"`I!EILLH&$RJ;J,T9
M8B#03/@T3+#]FQ(K&KNB0+-.G_QP9=#<N9D<N<=O1XF!FO1JT..X"I%2I((G
M<@.2942.48T!U'WO',:]?A=QR3;D<O&\)R]P([T<'L6]8?])Y%$^4=NFK0[;
MS]@I)EP7<]J:SCI+O^#]6&?EO9:Y7GS+\>!PVP@HWC!]H(]9$$9BXKPM6P':
M&@.^`KN"S*C&VPHT>&A2.$10Q]7=Z&J3,H*GYEA7Q!7<[/MM^^GE*$UM#"(M
MA_VXWQ](LQ3=#R)&8\U$ZFY(57>+.J+$8U4Q4GW*[,WK5#3WXG.C`C%8J^LB
MHKLM0%%A,RF'Y*(B@*S3;M?`;'MH$0YO@1)$ZL5GG&#Z.]>;XJ3*;X,1B:>Q
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M<#G>'L>)22`C&X?XFE9ON4Y`?/(!X9Z\`XINTM5#FCK)/0RJRS/YWVML"O$3
MN^MA'3]F=_<&U(_1&U6Y5,1-'$CZ:"!6_I@\)%D&J_V<J9QB#)8C\I?+)8<Y
M</]8JI52'>A.H1QGF>]<^P_66(/Q7W7BX4!G,"G*H65&K6ASWHH4>]Y4<A&'
MDE6K@6[2>7K+A<)PK;MVNBY>\FRN2/@?+_7!"!I93U0EJG3JZ<*JEYA:7RPQ
M&HIR8[H-IH?@/:=W3T]-==`5^HVKZU95>1N+D'CXX!((-`ZI,J:VV0S?4;6=
M`])",>=RGAK85M`9+XO+A",LGS"%!4F4;M&XKE*5]3F*WVQ&92'D@02:8I4S
M?R260W!JNF*PI-J<E`W`>I`XU(03JKB>GQV/RM4ZR;9$#2]+G7R5U6T&C?WV
M7HRVI(/,]48N.1"8!'_O*F2`KI\+<<7#?5BD&(T:XXL@CI*55O=O$1\)QP,R
M[1#<J3^06"[`(VFKIE:O%8Z^`7Q$;CDN,8&_HK_J`MS+XC')5X\Z/!E>0<Q!
M8;)'F:0JTX.RN@@6XFD:*'%9%=]=W2^+-="OBDNJ-T!(8P&_G$W"'#:AKO29
MXE><G.FD.N^)T,)9(%-*YY'^4`<ABZ9^DP&JO%&+]:HZ&5<B(_-0)^X?',5'
M1_UMW)`$GK.*9JW]#:$D;N?NWN0J/EJ1Y`K\2SF`U@:6WDAXK'W6X`/6I?9`
M%`)$=0<:,%6!:-?8B=Z02,"0TNQ.-5<RZ2'(H]CTCX6BQ#M@@NGL4]#W4>.S
M%X#C^4%%3J[&Z#UXE0?(.*!8@<7T;!XY2Z:I4+`JOS0-R@+\7S4_DGT$/1O&
MU=?"_%).>!+0*ZE-$P=5GNOE,*UQ`R*D<$8RX@J@$14V8W^3;LZK")CFQ,A/
MT<-10=.0B,1!UZP:2#%%=T/_CJZ]$'P<D6JIEAM$@+J;F"ENDTZ_$0'9>*Q4
MQ:*ZB$I]K::O<Q'8-N.&A+QZ3(W-)A+<.B\>B.9SI6#G],.RM8H`T5?$1"E7
MTY(`PV[XMK-9-&2=[;3WX;]''!TDB98+409O11DL41G4Z22!I/WZ(*UK.>%-
M@U('QOO'FR5%G92KY5JJK(*@PI+6;F>/^\BMHON"`*S?HAH5W3W*G`2R-YVF
M-=/$$GBGJ)[E^V7*]"160$E4!6QO228?E8G"F0XF/[Q&V8I#&@<7?'9-O4^*
M.ZL)-:N+$*[T]-"&LQ4E)*D&]"%_3[<]B`?5F@OUYKVZ&HBGEQ=>4LC/HZNK
MT?FU5X_4V'_AO*_X^E!RQS:E2*,OL_Q[RF[[E]]0"<+EY_0WG/PQU,D?:F8T
MMQB1+)OS-`>QLI<$W6WD^F'+NK8<J?P(VQO%6CEF=Q96N-3"ZOW<1]-T=^MJ
M3^QR#I;%=%U"E?0/8,B/?Q/FH6$;J+2-I.*:*D`#P<#5:SE"AY,Y0V#:/CVA
MDB.9CL#@1D4Z<(KRQ<HBWC!(.0'F2&4I1(*2CAK&I2:^)^6D,BX;:SY#+4IU
M7O#E/98]D&NI>VVQ(>@QD@R^E,N'(?FQ_&7D.79\9$B`W`*_81^9=^4D:X*O
MG-Z_:0;D1J'*9DM5?I]-6&@'G!=6?1!MG*=15&,.(2RJ`IB5\E:-(-=U.BF6
M&6O`FU1XC=VADIQ.D)XJ\C]=:Y(K3J<5AF"3O>O[G9]3O,NPO1%0G^0NW=%`
MT&+A)>+TSH4[G]_>0%V<5Q$B_LY[R6?>C_9WU%#3UR=?%AAZ_1IMG;=IIEZX
M:-I,9>`3JYKJAG>C8,K;_IO1^`3K'Y]=GIR/@RT2W>KJ3GF)*[%\''/S`I+(
MI#VMYCK/(82';A9<8)'1=;7FA5.R=S^0<DZJ.WH?_8)G]"'!S*XNUVVWCZP'
MDOSLE*"+=K%AB@X,6;&['G]!"MO:X\J,^*<*VJMP>TZBQW(%E-(*E/A1KK*4
M1"!3&1*"SZG[@TIKQYH9BF2+*!=PHZN46W3``GYE4SNK7LP(*(DBMO^@"C'5
MSXT9PF2VODFKR?K!63&M5)4AJ@1$89<B%)!TC2<UGI&?JP=1+*OGT%"(<I9\
MH21P(S1X*FG5AZ(K$MVDBD:#6-CK'L;=PR-G70[&,.FJL#^38J]+(/MU]_Q0
M=S8AJI!,K$`B<M5$6#/%=H4.)]H=[=EG0K*HY%L_W`.7LY)Q<2#&0!4MJ'(5
M2`SNM+^S>0>=E2FPU>D8+QKY]J0#6B5S3#=;$WF-YOL!SW#W366ARF>IUEN=
ML/TU$TK].!^0>/O"E^\%YV?<T%<7$=Y!<:81'&C*Q4*VPQ-"$_[,*IJ%84!S
M.[:BI<MEG3(^`[S?.O?_1%U5G-FM(=2D7].ZI<44XJ,V+E5Y8J]J_S+B3Z#6
MJ"_D'U"7!I/GR>VY5$DC+AJA.E?HK7AF#*G#'J,=HW-@:@>1F?Q6LV$<A:OC
M'NE7.)C4%36"NDP/*ZC9KG-G$H7P@/]F/DLL:>SKT`^1&+5-75Y>RNG'C34^
M:U)L0#%ERSH>Z*MV:WC$A1A;W:$=),I.3Q7QK><GS+740EU2*EB%-:#9N+T=
M:8U6:T13L4<*`;#*D&>?TCR[+PKM>*J93ZDXZD`LXE.#3IQ0K.LY%+=V;57R
M18S@#')A-QNVR[J"E-C>"NW[G?AH^XA#PB^D6`6<H#$#I-/F;=15M&L.[=15
MN0R>HQ3S5^U)[;2MTD;69NLA70N&3CP$>6%X<+!UI.H(;6M:1ZX!J^X5P7(X
MW_I>?'0X<*^LY?[X56\?U=BBVT?UKRSM>0OZ(ERN6KLZ5-6G1GCJQ(>#7GS8
MZS20P-K(H=K"3RI\2.XB&G=`\"=`BHO]5VA'$X6"RX=N[M?AH2Z1M)$N/ZFA
MS^&AZ83RZG#HS/+,QD'UXJ^$Z%33W%I'=BP\5^M<SZWS<\X,G;VVEQLONM3`
M:]"V")4)^-+[@8;)K'[)3)9L8S$71GM0>GC">KC"720%K0,.:`Y)-.?%W/!^
M241AU+I2IL]WGJ#24$HA+*0@`;.TI6;*!7++8+B]<=*5!VV!Y>`H'ARVZP06
M5#(4E6*DZW&=V(W22X42U!,XYUNMG+Z$B-$5$:/3KU@(RYI)=;2O,<:Q1F1\
MF[4G,HR[0VW0M+4/ZTSC?V_U&(D9BP..HJZ"G-@I_6=M9WMX-%6RA`/"&$9=
MKK(D^(1TG1?=^`OR%Y_H#Q49[GU];[7FYFW]ER#SL6*1M7%>+]:O35/7/X%R
MRY!UK,4JNC<4VDMG$^0);.>Q;ITAUYS`;-%O[M1.6B\V\-T?3^Z+'$^1%K:/
MF$F(E*[N4;^M-!*V6GR2-8<-"_PRYYQ065U.G^2X(=WJ6+UU2T4J>:.REI*2
M-M<SI<=3,V"[_!%<+'R]4$FW%F2LB.A*"!_;+1T#&Y?]DS`GJ\8=\GJ,4>2D
M:5@7E3VC8":6^C5SS3-L9:W,[D@*I"R'"<0LZH]*(9)P>W,L%K470U+%SC%^
M\I`)I=:5'D2V:?`B)<,:;X-0D68T*J:I[AO.2Y$B>/<`[?Q1:;4JUYY3D[_8
MV*`\'<8IU7PU^#9(-*Z%5&NKT?(6J!\F*HG=MZ:9QG#I0%VY6EI<7#>0J''=
MP#NZF:C55O1$8:2NV/%(5;ZQ6L=W_G_-^PPL9D$6LA\,6NV#[Z+]Z&#8:A]^
M%PT&K5Z7_NZVVD?P=Z?5']3_OG.5E9_V;W%W.D:"2HB`!G"$K\%;P^_@KT&?
M_SH8XLJ&0_NW/KW9:[7[W^U<2\:=NKJ=MOZ_'38.\Q98GT,Y9VC_&[-I/!"U
MG*=F\_2\9@/N-XB#3F%D9;Y['JKA]:A$-%(3%JE+22$;+(VBGXC@R1%F3/*8
MK=91AA`Y%/>B?4ET*&I&U?.D<2],@S?U+^OIG6[Z\9F9EO"/U(=C;"DANB!5
M90,`'GSY;TWT.K0;S3)(T90""HJ)<P0,=BTW94LQW(@8AL-:8$%\P27F7Q^6
MHB]Z>[HVJ$MK&C4-&YZJHXY="TH-&J!A9#SWM);\L1++X@%)N#^6`+)CUFNX
MI.#G=C(`8J=O.0RI'EHT15<V:A:<MS6STB4L#A?>?"U0"ZDW:%?&OK"-0G[1
MU&<=7DCH5MS']R\EGSA*%K4";N1-$2+(637FN>'X5@MI("ED4&5-$#@^SV(3
M@K+(IX'U-I>D(^V`O)5.M<58\I2!#.;IG=$]FX;3Z;=$X(IR(_RJVPU7(MMF
M[A\0/MD,[>!TXG9P>^9'IQ5:OOY!`=;^.>$:RO(69QA0S"D1)UVIV+(NTS"6
MA3DP9S:?KD%L>M10!QUJ7LQ(\Q(!BT8I+4YEVZ_9-XKM.6C_7-6`M0H@2GH?
M5H%BQQK/=F8R-PB<D:I3Z:!8NGC@_C#\*N*NNE2TOM3!.M9^8FR?FM(98=$:
MNOGL@3,@X$X+LBBT<*DI-Q`N1_IF4K*B'9,X%.D8%.LRZ'`Z,F1@>)]XWK'/
M*@!LE6V9;:J*=U-\3?B;*L[[_C8D!M_O_!DM[A2&$1WC:!RO0F85>@H"6GO@
MU@/>3?;(^GF$OQW81<^\"/-D;_=FCRJ^M'?(`;\OKGE3T\7[AC\XZ*)HV*8/
M.KV&(/:;/2[4MT-"I$Y`K'FOUV:)T]D05339P6V-ZGON^K2J)$F$JGQ3QIP8
M472]X=8.3CIN+G_WC/*9C>A1VU:TH9UP;3%@)^#A*=.JNL7<Y<CTL";+J(^*
M.OMOJ#R_+R2U;-,T=RL6OU:N0Z$?9+5!SEV5?"AM=$'%\T,K#`4IXL^C68H%
M3;%O'(R&*8$4.L7%<C$XBLGHB-FQ#M`<G1Y?CB@R4W[AGD-3RPCS'LA9&EL/
M*#46@PO3_''_1]2KU-JDZO@XG:R7G/HGEO*J@U]5&:'I>09:A*M8?M933DDX
MAHG]@Z9\4?&#2\&GJGM<BG"<,>1'"O)92:5'"KL1A3J6%!O'462ZAC"6`I^E
MYG.<:81%GO2C/3EEZT2MTZ0X`080'2POJHH.;*,H.4(5:Y^Q0&HQ1,T)0SCN
MH`P'<[8`9=$9QPB@A!U<G!Z)PE'Y!:<^FUT<ESH;E!RD;?EY58*JNPW8VT/A
M?+XH,BH8HI*/S23_^/M_DY4\6B=.LH.I=R4;PW=Q`01GTV#96"Q=!89`C*56
M\/^M("QL0Y!21Q1E>+-R;:MH8H=FX;S?VZ8/]'"H,;3N!M/Q2X38U!<%KA\`
M_U@?W1E]\T/E+:?`EWI%25%O0!TI,?=1?K&KP`(/1H/1"CU750DF]"UYZ#QD
MW:Q[E/IFBX--#$(4;4RV,91-<R0X3J12<2MAWZBY2D$Y87SV(7-R)XMNDVI%
M'F=JXR>HO"JO20@S;M/IFD(B%*9-@`:^GZ?S.[S<]@H$+!0A;`KK$?:J&L-.
M:1SK*BLJR'X;[*;J!BNHC:N<23)0D`P7@#3*`]A757=(H3_"Q484PS(U+2Q)
M@1\&^TU:4H@G>D1CG9\?%F!,5P2[!H?-J;X2`B]3.UU@LC)B=*0KI4LMP7;,
M\F+,<J!51C-45_78(E4P@3XGIWB?"*^WUF%QF6P7RGN>*".`(1F7;/M6:4?O
M,BK(Z?E?H_O`7@(7+*C*C;H>DHK4,Y&R',!2*6LA6VWV(QN[B4>GKD,42!N^
M%3-1WTM$L4%CK1IS>V92,O`O,=>AV5FHAA8?*+I@(P7B-I2EKB*@_(B:2KBT
MR5>N';(4?^5.6M&/*@;:"D"[)W?W).,T"<'C.O-!H/9$59<S-*)"-;`FVDS7
MS.=N5O#=/@KT:/2<J(C&2T$>2W:K83*9=JA(H/I,HCHRD2ZPZ=*J6&HZRJ`!
M5K;/K,Q(3^(HYCP/*MR@UJ7:NMV"TDQR#(P/RKJDQNG)5C9KI;3!8B*%8@(G
MJS)-PNR.ZW0H&Z;KC3.0(:MC8HDTC&F2)8O5'[$69\3.6^)8A6-C2Y0!!K')
MK%[*!U(9?\MWJ$RV7,L:<&?*8<0*`'P+M81@^ZS"*M`"M(&I5%^CIB]A2)5I
MGCJIJQ1\1S8&XS\Q-GO;_*]$7`D!45*(/8ZZ4;ZGCL117?U_N9X_),;@I'N;
MW4O31Z_]%L8'+'WST,-]EK,<%%B]`@0O1ML``3T_<<&6`"`]1(IV\6:1VH!6
MV;V*+3'5+D@FJTS#6E9Q'4N-)8/3MN)618T$5+V1^VI33J^XXF9:0I&E\]2A
M)PZ'KW&?LQ"7SG3JNQ$GL]+0.H<&RV83M5V3\)#(Q&*2!@Q;+\T'!!8K&I<N
MCF7\DF/2=G)]*-+*JY@[JINQ(]918E-5CL0KY@3B>.4>'O:=N=&44P!0Y23.
MW=0%F9=`2M!U1,Y-CL'?CO$%8A$'K8&*ST,YJ-_JFS\Y;-`$\,4X@/2TK@0:
M@OA$J;RO#H<JJ1<_/E#UR(*%+WG5>KFNM3)XK5[8/E"5\R[FW\(*H4QH<H'5
MV6XZK:H/5`$OTX*YLN;:R:!I:2>0DZ`M0?(3'Y>ROTE]`<4I,BE6"D0-2Y[(
M\5H%*:CP)RMJMU3=PB;?O!4=VA28US*#RZ*57QDNR<^*"(OF/J/H&JVR\^B6
M%B;Z-\&I--!0:KFT0+P#@K10&A.?K"*U",^[@KMIE9RY6V7F(N:(O4C[O?`%
M=K?M7PIY$]EG]^+R;,_5&+0)$'XB54".<@M!M?&<.0;E9E4]\`#14`>M:4<E
M(Y=\66J)I"8PJ4PFJ*&0(*7`.EUKEJ4B4SS*Q*AKVCDZW1(]1XKI&8F>5T(D
MV(RT62PXD&B&3D:*LP'T)Z9M5Y>ZP'H=W'K<`A$>%/EKE5Y/56@D<%$$_BE)
M$XBEW&M3S"H\2C6GYUHS-1%%G-!%F,WQMSITBRB=S4HL0YC.VR-/#E9U7%D7
MA!/B>')@T9C>"OP!5CTQ&H6S:S<HR/X)$[*=??K+`IV0LJOY*/FBFSIRVAX_
MMYRS/AA0R$$-RZJ[F:/<66HBH5OH%DNDP(6I&N+`:)XB*<((6`TC&LABW53F
M2H&MTL6SXEZWUR-88&D?NK,>$B(0LF=(`%F*$(H`6C-JAR)).T76_%-PSU)%
M6R<KW1R094D.EBN]]3G$3LQU1G?TAF/TP,N+<G^J>Q5L$8@&(_-D=*/-#2E#
M>%RE4-44^FR^6*]4G>L%0R\8].-&KMRJ6_S]CG$WO(6-[U0YKLMP?5Z[\R<C
MOP\.*=3KH&/]3VU(5KLU&&#PU6#X'89>=;[;.4M6;%'<I2R`O:@7]:,!%=[@
M^&&,+=<5Y'J#UN%W",P^S.7L'U%7$38IO<E1E/*,Z6&U#:^;9'1][X2K.+5\
M$MMV&_I<!U6C<\TU=;6M7)]_&Y$KX.;3R51WVLYM+TB3[$51EAG7=0:F4,+=
M1#Y92H#^5MT1-&OFA#4^`IT3H@.WEBEI%2*D[U[^?')UMO=$$[J<B++Y?#3U
M_'A8SAU3WA\8X'9-0KZH,+;!&PF&!$X(?JDH&XJ(>+3T6PT5QJ'ZR"HWF$>3
M6_5]-96;?I055K1IEDODEB#U3+BH%H.9@AO$:IB0#KVO&\WJ6O(48Z@4Q5(+
M?V5PY4P,*ZM=2L=#?98.:[9/6Q-_]2W;A\1LZS+3^CO6F$Q:X4,^KDEQ(+O-
MM`-2E1V*P:9<ZK*VVPH"?R"OL0RG44!7X;+JG.AV/X(YNFMW)0[Q_VU+A,17
M`X/Y=ZR*=P>M[F9-NV,4=$ZW^WJEVJ7M!*C)JG!+9AF7X_9LJZ+`+I0-QVH9
M$75A/XRLQI&@4O&P>=*GE$K[B;AFN9FK9?62,`EW4$)$3];&3=O"6!@D!4I7
MV>$VP+'S$)QPA[$4$;I&.1];-]7TG*W-SE#!G$T%3U0^R[Y5>*42PA",@'&Z
MIK"^II5S]QB)PS@Y(RJOADLR4:07ROVT757#3;>K.-?^=PF><DL<12=Z=>]P
M=2@!ICL2_?31K`G7*P/H(#,<]!1$J@SNZD2^I`I()#WJS")5%$G"U>P0+GZ%
M@]4&4L0(780<J$;_Q8"R]E%TT(X'@R-)(]R7B@6O^JU^+WK5:PT[^*S7.NAC
MG%@GZO7BPS[%W;?;ZK^8=+!#<BN,U>X<22:B_%?]VL/J'V0UXQ_VI;5?Y;4^
MMJSN'L3#?IMC_/=5]K9$_..+3ZAP%:A4T(!B+U4'2YU0M1[6D\M@=>+AX6$\
MQ(2':-AJ#XYT):Q.NQ>WNW"Z`)6>51,K"A3%VCWJ'$9[T2Z`>@#_:"Z0A8V3
MVO%AM\]3'G2;:V1UCP[C?@_7UV\-:"5.;K+PATX\..K&O4/]GE=,Z^KDP^CZ
MY&UT.;JZ_G-T?34Z'X^.L5"55SQ0U<RZ3+#0JA-D4ELJBZMB'>FJ6/6S12-=
MU\F+52O)5`\"`S=>,V_]`8A[#N3Z3X"$R#=Q::A'1^\OJ7M`[/A"%OSKY@];
MERTEW5!]N\1.9!/FJU(VJH3TY7JU1SKVQ*HJ6;@LV&GHYJK608$.VU3(%R17
M\VU"[L=W<9;:6;`Z^.=LV8I.ETETE:V0V5'%,P['.[E`<([@^N4)$,9BO<`(
M-P`?A0728V[SH+4-(B%KRKX"\'6.#H=6!H`=9:,B'%(G`I(RZ=([B4$SP>62
M->R5=M"-/.:%2;YC)4>R:]UP:-F*16>>F)X63*?M'YG*"4?BW'`39)\]85_W
MB9)ZA13.ZY11W"8?45#YB;FV*ZXZ"1K$E(OM81:_?7?OI>.OT\8$H$_5=A-C
MUU)Q48_5:`D16[7)=T'4!ZN04X->5;TW$;K`?7CEWSH.01EGO$*IXX]OQB<_
M?3PYOXY._G02J)AJQ2^=?&XN"\BTKM,V)0"K@W-73<"'8%/-2J>7G%)=Z2X>
M$Y5Z1"J%C:VPL'L&*#S/,#5AEBFPB`71K5+,\).+2_#B@5T$[0*_:T<E%O>'
MZXF%0]$F225N(JITB$?QH0#Z!5PX1YG0K('O&X_J5!6U>OIE7U:/^ZA4[1YT
M]@278[L_0*'4@143:"46JX8!HA`HJ1G;OF#X,=]\N]FN*F4$NB\AE=VF05;'
M!@E3LH*6'LC4PX8'V)H:#U]I)!R5QX5IJJ$*-U3)4&(A7AW%G2'7A>"W<02Y
MQ%VM3H)X9HTB(>"2YXQ@,4-J&\KJ(26]TJZ-0UXN5D3,MA3P]18Y<$R5%<0U
M=MH@H@Y:_6YXG8.V7NA!AP%D%J2KAD\+NN&<FI0&]&O58!G/3JL(5#1/)PPI
M,F1G.,&.R"%(!K'D2UI)IO3;`J1?5JD*W?#VKK1ZT[R/(:YQ0H<*T.Y4UQ"[
M*)B*3M:JGC)CW>C`MT)U2)FG#^AQHUS6$RLI`>]:?_/MG^M>1L>JF\QX#2HO
M!Z<<%SHAR^[5A,,AUY4OY0.WZ1,AV!56KIK`VV/$'_819-$95L'-\>&(NT;)
M6[I-T^D\R2<%_VY7#XUQUJNQU:.I;@F\J]*ZI'8MU&UW&A,9L*S!G0.N>1K;
M':"\RF!M#:$3%?43`I'M":Q],8Y@OUJY$>I*]4>D;XO5MD75ST1^AQR?V?(M
MI9*3JQ)DOHQ*..+)ERAJJH`JZM]06R"?KC/0>A[P?9)C4N1^D6=W!3!0].X1
M*5:A;GBFITP.X>V+,?=U59[7PF2N`4\0*HP_VI^P!$%2E6U[4&4F"N\#^SZK
M0S<P6&&[*CIR>SR<@ZV(N%-",\PNU"T>)!Y2'::SOM-+/L)JZ4>%%X1PU69*
MI@V$35!NJ#$"+AR/^M6A:-$JQ#]%$PYF6!#5);.(ON:*2ZT:KH)+S-P^%+*"
M0J0%1Q'&Q:"'#Z4DU!:4T%@!@]<*H:9YD@Z`2PQJ9Q0U*#7Y92VJR0_ZZW7;
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M8->18)>Z5D^B!8[`GE1K8YN&ASSQ/+TK0/!=6:$$DK.+JAZF+]\FL"@5JELS
M5L8EX41H`T4"C<Z@O9LW;O@>8=^@Y+.VRNRH8P@H&?`V'0[2`U@H1TP7&-S+
M[9K&QL&26&4=+?D?P[8SYCU8.IH].&3!P'ALW$'EC@ED.7K,ZH.&MXP[\G5O
M7O<J/?GP!6YX9XHK\RBY"''X^3O@2%@,]">[2;,.P*72PZJ=&]J``1]<:E'B
M?-(NS8UQT:DM;'E0D<!/7;PO#Y,<+E4%[U.KZ#`>#7L@1NL[I)*2%^OKPV=G
MHZL_1Q?OHO'I^_/3=Z?'(U!?1\?'%Q_/KT_/WT>7%Q].CT]/QM'N)4@:$P#%
MGE=W7YFQ+I0;D<KL;_E:I)]K+^2$J_0S`!<@L8)DPYU',>&"`M%)X8^=H)>;
M9/Z)7/1Y>J>,'R8[]38ETX\170`C\V2.1+WJ!-U(5BB9487&&9K`+8E(.\1(
M;=%?IN'ML=T&=F$L-RNG6"JV_ME'LYBX_$P_&+1\S6:._]&L?>XF8'LG?@X:
MS0?L>'NIO"";WW#PSBI8AB5B)MP_UW)\D?\^7U.)!?>GFB1DTX.#$'9\''4/
MVJ1D1"?)$O6LTO+9C*BFCN674P7Y*&'&+$.>FEY/.E"`!!.*R<?2\75)Z"5(
M!'59#M4$]'2J`:]3T'US.B4'60G3E\MB7JRE$J-W73:]3S6=^7*;HL?O1N,W
MBB*,QA^C\Z)%O^ZC^GG)WAN-..^T,=58_+0QZWW!-Q2C,.?1[GA]LZ*&-MWV
M8+_?WM/ON4TW/NJ@3:*9-P6U)HQ.**68H#<2'RL<PK&JC$3AE<Z$56!<7EU<
MGJ`+873^-CKYZ>/IY1F:V7;9->I1I#&HL=-UCNX?42)4&C7EKFS5WT/;7&UO
MT8[Q-G[(;E.K>!AB"."\JNRNIHH&7`4V>A4-XC[Y9>A_=]Z!8,PEG-BN_07_
M749#>;T?=X=M_N_.-?GD%\&M1$?Q<##D_^X`KJQG4KEOBLXZ.%Q.G!_$G:,.
MNJ;Z\>!P$.TUCAF#R,'J:-UXKV!E@X,#V@Q6NZ_K1[7Y@&H:Y6QU0O_L@D,-
M9C;"^"MJ]E7'_&>QO5^IV%[M83+#W+JN3W6<?];=^6?=G6]8=Z<6;;\VM'LK
MAO#O/OJ[%CS!>*[?;A/-]=O&6*[M.IG],\+JWRS"J@$C7BK8:BL<^&<DU9,C
MJ2ZNWH_.3_\3"V&HEUQ>G9X?GUZ./D08X_2GTVLRF[Q-01_*H^OT"[HU@!3L
M1Q_';Z/=5Y[`UB&7'(A/)R@^57^%3;0T???6LKQ+YBI-;P08`*<UQSB+'!1(
MH--LP_K7#QB*?@JJ7ND%,VBCC'+-5E\XE0@C*0FFWO>L!YJ8N)4BL/BFA^SA
MKG;X:FR;:K%B59'GJ!?IIQ[T1IJ/WBW)[("9J"E61U?2476BZ@A$RQ[0WD=A
M9RI11U6]8(.?!Y=STI4$>&K2ZDL@MI^.T<IV>74R!LU5)/<J;@3/7#'7<7H7
M4%[Y'87<-9@%U[2EKVC-._8X=>_8X_1JWF&R/4;K28SJO)*<KA`YZ['%Q`;<
MH!\%<XA+WG#T2U2S]9^+Y2<NYD`FLJ\Q;C[I)+:U3O"@35=>V2=BZJ/"R2\G
M6K=ONJ]-"KQW-6KT^*>,N=$H4!VLQB!2?<TUJ%1_%>M)]7'8>%)]:QC^.'Q:
M3Z#3;VU3B)#+ZCOO-X;@>?"Z.#L[O3ZCN#%<V?$%X>C)^78(2E>SW76N+S/U
M5]%K(<+\WT;&(E\VO%DA-69T[_JE"_UV+_P*^5%6;,X<4?@'63HQ1FP#NU)"
MQ2]1_0)@Q&7ZH*(U?D%11IJY.6D6>//\3^=K<BF45&H,9"_OKJPSB8;(9C=K
MT*'XDK#9.4K6J_N"<AFV_&Z1/'+=8O*253_JA3'Y33%?EY7$XO!J^V1$^0H`
MP:]/1VF@.TOR387VO&DQMOA?PM^51KKUG$0$#DQ&9I=IH<<(XXD5Z?PD).D-
M0D!U1GOB)L:K=!%]2.ECXRW^)3K+)O=)BG;Z=-'$0HV:2%>#YWW.)-6E>S34
MQ3D1\4SH',7LX$^@QH@ONCK$4:=UX$/O+57%TJVR>!QRV&B?=IXL_-$ZK_M]
M*T23&)G7/ME:('E@-R_R&;"*NB\Q2*\!XC7-H*5^%VLQ5H*-QQ9;`Q_NPR`N
M=U[W#KX!5)_&ZJ).(R^VV)Y'4A9+PX%\9I9KB<X[,OI1!%U/W',86_!'B4#T
M?A2NY8DS;T?169J2],LT_6*!,;18H1$9X2^10QP]<&(MLQO\[ND#&VKEC:JB
M$*XI"N'=FK5OP[*?M=1G#OKRR]S,S3;M17$W@CS'(POK^%77^/*@.8//9NM9
M=3AYS*7S3/T9RDCP!72`7,)%A;X5_%]HCGKX;9[@TNH_,<OR%`CQW.JDC`'H
M=5"4'AJ@0:DT+"K:@-'2%/*D?#B>*/<BJZH_Y:\??O7@J?DO,NC7X\-VDWQ+
MA.`9:D!O1$\C,#;N./1!_>I#;W\EY[&$;B?!VVZ<B_;4EUG*T[;V+.H7-F99
M/74_B],'2!]7%],-0JE?5K.<K,I&!2#R)VDW:AH(%V')6W<<_68P>`[6O3Q?
M#Z+(QONWI9'Z>8-7<P-?9M3G\!!)Z3*N8T\H]VIW:(,$A0%CA-BOL_P`-_AF
M$ST'<[\]UWBBMM-MT'8\3ZWOA:VX5*LC?,@F)/<0`C_G]KL4+6$[&;:W+DL+
M.BI9T*->(2USFS75@W>;KY70M6%OU'Q]L6*GM>33,SW.91+9U]>MX>OV\F0I
MX;F#OOPR`2>G:[+UD\K*'WZCU=?,]76;VDZR?L+]R9Z$9F%[XXMCZG:[_+:0
MW(*:]Y]+2[Z6H+_<'%O2I6\QX:^R/9%3?KWMZ0F_\?8H#/;7V)9,]&+21:]!
MNG`I2?77;K]&\1C9G7J4)1(SN^92,\;5#=`8XPM=E"(6@)AGD0XZLJH^$!T:
M%9``[6K#9'+!-B,2]*.^WB[BQ)^UP>I>F=DIGU:CZM68"49/E+DV"@R<[%^+
M86:;(5@U*+*>YNNA5)"AJ55^=E3BK]T5ZF\([U"AO1$V?(ZIQ!562;CP-:YO
M.-OU=@K22\V&!&6;^<ZM$$)=@PM_X!0`SE)Y^A'5#@M`IT$WC-FAE[Z2"/8;
MB.!9LJSW_%QJZXP4U5'>/`^SPPY[Q7Z5S6@9^+0J(%)M&,Z=XXL?^FB3:4);
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M/?8+-="]OB_6)8G9Q1IN23KGMZK#?)QCBCG"6R+%S<VBH>>ACY336R?`;//1
M,Q<<$L1^#B>(_EZEVZD$4DF"WBS_UV2<ZHF>!M/C*BBJM*IN_=M-%X*(G2U3
M.ZI=/J::<]84$N^DXKPL),9-3'J+"4.PH.BJL$,DC`_OW50!GRMY+N!0!>SM
MU,6WNG"YJ;\_@0,BLWV3*+(M!7S:`3UOE!#4&T:JO?D;B=%-DJ-5I%DZKC#6
M!LN$IE<UH:KNN#9%HQY94DS$(7V^:2)LFX!M`V?<;GLOSD<VJCK=@["J<UY\
MUG)XVY=_2V#HTLW^K=44U(0W<@]A9='Y)?ICD:^CR^(^^;2&U4WNY])ZE.HV
M!]WNW+J*ZL-DDVPE:4UNFN]8Y,/K(KHR\F&C]*K*6)KLZ6*I^J%P&4IK;W;#
MTT0G4M6,B9@C]7]0MRL>D]P/W_E*T)U9I9$Q"?F7VE1I#Z9-=/!RS3A^C!4(
M)01U5*?<FDPK0]+=O&&WPXHN7),7I55?Y_3RXDG+V(1$3X#%4^9Y/L0K\G%4
M!+0"CV/KRAE6\I"C$\/?8VSKPD5-M;RSWZ"N4EZ/IZ-LR.2L$YU"A3`VC.WD
M7]:,&\S5]*#3G)VZ"9A.<L]3@:@U9!&JT&1]1;'.3>3&3X<D5##)"77R9WVY
M#PLQZE=[,5FU:H^2:'M[V!`7K9+DFPPN'E>H*>E1?2W()3>4]XCK8N:X[(?G
M**7B'MY3*@'R])G9J>3-3'5$O*=43<0C^N'"`;6[HJ(C_L-!WWM()4C\-_M/
M64-X?U34Q']XX#^D@B=U"EF-FZ#3KO$FV5:ZJJ#]Y#L2=;:U+V[00[#\0)"A
M!DWN>*/O=%%%^STE*9!5OI%PC"5A69DKFR7=?^WX`]37::']'`3&B/^U6S^.
M7[M%\IFXR(LW7.U0?E677R*K^,L3U(M@TL?&FBZ_W;JB2XT,]77%788'X2HK
MO_VW*.VR8=+ZPBZU5^\R0>_"?4HU;H%+67<1#CA\VRKXX.2-OPG%U9I];F:X
MMMS+PJAU^ILU_LU$INL1&5-(QN-!AR'NQ_5EMJ38/@L8^%R-BM$$2'K'>U@M
M55/]O1]V96T&"YDP#[R28(XDVY`];%'-]P6VCD:!_;R8:^_A6#5TL5H3-9+4
M2ED;JUY-L`YF-7>3Z]:0P!AB!Z$J.6XAG"9+7:5(3FWJ9M.2/!*\X?7Z3(0M
M/@P+#8T?=CI/>SV02-GTNL\XFE]_YO;YP^=LWV-5&UY_[@+[#0O<>&O[S7J%
M(:\UF<&-=7UJ96^[],Y3U^QH=54"0_]C$JYK.5!CMG,E*;G2LMSK;^B)PO=>
MFW/=W44UBW#ZYTK-ZS<%"HDPX5L5)Q%'-^L5U]R^2:EBMM10FR2EQ&.CYQ[X
M+W)PIWC8[FC/KA>%O2L4(7VX+^)JA]X[5G&Q\XY>9<R=V3KM[WAH-M#%V#,G
MQU`DZ@O5P9]5E6XDA$XO4ROL:>XT^*'Y?D"=>O=-9:&/TAU"K;<Z8?MK)M3U
MP*N`Q!I:V(MF39TZ;%"^X/Q<(5I%CR6H%*",HLOL(\J6^#T<.&4>)=OA":$)
M?T;-N+Z@>X/Z,XG%@X-K?*FN0E=JJ`B(ZD&9X#2,>K]$)PK5]JO84T_C,,ZH
MQ)<JH60;8,R(2U!.RNJU:]!'PX&%M3NZ<%"R?A?G=5C40-RWI7>-B?$=4,R:
M`C[LW'A/EG'J/'FF)3?$,JX"N5Y=I^VS2#>Q%>8:G\S'.:!S<3>GD!+G`ZR@
MCH<Y+U1C9`DAP1OD^U:5U5"U!C9)=OZHJ<N2S`H\`#._'2H!]X`:0FRZ428F
MCKNMJ?)(-<7Z`C&FM[5&5Y.E&/;U.HH>TK!B?I<N=;<.O6=NA<SF!^!16?K9
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MIE`BU_W3KS<%!(VWL<LK[QRL+_N$'7U62NBA]EO`4SR!0U?;1,T("T)+&`:V
MVB(44\]X;\E-T+K6[;3ZOA#7&[0._:>-*GRE*KIWR>K;6F^CE-8<:[6K,B'5
M\WHB/XNKUC;\;K2J73F->NUNOG6WV6N3NS$HG+R9[8Y3>/!V]7_^E^_<L<HV
MU=8YS;TBAI_NT.+QR4O:H7=5_\YG!J-[VZ^$ZC<"]SA@P[9CUS?%H#5&L;\Q
MO5VWZEH+(M3&S?SB-"_V,'R9)B9[XI<H=(8'G1K/H.M1M!K`TFB>H;UFE`TK
MKB?=2I*I!YC3/G>+>;%)UR^U3>*>Z-BH*V[XY'DQV]!J">BY:L2#B?OF5HYU
M;^A&D#4=&+E-6?5K'!/[#8)V.4-&ZE]*?,-HFM2;L(K\^%#A_E8#L,E%-\>4
M[HBF-]ZV$[PNR]7O_R]02P$"%`,4````"`!4@@Q'/<YT6.$!```)'@``$P``
M````````````@`$`````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(4`Q0````(
M`%2"#$=(=07NQ0```"L"```+``````````````"``1("``!?<F5L<R\N<F5L
M<U!+`0(4`Q0````(`%2"#$=@@IJAT@$``(T=```:``````````````"``0`#
M``!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+`0(4`Q0````(`%2"#$?<
M9XOE`@,``+$,```0``````````````"``0H%``!D;V-0<F]P<R]A<'`N>&UL
M4$L!`A0#%`````@`5((,1WPRI=\_`0``:0,``!$``````````````(`!.@@`
M`&1O8U!R;W!S+V-O<F4N>&UL4$L!`A0#%`````@`5((,1YE<G",0!@``G"<`
M`!,``````````````(`!J`D``'AL+W1H96UE+W1H96UE,2YX;6Q02P$"%`,4
M````"`!4@@Q',65TR(`"```>#@``#0``````````````@`'I#P``>&PO<W1Y
M;&5S+GAM;%!+`0(4`Q0````(`%2"#$>9AK*%/`0```D0```/````````````
M``"``902``!X;"]W;W)K8F]O:RYX;6Q02P$"%`,4````"`!4@@Q'544DL4<"
M``"-!P``&```````````````@`']%@``>&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L!`A0#%`````@`5((,1V7PRQ9F`P``ZPT``!@``````````````(`!
M>AD``'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+`0(4`Q0````(`%2"#$=>
M`\XU;`(``/P(```8``````````````"``18=``!X;"]W;W)K<VAE971S+W-H
M965T,RYX;6Q02P$"%`,4````"`!4@@Q'M`ZN[MX#``!*$```&```````````
M````@`&X'P``>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!`A0#%`````@`
M5((,1STW_BPZ!```21,``!@``````````````(`!S",``'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+`0(4`Q0````(`%2"#$<J^Z63GP$``+$#```8````
M``````````"``3PH``!X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"%`,4
M````"`!4@@Q';IT=':$!``"Q`P``&```````````````@`$1*@``>&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L!`A0#%`````@`5((,1Z+VT;*A`0``L0,`
M`!@``````````````(`!Z"L``'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M`0(4`Q0````(`%2"#$?NM2_GH@$``+$#```8``````````````"``;\M``!X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"%`,4````"`!4@@Q'*W:?AZ(!
M``"Q`P``&0``````````````@`&7+P``>&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+`0(4`Q0````(`%2"#$?70]CWH0$``+$#```9``````````````"`
M`7`Q``!X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!`A0#%`````@`5((,
M1SFV=/ZB`0``L0,``!D``````````````(`!2#,``'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"%`,4````"`!4@@Q'^;*']:,!``"Q`P``&0``````
M````````@`$A-0``>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+`0(4`Q0`
M```(`%2"#$?O[\;[H@$``+$#```9``````````````"``?LV``!X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L!`A0#%`````@`5((,1R#('$.B`0``L0,`
M`!D``````````````(`!U#@``'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"%`,4````"`!4@@Q'HC\![\$!``![!```&0``````````````@`&M.@``
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+`0(4`Q0````(`%2"#$?7G[]^
MI`$``+$#```9``````````````"``:4\``!X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L!`A0#%`````@`5((,1Z"H]/2E`0``L0,``!D`````````````
M`(`!@#X``'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"%`,4````"`!4
M@@Q'I:YIG-@!``!%!0``&0``````````````@`%<0```>&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+`0(4`Q0````(`%2"#$>PM;[8,P(``"P'```9````
M``````````"``6M"``!X;"]W;W)K<VAE971S+W-H965T,C`N>&UL4$L!`A0#
M%`````@`5((,1WN.AGY2`@``2P<``!D``````````````(`!U40``'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6Q02P$"%`,4````"`!4@@Q'?EH\#ZT!``"W
M`P``&0``````````````@`%>1P``>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM
M;%!+`0(4`Q0````(`%2"#$<20.2]7P(``#<(```9``````````````"``4))
M``!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L!`A0#%`````@`5((,1\N>
MH00>`@``>08``!D``````````````(`!V$L``'AL+W=O<FMS:&5E=',O<VAE
M970R-"YX;6Q02P$"%`,4````"`!4@@Q'90'[5HD#``!4$@``&0``````````
M````@`$M3@``>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+`0(4`Q0````(
M`%2"#$>92'?VRP4``'PF```9``````````````"``>U1``!X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L!`A0#%`````@`5((,1U.CFSV;!```B!X``!D`
M`````````````(`![U<``'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M%`,4````"`!4@@Q'R9C5,(T#``#W$0``&0``````````````@`'!7```>&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+`0(4`Q0````(`%2"#$<W='K!?`(`
M`/T(```9``````````````"``85@``!X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L!`A0#%`````@`5((,1]`*$!<!`@``@`4``!D``````````````(`!
M.&,``'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"%`,4````"`!4@@Q'
M5D74C+X#``#M$@``&0``````````````@`%P90``>&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+`0(4`Q0````(`%2"#$<E1>,_.0(``"L'```9````````
M``````"``65I``!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L!`A0#%```
M``@`5((,1V)X:?S0`P``X!(``!D``````````````(`!U6L``'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"%`,4````"`!4@@Q'C-G/`X("``!M"0``
M&0``````````````@`'<;P``>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M`0(4`Q0````(`%2"#$>B%3D$``(``+0&```9``````````````"``95R``!X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L!`A0#%`````@`5((,1T:V^$6V
M`0``,P0``!D``````````````(`!S'0``'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"%`,4````"`!4@@Q'HJ1N`=4"``!(#```&0``````````````
M@`&Y=@``>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+`0(4`Q0````(`%2"
M#$?V=[MMZ`(``"T-```9``````````````"``<5Y``!X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L!`A0#%`````@`5((,1_;-59++`0``<00``!D`````
M`````````(`!Y'P``'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"%`,4
M````"`!4@@Q'[Y8$(MD!``"%!0``&0``````````````@`'F?@``>&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;%!+`0(4`Q0````(`%2"#$>UH6:GWP,``&@5
M```9``````````````"``?:```!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
M4$L!`A0#%`````@`5((,1Q5]C29V`@``@@@``!D``````````````(`!#(4`
M`'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"%`,4````"`!4@@Q''V=%
MKA@"``"2!P``&0``````````````@`&YAP``>&PO=V]R:W-H965T<R]S:&5E
M=#0S+GAM;%!+`0(4`Q0````(`%2"#$>MM5W[$00``*@3```9````````````
M``"``0B*``!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L!`A0#%`````@`
M5((,1_A)#&);`P``*`\``!D``````````````(`!4(X``'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"%`,4````"`!4@@Q''-?C$UH#``"Y$```&0``
M````````````@`'BD0``>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+`0(4
M`Q0````(`%2"#$=)`,J:IP$``/<#```9``````````````"``7.5``!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L!`A0#%`````@`5((,1[M*@HD4`P``
MR`T``!D``````````````(`!49<``'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"%`,4````"`!4@@Q'^DJ\_NA2``!N7`$`%```````````````@`&<
MF@``>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P4&`````#D`.0"!#P``MNT`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624278977872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Detail Textuals 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 07, 2013</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Jul. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital', window );">Capital structure yielded total market value of invested capital</a></td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="nump">$ 25,200,000<span></span>
</td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ValueOfCommonStock', window );">Total value of common stock</a></td>
<td class="nump">$ 819,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 870,000<span></span>
</td>
<td class="nump">$ 670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock value per share</a></td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="nump">$ 1.19<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=rttr_AverageStrikePutOptionApproachMember', window );">Average strike put option approach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountForLackOfMarketability', window );">Discounts for lack of control and lack of marketability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountForLackOfMarketability', window );">Discounts for lack of control and lack of marketability</a></td>
<td class="nump">35.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.80%<span></span>
</td>
<td class="nump">35.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountForLackOfMarketability', window );">Discounts for lack of control and lack of marketability</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock Price per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesATwoPreferredStockMember', window );">Series A-2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock Price per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesAThreePreferredStockMember', window );">Series A-3 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock Price per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock Price per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock Price per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents capital structure yielded total market value of invested capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_CapitalStructureYieldedTotalMarketValueOfInvestedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents value of common stock as on specified valuation date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountForLackOfMarketability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to the discount rate used to measure fair value for lack of ability to convert business interests into cash quickly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (bbb)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountForLackOfMarketability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=rttr_AverageStrikePutOptionApproachMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=rttr_AverageStrikePutOptionApproachMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rttr_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesATwoPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rttr_SeriesATwoPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesAThreePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rttr_SeriesAThreePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624280186064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Two Thousand Fourteen Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Unpaid principal on convertible notes</a></td>
<td class="nump">$ 535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest on convertible notes</a></td>
<td class="nump">18,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | Two Thousand Fourteen Notes One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Unpaid principal on convertible notes</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest on convertible notes</a></td>
<td class="nump">$ 537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_TermOfWarrantIssued', window );">Term of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Two Thousand Fourteen Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Convertible notes converted into Warrants</a></td>
<td class="nump">79,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Two Thousand Fourteen Notes One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Convertible notes converted into Warrants</a></td>
<td class="nump">7,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase an aggregate of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Two Thousand Fourteen Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes converted into Shares</a></td>
<td class="nump">79,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Two Thousand Fourteen Notes One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes converted into Shares</a></td>
<td class="nump">7,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Agreegate number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,369,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,081,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_FairValuePerShare', window );">Fair value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_DiscountOnInitialCarryingValue', window );">Discount on initial carrying value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock | Two Thousand Fourteen Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes converted into Shares</a></td>
<td class="nump">567,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock | Two Thousand Fourteen Notes One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes converted into Shares</a></td>
<td class="nump">54,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Unpaid principal balance</a></td>
<td class="nump">$ 535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfPricePerShare', window );">Percentage of price per share</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Additional interest expense</a></td>
<td class="nump">$ 184,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest', window );">Percentage of convertible debt and accrued interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note unpaid principal balance</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_DiscountOnInitialCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the discount on initial carrying value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_DiscountOnInitialCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_FairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents per share value of stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_FairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of converting the outstanding debt and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PercentageOfConvertingOutstandingDebtAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PercentageOfPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of price per share paid by investors for convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PercentageOfPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_TermOfWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of the warrants issued, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_TermOfWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.16(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20, 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.15(5))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.15(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rttr_TwoThousandFourteenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rttr_TwoThousandFourteenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rttr_TwoThousandFourteenNotesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rttr_TwoThousandFourteenNotesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624205302320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 02, 2014 </div>
<div>USD ($) </div>
<div>Option </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 29, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2013 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=rttr_PresidentAndFormerChiefExecutiveOfficerMember', window );">Andrew Ritter | Executive Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Annual base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_TuitionReimbursementAuthorizedAmount', window );">Tuition reimbursement, amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PeriodOfTuitionReimbursement', window );">Tuition reimbursement, payable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_BonusPercentageOfSalary', window );">Bonus percentage of salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=rttr_PresidentAndFormerChiefExecutiveOfficerMember', window );">Andrew Ritter | Executive Compensation Plan | General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued tuition reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=rttr_PresidentAndFormerChiefExecutiveOfficerMember', window );">Andrew Ritter | Stock Options | 2008 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares called by options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=rttr_ChiefStrategicOfficerMember', window );">Ira Ritter | Executive Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Annual base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_BonusPercentageOfSalary', window );">Bonus percentage of salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=rttr_ChiefStrategicOfficerMember', window );">Ira Ritter | Stock Options | 2008 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares called by options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AgreementAxis=rttr_StepLetterAgreementMember', window );">Step Letter Agreement | Michael Step</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Annual base salary</a></td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_NumberOfOptionGranted', window );">Number of option granted | Option</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AgreementAxis=rttr_StepLetterAgreementMember', window );">Step Letter Agreement | Michael Step | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares called by options | shares</a></td>
<td class="nump">646,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfSharesSubjectToRightOfRepurchase', window );">Percentage of shares subject to right of repurchase</a></td>
<td class="nump">91.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_DescriptionOfRightToRepurchaseLapse', window );">Description of right to repurchase lapse</a></td>
<td class="text">1/44th of the total number of shares subject to the right of repurchase<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AgreementAxis=rttr_StepLetterAgreementMember', window );">Step Letter Agreement | Michael Step | Stock Option 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares called by options | shares</a></td>
<td class="nump">73,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfSharesSubjectToRightOfRepurchase', window );">Percentage of shares subject to right of repurchase</a></td>
<td class="nump">91.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_DescriptionOfRightToRepurchaseLapse', window );">Description of right to repurchase lapse</a></td>
<td class="text">1/44th of the total number of shares subject to the right of repurchase<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AgreementAxis=rttr_StepLetterAgreementMember', window );">Step Letter Agreement | Michael Step | Stock Option 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares called by options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding', window );">Percentage shares of common stock deemed to be outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfSharesSubjectToRightOfRepurchase', window );">Percentage of shares subject to right of repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_DescriptionOfRightToRepurchaseLapse', window );">Description of right to repurchase lapse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1/36th of the total number of shares subject to the right of repurchase<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_BonusPercentageOfSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of the base salary targeted for bonus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_BonusPercentageOfSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_DescriptionOfRightToRepurchaseLapse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents description of right to repurchase lapse.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_DescriptionOfRightToRepurchaseLapse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_NumberOfOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of option granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_NumberOfOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PercentageOfSharesSubjectToRightOfRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of shares subject to right of repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PercentageOfSharesSubjectToRightOfRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage shares of common stock deemed to be outstanding on a fully-diluted basis after giving effect to the issuance of option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PercentageSharesOfCommonStockDeemedToBeOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PeriodOfTuitionReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents period of tuition reimbursement payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PeriodOfTuitionReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_TuitionReimbursementAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents authorized amount of tuition reimbursement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_TuitionReimbursementAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rttr_PresidentAndFormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rttr_PresidentAndFormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rttr_ExecutiveCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rttr_ExecutiveCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rttr_StockPlan2008Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rttr_StockPlan2008Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rttr_ChiefStrategicOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rttr_ChiefStrategicOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_AgreementAxis=rttr_StepLetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_AgreementAxis=rttr_StepLetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rttr_EmployeeStockOptionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rttr_EmployeeStockOptionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rttr_EmployeeStockOptionThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rttr_EmployeeStockOptionThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624279177168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details 4) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at December 31, 2014</a></td>
<td class="nump">1,788,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">103,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod', window );">Exercised/ Expired/ Forfeited</a></td>
<td class="num">(918)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at June 30, 2015</a></td>
<td class="nump">1,890,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at June 30, 2015</a></td>
<td class="nump">298,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Expected to be vested</a></td>
<td class="nump">1,592,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at December 31, 2014</a></td>
<td class="nump">$ 7.059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">5.863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Exercised/ Expired/ Forfeited</a></td>
<td class="num">(1.158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at June 30, 2015</a></td>
<td class="nump">7.062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at June 30, 2015</a></td>
<td class="nump">4.563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Expected to be vested</a></td>
<td class="nump">$ 4.563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan exercised or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited exercises or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExercisesAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624273158512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Nov. 07, 2013</div></th>
<th class="th"><div>Jul. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock-price volatility, Minimum</a></td>
<td class="nump">65.06%<span></span>
</td>
<td class="nump">55.32%<span></span>
</td>
<td class="nump">51.45%<span></span>
</td>
<td class="nump">55.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock-price volatility, Maximum</a></td>
<td class="nump">67.08%<span></span>
</td>
<td class="nump">62.09%<span></span>
</td>
<td class="nump">67.08%<span></span>
</td>
<td class="nump">62.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">1.79%<span></span>
</td>
<td class="nump">1.54%<span></span>
</td>
<td class="nump">0.77%<span></span>
</td>
<td class="nump">1.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">2.07%<span></span>
</td>
<td class="nump">2.67%<span></span>
</td>
<td class="nump">2.07%<span></span>
</td>
<td class="nump">3.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">10 months<span></span>
</td>
<td class="text">10 months<span></span>
</td>
<td class="text">10 months<span></span>
</td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock value per share</a></td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="nump">$ 1.19<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section D<br><br><br><br> -Subsection 2<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>24
<FILENAME>0001571049-15-006633-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001571049-15-006633-xbrl.zip
M4$L#!!0````(`'N!#$>O]:6&B;<``*[;"``1`!P`<G1T<BTR,#$U,#8S,"YX
M;6Q55`D``XFHRU6)J,M5=7@+``$$)0X```0Y`0``[%UM<Z,XMOZ^5?,?O/F\
M3@!C.\YV>BMQDI[,Y,4;9WIGZMY;*3568NY@<`M(QWNK]K=?28`-ML!@7BR,
MNKJZ$X3@Z.AYSM$1TM&G?WS,C-8[1+9NF>='\K%TU(*F9DUT\^W\Z+?GF_;I
MT3\^__273W]MMUM?H`D1<."DY=JXO'7][_;OET]W0?56_[AS+!WW6O\EG9Y(
M_1-%DKLMJ7/6E<_4T];H_G]:[7;PJ$M@X\?@.O0!RK&\*J-7KBS-G4'3:=UC
M45YU?.\/W9F2-UY/=,="K:_^.V7Z3I4\ZGGJ(GL"%G]K7;AOKNVTY,[?6E0(
M63F3U;..U+JX]]_S\0T9^AGYMX458-IGR''0^='4<>9G)R<_?OPX1KKC0#2?
M`C0#&G0=70.&?:Q9,]HNJ=?!FO*J&KKY9Z0J>>RQA=[PG5+GA!1_P\T-;B>E
M$WU9(7QS[\0K7-ZZ\>@?'7JO/!@,3FCI\E9;9]V('RJ?_'Y_-]:F<`;:NFD[
MP-0BLN@)LJ_?K]N6JLC]I!K>'4$%TS)-=\:^?^*@$V<QAR?XIC:^"R)=6];;
M7BE:@2K.86JUZVG5"6[5+-=TT")ZKPVUXS?K_<0O))W<:4MRNR,OJ[D(86K$
MU?-+244U6G$"=78=7,"X'7YH4_;]I(2B+UI!-]^A[;"K>&6,UIA`UVQV'5I$
MJLC1*K:NL2O@`M;MSAS%W(]+&!5<N_T&P'Q9YQ78WV@?^@6,IN,2`@:;68>6
M,"I]&`GX_?TN1"IWS2:$;QV<X-(C8DL(#<]L2K`G^-JBM#P#2$.6`9/)>S)'
MUAPB1\=RALP$?0"1_OS(UF=S8WEMBN#K^1$Q5>W`"!U_V).CD\"L#BW3@1].
M:PPUAUC'B+73_$)]<G[DW_AR8;\\OKYTI)<'Z_T%/U-ZEJ07[^_S(_OZQ1N"
MD-CFBP_=?AFYSH4Y&0+#>)R35RY+[^'L&T2KNT>`MI-6^M4RW)$U!7^Z]\`$
M;[3\SM#\*F,'^QAR:6@`VWY\'3N6]B>M-\:,A_;E"*L!8KI-:(E7ZVC53EQ3
M=Q:KW_4)N8*="&K17HIV2@#*X>VO1Y\E;"[5GM27E$\GZY57#[3A&Q$ON##!
MK_R8&[JF^XUN371<[GE4TEEG$94=?:;7MBCNTPGST3N\,Z1X_]6)ZL_S8I^H
M9[$]>/1Y>4M\5R9(<++1`2?L/L>LTJU)"`/4D9$:!,QM;'HZTJKVJC2XLJI_
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M0HYKZL2(^4\.U;[7#1P96R9<"L0J7+[CT81\^XO`.D:4O#*:L=K.[2]VZBW?
MH:3HL]SR)?5YX%)3]7SI<0EF=K\M]XLW@@WCZO,/2W"UD5Q=]GRCN,HC!Y=6
M\^4)F&]>A7O=U&?NC&]N-H(G:7Q::BNV[."5!8OTM.`B+_Y0<)%#+J;Q68*+
MH4"^&8-8$7`VU2"4&G"NS2=1NF:93]K@=_'?%)K!;Q&D-I7?I0:I!\5O'GG+
MO5]N!(>:Z2.E^VM,H#8F2IM!(-9UW3'@X^LMUMJ[/G&!X>$;09NB#(/C!JL8
MHN%4AZ\KG+R^ZAI$PGGZ)-R@87KGR>R``.!9ND%X5>%5D]8`,)TJZSI77[<W
MIP[*70-03RT5@K[RU@`H`^QY3+HB.>_0;6CH)MEH\8QT8!"K@RW.T)K-=(<0
M-M:1['-:<P?GD-L>[Z:FNL\O>BOY>VUEL).!2#>R6L<QM@],?)<[];!;!_.*
M]UK.)!3.L0(&'P$#)#F%Z=^D2R:SG\;P=]MC."?$Z!0;<I0\KS<!]Q`Z"8-9
MWHG$15112U9O[_O2OY!UVM*@K72+'^8&>[GV3,J1`<P',/-NH\7DBB))IWS/
MFS6>7,'#PQWHMYO1C=7PI(Q=6IEY0OMX[)"M[V^Z)EBQSHH$_0@.'`@'Q`!.
M#.#$`*X*4DK]8/=D)S(-P;K.U33EFI+(-KE2UX'54TMKD[F=K-L)-Q1;UG;"
MSOHD^>;UM&:>[5+6+1HU!_XSJK3C-5D;D\9WI%!I!>:Q]*V<OP#SA23V$0@5
M"-W%ZDHT(U!&JUO.-MHR01WS64R`O4BPY_@B)@A57T*!#T&HZ@@5UK8@5+6$
MZM!/XR\7<T18HZYG^OG%-:/7>8ZVU+:D9M*J2KZ@EI&\):M67VY-S9K!97J<
M.TL#-/L/L31>8E8#`_5B,L/.QR9SL1C!UQ_S57(LWFU-0@-7EB!52RM8`<@;
MD-H82&T&D(*5*^JV^=T45B^UFZP'5$N:OLWG/KCVS(*AU9CZM#P;3P&"-)/V
M%\N:$*`]6"8,;H?H'>//?D;`M`%-!WNY&+MSK&^(O,^:EFF[!IF:L5,0EYV'
ML58>9A^<R=='P0?6]9ZJC,TI>KU17.YY7/9"R_H/AK.%&-QHM28CC`8-ACD!
MDJSXZ[C!QJB73/VTKZ"V=IW?G+$YQJ?<)U'-@AAZ.YW;*,?LQ(!%A$XB=&IN
MZ,2)/<\\,!"ADPB=1.C$)9>71\ULLK8.P5-DC<N&D@I>ERN_/&H.0TF,ZSPK
M299*7@B46DLO7X'A4I+2DPOT[Z[G(2[>L<=]PU1&^I]PY#K^D0KS.;*`-JV'
M;68WS;=_:1I8B1G"6,AFAM;`4ZP9DI1@&4`4.\SKT:-+Q@Z<WT%R..#ZH24)
MNT?RK9/G%8&Q9Y3$ZJC$C_=!<7U6R^],KG4SJ[0EI2Q?5!>F<)]/3Y#%C_(3
M^JY99,FU-CF\36AH!PF>OT*;[(WQZ+>,GX;6C$0=7I!"WXJC)DP`[G/9\;J*
MF:G\(EX:ZK_07&WZCA0$JI1`W#L=0:!T!!(>:$\$FN(1CZ#005!HU96"1/E(
M)*A0+A4X!^'&F97[C+QYQ>(!A=,%3K)F.QQT`\'%;\+B`,%BEI4;I-=JEE6P
M2\S,-H5@>YF9/2R"[3V6%K.Y!Q))5WFXB2"=F`$6I"M[!EB03DQXU7+"2P!W
M"=PK'4'-L1##3?@_CVA+Z#SX'Q`@D>-EU]@GJNK"G0*E4&*?"2IQ024\$":=
M(GA4%QY%.JQ1)+KY(V&G$HM9VS:>#O>V\30'!U)O/&6VKA+`9-X.4U):K=T!
M<_W=Q4TF<8QEXE^]G.C_`@C',4[-8,)JR@HJD38U"ASKN9BWPX/K;4#EY`/.
MKB2.=_M7870KV^W/;?^/D(7?Y2S(,1XD=B;VAV[+O%PL![/$&KD.1,NR>J`@
M1=-"'Y?8;1186,/"C8M,W7$1)&=QZ!_DIYI$]9G@$-_,1B%BFW>XD`_,/7@?
MN;VVX="M\>YA*P"4`P;`\P]+`&`;`#J'#``R"2H@(.9E1/^+:1;1UR00G%EF
M'5F>W-\;[:IOGV_Y=,7L]&*/A*H',CC\-E6S71+E'E53/'KSG?TD4!WWSCT>
M]R284S5S0/9#G@1SLC`'5'.NDV`.@SGW@)Y'$3T>3>DQKD?W#K'S6B[ON<.*
M72:X7%4=X?:220;RA%\MPQU94_"G>P],\.95,S2_RD%]HXO=6I1%BWF8$14@
MU`N^'(E]400E^?LZN<;-;EOJ9.(FK:#T>.3FR*4K@H%A^'D>UW;W"3K&T'&+
MX@0#F\'`3B3?^,;)H9OTJT>^_APCQ5HEKL]\:"8%4KG#+/_8KS4L28SKXJQR
M?F:I^#D)EF`TV^%7M$(9&=Q#1RN[#`,I]S>O<[4L<5.QO:R*[;7E_HZ*352M
M]_%"&;`UR[P^=K_9^D0':#$&!,*K@=GMZ+$>A(]MPHK\R[:4_I&"]JXR6-4N
M]L-4IK[=9[8._C/RB7P=\?DZ*DS"QQ-AMN\UOK'0#*(D:I"ED@]@!J/#J?!^
M<7('W]3(NGEXJU:*P&Y8L>M#*[9ZZX_=X/2X@C&:-D88`GMZ:9DN';(N'T7O
ML$<0O>(7`5/#VL?"T(N>XS!P\*8!XQGIP+AQ<9GY1E8+Z`Y=.4R>]SB?6\AQ
M39W,8E3(A0TVU)0+5<8XW@%8NR`A.#QK)SP<)'E#JKK7#8@#(1,N><@J7"IT
MF5BD!@:`]#$"NHW[><]LWX'O'J$3^BG@?*K>*GMR05B>),N3`HCU-3-;YE%$
MM%_5O-H.TS]A/%0TKR9F",0,06UF"`Z*9&)6@>/Q#!^S"@W`.^W',?FD"]]T
MK9GH3M"!P#*76-Y[H'P(0_8&Q8PBC$G%TD2>^LNGXI:\U&UU0.9E%[U2EEUD
MU:I8E,;;HC2N@-3&0%K_,D6`Q)CTS@VD0B(H\2VK8N37*QX\H*]<G%N.#"[H
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M@710N37JE&ZBKH`1YU=4?GY%L\`C#KQH'H3:&$(5SNCF_Z@L/@AS-LG+U]?I
M@_X@S)7ER.!\4LXJ\>YE"IS$$:`0JP3$*@&Q2N`@C4#%8TJQ2J#>`TBQ2J#^
M-N%0K(*?>OOZ/6&LGR,=R*,I#$.%AB%-;^86,&_2D24F#L\J")N0)460L`G"
M)F1(1%13F]`HJQ!S$)=@^B$PO8!3P6K*X08QN(C4?\(*'+`5X"_QH+!'PAZE
MM4?@0]@C88^JMT<@W=F/PA[Q;H]2GUN$;WE\]80@5;QO*`C@%CEPLA106*+#
ML41[RR/%PIK?YCC$"1MT^#9(6!5A51K%\"R+L?8X19%G-9,(=4O<@70A']@6
M)"\+N->V1Q.*+4B%(T8Y8,3@H%@@IG#$=`X9,23=OL!,T9@9'AADHCMCF:T3
M@"D<,"_C*8Y+GB&:7<%O3F@'K?D.D:-_,^"#Y4![!!8`_]QPD*67@*74\-[=
M!.T*D!</<M(-MZ;M()=4I;?C<<SSU')M0*827.1`:-*^$!!/)\&F2GVOGZQ8
M@>Z]HKO:I=?-`GB3ES#O@G&2GL!9D#P6EHE_]::Z_P40`LNCVPX:V:SVK]`=
M483`<^/P+,`L1A]<(9FD?[#,9HRJD]&\H0F!Z.8A^M#&&WR`6HPY"DU03.\C
M(@8+S4SG#PA06/OZ>TUPO(_DP1']K19/)6A1X+8:W#[H=;&_/.-VI46!VVIP
M>VW`=]B\3%^%(S>L1X'=:K#[_`,:8K20'[MA/0KL5H3=J4ZC#('>W.B-:%+@
MMZ(XS8^2!7YSQVH130K\5AVOU765/<^83A7'I7ZKV$_`,V<JWZPN.".V=]>&
M,]'1J?`U>QS_"W]S,-P1/J=.W!%^9]_QN?`[>XS;A=\Y&.X(OU,G[@B_D_H<
M0@.8#V#FH9PB@UPA]X1)PTDREQR<"+<SV!2\V=K"F"`2H7"&S[K:\EKB5MCN
M/:8!6\]!19-&^9V8-4M@HP]<2J'(NO).')W$5V0RG@($+X$-)U\L:T*`]F"9
M,+@=HG>,/SMT*M_E8NS.L;XA"G(DD!/W\&B[)MM;]H'Y?#I>GH&XIFF!?Q[Q
MG^BXGJ"-8U)MBM]R!=^A8=&3R:MW6X(_57JS%+TNN,PEE[]"FQPFZT6`RX>3
MW6.XZ[R>IJ+A1V)"UF8WG.!P6+)0)X?R:J3O[</C;B)[+^R7QU<V3V/X6PT=
M4FI6-VV"GQ@UK4KSF;CL2MJ:]N;RH%/=,5M7!K.X[?\1LO"[G`697B.YO<E.
M93I0N%R$,M+-YJX#T;*L'BA(T;3('FQ6&P46UK!PXR)3=UP$21YX_8/\5),0
M/!,<XIO9*$04<>Y"Y(/&\I[P^(;<4:OYUQPHY.*,A81O+5LZZ/#G8KGEXH%\
ME^;A:S&W?>R/5_V<78_H27^;.OYH_!V:9&F)7U83IQO;H&6><F:SZM_I]3O$
M2!P2N[MKJ\VA1?M8=RF()TXP%+2MS9()GDXP+-!T5#UQ*LZNX@X"%0-`'$75
M<`"(DZ6:#@%Q4)3H?W'N4R//?>(7L]G1=YC)N<L!3.KW\Y6@NZEP%5@M!:M-
M!&KL6&#SL(,1%0K?0];[W=JVZZ&ZM@GB4[C_0@\Y\*8)F4KT@5EIEO@:8C)I
MCB(E/,?Z1^W1F6].HWB<+G4J8+IU)B4E3*_))^=GJ[:'&)0X(5,\?K<I6\!Z
MV]KJE*A^AN:&FNN5:+NT1=K%HWJ[L@6NM\YZI1SSUBK9]OZFO;*/@$O/O<WQ
MQUJ1](?CY"D\`&ZO<+LU-=+4=]::'W;&$U_+/UL&\4W8#)`'//XP(;*G^OP6
M"XZ@[7"PL*^.6*:OBN^3(MZ8F(4E2^>*-8$UH^ZC,X4HZ&)!T#H2E-&%@H;[
MI>&#141U7,="B\1,>()?:?F5J%*!]X+QGGH->*H,>/7`]S[R@<38]>6[LRXQ
M;RX210:W`\Q>(^!<6!*GF@XZ&@%S,4:I*Y5`C3)9"RKM._-U-50:NK9CS5:Y
M!26.N20XPP%G=L9S-#^?Q$]N3<G+Y/ZH.9N9W)G7Q^XW&WYW<8/IWMDE$]:N
M^RRX@V_`N*;*\6"-BURT&`%4Y9::#6!G@!B[N:&OQ*QVYP'W!.IG:VH+D+JN
MO'*12F$G2QBG*5"Z>?.A('2O@Y@&(I?K<0EW[/"B`47%(Q5C,QI@7L_'CR<R
MNX9!/2;R$NT!0[^WR'_X$L`N^-8$AF;AGX/Y_C<$X7(WQP7^:0(G0P,'8QHP
MJ#]>X%I#B^3X\]*)!17J,?#AB6=9.R?W.J9(Y_I"9._B*B*(?EM12XT@!/\$
M_P3_8B(>CX$9(YXH98ORF%LH2X/^FE/VY197>,6W._!.?X?X^=C8O9%-AA>V
M#1W[<G$/_M="=.EK,-O@(!PCN\"@>?YJ,N<@J%\F]5-WPTUZI$5VOK(@QZTI
M*F/RQ1^\#QB9[]).,^Z6W2X`R#/2@7'CXC+SC6SSU!VBVKA\:!5%O#EBWLJS
MK>5)0;=;)Y0Y5@XF&I5!21^MXGPNZWJY#"#Z1D"WL<YCTSMF\OJ\^\I:42-%
M[Q3R_:#H\4.!T6HGY*`JBE:9-#PH$O#3X<6,2>2?2AJ32.K+A?NV"1'6=:Z/
M:SIM2R5,^_A*6IY)IZ[SZ`IJY'JG!DKJM&6E%&NSKJ0-8^,K*:0\D46_(A>C
MYNOTO[;;K=^P-VZ-(?VPWFJUV\'UG_YR^Q_YOV^^CGZ&'_"JV^N?_O$$O^N?
M[Y%A+W[HM_\A93VU.]!45=6ZW:[V_'_3S]<WIVK_[.]_EWN][JE\^LO@5#Z_
M/O]9[G\Z[9U_^G)^HYZ?^2_QI"&#`0HWFRP"P/KTK\\@L%T$/_MJHH5!"X*R
MX'?R#,83?QM?;3Q.MRU5D?MGN"S[TU[FP8*0Y7/I*F;X.73S@SLC(;J%=GSU
M1GUR\0J:UDPW68]-JZ#((TZBTB>W?.Z&&AQ]+2G*J,>QA_B-!_H\HH49'^F-
M1ME/],JRROC=Q>J\L:Q-,5W\3/O[ZS81:?A+:'1MT%F:",,^D>DG;^;I";[1
MDW5,AVPT:?G<?(*ONQ^;>O3YZ?;Y^?JI-?KYXNG^8GC]V_/M\.)NW+I]&'XZ
MB7LUT<*JC'SH1<`@\X\?O\)%07*%[7/LNP)!ABY"N.1&MW%L34SKM3<R*DB6
MMF<Y/4'BWA55RHUN0#3$E]\L5)1*QC-@X*>VGB")C'"<U"+'/@%S$=90Y,5K
M';5*ZD4-D_WH.L0#D$D(IH@[C`M;!-/T(;Z-;DV@IF/![?.CVX>;H\_]_D!1
M.YU(IR;(%;3@RM+<F3]\+TB=LM3^IR=&^.'K+_2R-A2+I]7BKNC[(^\*!*'S
MNZ3TQ@#L;LHNP"ON#^B]._+X]<:O0'Z#K]@%-C_:\+7WL,7PM%.D(/]46&*$
MWD,$60[K@$U.YR;_D<,(WX&!:]@7SA"/XA88J5^!X;(!LKYZ6XT13671B`Q,
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M7!4I9%&Z5/!P5.WVMP@9'=R'DGA6%M2>XC^1D?VZ$)&8;S7U59F`:B]DG]8%
MV%6XHGJYWP]K+TFZBXFWA@08(QPZW9I#,-<=8%2AP4YG@$UF:``:(TM.<8O2
M:6<@*VJO(V62]PDZ0#?AY!H@$\?X-G8+[LPUR%&B>+A-OD]6H>FVW!_@0%0.
MQ<K;!2NN&47U0%N1^_W!0.KNV@Q*@:EE3""RR6#;87]3*%S[JCKH2FK(AVT*
MLKN8A7G9?J>+1P6=M%*&'`>.7?:CVHUX99M0136@O!@G2PNB;G$$T".BV;DG
MU,R/(*(?@DKIB-"'^5"+.D>?I6-)DN,\=YR(>VO4;N<5-%,5,:<[-U,7[(..
MFZD+]IF_C=0%^_#;VJAB9[=65:.\E0T7KC.UD/YO."G>M\4LN,#A*([MI;B6
MK,M5>0MR.[*XA29T4:%2WW9O]5IQ#5<D\J?&#=_FHF(:+O=JCO2M_BBFX:JB
M2&I/K6_#MSF?N'9W]X#TW3Q-3`N\!A36`GJJ$&>NQ9,I:6HVRV+$/30@NAJ1
M/3_*902;0KZ8Z5XN1V"5-N>@LRM5K/Z]#7U]ZRHQ&Y%D6W<4OE#7\/_L/6MO
MVTB2WP^X_]"8S<PF@*2($O4:8P[0V$[60&)[+.<.>U\.%-F2.*%(+1]VO+_^
MJJJ[R:9,69))R9Z$P,[&DLCNZNJJZGIWY]'9\%S@CWPJF/U>=U`<Q%D[$<J`
M7"FN,>K4[I2$^24.L*VX7DNE+PO\D;&^`?H;'G$+1"9(N3-^Q[V`<H]D]F0A
M^%V1&SY>A14D8/>[1BZ0\P0PY:#.9[27A-HP3*-_%+#SR"Z;>#88#08O@.VR
M<>Q1K[</D8@;0N%$!1L)TQ</3\6=01>](^L3[PQ,I<39!]HT2P!3*<GU`.QA
M99@I&V<S.F:G6PR-HJZ/W`=-SP/B&CM+4`.Q4@\[;QQ-(G9['5-/(]X"4%G8
M*R4]#&(.!T>#O5)*[8"&/FCW7PCQ9=-2NFW3Z'6>!?R5,&W\N?SM"/*R.^P;
MNK+R"(3]X:M6A`XZ_?Z@4O@JIM71:)BK-:@:@67IT1SU#3U+:C<`+WP[6/)/
M070$&FQN),(,BN<`62DA-C=28CD@*Z7&YF9RK!*59:#LX'YOI,EB*"_\.QY1
M+SGQN[I_^`BD:8Y,+0*Q"9!G`ULMB9J#[NB`P%8K.`W=#7=@Q):UUKIZCN,N
ML%)2_&7@!WG"/H*%UAZM%[X]!N,1I$]`=TAVTN;>!Z1#,LTS03H@:U2"I-+F
M6G?4WPK2)8^/JS:,C+9>=9B;?S_`JE85!J9NOY0`K'+U8##0#][*4%86LJXY
M!$8T=X`L'\P\H_Y-OA.)A].0_,5R9=E'4!`,@+JK:87[0%?IJBJEX,[('`Q[
MKV!5E9*_,1AVAOU7L*IJ#;S.H-<?5;VJ&^[P)34..W,CJDT]_/YTC5P1US:`
M2@-?Z3;TNYUA=S_@Q1WWNIP;WUFNAP7`MX$6-9+U!K];D6NCJ]WUDGA#&+':
M`[;7'9KMD?32/AO0`RVUVB-[-.@8J#F_RJ56K`1TVP-S^%K76K%:,1ST>BCS
MRZ]5<;8J;5/I(8=GR^)<%G2D&"V]:GP+9&4748[A-B^BTS+,HRVB'"MM7H3Y
M<CM1W2(&K7[G68OX'X[=@+DSON.A->>7"29D7<WH-2W;X<"L\C@A0[1X,=O:
MUCP/U`,MM@1+;5AL=Z3[#E[58DNP7N%B>STXL3NO=+$E6+1XL>UAW^Q5N=@S
MO@IA!DJEK(03_V_-Q/@4V")/$_,YMT1!BU(X'_7,T;,&=>CW6E6U=G*O:U8`
MT[Z<<6!,'P+19:TKW9VV":2QYR$BP.9*;U/'5L*P:GIT>_Y"$W:@64`5ZE8K
M_7LW]OC5[,*G!N()X)ON]DEOAYG-,/^9;HR1]]*HNWAVO0WHL'L\'.22<'=#
M747(KI0%1W`(]%]T(4U8R(]"-<.7HYH\BZ[+DX*+Y[X+9+\.'BWK>.T/VQUS
M\"JX]'LGG&8/'=WMLJ0#$(8<GCOCXM\+/]_-]_""W33:_5R&P-,`50Q\6<>3
MT6MW^U5!O]8=\O"X[W9RG6BW0E0U^&4#">W>T'P2^_O"O]8[\@AU#6W=M-T%
MI@.LH6S&^:@]&&W;AKU608D'LBWB4;>C.=`[<^\,V*%64UHZ]0=/[LL.R[GD
M,;;.OPX###`ZOS]\B?#2Y#23;VS#H27:6,(27#^![ZY4Z>8Q=@Q$@*G'1<L!
M?-2EE]W>X:@['!QDZ2`O46&);H.Q_:_$#?G&GMG'*/W*->_>&;(=ME*D^+T&
M*LXOLARX.RQ<])I_!0OO8@>#]M:5[PCO45=>/DNEW>MW>H=8>_&=)^)JH/53
MX`C$W0$57V\KO@]X!UQ6:6MW9!@#<^M5,]O7E2;OK#7PP/\[?A+84]!4"'7%
MZ5"[0IW_&153CNQS-7MUR41/PI:3=%:<A/QJ5K7T^J]?O/ADQ:+XP>.__32#
M87YE1GL5O_?Q)G2/_3UVEZ#&^OR>A<'2\O_>8/1-@T5`\K,3MK3"N>O_RMJK
M;R<`DA>$O[*_B;X0)PQA:N*EC!%>K/XK\P.?RV]='R^SE>]Y/(YYV(Q6%LI`
M?`XG/V'W0>ADW]*C]PLWYO0=UYYSG>`^`LA/&"ZA&<6`57N1/="\Y].O+L""
M4\.OP5?>A)?BA1CUIU_F\0EB8HI_7%[=GC/C%VNY.OG;$-!UHOXT.B?:MU<W
M'\>7%_\[OKVXNF3CRS-V?7-Q>7IQ/?[$QJ>W%_]]<7MQ/L%!WT_5\.]7^-=_
M_D>E2*<U69X[AR_^3$!WF#W\U7>"D&STVS72=D?:C8M`L.N%!>_8/(FQUPZL
M'@ZE%GNKZ+;3E@^F7\"D0<C`2&3:,_+:3NVA=\R-F,7.N&?=B\9$X2H0HH@M
MN.7@';-8.^,PUV>?@HB-_3GW$/VG@&;`G^]:+78+T\BQV;T5,<0KO&+AT)?\
MSG(LYKE+%R/QGK15L5>T>`%F^HPM"C+RZ(P:K--NFR!_'2X6X>/%LQ(7)#2!
M-":VRWT;8?GTZ;3!+)_B_'=@41"X<;!I8?"_"5_%Y*;-9C7Z-.NP55-GS=(O
MQM*.Z-(!Z`G@#Z3]T%K1,VP5!DYBQQ%\:<5L"1^P:S^QQR(!/+)Y`E^[=AA,
M7:PY`@8`\.#1N860`$>0"0H[X+@1*K)1GG-1$CAWPF#11@0QX,4+%LI.(FSZ
MP/"F^"#$QY8\MJ:!!]#9%J(/^#J8$4@Z,+%%W$D;Y)$_@QZ9);XM;H.0[ZU"
MCD^[=G.*`1!]]9'DZ!7>42]5)5P1MB##E2ZL.P[\ON069L3-$H^Y(KL?F-UB
M*W@#J"`]\0<GD5Q7#@6YWST0?R2D0&ES&NSFNOFQ,T0DR>O=O`<IGYRLL0I*
M/EH:(9Z^@65Y`$<`=@VNP(,5@=!JJ?$65D0OK`+LL.'"YL!BIIR*Q@A';AC%
M[,/9N`E+!_,25NN$R7SGB4`N`H`D<@7BY=X+(K)F,XX4!>.&S&#PF(<"<L6#
ME<>1*SP'J)?7(K$6B0=%VI7/P(CAK&/B&6ST&D3;15P9R@OAZ2"/5'@6N?P#
MS)<A?](TV%N\DYQ=!BW6[7:;G79GU#'?P0A*!`7,C5&*N,1WJV2*<BP`EB#1
M!OSD4J,=S#R'J=`V1N4&S$#/0HV($_.X('=`)"*\$PZB000(4-R=?[,7%JA+
MN(ZE&T4(L:ZQ3<Y/=4U,2"*16@@28`[B%]9)C='@11S_<CPY&__!U`T^H#5]
MY;3T'.Y:&1)HQ$WKL[T`96SZ^DBA'F$W&T!$^)\""+"1QP0HA2P*/-#R0(SX
M&V=9A:[-\>TWO1:,!G:N&+%!$LR:SV%#\12;AUC%"!+.YMR)Z.S2CB9\O].&
M\X3D4^NOQ&.MGNN_$B[[*Z'MU8@F74/"=`!%FG3VWP.[\S#*/L@35H2NI4FB
MF)^8B$[Q;^X2:!X4B#=&JZ^H&BTLL%]\3CH1``]*%TZD6*D%"B(H:.("K9R`
MA#=))W%0,1--:PIFVGV>VT42B0E\E"\9*Q<R)PB,64QJ$&JG^.".V,#/Z>`*
M\H:0+.O`#UIFQOTI\6H.^$>.--W-ACG6T=5,IA1L:C59TLM62/H:">Y*]3E^
MROAQ.R,6\L`F'EKGR0*>JLKGUMGJ<_M]/+F8L*L/[/KF?')^>4O.MQU\;#7*
M]Y'M-;9R0MVRI0<*Y<%,1.K@O$MURDC8E%/.?31,5Y;T@N%[H8.VE9"=5B95
M0-F!0<!TBMA<Y`B"\(+?T=E$[Z+8_.*3(XQ2"TE0CY>`'MO*Z88?Q^/KG)L.
MA24,[B4.0.YY<!#@%@HX093S*++"A]0JG%ENB$!'V-5;^+QF&U7J;.VK(*+3
M)1UG10&P2`W%G18;>UZJ"5(O<VN9B?=4O4N_S7`H(!;6>LAG'IP_8)L:39BK
M.6@9/?@2K%"P3(6"&8&A'S\%=DX=%;JXILX:`Z4-U^Q0"X_#"@_T0X7N4G(+
MJ#]6XKBR[,Q!K<9Y.?FR5:A(CQIF?8:))TU7,,K0N:B45C)NST_Q:RMT]"5G
MZX(5!"%"J5MGZ5^(LPP;4\NC]44+#@JF17,0UW;;NOV?OI"-HV$/W@FRL&GJ
M#UN$G-,:(O<;`P$1+R(FO(2Y&>@1C+0+>S<W'<O/8EO1@LT\H/1TEMW'#GE&
M#PTV3>)-4KR!\X.:&@N#WR.C5]I@(3H62$W.O0`L82]RA@`-@=7Q:V>"57PB
MH'_CL?1OL+09&7I]$T_I[H_Q4'`^/+G3,3L#N##NPKH&(<LD#R@Q`<#MHG]S
M!@*`*18J9!R)0B)Y=/LP]/;,7$^7_]*=D=DW2,"XC`+_S2,7"JU"K7U_TH)-
M]X,XHUJU&:Z'MII##NP[KCA+S8,F$)UAZ2F>`(G,P'Z"U3]P*\2('GE#T"\N
M<5^?;_7Y]EK/-W&2T-72V@.NCQ@4,DAGY'CA1NP/$6\&/KFA\T0Y=@&)S3]`
MB@2)!T(%><9RI"/C3QE%RCC]2=F!0`%S<@J[`':"-2"*E4TE91I2S.2DRKK,
MJ7FRYLD#\&1ZR*?Q1W%.<SP0@0A!ETPBUX>3!N"?RW"DC5^E$00]5*G<<3Q$
M%G'_G6H%(C+Y*#8,3`,'T-SRZ3:BZ0.B%>,/9)E&\,FWYICT@5X]`1=E@.AP
M@?7($!S0-<7C!$C,K:54'U/?HKUP^4S30S#WC@(H2^LK#Z7WDYY)B_Z8K/I#
MO2B@P&W(%R"=X"?O0<XG8JT8:`UUJ/25.@$7:WV$9CI[(U34\8.'[R*Z4J3#
MZ9S^FGZ)<V%$J)8)^_@-UX3#=*<?:^SNB-U/[K\2%X[(AQI_E5)GC<"G$3B.
MUZU\BAQEZ$3S-5DNMWHL-P2;\T&Q!6B(`/Y7"O?(D'DPRR9['&+JJA`3^@10
M!4Z6B=!>'0Y'"[DC-[R???VF8[2&^D#2<-[E56/4&A0$N?%\RCYEZQ/GE/`$
MT6F+(4J1)$;.5#^1[ASUJ(7'*IK8\-0,$().G\R'0N<@G(MTUL/1'264020R
MA;(W,D@T]\L]`,W0?XO*N9J&5M]@[DS[QE8:?`2\8,$9Z8@,+3NMBV%3C-:M
M13MSBDM:3-/02$=>0RG<T"%OIE^(K+=Y8[/"LXG,TH0[6EW(J6@-%)BY[P(Y
M6`B*!-#RE+&!_J]:%-3:_\&T_RGWD)5D%JA+?B/I-20Y0[1*_(7JL$L*=@!J
M*#&[+A_C0#$=%YG:\T!&QD&)%B$@F,#C5A3+7(!O\,<]]T#5%LZO%OM'<(],
MGQ>\!('/1:0G0M<ESS%*XDL7LG1R8>2^(;Q^:"S`O,L`7D%VP[10S"R8QAE_
MD:?4\ZRI3.>&S_",\(E%01)21C@:1"$EC\,JK3"$<9*87*[2[;GR+!^%3YK6
M*ER#15(&1%%.1J"`3"0^`Q9,48P52@*$2TEGL!=L:FP1A.LR6F#/L^ROE,.I
ME#,I*E5BJX4^&)1OCHB2">^E,NP*XWJ$69PM0L=B5)@X\2@U0L^;F&2B+GO@
M&M-]`2VW0`^_>Y55C%5;LO3]Y2'E<RJZ6W,J)E\^?Q[?_!.S*B87'R\O/ER<
MCB]OV?CT].K+Y>W%Y4=V??7IXK0N9JISZ5XBERXGJ7(JE1;NE)*&`BJ81R8R
M5N7!\:275X50*&PB8C2/(T_[.'YW"2^UV,05"C.`BS(?Q'F4P-E2!&)#^)^U
M(#`HW2)A>#W#;A]<->1)"-H!+@JK`1P.)Q0"#ZI#<%_G\A_:XJ_QN!&/9[)*
M&GVU(N^3[I2MD5J?0,=!6DJ`61D$$J#*I5B%[E*$Z64R!HIP!ZQ^.T:;P@Y)
M=@,>IY;_E9P*'I]+IX,FC&><1[DZ$RNU-PJJ3'9)<!.9)-*-10$8/'C@W/("
MG('#(65%$8]E,,,I7J;(K0XQ`2**X!`1)IIFNF"">Q/#JM)?EJRD?5'DF<O6
ML%9"4A\Q]1'S<N81CQG=B'8-6A`UTZSQ69\NQZ\5`JT;I#(%B=&A;8.DQ@*W
M+$$:_4WR>H*UGPJ20"G9#KM+I85$X\DIZ_3;#;V_`VZ/BX"HBT%HT(P)Z+>6
MWB.";A^@,I\U&+#2T;8\6P9`IK`@;-.#XCY]6I8]WLN+#IJ6N.D@EQX>H>--
MW77`G"14Q=\R?8VI*QI>#@8F4B14-764A`\RJWS)P8)R5".-^#YHTLDIOY=*
M`T4],`$B("O5HV0$<0RG1=W>0_J+'#I8R1KV*$JXHW6Z(*M2=&+"OGCLK<,C
M.W2GPDR]A!'94&3NWELA\`7FJ&XV7W-)\NE0Z4B#=T(EH'P'F3N:V<.80Y%D
MV:+.YIV:<MM*J*B</P#+R1`/`.<V4XS4<J06OH=$VG=3F%)O;:TD'QB/-]S&
M&)=6$'L=!C[\;0OG9(W=6FH?!VD7/ALG<UB*UOZ+*F=0NGX83WY7&M)X\H5:
M>>"O3:/7R&.;--OKM?*6#ZG;/;W'(=H:-_L8"+>DB(*_G233.%B!CMQI]YIF
M^]W6]\]$G`(CKP#"%QP&`\2B*\B4HM`^.\>LT/RI,99MT>`0.LV%Y7,`96I\
MYK*BGK,1FR>N,!BR*JTLR7:MATJT0F4OFQ%]1Z#0W2^X"*,G4U27*<?*"0`#
M(L<@TH:F"$PVP%.9!*(,@))GHJP>(`AB3,-7<1W`E\CY66]-($KC-M;H8J"'
M6Q2_]Q/IB5/U"FE)FE3T&WK6L:PEX'>6EV"L1JU=1&5$RSA?.,8HM1=C]6F5
M5DY-3IN8-$1.1FBYJ"P\PJ'8_4U:PX[(E&X_3)2@V);HO9!&G`@`T3>JJ/:!
MLKN(G=["DDJ/9:D+6D73*C4VH-+7Z@JILPT82,C!\$]6=J6"='+KI#7&A9DF
M@%%!.ZU-7X_TI[[(YZ(L%?WU*$<!ZCO:5!JQQ3YG-)!KYB4I01$W2N24I?0D
MNM2P%U6#LLT85:^0C0D,`G3V(!3,I](S"K!:F**Q6Q9&OE/NAL;JF7`Z:/9&
MG;JU(6W#3+TU!J#A^N;J^OSF]I_49O;\CR\7UY_/+V_KG.(Z*?N("%2R@F0<
MU^^&B.C(EX;N+/"\X!XGK)%:QA002=>$I=]^0B,,;PJ3"'P&KN3$P_;/)VQ*
M&8]-2HY<18`"]==^6-S#+'@>@B2@V$:=V=SSY)CIYQ4&),5G#6^APA(V^,7$
M;D5JTR".@^6)_JQ31)("V3"]']R'UNJWG\2_J13!Q>AV6C-R_PU('*[B724-
MOI5^B)T:H(H`$G0F7/RXWY[S%X$1&!"(V\>KVTO#JRIG?FR,_A5@K'+7]:3%
M[PFK[^/P1Y#M3)YE3;$0.()AQE>R!1G@4G%0,$ZI%`$@Q?ZNKI/W.AZ2C,Y!
M9UR2=^B3.UM/VZ@WX+B2!^W['V@+_K*`OU+:,;_[+=APA$T!__,0[PQH*A/3
MMCF?@67UW-/-X[,X,_7ZAK(R3RD_`[M]Y6SW)U`LQS#,#8;J[ANC1NJ/U%`]
M<B)'!YT]AXELG#<[OAXBR6COIYCL-<SAH!P,.ZWE1\7`SKQ"+IRRG%(D-.C5
M#TGHNU042;$#]QO^_13%;ASIV7RS<<3!5O8I!\P^YP2A\3!#"P*DL<U&9]#>
MB^3*8:#&WW,P<.1C3N31!EA\L"KT3!<L>"NBRS_P-+Q[OZKMXJ@QZ.TE>+?/
M^#VMYI6<'.-<,YA5R&V7TDP.)FYJ4:>3U=M>PQ@9U<BZ=S\2WLQ&;]@[%-Z.
M;0%M!.VI\Z(A+S%9Z^?T+!;NM'JEV/#8[Q=2#0U"*4D>WT233YD3>PZ:4UAZ
M_7XI8OS!$0A2<-`Y`@)SC/U>=/U*/Q?&^S6W0!WNKY,CMM1@9\)7W?M4<&%5
MM]W6.N:!2']C-'+?87D8#!3,14?:?)OVG;KS8R*LR$7T'AKYR=:`Z;?;]-Z;
M3J,'?^Y]#X`^4WXBS$',RK%=7]WL(&K*G:7KR_L.[WB*+)5XJC?I_I)VY3Y-
MNW)/<O<89'=C%:89[I,TJ"<;TNV&XDH">$OD+L,:,#FQ3C=\V73#WM9L]=.K
MSY\O;C'M<$)9B*=7U!OJ_'+'QE`UZNM,Q,H1>+Y<><$#I2&.YR#,=RU)JG&9
MPZ5;0(QNC<`]$?C9M1<6QQ(BOJI16-/@$1%XY1?4OW0:+"N04\TFR/HB]9&:
M#0EHF:6$)WN+#VN-(I"8V2?Q5"IB]:O!&J+X2B?^S7=RRQJ:S1<R1#`357`%
MH>QE@24TI)1BV0Q/Y;UHFU`(75;H1G5).F145805=9YL:.2KFJ`IWG0?61[>
M@X5W2'?[XE)KTJWA4=$37)H,<]E-898V9X"Q5DD($T5\IVKONO5S;2P?H/7S
MS`VQ!_-]D!*FI/8\%^C4VC?[C5YW0(0^Z#8&@\%3'0M$EY0U>UC6UH'1B0W3
M(YY>Y:Z9#V]ZK6$_:Z[08N=8BBEF0J,^;7+"W.62.ZZPIN6(5`D!IBQ=<V:E
ME2:J<R;^32PI99%IOC>'2"8;<GIP9P7.P!PGTDI3=[*.]6)8P?A^0IFUV*13
M=(FQ@SN2HM,'45(JP,=*SC^Q)P2)5O+&X3LA3Y$M>]`H82R:IE&-8%J*G-,B
M=-1GLB]K]*,&FLG[WK`I3>#+*LHB`*CC-I5Z,%P"MIL3M93PF&E*#X5$H_'>
M-'?$XK.0J&&++K<K`!<A57WC+)#3H>82,337B2R>%.3O6"3":6-H0;FBSD=7
MHV]!$Y`=M4ZGFX!BN6?6^J[194'9!HDF/;*@F]EN:"=++/FTZ^M]:H7P6(=!
MO'!#1XDF[+NTY#F!FK5L]()H2X?)#?>H/&[HR*Z3,$HL/V7K5'\3!?!21Q.L
M)V%#I4R#2UQ#FJI<1KO;:'=Z:8.N7=M@4M,#F">8BW+]5&@6BQ\A.P1$>+[)
MBTK9H-7[64V:@9#KW./@FAQ9V:XW$+/B/';$!29XBCTT58\LNL-$UK#/W3M\
M33;LEX!MDYOZ-K?8A+H//#1GJ%:#;*?N+6\'O9_?K2WBB5&H8O]89]ESCB[:
M2JF"((#&^V[_A4^J+2=06A2K*2Z^=BUO#OUB$.#8`,6-QAH5G5X;MV5M^^H#
M[1"F3&W4[(&W+VFWPTWG2,ZP45?:Z#9^R&V.PE`1[\IZ4'=#"[4-!>::=P&/
M),4,:<]%-4`$,M4"I;FF_%J5.R8"Q[X3`KPWKG#9@=ES$5KR8XW2VK%T0.?R
MY/_;>]/FMI%D7?CS>R+.?\#KTWVO'4'2!'=VSSA"EN4>S=B6CJ7NCO[D@,BB
MA&D08&.1K/GUMS)K00$L@``)KL(]=V8L$$M59E5F5BY/DD68]BXS=*5NMK/W
MO0<`1U1B?T!8?`^JCR!7XI'C(<7N7WB:N`$S/!B6;<H-O71'R@6-AA2D>4#6
M'MT<<Y9D88OC"?:07'8N3]37,OL=@.WAGWF[;;6#&P#F["GAS9,M)\ANTP+K
MAWXATR4.+V`_WD!V![FGYR_^H_%:)='-59(HRSXZ.@3;Q[P*W[Z+I.=:&=GR
M^4V0,J%_E]C14,"Z$D<>1BI)CJ0SD;G;L5N"%3!M_4/79(YW<!4RK#&7+1=E
M?HFG`^.'SKB?>(8%!V(>H%F`3,BP#2+TB?Y@COBWK6?6\9*YR)C3'P?#O65(
MS`C-</H.>WY'B4986.(,B93J7JH>E*S)Q`?LLQ_,CHE?`SM$]RZ9.Y1<3$HB
M$[8,8C"UQ?*!6/_OR"^5`R0,)48&>+E,9I*P:1R*+3'MK9I''3C3G8)TK751
MM>>!.X_+]N2NX1)D@Q,"$Y[U&:'>`WNF%D;.B#04^.J=:F/13+'U1HUQWRSI
M035>H__*%PV"Z'MP/P!Z)8==I?:68H`HM@L;B6J.P)`2=D6GW1XIW0ND#0?[
M\Y&`_PM-`A@-M6(`U1*4#3`7<39CR%5H^2SZ'JSH6U<OHGK+;78&/X?&R>\]
M-V)("DM+'GH)R35Z+M=H?3ROU^;68#G7/+`M->+VR:--YWN'J]M;`")VY-H,
MCAR3I)SGC".),*ZDR*:*`UJ/HYD$812=!*?*0P%(3D:3V`%.!!U#RB02Z@?F
M$Z/7_A%'T8T#=6HV5^Z0DZ?D6G/4N[-B:B4"=FA0B=RAV(*#^"\X)]0S20))
MUYB`VI''$EB_8"+A`659!<FX/FSW8&9-$DDJ"$Z?-IEJJ-X*H'ICY)Y\XC!2
M-$-OP8>T3"V!F-,&M-XRU.+O%D6<^++MP_16@,U+J:$O[A8?:G7ZMAM;8_FP
M2>F[EQ(#9M;<=IY_,H+G^9WG)/@[ZJZ%0R8V1])>_/CAS/A,"+J=F=EXI>JO
MV"YL:2/$\E_0_&3AVTZB]TF72Q3-6=""7@U-6!M,=G#=F<C(Y(Y6NC25.D.#
MTH6*%NCT8`6!!\67O(5L?-.<3TAFU,`LXX8?7Z^;OW1&B7/EPH([/;R1Q0`L
M)Y7,T&ET!^W4$759MH'8@^FY4UU&4YP:BNF@,D$T)WS!+(T[:BJX2LHJRR\T
MNX/X3SXR)G=]"[;\,\OG04\H_8-E\MP1N@%=GANE^3#WCG9;%=125R20X_^T
M8-?4XKD6SR]$/)\[](Q!IVG<^G#0^!BQ,$9<J+R1T$XYZE*U)\+K7$!4&S\,
M68!+FG8ZYQV^<,$03-"3QZ=`CU863S!;6#YK'#2+L*[E&IV$'>A:Q`*G$T&0
M$`CRLRBEF3:,!^\)FAORSD6NQX)/;+#0Q$:$3JT0T_EP/NH1$YKB.-`ZBC[O
M0G4\G8\(?\7=@8`"*<608\Y"+U6AKAKB_$?56F\T7JE)8D<C5R9>4IDT8O46
M:P?\,_D!>`6L&3J-[@#`9"CQA$:PW2"DQV9FM2<4`[S'L>)4P:2YC\_S$HEX
M_;#Y8RMVF+G6&[J4D,O[OV8M/;'8Y`H3T<E4I+%X='$CN(&U0XW))=-M#(9I
M=_=ZMD0JEJU;$H/&R!P9Y<V#?T;T8M=48Z6U-5!;`[4UL+_#&E6*T))OT\-:
M,;W_VGY33/?WVTG='U@.0\'A\H[*9,`PHXI]8BUL2&`'ER>\KV'PIGWT;VPZ
MSBL]1+T!B"#EP,/Z#7<PY>BMZ+@W"4&C38D,>],O@_40+-L5K'`C:4*@>G?C
MSH=*N@KY/J'V@)J#GYAV;"&`A'YM%R67N6MZ[91<J*O9R1UG^9J%315C3&0X
M^&0:39AG'>POA6!HI[%\!>@]R8.Y=#V^R37XV,.ZYX!>R*!]&8)$<5O$KDW;
M38U3VHB#QGC<W:*)F'C_UBQ$W*B<+NO21"&*V6V,1X-M&LZ)#R3)4I')_&M&
M35O1^C5#R/\4JI<Y;/6`G@ZN1(X3*=\R\0)H^)IRQA6QNH6P.@FSN]<8C=-U
M>ELSN\>-]M@\8K.[R<V>DS:]"U0]U>9X;8[KS?%/]@0Q#"\>=^.(2RH482K%
MJ:#I?N,I-8,`&!,G"N!=#A\[O<["(<)(1+2&"#M+4`5#+;20FCI4M&*H8DH-
M+L=;+*5#&#.Z8KDEY;'_G4:^J":%'(K,/`]F_HDO\P)3^A(Y5"H-Q6#1B%P>
M%58`JX;K:S4G,)(9N<O?QJ[D2H9@@J.)[$`D*`2?7'L>S:E)0V<,2#Z,_*DB
MA;3%+TW(GP['BW("PKL6U+L7U-N0TZOHB6_P-I;;9Q!TG488+U8.F^R\0S<P
MG!/C#*U+;I!?LX(:(1FN^89_C=EA,Y8:!ADJ;T2-3E]L]I_9D;-7])7J$3KI
M7Y$G4%$&U(Z_P7T/]$/==3ZDOBSK.+LJEN.N^B"]";T5J0.U/-CU^HU>OY<T
MS&V_TJ-=\A/;.-H=CFA7K/3A:9CIM:2O)7TI2:^3[TP^@GEVQB`5+Y@0_"R]
M4-?"F%Z6[AK'8T6!9K.\?W&U0%XQPSP_8\6"-\?3>&IR]_0$;4VM96I]\4)8
MZS&&EBN7IEC>*"H"W#@!"7DYOW7G/9*&@N*T\$(XY2?PG)9W'@H9$"NX^W`?
MNEZ(!AP53KQP3A0,9&Q<*Z+:R4+Y3[>;K`F5T%:B,`_^9N$:2\Z%I2CZ&=D<
M(,M@.'>$N,:<8"Y/=C+C=BNN3V6!U=NQ#+4^PMJ,_(47D%7%1.B'4KP]TI&7
M?WQ1:N-BCQ!=[!;N3J*-A:+](9.=4\ZRU[!C;'?B1%*`\"<7CC5A416(AWE/
ML/$4;#=B^6X3\/L:B)%AB^8D<)N'&()3='Q9#EZBMU,&_\G<8`O0H'X,X)!T
MW^$O`7T`]KX[%8X^/+U!S.X1_9EO8&0"UH[3.ND$Y8`4G5XB.+.LU(5;4B1`
MHPF5?!4/'/,W`.:>XM2#R1(;'7@I()8,IFJ9^(8E5V>NBU5VXLJ5D5P/F0?\
M.,2<N32""M?&&Z94["!SA2;9#%>NO2!LGG.N24KH+&4<(?BSS4XS?Q&0[PO;
M3R#4)GFV@CL90\IC"LQD`8^)]4=W!=!,4=,\THASLE&5HASE@>NI-XF`]:+C
M$ZA;QI2T\]U*+N?LQ`4%(R6(]3M;`R2Q`O!V*"A<+DO40!G1-0'15A_PKJG>
M-[BNA_`$ISA#Q4PZLN?6E!28#HOV`BJF]VPYX;-\7E98"C<])+?4(!.UWM\&
M@/!R0"?962$%CV*%"2&'G28"UF@B=D^"?$\N]328JV6`Z'!T\;'7=HNT.-P\
M)=G"\M',MHF#FS,*R!LT1=BXZ/-@Q`=B+S))$">!I8?!TJ:X9)C&)V[U/?"W
MY]N4NTLOF*4L)5$EI1Q@J,RC!CZ6-#_0&3]XSG3I"-,R,C!N-%:7<$JDU$O"
M'TP)GESY*+OO*`7H<*8D+<[A+E0)P0,A')T7^Z5Z('CR.<<CG;R8/(@<N406
ML:?:<E4>F&WI-5)]2E390HI(8*0*-$`L+F=IXA@UT>):+-9B<3?X4SH\O$(Y
M!S7D5+WLCX!:^?VEM-!.#$-JL00U@I6YF/^GG.PQ2-EM],RNBF*5#312MMV2
MX=@LZ3#@_NV@1CRH0X2''B)<-VOOM?UFG;!>I]T8#\>L/87(TO6DGQOLT_P6
M3P;V>,*4B7)!HWHQ'?1B6F\U];J=1J_;BU<0NALQRM+I_Q@'6UFS"\MUJ3GD
M![S]GAKM`3E.W`D#D\)CH#R9^61.+1]T>2G)Y3)VB;%/'J`63A[TH(K@:.:Z
MED%MUK9,0$BQL9K]3J/;&\IO"D`?=)K>/3>,'\:M;MSYVZ44,LQ>N]'N];*?
M86W+NZU.5SX8SX['?.M8[.8:S:E;+V],P)I&1<VF1'Z)A;YGM\G.<X084^E,
M1I<)GACO9*V2\ZRO'G*5+&YK\E=$7V*8C>YXM%Z'K$3N"4?Y4W'/FXA[CBXA
MEH6>0-=I<$\U?S"4C?:R,):UPP>SH^S@">\?F9X$.!AQR)K19J"S0XX1GA*8
M=SW1%(!7AB8O0E@>0_+B,,,/*S%#158\X#3X'KUM7I_*:_&\0P)^@HX*P6Z(
M5V/QO]BUIJ:B\H_=.=;DSV00"?P^#BY(J)D%`QMK3*FDM.[IP0_F@E8OM*I[
M(-:46M\^#QX9YY38]#?7MA)^)@NZ'#/=%#<OYS6JV:AK?:XN(%,KX,$-47,D
MC@R^"%0D*X#[<3MPV31<="Z!V[L_MHRO.`A6E=M0ZWBQ(A7J=J%;7].Q7<+J
M4AM8))RN->X+7#ZIY.+B7'YN81"_"3V&8P.'7"NUC$6JK\H-96RIKW=ELJSZ
M<5D/G/]IEMD0$R%)$IX20==@Z=+F,M7,M::M15WU*+Y8-[[<S0>CW+B<42C!
M9*#U*I-,*/,4^01;&NZ@6V#A^<SQC>(0Y]@`4Q'RC60OV;BGTA4U*R&'U90E
M\9ERC'U4C;BFQ$M[R$49,]KK[5*%85I;K=58K?>64].N%N3;3FO"+$R66\];
M]J&S^-%S'IEMPDS6>X#JL4*T12V?Y9QPBX1]E8X6LWVIF+V+Z,\D"%K&QW2U
M?E)ET$<<6>2C?G-J!XLH)!S@'6+Y46`X=FC?,[>#&`E/5+19?^<5@Z$SII>@
MPD'D/"8^XUA/001VMT\<*Q1M?JBF<`B#LH+<'^*'SPT.$T!)P%)@?6L2PN/X
M&NG3PM>@BYN/ML6S35EU1)(2K.,$2^8-J#7'0'$"NE"A6X2%^9+XDH9ALR0A
M\IW:B-SI%%#[$$U$R-Z5Q1YQCA6U(;T@\J%K-C-BXYL<+PB8@P@9XECV'#%0
MD>'L3QL<3B[$GD&]4RK<,7P:'H7FN<<30%B@BIIN*M"O4UVK/P!!<&SKSG;L
M,&Y'(1_!P;0,%'TBUXQACB6[L$<NS_2`5/&&'(@7A:Q/.&:NVF!/0.(51,CI
MP.U)V#+>DXD5!7$B>/I-,$K(:8<WR`13K#4#AYKM8F$*:_@DZ^=XLA^L;O2J
M*3E=Z@.BB;E\,+T`)!=3#)+T4M;E@I_OD$%\^<K=H9@Q?WL;!<U[RUK\%`/Y
M!F?N]%Q-W/Y@!Y"E3-?'+947[QUO\N>[__ZOOXDGL3,5).C1U7>!:'%?Z.`T
M#^%>H']\);._OSIG__XV^'SQK6U^^Z?E?@-S[;;=_L;^_^W5MV[[&ST\):^_
M>I<0V+%L?<MW=L'(I1H130O\M%PM*O5+Q#^U<EY1-!58"%^N;B^,@1)UEB[B
MSL_*U9O;J_-__>/JTX>+KS>*$]FX^-]?+V__,%Y_N/AX>7YY^\8X^_+!N/YZ
M\?'BZ]>+#P8^9MS\^OZ?%^>WQNV502]>?+Z^O;SZ4L`JJ=FVAG%2$RUSK9^S
M@`>*HGKY;71J<U8UH:])6XZT+)`FD@(%H%XOU58,G)M1^.#YZ&D$TS(((F+T
M8_S2..R7R-?C13$+RZ>&L!.E,HU^:+?:;1/;/>/SK)))6EV\`1K#4@2[$LQK
M:B2>0](,&)8LX_#2%7X8L%345N&)OMHPH3/^2N4-"?@J]BF&MXK683SIDDTW
M*8TZ,2"-A@S&TN3K55L+A/V3]B+9_YV#(_=9VH-8XK!>92H6;!JYBN75!^N1
ML."Z-07*B/2!&1Q(Z5XPFY08S6$+L%JAS`]PZW#G!`MZ&*@W0VV<[4:"7,MZ
MZ5W99\=-MWJQ;>2M3%@,FG)D6[6T&JK?"#V9]MP.N5]NX<>]'Y_!@==@SB*L
M[!3NJ9A=8+&I@$-:TV8A-P.3Q5".1#G$?8RA%[\.[+$[QPY8`F^,S,+?Q>)>
ML@931*'1;<7>R#U?GC&SO_-2<G`86BS';N$]H;N0#0C2AG$(\?=]B,!+<RR>
M0?HSL@(;,H&9R<>:C:ND9+`.H6]/!)@,_2:XHNK%7DN(G:FC_!R<='MHS5&F
MH:*NQVF183)6HCW(:<YQ*5G0D`<6>8A)'5U4*+JRQOF*N?LVB+/,B?,XP@8G
MV6&CDR!`PS`;@]&PT5>N]!KT&-GH#7KRRK`QZ(\:YJ@CK\!`>O!4BI@W3!B=
M->FHY+\[RK^[\M_OV5OX7^?+?%`[73?*GK"7.%5OT%JJ[4^J9?7YT%E+&;T_
MV,D4X&D$U)SJBW*QPNH.82B2M@T>6U/7%'.+7B1SEN%.31$B7B53A%)EK]U&
MM].AXB#+$\9<6S$HHT3@@-@A8B*P0G08E:@$?[`AM1)A$]187-RA-V'@)79V
M&7F3%#>I\Q`44DG9:_N<#`%/_%=GF%V)6V^,L@6Y.%FZ7S`K[=6++:GD3U%5
MW61.)#[15\8=))_ZLLKR8*LNTQ)PIXTWODH1EC[)V,6D\YD"S<NJ@2`G$LMR
M`D66X>F-R\%0:=*4/G+JC1TJ7;)M'9953<4]RSE`.X]E+/#J(_YJ'N%G/7/G
MUK^IV`QE!2HB">D5Q#KVUZ.'I:FA=T\0,`Z[8W"LHXEC!<&RR>D3+)":"L5"
M6,**9DR8$X2^4XD7&FN>.P00P]0)#I0':HAC(DH/K"QZ15A@FWYYRA1'?)A.
M%WRW6X,.+UU52UYCZI0R2?F+S'$\*'J2=R(&+"=:9-U%H1&Y"`$]M4$7NM.@
MD?[T^_2W6L8O]"NNRG0U+T#1VFR!-')67MZ<,&\(F&ECIUXK*&@KZ%IXQ:GN
M[SGH\PV`,@4:8[Q\4?!FRC7^#^M4596JE5VQ#D/=JB?2M[H4WUH#UQIX"QKX
M@Q!L:RK@VZ1JT^NPM&#"XXJN9E<1LT]4)3+M2F6@/3.FA`H[?PGA=(6WFAUJ
M>!&5>+N!!1&@]=#YT.\/%-VTI%E,O9^IV\E[J*-_J#?N#_,>Z^H?&_<[O>S'
MEC00UV_MEMGNX<V9*N2UZKW'W0,9C!Q-%QW86NX8(L*J6BA+PT`*3Z)YY+!*
M*Y%'&K^&*5KXA+*$LE_WP*P9*&VAEH?R&D12Y<L#L!%!8X/I`54K]`[+1X.0
MX1WRV^*GX4;Z%68PYA-65T/7$<TZA5$QC"\L^SKQ)HT'4#5/UJ+^6;ZM\&2)
M%/0$.UPO_@Z&)-*\F>J9<Y9G$V]B--2JK59MU75UE`>+=;7;I8J1R-%#E?-*
M`RH<`L^)!(`#/6RBZHL6*3=APR`V"J]'>K<;(OB0STHRV)]9SJ[4WA);40&Y
MR#]=!9'LV"C19"6@G09:BY^*\"@$Z32QO-"=AE3M\KZ1.I^).6!5A$1A2I`/
M#R)QIG\0D)")<]L-(B@PL'E/Q@5@488Q>"6]I*<7)Q![-9@8OGPOUEQ0D1U_
M4"#Q3J$<V+X3".`(0XL]?GE/7TIB[D00]+==!E7K"X`1!&V*'$?!^";T9(T%
M.(C:_@1%-'JH$K69-%TN5*PH?@,Y-N5#BD!.J*O\(W#VDV?+1\<'BY%&,]P&
M][BB898XL_,<@,20^:X1,7W&BN3FT$P+'>:X82;6PH8F*QPWA55R2/+8U!QX
M<NE##_9"5IU((VB-O<&";6QCQ(\M.2/:0[3,>M+4&G34-;_DU58XH[7RDNZ)
M0IX(43JSY'XXPW(7@>BE;"IUF<L5'J_M^$7HXE<2Z3AC#L`;\+)<[3715CM,
M6`SH-F[M4`2*IJ9GO0@K6H01LQ-YNQ,6^+WB@5\D952OQ&H!$&HZ%D729F4F
M8UV:%60S\&*5S*R%@!XEP83H:7*O"I688./,K/?+TP=`G])W*Y$8A!F1N0OW
M/M10R]X82QW:C1\Z;>%S4<YYB4H=-)WXDXB8]^3;6.$N_X`140-I$E<,P%2H
M.<CR+Y?!35H#Z>C1M-E!HS+._W"7T(],^32X3='45:&(\M[7,F0)!'V3FOZ0
M3E+)9&T2)4!$[]#JGN&B6!&,W"1)K'!V2I$U5I=AU))U;VI?+NZ/#`JBUOBU
M[7DXF8N7VE8:2PG'Z/%8ZI*1D;67\=7_Z73-6:?-OMMI=`?C1J<S*O<.9>1+
M"D?CS>)HO-""&_(35V8_=LU&MU\>N1ATV)/E`_IND&@&4LT'C-=PEU(#_#O_
MEEKTN\(@2CFGNHWVR&R,QMVE=VO$5:*%Y@54IO`!(/*PQ="8P:\&+G#C]?`-
M3ZUBJ:D\052$S9B;*$$EP$@6+K3B-F.^AQHQ[U7?G":-59"1.Y.GY'N,G:P;
M@O<DOP^67YQ6`\:7[2:<[VHV#T'`E@1>Z-G-N3$R^\U>FPTEQ2V,?5-#RYM8
M"IYS9N`.AB,G@^">#/?HD1@SRQ89]1SBD[5"X]!1EC;;?M@:==-QSN4('HN:
MLT%R$S5M?\M!`3`I8CQ)\WDIHM`;BJPC89!.Z-.8>22+S?/&H^YV%4^412D)
MBR4$-C6H+9_C$26(J*05(.`X.NLE=B+O:BKM:):693EJTA1/.LAVA!ZRTF*H
MR8>AM6I5OQ8FJ.XXN"S.&^($!S\C2BY`207:\H#5.C8I>XHTM*I95_>UVC2U
MX:CR&1*FJ[&K[(9\X_F'?I?!>O.`(=5K5#@LP`N$844>4K013C@(T^:C.6IT
M>QTP-=32)!?E2%*$9)CW_<&PT>^,D[]NW=X?CAO=86\M\YX_*BWO3;.7ZCU=
M[^FJ]_2PO<&6[G>'L)]A#T,&#2Y2.A9*_<@.'F2\O\C>[C4Z_9UO[49_5+9K
M#]O8^&`%^_K@#)S:HC]NLY";Y;PEX-*NYEWX6&R,:_,-;'BM_RH##L\*C6'_
M1['->!X4C(Z>@%F42KQA*8M,.8@D8?+4([L*WLNEE>C9D?(:C'J-7J_/$@?C
MFMX&Y'1/(H;4:S$P7\41`M$K:)4"68*0-,8FF2`"SV*;IL[TF'IG\0HX8?KP
MS"@U&#8E=ZQ#\)+4I:0#1:VG71;5XNVS1#Z4UP762,*]P]'\*&7(=_I!]YZ.
M$-P]VUDJUE*F7"+!+OWC*F(DE]!9@.E\#09VPU/8C7L+.[_$#6]\AK%-Z1+A
M9'#!Q.I-]*8(!47IXZQW32VNZL#AG@*'US[!O?#1\Y^@9.G&<E!VZ:#>ZFAB
M;9#L(EGHB_>H;V767DH7B1M9I)H2?24!L:ALYV5.C\3Q%BB`SV1G(GP]_,?X
MA%T>2`("]ZO\^4/\S!(`KF5<1TP)GX/#\XKYZ.-OJ&^D=[Z%NQ(O83[4)P$/
MXCRS/A.>`YGNF/*.^&__\IS(N/8>K#\CXY9,'ES*XGO\Y=.G\\17_G5]NS1*
M]>G/EFO=X^!TSWY.QN$P^"(G`WHOB.X"JED9S07JL,=:1<7\&B"[,#4GJRT=
M_?$CN?,CRU]ZCI77+Z^"'O[:9>TZ>!<Z5NW`#**T/<772:U?R^F%?!BRFHZE
MZ+B.'#HBBM?'_^->IR#@M9K.N"/A$^'@(1)E'G3)]6?^O[<-JO[^ET&%4J'[
M#_O^(=9-S\9[WHY))"[`B^;$<GE2Z#^L)\NVJ9Y^M$5C2VC0A*=JAQ\5Z3=`
MV,^M/PG`QK"3&60`*,5WR>HM>M2&]_]@-H;]N*DG/W_*;`.9BTM\X!'3'<H^
MG2K[%$HY'E$+PZOXJ,6+[HA+9C:>ZF"LKZ71#+7*U!RQ7>$9^->U-$FX7E6N
ML*Y+B/N=3I=]X*U6Q?@:'"A6.`3HD]-H@B.XQGLO+XT)I0$BH84`EI8>]]?K
MYB^=4<M(@V0R3#7^?>V:2%I?4-8%T&LP:+7P#>YAZ1^Y/E+/O?<2A%>:'K$A
M-K#8#.A:XE,*55O&I0OEL@S#5N$I1W*80]H0;Z8J&IUY4:AY$W-YP:?1MJ!#
M8A7\_EJ$>^*]T*"-+UJQ`::^QSW1O+N0E\PMK!"'AUE7+G9KTT\(2GC5^<3Y
M-[(EO)S,->NX">19WAHV7;Z/'H>0HOMC0:`C6@-N=.B&AII+*J"<Z1,`)[.*
M?=:3BEG0?"UE,Z7!-\0SYD.Q;KC`=:5Y?`$2HDW*^F-9]"^#-T^&3L;>L^6$
MS[(7*+T%5A#X+[L=%`A@:!-T[%!;F(Y(L4Q-!1H!S'#;C=@^\[V("K?E'$;V
M1+</](_H_0XK^V0@8&+C?Q;'@M?TTC0&HJ;<>WK#'63$GX`8;!GT^),:56>@
MJYJ0CS!Z"^B$112FOXIKG656FHW>8-P8CWM%,#.0<I]3J5RRN#BP0CN8L3JW
MW&U^YXA6?D*2IU@4<![59GIMIN^-CKFG^",B;6V/'_>"S#7*%*&>H1<?+(T^
MT$G]+'$MM4$:VE9U$XF;$GXFIB[D$>&!JS\./0F1+-A:"'9@S64OT;@+@JJ*
MI,TB]?T2N&:6+C9[/&25[K+PA,H7Z&ES,PYS<84=K9P8U`/&W*)F#C/YTH>-
M2!J`&0>HYR0DAA;881GQI&5<<-4N^"3\AM*JHGIX2SIXY:3XR2_Q>EQLL$]#
MWBM6QB&YP>`KQQPXK`#H0VJ=9YU!62=5%L%C/7E3$SU$BXF;TO#&&WQJQ6$K
M:U_;PHYGQX(MVEZ%^$Z/DM[2@-B&LM2AY+W!X4?EX@N(=SY9.D:P5!W>VL3U
MGM">1JC9VO=;*^P#<*`)D$$ION,N;VK2`((#>O,[II58]8RNB,=L-^E_CQD0
M)<H!*+AFP=L9#]X&$+R5?<H]=[6:UY;;%'DY8%$9#\]W/@(<4N)$.&E(7>&N
ME-?F&ZC$@225!P_WLKP+2/.Z`[$I`Y3X=$HR/M/@:-!"2RLP34R+EK=MXE7^
M'IT>KD?GZV,^D>A]SGIK&]="1F;$E1HZ?V,#_1K)TJ!2:,@9`,A9+5N2^4UQ
M5A9]59POHZU#[+3[C?ZX6S:=,<KH0G%Y?:5M1UZXJ3AT(O?#T/])I$G*7^IV
MXSM-K?D"[<:'BETJ%T.BW?CO9U^_GGVYO3FB_)OZ='S<2_1,]9_:+M:4&8.&
M2*335I-CO3`KKY0IA>E6Q[I29Y9E\$@";#4HW.-Q.?',Z$&!2L=<#XI&G$8*
MU!77-FR]K;9NP\8A7LMY_@\_),N22SB'329T3&B08,X2V*6WWL*>@'4*FT4Z
M5R0\=N(5<S!BX,J4S#"ZR1$YZ=^^_2B!H!N`L!YXC14O"2;>`DI')H3[EZ`5
M2`(&@-?#BP+ZN'Q<^5YLD@9"7-`G'X@C33UJ`WLL^QISL9[9A\#$N_,H$<#&
M56KZ$:XH4;\/5JY2P[^R?G_)G.--09DY)^D0//`88JKO!I\TM<LFA$79P'2"
M/&67MSL-6/"0%[K@6WC#%6&TAAPPW#(<V[JS'1A5O9EJ";1M"13W2**;#ER&
M&)<':-PY@E0S]2IUN%H)0;?D,K8]"VQ3BR&2QT>.KQ!"CR/,7*P+R+>4>I^'
MGK\&:1/5IUN@&D.Q;U+^.-8BH)03_]+0;JFJ=$V:5@R=SPIL]96IZF)DS*"?
M=[TGWUK\_17[WVR0?)CP3\:(GIP*+H.2!:B'.R"Z""A3Z`+N'.#@#FQ`;!,\
M$?#'PV)TID<RQBJ9_#N^FIIB9W1W6O?DE"B;*$L^73%D<+$K`0M,<!D=!@O*
M+A.AUMA4FDDX@>1O0L'"9)._X!=_HD<RQZY\NZCU\"^7<4<[\.-;<3*UXAJ\
M;B?/OG(RV[BC;+KWO<B="L[]SV1"R&R6BW<R[HQD[5[R3+84K,JAK%@.W8QS
M].JG$D<NA\S"-=[3&:1?A`D&[$W<WUOD-54-9RUBY'S]AR*/]W-H`)[IK1%@
MX^6*A]\<VT,<#^'LR6[[!100F6JF5)CL&_`Y@\C-:K]V*C/9KC1;&HZQO&2T
MLOZ5JEBF;R^^+Z![]5NHJ)\16[^XQ$<SW[<>O[:@?C=8`16.YK__2QU/J565
MS;-"TZHY5'XTV^?/-C5%YGBN<CS.]0JJ=#2K3:V7N<_S[+>=,6>%#7@@.SQ7
MV:='U&GU4YJ<Q2_6W^7*&W>U@M@G]>R;>A&=T(ZW>M$!5;';R]+[B/BU[4U?
M=!P;[_MB-,[`O_S;6WUR**2-BES3.*OT:@8Y%,0-,.WC*RLM/X=*:ZS(>&]1
M4UWD]VXUSU0;!UX)R+L<S$P$E\O@[VH#PEFAT72`NBI`7DV"Z6AE@NG-[=7Y
MOYKOSVXN/ACG5Y^O+[[<G-U>7GU)>;]TT?L*J,YR14^![*L34NI%&F>BJ(59
MNEQ.3,ELWH$`P6H'(6,8G@$T]7"7*@42+\`$%594>>U8+E@6[;%R`9-7Z+61
M>NTU)"3(1GMALIL.W*'FKK;>8!897A;]RE/5$_?868?RD=(!@%<\_YEGK;&"
MS0!Q1B#G[9$D?\#AL2LR&9978>5TM2'SA>,]$V`Y).X`>,34]NF$/%^T.'2A
ML`Q$^\_&@_=$*"&SQS"WG@T$2[LC;"KY/77DUUO&>T)7*&)KI%I2NIYA00$*
M>[GRWK@T+LTHST_SJ67$N^TL[H<$?R8,29:I/+>^V_-HKI1E+%6MII%.,?V0
M#Y!G+-J!T>V,&IW1.#'4Q")C:86IG&/,DH1&2[Q&UTX7R,*+WGM0E`.5)X)=
M#)9%-*Q_;;\1E2L3GA>-C39U?#->G[U1V87E/XPS5`)X#;"WL:80RGSIB]@B
M%;W4V3L:K/+(;/^H9E(B^QP`&Z($<@W3C,%O$9*7"J8_2<B1>96&36S@4UX1
M@]_[&=CZ^GUJH`)R6(PW_<'V)A_$1%%;0TC8H/K]6>'WV=J0NQOV0&+5,S%"
MGZ<,?T1TX6+K!)<)>\SU0LS5A215JC9<M=M1=FYIK94VQ/NH";A,P"N^SB^9
M\*2;^T-"#UT(50'+7#U#U/2NC<YM42L7'0#E;X-A8H!>E8`:Z?!Z-XT%$A<U
M\$6?US6RTQXTS&%'&!Z\FH&:#),(%;DWFU&C@>\2:5`MHS',6*T"'1%]WZ`K
MOXT0:C,1$\.WF",HF1W+6WP"0&_)S&YMU6NW97SQ5`3_Q$>$XJ9Z//Z>D@4>
MV-\-:E&%#P%+`D_X^'HZ4TE,,Y!X)OB-H*'7A3H35&='^0QY#1C[0[LU'`/1
M?S!;G:':@9RA#&,5BH18H.-`3:P4$E/68)T'AS3$.AV`V[`989;+YOJ)4I/$
M6.<2(EC@$`+6;Q!0<X,7!CGVG\2Q'SQ/`A9F?%?4S0D&*495QO*BO]PAVL<=
MNF#!#)H\V(0!VR%FW1GEB</-Z!739A5!"(-'!U)D&_3,QKA\[U1<=V"1>92C
M<2$YFVCV=&#!:!"2.WUV2JA-HUK35$PMI1.SIF16[$Y%LH*+X"^)\6JVF>G.
MFO'&VRE[+V=N-+,QI(?OX6!0<J^UC#/`H9$EOQD;6`R.L'0,IF^ZC?&HGU06
M"O3B7N1^OS4:,+G?;76Z2M%O$0W'SXM2H8D"IV6UUL<F)G08*3>$V1CUNXU1
MU\Q1PK48JL50U5Y61>@H6"E,F6I\JZ(Q$S<G`-F$^(^X0SFZ-$.2=9BY-*7;
MTJ:?9E6^XF&^6Z"0&;\,9L&OKA5-T4",<5<`BIK#Z-(-<[7@@##XE[6@JOR[
M/:=W4)N(&FM#8VX[CD`-^V$T0@@Y8?;DFII][ND%*48%X$*X=[G-E_S2:,3`
MZ=A7AHFOA`\^(>6_DR$20MGC*#6$3FLL)PMR$<!OC,A5^)?@&>`:JZ#.H$G`
M:@4^9_O0438B\4$@VP%[C8V"G$Q":5&I$$K02-LRGD3QC<6*;X0P!%W3&K!N
M\;4HJYU->W4V?:&SEF=GV+\W0HY]Y2!3-:EKM;LM:GU<\B%IHE+Y_B.P])58
M7;Z)WQXT^L/R"&/)T(/J4QJ,&_U1.\NG!/$L8<XS)=H=-,;C[FH'4\I4SCX)
M))Z5H=(JO4`=[@4R>^IAX)8=0G0?9QVD'E0T%!:$BZ%W,SDT;'2&$L!(#7@I
M/&XP7U.G_V.,_3:S?0@$N:X-S3`5>`:X%4;'0?:9EP/#37*8C`G*%.1#:,$X
MS]BR`YLW,I#@@&GX[H";..@$2D.^8D,I[5E6)80ZK^*$$9TO<S&;S!9TNT18
M%9A/@`33Q=LJI42%AO2R=3L4]F:WT=^*43L0'^A58<\VQ%D@LY=+52>!VHRL
MS<@]F)&_64Y4QR)K&W%GKAG9X%K7W1IUC/80S]*H%',B/O*`1';5,U`4B+#<
M>TA1;MY,'CP'M!&N^29H6E2()'SPIE3S)VS(V.H*6&842])A-P>8D3?W$-G,
M"CR7]32".%#B+M`Z8J)\+&`04,MW+G)BH&&T'S?N`55[#[>C_9:BC-(4/-5N
M+)E&F,AGFR`0&V_%%-!EB(AUT&.SA7W5Z'`?/1@?H+&QADLLTB2](@Y5@8$$
M=`,3AX&G*YTRO6R6"<7(W30Q>Q2SEB=G)7.'ZAU5RY]JJ753>HU:LQG=`T'F
M5EOM&F9R:979N%VSK\XW?Y'+_7:EYO.FQ!$8G6R11RP]]($J!GJ*XDD@'#\5
M]XQ#OJL*3,!]Q@BM^=J<*7#>_5G1@U$0QQP+:&O]>0[3QXN=(%'Q!B2$%]$C
M,S;,RT9LK!=5@2V8A\NX!JT2N(PY((IER%@"MK$&7BP+8)0H\N-E@5"/R^M[
M#<V`#64P##@EAF3J;CZ;VVQG3_GIU?1>.9N;+-E;='+;`0(4HJ37'>,>/3:F
MB5K:OAD+)I6%F\Y'EI]OC%?&1]KMU'36T[E7+9W-HZ;S8'`LZ[FF\Z;K.4.R
M9V-K&&6$?J&Y70A_%C;GI`K*>+:)DP>A54R#:C[5;E&K5?=B'<G+0D+4(]G*
M2`JO4(;OM,7UR<[++!`<NV:W08E!O]4>_&@TC<&PU1X=!G?Z_5:W@V/JM-KC
M`QF3V>KUCXQ.!R!QO]K!G\T9G,%DUU7?"LDVJ&&VAF,@!J7%\##X8[;Z/3:B
MP8&,J-T:#@^-1CWD6K?5[AV@1+[%4I29"*5MA0):V*/=,Z(>1OXP#D":,LB-
MA407KWC26"YT$.2'#,7A88SDP&F2@6=61R_6C5X4#5<P4C1#;Z'VY,J.7Y2A
M%G^W..J7[3>U9N"B@F@%I89>O(D/M3I]VXV="/E`[^F[E]P2,VMN.\\_&<'S
M_,YS$OP====R^XC-D4R16_(;L%A].O]0\R^6ZYWV.@#($$0^9;W1?XCO09YW
M.D/>!:`J`QNEBX=9C!-_](Q)Y/N00[!`%!U(.;:>$4\HOCNG3WNB\+6<9*GW
M2KU75NR5V&]1>+><9:?9)&HX$)S-)Z`^$:5M8LVA>?*=8T\`O\ZWIE"B$:I[
M3TEP0R0R'ZJA6%T$)FOSJKX'&SHR`YOB)VR6OIYZO\&RN^VX2#1KZ'2=4TKY
MO+NKNL4%DH/`I<!7^KBU<O#F[B"K$<"Y>&DBKT1,9K^SQ'[^EKBZD1YGZIU>
M[_1*=GJ&;Z>4;O3U[X`]RK*%N/KZM773,FXAU32B&PF]]EB^@LEY>F0_R`]"
MO3KQL+(H^0K7"T7M#=TQD<^V>;V'ZCVT'VT9KZJR5B6BI2A-C1.MB/G.6,Z_
MP^RW5-6[BLJ1"=^D:$B.^KC@";2\?`U>ZMM0GF=,/5B,GNR=3I55G"P/&YQN
M<]R;+(,0<ODID6#WL8(X=8:@Y2.!7(FQ3X3N!#`8FY<!6CAJG]#-1)+E>N*U
MP?)6AH3[N$P@L.<+CD;#TPSYT&7AY<W%.2/.\JVI@H;D9[AU+PP-7M$(NY/N
M]*8HS0/;'D$ZZ>+RK4D(`HA^1-[/_9`EY4_M!Z@3B3=&=A)P04(AKI>["_G&
MR;UI`>!2O$$M47(=06D-B`+`GQ,[:TF:)9+X\TIB(,49JEN4[&,Q`D0;AAUG
MNQ%^#N3,OZ/I/0>I,\@CJXWC0D)SJ&@D=SL[I*<F0LD$-_^G2.V.;G:RC`C1
M8ERP_'U/%*@R:5I7S-2EHSLDX$U<2V;,+(XXD*AM<X5RI..YMTDL*42U@-Q3
M7`!,4Y4#1?P!-?=JQ;>+@E5PVX*RXN4RTX3!NESTPNRX-/2(\RR6_"KASPWU
MIP<B$4C%HYJ*4*Z'B]6[@A;.-O%U."(25H)N;QM."0A1H8"Y-M1J3CTQ"OCU
M6,L`=H"'6M"6<:5"(^*I)>$8V$1N:`$T1#G3<K\"ZT^@G>T"TL=D`H@9=+D^
M8O&?%'ZV.W&BJ623YSC>$RS#>JO5D;G:?U*9_P1]'`PYR0J%]T"1U('G3'-$
M@(O4@36U\,F,^+X$M1'G;]9SIL%_!V=&P#!FZ%<?;8?<QYA->:]#@$*PSO',
MY`6%15-:DC@V53E3=@Y0QE1@#"L2L6M79;W5<K>:/0=T>-3'<=%Z8.3$NSR)
M9%2OO7KM;2KF=2N,.T;Y0J,BDF&2<*^+[5+KU*:_*[#]]4JL5^(F*U'I^E`D
MTB_,"$*?\^:(M,=Q0DHNQ&V>$^+_M("V]:FAWL2GO8F#.'TZT=*%M4$4F3<L
MSR=.[ZE51[WJ-C5B8B]5LK<1Z]:#@5]^Q(,8%;6SP0^%?2D!*-\U+J^O`%H.
M<&0G]*[`5MHU"4W4,.[I21./AX^6[:"?C_5IC)47=H.LUW.]GC=<S]"G0:S6
M%9[N!!1AG;=0AV]V'KYA$@SQO8QDEA3S(/J\-P++!@XLA_!FT[8_-:A5(!*`
M"X44P/)_M'S;B^@/#K:URWLV[3!<[L,(P8DZ?'"`L&3C'OYU-+AD6P8CVQ"+
M"K!%V-^LTPY\S)GJ*^'^():?H[GXI.103/GJ\I\J5-*WPZG?8,KE.0B6%TJ!
M:W%\,Y`6^09%Y66ZN9!74A1UVNW^:D/.S!)=I=&)>F97O.J<*2-6*?S:>K-Z
M&..J1F&.1N)5T+ILO#YKUJCFUXQ+L$)7OKO)?-E&A!SGP#AK=HQKJ<,EU5_?
MZ0B_\4=_:+=ZNRY,SR'L")`DVNUE1E=)W^XR?;=&W$'G0-:LV4;2FMTMDO;]
MS@AKMLP-A$'%JY8#EFV'IN<[I&EW`TE0[6+5Z;J-9Z@JLJU0L-]JKZ!@[8ZH
MPR\GZCC,MPPS?7]G,THT\#.#9X\77^94*K.TI`!+,\"Q81F?/IV+3FG^PF-I
M(G4QY0FM*ZVZ6[FN;F0/Q[1##)LP\O0VK!R`U9-JI]=M=#N=QJ#?+ML+DJU@
MR,]#F.K.6'2JM++7N=FDRZLY;)E]PX?LWX`(%_=LP\^;0]XA<G]:J6X3\B*5
M^$=H6\5+=GA3UF5']!?OD<SOB!^3EJW7;J/J>IY&YEUK5B9@T1'<P@.B6.9O
MI2J.<=1@'RY\*&/6C1B;7DVHZIKB5^27S^8$*J)=X]*E;PLC)I;.0>IB??`U
M2RDX8U4#6,CP6LRKT_[Y[/+\^DS^;?[\1MPI*H)E:S[CE\B>DH9R@7[GVK<?
M$;"@^0^`11!CO6`%CS=D(M`->*-H*\![9%WA:YA">CCL2XE!)1NN/,HA3+&V
MD0XD9X7\,W*>X\M=$Z]W6$KU!S))/<9_;[,2E<^,:6>":394/\85U#@:P5$Z
MD-<6="^+F7/ITK5%XL?ADV=!H+SQ#5\@RF)0%@+<SXM'<4VP0:57$FL8!<%Z
MRWG&NG8LQ5'R2F*\&,UV2:PV^G%`S:&KG4Z!IZ.(W',8G'P3W7D*+HT%87_\
ME.UB;@NORZ>;`I+7F1Y%O)FX6#<U#3JW)R_Q^,*SW5!LS\1'Y,;L_,Q']*PL
M"LR``^%I3?!O-D'U&1@0TIVO*RHEXGZKR:I!7M>/CUB&&\%J`6)-[1EFPH>R
MW9X"Q9->-@B&,+<`+PB_^Y/:/0@:-XMWR"I=^CEV$^X%!UH;T9U,F7$N6?D9
MG_DY===M//'X%I$3^)Z>Q@//H7-DO]1]OVJ%7C6U?L%,()0EE@]=O$(%<T+F
M"^E6H_%D!<OBL'@]7R#5#6Q:*@<Y-@9#W,)D)L3-`-0,MD'E*VT74#"@ZMU:
MV"%4U;$SHRI&Z#UTL"QA:J*K/7AR4T.(^VEG/,)OY_!<,'WV$28D+8XS1H7!
M/&@ZQ+T'M:*.B),+$K4,69G#Y"9ODFDYCC>1ZEI1(D)5LX;GOF7CBSC.`B6`
M(`054EYTS]09RT_(X0`<L2/7#@/1UQW_,``]P4^?I(35Q<XM3,?(\Q>[*+NR
MKSC@+YWJC9OH+J"*D[@K?`3R$>5U28B(BB@C8PK4O(CC-\J_N_+?[YEI(MVZ
M2V3AP#JZ7NWM5IO:/1BKP?\9T$^@#YR]$UVWR=[B-6Q#K0&V6+>.$F<:"P;1
MR3'V1+QF#@]11@A&:6H[OUDZ$?*=!P%`UK18B+Z<S2ZWJ!S'6^B/K`X%[X?_
M++F"$.XP1K>B]C&A7')943:>%Y)2@T^[D"M&*9Q/FV<HJ9?4I&R9*6QJ\3RK
M'%5DJ2S4Q-)VS`G#OS@>#32LY"I-'K`\$&TKU2/J*YN/@/Y"Y2P>>J3*2BK.
M['J]A,YL;#BCEO$/[PD<8PWE"(YXM5,R02`MB4J65=1Z1\(G0K('O"R,E?7,
MK]"3@CT'V\6'2C"@+,#ED";X[`#EAUL"RY)7^CQK`9,K8*[Y9E2\!1D6I2V;
M)#L,0FWN@;5#CTK\L#JU)]#M7!I';&E1N[7)[-;X,,X1&UT/H(^FT20T!#^Q
MS7KP8,P<[PF/Q?3]Y!'*5EGS9?ZQ4#V9/5ATD-X$092G>3N$[]4,VQ8.J3$X
M2+*5>TPAA/&PE!,RV[DP"?;QB0/UX0Q_$LU1+P%.88G"1MB5\2R838$O5QO/
M"[@=V`=30@!IV@'(6$&(VN*H+8XM6!SRG*DV.,_W^BX@+P&/752J.T3LANSS
M)=RC5+\P<$4W@?`<H\FIP'3"-<<TNCS;JN]1`)FS1`&XT]"S!]+&C]PG*R[W
M1`!:OF]=2BIZ"@2UC!I(;EXJJ99*?2@7'7;*ULQ"$(8-2D)*`'0NQX'.)O"2
MY#)>@RI$]R?@Z+Q)0500V<^>V47,"*FE12TM*J;6Y]@VC$-%6%I4U#N4"LU0
M97O'+0_5EEY$_H0:GXH7J+!5":^`0(-J628<#MJ^],+G1.:V@'N)O6!V$%N_
M">N<3]H2TV:C968K^S!'I:*B+/+C!Y`\@9PM,P&4NA.^_R5DEMSM]!Y[CC"2
M:FPC+CK,LLV9J2V]/NQLP.9L+>B88C\7C.=.VH("(C=UMM`J!<Y@NG*H<03H
MF8CWC>0I>#0">RD!Y?V#V6_UC3G4K8'-](/9:_7B/]$M,VJ-XROT!8S@J=>,
MS'&#;@;ZAM&PS?Z%#P_87RQ=@?O[F`\U/M#)X28+AG+E]^YB;;5':BT<S#N-
MZ+^KSY#%"'CE[CB@+#)[N,H14FB5/$D#%HOM;4O/MBCYX\)42&"P;ZF=)KX3
M1'?_AE0B71B"?\K^#Z,!)OGP8R:50!.P\R(G%()(`-[`N=$G;";LA.@D+%LV
M):$>\KZOE.SR28B.#%2\_R[L4QZ$G;,>0R+ZRKZBA#EX*!7I%L34$1%62)6X
MHZ8F5:4+$8I@BT!8GT#?>P^=[^@YFDD4QK3+@:<"2-!&N(%A1C:ON6+F?HC7
M5]>?W]31UMJ6W::O7:8:T<6&3G0N+`JX<W,E"<BU*;D+TR(EQX`2HD3:4<F@
MXP3Q",50T;G.S$=K`CY^=)>)#3N-Y/D0ON^0[\M6&A.2$;42_="B6_J9&9O,
M"EI"HFC(0[/HY?!()W7'3KZ8/P+^6[KKX8#PG0I:/"FWC%]!3(E1-Y@'6B45
MB`"$MQ4AV0GE@.A1P=WC4SS"@QP$(U@BR;*W)(TQ1C+V>,H/P-M=,$L]W:]&
M:\NA%:B:VTHV#8AHG`P6G$_L!9/I_.X'C]J_/AL,/<Y`9PBZ">@L)K$?/D$%
M"5VK3@U_4H:4G/_R\%K&>]:C"EG,5$S`(J)Q2UQ003$`YS)9P-,`<0J7ZBDX
M[D%#"W`.!5(]"<3=B>>#">JYTFY.T,HEH`0M_SFF%;Y(.>9@`SQ!OE0+D!0Z
ML3H>OCH4WS-]-YLHJ#Y"]1FH7G;BXCIH0><)3S-WE_=$U5;P8"_TW$CR-.)+
MV`KY1QK<L0,J7:@P=7P)]<HS,^+(R]+K:MN]UG!;T'"@)2!\0&1/R=48X[!4
MV>I%U1&+XMR^E&G5R.2>!-.FOR\B:ONRL_:";4MM\Y%DQXR94!LUG,8!PFF,
MH/KFQ8-IZ``8'`W&4XR;4-`3D8?XM)>/KH\<\0I6!24^77U]/61%F<''J?0?
MJ'(M.H&,2MLR!;5\/75&`UQ1^V2"&(JY]Y&L`R0B1M_K53)\X70RN*]I?7*V
MCYF<YJA;R?#!46<(_]S:M#2/FI:=?C5+4S@V!3W;&XJK3<$6-//Y3<:OBVJ:
M=8OX=2_KCUKM]H_[^/+`/+`O;P4+0O/YC"[`^Z!$N]7O[X4%],/#O7RXTVJ;
M&[!^X]W^F;5.?C9>/Q/+#[2UW]NF@0XC9^L?U8'(;%^ZY7.ZABNIW3[54NN#
M'6`=<D!%NGN/:350!-#MMT8_@FNGU_XQZ84!SZSPYV,+8\]!/[^XQL(`%G?S
MB["DF@_!?=RQXX;[144UEE*%IGL\58ICM@!4(5E\T^XB>B#+JJFS+XYV<2I;
M6?>OFH+KP#ZP0IJ>P)+/VA@R@K;P@@"[CF&,+J#:"\*7N$<@@N?:F/S*:]@]
MR!>@`T\&9F3$=.%[=T(T,!Q0^H-LJTSG!XEO/(_L]?7O%U\_OUFS2)5+#%&P
M(F**,D^O@56;HI*?OF@681X:S[932TDA7L-[27#Y)WI"(M+_LY+K*ZG#9%QV
MG]!DZTD9[1+/B]I#S#86\28^PE1F,0L;<RD.P2N0PSRXQJ&P>>F3A?G$36L*
M>X+$#Z$Q+W,:`YGM$6A'SF)1J=%BUB1=3)*GB4BIRG49>Q//LN(,7H^6C&EF
MZX#LQJ9*05(J'+B\]C!5>Z9D<*=(BQCA=\3H]7]D>9J9RQV9T.>WL1"[7`HB
M]ND3B4R.01*\BZ\@+PH!P2+.\CS/JEVJ95QM\+WXK.R(I5U?77\^@K3D3K_5
M69UU;,;)RE@I4V&"<=*X1<)-0D]GH_;JU+E:X&P/J*3X$3&5C;L0I1/29*%O
MZ=`MPQ1N7-EM@5UV#T5J/E6L5`:%(O-'@3\"(S!YXM2:I0GIP[.86&HQLZ`8
M[ECR,$I/S8.EH^>A[+]365"K0STU`5<2T(9_(/)RD]GJ";RXFV@^AS2\6W`W
MLC84]K:I6ZN'%[D8+Q4D.L![]:=Y%IK::LRX]RU^2,NLC47(/L*3JRD5F_(*
M%>9)$$$MG&4LR[F!I=10)!46^@741FAL>&#5`J(*@*CT,5D6MQ8#GPMXQEN0
MG:Y6[Z$49;;4Z:E.32O6`6?<WWN61EY&RT&/KM.K)L7EBT3'9!T47A()N^-*
MAG<ABABPUU2U!*PF$>C0"2BUY4?0EI!B69-Q%\.K("VU:#+"/@E]@@/B'1!^
ME1;D@8SKX`@%1G>%FNU$*73#CR4',J2#H]&E&_JV&]B3<LJI`OFZ5L'#IM/]
M!4Z;I0H<\A6=KL'HT65G;S[@*WZ8_X4=YFO:5JT0:XI62-&ECGHU8:L4`QOJ
MD.VW:ZV\3:.^`J/1[9BZ%VT[.QIQU[?]8?R0MKGQECYT*!UIJ^_RJZUE:3?Z
M_:W3-F/U##M&$_#Z=\3<7JNW]=(%_%"W-31A9MW68+EL86]M>'4RHG*N=KN-
M44_7_WO[Z\G4M9<]E0\+>7LP+8B7Q>1VI%-;T\EZ-TS5]JW>ALK9T8<V6SU5
M2Z/*&ZWK"&:V$21T;PL(E("V;_@+7DC5BJ'*>\MKEU%CT!DTAKW]+"3(8H-U
MU&UU=F.^P`</9"'5K7?K#*<M(&O%R%9J&0A/!I*(A.G,(2A]RLY@@JH1:(:+
M"5-6R#I,0]\QZ##-4+P?+/>>`+:C3'MGC958M0ZAA)[62%D'F(Y4(V4=6;A*
MZR=E]&0)Y3!%9WI\KE/M'"0X5Z>R`,L+XL+1#OP0E\_OHESCC)5^Y,SJSC>,
MMZ4_L(U,L0/F]G:/YU*]=61_@*0-DX:_TIXODR\SNQE:>C4_'#(+XX2S]=^#
M+5(46+61>)/9&(Y&C:&I#5I4/*"JR2%9],.:5!B*%PQ;;;W'O_@8<N:R=3^`
M,-#`W.(E;4HR0`6>`)SS)BN/NYZZC79'%P'<X)M[G`\X!;3NAW6_N#O/(UO$
M6BF?L:*$EIF^-2Z^+VP?_O'1\V?$UJ\S\55M>+XPY<LH])),+?-JA>FOQ^:H
ME*3()(`6J.Q4J6:VS/[6Z+8-`:M1_0GWQ6&)(K,Q&K<;HTZ>-;)[X5I.+PM-
M/-#%T0Y4IF8N4BXNF>]E]=(YU7W?&8\:O6XYXW(S&NR#@GGK?$W"]5K]<K;%
M6F3;581*/\).JQ]O%XZPQ?",&&1)"2XKKUJ?S_@28^I%=--6OUFRWYZ0X_UQ
MI]$=;;9CRE)C;]0LO7$*$7'SO5.,`!EAN;^]C8+FO64M?@+H2L<+(I]<S53T
M@J^L)]6Y%X0!IAB_!X"#:^L9$#N"6SJ\]XXW^?/=?__7W\2K^"/7EA\^WRK]
MX^-/R,<0])+^\97,_O[JG/W[V^#SQ;>V^>V?EOL-5-!MN_V-_?_;JV_=]C>J
MGY+77[V#2<E(2^S.?\N<[JN]^HF@BC92DPZ(%`U!E(@7:`,T2M1C@X"+\&!]
MN;J],,8*QHJL[^_\K%S]>O'I[/;B@W%]]O7V#^/VZ]F7F[/SV\NK+S<IQY<N
MT%63?XT`;TVT--'.C"D]N$]"ST]#I-D!MGUV+0385>_ZI_5('-LU?J-S`;PQ
MD$#09\SXY;IA?/ITWD@T;%^P7U<_V+IN"=C!!^(`<E)`"6W/J'7AAART#"'@
M[&P`T!O6!NZL:3;B?W>4?W?EO]\S[%O^U[F*Z(:(&-BY#%#-6%MI;HDD(,P6
MO@TX4-E0'AG(B]F(2?4"K7=U!42[%@L3<599(@4@B+$T#-Q$$D*&K]N&\=EO
M&9>^97RU809`J4>&]W)^<06[]XQ.T[&,7Z`[KG'I3NAN?2U6>Z?],_M97C!_
M?J.@T6(V"<#0('B9.1X-Q5:WL:\:@![B3Q//7W@^:TPJ,!\IUT*X=$^W$$P(
MV@F[$]A7@(\(+1#IEDKT$+5=P&<ED'N"2+UNP!$:85(V](NGTHS8\$U$#N=3
M4U).&,0VW>KA`\MB">SOXD],04F>WYDL2<$C]K`G.\/W'O/^["J<=F/]#_8:
M#(]5`#,BVCGV7:3RDE%2R%\<V'1.11%2D7XY)@F7I+^Z5C0%IRTE(*QE@-:Z
M">DLT/A$\+<%\5F_NEIVU;)KJT2[0HQAJGU=1$ZD)QDR34(K/E"9Y'JA@8%I
MT:>;;NX[0A`8470U9:8"/!'&QZ.X+ZPE&P'#$_#:*;SER:8;ZX%:*@C="%8/
M7*5T8O^&S>V#[!%M990-$1_S2IS-U"/=3707D+\B.K&+Q\2YKS[`[>H`MY2F
M,+/FMO/\DY&B30/__OF5`6D,D!6R?`(TVRN/@#>_OK^Y^-]?+[[<&A>_T?].
MG_P2*0^U_*B%[J&N_"L7.XP88V$/J0([(:@M.F.`V$8#]!Q/@L]P$OR3FC3&
M.:4J)9=KT[OLN2V$,^]BW0"`[B`"P4Y?Q*0XMU91:K,7)ZVP3F,X:AO!7Q$`
MC\P(01A>>A`#?&^D)"B$3QX]&[KWQ`&.QV-@1B5[*WWGHSWE9J1E`$H_O(E:
M:>%S$X"_7P_,-]Q@:^`QD;C8<-@3.,(A.P1S'%W#Y#G/'$E8P.P&5`6$%H/V
M9SWM!4(X;V!//^VB:IO#D+B)QD?'NC*(SMM\Z$G3&`FUL)[!-/;A(""@C&>V
M'X1L`L(5@),$^Q'05MG=])<?Q@USV$.4278WO(%;JAT)>6YVU;<T&+NQ>[B%
MR,?Q*V4CB?")(/8YOC3.^:9/(()Q/"U!?#E%/.K0/4JY'N$O/YCM1K?3;_4Z
M^G'VVW*@`Y,1*![0@GM=C:F'=@8=M1--20X6O$?/+,`FX*%$W@1J>\QNIO,5
M-G>#OXZEU4-G^R#$+B'6=Q(D605V3IQACXGUWRGSIQDT$`CT,VKB-Z'O&:>\
M7!OHT6`MW>$`Z$7.%"(K=,7]&RP;^GZ.%!]C18N>'G?T\.6ZO/<$?P5YHJ.'
M3[1J556KJN-151>S&3N!,XW5Z:U666Z24^KG.2TQ%L4&:,W9>?W<H6?N">78
M3;18T`^!(#WW/'&2-L[NZ8D?-]EK^++J2N%OX`_*&Q/.%12H7ZD:\R?TZ1N0
MEW`/Y;7QV8/_A8MG"1>-N#OII*'#NG0M9^*Q^Z%@(_90J$_??%8?9+(J:Z@&
M4B%0E)8_CQL^%*5,`]5BW*#,,`?`K#9T3>,?!N08L@C9SYT^:UNV1-&+[]@9
MZCZ7I!HY5@NU6J@=A5#[51I'F4N]8=`=+,OTN-ULN=2HH/9(`/*03MF9TJ%)
MDP,;38##DGD59S;&9<`"(;YOAQZUW$$\!A"HF7/S$/R2&'D'%H:0Z^1.XQZ\
M:*A1*QY?&"^57RPJ/T.OZ5&F>H$UF5`C"JUM:KQ,(VJ<J&+LDEF^4^.7JQMU
M_S9$2XZ%%]C":J;'`&YXPX_JH\PSBMYB%<W=8?8:C^JH#ZBFFY!K,7%",GE@
M4DU]'WR#=<T"$J!DC2`@Y(.T"Y\9I8(E>948Y^5U4NY>*X<@;"#"12'*V*0:
MFU-#GXAB$,66O'L&*Q<F`FOBAQ%#`$"=PDX85/`^![QU"`+-2Z4I#BIACO1/
MVK%B`%-U!!X_,"9J/V$P=L#<=1",$\[Q%#E2(;>X4QY)ZADBMH(5[P$;FN3-
M(A]YPL?"#7YC&A'A$N=]ZVSF:9Q;4[),V#LP@_^*(/$91L0[`6:,ETZMMI-K
ME7)$*B7?O',"+_:)P,DR9E)BGU!:HKL!Y4PO*6>HH89B)BXT__CAC/EO'GE;
M,ASCU(_N$_W2DCX+H2.\)VB;2'_B+7X=Z.GXG&KJ"5]):H'`L*&NG4FW!54\
M<\J,*.2BG,YX:J-(NZ32?#I%Q9)J]01401$@^\=U^VWC3]MA'4<3GQ-##[BC
MHD/O!!<%W(T_3H1Q'#":IU]@NT%((%0!#R,UY>-T*M%J.Z"5VDZU0*H%TE$(
MI$M7-D2,Q0#(%3RLPU+'TWJ>89+<N.@+Q0[#!L=`$MT<5S?IY1UT%I;HNH,X
M+:;2?"=MTS$H]93!R@P#-)<XU#KVC<249][[F`O+,1>6PK8I99`E'.>62%\2
MTDJ:1_S#+KGW0AM/WEQ^8DR5)0S<>QYV&PH?V+`SWV5CER/A/+4,B&,VHX5R
MQQU3"_2E,^M19J#]]W])!FG<_?1^9!N8972H6$U!?PVH;8TCO8G;<5K"B4Q8
MO0[WQ!/+=VQV)'AMO^%]/S$_BQK_Z$E-*0U.6T@[<7@3/F0#J(UKG'3G[FTW
M%MPAQH?I#5^OF[]T1FC9OK;YIV:VP]VH\/A'NG_HVFO^;YR/<T,F]'B$U(8'
M+[XS0!0$EZ<K(JG^`O@>Q#9"/&%P(JF#YXDN`??:EAW\LD<:/>)L9:(>8_1F
M"YDW#SR+[JG$RE`SO8WE`#LP9%G3<1`^,YJNAMP_\*R_<SJ/>Q)<TQ/HY+F.
MN^\G<5HPP[@2/:HQ(;Y.AZYME-T032Y`V21]`@M0)"LN?!OZX%'-BH9(@`XO
MEAC48,%-YH(W[BSW3_IT@\[J7N3@3;`+++QS1C`#,?8T44WE6"Z<7M(]V@L;
M(F`V\'[.V*>/6PW8+I#%<8.`A#S".-5/DZ41TMG$B80P.'[HP5QN>]J$+$W>
M.#I:<)V*B9CS>:*;=3P'E^4N=L:JY$X)ZWPYK$KL"\N'2&1P37Q4]K7(WFNM
M"PDA?8(:$Z*]2RVM:VF]&Z*IINF4@)2S74J/.PL:Z#BP*)6VUI`);SL1'&I2
M/T&4@PIG?VI!SU-IB*-W*T!L0[!I;\Z-SJ"=B(@">[#%L!!)QB*Q"?"WEG+B
M,][CT%RZ9U)CP$(3RYE$CCAV3>U'&X\M\FY^+!'-OINB<;C:]#L)L+B$H=@R
M/G`:[&\,2NOS$+*!(/^+'2+G)'SPIB(C*GSRFJB)^'6NA,DC''7H18\.&3E*
MCS=,K2V\D&#FE/,L?S&2_6WYR25VDV'L`7N/&-=4!QNOIR28^/8=2Z+_0M]H
MC%B0_,GR6>]>+[O^*%$>)%\EWS1\PU0LG*&$*X-]2$2NHE#JT&DVI^[(Q(I8
M1.<Y3N2!K+&FI$@M1VKAN]7*0<=)['K#FH-]R[P6BMSE5S&CGF7H8W:9B)G-
M("1*#6"S2>?<'+;H;O1ABP=BYP8+QPZ+VL'<+<;R0M#H-(<Y1N<*4U*U.K^0
MIS-IP5_[GDO_.6'9E^RIV@S=IQGZE0!.H1&SR$CRJ#9*:[FX&Z)=NDO^3U:P
M!_+KX]G->V&#G-W\2JV"%I;S-<U^(TEMF]5Q(NJV-`D^RLK'N#QO98W)+QYS
MI-&MX%/[YB:Z"[T%M4([[7ZSUWZS\OFX9@F&\*O+4U^8A_J.FGJ01'1!_PZ3
M<OGLSJ:2&S.$0/[9;D3`/VP9B0'%AG+L9.%1Y?O(9B:Y3^XM'XW)N"@T\2FH
MJ@1S*OXB>#NHR?3T0##10\VJ!ZB0D.6&!,JK,9,F?L$D,>1[CSE)&`U!P_',
MCT`6D<T\+W3!R)M*>@48-*9/N835GN'98N&3A84V<5S(&L35EC(=WG+=B/N.
M,'W*G@,..R2:TT>9*=U0"$+U+1J"!,)1$!(2<\<4>N8?\ESFR@G`QB;H%&]H
M#%'K_A[H$F+.BQ4:O@7I0\LT9-S/TLL%B<D=59"YCDGK<<X1!K9DTKJ66'A\
M8]OI-=;N;?@NZ]&R'1%34D)P@#S/$Q#HCYC[2H\@L(.AJEJ&XD1@AK,N&7YB
M@Q&IK/%N-UG2ZH#5$&/@2GT\2*P`<2VNBV@9G^,U0$>#E<]N2(]`?"6(Q0T2
M66XI>*>(YLBC,XOHV)254`X`,\13'-T@F.^$)ES.X4='5:W95=:64NVP:YXY
M!X>U\,R=7M!MN(!'MV%YY0'EKZ'Y!$)L&Y#RMZ#4<L#WEU2;_1_29):X^/2:
M0/KLHQ)#_X5CZM<#6C6@`\$,+S_&*A'@!9;#RZ;H,8RQ2JZK0/&G1-4*VL\?
MA>0ZX!8(99>)D<!2;":JV%*_":L%)IO\!;_X$X<MW7S6%_3X/\>SU"=[=OI=
M*PZ!955*-XEC_'*9=K0#/\K5UCMYII53K$8V@KE6YXK&-@,S[8F-X7C/,28)
M&(W@,2#BL)U#8K$:>FLU@AF,TV-1>V'VT:T3;.WKO6Q"Y.$2R\>7"*FV!FGT
M<C&<"XRA]%Q>$@4VWBL,T'RE=;H"6OUCY+LVU@XRJ,+O\.^\%;L9.GU1@89O
M'*[</M4-AI&I>B6RUF!XEZ?MC*;7Z`RU/8\/LIU!S:/M\6B[ZEHO$6^]4*TG
M7Z6E5[)F\QORQ[M)2YMQ8]@OU09A]1=/:38'H@'/)I-HSG,(I]`X>F)C`'MK
M(JT6I[L6IZ_[#7-L5B-/M]?S[(7RIM?HCTIU5*R@K]JV5%SVT/+T7@-S9@$^
M8'-1M.O&.9L^7\&B9Y_4+S3>9V?E@;"*Y5YT''3!#P8;+?B:25MG$M48PU)=
M_+;5@6EU`DD"D7OR0*:10ZYF6"/PX#ETF@$\$SY#2O_OO"C@RO^*2$YU%DJ=
MA;)_?_X!#JA*W_^I4^M`H@_[39;XG9>8&6>LQ.R4*%LG3.R=!:<6#Q6&R`MG
MW-$._/A6W(7`%;WV[<GII^OL)!8_[HQD'Z1DIWDU=]"0R0_Y@=3N6B'@;D4!
MZ,X@)Q;<,T>-;B?/A2A?4]5PUB)&SM>+Q,,[_1P:C%O=O)C49@38>C!`'`_A
M[,EN^X5!2VNFM+YC9.,H2[/:KYW*3';MQUU>,MFN7:%8IF\OOB\`7?DMX.3-
MB%VN`7P=+%@]FE)KJLY;.$'^;%-/9(XG9=LD6JG6*ZC:S)>5AM;+W.?;CHL4
M&L0*"_!`=GBNJL^)TG`]SJ(7Z^_R`PZN[6RK%PZ%5K#;ZV#HUMFT\;ZO*!:Z
M=G0S(T0*&$KOK0`:'V-'E;,GRY_BJZ\8_MIO#)'`<\^"()JS:[<PKCIN6L=-
M#\4+RS[&#JG;],%V-Y__[8-/B&AJRJ#_*RTMKSFTZ?QO[.^;\:>"6"&?>*^;
M65RU5S8+Y=E?*A[:)=/W4_[*A]==<O+6G*F2,VN4B@K.9$W],#@S6`JR'!EG
M-M@S-6<.8\]LU\&0II9V;A??%PSV%1&KH4?Z,_0JW="VT'X*VCS]J'NQCN3K
MEG#6(ZET)-MT<I=;GXA2W%Q`QH3QZ$$'$,!(W`8E!OU6>_"CT30&PU9[=!C<
MZ?=;W0Z.J=-JCP]D3&:KUS\R.AV`Q/UJ!W\V9W#ZE+V=?2LDVZ"&V1J.@1B4
M%L/#X(_9ZO?8B`8',J)V:S@\-!KUD&O=5KMW@!+Y%GHB>3/1&&(K%-#Z>'?/
MB'H8^<,X`&G*&I`L9")EQ9/^H=\::2OD=D[^'\R6J2UZW_U(#IPF98(W%<1=
M(*+CAZ&OO!;S>H.OK('H]*/OS6\LAP17L]\LW_:BX-Q!E'4>/-I+&$<)C!2-
MR(A,V]ZJH$L<(EH=&RH1YEDS4+/EZ$S"F<"=#^!FX`Z%57Z,48D\[3^(Y>=L
MH^P4\/*?*K1O=SAUW*@&[IL72@&4*:DV:05T<;;.-3:,01K2`R\[>'3:[;S\
M%!D'+I50GO/I7IRH?\YZ&3%SX+65AXTAY%A5HS!'LO3@!SAQK<\:9IIORAC!
M"IV.WF2^;"-2L4T%^EFS8US[HAFJI/KK.QWA-_[H#^U6K[#UN;T5+P@[@N-B
MN[W,Z"KIVUVF[]:(.UC&%]C/FC7;2%JSNT72OM\98:EUNH$PJ'C5:NN>JJ+I
M^0YIJDD`V]-BU>FZC6>H*K*M4+#?:J^@8'QF8G\O=.^4/<?6.$DD&IF5.2UH
MFX]E'2'2S=`J.U)H>*!T>&.GKJ+'+$:*9N@MU+YNNG,72Y\K0RW^;F&=EDVK
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M57FZH#,:X#HZA(PX\V!&TEMJ,;#%Y;3IA+]XCPSY@RF8[OK3;A\*`\S1$LC(
M`3/@GY'S+&!7.NO/^6"HW^D?T_)/`]^TMR-$"X?U-?/Y+3>1K\)XLCY9;+2#
M[$M]BJ%Y8%_>2E;19LEOVZ9$N]7O[X4%],-;SS33?KC3:IL[2XG4?/^S%48^
M-#9_C=UTM"?F;=-`%UG8^D>UD&-;EV[EW$N+#0Z0"7^NUDF<]L5NX92I]0TO
MG2^K\O7&V41;=1HDRL5ELA)X6(@;L+PD*#1G3>S?/^OSF7@J$Z*,T?%=4Z9Y
M4X$2RT%B\4<X:<GIU-Z+T_9>I&K"QDN`>X=4%&8>].@ZO27)5]GPOD1HPWLS
M@T4&3Y6$6RRQWA1O-;.]XHLAH.PO#=K!0/50DW$'PWLA<.<G."`>V?N5&AV^
M\TQU]8&,Z^`(!1FMZVJVET,AEO_LS0YD2`='HTLW]&TWL"?EE--VY.LA.H/Q
M?%<JE)8_12V>XJ&MJT-D!#^,&RKF=\V-?7$CKJ6H>;`O'BQEO-:LV*]PVH[V
MW`0*/U6`47GBM3XZF`4(NVW/_0_M5GO;I;[L0]IRI2U]J'"-2>5MMU.KI_*Z
M'6V<M=WH][=.VXS5,^P830/^=S?,[;5Z6P^KX8>ZK:$),^NV!LLAM7U)(U,G
M(RKG:K?;&/6V776?562O*1@YE0\+>;L%<(NUI).I:_6[#>G4UM2F[8:I^@Y<
M6U`Y._K0=E;/NM*H\M))/18,74![DPIF#Y2`MA*P7D@5B:'*JT6URZ@QZ`P:
M0TUM]RX6$L#8P#KJMCJ[,5]V@)M3="$=?/9/!_%=CR#]9Z]9.:NZ2:A#4E&-
MSJ#\R@Z?CPQZR.STNS7VT''%=@ZY,VT\\+6!?+;8Q_U*`5A\&5PXVH$?XO(1
MJL3@NB1G5G>^P6L,RWR@;F.-K*\&N(6KC5%;=EO>>1MKE1^L>=;F[^']P):1
MLLS&<#1J#/60EA4/J&IR2!:5[(HFJ3`4+QBVVGHG<?$QE.]?6!TLSI%TLC;;
MW4:[DX=,M\8W]S@?.$=J3ZSK?G%WF%39S3@UC:Y?J5IF^M;885/K,@J])%/+
MO%IA^NNQ.2HE*3()D(=4<G)4,UMF?VMTVX:`U:C^5?U?]RE:&Z-QNS'JY%DC
MNQ>NY?2RT,0:%,2#E:F9B[2BUL''ON\[XU&CURUG7.ZS>?=Z%,Q;YVL2KM?J
ME[,MJNRL73E@X\H>P+*]4.@9=X1^)RAG591MV:SE"KY$M#FN?+-DOSTAQ_OC
M3J,[VFS'[+H!]MK4++UQ"A%Q\[VS47=J]O?4?M0\SJ_F]T`H%RU(Q![@[LL@
MB,CT0^33&;%H!BN"^4*>\*=`&U_X^(<:7^@EXPOFMP]DDKI^$UHA!E:PO)IC
MNIU]MX-O#(SV7$+1XB^?T6ORRHA<FWV8@=6],J9D8L\M)_C[J\LO'U^]ZW0'
MXTYGI%"HT)PJHL)Y%-`%@(1(!U2`$)VQYOI-=!?84]ORGP'M3B7$Y?55T6GW
M6$QNHVGC3^P1=`72)UB]BFZF9\&WJYE^0M5,]->;#]\6Q/^&0U#GVWGU#K!O
M4Z$[W<`WG9TN+I85+UNYGM^O6,]Y\P4$ZF.;[YFYP80A<_;H)MS9:,*]HUO1
M9]V-)CSH'-N$5ZFD_"W</2(&LUH.99;?F/K@9@:."6^$7C:W3][M@Q<%ECO]
M:#^2,F0Q[.G?7WWTO-#U0M(TOYE`J.'QR3KMUB](LQO[^_HDZP#)3D=X%"39
M!1CKMU[JZA?;W6#Q=;X=J532&A8%"7E+W"4RWC[8?DB(NPDIN\=ILV@%?%'1
MYT4;DZU71D\HA+OVO0DATP`@L^%FRYV02_I]VW*NZ5'7GES-Z+3`#;V?0PLE
M@3KQYH">T]KI$TOA2<A.?3P-CS(2\1F>?'JS>__!#B9>1"^?N7`4GMM!@)6Z
MAS'U/F7Q@,^\_"34W1(_*,]Z0+)S+P@/9;*4S^82FW.&7>`4CMF3^SZ$ZY@Z
M[!4[@2<GL+\98_+J[?."";.+^<+QG@E1_$5<^IU;P<-[SXU@)5Y\)Y,(@.ZX
M1XD.$`'OD'_NU&9N)GC?Q\B=^I8=T%G@PU>+A>>'0$`J9OF;#X;F"3R_+U04
MX]6;A6.'Y[(%R%?PIYGKD-\<:M)KXXDMHJ7#`K1G2$VJQ!C5^3'8L:O9%=5`
M%@B6&W*/VV\+$^&O7O)-F?%4,H<C9?KOGO\GO7YN+>S0<BI2_*N645<5R,D1
MO$NJ63KN\/G:L=P0M@-EQ@*&_VM`9I'SR9[I+96RN=??,C_T_EGN6/#R1B'Q
MY6]\Q[R[[O^14*JKAGRP,_P8^91K='><P<'R._PKD),<;F&2O_A>H-\8?,GI
M_-@9_NWL)==^]6X\[`\+#!_'L_.1;[3Z\F;=[XV.?-8Y*S)OXKW.L+W;B5<B
M&_>R4,L<YTYGH58]ZQTOU+/)))I'#D!+?B`+G[X2@X_TWP[!,BIW>C:G]I_]
M'[R>^>)=R-Y>?Z385E6-?-?4J&J#]\VQN5UJT%.[/:'FJ1J57F%\:AG=[FBN
MG]W[!!TZS(D3DL4G+`:3U_E1X]8.X81Q2<\HC_8TLAPF&QYL,HO/-&R@!;9)
M=Y`\=>BFN"$)BI_C]%.[IAO>AAQ<$`#TB$;\G,E^`P9^L>;\*"CN48<+=Q2A
MC'GPE$$ZW(30KN(>?4K;H$-GW"]$!SQPQ(<BN,Q3[X]JB["1+QW\NOQ$I9U@
M)9#XXLW,3WH6A0^>;_\G@WI,=.(AU@$B=98/M^GK^W>2*$]_MAU"^>\2.2#=
MC_(;5YIH2$;VR&`\[E90"IW%C9K56V;U[9-7E-5F=SP:G""ON^WF#5DT`3FE
M6MU8=%TD=`?^#%<Z[?:H<`[7:-PW7S9K\I1SS8A-&:&U#W9N-Q1E9`&UU1OT
MN^D\L9I1NV-4";TS[`Z'I\BJ4AFP^V35`_U$82.AW6UW^B?(+:J**%>:U9^@
MU[,*/]$WN`&Y>(199IF%1?4>W'(U8X.`1_!V>MBB,Z+'+3G`PDJP3__OI2R!
MPC0^Z*7R8@]ZY?SG&?:AV:_0/@%?6&?4&:53X/9&[6`3_#)1O(\I:*O\<Q@#
M;O<SO/3=\ION*\P![_ELN_8\FN=NQO2NPVW&WZV-@>2DJ"]E(N^&PB^0L=;W
M'3+6;'7*F**GSMBC.&J4K`\KY>.J&7P`#-:=)6L>;\9C;=!\-VJWYN6!\G(-
M35M.N0(.\XMG9FFXW0+$[;*-4A.W=+9IT6V"]P%.L_"=N.&&!8ZZ2N::83MD
MV(5#'LL59;TSE]$%:I;MD&6W3\0IN<N@MT/-LOVQ+"Z]S3(;B_M<T@6X-2/W
MSDC59JR=9T?!R&05]X:[LA:OA\K,-7:FIL*\9N8NCQ`)H(`-=V;M.3E49JZS
M,_?I.I&@"O0R?0^]@\4;KV8*&-`'\`)/;[WW1,4VKJPD_=#28]*EV5UVGN\+
MZ(;2I'JW3&41U[V)[OY-)N&M]Q78=#7[2NC7)P^4M2^'OLQN7";O:AI)PGX@
MP<2W\9OT=X83%-_V";I+G1H]WYEONX/PP?!F1OA`C-"#PGD7DP;@&DM.,`)&
M.T#(A;L0[Q1^]B5Q.-D+4%!2^S;"%)6OQ)[?17[`B"$3%,[F`&%25?+<014Z
MF2,%,:`(%=2=CVA"NH>.MRCLW77WCWC;9DY0M1K$JOY*L.#PDVW=V0YF,YU'
MOI]%C342?G9-C&^7[L2;$PDV]<F;,,V-1@1QJ?IUH))R.J<&7P#)[O15@&#M
M!EJO5WKI=<Q$;=E*.LJEAWEC":EJ.9;_?+RK;H4FZ8D-FC'Q/1-F"Y6(6C)T
M^P7)H/W.2B(4+;`ZQ,(I78V<IDA:D?5:&JU!P3:>69J43$T-^737]Y9ZNOO:
M-8W0VP8/3,:#LX6?+DX"3:*[OC\>3*W/A(0Y+,@G7P'J59&[R^?Q&_9?P`FR
MO@RW'EQ2FIJPG-8\T["_YWJ^'?`I(TF[TQV4<=!5Q(M*<K>KX__>ZSGWQW_3
M[%91H7O<_.^,MU2ILUW^GSO4II]8SJUO6PXH3D"2`_S.<+Y1X49W,*RB(O4$
MUT0%EL<1K*L"-EBQNN:]+*+#6D9=>6I9JF58OKYWMB),*ODKHG3`XB\YEM3U
MHHM@W![O69(`J:I"[3C$$\U5N5R8-'10&C`9IOB2R!>+Y7V03ZMC=FD+[&76
MQU@7O0Z=EM#(TW1"87>W6A[>I>4A_A>(/LID#)HHCK;*7&C[5T;5NMHRW95;
M94?-[WWY]5X2OZ6#=TFL7NF5S($?3%\2[]8JG:P,0N(\*+ASEB!:3H/Z`[YS
M+,W..49#9=L`+B]I9[[0M?&BN;V%Q,[8I_&+YTV!KU^H[2)N)_XCY5UP2R<4
M6!-XC,XH6BP<F_A,F5(>1TX(V97\A7Q6S#&C]ZG@T.@K)P^DL"V\>PF_@2\H
MF6Z:C7G_TBSAW0/Q9C.DYO=^3CY9H;Z*T'@/B^&G=O3)8EZ[5PF^UV$Q;YN`
M3U4`.RTS`_V?`[-4X>AQ\()O)$KPIN80JKN^NT!F$03);L\\976V*^?`!]LG
MD]#S-;8F_S<;,Q8%0(%2<1%&]4_-H)TQB%J"P)["H=I2)=0GP9R-4([61#/2
M:A2J3L;#P>G99AL`$^GI5!54]"&2Z<7YF0X51+I>'`>P.%ZH^^+0T,:T8K@_
MZG8J3.NJ21\#X:PB_:#=[Y^>G79XD&U:XG>[HUYMI&T??"UCY;?->N5O#>=G
MM>F=S&6KZ5\MFLM*^@\Z@V%OZPPX0!_P(85>5^^207]X!%:I&J5E[S;K:%HB
M>OKNNCOX7`$C-92N.;B3>.BI</`T`IRGPHU#R=:LZ;GS`!>#':HIOJ.(U;MK
M\Q3(_4+]MR6=^Z<BSEXHMT^,?R7\`54U>,Q$<Z5BL'TZ<O`(TJNWO981%^EL
M,O$C,L5]=^O)3:NE7#>!'%5`IFP,";A'J;1Q_N1R'>ZP'^-19=!]-WPY;%2U
M+0-)JIAJ57)A+QIW\QUV\KOCB"RAX]D=&Y?G))!4DKV>#^2PJ'5W5%#RE)64
MVN]T>^FF:153MN9<8<Z5*6?IM=N]=+Y7S;EM%(1G<*#37DX:W@(#4"ARV)6S
M24@'_8'`_.#YJQD([^#],T2SZ4O]<#60\C'C%17#$)8(/25)AP%@0?%SQPJ"
MJ]GO%C`PO/*QFA,#DF1:C<;7?H$)"DC*`5\@_RT[_/H]L']R;>?OKT*J,U^]
M38:PM1]8U4QD#=#W*B:28&#/3*;8K9K(NVHFG7D^UXFB@YAT]DI54.$.GLV%
M9K%Z<R:Z[,@?`_YK<&`4R6M.-,:V857,=.7.6/$JO3-+8CL6KRN11X>+OR([
M?`85204[_1*2BW]V#2)M-+FM4N=P%M+!TFAG`G??-))6'36C?-8OQ'(<>LA]
M3K]K-_M-Z9U5U-KM=LUN?[2"4,7GN2.2'81^VP+)>`,:-%L5YSYWN00??6^N
M7`Y^M\,']9$<A^ZWLX5?D&`9@Z`VM?H+4I">(>BE7WPO6ERZ$Q'ST3_/5ZA/
M#P[TY\^6:['SDVS?`KXPVZ4G!-MR>/R"VD,[\53UQHDTX`W9L&V.E@XZO4".
MCJOFJ/@_R=FS.3T!V__!05_-/I"[\(,=3*!1V;5/YG8T+\"[7@;OXNLK6JAU
M%,2&E0-2UR6EOD^L@%`5@_][Z5Z%#\3_XKD3UO+J+`A(AA"N=`[-?KNKY!87
M')<ZE6O?FQ`R129>!D$$/H9$'\FJJW@S71/*@ELYJ.29GCN.J!K!'\43YUY0
MB`>;#M\<][I#I00Y;SBI@2OS_.*%)*"/9I[%*ETX71[C6362Q`D3HQ"6PSAA
M!P$ZN-QI8H)7L]L'NNZHTK:<Z^C.P<9BQ,]R,E3,B6Y_8*HAD[4'&SL2XD47
M=__,;XU:Z9S,D3SUYHY$:4!*9^"3J9@)3O0KF8"=9<]L0,@_FS+/(9VT94\O
MW7-K84//SJU/9C#H#]I=V>=SW8%JN]@*-F)6!4]DXCOQV(.1A=*R=H",W=9U
MQLVA>\VG_2!:MWLOA4\;$#-N8+Q%;J_D5'=-3AT%=PYR%Y5HN2G#92?#D2/:
M+YG-,TZ.*0>Y33;K@G.BV^=X.)7(%Z]X4U$;G=B+\$A,A`/K`)3,PRA"2JUU
M)F=U\7U"P($NUX7P/KP$#JQE7JTFG5XH57,\?G?=Z7W6;;8XH]9U*9W9X,IP
MM8Q+>^.%FSM([8J-S_*2`54['+1KP&QKUH!F,#OH-:HDJOQ.('Q%[WDD/AU1
M(IB:%QS6)?H=;NIFAJV=&7;NMZI$(]^,"_5ZV$TJ;_$TA'H]G-QZB`^5!5>$
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MW?:V)MK-TUDFM4325:.GP=$"=N!!<%0MI_9<:H&%]IU#;2]>>,)*:=#K`%5!
M9/KKPG/9C5`MM`O?'Z\B[W0&?;7>OOQ@DR5]ZC.?[+\B>XK49S\0MSIS7S*8
MEW'C%WEYN&^3X'UR+&5M\K%:H+9R4@=*@[/N!D1HMU0WP_$2X7RCA:!F@12D
M`3O*\.*X2H^XVU_SRV/?[XPV9YY^1GJ6?@"G/J'2G`Z*GD4_>(YC^6=S*,6N
M1C=MC8%]/$>/^VHDI_#<#I@@9^9F%&GW^X,3HTAG78ITF:\E4Z@?*3W6UG%L
MA?3&_>%I461MF=EE2<O5BA#V^]5,7A5O"2[!KPD=;;1D,3N)@H%T5*KY@4Q2
MURL0KBHUFGW((5B"AR@YM^H)LP^EDZ#+0,G(WX0NZ5!#\1!E.R-$V=8=??)-
MA'8ZQ*L/@Q08FQ;*57=]K4/(!F-K#[]]\1Z7T\ITUXN/+9U8LR;==#Z90J@B
M.QB;^>UJ$FI#XDO7UT\UW91NU<25]S6V+1J`++14]3+=JP6'4UIJNWL(4ZK.
MT9"<$I[>6'B$X^\Q%Y1V8A__R''^;HJ"^NYZ^`<_36K&(\?ZT;+]WRPG`@,)
MIU(Y@N063LK#UDB$8)?&'Z/[<%"R*Y<7#YY3`CS;[CW>?D#37-('T%&AP!16
M8Y.EK!QW&CM^L@'+UE^5U9``G=8C<Z0FLZTWO7=ZK_9*^+!U!,Z#YX>PSP`.
M3X;9,C[*HY%PZZ4;A'Z$61'P@*;!.3Y8#(ECF+1Q,[Y^.E0I@J[0[1>ER5)&
M!PKU7+&XFZ/P.F1<E<(RU.%3)2:LKZ7GWW3OE<0=&!5$J%CCG4M*&I\$^_0=
M5$\P>N[2U4:7($<2$Y-=XP,XYX"3F-C%T2>/9`<61`CJ*E9M@<F?)JV*1*5'
MW5YG;5+!6.(P)Q\WK$`Q/#4F6E&;R?7VYR94RX@,]P?#?D?Q/Y0CQLF3L41/
MKWZOTS]^0A;#K=_&2AR.NVJ>6$V_\DMPV!_M9@7&&/D\'WF'Q$P<UP^#D%GD
M.'V:;FMS%Z5H_,1':T)RHF^[REG8T(9>>3C-FK3.]N-I:O#(\9XJ=-9>K]?K
M+YM[RG2S-]Z5;]_;+G2DHZ<-I-Q>39&J:9,^MZ^<?*(7AO=L.>%S7I9FG$S-
M0TKM-&66KY_=^X1(2?*5!,3R)P_4'/]`'HGC+?`G<0_'9./DD9>ARP/XG^$-
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M)TQC<*(^L:YF6,=QZ"5T-W]%5!A\]+QPN?GU4#9K4284QQQ8I?"M)ZJ`&>=_
MI5+-E^Q>JTJN??RR^MLE?6!&;P_))_L10PQT18&1S7I6O7_^;/W;\W%A"S,<
MUQE4)6,KP`*K>:1"V!9BQ[NX^Q&__RLEGNV#'G`<[XFJB(]3ZVRQ\+W'C`XZ
M-?.J85Y/P[P\9BS53%S-+N?P$V`.!)?NOVS'6Z\HM>:8CF-_WB]7MO73M1\Z
M'DA&T4LB6@L_U+RI<C=AWE&21X#J+3F4(GX64U`\7M"O0H"83Z;673MD6"P#
M2W"F6+W^%W*8<!;E&UM`=D.[V^FWU,AS[L37`;N@;R!/E@,>PH.D&P!AK($"
MHDRK$B0BF<U(=T,T9Q$#`0FK5K-4`IJ0D_+28\5H[73J[C;GM'\";M`VM";@
M\@K<"&CI91*P0J2JDR3@;YY#7^-0,0Z?XT@S.Q&&_7ZW"G2[TI,[())6+1YK
MDE8N,`?]=A6M`8Z9I%6+T+ZIQNA/EZ3LM+`363KH5(+#7WIR!T32JF5I3=+J
M9>FP/7KA)*U:EIX<2;_:P9\??4)$ZM:NK5)*_"K`>$M.[6#(6?F!W>QM2XH>
M`SDK/[Z;PY=,SNH/\\,JNL,<-#EW:(6V.X.=DG,?JFB'%FB[V]ZI*CHP<E8N
M.SM+4"`OB9R5R\[#(.?=ZF_>E;%V(?"DS_LO+2W?79OMSRD2;66X>R1*:9GW
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M-D*QU,P[0N8)')U2S-.`=Y\"\^2WZ-G9M]W`GAPFR]:P*ROL[5R(9B^>26N8
M(NTMFB(UFRHS.VHV'8F)43/J2,R)FE'[]'&H1:<L::@4\[JMH5DS[Q"8EUTQ
MG,.\P=9.83G,PZKN3;_VT?-GQ`XCGP0"V"0XHX;7]X7-BM?E2*K.40E@6`F,
M+>PO/^+EZKN;6)4;@7\*$!Z_1+"$=M$6&NK\QZ->MXKLGJQY5$FDWT@`1U-D
M!@MY>'!)Z1^P4]J9_7&G.ZJ0>$7GMX=-G/(+B+NS&T]ML,'S>E::+;._^YV>
M-_LM28'2!-].K[@NA%?Z@PKC*P7GN/D:3[SN`PDFOHTCJ,:<N'8L]XLUY\`9
M8$7`%;A'M2-6VQNOWOT?)_QY:C\:0?CLD+^_@N$T+<>^=W\R_AT%H3U[_MEX
MLJ?>4_"38?YLX.\AG7T`J'<_&:[G$G[5=J=T\C\9[<7WGXVYY=_;+O]CYL%U
ML[T(C?\;VG,2&"YY,GQO;KG_MV'@E881T+4^H]]ZL$/2#!;6A,#;?;H0?C8<
M$H;$QZM4#,77)Y[C^3\9_\-ZA-*'/7\:WX7?;CZ1NS]M.F888A#ZWI^D2><3
M/BAC@^LDG#S(%[_Z/_?AS[</Q""<B\8"5SZ=LT&LR8/A,5[:`5VL=&1S&S`4
M[YZ-D#[SWJ.D-[R9\<'VJ1SU?#JYNRBD5'0<XXX8K^TWANWBK1.Z:N!.B[[*
MA=XT]B.AG(#^7OP+K\_>&/=@3-'WAQ[<2#@O*:6\AF&%^"*@(;P(;X5_!)$<
M90.&:5'R_\A>_>`Y4^(WZ%PI78.`/D_?:L+/]#EXV<RR?6#@GR0T'M$$IIO3
M0"5D>&S@4T@[$=_[V:!D>?T^-=!GPP-`1#G>]`?;FWR0ZB-*1PTA84%2=15&
ME.[/"5)6^/V6`6N#O9:2%K8:G74$T$1X,^S%`)ZG#'^$ADI6L76"RX0]YGHA
M77S0.8W.*21N\YF>`F!85!^T8,^^I9L65NFFVBA+3L4M$1^HAH(UH[9/`H?\
M9R18HH/?E2L-_[-@&TJCK."[%+MJ^:1U:X<.(+51R^;1GD:6DY"4_Z`3OB4N
MG_/5DTO\X,%>B,2ZPJ=G;4<J4X!;54/;%\HJQ%L5_%J;(6!)U]Q8XL8718PN
M,^0PR%R%Z8M7`P'<"+C7>'E%`EU6QOWR]:)^GPQI])U,(M@35[,9X/WA`8&_
MHTCC$P`4-<?]*BJW,PA5[?FCF/=F*1VT0*?3:OFP6])GDR>Y">2L&'*[_GM?
MH!4''O3AU<&M%UJ.^ONY%X1?O/`/0B<V\>Y=^S\<1YN/HBIY5/2`DHE^V.R#
M_R@%;;\3$KS;!<T9@^DVXY?@OHKZQ!0^&UZ;?PP_#S[L@+S:V::Z<LNO96R?
MPY854&64[.J]:CZ%6V&H:U/HR..6G&9W/%*AFTK/7D$TCQ?I+YXW#5@/3I)<
MR,$M>#2L"7+`<;P)M3>FL$XK*=`L3,*R0Z4*`Q!P;>(+P-T@<D*(PTC(WHDW
M)[)APB>8&$PQNT\&QXHMB%2^=/A<@\0:5UM5C"I;-'J:C()^7`?.J+*%K*?)
MJ,'!\VEK8>^CXM.P.CX)#9=L67,NV^71=]NKVS=HN&$.=97.9G/F^<UARU24
M:^ZGY5HZMQ8VM>-N0C^:0,SJ#YLX4P@1THO*N1WT/S/^^`-YQX7URD@UQX#1
M6.V:L>Y0MSS7=8I+-7,U>[U#GZRNDK!`S:ENLOW^H4^6<O!J$FIMZ:7K*PZS
M_4ZED^4_*YV?M[X908D-E3DL#V'MT56P?:`WTC9&5\UZA]&9XZW0KJ(%:B8D
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MCCCT`>ON6^+GMTO#/O.3WZ#FLW@)_>>*,?,[WLZH$=P4;WQE>/Z4^']_9;;:
MXE6A]_=7\4#$U9GOS7,'69(`G7P"=(Z!`#L?9"=CD)W"@RS-I4X^ESJ'P:5\
M`G0V(4`WGP#=8R!`=Q,"]/()T#L&`N@&F1BA3P(O\B>DC`*(Q_9][E#JN/=4
MD;C-7V]2!%-DR;NS64A\X]Y^M-U[@\QF5$=!HA9D(D$`PG*?_R]Z&OCQWX#9
M&);QZ=,YYG/1G_R%Q^*/K;^]3<SG`"9(=3@+!T!"U4*X-'@"V!/Q"9\:I*?9
M+LNDL^[O?7+/$[NZC6ZGTQ@,!RSO*Q"Y82IMP-+EKV0$A'2]?T8N,3KCA@&^
MEH9A99,Y]KX8/@$RRUR_V5H?-8?LHSIV)*^`U0%7@=+V3]S,,NQIVK/7_*?E
M+G=QZ[:;]'NIZ[SY\N\6!*S"*Q];_/$NS(_$A:(5_IM(5'C'/T^PF9OX"SH0
MA?;,AH2[R0.9)Y=&0":M>^_Q[?GEOZB1UJ;&_J`];'?^]C;]L'A=0.XQ=H9_
M3NG'OB\<>V+SA"UC"JT287G__94P]C(G\NH=\_'II\.&L/2%=V)H<B!O=;-F
MB7QRT*'E8X[+.Z!QD_(!P/C2OTGR395;!\UN._X$^T7\+3[R-L%VN@[^/^X-
MT<U<AM`PW0`3/2!-/2.@N(-ELQPJ_![8/[DVW?VA'Q$F7E?/!Y.&Y(\!_Y65
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M$C/@]O&*>1RWG5PH`RV.F4,X!$^9T!;]AFH%WPYMH@_@;WGYY"F<RR\?H<=Z
MOS_N%DRR6SE%Y@7/WBPB0U@S+YFDP0U)'`A/U)C2.4&M9C))X3!W2$S(C/F\
M>B=NR9]8E5O&AC(.>N_R+A"_%-@%*]EJ-JE-U4R*W)JMNV%KKVEVFEUS#;:*
M8=_2$X?G6_[SQ5\1_>*UY5_Y.-MIHA8G-\9<Y0(H5A@.P$$*^$S!2:@6107S
MKE2>E7$&9,R!2>NS*'SP?,BKW\/8<[PTN8-FJN>(!JP`8QS1J(NMC2WMYPQ3
MA)Y]AZ-!;Y"YF]-#KV`Q[7B&W>YX/!B,5LR0#;NJE7>04U3&GC//<\OWG^DM
M9W-(O#BCYPS[+@IA<+<>E=-9U3Y;UT;I.I5!I]T=F)W,.:^>Q]:(L#W5E"MT
MDH\7%NT;X2*5'$Y1P5WUF++-:).=!<\6_G*2$V6DYKK6$4DG&Z"I>P9@C/Z<
M^.</-IGI:["^G5O!PWO/C9CO5MS"'(C4]@%\%\N=$#K&*=;C!?B-CU/K,R$A
MI1T^>[6@*S:$V=ODP`-]6IH))T89RF4:\L6<*&O1G8]S-?6WYF_I-MN]@OX6
MO'4M?\O6MPBR]2;TZ7CN[4F](;(V1`Z=ZN6_M>6/DY1$46,_6D5US'LBUZQ2
MTLRUU&"!X5R5VDW0IH![M3QM\FK,?B$N\>D[W.G9=&Z[=@"OH+-(5)FM2=US
MA[YP8CFWOFTY'R,T9"`-WPXQ-%A+H6(?SF%?[-(KQ,<]2L3UUL(V@S)%I>2&
MR4MGDPDUK*<XPUM/DBVGO+B6!<6D[[`?2]\,*E<<&#UY<M>BMQ:]IY,W6D;T
MUK)@IZ+WA#4=4-BW[*`^:+\P.5N`\;4]^Y)V>:[KH-^NK==:A-8B])!$:&V7
M'MHNWZX(Y9@-RT%XP&SHZ*Y7$,XLC&IZ?`)N1]%),90$)6,AETG2K8D.3&TL
M)CK8K9TU1,?6EW&>C#CA1;M5K?RRENBV>O1Y@;XTX8`6_LJTLUZ_VS,K+)W3
MT$@6WUXMH/R,ZM5/A#[]E<2@D1Q9B=+OP7F&'^@`MU(@E=#4BK>HW-`*J>_-
M(:8.5&K)X<:"(S'N+>80F$5-87;K<!LI-/^,G*8&24]SO>9K,;Y2L3XLR%>\
M-:[6V#M?$Q!I1\17==PGSE>N;M.XG)KK]7XMQM=V<:.MG:RNVCM?Z_UZN'RM
M#*JRYNL>[*;J($LKL[..!**U,OMCBQ"MU4]W<[5\7.S=7%WM@KT?R,*GK\W.
MF2[=PF)C-_[JGA^ZP6\PJ0*-;K8[J4X_;U;,I:WT?N1]G**[?Y-)>.LA?MC5
M["M9\&:#Z[2R:G=TK:P2"!HW(5E\PL;2*>R,/'?6AL&'%5M^;`ZX/Z<,?5XL
M46^?O)W056F+3'^'V^C=\K9/UN(TR"FL3_-MKQ<^""S2$!I.&&Z$5F&,5!HP
ML@EL4Q^H`C_[DBZ<X@6(]]((':_;/=)Z4T>Y4D5[YE"ZN527_$8"\$'?T./)
M-'+(%S:12M3P04(J8@1BV!F:FW9A+TM340!5`'.I,]9D,RC9`Y]MAWZ!TD@2
M5_>CS#&0:W=WQ62K\QF.-8XJ5%(F+T0"0"&.9)V_^2+91T2WR*?WF=U4AC15
MQ9P!G3NY4.(K>2Z1-)179RR78'G,ITTEU6^LPR^BOE+5!'VIX!*'&@8<B1SA
M7PNF->+<HW&_NBAW4?;E!XIS^+@K'JQ7A'&L^N)X*_<K+I;:N=!>QX?](@3V
MB6STE?*W.QB:^Y&_[&2A=#EG]WZU``KJ^<KEJ3W9K6)SN%?T5+6G"KD,7@Q&
MYDB<N(K1I8@>Z[:;-V1QL(@9M<XZ(K298]-/W69[O!XV\`'IIU/9P*NA%LWN
MX$#/`OW38$$M0VL9NI8,[?2/6X:>R@9>W?Z@.ZBP$U(U,K2BHL1=P(!^HF]P
M`W+QF&?('Z$4/18@T"+T/X&27IXP=38)*9L^$-CM,.2K&9PF@_?/MP^V3_>C
MGY&Z=&H;*C?IIMU6ZG:+$V[O:`BU`#I\,ZX6-SL4-WO:+$<K7,J)YPTBC`\^
MV0R:X52%UBZMIHW3)6(NU@)UBP)UKS9%O<F/R3*IM_1Q;.FE#.I+F)OE,*P$
M/G_N'=F7@73P.W]%%4R[J\E4SZ'SWH]OZQ/\RJT%[7$)6LFQ6LS68O:0=_TJ
M(=LO+V3Q_IH357H5^@FOPNZ47$9![FZM#9FN_/*4W[K`'\=0R'`0U1Q[5;+K
MUC?4BO8()<PJ1=M;4]&J]\OA7WR?$&A;*N?*G\J#VCM^;WSQ8^)J0IVF(;/S
MDWM&R[H]VS(JV,;I29HCLF4*@2*=N*M@I1USX%;,$;D*MB[+7XR,.4@)7Y[*
M0-&K&:,1)"DR6!_?H@^'9"KI5RZE\@7*]OU(7AWW^$>S>'A`.=2U5-]<JB>R
MDN]69R7?I;.2\;\X<`C"P`3Q,6%?YOW1":45)[!NNAR_:D:I"'"[0OZOU\$:
MY:B]/OV_K7<@V/CUZEIC[S;K-5#40+GN#CY7P&(-#PJ6)J]?NWW@.>T':OM5
MB/9S."F6)QL[2$-MK%7*O-8N?`G"[S!W:'TZJT]G%>W\C?4ZJ^X4D+)G4?C@
M^?9_R#0?K>!%2I.=F=-9/-F[>^X`F%"+]%K`UNZO%[;I:X?6Z7,V"S%M/-Y^
MC\Q3\E`=`%,/T>=TG(2LC9W:V*E/DT>R6W>ERP[V>)A5G5!+R)U)R+4[DYZ>
M1-Q33MM7,B'V(CS(E/P];-#BV"Q%"+>[+/`74VEUB&5N)T?D6DW5"=I'ILS6
M.F57)S5?WF;<GNE6H_?MY10-$R][\#V*#52@V"`^YL(X*C8/Z(./Q(<E1@_!
M<,)___RK:_\5$:6+)*./<N.U3V;$]P'@&#IY>"X^>=@BH>A$Q1XN.-WC5DR9
MQ#F;0Z=M=CDD57G@JU]L>=MG1/^?LG=63?$0-M97,B5D#DCA<M;X[,O89R5F
M7V^[0UJ*N4ILT!_W>H->R9THTEV5+U_Y]KWM6LYE$$1T4%2[YEH$W[YXC]`^
MN)UN*[Q\/=D%^CJ"]-ISRW&8BD_W@I9_`[@MU>3XT+\\)[KV'JP_H\^6:S&G
M\R=GPA^Y">G*@$OGC@4E^6S:\-P-724D>)^<J8ZLWQ:BKW$J9F^VS+&``5A!
MKWP1U^;K:MF%<%6FZ]LN<LK7["EVH"+S4$!U#ZBU8P5B?%!&C,==&<OZJ"6A
MU,B35C"=_O[*TP/#?NS]U-)L)\+I4%I2'J,H.DRW1BUX=B5X#F;O[$+,.$"2
M3H)4YE!W_8C"*P5:E==RZ=2B*P68OC5AV&FVAP6%(=YJ#G<H#%_J#L\]K/?;
MNQ6?ATVJ`Q.&M4PZ*IFT81^I$]M+)5"URG66XN2'_Z9__C]02P,$%`````@`
M>X$,1P\):<LH!P``PU,``!4`'`!R='1R+3(P,34P-C,P7V-A;"YX;6Q55`D`
M`XFHRU6)J,M5=7@+``$$)0X```0Y`0``Y5Q;<]HZ$'[O3/^##WVMN82VI\DT
M[3A`6F8(<`+IZ7GJ"%L$36V)2G(2^NN/9.P$L&6+7(Q()@\A9E?:_3Y)*VG7
M^?3E)O"M*T@9(OBXTJC6*Q;$+O$0OCRN7(Q/[8^5+Y]?O_KTEVW_.#GO66WB
MA@'$W#H3,E,$/>L:\9G5^6-W/,0)M;XOV[(:U6:U7GUGB8_C64B9!Q9O+2>\
M#!FW&LVWUD&]\=YJ'!PUWATUZY9S9MFV[,='^-<$,&@)NS`[KLPXGQ_5:M?7
MU]6;"?6KA%[6#NKU9BT1K"PECVX86I.^;B:RC=J/L][(G<$`V`@S#K![IR6;
MR=)K'!X>UJ)OA2A#1RS2[Q$7\`BI0KLLI83\RT[$;/G(;AS8S4;UAGD5B0$E
M/CR'4ROJ_H@OYO"XPE`P]X79\KN+\^Z:`11Q#NE\!F@`7!ARY`*?55T2U*1T
MK37HMSO]4:=]XO2<?JLS^M;IC$>5N/D9A=/C"N6<VI*2^H=F71KR1J%5DP:*
M]MW0CY#HB3;6#(4W'&(/>DG[TH1'L#8:&\1=Z\J7;!"Z[DG<4P3Y%+!)A'O(
M[$L`YC7I80WZG"5/(I_M>B.&_TW\^*?#&.2L%5(JQGK2@0\FT(^Z_9DM5RO9
MRA9@,P=[\E?G=XBN@"^L8`YO`4H78@9_!WX(<ZS7T]^DW*'K#@+J)GV(CRF^
MUP=_+%%C81!$K=F(PR#1GU(2Y`&<]$ONXX=%J`>I6.3$&A<R82292P.`7[&N
M(;J<<?%5Z10.*9P#Y'5NYA`S6#S@LN7-ITCA9TS)@4F4+/TIG/3"KAU#KL)Z
M@Q"]85\FP@,^@W1I99]@MW#09\L;B[_"/;VQ7B8/;3B%PCCO%&&Y*6H1MFIQ
M'^9Q4JQK+#\:;L=<-<WA:DC)'%*^&/H`<Q'L9*";!X4TY:H9RU"^LS$Y[\PA
MIX?`!/F((ZBQ9\P0+M=:QW5)*#9(0[``$U]CTZ%0V.'P40.>"H8*9\V+BL)2
M&D)OJ[&DUMD7<E0NFQ<MH["^%3LJC;W@1NFN>;%QQ(G[:T9\81>3H8(O<DC)
M$"X[DL?[C\B2HC-ZEO0.QX\:ZHP37]I-\U;=%@D"@K6H2(GN!0]I!\U;6AW/
M0TL;A@!Y7=P"<\2E0>K`I]#8"TJ4[IJWM)Y##A"&7@=0C/`E$Q$[#"2ZT!/'
M*.2BO/BGH;P7?.F`8/2A1!RAMHJ1A:IF[&!RW=HD,6<K8U`X&L-@3BB@BZ4S
MR0VV$\A#C,,Y19.0RX/,F`Q!P?9S^[;VD-9[`*89__8-B2Q)S8!2V\CH?7[]
M*OEYLFSD:.R,.V>=_G@T.&TYHV^GO<&_HPL,0A$;[]*'A>G)@F;*RU<6&%)R
M$J,/N4R'#2FY0L*[D\4%@V*G,9A#*G`0\\/EZ&JY&!(L'H3B6?PEP7G)CP<V
M7'8R1YC;Q8(LV".LP*T5N9WFTQZ'NLW580,($W.A;3BGT$61'[F9AQ6Q9\C4
M.@Q&9DC]J'%QM!>K(CP!PFMQRI29W<CH.,F;=WK3:^`9DJL+G5[@+IGV@%".
M_D2&#J9M..%MQ*+;]2&%`0J#/,8+=9\CV<6`Z1T;R^59Q`D*Q<ALP^7O+EZO
MWLBAN5#U&;)<#%=,\GLUR;8)+$<W_G>)\,(Z&-T67@3G"O!BZC\83OU&EG0K
MTC=U7P3=*<!BHO\V>R%/)URWI7I3_:6PG8(M)ORCV81'RU)\WWE?UE5MO`CJ
ME0#&_!^:Q+\"E"Z^@NPI;GUT&RXYP0X6LE:,C8GC_@X1A<IRLKR\NWXC.[PK
M?AS"4ZG[+0`LODBRR\ZA*$!9EGL^P2S0;7@WLV`PC1(#7<;"VVI7C7&?J6;>
M2-^25-5(SP;)P+$M_'<A]-BI`"BQ=C!=J?'(KP4NT'U^_!;#95XUS*K1?<*A
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MQ@L01HQ+IZY@\9`OTC2;'&W_DUV<09Q%B>3EDIL7*U:D]B!:K_IDX#Q9WHG)
M!7%I9!>+O:EXDEO^H%#9[<Q(#YYTZ8+*5Q.W3W&U'%G?BQ1-C`P-TVE1>JH[
M7;*.F;?_95+\\3]02P,$%`````@`>X$,1U5T>AOQ.```G#T$`!4`'`!R='1R
M+3(P,34P-C,P7V1E9BYX;6Q55`D``XFHRU6)J,M5=7@+``$$)0X```0Y`0``
M[7UK<^.VDO;WK=K_,._LUYW,6$[.25*;W=+8\AS7\5AZ94VR^:2B*<AB0I$.
M2-JC\^L7('4A15Q)@&AJ5*E*'!L`N_O!I=$W_-?_?%V';UX03H(X^N7MQ7<?
MWKY!D1\O@NCIE[=?9C?O?GS[/__][__V7__OW;O__3B]>W,=^]D:1>F;SZ3-
M,D"+-Z]!NGHS^M>[T2)(8_SFUV*L-Q??77[WX;OOWY`?9ZL,)PMO\Y]OAME3
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M89-$5L9M0^&*$(/][!&]VS-ND$[6Z&VHC>)T:'3);`?,:=H1Q!K\F$(Z,@[2
M%.'GE8?7GH^R-/"],/G.C]?O<UJOQO?7H_N'T?7'X=WP_FKT\(_1:/8P\3#9
MM5>H:%VE&J<I?D?WXP]_N_R0DZ<TAI1X\3?&^,F+@G_E^^DP6DQP$/G!LQ<.
M_31X"=(`)=<H]8)PAKZF64YS`V%H?Z0E4Y/I>#*:SGX?$OG]_R^WD\^C^UGQ
MA6;TB\9K2RJ.R2))-T0LH[^RX)F>ZHOV$E<8MB7A5_%Z':1TW(1\Y"J.4J*L
M$*7%S(Q1'[TK-B[L\G'1&2,#NXP,.F/DTBXCEYTQ\KU=1KYOR\A#&OM_KN)P
M02X5UV@9^$&:[^)HB3!&B_S/#]GC'\A/9_$4+=#ZF>[T)M:/H4]#$$"S=6?H
MTQ`$T&R]&OHT!`$T6^>&/MU2`+\-I]/A_>RAC1IU/$9;DCR,/;+[&5`W.$-1
M`MM-F]GXZI\?AT2%OQI_GA!=?CB[)4I]P7_#'5$\9-MY+AJ]X0(6#VEB87[T
M$D1.P/4SN61Z]<G??-G)!NZ`^!;GIG3D#LAO<>I)1^Z`_!9GEG1D&V:'Z>AN
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MF.PPO[Q-<8;<@705>DDR7N9;WO!KH#2[COO,!S:@$QBW!5#NX9'`R."!BVC7
MX)1INZZX2!BHU!O/+VW`P?/:"+!@R9@-"Y.)T\%C?EUVFUG#I>KWLP;,GALA
M0/G5JT.0Z-49K>GJK]ZM/U?<=PS`Q!WG/U@!C>5:K`/&7A9LI*1L[-"Z<+Z>
M9FC]'&,/;ZAO(]T0!6N,\[FY^-4+,S1!^(&H:"+507&$^=\<@J>C7:CS`Q;%
MG,!DF*6K&`?_.BCA<O2.>\[_WD_4&'SLT!K`1.LV23)]I(I>\Q_[C-*>AQU"
MES`1&F<IC;6BD62Z,)6ZSG_J,U951G:`?>\<L.HYV^`44QM@?O&A)^BI\[,#
M\0=@(&H<8N*.\PLKY@SKH+'XV('U-Y!@2<\P?J?YA17#14<@'7C8`?1WD`"I
M'6&2GO,+.T:-;J`Z8F2'UX_.\:)!*''4]/Q2Z#V_^+XGN"DRL\/N)TC8:1Q;
M@E[S"Y>VCH98L9@XW)'A@20]KC@]YA=]L64(&-@#X]YZ4:-2[9@2=9M?],5P
M(>-BCQ/';O&^ZH2U[);5#C]7GDIUIS;]S5S^P3N!,U9W""T7;6.*><Y8G>X=
MNF@;"/%HKFLRUG-W;O:8!(O`PYL'+T2*[EQ>'X?N7%W0.$Y>`6=@G(HETNZ]
M-?EQAKTH\?P\U$CF9)1W=NX$%F'`@4V%J6\'/RA.8SM`JCF1NP3T=C*6^HKW
M;>9.K[5*"X6-39D#,*+/62FN"=<9V>Z?R(T[B!>%;GJ/7O,_B4.35`9PXLMO
MK\EH,PG'1UR^`!*F?16K$K>/$V^^0?@$?,'Q$T]P[".T2&Z(!"BMM,[#+96V
M%TZRQS#PQ\LEPC);KN(83CS]YA#5X=.$GYES^9MXFSR-<+S\0J[9^)5<I\DW
MKX/$C[-==N%Z'23TO.=>6+4&<>+[-W0EU&44D+]Y3_G^)*`S[BI.4M'9*.KF
M)##`X`(4LP;'R\PYNG/O0@O]IMK?3:"`=?VFSJ3$(=VM=5)47*+[LSNO&C$)
MO2@MEXX0F2O5.[O()?%7:)'1VPZ7/&F6B>(0#O)/E$3.6RSJ;/7;M,EE[^-F
M1KXM,7(J](:0O:(!)E<55>`3S(6?SR;YLM1ZIM#;M?E3$0]-,"O\?4M@`K&%
MVD<5GEF4ID!G1`':DRLUDG)Z.#69*BXIKKN<PQ`8E&XR3&2:841XNPF^TI\2
M*5#\3DZSGEIA)>0)CF&4R^.7!"VS\"Y8B@/'I;V=ICZU46S5>.L!DI]PG#12
M3?..3I.@K."W8PN.K7OH^]DZ"VF<YS5ZQL@/MH4^GD.TM60,US%.MX8-+F<"
MD$U]PFFV59OI8%``<%*UN%3>(]%D$'5SFJ)E9;T73$G,YQW;ZN1E5:',I+/)
M[FRRZZO)[C8B*PX=`I*W]?XEICI!KY,PT8GY`W.3Y)`IM>,(^[DVQTEDKP48
M/`.<)<B`&-UL8`?/S/8)10A[(56'%VLBZ"3%A.(7-/I*"Q`BJ2U'J;]3$YQT
M.;&15&4,#)+E:XX`L'(SF.8V!97FB`F)5:9;95_]#8*V`5B"+XG4>.6^)C*$
M!-\1I@;)^G6=$Z0HKZ/YJLJ**[V;`]KP":/\0QS5N=[(=>Z.BHP9T!SS8&`S
MEXF4JQVQFKG27]G"$0G0I'9J6(2.]<GFLC2I+7)D^I"BYSM$S[/]U[DJG[B#
M$QV/-P<9TA41#D:'FP4IO>K?1HO@)5@0)4%BNV"VMZ/5V=R+9>S`\;K5*/PM
M2%=3%.:::+(*GF?QB/";;J278,V1+/E5E2T97&@4D91R!W<-=@<Q$,N';:SA
M64&N5@%:CKXB/Z-7_/%R&?@(RP..^+V<NM$;+#XVLF(&[6DE$XR28(%RL\!-
MC-<(ZP&D/XA3/W=KO!KQ:^)0Y5WZZ8<?J,$,/>79:'*T!%V<NJC-8"/F#E!D
MRJN'%PKA[95VEO)_NE`X:WS`@2)/T:T]!C2D#XX]Y;>7Y./FT&:;D9;S<V`J
M6E#C*LW5EU>&L/`Y6\5(E976.KSL:6"+>3#ZS6E,)B#JL>-9!4]['JV?PWB#
M4)Y(.<ZID.K.W#Z.B^/:V@G84T0H!7OZ->.SL]=8K*")^CBNDML-9DI2L*A4
MLSY-.O!=]`J]')?)=0Q<50YP5+\=1[(<TU(S2S5TN]#!C]D`%&ZMJN\<3T''
MMMJ:1,6"/U`-1J-H+GD@.F)3"#IP^>T-0N5-EQ(B.4C$W=P6(69,9=89(&?!
MIJ>55G@G'QM\^/"CS,=::SJ_<)J(HR1>#MEPG'?FX\,OK)@FNSAU)5S!J3YE
M)\AX8*=DD9'`<"I^+=`./($YP&VA!N1XMP,?/,M.-]'A`Y=O5LG7%!M,9=;`
M@+EU.R5E[4>`':OY?.#".-<B`%?&C$5[S2S+Y3-%P?HQPTD1_;=_+V:XIF4?
M>1J@2M_YP(71K6TPM"IG)JPQO.B"O+S?>,DBA1M,(.@S'S@+?6P!A(PC.&:8
MG>DN][JCQ5W@/09A7MSQ*L-87`=!VG<^<%:<N]V.IL29"36>LXKN,\K:>%G8
M4C]A+TJ9[TOQ&\\'S@IKMU@W7%8`57V5V=5Y9O4=;QKONAG_UGS@K#AWNP5I
M11)PWD!M[JPI5DJ2+Y7D-BH.GM]0\+0B*V?X0K3H)Z(U(^P'"<H+U%N)+-"F
M8CYP5FW<\D0T*R/Q*[#TG[;:FD_H(U_>/AFW++TB=TT3.1:S^",2/Z/7<*3Y
MI;/*UNTTNP9\FGA@5`KA;I-[R![_0'XZBZ=T;HV74_2<87]%YJ,<//D8\TL7
M!@5SL*EQ:.2U40YBURCQ<9`/1SY+OTZ(V'_]SGOF`Z70=7[9,RN"#F-&WAKE
MP/(QCK*D,D^\T,,;'A2<YO/+/AH.!,S`>C94.?__XEP`X%P`X*@`0'W3Z$7E
MK69Y`[VK&<!C`XR)_Q3BO!V7[*IA:_J2)63]/)-,BA.(M]CIE(+G5#:;+G!R
M`<S<BF0B&=B+6[ORDE6N>],27?M<TL)01-3Q94RTX/SMLVB1BS\1U0QJ-%C_
MZEFTXM5F7JXN2>)*.PV'<U7*HATJ)A`V6>P".,00BBZ!P+J#B.Z;A?<9(;HK
MY12.GY]CG&91[@P61QK+>[I[*K?%ZF+@I\2IQ65)FE`[T0P'7GB3Y5;WP[FB
M"UNST=R]GFL6RL;<6SQ9*1G8"Y(F:U#>U=USN887H1*K=D._=B1_#D*4I'&$
M!&8K:9\>EKY0XLD!!&(]1-S+6:$)-6%J`&"T=D2W"$#0^*Q`T8$&QZ)AOZ>.
M(TF.MUIO-X455&>[(C!LMAP!(ZV9H-;;3?4$6\`8+X=@QN@XI28YB7=JW\92
M680N7%,5'N#$<.=D2:V\I5:6"AJH^X&J@A0(^T`O&`M[$VD#\97HBQV>@^,S
M$=TZ6TL!J+2S535"S9-Q/)/9@J\1#$;D%E*[K1B^G*=V_]U(3@CD)&%+E1+,
MI';_71.T`T_0EUIKU(`<0';@@W=(=9/:;:=`AI'4;KJFV&`JLP8&S(?L,4%_
M983)T0LJ'JR7''V<'I8*8W1Q[`DX`I2:5R=2'AO%ZV.K<(+R42<2N3)(!UX@
M+Z=6*`$YVLS"!>](.Z)6>H0QV[LI<:&V/I1`.K`!"IA@$7AX\^#1:OIY!)O"
M`<7L8ZGN15='%)<G0*F^!^)H7.)X.<->E'B^DIHO[VRK7H;6L<6'@0.=$EMP
M5IQU"`&=:5:PA'>\W4[&TB-MW\9-71/-U<*Y2Y=YZ+@.*L^3QVS<SP(F7%8L
M!GUL#<=#GR8^7B,:QTYI'R]I1%#R<3-;!7@Q\7#*S655'Z%W!40:\`?'L=>X
MZLDVB.Q7E-#:$C2Z[!GY*2U-0'^UK3)!U:FB/(KHN.J(A-,M"&)00'"\"S1T
M43!KZ)_G`W>!E:T0W1$/Z,Y`)]"C?(X],C.AZ'0B_.=5%4I)_K)%;_I[O:OW
M8ET:XN(^?3IHJD6-/N$X$5H?S'^M=U5I+,MB-[5^[._4`E$OKV_%=*Q*PD05
M*\>3JKPE%TOFPL9\8GRF=X6!;`G!9FFMH>_C#"WR_)=9O+^,\^Z]G.;SRS[6
M'!8P8Z1LEJ&52\U6MTE"*+W.\'YF_.J%&;I'K_E?A+J#2O_Y94_K#BMS)ZO*
MU2&BS`?M!0BRV_?4Z<1A'HQBK_G"M@YLDI&<.J&$<U**H4Q&]A)B=%Z9YQUJ
M>H.X<V,TG)K59!D]@=G+0.<_0<^#2=2EWZ`(A;$[M[[9C1&(:]?F#EGS[EX8
M>N%O:_,H+.13+R5G\V8<?2;G]2K<D/L'/\]<M7NOM$8]P8C#-(&6<1V<R[B>
MR[@>E7'MNHHKW-IMO:OQVHK7DZ_KY:@X:SM03`!LLD(K<(@A%/(`@74'A3_N
MR,4C2E`>N*U;.$JEKY/RJ&U7&`-#15Z[+YK3N')4/XN:2EBR6&'-2M4BEY5(
M9:+4D'X'=47MB!_"46,!AU.I&.4LD%8^T15183+5\W)1SJ)0S:-29JKCL^-`
M`^G:9KF4^KNKTVD!F@I;)G(#7#XUT[\ZG5P^X$!Q"F^$N*H<RH>7/0UL,0\F
MN^TT)A,0UYGC604O=]+LFS-.*JE:WPG84T0H!3#X:I;W[&T%@0H/<+(`&Q2<
M=%P#H"I(@;`/],*:[)K2!G(PZ8L=WEG2L+RGRWS\XYG,%GR-8#@B][ZJB;S<
M#E!%5;[(CPFV:`6A)_]X6?AD<G5`X+I@M>UA250A+R92E15%+;:2LUL[*V0J
M%IJ"@(T6+;4K80@."".B[L#E\`E[B\Q+R;UCY]H56TUY[=T4!97-5(:P10S8
M$W.WM5)ZEO#>@#^[?H5MKCR-/";B\\(B&VH;KK"]?`O<"BK=;97YM`N2!G,6
M"P\U0$5(;,]RK548,F%%X$A_BGP4/*>-%H=*7TNE("WCH<H9G%(ZIU'<Q5+9
MR9X6=RE5JP10%KOWQ5V<E%L$6MRE5+812&&JWA9WZ5N%2:N2@).SWL?B+GTK
MBVE+"";J3BG<!_<V@]%7'R7)>+D/L=K2*`H;UQBE=U4I&_((I[+3MU18LE4%
MI'/Q%LO%6]PK[N?B+>?B+>?B+>?B+>?B+5`V1B"!/BZ*MP`M$')Y+A!R+A#B
MN$"(R]R;WI4`X;$!)ASN%'(E'%42X6+;T/C4C/7S3#(I3B`JC],I!2],VFS*
MC0O?K>U-@#T_1#(``ZY>ODWO:IVP6#`11^8J_\-1G1.F&`62WE,+:Y[KB1K(
M::0K<W@'2+,\&Q=>3LXD9DO]F%PX\FZ49./"^Z@G[R-RX>SC1CQ;=FJ../-M
M@:HUXLZ(:Z=>24L'%\7&C`&W5,;DFP89B*Y@'>TN"J*57'57B:S2%JNQK5HP
M5CQCC*(>8L[`K+?K`".?C"W5,ZH-W1;=:(\.GRLX"LDV6$ZBAI1:];B2QA$7
M<&II;`F3GC:5=L[K:1R+4RCT`\U@=J6F4@=R@C<3/[P[/\?4FIM1L1?Y*R2J
M;=I@%+=U.>KK0<MGP&.H1W"*BJ(V&,5MS0]S<%88@J,@*!`NK*;::!Q+=4>Z
MQ[3*DL6LYTK20_[9WY&')>4:A)UL%2,Q@X$:_183G2O?)ELQ_;*&M"L]W)3'
M:"[J&O'BO&7ZC[F4?IYX*XWZ64"AQH+%#6,81>1.6^3?*.<I"3OULU2"E"6+
M>T@Y)6JX*(IP>^$^.8IKRA)WZV>)!`6F@%5'Z'?R>I\K(YB7!9STJL:E'[8,
MTH,:'>54R^:6X<_UNS*"!6&<0&F$"H?Y^U[/R"<_%H^[CK,T2;UH083]&Z)E
M1TB;%X3)9C[Z2O;U($$3'/C2^B_."/OVBBX8$]L)5&C8RJ+$=+&$+4[7VK>^
MO5H-(DF8*-APKH-5JOS4LX(1UJ4!I[1$+^O*]+34A6DA`"J987`;=J3!J>H<
MESVK7^M`/OMY::,`[KF@1*L(+?6:$A:,OM]J40D>,"IU)3AV7Z"5![X_5QXX
M5QXXJCQ0/P5Z47K@-B+3'SVD9'%2HN[HER@BXE!%0:_^EB40,P4F]H=#IC3"
M3MC/==D`B>RU`(-7#<`29$!B)&U@!R^"\A.*R#T@)'O*<+$F@DZH0D/42FK3
MC1)Y:)92?Z?I^-+EQ$92E3$P2#YDCPGZ*R,LCE[(OQ3J[G!Z]#?_GL\0H)C(
M.HWR.BB\/JXS]04"5T;H\.8\X)74!B(@YYE)K."=8T?$RD.*6>V=5@,0+@TE
MA.#5"+A#28+0'?(2FFU2JH`S)H>!1_=U^C>RKR.\'B_I5H\]G_7&3[L!G50=
M,&#V;<PMG)SX(TJG=*YN-:BBL`7]C1>*U!35(>R4-K"/L@9_%M\@K3[`YF-*
MRVU41+A.D>JK=/5^MFH3=/D<'9LK.'%_^<0A+!8393MYA+LHH[V;?'8CNR2'
M&Q.A<YS54EVS]27[F?"P"C?\S:W)*+U"IY&8(+E-\H)ZJS@D%"5$W0W\@+K@
M)F16((S1(O\S4<#^0'XZBZ=H@=8YL567RH6Z2\70:R.A1]]$R:D3N5R$[;7<
M+(;T=W^%%AGUR^6D?-SDA/$<,@J].G3'R&3)T]Z%Q/>[]//>W%:6B<P<Q>OC
MT/>BB!4'8`%#8*YH9=JD5HYZ8]<>%J&,V;`PF3@=/*"8F\P`TT$IJ`>$B2HS
M'$>H>KB+8UO$O9QZ/-@3G*&>27FP+O39:]Q`Z)Q>=AP7EH3.Y\'B"_2[;]-T
M]R9RY_6SY(>P)'D!%W`,9P6Q'Q514NCEU+BM@I$:#W`J;Q5T7C5"B-G+:7%<
M?81X/,!)M3ZZK*N_S"SNZ,30W/"2*>4$CF>\2NK$PV.<*Y&+7[TP0Q.$<^J5
M4>,-X,8@;00^$4MP3JZK.'I!.`W(W9@U^VZ3)$.++\]Q5#0L7[Q95QS]T=Q6
M9M5$N"%_<([!*M5WP5]9L,@CK(H_H$B8^:/0VVTIUU8+ELL/U#/RFJ9$H&@Q
M)7L,V5VNXS#T\'`=9TP'H/88E@K`=@&EA"LXSL`JV06%X^7^MSL^DEN:/T9+
MGBD#JS"6K<*R'0"LR)U%I^(DP_[*XV=+UANY+4>J*&XVV>+:#^IEWPRFP&X/
MVYQ$!763WP<\)`ILBY/<>^B*'9Q=L6=7[+?HBLT>DV`1>'CSX.TY5,@,8/;I
MK2M6P!`8UU^)-/KRXWA)*P$GGJ^45"7O[-Q5*\*``YL*4]\.?E!<NW:`A)=4
M<#L92^WY^S9NWYQ56BAL;,H<@!%]SDJAF%YG>%\ZIU!8[]%K_B=Q-)'*`&!<
MQBI*BBI'<$SZ1J]58)S,;2Y6H'S,$QS[""V2&\(NI=6+?+2K(YX]AGE5$T1G
MFM!$I#@&&/^SDF5(G2F;-;ZWI<3'RR_D^HQ?R369%ML/$I^:JHIH[/4Z2.BQ
MS:_XK3,(&!>TU)ZDR14@@_N>\OV&3J?759PP:^>K=.N50UK,!QP[.@`W9H\<
MU0WYDUC3>VAFO#R;&<]FQF_1S'C.^#AG?)PS/LX9'Y`R/J`&^D()DF@3Z`O*
M6+B=>:._LB#=T!K)<93G*RN>/ZQ^#LM@F3F#.$S!L0X>$2C=^YCMG9?`DHF;
MC1*/%S!KRA`XT,XF(RC!.Z)^\VAU('G9JTH[IQ99[@)@(W%,.!C)4S-C'*FI
M!+6V3LVMF@BPB(=SECRL8IS2.EC7Z%&I]B6KO1T[:@='/H<9.)ZF&H7R>`AV
M#UM&4?7SGB=K16A*CPI`V<),@@/EO#>%$KRCOF1IOX]3E$R\#=T=%`X?03^W
M*5.B12)U-["9`0,79>DV2E*<Y8_RB$^E>F-+R4_VSR0V*W#2UJKTT:`IZ:['
MZV(KJTGY3.+(6@68*A=`5TU;=(`<2J9@ZJ`FSNPUGJWB+/'HHU,93A&*\GU6
M7"9$W,MM;IAPVE<A4.2E>^F/(_XQK];1;<*8*0PJ[`"Z@W84LWK1IT!(99;@
MX+AE<6MR&N/\$=C]R^S(SVBP&4JNO#!$BX^;;;MDVU`A]J+IR/.+'L50&N`5
MCOV"%1!:2A4N7)V[6"&:Y)__1A3.UVC`^44/XC/;LV@QI+8HE;^=;,6^Q#U,
MZTWG%SV(M!01#R<,EKD]5%ZCW?]QOR>('JEN--Y\T*<0RZ8<FHBIY2RG&R_`
MLO),[(;S00^*]/!)MU@&8A?$/HZV*0=7!-0-49UR(G@"%O>:#WI00T>1#W'E
M"`"F6'TC['S0H[HX`AYVT/SH')K;*"5*19)NB;O*B,J1OZ%]'T=^\3\"F!1Z
MSP=0@K@4(%/D1U+THV/[WR%38#OCT.)@/"BG%8C4`KV!YH,>Y8/JLW:X8L,'
M^*#)C',:36#-&W,^Z)%%I167^QG@WLI2Y6.,@Z>`D$%_6U3B4D>:T7<^Z)&E
M1(F;/7)MC"$*;W_)TK3%'>:#'A@HY"SLA>W>3[D[NK</)]%9H:"XE%K/!SVP
M64CHW^-A^>&[G6H;/8VS-$F]:$&3BNE"C!9#W\<9W6<+"E66AL9P\\L>6"+:
M,KB'T7UV;]45=>/Y2%KEE-=E?MD#2X8*$WMX3B<;]WOU;%S>DQG-R+@39.(:
M&5<K8]<L;[P<W=9C=IC!:PH#U@[94@2N\H`YDV3XA!$2Q*[5&SG,WC4B?P:D
MQ_S9B_W8?XD;\,1JYBHIERT<D0!-YM\:%J'C,+'FLNP@(&R*$D1X69&%=(U>
M4!@_YT3N*+DC%RCZK*LP.DEG#"<ILKR9RL!`DQ=[P$PRNKG1*(K"VK,G08R%
MI)N3NG@:XI>3;_$5M?W')AZF(2Q*!V.IK9V451CG8Y7-#D%0W.LKK2TE0&J>
MFD<B4Y#NGOH.SM!6X@5UHC:7<P?GZS_C,)O$*^_/;(;\512'\1-]7SWTQ=NX
MI)N3_%+)E&7(7<Y%%X+_[$7>4W%ZJXN=T<E)-;XV0F?S`"<>UVQI*3L)I*Y.
M7R5^X<31MJUU9"E-T4#Q*4&N(I,-,*E6[2$!DEYE#!MX.;_F'P,&\Z9>:45P
M=C8Q%V`PXE@$:"Q&<;A>Q5&*/;JK3Q!>QGA]$^-QNB+'`*W!069Y_D[@R,.1
M\&U:H]]Q\R"?)>.[-0G!486F\<8+T\W6/2Z:)96&;E(O;<-<8Q&.GB-,>RM^
M3^8<V=I>`K]Y2F!M(#?IG99QUA>!.'^H\[<%1?27XKZ6I<#J0WY<T[DA'_C;
MFB@*@K:7)E/E;A?AEY,J?NQ3UN]D,%04$Z1R\;\-I]/A_>RAB#A)WFZWEN;_
M.$^_NU,O'\_KV'JI"-.&=Z'-TS@,R9[_ZF%N]J;V.,ZO0Q(L*BM%7TI@5",F
MZ:7P0=VY5^[J:#ML.F>5,CPKHK%F!F=^^A/]F9\@+>S34R@4A+&[#':#P2[!
M=T'N.0'.5=TE"G11X8]R<C@)!+;;`]O="AJ@)PJ8E/8[580*H>P*$G2SFGY#
M]-]H,23ZO_>$*MGS394*U3'[KV`H2P],E3\0529`K6#-%6"D"$77>HN$GB9J
MC>*0)X!T>[&Z49`X5)G5G[0_\BU/"(B:F(36IHJ:RK#GJ6!,Y;.H',@>(!1T
MZBIWJ9E:I\(UU\_)3"V2Y2.!P%,2)\;OX[KJMGQV*B%;\`\E2())HFK4$;.7
MTW`PZ8Q3@FC'OS4E^0&]H.AWY.'=MBR.;N4U!W:!K4Z;:@8FC^&370=`8O!,
M+HA:&-Z%$R_?=@95\\H=/?)LVEWGX-EGPTJ7NT>?^2+55KQZ__BS4<T+P.//
M8J@TM2^`;S\;/'<</WTBE+K^D0/H"10+4$%7$AIBUD%ZGAD-&L*[S[QIKZY%
M0WKY&>Y3#0`*B9K14+1XAA,I#\+S9^EQ:@>S0(%328A9_=IFN7[8;'SUSX_#
MA]'UU?CS9'3_,)S=CN^WP9H775_@\B#DCQY1T<LI)J6<E(^;0Y.)M\DS5J@)
M7N62UWYP!Q?!TJN",O(3'OVR>Z.Q;SBX9AH!E;/$3<JEWS=7L[GE[F^N1I'E
M3!X!^]`4P\99S8ZOM4(9"X_M*A.G@P>0NZLA8."EF)--8AU':HGEM;80+K9'
M$Y^#!8-RFU8#FKH^G+W&BIG["KT@7"R%HE;CP6)EL-VW22/41.Z\?A`N<^J2
M%W`!)Q?(?%T+*,\^R#8B,0]P`J@+.J\:(<3LY:0D67.$>#R8>$B1_R!!$"^V
M"GR>_"HJ,,EN;:<&&92;B)AQBT=+_9OBNHB\]I:*D"E6GN1+3DG,!Q8L5K4U
M)V@(-2A-2;P#3Q?U]Y3?70]>)%6=N1UL%6M3B'D63EJ&R(4\=";KA^"KEJCW
M[=U4\S(AZ0H+%C?NH\^.\GB.^.BW]T&D-]=EPSBLKM42%Q7.3%PCU.":H:A&
MRVP5X!2A2`LP^4`.*V6UA$R--XM/JQ]OHG&F#U"UD\-R5FU/D!H?<%Y>+Q?.
MDKWV)^TSOW!I%;'J(Q.Q+#FJ.GXI2^3IOG3GZ?X4QXND>&08K9_#>(/0KDK;
MC""4>'ZE*)22@UMS3"!^;36JFWBS-49VZL/6QXVW+%L+H=\.Z\(N0KXB<5)7
MV@%U3&OBQIX0QXR"\:@U-WL=6(H6D]"+[KTUW_YA\W.NW>`U;`5'M7G6SS/)
MI#B!./"=3BEX;O_1;M_-*V[F5$B].]P^3L,`;&T"[/DAD@$8<'/&KKU425?8
MM;,38`!(5R@Q"B=<?4^9='<^:FDI*D'OB"Z+5"+Y/=7P5HF^Z"&=:0TPZ,"=
ME!>%TO8IB7LY#?)@3&2&.5#*0+<2EWLVQ+V<!FTTEWB%`8O>)=:W1R'-GM,7
M>KF?DY?DVHO]B`6+?B+6UV>O*&RROY3[V8K/L"WY8QXL>GN8GU?RR<E[NHD<
M,"#^&A<6P\281XR2STW>T^WS8"V.V!H7)A[U,/1T$[V'2BYB^S:6(@=@W,(J
M7,()1L[)DAH_2JULQ0HHW[VJ@A0(N^[_[Z6T@5RW],4.S^[WF8ANG:VE`%3:
MN8G'X,UDMN!K!,,1N?=53>3E=F[C*Q1%?DPP'+-:XP"1PJ1;U+1.;J,B'.@3
MCA,K>?C\K\TO7!H[;/CO[<BH1U..ZX=@<BBJU&S%AZ=-Q?S"I77(Q10U*SLX
M&K#9M7G$=_Y'>JN[\0+\JQ=FK::O64KF%RXM;>!W627Y`<I9-'S$;+F]C5(<
MD"N"W^WDY7Q_/G!IH@0_9052D]CD.H[=I?$#-:[=%AL^UZHZUZHZUZJ"%_J[
MBTV2&)'+S8`&_AJN2'7$,1B+CW+$):RHVV-QBH4.+URVL=B!V)>;R;^+*LA4
M6:'?I7^2%-.I-W4:'2J+ZQ00#69>-TO]@!G.:?@$.&;Y%,R!<&+W(828EL$U
M;;83L@YF^9_$3`)RQ#J=4O"\P6:S0&!XK,QN`NSY(9*!/37L-O()T<&+$ER2
M'DXC>X7B8^AG0C;LR?L^CI+42S/2?J,L<F$GIX&]NE*7<0)'UYH%*=4R;Z-%
M\!(L,B^4*,K,]I9B?Z%IS%S>X;@C:R3^%J2K*0IS$22KX'D6C\AVD&ZDNHSF
M2+;BCY4U7CXXBF#*^0.C>[A$&8@V:A_N#HQ#NV/E'W%(:U%-R&Y'MJ+Q:X0P
M)>DV2A%&22H^-;4&<1NEWF3-,4Y7;8[M(3A.5PCOZ!'CQ&CJIMB=830X?,%1
M<32S"*R87*&I,A5^X82A-(APMQ->W22?@!OL>T0O&#6BB;2!'/_Z8H=G06J8
M3P`FN)UK`JP1#$?DS?()7%KG%$5^3#"<X[=QH,O^%<V\JN0P2U<Q#OYUB!LS
M&2G%^Q:40&U+M3I-B\KF$S5-Z:T$CU^CQ,=!3A37#6_Z0U`BI<W-(7MRLECX
M@#[ODZS(E7%[7_2>B()-P[$_>_A/E.:QKKMZM>-H'PP[3&3Y(P9'AQ*A;'BJ
MF!,.G*M*8V'E__H5)6D0/16!UZ(WE$U^9CYP62,"Y&'&D5+OXMW/CS.?`][/
M`>_G@/>3JG5M->`14,S[*42IG:M>GV?2N>KUN>JU8MC4N>JU-$V"_@/736K%
M"P%-8RBS"\>@KN^VL^._:.`CY48%5ZD%L^DU$#60TTM7YO`.G&;N49?NFJ-)
MK.(<-1*#[=(WZM*UH2;O(W+A[./GT.MSZ/4Y]/H<>GT.O781>OT5^1G-BQHO
MEX&/,*W'M+NJ)9*`:WG7TPBS5N,3S-(\IE=NGF!VZ'M0MIP[."K0;>3':_20
M>FFN'=S1+U%YBQ4A0:]O)'Q;(@$X41(<0J6'H["?\Z!OF?BU0#OP!&8GM84:
M$`7&#GSP+"B?4(0P4<^BQ7"Q)J).4NS1`V'TE>Y%<KN64G^W`>GR-<4&4YDU
M,&">R[*?7O39R=1GES!X$^,E"M(,HSV7%N<>XVOG,'Y-8<$QJ[5E<)RE2>J1
MZU3T5&0N6)QYM6^=7NB_55'!N;<TO[GU]46*D\L\<"1$$\\7.MXYB\RN28;]
M%?T3.2+R7]O8.#F?.F<JZ$C*Q(.-O*0IA-<E.Q:'9IZE7*WW?.#26&XOZ4F9
M^1U^?^OOEK'=*LGU.<"%J;H#19_QM?G`I?$>Y,8A%M9N[OW=_=RC`9*W29*A
MQ76&]_E8Q;Y7BI[<)P4*IY;V8/,!Z)C4-C.GD2QV$^-'YQ-C&.:#HP5;2%N3
MG6`RJ`TP'[A\J=/F!%#G?P?Z3\Y!'U4?1F)3?A]'+RBARCB51#*+4R\L__TJ
M3M+[./T=I5/DQT\1+5-0GO`JH>LVOS\?N+2=VYQRG8GO8"0]W2E;[-=$X]_^
MBK83Y8QW2\A\<*IV_>[EN)_-')L_O,3S@;O$<\UG])0N(OI/\T%(,U>CNDER
MN<;(3E/*S3VIV%H(?+?=.8%<#_O645>:P'&TYW/:N+7/G=/&SS/IG#9^3AL_
MIXT;2QN'K(L3`67/SV&`L$2Y:#<PT/?[C&@CK24#,:I,C94=(QKG2Y.!73_=
MUQYA,S.G)I7>;CN=31P@*@C4&=1!6M]5'"7D"S1@1YS$5VL(Y`F^IFN3$8#`
M8A',&M:K-F,E>A?&@5YF$D[4K7[A$SN!K@UJS/PHE'2M#D0?10WDG-&5.;S;
M:<,G.%R&RA[-8K;8:_3"D7BS%SA<AH.J2?R87CCWK&UY:\EA6VIEJ7H!C//V
MB$\X*0=;PJ27E$H[6\4*E,_=8W$*A7Z@&<Q^U%3J0([@9N*'=Q!SC*NYX90L
M;;(9C".YDJ0QBJ5"$8I'2GT]:'D)>`R!@=-"78\3MNE*^(:3462I+H1C@ZM,
M_%J@'7B"OAA;HP;D"+0#'[PC<HH21,2S(KO--7I!8?Q,"5>MY:'0VVV!!OEZ
MXE@8U!@#`^,)U/&`44O!7,B?'1G!,>8:K!%!2P!VFN,G_3:4$@M@IJ.2Q.#H
ME/VN[P&D:@*8R<>4D(G\='"3S59)#S,40"F@`'%BRN0&+!W_4<[T(S/B<&MD
MFE)ND\/+J[+):?I[4,H[F)V*-J0$*!>_Z6IS^;@MC,H/[G<\CG!,)/1+WV97
MXWZ?D$Z3(WD16JT&A5+-H?5L,",*$WG]4NQ;'\S#,$4X(G1O)^_.X,[5ZSLF
MX!0GE'70Q/YU>`G-E^>7M,\O:6M\X_R2-E<N_7Y)>^^*N`J])"'RH)N'+&^)
MUP=H@K3A9RE$[(-QP)1ID_I`ZXU=IRP+9<R&A<G$Z>`!Q`]M")@.DF2(PAB@
M9#B.T(0T0QAORRJ),V;$O9RFYK(G.$OOE?%@7>BSU[B!T#F]["2Z6A(ZGP<3
MH=(2J9-&328[MY^E)%%+DA=P`<A+G1/[41$EA5Y.,_I4,%+C`4Z$>D'G52.$
MF+V<OM:LCQ"/!SC.=+VL2BN!$]#N)&5VX>3DZ"?]64HZ:Y!@R<V!.B(7S`VC
MB;"!7"JTI0XO;K5ACB64C#_^N\8U@N&(O%F2I4L_O:+(CPF&LZ/_ZH59?F;-
MD+^*@K\RV3G,[F`IH0_:J<QG'LZ%I$ZC/$N0T\56MIEZFB9?WJH`'3@!L\^9
M10C(D6\2J@Z,B=LHNH<4!W^B2986'N+A\S../7\EMK*H]+7UV+-BHJ9H&3`L
M+JH<@5E"Q2L@Q>L@>03D!.'\=S*G,JN/V[>`K;I%12Q;M%]>><]!ZH5D/F4^
M#>G_/4#A`BWR*O.?/?PG2ND,)2?U[;8*_;8#;\4U'>_T'N]M+0X3B@H']>U'
M";/K.,IM33P\ZRVAI&<91HK-*!S;Z(T7X)S&V^@Y2Y/K(/'C+$IO8GSG^7^.
ME\5L\AZ#,$@W@KU5:QPHN4_F]UMM,<"QP>8\*Z6!?`L/K];>164G`>W^Z3@@
M<#JZ&\Y&UY/A=/;[;#J\?QA>S6[']P_5D,"N(P*G**3!NQ,/IQO-ETQD79U&
M\W&(2SYN*G]1CMS3&,]!E)X"%+R%TY##?L?;J?$J<VXI#P(J(D\39XXC0(=W
M,!?0,FU2ZTV]L>MP/#VARX&#%Y_7&B`@=C5;2'5A8R,Z3NA]PG'V?!OY$IL:
MHZW3X#SV[&;9SMB4@UP(Y62K1B<2N'<J;!Y!X)Z>X-"IM;W5^KE^.$(B?"W$
MX#WZ8`DRV(=3*^PZ>6X!/\>8$/'9B[S"8/"0TO]_"GRRG=\$D1?Y`7T0-7^*
M((B>9*\R-!O/::BG=`FQ#,_-&06S(LT7^83TS(.1\U#,+)Q0!SLE(AT_"2$1
MOA9B>XZ@K[ZVD`$Y#VU@!R\T\A.*$/9"LN$/%VLBZ(0>`<$+4BWJJ=3?[7,5
MTO7$AE*9,S!8<LZ++<')#9%,^1CY+4A7Y2[Z&JSJR(Y#:1M;P0VP+;EP=EQ\
M(GM,T%\9+4[[0B,GW?J8CJA1\2WQNKCP*55)D;J,&,U=U&W@"Y#G"6(3WF]'
MSS%3&^E;\YP>$%PX'(#4X-P`?%2^3J+\V4Q>']?.&8&\E0&"YY`Q#!$0C=\D
M5O`T_2-BY4FSK/9NGS\7+0TEA&QY=!+D?_<4OQ!M+J"`?$]_H#A\7\*!_&I^
MAYZ\<!2E`3>*@-$*@H]&Z8QATV[:Y:(JZX(([K9TW,25ZX0CM+IDCXAU-(.U
MI>IX;V\HWBX<%V0A97A#;HJ20B"UADY<#:PIR/(J,(BU)\-IX)--;(4>R%Y&
MYT+JA<'GF/Z'_,H;1HM;\AD_)C^+1:P[CI.J$8H(-.`%D%>\;]4CM"Y?K$(0
M[CTOYT(0P(4-Y'IT"H4@^OWTLW)5`B.%('B1@$\8Y38]SC9=;P3B,6>EC9I-
MNXD4+YDPN1HUJYFS)Y<Y\A$)T>B#RZ:EZ'AG;2/.+F)^U[FWZ8JTI(ZDA^SY
M.=P0!?(JCLG**[SA.[HD$<':([EY')D[=5F0-.()S%%X0Z6*[H(71"X$*3ED
M`K(C#I,$T8(JG[T_8IQ7IY/HXAJC@'@_64M=UV0.3OZG@/`#V??>6FZTUQS)
M^4/*NI!I`\_CN@_KVCKV0"XJKB8!O/O.51REV/-I>$?QVI?TYL/IX;;X1I/U
MR`95P)Y%/0HC;[R\0U["BA`Y;N*X>H9R@`B+;CB&Q#M$I@>BA-$'@DK5XL:%
M<A8]Y40G,X37M*9',2T$"Z/9@([+8VA'^S3G$HX]\XC4*3J\Q5Z4RYSF1G&1
M6JLZA./*&=KPZO`%I[`-G^I[)%JRPGZ.GZ<U"-V6&3C7#]5-A/"`7KV0[B4&
M-M[2:([?>[6VZQZQ:.)1:X[*LJVS,XMW3Q,7502_1.2#>ZL&3YE1ZNSXL50]
M-4>9(Q,/-XLAF1*R`XP6-W$8QJ]D:MPLO+RXXPN_Y)Y"5\>OE3:"0\:/B<>,
M>6!DV%^1)3E>WJ[I!^FKF,EM],\@C+D^$5&?^<!EB5%=\4L8L?C,+_G0KO8E
M_1Q/U$?-Y@.G14'UI,N@W>+;N4=?RW>TT=>@>$>U,&G+MGN-(>8#IS4\6P$A
MX^MP]W6N@.7%*8M*L=<9WK_!7:X@>Q/CW:.]`MU+;Z#YH!^6B^;<[3%V;^`H
ME2&=>'B,\_S&15ZP4J%^LD+O^:!?I@M%EO80<@P5C(P\2O<4+2NL)\'Z^9#P
MQ=MBK\;WUZ/[A]'UQ^'=\/YJ]/"/T6CV\/8-'?'+]%8G=X\SU!%"E.0*G6U3
M!CF?_6\GS^#>J:0(UAMWO30+R_3P,9'9%(\:.EQM7`D?K[)CWL!8_0K"KC*,
M:2B%JNR/V[N#@#UIV.*O<0G&W^0E*QH"0?XS(G<S<@^C5HQA>N5AO"$';+X;
MBXXEI?ZN0>),LMJ!I"8,*-A-,'KV@L76J+CE48`5NWU/L.$PN],-7&-1X45U
M$^N+[(^8VYT@KF4^3E<(%[3=QY$OE3V[O6L,9,+G<`EEXE]O7S<MJH^AJS@I
MTREV]\C[0@='@7LHJV6":91CNIF$'EGQT8*><,]K*4;";M#A$?.\<Y>Z1J;@
M17IH@)?VCH^=6].U7.^"XJT/^IQY5#R_O(I#0EM"YT&Z4;AS*`_1AYN@NCS`
M!!*42%:_*`HZN8-)=S(*P`-[F1SZ^8,[R<3;T#AM!6V8W0$$2JJZ,8=G0)C@
M#"WJC(EAX?3I&3(\SJ$HS[ENKP4-KT>?@.%R#455UD*DYV`(<'"N&,_0FA:\
MQIOBB-R9X89KNN,.TQ0'CUE*=]U9//$D,.F/!0+%1KI"`[E!V1$;:>D@]?*V
M("KHY\XWR@G>VC]R8F6^`E9KE_<F7428W$+1\TK.=*G/YKAIGT"H\PEEZQHN
M%D'QZ8D7+&XC_JO*LAY]PH/+-90]:DI+)D=H,?)P1`[!A%P+LG66UWR^)B+V
M`]')HM"Y3V"IR`**\E?G3DL#Z!4N+%[[8D5M83WML78FEPJ<=;2U#TL+GE<;
M=E[H7-F.?<P1-X656;E<5N[<&3YY3O1XF<\E66US;A_G]3J8LXV+8)UG,/IT
MB3)IX05&8[<US&5SJJ95,[B%@L04+1!:T^E4O8#):_*).[H[?/ASJZZPB7F'
M@E'+U0*D#(F!95.K*')A,TC]83:<C3Z/[F</XYNKX<,_;N[&OSU\B;R,W,EH
M!'F;J'7)V)V%L4OH.,>UGW4_T:,VD%6_JSAZ(3<&0O%V#_FX^1(%?V7H&B4^
M#G)>))J@\A#]4`S5)0+FY#NF6*E2EZB74\U1=TI*`2R+XV0Q`Z*_6`2/I]<H
MH<9]"/KPN;UZ.XM+%G[9P\^*_1UJ^O*9=O3$LZI(+#[/?2"!=_UH")+.</W$
M3$M@4!Q7]RBE*4\3'+\$1&,GFT9"R_;M2]D,_31X*2)$B.(41!GYW7A7,5<E
M:]+0!_H08VM*EH#F1O$:[UV<B/30:CMW2)F=RPQTR]*`HL\,%W]D29K7GYK%
M4T2N-WX0H@JQ9`-2$XM*(JZ-SYWJE+&##93MX1H]8^0'N2@$,Z;2S&$:B\5U
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MM)4WE'L?AX^B<)S%\T3W`ST^3[1E"477V.V#VW@36LA^7TU0X01A=@.W'S2<
MZ;PS@RTK**<$8=Y':)'<$.GL2*2O[^UC@$2P2ON>++9RJ4'9SLNDWL<I4K#>
M<;M\"W!6901%D6_'O[7#^&1G1%MY0SFPV87BB\=HCFUDHHARG6'ZH)CIR06*
MB?#4WT!HBQ_O`80?6,#1?[H&[R:,7ZG'C_QXN!=&"\:V0F,UPCC),%*X4;4>
MNB^0MY/?[LU&\Z^P4Y^1%Q8:8)`D^0D3+2HJ_W@Y6Z%;*E\OG&2/8>"/ETM$
MGP;C)22T'-5A7H*AF5Y]#KZEC*VEH>PJZ^\^E5,R13[-N`Z6`<V*42^XU7;$
M$P.]C6Q%%[#.]_[C3)VBPF7QZQ0M+D2;N[3OZ8"N(:_V&C8WK6Q_BW_('O]`
M?DI#-9^W#]/RUJRDU^E`I"0C*`KS=4"O;]$BJ2:YR0Q;PFZG`Z6:E$0ZM+L2
MKE0=0.D^E7&=4[4+<!;:MM1'.3VDM62X>V_>-?"W48HPX9^>[\+`IE*STX.N
M*H7V5QEC$6GQ&LV\K]1F*H&GVO(4$3J2Q>ZM>M7'@-_381_)`4K^Y_\`4$L#
M!!0````(`'N!#$=[KWIPSFX``.LC!@`5`!P`<G1T<BTR,#$U,#8S,%]L86(N
M>&UL550)``.)J,M5B:C+575X"P`!!"4.```$.0$``.V]:W/D-I8H^'TC]C]@
M??>N[8A45<EEN^V>F;Z1):G<ZE95JB79OE['AH,BD9EL,\DT'ZK*_O6+`X!,
M,DF``/@`5#W1,=/52N`0Y^"\`)S'?_ZOC[L(/>$T"Y/XOSX[?_'J,X1C/PG"
M>/-?G_WX\/;LN\_^UU_^S__C/_^OL[/__>;N!ETF?K'#<8[>D3'K$`?H0YAO
MT=6_SJZ",$]2]!.#A<Y?O'[QZL77B/SS85ND6>`=%FA9;(HL1^>O%^BK5^??
MH/.O_GS^]9]?OT++=^CL#+X3A?'OCUZ&$5E7G/W79]L\W__YY<L/'SZ\^/B8
M1B^2=//RJU>O7K\L!W[&1O[Y8Q8V1G]X78X]?_F_W]W<^UN\\\[".,N]V#_.
M`C!=\\Z___[[E_17,C0+_YS1^3>)[^644KWK0L(1\+_.RF%G\*>S\Z_.7I^_
M^)@%GP$-TB3"=WB-Z.?_G!_V^+\^R\+=/H)ET[]M4[SN7D.4IB]A_LL8;[P<
M!P#_>X!__BW`_Q_\SS?>(XX^0S#RQ[MK(3K?-V"Q22__@N98X2U.PR2XBLV6
M>C)[UC7?YUZ:#UAU;?Y,ZWY(<B\R6G%MYDQK?8_-:%O-FXNF1`]B,YH>9XZX
MUKR]3FU"'BD(FAK^?4.^WU@9_ICC.,!!N3:8*=&6%##5LE3Y)WX#6`3J-DF;
M>*9YGIZ!]7CU[>M7%!/XRV^E85K&1.SS,#]<Q^LDW5%UO7S,\M3S\Q(073H%
M_]MWK[__T]>O__KU#]]\??Z;.J"7?RDIT%APBK.D2'VLA3W;A.;*O,??7GUS
M_OVWW_SMV^L_??M:8V5@V`@8,-\X/OOQ_K._5":;S$-L(JK-1+^6<_^__V2+
MJ7!;ILW]\%*_7"CY9P]R?,1+/R'V=I^?-?!<I\ENT`:4ZTH&$>NE,M=Q-"F*
M&?9?;)*GEP$.":KG7\,_@"._/GMUSNWX_R!_^HU]]PYO0OA<G+_W=KB#!=_^
M\/TWWYU_]=6?_O3M]]___=7W7[_]^OHWX?P9..^OU^=_>O7ZZZ^___Z[\_-W
M7YU_^]=O_RY>4)OA.(\=QR$8:(.Y]$A[PE-Z9)B#E2X(/Z=>=$T4[,>_XT.?
M.A-/G%M]R5`0<`\?B.A(1(9:5TZ]^]"IC/HV82J.N2C2E'SP;9CY7O0+]E+B
M#%\2]T)'`0EAV%1"$L1.68D/16PL@L'$``8(ACNECOHVJU<E]>S4M&KI;1CA
M]()\;9.D&DJI.<V>2CI=OD`AT6&H'.>0-NHD?X\NZJ+]Q+8KV>V2^#Y/_-_O
MMQ[9UE61PUT,W#3I.T52:/9=I!YD12:/SD)TV@*QB:@VTRF5I;ZKBOZ4PI9.
MQ:'E6>&!@%717XWQ-A37R8*%)S[XW0E-U45AH8KJ(._4.U_=%^JZ2-T`;&H@
M$4I")F$#W72,I/O3JUADFS,51RW)!P/XZ-O(ZS)L+=%H3K"A34Z7?,HIU>\(
M!CBA3SJI+%0H722>6J,<7?&WY"^9B4XY!>&"5FFC)=0K]5,7'>RD9A'LD[)N
MZ=ZD>;B+Z341?PF-<'NR31^F"Y4^GN(FRQI7:9!6U=D1;8HN)ZV][)'B4V1G
M&\_;`SM]\Q)'>5;^A3Z>U/B*__FW^YQ81UC*:OTVC+W8#\EZDBSL>4'IE#`M
MF+;TFB;BITQ934/)&E4343G3\KO*\&U1T80&^SP?0R^S#.>9ZN.?8-;<JE&X
M^)971@=(N&SP>I]P^IA4C]AC+?O^_NKAWKK2EO-(I[:6,LC<7,TO?$WU<C<0
MVXI8A%HWZR]0>;]O3P9&0:=$PZ/CG3,64H93L@XR;IM/<"Z\;+N,`_BOJS^*
M\,F+R&JR97[AI>DAC#<_>5'1>_VG!\R6\5!%M<6)9`+RX@#1?]2F+I"7HW(V
MHM-'%[6\%C$U/9I.6$NG$-BWHA?G8+8</>)-&,?`5\2/9HN8"+=C-.D\F&$B
M24*<K+D\6GI0Z@GI*,'Y]/QMBO=>&%Q]W.,XP]SJZ#I(W4!L.T@BU$X9D(]#
M?&#E*<VKLT=%!;.![KE'4G93<H]DO&;I7*%W6)Y1/"0G,C$/G9P7QI>"6OS\
M."NF<?7(MWXP4-AT]2.S+<Y>Y5N<LB6\)^B:&81N(+8-@@BU4WZBXU`I!\>A
M#AD$/50</2M+64W)&,CX;#Z1N<1K3+X<L,M<?)%D]>6\Q\H&HA^0+:.A@F+K
M'8K/X=?]&-%9=8$B_\8S2]7XV"5K\@\XD/DPS1F[H\R44ENDRI%S'E@2<D3,
M#[=D-VB^"CE+[7=".>OQ1B6P;%NK'D3;KC\;OD!T`KV8JJ98$+0I<*-(X2-2
M\11(R=S3,9%B7NM>C!K<AGB^7^R*"#(=48#W*?9#FI3EG"U7$4O%\UVO3,Y]
MS-,[WUD^V`E/=,X<Y(2RT+U.RR<WC2/;[.QY$WJ/813F(<Z(I-!H\&T2!40M
M@]3D!],'3V6XMFVD!@%.6:XVM;*51`T[^CHZ!-'KY9OKF^N'ZZM[M'Q_B>X?
M5A=__^OJYO+J[OYS=/6/'Z\??D%?7%Z]O;ZX?OC2.<.BR^-*1D:3P:U(='_0
M0J?6DD"P99BD2$GDTH68A>$(E3A$QTG.F+A^=I.:O5Y>F]%3\_VDB//LUCMX
MCY'I0Y8`BFTS)T2NY>GQ@8B/=/$M2Q^9/1OIG&F2\YQ:L(^,X6:5GK3`05N>
ME8\^0@#63D,2E#HX#<:B+MOCP/6D"2HV7X`U.43I@-7#7S._CRD)2O_;AQUQ
MZ7]14>(T]K1D7V1&10><-'L^FA'':+^7.2!$YH;&(0NCQ%;SR(?V39S2VIMQ
M%<_C_&)X;IE=`A[P;I^D7GI@%PYE$.!R!^[@,L_3\+'(P25\2&X]$P.C_P';
MIL>$)"V6+6'P^[S%,0Z;P5F@.B24)XC!<LAFC4&'V[1\GL[@<@MEQ>,_L9\#
MON2/Y`/PB+1`__>K%Z]>G9,#5HJ>(/QT@>($9:R6BE?DVR0-_X6#!0JS#)Q*
MN"=-CH5&D)?!&]7?BABCUZ]8E>+_0.??+E[_Z;O%MU]_VP7I_/7B]???+[[]
M]KOR5RGL2^SCW2,QS*_/*?ROG3/+QH*L9+!-I7C.1%B-5X=.)6[W?:'30&A=
ML-<'?UZ^(W1K&=<N,@?@B1F>7P1X'?IA;N7A0)>=5'P#AQX#*B5.UR3*N.J+
MMVZ!L&WGN]$26S!>XNLG9J"NJ;EPR%SKHI,Q=$Y-[W^@;Q:O7KV"_^NRFT>[
MK&.+OUM\]]V?%M]T@WSFAE<B':J)!`+1F#'+\EC&32^A\G2>M=S)-@*M]Z]&
MH3Z+4CP0`:'<?B45W#\M_O3==XM77ZGYNR?R^\TK&>BOO_T&7.WGXTBK\;**
ME18(P(PO)D%`ZW5XT:T7!M?QA;</<Z_%=KU/2`(PMFVT&+W6@T,U$L%0%,:(
M#W;(1ANA`VEF9P0=OQL=ZP:PAP75WA^E_#>?.-WAW`MC'%QY*20W9\MCW.LE
M.V"HFD8%2+:,I1*2IPQ93D+E+/1%;1ZZ%!R_+)A2(_26C0!G.FH\5+HZ,EE&
MQIJ959<PJ>%5%B^;-U"Z5K@#@FT#W(G4@)LGA_(DE%!C;T^9<U=.NGRD8XR%
M;.A.1+G!,VTW'`<>;44(JD6*N_6(JXH+$ZM3C#KUR!<BU\*%UUXI<ZJ^_<HX
MTT(ET0?0V/JFJS';OMDZ049<!_17.L3A<I^-_=`K[%G?#`N<=!%Y6;9:4^9>
M?@R5$]C$`.P]Q(E1:MW3P1"XZZ*#T*\PS'Z7/N7-Z7F5DN_,C%?6M05<)CMR
M&-!561T0;*NM3J3Z^(L-=$^!B7=(28D)MV=&18938I[?-%]HWM'[:V55)@%A
M39E)T6I92CH:O4$G+Z'H5S9E_`@"_2L?0XSXE4'XA-&^^2[J1E3$*/ODCN7I
MER:Y[>D5I3GOB0.,=^!=*2H'J:;L@6;;*O4BV[XK+B>,HS1&6ZBIN!J%-3IG
MD-7(HV2<E3C6PHGC)HSQ-?FG_E'C.-/Z&:..A.3<"L,0'>?@Z:*U$6K'BM-=
ML!8(?^NEJY0N*Z`/^[<XI0T.=56[*EC;.EX=_?Y0=S(9)2EBTUFD#33_8<TQ
M)U'\FILWEP58',-ST!=AC((DBKPT@]K2+%C&O:<#34J:!(_WR(`UD6<-3)=5
M8).J">D#8\N>]*/7+\J\G^UQEJGX&JYP9G%M!;<Y8U@5226ULFJ,:EG^6$3F
M0#/;`.68:3U!4UD&#4)5QUFA'1D,.]%US3YVD<K$)G8PK&4YE'=Z5]=1,_=X
M5U=\\N[N0C&4M'8?WQ9V;,+L@IB($7;+&DJZV)M1W&Z>U5@G4$6HMJVD,O*]
M"5KC'3_G3-@RPICG@CR[4Z8>IQND43ESQFPNR_2(V0/%EEWM1:Y75H>=+Z=Y
M3!R`%9?'WF.DE>?$"?"B^H;]U9WP/#61D[H&2O)F5XF8G9,ED-QR`'I.R2)%
MXGA6MC)638%S]"S<SY8&EMOJ2;AK*08'X3XP+MEK^3%8)&>FI^#Y++8J7DU)
M<_&PJ\B4V@;-YE&WEC<]UCE7!:1M&Z>&MKQRP7,YW@["U?!@.[5?/2'"=4M?
M1[Q"]KF<[35$6RT.6%FNK:@OTR.]#(0#5504CH=-M>3B2=X(']4SO`N%2HP.
MM_V<9U&0S(ZU(C`.V?N>HU^7,#E89$P;H:8T=>/CDLDR/L7*6="B1!F<7Z4P
MG#%.\A->MT"Y=6XU0\G]$ZL*#^J9*)MGU>O83W:X"E$V;68G`F/;1HG1.^4_
M-A+50M"%562MJ_2>35-2Z?(=F['5!SGM>3EA?=KV&'J1\J8JNA6.^P'94NXJ
M*+8Z991S6$-O5A.#3W.MP/$P_/P*O[*=SI^=T?7*S"E5^*J<.6>&7X8)7;9D
M+9?X"4<);?[+EZ6K^^7`;%N`/E3;Z7UL/.7(VHQ2^APZKPQ"+3C.<,Z^*;&G
M8BI?/V^JB%V:YRD5IE??OGY%10G^\MLML9YQ3L6ZSTRUQL]MC3H6W'HXHK\R
MBV/Q!*&^4G^2E0:)7P";T";P(RSV#GK*9QBZ+#)C%\:TWP\K(PRWWT&88C^/
M#BC%K+!AGJ`]A?G"NBT4,7JGR1-P^7R6[0<<$V,;$7E?!KLP#L'`0@T$0]O6
M!\ZV=>M']Y09^0S*>LTY#EJX8>AYC3G.63E%5E6R<VI\:N%45[JZVJ>X:J+U
M4UL-!?$IYDK0"G2X\&A7+%19."M1F$@.8=;M3B\KJ9VY3OC(@@BPFY:;).L2
M`GDWR@X0MBU.-UIBP>#W:E_`P`D*:!L7R-7%(R(#G#,A$AY3:U4J9+#YY.1]
M$B?-97"1U;T`[`=DRY2HH'C*>?4YE1#Q:5^Z=@-H@B#K!1QRS+C9^=*=NS]E
MOI3:(56FG//%YPEG.9QOV7JN8^*?D[_H/_D(X-BV4!($VX\^Y5`N8@M4CG;H
M%*2%$/NI)5<+%&/W+OKZ>%'Q)4O*B#-WK6\+O/+11S#=V@%(B$ZW*N^P6`Z$
M(>AB$78NW-[I1\Y3\C.0E*%FE@NA+,@=W-I4VW:EB48W]TS%]N;''.FB^35`
MIR?FG+'H8".U0TZ+AV8\W.!<>OSO]CP;DZP=6DZ6WCJ@X+QYN'>BZ;LQ*EWG
M>SMG*<7%.G'7.#]E![0;,Z>LO4-HE_Z0'S@[E(>M'-/+\"D,<!QD)\%FU[N]
M08RA%FS;SH(F(7I24U$%8%'JW&.@(@/BT'EU(.X7PL+U*"AAS:U/7,/7NC-F
M(N@&"?-*4FY+O=U5]<0NP\Q/BECYJKH7CAM)])T(]JFJXR14SG+`!31`;.G[
M*:9X)&LBB6P<@K0+UHSB8KJ^&@.<'!N(.E(]0"R/&N4#A,(X($RPX9,MG[PP
M@B/20U++!.'M\=YX6>A#L&(8%;EZJN"PK_QV_MNY-8=I,($DYU*`ABIPZ"%!
M]<0I#A%1D&@)X;X,J`/7-Y-0!<XVR-OOH]`OC^A^+>N*PSIB;]W9&(&M55R/
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MZ13LKG,=-$BB+/1H6ZTOO&S[-DH^:"<P2V%8[]O6C9BX@QL1>9B`Z`S+R?3Z
MY%8Q<0K[->M#,RSB-DW`(P_>''[,<'`=5P&^2Y\XVF$>XNPBB<D?"O(W_F,2
MRUA5J@!&^JIM^S<:\;K<0BH%)6CT>$!?`'1R)OH2':/+CU]8H.,WT/$C%B-^
M[9".DFU-E0<(<BU7Q:M`.F<0QY5")0,YJ@C.IZ^6QYN$A^0.`]'#"#?N,1X2
M1<1T#>TDW[9EH"<B9.N-H';SDR>H^A!JAP&1GS5UGFOI#'9HFE8TC<O;!/)7
M^+</Y"P8!3L5H3M9$U/*M=0;FU"HY].*EW#WZH>=%\!]MJ<QU[9'=8+(*>?7
M?W;HS&]SU4.<,(UUE_F]SKE.7:ROY`!U\/V,;DQ$@>.@O.3$P46R`PK3]8BK
M3G0K3S5HUEP-561;AJZ<R&X!SQYA*JK/M5-[8EPL6?@+P\VOS7##I1D;*YN*
M9(CP*/D2.G(XH[+9)6D>_HNN8;6^Q(]Y&:)RF^)=6.QT789^@+;]"!646]JF
M-@>N(6%6%8J&ON`3W6JO8(1GXPT<D`P$\7;6C;LRYRI9?%6VG;6*;HJ)FKC$
M[+]KIXH+;Q_F7J1[1Z$!T98[H(5T1[E=.@E]44[_$@ZWM;*G#(1K5P.#D+[8
MDO\%C5`:I_@LP[SV3A1ZCV'DV(E>G[>EME6;L6U*,=$G>R\,Q&Y\7YEF.3S;
MUE4!846YY?/&=^-'2,\PP+)$QV8QK&&LI6-/%?G4JCGEJ>RT;F:<+ZG.'&!+
M.\$Y9$@%Z*I:T;(>`Y^/&`!7#:@BL@PK3Q^5\99DJJ]T4'')T,O(H&OE)2)G
M4[.04Q2<'+);[P`QT\-M_"E`]XQ\&V5%O5).1'RF0U?W)EA6Z.R[T7'0R@NX
MU=#,=[.J96E,"Z(WCP<A<R/?`<L="]^)J+H8PEQ4F^S`O;DACB4RSM6=U6%.
M35LHY$SK+O8%L\YR^=/462+`[AE&,0FT'&\.P9Y\3H8VPR\2X^6@R>SA:T/3
M*6?JYQ+WJVI<!W[%8@FK8<29+I[7B;/X)/3I#59SHVS5LT9\6!$L!U"W65!K
M!'W95X%KN+*T;D%85=VY,T=TOVK;AQR->)J6IOK`)Y<Y,IQTIYDC846KYY<Y
M8BB%0S)'S$1PQAI<WH%'>2_]/XHPQ00!LJK\<$NX((?NFN2OM,V?JG>K`=%:
M72X=I-O-\@Y5D@&?CLKY"T0A+%B#V1*($Y[*,)S)"K=P0$_6:,_GL?Y&(ASM
M%;'29FAY.2M=;GXNKL:\+L8S=RTF=2D<*)`U*94:QYE_`_=A1K?!%9WS-HR]
MV!]RO-$Y7NI^S;$+,WUB:>J>Z@-.'V?F)=GI,69=T>CY7*L82IG)]8J)B!W_
M,V\1X<3'.,C>$I)>9UE!EHU7ZUJI/N5S2R\@>V6$^U%LQURR.8S;RUFTCDRM
M:*<3,C\<O;"&'B\$5>P)CGZ49"#BY,]A3)C8B]"^>(Q"G_QEC5/RDS,BK\S&
M/<5WU7C8CGB^3W)L&ADFA&/[8"%!4,BTA!\?DS1-/@!S%G&`4Q3#5&=#I_IV
M4;$6O70+GXL3.X_S^DR=UDF=57>?.H=1AQZ0]S7J?,+.Z0Q.Z>SZ!-:ZC`/X
M+[@-?/(BN#&\I0663V-==.V>%FS;ME"3$)UG-+A5IO^H05@@!@-U!(HY%`LV
M$'U0!0'_&:[*0"TX=#<X`G9AM7U!/<ZO"U'K+H^)4"NY0082/:\J@]*;D%I"
M_GF\AHR##NT+B>+DB%6DVMWE!W_'EGLT`H$ZU1[`7"`.M?9Z`.JPRT5"1]"N
MW>%-0"("ZHP2ILLS<B>Y>RSID3I'(XG.@`8\-.#>B]C%0IAE]"8P#LH+AXLD
MR[/5^F&+K]FERRV]<UGQ*Q=5#VB,3UEMPS.83)W)'=!A>$VKGG.05$54-V`^
M0(41T.-#\=)K,&W,6ZV,3J.JWPHE`#&N!48EW5;L\K.D&_0HJBY&Z9=@!/D6
MXA]#[&NH_!SX*C'7T%V*Z(4S3LR(8MK?ZV<$&3W]SZPN3T(T:)K1ZC?TCG2Y
M@S0^]N<<!^?*/DTO(&M.BP**+:^DFD/[3<"L!6+S4#71#7]C,'9>1)1J436.
M..EZM$#DGQCO:)>OT]Y*87S2]\L=9T25K^7>AB)3#W`G:L\3]\7C/[&?0\G9
M/0\YTW(7>D!9=0=ZT6SSZ)&K4,:FL,K&Y22'#+DV=EV&^N1U$MUW(?W,K+`:
M=_=;6276GK&V<MFKKMGO4^O%70K#EJWL0:Q5#?C82ORD=>]BHB=V_5QR391<
M[:"MST,J!DZ!"6UUQ*Y*4J[62LVQ-5J,RT';?D?0(T-/"^T%:I3VM-Y0>T+,
MGT7KZ=&X5"_V0)?[YRP>0?@%9_FM%RIW,6W,L5>'I;'P=E4']C."WQTP@SW+
MI=?PM$XAM,@-^6!G#%T7E_042FFQR*P%49(=?O`^0I1/)UOWU9UH3+=MD-KH
M=)0P@:8]=(@%AA^X^B;OYS#2.=,@8"G5BB,=_#2?.*S2C1?S&ML729PE41C0
M_[&,@UMV#.;UM_D3CA=5_1"ULR;&^9@MHS(6J5K%=FIP:7S9$3)]0:G#!O>I
M@HZ.X%ULO#DJ:TD-RIA\-6.PIY<7*5ZM!V0^MB'8MD>=2+4>S>D@X.5ZOL\#
M_IBC-P3IW\>/%C`W44H(K>Y^6+Z__G^7#]>K]VCY_A+=WEV_O[B^7=Z@Y<7#
M]4_7#]=7]\[9+3$#JB4(BKAOP(T[]'?.5NNZT*H:F=[Y<]L-!81.^8B.9JGL
M-9WOD&Y7W:1.=:VX0_-I8+X67AY5(P)$#,"V_NU"2<AEQU&N:E\E=);WU_=H
M]98HW:O[J_</5`L[IVR%O*:D:T6,-F-3JNK3M\2]\DW:\8HA6.MT)T-*4$8:
MI*4<[9)J5M\H>4^TOEV:C^7NPTT<KD,?RIFT5@7ZBJHK79VM"-6V(E=&OM7(
M[S@1=;*LFYK>'-\?W[U;WOT"!N#^^H?WUV^O+Y;O'XC??;'Z\?W#]?L?T.WJ
MYOK"10=<C\&5#(46=\^:;-M=FTC7B/0#LI@+WXMB1]YMO3I7LSB7B\9%>1_[
MDL&5-M$!_CQ&J1L;'"W8MLV.)B'T&+J>&>*F%1J*_MWJ]NKNX1=Z!W3UCQ^O
M;]^1`XES=L>$VU43Z759?<YPZMTNS-F=;QRP_-P-COUAZ6):0.V%6>NAWA7P
MR>>S--@Z!+6$+XO1Q@;;WA-YK+_GCK&YL3'3A&[;G&D3PYSSW31HPPFP>O?N
M^@',V#VU:A<K>JBZ>N_DB<J,^=6RHTTX?\;+$@@?VR910%@%S&Y^@$HVNN:L
M!XHM^]6+7.M2H#;A<\2F()CCHH52VSJI25+:-]O,.(+Y40=LV_+HD$"=>]TW
M.(/P?EA=_/VOJYO+J[O[S]'EU=OKB^L'_IY^]?;J[N[J$M$QZ/['-W^[NGA`
M#RM$_GCU[M;)-Q]M,5"[XM.4@?G$_F<O33UF'^_"S3;/F@O3-4:JX&Q9)75T
M3QF]G$E=2C:W+=_N&2K-_95:++W-'1!24GY(V^8(9EM-U>Q"1LA<CED(=026
M=W=+<MYP*(E49=E5WFA&,URX&"=K]*'<$*B%@8,7J-JAI,BKW&Z/#"8J/7QB
M"6X9]HN4%=3)MUZ.-O!'2$AEFI_^,P7!@1S4*@.U-NN+(BN\*#K03ACYX4M6
MD)86WX!EI(@`]5"VQSZ\%Z%]&OH8?0CS;1B3O_LXS3WRKSS<83+3VV''LE>%
M8MV?L"J2Z3ES5$O^H+4IH",NY<D['$'[%%J8XA[*!3^230W*3A^Z]G/@5^SE
MN0XD3CL3MBZ-=9"(PV1%5A:(@CVC<%'53<>Q(E:CDV>U9P&X&Q`*'"P0_HA3
M/\PPUPE[HBMH[6IG_)!QQ*<G^78$V7%0H;RI+]?X&#[T<[8/Y\/)-;:.<<M5
MFXY.]/A^]F9Y?P57R>]NK][?NQFO.9)$*9WHQQ&G^;0-7]>ME^:'!V(U,JAQ
M8M!%IQ>.+1=$`<&V]\^DG,Y!]4DNGN15=U!J(Q6WSSY?CG#QK`/:MG73(X,&
M([M_^SP0]:N;Y0,Q3+=+B.%YN%L2XW0!ULF]ATX#5E<R1?I\/N.K4O&8X3\*
M8ONNGDS.P\+YUIXUQ0BU_*9J*&)C7;0J?1LD?\*4[XX]-C-_K!0"LFTA9"@J
M<)Z;NE\+J1_?W%_]X\>K]P_HZJ>KCKMFZPJ^EPO5W@I[6'#&&PI>YNB"G&,V
M.*,I"0>9:'7?_,BA6+NR[$.N=5U0%KOB,Q8L/^>`?N7_;4W$1L:OJE!-#['.
M6"HU;I3?$*JPXGSR=>6E,:$SM.N@5P7]`B95/WW@;%NP?G1/6;*<`1U[V"6<
M.T(W,JK0T>8FR6JH.F?>%-E5R<BI\>J<7?P^U'+OTB0F__19L1FV-$/CIPW7
M7J<^;0*T6?A#(WNU`<0=P9T*_3OLXY/\W08<9PRI*:_W=-DS8G0'T@7'3Q)T
MQ^0J(:V9X?I`6Q>X:7>-\+WWMS@H"$[E;(HQ+J<Z9X?5.7E8`J#%6T.^([Q+
M1"MPMHP&6J4L#E';+)M_P-J]XP"2"!F^[,72%;>^J(6\I67`JVWAGX\T6;';
M>>FA;'Y5Q@,Z8\0'BXC\8G>@?%A1%:>O[4NR::Q$-P^7^LF+"E:]+"/;R_Y&
M&=K\NGC<K]MV%T8GIE3SM(-J$/T*[W6!^(<6J/H4JGW+NBYRA))>C20%ZX-.
M-=:;R/-_/R/#"")$A=,19Q`="">3'<ZW2:NJM'7/9AIA5KMUGT*2!Z1`'-=S
M"Q&=&9PNPR<<O"64O/?(EJ[6/WEIF!391418`/XW76*O/FO7AASI4U9J=8Y&
M)J%\K=:(@48E;`3`$84.OW+XB'\`_L3T%]-/]E[>;%`+-,^>D2LMR463&#)*
MKCPA(\(T0'LOA8R'(T'LED<=5]K$E51'$[69LFMF9*%:*DY6\Q(DS$1^?>*R
MYW/9(W^BK6A>-!EK/G?TK1>F8![P=;PO\NPZSO*44IB1(UR'.+B.J8EI.-7_
M*(@['>8TC^@Z7B?ICF[),.]TVL78=E:G)O4I@\+WJ"L*+7WABPM4^R8Z?A0\
ML/IGRV/U`M4_C6K?=MN7G9O0E3$)Z??0!YP2-W>_CT*1=^M[D4^[S($3S$_L
MJ]MWSOFWLV@')7=W#M4PXR5`Y;+70_&7<$>QH6\0;P[=7CUWZ'^@EQG7\2TF
MYB3X&<.=!@Z63SCU-IC^>.GEN**9GH_MQB*MW5M:WIJ6<JG=.C12?FI+0H\'
MV>U$=2_Q`T\1CA%;W0*5ZT-\@6P(@B6BFOVPK>Z?QTZ59B#%&_(5N+8`O0Z+
M\^+#YQGO(LIN-E@F)#]@U`?AW3Y*#ABSN@UQ$I]5?W'G+M<%]26_#W9`=]F]
M4Z[C7;\+6K)6T8?Q[Y$UOVC;'1^%:*KWQ77`K>OB$KIU-6N17NGQ-.V=OF4E
MS>1QT)F.:<FI967HQ;"1:`ZX#*XW2Z/]T<+8#_=>M*SZU-,O*MWVJL*R<IVK
MCJBL(Q]:TA9\?"XZ3N8:87PUH'^/9HYI[:(L]Q[)L3<]J5V3U$D!\KRO2.%5
MT*V4AC'GQMZ;53VVGC<S*0Q"HG[A=I1?ABX_AMJ-`\6`K%M^"8HM`^75PD[0
MKS#*2BZ<(:FU#$?/ALW(@\?OO_=VY)^U+-'+9.>%+94E/*GT0[)VT:""9`\[
MLG$.)6<J;YS\]*:Z:S.V]+Y=O<.[1YSJJL'C1-MJKXY"JX'W[0K]RGZ=O0*5
M^:)C8B>)DW!;/$:A7Z6!.:>>6[RCUK7[A'$F=<=OPAA?YWC79>5-G*`C/$?=
M\CK"AJXY@$`4QO/PSV4H4UQ"^/%X$D?KJ@DXYWZX.O:C(F#/6AZX\Q%^@1ZV
M9/QQ#!29I(%=Y)S.'7UZOD]2.IY,/;XC>EF6D"_`J1[*0J*`:G>THXR?H0"3
M-;"O)62!28IV7GQ`T,F^O#EE:[!N`4WE;,@!X53(9JZ]?DTKC5X6H'/9/2F]
M<,C>XP_T)_T3@QI4VW94&?G.DNN(S41L:O40PV8O$.2D,0`N7?V98KS<I!AO
MX#$I+D"B:;P+G<7KU#KE:QBC^;Y"SD]V.Z+6.(Y9$CD8LZHEN^K5XE4%=^97
M]HRMBP9_E<F[6B_@G0"LODX+4.I6-[=5?=7.)&U;[[:J.#!!JDD610H$:W$L
M&HN^(`Y"D$211WR&ZJ]?.E%*5PM;?KJG2"[Z2N-*T1FR+&5Z[),LA,":DB!M
M1SK<$!\R8LK^%)^%@U5_>\G2_^HLT1>S)@_[&`<91+G">H@?C_EQF9V6R\.R
MKH^F#MBVFZ9#@HZ,8CJ71>^6LY'BA8-5)V8(VLO-)F7NVB:%TA[[!ADRKIWJ
MFM@Y[T:;\553CK6X?L!=35EY=[7^,0YP^@$Z+<0;*(T(M0I86[C=CBA4>+]5
MNJW1@VCEOD87Z9:\EC6N5VM4AX`J$/0>IP;$=F;+4(P;6`85EO!ZZD^(I?Z]
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MVN/4@P/F/=Y0CTC5SQ`#L%8Y5H*2^&6W&HW*X4ZX#V;()!4RCT46QCC+4,;F
M.>-!]#*>O+IK#]<-Z?6<I+\3@!?>/LR]UC[)^\DVI]KM\GR*1JM#,AN`^`@G
MC)#>ROV)5CZ@Q7/?TANWG6EZ`#2>:`HV]'ANXH6\JG;$HQ?1@WJVQ>18$)!#
MOFN=E#N%1J&-<I?$V$BL%1>=54EDTX9GOVIK+\(F59@=RE30W%G%ZJ-*V^I`
M#?$WAP?R;9.T+A60M@^C:FAK,?`"P4Q7$\`T]GE8B>W6)CO`R[`BO:PP%5"V
M-+`:FD:\ZUJVF,:.2M6O^G;.QZV0<5_D.*W68I8])@)C6\.*T>MX5*(CZ[Z`
MBXEF^AAECK==Z&%!)4,@Y[\9RU06:1SF18J)>+\-/\*_,J%$=2H;"01;JEZ*
M5*N:8SF8<ETY?#I9TH_K'H#.F@]WQC3U\YO4(O4RFP-NTXTDY=/,V;R9,^G3
MS'^]D>1`]AQ@;\3IGM95O?HF#W/_3W?8`3;^,</K(KH)U\J7,"J@G//^&VAJ
M>O]L+H+)3KQ9F"%YE>7ACF8*=R'BWB&FS9AFAY@65SH@=#]`>L!H=H-!<]9F
ME,AJ2AV=YM011QO#AP2>&?;/O,M<@UF'V;\ZI\XGADO?+W90+AP'E_`^!`43
MH!(.WD>85P=8[I(TY\4"A*M7-9"C?<^6%1V18*T4J2-H5(>]0!5T*B=U^`MT
MHBH635TQGI+HCO-UB69!#;8S-GQL`9,:^I&E:\826+&?[/!]3E9.SP+P)5BO
MP2.2#)1M/T".9KL&%8Q&U7!4CG?UJ4AA%]7*4_5NH77.U'L4D@.Q9<KZ4-/@
M1]>>?Y1V3:I*5;9L/B[\`<<X]2+0W\$NC,,L3VG;D2N6#67V`*0&U+;.5$7]
ME%OY/.8Q-68B/M7-QZ(Q\/6:^/*<.>?LA197*UD.'98>$*=)L]ER&O1)<V%C
M"`/%L:]5?+P7B)5T>074.G/[V!2>"E^;Y%"9<0/4JAX"/'020B0;-08?DR)G
M^>"<`"P_O`;:D0QQ5985)X4K\NL`L:(EW6B[%`V_OV.FU>#G4R0ZZ]:Q9Y].
M+WYRP3!?>BV"V(,R+L4>@H2]<I8=5E=E"A4S(N2E,9A:[<C0.<>*)6@O7,+*
M@@.`!2W?O^P&&Y.-Q)LD+4ORVN?G?F[HU=3=[#.D`7>.]S<XSW%:@=8[<O1`
ML:JP9<BUTPOQ'K'!J,;]+ITCQL')(:ND@TM-M.MNVK%K7@;(1@S92M`=LUN]
MTM9OP_I$;;Z;BX<PA^2%ZS@(G\*@(&>S;M^N\QJG>[*M^S(1*JVG31@'EN0X
MTN*-K09A5>[%9%MBD:M^#O/M'>9MC[?A_B&Y@MZ\!Z'3);V8T`5O^XY,GQQM
MQ7D<#.7OV7"K%[NC[I#.)9+9[L\8_[\-\?KJ(_8+N-I:K=>ACU.]B&49"%OJ
M58Y6Z]()1J-J..+CK?EB(Z#T+O2W'EDI&&]G+(4"LTGM13^G#2EH2C8R##!]
MO'Y+O#V<ZLF&V`?3@VSU_*)+A':L&9]/+V\9!.2:>$V'/IF6X@_H+@1OV:%C
MSU"\:D>AOX:;+<YRE'HQ3?)?LSW&U>XF#-8"?=@F:.MEJ(A80"STQ/$V.(7"
M?`3:GMB_\#&,P#4@0&A]`,P\!;CWAMFL&4_50N<Q(0<O\(6#,,4^D>OL!7&+
MD1<$(0M?@D%\/3[EN=:JT!<75ZLOR4K(1Z(L08^83B*Z,B3GN[BJ4\"^E-*K
M>DHXQXYU1LJJ_ZAGHJF&/'T!\'MX5L,;6IM:W?GHG6_GP4N*4+?;40VWKA>'
MXG.=>K94W]"EU^N9T%W)JETI-0=7#7ZRVWOQP9'K7`4)DCS"]8K/C+'#'XC&
M-:WUT)QL^P!]BDK+28#?G2[3T+D92L?=KIV8N9%2JY'\,B6^RH:]PKPY',?P
MFKETR<=UQP%$L$([5\T.OE-\VVK[IO$)V4J58K4SF4`X%_<W)3?UM^>9AI7F
MD\6KW3Y*#IC5B%SM`0.SR$(Q(-N*7H9BB]7Y6%XBEHVVE!4_'E+'(ST=Z%8:
MF0XF]5VQDMUO*`(ZMKE/D`8<Y#I`/WQ(-$YR4@!6CG(]**G)-YGAT&E.$Z4&
M)E\Y<*337'\]-"=&WM%\H@];G.)'N&="N-RW,&.W3Q%K")UB'X-B"V-VJU1`
M;8P%RHK'?V(_AQ%/.*,AG'!9E9`Q*5QJY6GH4QVR0%Y'+]FX<<N5DS'9'OOA
M.B0?I5T'%U`LL]9-&H8?0PO0,LJW2;'9PM^A)`GYOR<O98E9Y),Q!"E$T8%`
M64-0`E\B7,5A2/=#"=M,P/4C3OV0N`_LUJPDPQFK\8SVWB&C/P!&OV->VY,L
MB/8VXO=QT'>#ME%AD].SVO4=IU]&$W')WQ@%:`_NYI\(Q!BNX:!5)OD`![WS
MTM]Q3N\%Z1<)K>CANTA3V$#^,VO4"`VY(7*V1OX7I2JG-WV/QS[?'N$CS\\7
M9'`.#;QI^Q"BF&/H5?VO(QT(,</CS2)'.(0MWA21ET*/.2\]U/;^$<=DUYP)
M\U)1R.*+`05M/+*Q(!,T$T]40%E]2NE%4]&$P!P'GTJTT6M@]=JAQQ%M3/[;
ML/RW8?GW,"S&FE?YQ4E)@\]8289?FN@$%C;F6"O(U%QXZUV>_"\$O[L6/-A%
M<'G]H3:UYV</LTC`^2]WY=5C^JYG:TSC:NB>_'95!_WA;FUY&5:_M(6/Z%R#
M],"P<Q/2BYCX7K`^A=:4<>DZ9$R\7+@>T<:GYL@>(V7\.FI[,MZ5(ZV:?$E.
MM0K"=?S/5#G=-Y)RIEJ9MC=S5C'5RN"]D10O[<GOOA$7+[410V*&(T4BA!\A
M@HU)&"(G+X_,]"+$.1].;7Y4!.P\YJ$<\I[I.2;#QS%P$BO/&-`X/"(JCL?%
MP?AF`GF6)5"EB8R&HPL*J&5#.\K>C=-?0A9(3D`[+R9'C8^XBK!C:W!#WG5D
MR"C1_%2`YG,C>:A-5E=$NLYD)PS;+J4`L8X&W'38YPT[ZL3=EB8FRSB&C*Q'
M#SIATJ.[<RZRC-F4'&4)IPTPD0\%O0&YP^'NL4@SEB1?Y%M(G\906:[H+P2I
M#LB*B51$L97RQZ:AQCQTG(C83/L.]$#\TOJ\!?+H>.15`!QP``PQK%\0'[>-
M(PAQI%T4<,3LZLBEV.QJ".60E!W:8GNU[OJ:UCN2%)#=A!PYBJTK&SH<K=:H
M4XLX86)-\!+HC+UWH%[PGD)SZ$U)$[V:PF"H"+5$B;)CSP$JDJB0?M(OAO,'
M,-)D71S<A!Y-5B('APOV6*3Z/M`/R-:C@0J*HE?JLY1-0K59"\3G.=#EQP2W
MI>^G!9RUNR3/NGG69DSI.XHJ5PXPS\?FUD#-'U(O)A_2LLO=$*P:9!%2@B;F
MJW49\L"'NF."-3&A[=@I)IN),#$WMZJHU.QL+,`*!44*L0=P'<9LL6.F5BI5
M_396)E(.9>J(,AS*Y=-?L^.10M48C_]A9W-T#$C8BMF"(6=PNQ4TG[QJGT&/
M!U0?QS_%LGH6Z*@]V/=J%QD.>`ES$/']:;26[T40#$;HEMA)F[!&BG?>QW!7
M[)"WV:2T]T<[E(W\"TK@$A[+:,!@[0(E3VADF#L]M2;38L/2PPQ5F$/:7YC@
MQJ/OJ-G*KF-V8/P9AYLML6)+PO;>!E_Q",1;".+3?5:9<VFV7VOFW8;6(Q`/
MI.1^UZ**'.71E\3Y8CK!H>0XNQ1SZ03A!D7*W]%MQ3(7S'C<=W&.];<X"XI/
MZ8EO;JTW2I`-^1;$5Y,/,(.V6K.]IZ'$EQ#9'CPD;_"JR+/<BZ%BJ^Z;@"YX
MVR\%^N3H>#_@0$IW?;6N1(KZ8PP2>DC0&XQJP)S02I,00N"8!HP0.2TBE4Q(
MB$&O$,,IT7R;,"0*@O`DM"ZBZ'`6A%$!%RWDN!AF/*%D$S[1A(_UFB?!E&D@
M'E&VQTL:QZYBS#60TEN(F?H91:.6AX1[EI;TD-R!1E^M"3,0]MT2*Z`4FZ$%
MT$J,AB;*$C6QJFXX.`30D10&_'2$8C]N8SR<C\?V6OY:2G$F/Z73X:P?RC$0
MZ6XMJ(J_([$=)O(MCO$P$.X!NND29WX:4BM```-\\ID*_HVW[U1)8MVM`L^J
M/Z>&\"F?UF91M4-Y$111-1/1J>ZX:\/Q!%&C>-+TV@K/:!(\S;TQ,T1KBB=0
MQ-DQ+TE#<OO=(G6Q':!KWB1QD374&PWM57)Y1'.M>#=B1$[9C(Y$)^Y,9T#S
M_/Z*+A8G!GH:+/0]$'4TA,X&K4U\C#5'N9=N,)RE()_]$>`[XFGT2)#8J9"+
MSY"4+"_;4N#0F[RJ9\QNK\CW:!8-0?(BB5EJ?J;=-]#L"U9]#%.BM+*ZH)0"
M$SY(ZFK5A4,U8.@(S;VNA6,1I";!56]#6F^""BDM[U"K3<Z)M*\1R3\2B5VF
MP)5L!O4\'+/N@^2JW]X/$:HYM85&0T93V';2/(T),9J.F*H=I'XU]-%H\?9R
MB=YA3,O\,)*L]I#26<0T`K,EXA:\E?&0K==6;S7(?,Y*<3S1[G6+ANF,`8KP
M;>!Q1J6?;["I0<$V!7!6'2(E=%O2''@R:7:P>)L9FG*EY9`79X2>H-TGZ\JN
MJ[#M^F3J0MOO@"E+[!!OBPP)?2]Z@-Y`;POZFG5,W-=0/!T:V0RT'5_+E`PM
M5XL#0A02XJ#0$=:\:DH]+-<!,KC@>HU%`*E*,Z*.*W[6((4A<;.&:(LA7A;Y
M5.J%V6ANE@(\NWZ6$L(M#^0XRR$--C.6+OE91OC)'2TY\JXY6NIRJ^!I*0OM
ML!"?\K#X+HQPEB<QEK3=ZHPA$`.P%<(C0ZDC?*6Z4*C&R]IQV0E6T4&IZ[:Y
M?F^RJ]`\WJ`X8LE5^%$:@M+'C!/(BE[U5Q50M@.'Y6CJ2-!4E[6#@F#UT)/>
M5SHI5L9\IVR;E/AW9%&K+C-7L;@WA)I&Z0#EC*GJ1%--Y*JIB,QUJ++N*&AV
M2!?4K734.BNA)_5\NS4+^3^'+;581/5LME`^IU(ILNYD>MJT`Z1SUKP3;5T5
M8[.7V<3H=JF:_$/BN!.CA*:!RB&8/P,O1BS*9MZ,4([G2XN_@VQ+G<XCQPFV
MBI#4E]QB/?C-M7XC+1I+2RV<$GAF7C!KF%N?:KO$0!,-`8>XVERD8P^4LJG;
M&S`?W[P+8ZBPHG9>ZIYD2Y><+KU5/(;][L([I>:2G=%^G=PAU8!=K#%CH9CB
M,<-_%,1]N7HB_T]R42TONR``8UL[BM%K%>*J1B(Z5'9?;5UO]NR:6D4*Z999
MY4"U4-]^`-8*QTE04N0[BQ9;D\@J.JYOBZQQFYG_UPW$,5TG;A-[RG%.W3D,
MQ<9U76W@[<K8;>QV>DH/`-TSW6F=U\$FW8WE[%_DJZ[_HHKB=^!Z7G71"MWO
M>'N!8@\%;FBN@>=7F0OEA9$C]_-2@='LBC=<?/FY8>GGA1==8J@U#KNX6D.4
M2_;F\+`-T^#62_.NK&KQ3:`&6*NW\%KHBPZZ;#8Z3H>D;`H`O3D@"@)1&$Z8
MQO'P]AC>P1%O(FYKBO?C`>44[_TD>)M?T`]"O*:)=KHT<.RJ7E_N^Z_KM87>
MH4JV/743?\(9U$F$I*X]]G.HZ05_XA43P?BPHKW*I\VYUO/LJI[K$WR"8NA\
M$0O$ED%3'LN%0$HC_'F!:HLIZZ<_[PKAPVE?JZ%.ZPR6V:&X1KPG`LNZ*V9+
M,4Q3,=Q,*\RG?N'<H7L]0N?8O@WA"^\Z1SGAS/6LL_34:/:V]^2%$3TG1>$N
M=.^*H\XD2C<:-0Z9V9-X[)?1QU,9I?\/Q#&,-[0@5JU\CI;;,/K'K?H($Y!R
M`H>`_A?BGV35^HAW</RJ`V^<<U&S)$*SXA4S].ZX/S,0XK:#``XZ-U/IJGY/
M9B)%]7Q.C<UJ^S^D2:;_)#[!$FP[5=.0M:\=7C99/[P)^Y2,3(EZTXT,_1@'
M.(T.H,S+VD[/LG7)*$028&[=*YY0!XW3<L18`3T#/5ZW1@R!\\EO^+J^^>QN
M\;H)U[Y/A^@-VG:"ZY\G[EP2+95OHP,*8X3_@`MVC[:B)S[W1"W$9VQ)J$:;
MU0E%)L)[UOM%-<Q_:F!<,^!N^=4CZY-I+@;%RF3`FS%OOTV+'SPDU<.TU@.Q
M"(;5UV`Q8J(.Y*STQ4-R+)/IA.MDB`VK[Y@GQS@+AUYNU=&I/=,RLP$ZQ!/B
MZ-C+;(]T]3_#RD5K@-S?A.0@GF$:/C:HV)L2("N!8(HHGG(<G\8C(6<M>:0?
M=V6(HS1#L9<`+_1JY8Z!@*F&U=Y<ZWZ)-E7$868:HCE9SC>9JIE2IP?4X;SO
M!NK:F=\PV[GB:B,AW)G[#;,=<E$&H&J2_PT`'7->=`5[:`YX2ZIGS.#T/AID
M<#8F6<O@/%EZ*VR`_>Y&I1K-15LWQE+^D.=P=C#'`",+^5&K-:M&3^\"=!OE
M=`*P:CP%*)VR`DU^6ZW++A;T[=ZY%C:*N-0,`ZP2CK*\#0-,<DS]RUBN7]5+
M^&U$,=#H`".8:N5D*D1#B?EME?L;@(>TO)]M$5#FE=X#EY3'!K#]#ZD7%(1N
M0=62Q.!()01BU0I(4.MXU65#4:VMD5.9JF-@Y)!5T\"D40VW1.K89\@QT]8G
M3_WFK4>81NH'?PTW-5[$'GOX;0Y_$5*R>:JPK'>!ER,J;P#/YR(VN;J]Y--M
M-]88!4MB)$..)7](C3B6^XFP'-;K70]18>=5.<Z.^`J:\JK6VKU?6`=H&#VM
M(M:BEC6*6#GKL=_,^L/8KS##RA%],19:C:M5Y[2#F:PH.QV3:H4[[.-PGP]W
M.I0`6?$X%%%L\QR=9L'7T*X=,A##Y(BA(WIC1!0KQ9$>L750AQ@*5*][H2&6
M(YU>JJ/1U4<?9]EJ7;WY\,_IW6!K@K;],*Q'!OD1IW;?P8#`'X^OQB4<AUZ)
M1\,>HKWB&**&,</\^&:ZGPKM08_&PS`7GH5J/9MK/T!(-2,+&=*FC&-.D)ER
M4'I6UM<,0Y0<V:(P@+#<.+C(Q$T-.@Z+G3/M7+\(D&C)8CF.=I`G(UVH!:R%
M`?DYQ1_079B3#]#R']>IQ_^G`PZ-*AK2J)+C+@%^%_<K1WP7J:A([D(D<C)?
M5,AE2%Q%`MNL).C);-N)FBUD3OFK'.#6DXKR\M\G\1G>09TJC%'`1UL)Y]3A
M"A4;)V6H^:2!9Y[H],JH3[$5']5<MB@_R;&.&1VTED8;M0D].U_H-6CLGFQ;
M1YZB(N065[MG=.Z%DG+IV@CK2;T00_&0>K&_Q<K]"$U`.I:2*T!;O10.JW/#
M04S;IW"T7%M%I-^&:09.;AP2;R+ST@.<?'."99E;ZR<[XG_[K!!0X.6S)_'9
MW6EG3)B!2)NDS4KDV27UI=W[T`2T;?.I1P93)G>N)^+LZ#OG=ACP_Y!Z)1+F
M=TKFI;EOADISYMPW0U4LSX]29O5I<^"FL>,CHOZ,;+DD'6P$.@Z^L6]4S:"0
M?\%>:A)%+8=D]=&Q#TG1:98',S!IHU/<LJ]&R#%L#A2;B<ONF#\7ZB)5>P)H
MXL3R1QFZCCWZ*8E>_QN?BMR-I2#(00*`:[SK2:9;>=R3HM.C!^"Z`,:[87CU
MT8'U@R#8%ON!:(AE/>$(.O+$UR\ZXG>^'KDY_F>\@&<E>6[.L"+"IXN6ARW;
MEU'5]3HCC7T+K@3P-$J0-L2@"4[XR9THP4XF%TM>%X</*2-'8[18S,VP,#\Y
M)+LEY7J0;`>>T,`U'K(W0[S>@()LFJC5R[+UA.<9%XLR7ZVIEA-LH'+DH>5B
M<RI442@YIR"`(T4(+P-6^L6+JK`])?/<!\-Z/F,W8O(@W^.<*;.!!Z0OJB%5
M0Z,6LTK\NAAZ;V7H@GPT],FO#RG85`A7@Y9RJ1=FX..R*.<D15Y7'3H'W`9]
MB@AC>KTN4CGB3BB*J5HZHUA&GT&OGT8_+E9^?[5F5?>-'O/&7H,3KW[C$W;Z
M3H!EGS\01?99!Q(H9J;JD0+K(HH.]*J!$$Y0I-O^\^KT%*G7:@<>>?0BJ%?G
MC*LWASY3?YR=1IE9?\4=VJ5Q5>193EP;XM'\C*'S$1E#>)\80]Z_$=^F8?O0
M,W-C2]55.O;./-_F6.M&6UOB`I6+1'R59:]:C.@ZW0WIL[=1=8H^8J[+70X@
ML$DJSDQ[&"#R!-`788R")(K@/96<8E`&B_S2^EG%&;(:ASS,J\2?CV6MX25L
MQSYILZWV`IPX:8U,TBE-7,.*V>FI;IV>[<Z%R7'6Z-1@+U3WN9?FSE*D-@9Y
M.;K$/GWP1:_/%XCHDJ\G(LI5'#P7DORMB#%Z_8J2XQLW#YY3*/996AB*M/JS
M-(PNG"T_]4.D&Z?%?[,#X9C'F9J]M76OZ3:-JN.<I#WC')Z)8U1RST]QFT#6
MO1:KYFV.&P!7C_HW.,LPOL$>O.#7T,E6A*4]"/"$WW#V@-/=:GV1Q'GJ^<JU
M9@=^Q?:AW9@XK=9U%!#BD.I.!/@')3#$H"T0P&-MXAE$IT[>HQ'EM@K)C&`"
M\C8IQEV5*JT?FX8)B=+9:)"$S*<N3E9S1U8(5YIQAM^%,31-@K]XD7*5&65X
MMHX@&@BW7Z-/Y1K&(CY]@3@`Q"$XX/H/0!;L'DH!/W!):=MXM$[XOS+T%60Y
M)<5FB\Y?TZH/A(V=\.0'H%SN'P^B32UIKF%RI>+[:`KI:`TT_!2^=QVSJ%;X
MB%8T>B\P9\K,"E#MZYW!)I%_(![L?-?!@E9\A1$PI!6>.89A+!.RR0-)1T6Q
M.Z)4@*IC^:"JXJE7]E4BFW.>@\@*EG'`5!E7;ZI>3/=D6RZ+"!4]_\0!=T05
M$;ILS'Z&`JM^D:;MD!%KMEC*6E+#*^.K&1\]_"T.BHA(ZGV>^+^_.5Q$7I8]
M>(]1EX#(WY\DH&P?]N5HMAX(^&@:@`SCX36`SD"_TCGN%1A4V$>U9[S>31S@
M`=[C-,39<A7C6S(,@R#3KV@D]/>`L))@U(M6B[_H!`0S4#6%<QJ;9#N]R!BE
ML_,:1AE,.:)B-W%&C?G$>3.]G&<M\TE[L^H/!'$2D_$8[T#$4<:W$>V;FPB)
M7_7W.M&X%TQ-ANN0_.5#F&^)RTM_V"910%CP<X3_*,+\@,+UR9?)!^KK()2(
M#O!Z`24DV=M765`RS+("IUU?RO%NGZ10>_+X%0"Z8_-#%N,3!IC"\>&>+8E.
MP#;9=;BR>_B0*"H[L6O>`\KJ4;<739&F@'*!,RD_XU.N,7)G7YWB9D<-&O.4
M\F&OES>MG^.U-_&_U>.,ZA$J1@WU!L5`;/J#,M2$2I&6"W-#+8Z*V-EK-Q2B
M`0^I>H8R+K3M&^ILV7^KOS'5WTC7-)2B%T,\2150UJ]II&@*=,M%2U\Z525S
M(&XG(N3>Q5,_9ZI=//6RY7S21G4'OP&["6-\352'<M1#]V1;[P4B5$[YC=UN
M5O>=O\)81`>[TWQ'NBW2NW;9GLS(5DE,%$@>$A/69'.68W\-)B;X<9_$;&#6
M8>/[I-'D$[:5OAE96@Q\A')J#Q:\B@ABH%!!8*$C,(>*BXQ#BF-J&_1<(;AF
M#/VPAKY?`8!Q/4;&JMT<FR:GOBLD^I_^+2L>_XG]'++4:QXBHQGD=X0Q^:4D
M+IT!:=B,S%9RKT=7"CJFVUSIS*=[FPN["<D)(*"G*/8#-"92-?`JH&R9>S4T
M.UK)-O5E;2(ZSH22MDR5.A'=9X9K';5]-7!Q3+9QQMW18%FI\Z/.K[;$\3)\
M@J:RP9V78\)CE[2<Q7*7%.I!@?J`;;L].B3H%=AR.H+Y"Q#4,P;BC,%PR,<9
M!^^,X<UC(X,2_92B;U661V)/'0.LR_2VY)PM8K6N_EHN-;N&;"OH&V%FA%4`
MNV&2U4C0*^\,#+BSQY\J2!!GRF$Y:*B'4H!+?A$'V">,3?X2U!'W&(AZ721W
MJB$9BX.&@5>7A2&Q_(1OMIZXHH$DS+@QTVZ4_@D2+9[COT^4O6\>>Z^Z;II&
M+C&'%A_E^W"H1]*7!0,\!/ES\/[#[C/V'$;@6B1]EW`HA,UW2,;,U4_T"Y0X
M4$-$Q$(7]?N9)R\J\(228%B*HV?M][6UJQ7ZLV+@I:B</LXE:;@)H;0ZO8YD
MTFW:B:)_-<IX[Y,LS,,G8<N)>Q4VLEM-0;/@@24]`QUZP&9<T4=X*+B0Q*#G
MEQ]#_;KM4F"V3_A]J+;*O["PA.,X]"N,=##90&4/U5Y]%39P/MX\6<1ELO/"
MKB>X3A'LGFS+,HI0Z>,Y]"L;ZLZKKW13I%I.MB/S,=7/'A1\R,V"=9J3;2NT
M4U1.F8G_[F;\C>+BW>D=)64@)>W:Q3USACN`#ZL1TBN>:"UZI@,%J:ON1&M6
MT]4[H_*%G",/\A&PS9QGZ"3-H8C/)7[,'\C7C'S:3B"V5;\(M79M33+N#"K`
M(!BY0##663]6ME^*56_%FV61[_0\5]%T>[<Z(G04N<TU%[9G?WJ.ZK+-L1*\
M^#[)<7;K'2`6W\RME0.SK>OZ4)6%'M()B,]PTQ$>#3WG]+D2C^J&M`D9=#[9
M`]&_CK,\I8\M`J>B4_-TS+2EU3N1..4U&(2.HRPZ#JKD5-'APEVPQ4+OO9W8
M1Y"*F!".;:4M0;"'R18(1EOU&LQ(KJ/0>O9M0"C`PX?D89L4F1<';\E6YQC'
M5&5JI/'V@+"2Q-N+UBE703V#<@8JIW"#.9D?H%G694RD'&CYK(U.+:H@C-=)
MNF-QP"F./-Z4#G(]H8@\P]&1GL]J(B9.4%:2KPE4P"K6/!\H0K,:-:2"K(YN
M@")03IT3IL+2H>@C$^R>A>X8(E4J[H26@,Z>L,O?.U;I'31AJ#H88[](PQRR
MB[THPL&;0_G4PP?JIO8:?\9R$O``\@C3A<LGOR1%='"C=WL%&3'04$:Q!%[-
M<*$V^O@$JM`D>J&,4T1>C+S-)L4;HC'JZ9DV<BYGHD,[%Y6^D_D5/WRP^.PZ
MB9`K/56-HDCF3.-(?(R#["TA':1S>H2LM0AS%G<>!\>$,OH7W;L%PZ_8OGDP
M)DX[4I(!0L"AJ`353/*XKW*6:WF9G:^W5N^81Z/)#VF200@XITQ_KKKUZYIA
MLJ*8[S5`4(:<\VA_&JZ-6%JWVOU.QSP[ESJ="+3.,?">N#KZ-FR@_?)K&JLG
M<E(:5E[VP87K&J7UU\Y9.4<%#E8GZ"P@U^OSV_B7^%U\^1#_E?S7_>>('<L6
MM#D-_NCM]A%>D%'GOWSS[OSUY>?DL':$O866-ON$UG-8>SY-IDO(6?R`O91`
M")\P[V^SH.HVWX;L/!MX!V?NA<3R*+D,$@JCY?-:HU=>]6/E])QK/S(;?<2V
M-V%*&HT36K,K;6V,M4/9+!1I=Z`5G3WL/L\_/W2'=K<?"V7W.L/:0-MZO]<)
MM+)6[,8`O3_`.7[KA>E/D!YVBU.:7Z7D&K=G67&,NQ9_RF8P!M%!CA0"TEOY
M2>K>7/F4^FZR"D;-1F,<(X8A4?3'PF:ERG?$817*B-A=%0G(`$F]##.?UDB(
MK^,P#[WH@E#I0+0G_8[66V4/**L/E;UHMN)B^`2TBA&?@LHY3/"=<)0&(@>E
MGCER?HG<K!G6YL^6VDC?-<^[02\-''NT5)/4_A=+)3&U'DNM_`PIF&XO2TJ$
MCG$HL9W7+V4\?HSW7@AE0\/8#_=$BH[502EN<5>`E,5T*BF[]215R7AM/I&Y
MCG-,^"#GW[^`+I!QOHR#]PEK":E?*E`%I.W;(#6T3]FSG&5+NB9`:>G[:<$J
M[S+47)&XP2RF<[159]EY(\N/A7TORAK)QV#C>A7@KDM<8:2]!E2;20U:R'?&
MHA\A+%`%HQ&AWBA@[H2Q'(SYQ:GTGM;79@"<L:)F?-Z;%Z+-Y`Y)]O$6;44K
MI$N$O#?#P>Q#MNWS$!(9JH+Z6PV':4DOS$:97E7A;.V.P2*DG-PS1'YLJ905
M+P4'?V5E2PW]@RY`;K@$W2CVBGXYC:>U3U3$>[C=5T.O=5Q^]"*(67+4MDO8
M4L.<BWER2-U=3+8XSKT-C?<*?=ECDZ1`J1"*W7J\$N1:L9+56(C48H$,UEZE
M1D>)ACD"2DZ6[M7`J?E.)48/407Q>"#F_(F<;Y,THS%<K1.^8_?3O>*H4/6W
M1Q;GOV*[^KC'<89!;ZE:XZZIMNQO-QK"*S(^;$$MK1,65@V!91"$(+I02+?$
M!;,9SIA5"4=)#:F8G48RG>6!(M[48F>HH8X#?M-8KL'8L.I\PQFSJT<8N5$^
MPD+U""7JZQ)PJ+S2+0&Z:;5'HPA-@3J:LP#(`"$:WLG-MJ.6?A@=A'Z`?V02
MVLNYQBA""CGL!!@H%CT705^KV*HQ\];SL;"'ET)UG=I\-TH6-1#JK2D#HUT[
MMROB`@^]J'@.9W89MVE49&JQV@`WX[[6S_X2KT,_S*M4K*HO)FLO^I#<5<U%
M'P0!(&*U,^A#5AV.@23J[,S`P2$.CSH8IUF3'"9Z2-`1*OJ5PAV_](:YV1V;
M/OX6!T5$S6V]<@4QQ+D7QM3T)BQFE'_T<V)[&1F5F^,Z9I/'D,)^PSR""`[0
M-'?$H2*$VI)/7N(G'"5[6EUNDV+:4>$F].'PI%&&2PN@E3!U393;7BB;3K5#
M#0"J(*#_Q]OM_P-Q0-/5Y=&/"A^,>F?U&N^1>-RHHHNG1I>6L$OI,29:IBZ2
MD!,4,;;N]1@32QQ9;R#N@SH&@FZ$BA;L";+ZCD&%L#Y8EKL*]B':[M?'_!68
MPY_T:WQHIW;@V/AY(OP<\KOT,9-JU3U'&VK=H(2A[94@'?.7%*53I8FABF@.
MT",5P%LOA1HY*M60Q1.M>#$"%%HW_)4*X.,$U9`M.".*&$C%HQ(%]"',MR@(
MU[18"9$;!M.1E#49OXEMJX391N1]O1+.,A!6+:80+06)$!1MMFA%E+%Y?M*A
MS5;*9D/*E@,DYN])5-PF6^_WX@'[VSB)D@V!?A/Y&L?B/AA6;$@_8J?L!C,0
MFX+J<Q:(S'*C<=7XF-U<.&`M]3&2J@8INNB+S_Y^^_#9EXY83T7Y$QM2->$;
M14.\\V)OPXZ^$OT@UH%R2%8M;!^2,HDZSK"K*6;`SH*V&`\K99UQ@C+5&.\L
M:0Q3:5)V+%2$<O[7OILPQM<YWJF=7`=_Q(J',@)IQG[I`]B(`G?A$#T!@2B"
M(?QX+'6(UF'LQ3ZM]<"$$12$'Q4!#:E!'LKA/>H%>MB2\<<Q$)5;9*RR/12.
MB(ANYA43:6^SAI+)LH1\`?)QV'&%NN]H1Z4LHZ^),?L:5%A,4K3SX@/R/N*L
MK)O/UN"&TS*64(N]FI$D>K[0'L%;`605,9UZD<1YZL%R;W$*C/$V25=D8],,
M^F_C.*.,<N6E<6?-6&D2U;@?MYTR.#8IU9^VCI^@N87T(R!__#,TXIY]:('J
MGT+L6TXX?'-1\=8[[*@OE6(?AT]0(Y909\]`0<A$6B=S4",S^6;X1,NW.^-0
M32K%2AF*4XCPC-HO.7A1?N#AZ*KAC">S;`4QMA;?4AAL0)D)X42T8N^BN7Q"
M3-,?A9?F.(T.*&6SK'L1<KZ1!B9V,LV,G:3!\V#)P9=%2O3<+2OM6JM#0`3S
M'J=/H8_U6YOK0;=MJ;6)T7E>X<GYB(%`#$99T6-1_@K6I83DP$O_:"1H]W]A
ME4PF*DH_Q*48OMTRU*P;?S/15K+N1G)MN=J\*.!:O2?0;)'4ZBV$1"'`PF+P
MHNAGM[HO=8;EZE+%":X31*OH5\R>*WI%O]*V(!9$PH+6>GP;DEU'-?9MGF5^
M%$:0J`OG?!$DZA(OC+F0<*'%]M_:Q#96A6/%5=R30WS\"SG2EY6%#-Y+13#L
MYB8)$6MY>S`2P=!C22[WWD8U\3F#[D?3-0H9D!.EC,=)S>N,;E,#+<=>.GMD
M22$-22I(EBV,\E.G(A2G[(SL+4YB:B3OD&Z9&[4G+:V=L\R.M:SY4?SP.CPG
MW?$FPAI=PFH3GT?#*#FFGT)O*"T,GV$;J`[A-#]DM25S@+_;^84?X-^*+5"E
M`*S$Y_2@U*TI:EU15Z4YXW/L1PYK8C35NO4C@3077O-PX^IZO>J/2C1X2GN:
MH0V#X$A4C8H(B2-F%.1G;/$N6\8%5Q_W84JOL-<X[!9XL7>O"=KJX5>;#.I*
MHH*".!A4P7'GL#P8_VKL2S[XY81HFA^F!^.IJH%P10_,Z;$NH3IV"#?3`/UG
M<R/QGTB3J;QXJ0%QQV%IHJ:MCZSWGC+%K/9KK[/OBD<CQ^B]@B)Q*$A85=`T
M79JVE$WEU@@ZX8H/-8;*L^<[[CH\O032]WYXH?)5K>-Z.2:S=8Z:BSJVCEMS
MX7?2;_U8VIS%#:,B#G,'#VK32/4X_I&2ZIA9/^J<"O6LAOX7G7/#3(@VLA9U
MZ*`Y/^V<.G_:0]]`!;MV4IU:=0SR3DTUE1U5K5U9=^BWGIU+._`0K:20G>E#
M.Q&5G#J06T#<1.G6`'\"OJ_D\#_=?LR>(,2+2:_6-+K_C4>T?3U#KY;2E[TY
M',?P?*TEX8)`*_1^O`_:BAP:DV2RVMYTYMDC3&VF[]8_`#VVZ@/+/#KZ%>>R
M`4;G-FG\TMBL-J-4]JU7M-RW7IC^Y$4%7F99P8H,9)![Z!.G[3)\"@,<!W=>
MKNP_S;<@V\%6<Y"\,\&L1\*E`@YM2<(4T<^CVO<7J%P!*I>`8`U..&PV*5Z1
M)2C)<@AQY&!RWUP*0"T?<";I?^8*]J<D(F"B,#\`3N_".-P5.V6_:+X567.<
MYB2Z#5U[7`O5M@O$E^-$"0:KU*](1%O.G+&CY5,U64@I>Y[J[`I"[LK.K1T^
M+57L?12HXOF-</?*/DGO5[0);JAFMIQ/WR-6W85^%=U-L4_35Y8J$'M.LTQ[
M/%.5?1=FO[]-,2[;G-KVG67K^20\9SG!9U3.L!`$*ZE:1G_J;K,>Z6'TV1KH
M4W6$3V7T^32<905],)^KW*\,/B6MZX";+%O7)^4DRS?`"2W\J7O(>EL@UL;_
M#GZQ@KZ8WRON5Q8S:^?'?L0>==S]!YSNSK6\X&E68-7OG8JH-JXAX-ONN+5S
M41;^#A$-K&FFE3K:<TN,LJ<ZI<`.:>]+JUWPR`E:\E.GU*$,A-UFOB*T6O6H
MZ4`(@:1#65E?6PT[1\"GEN'+"IF`/+*X/EK?UK%X/3G[*;2ME?'>J&*A5G%1
M/ME*WH<$%45AL-6K<Q`N3@J"!J_(#(L*EPU@?BA)]_`A>=@F1>;%P=OP"1N4
MB11#L6H99,B=\A`M$DD&HW(T@N$.5HO408I\SJ7`=IVE,WU$:T)V86'7E/5*
M3;\UZQ.9\63Z/ORHT4E7.-F*09.@TB_`9+1#/7,U4"%?^=8!"ZRQXJ:TMA9O
MQ][VR8'8WO8(P7BR>45KWR<G?WT?QB-8X5[8+MEF!4+T"SP%`@TEVS\!)/>-
MN0$5R"*^0V<@==^[:^D-\&IJE.^@!UX7CD[Y`:K2K.T=*(KR>'KI`<>MSSUL
MPS3'.#9W)A2@NN!E*"'?KXT(F&Y=5,)RUSDQH@!AJE=4$YV_=L]Y,<*HH8,(
M<E0'M;%SPKM1EUAEMT=97$>\?R"<(=4QZF>R)B27?)T6D@IW$7R*^RY,+W*3
M%/(>[TZB;_E-G=#"Q"E_I%N:].\FND3I&<1(W>BVM1CA2\\NFO1&TAYC\.NY
MFVTTQF.H:8(63[EI/E%K=K>_2&)B%3*R:+)$_9YX<F"V`__Z4&V]EY7C$9U`
MN[/S*8C.<<82:&VF4H"7RD[.QZ3JN12J>E\#HBW]KH7T*>_J9E(Y$<TT"./C
M`&>LCC[;2JV+-L_:%="NL$Y=@Z(,U[9MT2"`JJ@*(KJ=.`:.@+8@$-LYFZK+
MVDKF59.OW;"T$),XAGVE<%RTJAQ!;5OJ3#BP`7+OO+Q(P0OX`BXXLB^?A?&L
M<Z*QR:RQH=U"?3\D29`MX^!]$N/=/DH.&-_C]"GT<?9`3HZ9Y\.Z1>7YY,DC
M`S]GVZP.)Y=J:3X*%=%WXR-<5`)&-<@VR_%-NMDZ!FP<QII/[N@MRR6QJ(+X
M]TX5U)QDRV*=+OV4H]FU&PP0!+9;4^&=1)?JZRZ*6V`2832X5/Y.I]M6GFUT
M9*PC"`.WKM4$FZ*DI;IW9,#;)>UQH1-`W7[$[0%A)1JB%ZW.KC$=<0Y6`ZA'
MPTL8@FPAJ$$;A5IFA,<P(9X.;66S@%2)G,@!M"+.$X3_*(CCS_T?O_[8X]5*
MZCJ22:$F>>)`!R6Q&UDS&`9U]H"R&M?0BZ:JIG`T.M,0OU)CN!20J8W*)Z$Y
MC,5*.51"23Q'UB17$7[2"L/L!>*,GW&"FJK^8-,<]S64<"L#B\X=]39ZD/@D
MM(:!`!EY'!TB.+*F>/B`(Z.$SEY@SOD=)ZBJ:@XV[9GX'DHXEAKD*\>]CQYD
M/@E-,D#`!GD@':(ZMF;13P91`..,']*;&B#4)^[E=@S`K]0E+B1T&*'Q26@1
M(U$R\DC&SN[HO&<Q3_%0`.><7]*;4""\/74WY6,`GL+$"<>\DUYT/@G-,DC4
M!GDHSN24J+U3WYBGDNA^P'X&B3Y)9(DC.K$4-TYGBQBRBF*2B!F?/(,TK!6+
MM*):(+N.62VKGS&DM.-@28R0M\'T1WB;K6*TM(.;9EZ>[??\^;=C@MJJJS)Z
MDJT&A3%BZUF@<D6(+XD-8>$)QQA,)WPB=[;D*LO#G0=4JX6I0H-G5N./>"AD
M93NR1321QQF/P[**F;;(]2#]\ES5>X70=9RG89R%ODBICYNAJ;48^Y[6M*2>
M5V'7]'.U$CM*VBFBG]""4]!![W8&L9\F7=I`YI^/6ET5>9:3PU,8;^Z2*'J;
MI/#CW,ZQ8!7/W0<6$G=*S5G[*/H5/HOX=]VXX)N=MN\+N`$"WW1EKY6`#>F9
MT_N4"O"`"_ZAZR(+6>,P+PAW7WW$J1]F&.Y`KC[NPY2"JA2ZTA/CC,NQ\E0Y
M*[D[E2!Z(U>";[@2Y.-$2K"V$%2M!"TAE.NX%N)'<N_2@>='JZ0GDQ%_;N"D
MR;=>#H\)CW!CFN-T%\8>IVV^Q2BNE"HM@Y^A(@[@?^]KLS]@LDV^1_1B%)&M
M"HJ4/EB0V2G>)VD._XN7T_?@D8.`*:*<]GSQ_2)-,9D)_\L[?I_,@)"F'&5[
M[(?KD(`E)P2B>_/4\_/"BY"W23%[\#AY)8'OTBZU?)%H3RB`,"=5@`@%Z*HQ
M$`P'K><2<Y;XGK%$C#=P<Z+^KFZ5(\H9P4LF,?`/#A"WQ,7.(_7\MD'\V#V[
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M$ON_+^`U[8`+E_,*1N#Y'*QJUW":=GBNNTG;-G>N6U`3^SK%U?_<MM.1-P$S
MS?UO]U*@HZ2=V+KA!R&()[@EFP\_:50JZ)IGYXC0B4!+G]"P"1A&>=BAT@-J
MZZ>+/B+A@HNONVZFI!O)O?L.5"SY@6(QD#AE0AD8()#79.5Q'CYA"IVI`X,Z
M`!(P5O/_I>BU$P/X8,Y";+B#V?Z&6-6#N1Q*]M?"II;DWXA-8]%W1-\^8I;S
M#P%J<72@Z?X\>9?E/!-A79-S=NY])&-CO`[S%^@Z1U4S,0]R:"J2L2P]?E@G
MY_!_%%[$PNCJ/.):K8!^J>ZO$=`KT@.TSGM",L(I!1E_4%$\;0TJAV#%->A#
MJA5F7QOOAL89&2>K^F8X+HUZ(K!0N+>KRB4TM,^';>AO49BA"&=D=/!$%!!Q
MGI,B@_L\&DG+)Z8(Y!<`$OU#WR'V24A.D41_Q40]U55/[0,+]%CD)U^!'D3$
M*:=C0:]MB#)+O8BH/.QE(6BX!&4X1\6>_NP%NS`.LQRGCE1,4M(!8F](10$,
MT%!7?)__FD30=?N6G(+(OJP^$!IGVW!?-H$R<)7T(%OUGG2)T#K7E\("`!"!
M@#@(5,$X-D]SS\T:#?TS=/[J?S*!WA)8$T0QF7M?0Y&L:\GXJ!X_;!,$N**<
M[/J>[WI2[7K54RZ,J7:$<YH7'QQSHXR40+]G9:(!!JBR%;PKE=_4<+&ZYEEQ
MK+H1.&5$.@I5,N>.#Z6S_%)^''"7U);=%/^D@03X2R#<9"5>'/Z+?MH1YT,B
M$V*70RP0-D)#&C>SESCSTW#?M;E2#3?^UZTZ+%,0<X)8C.8CT`+5/NB.]S,'
M+6N_TL-521<6)@%'I_HIJ)6';M%MFH,Z-=T*:C2H$2O%D<>CP$^(5HLM";.L
MZ`@9L>M33:;O^OVNJ93=`.W_0'[-P$_F3J"WP:LUE)QZYZ6_XYQ62"$_T66M
MXJJ$RC+K"RAHF[R1/F7%`QR-3*<B5@%&1\AHM6;%VAAP7B7HMJK9MHKKE966
MF>4W?2O4VA^I113.&JBU8]1ZJBK<\;OSF-W'HP"HY65B?>6`SSL9Y9IWB=.0
MD0UD[YX>J"U7:J./J^3$_OF(&N[XGV&WB!^Q7\`-[6J])J!3&@17OD9I',55
MX%A1S&H(=L3[L%FHG,;BCZMW.G<.[T,13$H$X0Z^>HAT0-69(5;38W4<V0M'
MG$.C>OH2&Q*$]_1E@SFI\/L^R4+JO#X>Z/]^3*"[+9D<A"GVB4B=$*F$:_-N
MT$P4>S65NCS/%_QZNB:]IXT>*+9#2X7(]:HFM]XEAN/C7C$W.>,IQ3]*N>[Y
MQ(_7PN95BZQ-^>GG6MJ@FXQ3QGS7<ZK"R4JDV2A5H$;+8\7(\NYI[4SBS0S"
M.6D9`K%D/@/%1O^:W1).W\)/!)?EK/4$1-^W[8],0-`)]!O[&*J^1F_DZ6].
M.4,S$'-5IFLF:,^'PWNGM]FD-'\2#BG0Q8$]5\0)BA+R[12"3;,PP&E5L&6?
M)H\TSP7*-/K;$#\=-X)H-.JWH*^^Z<Y]D5+9(K7Z=[D[V=1-*EMWB*?:H6E3
MB>2J=L@;"4YWJW7U4<&RU-Y`U$#9>>-01;-U*T\FPIO%\<%9J._MWZ<-P[(1
M@%M==PM;^#EPS6:,;_WQEZ.N@+$CEV1Z(BNYT5>75[W[^I'<8K!#U_25_9+6
M:F;N.=.$M:#DZH%!_3BO#]G::=V$"#,D8$]Z%"<BJ7L0'X-,[7-V58[;NN`/
M%PKY,=I4(F:\06\VB>SVI-XG,2O:2-DV>TAR+ZK_?I%D^?LD_P7G=]A/-G'X
M+QS4T=.^D)]E4;;/TW.17ACBSS^,1(IL@:JO,X5%%%5#T9$/HP/.T?'3BV:*
MH5-';EOT_C%.JZ%-)\@GP$`QQA69V2F114(X=\:;55>HO:',J"@^`9W,S`\Y
MY?(_P;AS5?=NYE79<@UG)_YTZAE6T:FCV5+HS6AM,4Z\_5@G?[O\'2,64=-M
MW8V;E:V/>MX9S]:.+I%ZQ584B8UW)[5>[&\.]\5^'X4X77X,M5WE@5^S[0,/
M)E;K4,Y_1K_"@%8`C'4?:ASNT+P5'\`:[LI-N=C+9.>%71ED/2_J1E^Q'UYB
M2!S9Y14%2>,8:T!+]R-#-;#D>%?)%P-M1<*FV%F]L(@!S#/@5>F"G$:**(<.
MQ09%'-JSK>8]=B%SRJ6U,6[%-)I@X%`FH,K*&^D?>R_-#ZP,S(<M^7]9J1QH
M&6ARCH!7GLH)QN&3<SE\0MGIS\$3"<Y\MO&.;`2AP)9HG$O\A*-D#_L./5[B
M3+$\@@XH6U9.#<TVH[)9U(+5YB$^T8W,C!%Q#&HX8C;1&2NLP:E24ZO.IL\@
MHK`=%:G<G7K2LK[]"W+G?#@=R><*LO9.VE58"[IVCN*24&S61\+B>[%E`9PE
M#$Y3'8Q2.4;M!+6,*'3`*%,+EQOV!<LM?,R((JOVPL[V2Z6S?067OAS8C[L;
MFRYU"F2B@ML"A\I"&-[8Z)^49N&(UAXM4$"#5%CB*WOU\-(P@S_1DQ_^HPCS
MPUD'T6K1?!GZ8DUUMD=6BA<L`)#FQ5*2+U`1A_FB62,'E#POPT4_04QCEJ>4
M7-F7Z$.8;^&)_*S*LG4D8G`49:;2T,9<D\WG'$.E`LH,#]C?QN$?!39YSA!`
ML>V&"I$[E;%J(*I&NOH2(=\P)8=#NELV64_O34`XW]8]B`0A)89S[6J^;X.D
M-P$]NS/`&>7M8N[S-/P=WQ8Y<X.7^WV:>/[6X(9=":#52W=%E$^YK.P$Q>8A
M,K$L^UY.=?!Z?B"N&<-U3W#E%=,]/M6AB_S9<+1[>:\CJ?WW^1IB.N2QSMN'
MN1>1KQ0^G*E_"7$40$-V\L=:<:?5^II'NO`)2J=<8^!6#K@#2-%Z3V._H`H6
MXL`0A=:L?[=:HQ(BXA/MGVHG($96$>/`B9%38C3JLI$36%@2PY^(&/J'W!&I
M43O?^@,)X\@!<Z@*$9\M!^J/`6J1P[V@6=$TS%K+Q>J8;M6AZD2GRTFGVH@-
M8SD2[CA*2C@P]5I)3#VKW2%_2`F5FJ+HQ`=*5<*_]]AG;;.>JD,65+)T++!!
M+%#]GI!0FN8[O$.M2[J,ZYBXH=EEF/E)$>=OD_3&\W]?K9DV\A[#*,P/JB=Z
M/:"VCOFZJ)_R,2WXRW0+@[!`)0P:VP]0@+<;<)P(@AB*>3F!M:J*.)Y$A'*R
M)/K06OYM)\/=VH6($=-+;TGT.;[K/[-&4_A;'!0143]WK##\+<28U>ZSLS>'
MQB]0'$4[0L+H([:OFTU)TWH(Y'!`$/AX1"?4W_V(UG@\G/S\*X7HWIWU()Y1
M>T,?P#!SQ@.JK$WP`".(VU*&:"\Z4`/IML_7X&]K3S)#B:]B"[3WT@[C"A]I
MI"J@`X)M==V)5`\#6GRBT26OCOH4[LZ09YHX(%!_2)-B?QW[&A7H.R=:N0`5
MH-"ZEJ?#$!U'7'K?C<CE(1@X<,.HN/+:I4`8DU/%CD>V/"9%CD[1<N1^4"89
MXKL_B5A8]V!,8D9DH%PR#6TTY3:B-M[5&!*%7=0V&]U;:)TS]4)*Y$`<\Z`5
M?98&/[H68J*T:R9>\WBYF^D^2<D7WGFQQT(E[W/XWYO0)QKY;1A[L1]"D0.:
M;!;&&Z,43\./6,X$-29-.]V2@T)'6*@"1N.@*W#H",_!Z)5)B+*K8$$$;DD5
MN"]=5U3Q*X`.O>N,2(U&7JMO2!K'WH"&*A>5'-A!FL6Z^;X)8WR=X]W0"[$C
M',>,>!U!#3L.TQ"=Y[PM;VVAB3D_W3_KC,E36K.WA";UR[J?PWQ;GS+2J4CY
M<XZ>G#3(I2P%BS)3/&-Y+G6X+/ND,=4)'V%Z,K&2#WE-65C,-9^4U4<XJ6J*
MU8ROK,5CAO\H('?^B?P_T2-J=T6=KKG6*B!U(]*N_U4.0W2<S:=,=:*J&#3)
M;NBR4X;]%YODZ66`0^"DK^$?P$!?UQB(_.FW&[SQHBO:(E/G8JYKJBUSTHW&
M*=?0$8@-<>VN3;(14HTEWH6IV(5]2.VBK#5^;KW2L>!6)5;.#Z[<=8EHW*DV
M!`0><H-%M$Z1'H@=^]WD:JHUV^Z=4P<RK7L3-@:\OM]=O"'21,&EZQR%I4L?
MY!I;XZ&(ZF_6S-FUJQF1U"C<N0A$9H`,WT&G67^+[R&_G^Y=%+Y+X+_(G[QE
M'%S'7N0GY-\:[^S:0*V\P1N@WF))#@+582`.A/S1HQ?,#`[]G^Z\WX^!_?T[
M!Y[SQT!$IEGZ]GA)[X2K/5ZZH'U&$,G>J`%#(1\2]T.^$N#@@HP,?2^BQ50/
MY$,724+6P&H;;5),[Z)-DK7UP=M-W38A1RL^AP%!)116S_=`]58-$*H@.>CW
MC$J($O]R@D-.TBAX2G6=QXG@E]R0,6J`AO-KW."5GW',MS+7$`I)XJ;J8<;4
M*;*T'-]`L=UKPF#Q)GR,\#++<)Z].;SS_IFD%Y&793IAX#H@K:5-::'=2IJB
ML\_H='2<CQ@`2(6@(!"%X5J@N,&.R[.&M+?;">X^KNP]46%F<>2ZX&V_A^F3
M0X_S%PV^!T#N!JD;LH;2`X\97\PG%A>0Y.CY>>%%=]"I2-P)H%.#B*;;4N9B
M=#HJZ9<C$1OJQO%:'Y/KW3Y-0`A_6-T[8UIZ^$IJ1N1,9>VQ\T82\R-/,Q3!
ML6T$)`CV/X3>V`WU,:.XCNKNV;8A5Q$I]E;K&^QEO8_GK?%V$HX:"VX=?LFO
M4(Z$_F[_;E)AL<D:19,LUB"?2+K:>G1IN7`X3F?%XS^QGT./%(J((_>$'8PM
M21QJ<?5\JGW%#MWQAGX^NSLV@WB/NPJ#2[6-')AM)=^'ZBG+5>.9/!-/_J[6
M_62!R"PG+N],\7OG?0QWQ0ZE@!69BW;$W=C2RA_T7QGZYA7*MVE2;+;HVW/G
M;)L2ZRH9.!6^G4\D;S`Y%6%8"EE1K<M`UEXF_N!%#SC=J9Y23$#;.L&8D:$=
M@010$`=3;S6203N1#@D'8`B@.7'Z&8<*\.=C&Q`PEOACCJ&<3Y?QMW96&L#Y
MTG.4.=L/\&UY(Y"'Y(JW66'E4'^,`YQ6-]Q:+VMJ$*T^IJDB?<J@99^?AP25
M,\M*R'3NA`])QN]E0W$%0_O#ZAY=WSKT.&:*5*-(:+9%29&OH^0#<2[^*,*4
M=?(N^PV5:JB@.^OJ(YB6_/:_>^D([W"M<\?)_C:)R"X0!?<V\&@AYB?%0L@J
M<*R<P-40%,E<.0U5\Q"9B,J9HPMBCE.=$_LPY"I96Q^1NURRTN-D)HB@&[%&
M9FB>JIB]&MJ.W`AH"*;XID!=*H>H$,(`6^(.K=;EA?H/278=_SV,$N4;WWY`
M=MT4.8HM`>/#:>'SZI$AR=!UC.@<AYP2/<S`__B=_+9)O9U+C90UT:A4`]J7
M6P75QVOO0=`5DLYVS<M0$#8%YZ)?T@8H!`+K-@U]?(M3@*CD/YS.L>(KM!?>
MXG\BQ'0(M`RE#&+_VEYAU82?]W35<&T'\HN^(/P=$'/@I5GUQR\=,/7]R-3,
M>ALO1XRW0`+$AKJ;_<>307ILN/H89G!YP6/HC.X4=.!:-=EZ!.B7<WZO4(*8
M/F#5V*0/Q+RM*]BY&Y>8E\&I56BR&[ID*H)(]4T?;1SS'@RT0K\SH:L2](J<
MBQH80Y.$6[)1A##?"4.OA$,555.-O?J^JJ/%6C$BM-L%P$4`V"R>:N2UGHK;
MZ9KI0MG"]^0'FTL]T922E=YVK'0.B>S#LA2R'GZ=,8)K8`MS20OUFGA.^35]
M"9\!]T%*`K[)FS[7%U9_HX2P^?JX\J:/+F_!7T@R6F>G7"(<=-DB3478$;KU
M:('W!0C2\5$S@S(Z<"EF0Q_,0+)2I4PO8T-*&4`0]VK],^U;GJ]2&K7*=JKZ
M:W9'7,NW20IK$9EX73B_G9MZ`*8K'B+Y+!5@M48</EJE+/(:<:8^_I2A7^'C
MB']]F`<Q):X]TEI"MV:L#3BJRY9KD_#E7V8Z+IGN<"LL%*7`<&LV`(50S3/%
M0.(P"IF!(CH7*GQ2HK/*;OD6HT>\">,8#DWT]SU5*?#F!#]"K$GMS[5CU!0:
MYV<,_Q\'O"%M^>)*3S6FVD<1YLB:2!.3:;12N0A4MC>N0C38E<K4*FH"(O2I
M*SG&;FDQ=<Y4UFBJ%'=`NZDSQW/1=".=^.#4>9UE!0XNBY0LEOEXU"?,+I*8
MD"LC*$*32OAW#NEX]]@G0_,0=[WSC@1XP#EN%(R&W^NP)2"V!G[66K!C&CF*
M'1<";%!;"CJN9?#);#9*].C)Y6:3X@V4^?;9EPA=,KH*0![$H='_M=A#\"G\
M-4HR+C_P/Z]O5U9/;:.0LW5`&RXGH]RL7N(U3LFY>+4F_TV6<9%DQ`?$/BA3
MVH;W(5D&00CZSHMNO3"XCD_:79_Z1^80S;VCX5@,$?SRZZC\/*+?1_4%0.SJ
M<0D(U@#Q(1>G+>$=1K]'VBLJ)"45?$J%M$X%8@:](Q7V9"EG85SV?[?F.`UB
MV2ZW:<"&S.LT#>(<R=L9Z.VJRW<PF#/@VC).8A;9QSM#$#!0[OF)*L3QCHS-
MH/]:LL^[,(:$**B^M8T.=[065Y<G9`#%7/&9K7:(LCO)BFEDO2'^5<0_B_AW
M!QWZID.Q1Z&5R.PX,FG'N_]L*DJ;H;K4DB8IYU5%VOO<HWZ\'6W)GO+"^D2_
ME!O)0X-AF)?3L1'+`R.'O.0Q"C?5!.]WHL!2HG9B<JQK9"O0GT!!)7&,6:%^
MVK.`G.Q2*%65'WBP`(#/<;JC/J]7J^J%:LK/R^"GI!*MTV3E(7W#14_J`U\(
M5D6>Y5X<0,Y41!","=%^PBP,@'=S9E>+PH?ZN19@KEUGI]'@%T/T1OYB^(:_
M&/)QC1?#\L$0U9:-JG4COG!4M3=G2Q\6"N`B@;6?%FM5!KR*7$^<7!E?A[U`
MA!GEK#/`8;8]GM=>S<F[LGH7Y=S@R'+LCB5@5U!@@,9^5Z&W%QR/AP16?>?E
MWF-T6,7<3!.L.^L?ZDP?H+CUUC?\UJ]4G>24#U]#_'-H%5>^,/WB\,"I<;'J
MT74,N5+/$?T&+(92CAS4**V<JL<N].:-ME+B*&$,E@)A9U8PRMLM40]Q9:VH
M5JCV$C8RD^SDB?,Y<ZV]ZO:3TN#-X<<X_*/`ESCSTY`B(*BNJ@W"_+U!=Y7#
M=4SM[:#V#8O%4DU)<7H7KKE;%CE16OA49=:(_-9>RZ#W_<;#%/W`PGX]4@WD
M>YG*J'JH**ZD!OPVY=>;#\D%?<ZB7Y,'J:O.'Q`OHKG"D7AGM4;5U\`98M_C
M\=BC!+I/@5B/%]24C2-^#*N\B:6]Z`]UGNJ,]%"EZ\Q1'>K;W7,?Z#=V<5_M
M8E;N8OTQ>L00M!H"=SC`>`<M!"M4*`J&FD,#W#B*Q&#]X^F5X\=;(CBYHID(
M<2V](\'?116DQYQ]&DEG`^PI*#TVD54P,=SY\=16$X%5&F["V(MHP`H-GA/I
MI[YYOYW#?TR5D>JJAFB=4Q*77V&17=TAGM:0Z-$@MR=6+BEQ"2DN>ZOAJHJL
MTJ4:>DDXKPY0V-%6S<5MF"$<85ZCJ"I0HK!AK7=!_K]OR-+^0OY-_@ORP<C/
M_S]02P,$%`````@`>X$,1T?MXN(Z10``UE4%`!4`'`!R='1R+3(P,34P-C,P
M7W!R92YX;6Q55`D``XFHRU6)J,M5=7@+``$$)0X```0Y`0``[7UM<^,VLN[W
M6W7_P]R<KV<RL3V;9+;.GE,:69Y5K2UI)4WFY).*IF"+&XI4^.(9[Z^_`"E*
ME(17$E0#&%6J$L<&0'0_C;=&]X/_^I]OZ_#-"TK2(([^]L/5CS_]\`9%?KP,
MHN>__?!Y?O?VUQ_^Y[__[__YK__W]NW_?IS>O[F-_7R-HNS-`R[S%*#EFZ]!
MMGHS^/?;P3+(XN3-;V5;;ZY^O/GQIQ_?O\$_SE=YDBZ]U_]\T\N?\S1[<W7S
MGV^N?[KZRYNKZ[]>O?_KS4]O>@]OWKXEWPF#Z(]'+T5O<+^B]&\_K+)L\]=W
M[[Y^_?KCM\<D_#%.GM]=__33S;NJX`]ER;]^2X.#TE]OJK)7[_[WX7[FK]#:
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MV>?(R_&H1DMI`43MG$V(?F_V][O[\9>6,E":$8H@&*)!ZH=QFB=HG#Q[4?#O
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M\C%%?^9X.`U>4'OH3YIKV='9YX>'WO3W\=UL^&DTO!OV>Z-YK]\??Q[-AZ-/
MD_']L#\<S%K-ZHJ?:"G09$HV3_/?>WA+\L_/PPG9C<R]Q[!AYSG-M>SHE]X4
M&]Q\UJ)S1TVT-87YN/^/CSV\C>N/'R9X/U?L0%MTC]M@R\Z*-VBW*/."<(Z^
M97EQCF@@@/)'6@I%V;=ID$+<:EO#D=JL:9"DT8<ZF$_*+^B;4*KVVG:5LN-<
MMM>Z1+,M.\[9<FJP&OG6SR7&5;=R7)U-D.MN!;D^FR`WW0IR<S9!WG<KR/O6
M:T6S(YB.Q4/+ETT0O]GTH>G3)BB@V;2CZ=,F**#9=*7ITR8HH-DTI^G3F@Y^
M;7:1QVVT[=+6H:1AFF4TI<-H3EQ);33(;[&3H_2V\8;3-[_)3O1[>(W6KOLJ
M'^A2^PW7#GZ377:XX5S/;[++#C><F_E-=CA_M-]5BAH^0^=UCLHNMGR"C[38
MT0E;/D/W6^S'A"V?\[KD>$`TNSS1[5T\O/'0XD?D-JG485JL4I@DY8<B].QE
M:$DBE3Z02*6KGPN1MK^^]QY12!>@'O;TX:"MLM*[_WYSCAY.4!+$RT'4K*M'
MM<_:YUGF)5F+7M?JGZG?\SCSPD8]KM4\4U]'J)EN=_7.I5-\T$/-=+JOJ;&O
MV6D_E16YUR">I3:U2YU[W(V##N+Y#$7+??@6:4![Y&(1>1K[!Q\.2:QGG(AF
M=O*;!:_QWF.:)9Z?50V%1/*B^85TW<5/Y7PNU<>M;@J]I\C_\3E^>;=$`=;_
MU7OR`^G_^[<_76U#3O\#_VI1?GF*G@/RP2@;>6M$Z3"KZ&*[OZHCV4L.^^HE
M?M4B_O$$QL,8V6V)=YOB;/767P7AS@*>DGBMKK^J+[%0DC=QLD3)WW[`=?(4
M=S(N_"=>>!8(^EB2Q`N'V.2__0.]<C$X*KNXMA>$4U$J%*[.#$,_3XBT=T&*
MYY'?D9?@I?\63Z8,)%C%%S<V@L&1IL+C&F18W`4A2OJX)\]QPA\4!R47[VU$
M@2Y(!<`-S+P4K]=Q5#J7\5*+TG&>D50*DBC"GZ0X%1=_L1<>@5P56N_/C%8E
MUAPWR\"E7F3QLXT('$E0Z?HO0+K>'1$YZP2U[.(7F[5_+$H%P\]GAJ&'.[,D
M';H+/=9<=%!F\:N-:C\6H5+W+T!6O]\DW.'?I`*[/RJ]^&`C!&QA*C!^!06C
M')'R<-3*+ZY^LA^1(WDJ4#[007EW['<X%E^[+X*1EMC(0IZ\]+%0=IZ^??:\
M#3&3O[Q#8996ORG\%#5[V?YZ,</2(:*T\=-=$'F1'V#-Q6D@<%:H5&_LKV@N
M52]-499*]/^P()#GXD29V-;0$/^8'ELYL]M,-\6;314+<E]*S^QKT=$7E#S&
M>S<A!&K;8Z<T>$?E@1P?;&1X")[VW0D@^UZZ(E&7^#\DOOK%"XLXS*SO)<DK
M/A+]YH4Y;6^L5!_(J2($D(ZWK$BZ\,_JWO[SHC])T,8+EH-OY`(8;37$09M:
M'LA9TQ!=E@ALOZ4]<!ZH0G8V!G+F-(3ON.ML]Z8J;/5[S//"-LY6*"D%&\61
M+X2/6A[((Z2ZF++Z[L+PN]WVL]Q>HWZ<UH4<(1ZFPKI`/B=5?&7DT#=F(5?.
M,B]M$GKE^;=*3N/#S*L&Y-Y215@@`ONZPQYP2U4(%U`@9UBS\TO-V75ZMV'/
M6GD?>(]!6*0_8]NKYU00.\Q>)<ZBLDU`N=;4?0PJ$NT66IM/K36!Y7T0[$J+
M*UAODA)^0A.@".>$JV*;;)].O%?"XB!QS*%66%S!NIT$2#'F<*8H+FR<L71)
MCKMYHAD^N/0ZBRM8;U-3?-G2N+"E*LY]2@`S:BRN8-U-C>#ER*)O4P8'KA*N
M-#7`NJ`:04H7@QW28L\6>X[6FSCQDM=R\U&YO7MKL@+ULBP)'O.,K$+SN$RA
MY("MW-;B"M:/I6$KUDAF%Y;Q1J<QGHIA75X:3($OG#8_&.BV_)#!0'1?2"F]
MN()U?`E`8EXCT>1PX$ZP%B`KO/P]*KJX@O6(-4*2)H0+LW%ON0S*3D^\8#F,
M^MXFR(@$[",5O<;B&MH/U@!5CBPN7#],2=)PA)8#+XGPWB+%Y\=\G8<D>7#+
M+</!65QY<0T=7M4`<CFQ7#A,GZI':8.UN(;U@#5"ER[&]W"ET>(J8W%MC"],
M@V.;*:*^,0UG!;O;GH*B6":.MRQHQ`T5/Z28.:(/)=:<.*H!BG[HI>GXJ3"Z
MWK>`=R/,KF,$0`=&Q03B5%Z]*=4M#B6UGMW&:[S.\XXEIX6-`(%E3B<G$HJP
MI@!!B`G1FEC3X0GX`:T?4<+=='(K0@+$-J[3+29?>A>N6=EA![QI;U_8B*$F
M-]_5)&1%11B5<73TLM@E_PANWV5*_I&&G9?&G*00=L;2L5\#3DHZA49QSZ8Q
M,0D&S99;/>!<(RXNLML]C<E%>PS)/P[L%('35>A@-=DMUI)76E\SV+QA!$Y<
M49YPZQW7!B#,5'L4J8"WE^.DD'-9W(1-4%)0Y,C'=[!:`$Y>H6-'QUE>(B=.
M>T?BEI1(O3Q;Q4GP[_WY10S]<4W@;)86D%,D<6.BILHY3--<'>>R%G`"3&N,
M=U*X$8E#E9'/]R9;U;Q<&$6HCV31=F-D4.A5@^5;K@'H]!@5\.4E<B'P^NCU
M(/G%FU\1.D6F.>`T2?3%9)L%M'#E9E>"SI%I"_!>"C9YH=W@RBW;@IK0N3)M
M83X2A<V<:`_6M6C3!NNU1&WH9!H5S"7%89,T6HF[PC+-J06=*-,09YH8;+Y'
MB_$5KLZ,&M!9+ZUPW8NP]YBX!*K<JLRE&`=/=FD![Y$<.XRUITD`!ES,YKWY
MX&$PFL_&=^/)8%J\!#C[''GY,L"+T[F#+H81[B+:H2819\&H`1!:,=Z@Q"./
M>1<L4(0JJ"3=DV%[%=8%#L!@:YDQF&0$<N)&88KQP+HD%)JWZ`6%<4$.M966
M>^W+J0<<E2$%'NL2F"\6:,8@XUFL";;J*"MDI0!V7`0XXJ(!-A0)7,CX^X0B
MK(H0JZ"W7`=1\3I6%KP@\=@3U`1F>&TQ^L2"N9`-N%-0I1B9A;4J"QQ0TP)<
MFB@NI`+MY"HW&?=Q*@7HOC1P2(T.2`^$<2'+;Q1'\:%P6ZU(;(:%=8'C:Y0W
MPS("N1%S,8Q>4)H1K91R#B.\3N#?<`]P]"K`$352F-'AYDCD`&%&0>YUJAW>
ME$VO`1Q.TP)@MD`N[*L+Z>1`W<H-'"W3%LF]%"[0ZX]0)K61.B@''?.BOJ0>
M]]X%Z`XOA6^#EV")HF5ZI)SA>L/?/ZDT`QW[H@R\JG`N$*`<RDSR+-:%$+=!
M6O#D2MO":57HT)B6^-,%@HUU8W@9#V:LWHL7A"4I8NW::<OT\=%+`Y\X4(,P
MSZB7JNT:A(Z3D<:\O9@N$)16!$]5C(C8/"1K0L?.*(]]"7E<")#[@H+G%9:G
MAX_RWC,:Y21_;OQ4B%R[DY:W@V8-0H?<*)M'<S$["[4SY&:_WYO]_>Y^_.7P
M8O_RCWW_`#%@D-<A[\+XJTPL`[?:A>]"D>^"J?GF+!?GCRN+\(R<XH]O,\D_
MOGZ.@C]S=(M2/PF*;@GX*V2;,`4W07:U@CCFHCCRUDC,6,&N!8R5"@:2*![(
MI@$XQDFR_MW=<?C@0,0DG5"J;QI`A^JE'!45!`../9-`ED6GT1!HA>:LQEU-
M3B>>AVO+2&+'FDGM.)_([KRW+F2G-DEBXI!>XK4D1<MAM`OPZ/E9\%(^GQ-'
M^!<Y_MWVCW$DLZO6]`$CD#Y`D'F_HT6?+H08-[K1@[V1U3H:N'=_+H14]);_
MRLN`D70>3Y$?1WX0H@,Q\?(EIU")J:23S[EK;MV@X\+&XQ;ASOI!H4:.O1T4
M`WU"NL-Q=OHR?%TW#LQ18=$XWDUO;U[0$F^H29A-(:(XZ%ZR@>_%/F3UJ6F>
M@+2<=9QDP;\+L<9/M^@QJ^[J\0EM'>1KGM$(ZWXW]B+68A4!9?.2@C67(#P8
M;E'YWYJNMF]:R>6$RC;B[K9%19-N6@X>&!LO6(J7)F%5X&MPQ1$AMH1CS;3=
MGGPH\8_0,UG13,&_"M/VMZ\<IRFB9GBJMN":-3#TU';G8:91]/QBT4PGWJO@
M1EA<US5#.-&-IG4!</-)%3+)<<?W#ZVIVL!Q=0?-X$1#512U2Y90S'O;U^R;
MF@.K#==L@JFK*M3:7L-HMPWO[,K&X:-)6XWKFHQ`D[1H&B@S1SN\+E3]@.77
MA<KZ=,$KCW=O6Y=4S_\S#Q*$M8)%S5XGH8=W]]&2$(47M#R\O"'Y1@R<IQJ.
MHY-<(P5-NG"$;J?-SF8CARVLK<9UW0X8MQ)NG_GK;B54_8#E*Z&R/EUP"5?S
M]S:.D-"U8B4@%M.;5#4#YZ*&8X6UVM&UY<+ZAA7G([1,[[!F*_'&3[6X4)Y1
M".LZ;!EBO3FQ<:Z).8HS).$C9E;Y/HSA4$N:EHS0PGU(9_L/APVIK<;M]P(1
M\?$IDOR'G"1?O)"LOQ.4!/'RV`7+R[%2:<:6?:R:;ERUA1X>(DGRBBV_>"9$
MV0B.ZIN2ZM$8_U-Y=%U`;`K+PCU,,J<-8'%MRI/A^HR@D&E']:+%$`81T!FE
MRO<F\1CXQ[TG*%I25D82`QC&:9[(\*JV;MHFLVFGPXI%QJCLT.)>W@O+DU>0
MIL4F*UH>'-3'3_,5&D98,"^<Y(]AX(^?<(?I+[CH:!4T4U336#E()FVK94VA
M_JJG((;-W&Z_6?6OZ/X4^:&')7L*2'IT;[D,RCY.O`#OK;8Q`BQ[:=&B<[;2
M1KM=>4S.S1)SDJ[=6Y,@LO+7&5I>\58D85V73$9!8YK.,[K9"?8/9.6/_T)^
M1K(>-GGBK^@'5)E:+@$LI25-YQ48+]F.;_607$'D/.=6<\D"Y/2DZ:1B#",M
MV3*A;$>_T9"<EM^*BU:BI$5-1Q+0"-SR'02R$>(&V=:*N0C[H1XJZDF;<279
MCG/O&[D+$D![6-)-=(^T43WG;#VUZ%X'X^39B[;)J%A?$WSV\8.-%^[U=>Z'
M0^L]PAOI-`Z#Y;Y[>Z6,G[;@>N'.HR3U0*>.]@$>)1UY&<'K2>ZJ\J0P\(6!
M+JVS;B!I\G;%U0`Y7@GE<5IPXNV^)C]`&:=!2IN<<22J`C`TMKW9)KW1/:3,
MLD`#0T*-#%NG2>"BJ<_R]=I+7L=/L^`Y"IYPN2C;"SW!,X@/L#R=]D"&IXE9
M"6"T<-4YQ_A]#/D^`+D&@!<<KLH9(TM:,!>'6Y41<9`,<?ZX/7I6AL08$]8%
M&&K,/NW5+C/@5)H!'G8R*#!]*$I2NC@&BXO*DH:(!$L4P7+/*()8YSA=40M5
M4&D'8(A*]4]FD*HU!,[,K(8*\_Y+4687!VW]X:I;A+</058>:NO7!?O[H\H?
M?.X!7>\FF5JS5Q+S+?4*"*\BQ`:6VB&UT2K=!GB@I4#YK*VL@GPN#LHO7I+@
M;<39E\WJNW@&F)(WK-)#M4L,-\D6E,8=P_%3?8HW8.@%@4>%O(YH]_HT:5P<
M`^5;*,=\I.<>$;6[AJ=Z/Z8H)/F#1:!5P9SZ2'I:I2Y*#)1V#0.L6](=_ECO
ML,QJUK)EX-'<&DAFZ$9;K;@S*TP'][WYX';2F\Y_GT][HUFO/Q^.1[-SSP9;
MW4\\?-"?XUDXQ0A*IO^+J@*,:%:7U/:B"JT`CU0)"!AC44U&=\9=_3KC,45_
MYOA+@Q<$L#,]_K[,R8]1!>+,=]05J3,>JP[TF8ZM5M9ICB.).V-E]OGAH3?]
M?7PW&WX:#>^&_=YHWNOWQY]'\^'HTV1\/^P/![/+Q5_S1SY*<^AC`)Y16O3H
M56I[R:UHX46?4"`'GODX?F)='FY!S<6U=7B+)=HE\5B,^`A]K2DGB2/\HU]&
M4)4"RYN`:E/`F<A-;**!B#M>%/O7VLET/!G@LV!O=#OXY^?AA#PO7SS;>/9U
M];NY\V]UTV_*:MO%_;Z;N]DOO>D4;V!G,*/*S'L(36=!?X66>8BV.9<GMUQ5
MS\=)V7&ILV+3-FV]"=$AN#N#=38?]__QL3<;W/;'#Y/!:-8CWE&8H7NY,*'8
MYK&;OO?52\K0BG%A="DAD"D'7YKF981%6N"G./HU?,C1ZQ3M2@(]9#.NQ/="
M3I+`1X0"`@4O:$DX$F<>G@W&3[]Y21#G:9]00Z"*8U5H:AI;!SZ`Z[8OO9IQ
MX2!_YP5)08@UC#9YE@XCK+J\T&)_QT<RC`H='ZS7_\SQ2AT0@WC!59]BO-81
MV:6GP4Z_"^PBZ&I6[%IGG?D<SKF.4Q_&[9&-Y7/A<?GX2E]2MJO)IV('.HQ*
MSL@OB&Q$T;+W@A+O&15_O,48[I"07_8A^[5X[^1X@-;ICG#'YO%"V6G5M5G?
M:6T3M5];[775&E_\Q4W+U:&8'2F0_6=B,37`+<J\("3BY[CFA2B@+5$`XTPB
M!F+.(+=7J>XF08"B!J`X'_4%R03+P$M>R9&IHJ3[%O"8(IAU@$Z9JH"Q`V98
M4EF.\5Z>D;?&/]:BZ6[CM1=$/+"%E:$II7FX,:"6D<ENS(>3\0-:/Z*$`^VN
M#/"Y0@X..I1U&70AII<X4SPQW5>DULV7XUT30!OM=E-P`R&U^>R`IN3JD2VT
MO,T)>7!Y=BU.$>D(?2W^Q%V#I1I8_&RR-1S@R9BI9<4$'OL:G5YI*6[ATZZ"
MST0.*5J=Q2^V8\^1S`67/>UA-5GR?N4V%K]:;@TJDFIS@.O=">S?6/P<X?Y]
M30(21UB1O)9T"+M7!UA[`:5&%A\L1;V1J"[X<3MXM71Q]9.E5B`KG38/*NSJ
M3]_K%'<6+;:$A_475X#<A5UN"4_%W#&MZ[>*\WO6*;2/35WIKE)ZTH,12RZ=
M31AD^Y<WIJ2KO*=)5)NRCA"T@8!.G+!&.?$5[4A_H^<9>BZ6%EYB"ZL.I+N[
M$>H\2;2=J/3NF;_$R1_D;27^LU2'I8`<TNJXT/L.?7K1Q7.`5Z<(+:L\NI[O
MY^N\N&[?,IYQAIRX,I#+NOG8DQ+)A1/,>9XR!71S-X)?5JH.CS(`*1)2=-RP
M(2'VY^A_?_O>-CF\1NU\S4CB+0?@)8M76P@F.VV5$72EVH2]&;T*$MH=@,$4
M[^/K''];$&(E41LXI4<%2.:-CH2,CEH!D5`8>R51&SCX2A)#10,X$,]N`R#1
MX#E>D'>R":.R&#6`8[0DL6(<?I@B.>%4O,OQD9X\)E:\'OB-_)0*8697`LZ5
M:(4T5RI'@C;HVKGG!/')5P8*V#K#HEX7T?+@/::,GU/TE(?WP1-OCR]1&RAT
M2PU#1?P/I'-BVF>*^BF)TT;30%$1*%*K4_`KP:`OF;2Y#/>N>]QO/]C>QV]"
MM`UMZ*WC)-M&.C"UPG<P:OD$4`"8#F/2J(+V-VH?2K.+T#/ICV'SS0@U<I7A
M:E"A89U.-ENY]-VEQ9D7PCIM*>\L+D%O32Z^VXOOUEW?[3#"0P_M<H7OR9<(
M2GR?+:>6];Y:OFQ.HBWTSG+K`?ME!7@I@>R()_83BE#BA63;N%P'44!F.\*D
M-/A&Z#J0T&$G51_82RM$D`Z\K&AN']LU>?!@O;=G\>!9GWY;/U!RT*X7`_;,
MRJ%"1_1(#)?"67BO"8,>D,Q_"YL1<,WY()<R2%3/[M>K946$VB(QP.P])ZC8
M"3".+J>%(',:9/1+@>6X_Z9BP#Q0T(I!YC"<*)2G=/#3`8N5.4.;>T06CUU7
MF5M\?@7(5`.*FBE@\+KNQ)Y]'F1D2SN,EL%+L,3KN<`50RT/F3.@/K6)1+%\
M!WXBUI<@6Q5TG"29?Q5LYO&`D!V_"MTPBBT![^.9<$JB+Q3.;B=-?Q6@I\$W
MY.?$_S!^>@I\E(A#YMBU@$,I&N!'-P2^B&8RGY$,J6")BO/J79RL4:(&KWHC
MP+$3K=%N)#%T4`7K($DZ/2.>1/1<L/.(L>94`0YDT(,L7SXW\GX+8G:)#(>#
M<J`4-<WW9B<R:(,0B)501,2?LICX]YJ(EL1%27@\Q=2R'7P.BM^&;1*,N_2.
M9+=[^S=8;\+X%:$:;[YP\\>LL[@"OG7O"F*Z17'U8.8&D=+E^=>8OT?@U5E<
M`5-1GP=Q*3T8NBND=1M78%^_2]1:7`'S5P/#?J@)-[:1E39$>;*U8HLK*QU\
MQR)HBUL%2HZ1W?T=VSOP_?HQ"GRP]ITV[-ICYR6H3T6DUX()EE]M<06<D72J
M=MK<*!;"S'U0,9F3CN(/_"JZI3HINK@"SAB2`H?1<>AMBJD!PU>`S,W-US*!
M1-K(K5P*%+Z&3<$10:8$]%XDN_T0YXD5OH9U58DQI&,O+9R9BRUG=KL7/<0C
M4W=Q;5\(E:Q<VBBU88;U]L8EK>\/.:.85GQQ#1B8)0T3?>"RY#%SG,[S@'1C
MBH+U8YZD94!:GJWB)/@W(JF_.36#6KKNXAHPKJLADDK"06^M65$!!5W_^(DF
M!C,(@%-G<6VFVT>(HT@H-QQYE<-R^]3R?>`]!F'QUD,_3Q(ZYM)U%]>`#YRU
MG(VEA(,EA&:,X#V-/.E+\<#Z/H/C>.A2"R^N`1\G:S-FF=(X\@2-Z":#=9%1
MZ:5\LVV_&K6Y_5?]UN(:\(VSEI-!)\K0MEL'Y%MK?K=6#M&T&*/I,"I7VR\H
M>%[A(=O#P\Q[QD=6E/A!BHKG!3N)5%'NQ>+:3,^?%BO6JZ;*OG_6;-_DG[9;
M7)]`]XS*83E^(HJ-H\('?DL2-);S^",:YUF:>=&2_L1CPY86-X!O$;7<#C<0
MM;*!7XT[Y&R%J:;F6?[X+^1G\WA*C'K\-$6;//%7>""(L1>WL;@QT^FD@+J<
MD!7>'\S"^Q:E?A(47<$])AW'_=]U_-[;L&&6J+JXL<_II"+;WE-A%JH?XRA/
M#RS4"[WDE84DH_CBQE)'$T>>'6(=.)<,9A&XNM`(7&@$'*81@$P!,7,#HY0!
MHO$5Q4L"2-/`6=@0\!.#T'U2YDIN][RA-_O#P9AP)H$;3PNZ;$+G#0)Y!K'8
M71(FJUU>:^D#PAO.IQCOTXH'WO$YO_@EC[^F46-VD4&TDA,L*5$7^'SBG(;-
M`?%`M$-2AU6`,T4PS.)NZ3T@1(9"(<YXLXF3+(^*&U%^3+2X)A`+1%N`*'!+
MR6IF0$\?%R$'[WD2>.%=7KAP]U.A*NC-6@,BB.C`$!K+#_L*$VOP8P$2+TB;
MC'YQ52#RB"Z&OY2PVE9\G1#7A'T(0I1F<80X3@)A'<LX(Z3D`<O]4\2,OR/C
MUX)B:)`#0`$T>-(%!=1V\\LX$N1:R]6&(E>014021[I@9NZ?N/T7\B;(U89B
M4.@*5J,H$?1XR:;$@R3PK._*0%$CM'2K'_3?\JS!0A:A'[-6"HK'@*Y\#D#[
M[MKM=W[`)ZEUOA9B=%`.FK#@&`$Z3B==!O4&&YML;68T>IMDZU]LS]7K)MD:
MF"I!!)D2T'N1[)Y^SY-L#42H((\A'7MIX9S@>9_ECRGZ,\<*&KR@\L5YP;3.
MJ`'%JM!R2N=(HRW8'2BRY%0R<7@(JPXT<P(/)FE@]Z+8/7T?B2:<KJGEH4@3
MY/"1PG0OB#-3<;`,O.1UYA'JZR*T1&(RIM8QE35!8CIFRE.A_(NEPW8O$8DP
M&C_-$R]*/5]JDRVN#,6N(`<=`VXIJ>R>K8>3L7"&WI6!HE90!(1Q:JI+8:9'
MOWLJ(C/I$=I3$?VL+Q%,TZ4;E7R2!1ZUL`6D"`J\FW52!,,8:+9.T9Y/<GIN
M$0F=)8*/GTAT1?KQ=;X*DN7$2S)FII=\"Q:0$M!!51/1#:Z:QBP,VWB>WU!*
MTM5)H,\&^1E)6":_VB:NDTFOI&O@[:S.U`4+:`:8;V&=4T?:(G)`#9L$H7&,
MCOQY<6.FQTS&(*K^:[OR@)^%'L7F_4C-'"&6C)57)%O7DG=%4X[N[UE`0\&?
M7[I0B#8?+KQ]MIA^#TE>/B5QRO4IZ?^:!609G:U]#'5H<V;9:9E&T)>93_*A
MWRIYRH"F]@&VR?IB4H[6JR[,D?(9"PA+]%LB0P^&\@WU?#_)T;+(`9G'.P<,
MRU_!*+ZX,3,+5NB<X,@#SB6D:=H@3N]AFF(I;_-D9Y._>6&.1NAK\1?NMDFF
M_N+&3/^PU$"7%;!+JJ(S&@3UX7B.`=#+FXBVX!*6(;BNS0',-9SB>](J.`M:
M,NH5[;H-"W$7J4C[O6Q['E"5E]Q9:[=:(T;!*V?4A]D\:BJKYG:C-F><9]Z9
MM[F<*K9#RE5'=6]D%(`U&IVTO!N8>AE>I5['T0->N5;A*SX^L+.69:N;N!@+
MM][2NNF.$-]@@LCK"T'DA2#288)(<_F\S'3IZ^?S`N28-)O/"])[WA1)'58!
M3O[(,(M[O,V+4E3$QJMR^LC4!2)X;`L2!7)):<V,8=5.ZV.F2[HQJX]Y_(N=
MD/H`.I)%ZE=`S%1NQ+,P^@!&'XOQD`21*I8]$Z=V.A_`X&/]F-;%,C2TG-]_
M7+7-4*W5AV0T[`#8`\%@V0LAGT"PB]&0*0,8B^'E$01@CD6V23`N\3N2W>X<
M3;WO(``1-78.,=VBN'IP@/Q*D?W/S)!2>?:_&WWW2-:P_\$FSA\JGP/0OKMV
MS[8-V?\,X&BL(4#'Z:3+#DR`#]XW.;CJY8PB:V3#==QE0P^Y9$T>/Y7^[V*A
MYKAZ:64MXUODR@'&LBB)#=^I2R\-Q9+(5[0$*/",B`Q4/B7>,O<RO`>N+H[X
M;B!6>2@60Y&V*=CP1##3(=L]&XM5[ATEN<#(L(R@^#`^U9D>9Z0FHIF#MOX\
M]9!<F'MAF0BRO53?.A0X_G:9ZE#TA*TA5I#/R'>A&D#*%=-,?X@01H%,T.P[
M#/"FR$?!)FLT,&7J0G$,MH935C@WR&?<X#,!HD)L8VN=*Z3#&'^3[ON,YS,Q
ME.91VC;UJT.;6P;0TVDWFXGY9);Z;9*GC.^<^PF0S<1\!D[]ELC0`S3-D\0A
M?N<N''SS49J.GW;A8EOY>%'E"JU80(`I/M++B:F-*P%P,72#P9(YT(\9+*'H
MABY<)1URE5CZ=,^%J\0"KI(+3XD-/"5F;;LN/"7*/"7ZB68,)K.XN9!97,@L
M'":S@$SU,?,^62G31U\\_27/IVDB!,Q]-M,>&GJQFDENM_7I3?(!?FRO(X#I
MYL33@@,![FH9/F;>2DLG^/Q%7]B1+?D]!F0BT)DQZ)VU>Y9MEMP#<W7)T#\=
MI.,..S#Q-<OL@;G<4\/JJ,/0:3T&.?DA>2PTN_EU,E=\9XY^*.(+(9Y:O/UU
M2@P#'?[]5$0U1"L,S3#1!`.!&_]`-@?6T]L@03YN6[B@'A:$)HQHCRQ;+C=6
MWFU<CV"]K96RE`?B2`++:86VT@C7SH-RT&P0QQ!P@=IWV>Y#(\.=5;BJ$B_R
M5XA'N=B@%6@VB5/\E!RY+)&`;[W/90P\KL8&K4!S5>@SA@.1W%AZ)83FDCPV
M:@>*+Z,#BS@4RM"\Q8.XZ:++OR,O$5`V<"M!,6K((B@G`70ZH@Q<>`$BO5;`
MZJ`&%,%&<Z!.N@^=E'=AU^B,74,C!U[KM^T.4I=9P!T4LI9$X40*Z+T,`Y)>
M%.5>6*:"2&?-<"M92Y@@E,K0K4<]N:>W+-FQO7"7YL-TT?*K64N4("&7MDV)
MC9F^YF2@FQF'PC.PCM5A.6]M8\Z(K5;('A4=)42+;%+SYZRG1>A`']\U+\*!
M;HJ7NS;(QS^6SYB.\RS-O&B)<?J""-D)+H,7=[SV#+[A92A(T20)?"'Q#%C'
MODO&!6V:^\[I&;9ZK"FLG#LZM/:3;WV71`T\94"S-5SHOVIL5V8&JG6ZEQ`I
MQ`5>"1L);2SFN="M!VU\&3::X.G:`;1QE=UGW=A'E`R@HKUWV3#?Y(4EHF6$
MJ3Q1A&%NZ>^7*8(%JPQ91`?WY`:S1;R_L$5<V"(N;!$"HQU&>&2A&0:GV#7<
MDR\1F/BQW)Q:=C))\`5R$F)AX#>W'C#3@P`O)9`=(7#XA"*\?P^QX?>6ZR`*
MR+Q&-G3$!1VEXA!0J?K`Q`Y"!.G`RXKF1H!X_IBB/W.LGL$+_I<$$Q"CAIU<
M#FQA+&=VH`@FYOAAU0%F?>"`)(WJ3A"[I^TCR<21^K3RP`P17'2D`-7.&V%9
ML+"9-XVM8X5_M9V"X!ZE*4+WR$M)UF&-0&J\060/$3V3OV%-H60]?B):$!SN
MFS5H*"W%`=#T<=Y87NB89CWV<R3EE,QWVTUG29A#?N.%O-V9;!-0I!4:C$1%
M1$.3?@X?-O03(L@P*L.^2>]E(J5I]:!X+5J@*BT7=&:0KB4"BX;54]KHUFZY
M*P"E/!3)A989GB$/;&PG8YP>3C6G,\T#EGX5OK*GY2:M6(9L(T5U=U%X_CNF
M@LES%8=8HO06/05^0&Y+)Y4<Q9_Q`>9?R,_F\10MT;H0]O#^Z=S73_5.#_[,
M@^QU%&<R]TW\BDH73/HNTN*HU++\DW&<6L`744(%,V96OD0.,$+5!)QXR3@I
M'+O+W[PP1WC_4,@L!SBK-M!EE$;@.9+!/I#=Y:15FOPF##*\9.$%(<5B30EX
MW)!&Q::`;[":VD8#,;6MS<>&8NG*?'59FAM+XJ_0,B<!2T77/K[V0R]E1HE(
MU+)T:>9+9/F-1'6]6LBTE5!TA<BJ`[T"\W%B3;%L8>R&MBZ0\/+PM##XDLG!
MA;&3HLE@&/GM#"7X/-X;1^AP'>/'L_)K`<=IT-5.\3((I0`]Y?`!FW^-&P#&
MJ`44;-$4,+84T/<V`LP(C5@3U%CU@`,IE''CR`$=ZZ]I]U((^E$28XE:P+$5
M,@C+20%]<Z83WWXC?*FU@%_L4,>7)84;UVEU?=QS8FNXY8'B)5J=.EB"6!ZV
M>.2;D??G\RM"/]'!1(L.KE@8Z'U3%V@W<.K+-0#]VD<K]'E"=>:J/>NM#O%`
M9P&>[6AF/TS3'"T_;^)H[ZKFWO(HMP;]8HBB=324T(WMW*'$]\&?>;`L\"K_
M@"(N48!$;:BW1K1,%4R)W-CK'0I[2Q*@4;2<XID1SXFW<1AZ26\=Y]3H.>4V
MH)\N:64(`KE<H-$[%+B4;?RT^VVE@71(6"X($;RT44BT!?WB22OCD)0/FE*.
M%3F;)_[*8Y/"G!:"?I%$$BQZQ[615)V@($^AKI$G:+L]*<23V-ZSZU@`J(3@
MNACR-G$:D`Q5^X,MKB_!%I=@BTNP!2_],U@&7O(Z\W822N1K4^M8&6S!$<9R
M:/?RC+PU_I$\.I5B2Y<AWQ!7A@[&X.'&@%I&)KLQ'T[&PKNH71G@(`TY..A0
MUF5P@C5#S[43["%2X[63_6P91)YRBWZ;)SN2UG+K/D)?BS_Q(QIE&C`H_.,`
M/,8$+"N3$T-:Z_G4H"@0&:`Y8KB0-C))8A^A97J'%46D]"(?5:^BY8]A08")
MB(%S?822;1@4("(!O8I8T!%?+(_@]EVT\=/G"/?O:Q(4;U`&J4_\G&4FZWH=
MI.0FC/T$F4HCP/$BDA`WDLN%]\CV,N]6,&+6_3BEOB,H4\W,^!'VJ!:(XL9]
MH`&1`R;&E3"MHJ&$VFX+G<G5O[DXJ2].ZHN3^I(1R#PX7S("+QF!IF*H/R7"
MG$BI-BD1CKBF=T9>+D?DO9\X*BB=)&=@6CT;7=4B@2QW61]))9R-J>6AB9U%
M$-&198EB][S\Q2-\IV)*YX-RP(YF)A)TX(Z[[L2$6Z-?$F)W4A;86ZR('ZW[
M;F0BS59QDA%6X5OT*/4(`JV\C7F$+$$L9^(^$4L<0D.O`>WY9>(C"6?M'3BK
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M*7R\_KO!>T.=U@;?4.('6[*`W1]W<QGO]8-&[2VN30QW5%P+9(34MJ'4>=J[
M\X)$1(M&+[BX-I'@BC&,J;WO,`2U#215&/TXVJ9,]+$UO>*M:B$`"Q]^K<6U
MB014#+#$HD"SR'1Z^:!^[;"X-B=62FH*98NAC;P$%-EAA.=HE&9;P?IY0M2(
M]WBC./++_^&@+%%[<6TB510;<4F1NN,E.O?UQ#[986OL:+EW/=8S(WC[*;6&
M%M<FY@&S;4)=NLH\/KAM'OO=X[B03X>EL-I<7-OEOVLEZ-X'XY`!C9/@.<`B
MD-^6)'SRAD*IN[BVRS4G)=`.>,,>!*D_4"UB!^!76%S;X1,32['#RNXG0*H=
MS_;!8F*0$EN^6NG%C1UN,H$(.SBA7&420Z\ZCT3/XSQ+,R]:DFQV,H5$RY[O
M)SE98$KI9`:F0G.+&SN<7VUEW%F!W;GAAQ$$=YZ/A-30K"J+&SO<9S)R[-"]
M)'-7R=SOO\=D;M:S9\T4RDK?;MVF9<G=.N0U+#JP]YP@Q`G"/2T$E+"M1?<4
M.(]E,Q4?9EPMK1A0'C9=H3RE@Z=<,]0^Q7K#,J^P==VB%Q3&FT*BJMOW^*2$
M=];\*$R5-H!2K%E@4"!3E`8X38'YN`"9+TAP4.F2VG6?CZ2@&E#RM`)X8@%@
M@Z)$D]_$2TA4E]0:52L+E/W<^5)U*")8GKLD:I(KUT%IH+1GKIHE$-EUWK#E
M[!]QF$_BE?='/D?^*HK#^!GW]C[T^?.>H!I0;K-`\Q28Q'*8N5SM^_W@1=YS
MN=#*@T:I!)3!W`8RNA1N)'OH9=("RF3N8+F3DM7R#/:V5%O0J<U<:.APTJ6P
M.V]=_P/S!CU76@.),4#Y<IBYK#:<J^XYV7A:VH7*@.[JO*)#'Y;GQS.\)B0P
MIMS3]..H<#;/XPE*GN)D?1<GXVR%-49(>U"4%D8P\)*(^SJZUN]`97?K,QKZ
M9*5=26YL0J?QJQ=FK]MH`9Z1'12$RB'OW$I.I(3._3I#&G+Y>VSN>$%_"?SF
MZ<@G#4&EHG=M)NI:Z"Y3[>Q/O?)DKX4`/M72"_:YN4U-2]SP=V=G$KHV])7G
M`]54L:*%F/R'GT7U7#(!24UU]];'^2-^OO2FT]YH/BM#>-)SA^Y4(>L8N3)=
ME,2#D"2X,$[S1":&1[(%@)<9J-FRHH<9V)6`0W?D]<SW1=$EL]LE115-X%5F
MU@%^GX$/DP*T+CW/<"B9K/.85@OXP08N4@K@FAI&-$,O*/H=>4DU7?&O[AC%
MS7A_@:5QFN./*8<3[*54A?"\PW(5@=]@T#;3U@6R_`T&JGRU-`M5K&M5(6.3
MN"1:U9B=QF%X%R=?O62I!/^AC+H&_*8\]69>DFDZ@E([_XG\S.90XM6!#%EJ
M"ZB,<+NA;)0C@<L!M!Q\VP1)X8A[0H$JKLQ6(..>ND.:)^[.`^[<LJUI,@<,
MJSK;9%Y[/%C+9#Z(EF>8!'BI2Z)ZH!%5G8_T2L*=`]&YP7UV`CV@F"PVU%\0
M^3=:]C`XWC,Z$*#IG""C!<NV?0*1FNP*Y9J$"O;2;C$Z%&'A#I,AE-X-J.I'
M0./(C#`JKFK<W<R>?[T##!0S:+U[;^7.6#!XFFZ<)9H%#1TS:8*JE`&\!5<Q
M'HD3B)2U\-HQS@U^X-*6-0&NIH`C1U405QP;4NC+MNF&)4AKL+M`4X!0GJW9
M'[+Q7")Z+A$]EXB>2T3/):+G$M%SB>@Q":1+1,\EHN<[C>@QXB$^(YX,D#[L
MZ)/:W0GD[.Y8(QX0T&-"$K)VZ$,!HKK]Z*5H64\U!DJ#V9^Z2%K9OCM3%'H9
MZ6&:I44"VB/I\,1[)<G3J<19NEW#VR,V[9^S9C^2#IY`U2,&6J:1?WS=%]G*
MT"/^G=W39[TTS<OTKY2D&?M8]-O@)5AB"YIB/7`4V/FW@9>AU@;"F&/.H3=H
MGZ[!UOU;C.$+PB![);IZ"*)@G:_/;>;43@"OF5;9.TN!CO`CG$%EWC<##+_L
M!%`0LPN&OU.@&V\/:U79-$C_N$L0JIX<`9CO.5T`BM.VRNCYZNN0;<`IDS_O
M3,_I`E0,N_TVO]<?]//4&HW^4:RQ1Y6E<8Z2-<^1U=U'H0E0.S7LSC0&S0>D
MT9191$&GA:`I53LUE9V$VA[L#D$=H?-Q_Q\?>[/!;7_\,!F,9KWY<#S:.D*O
M+IY0J&"CF;]"RSS$W16NO"EKZ17%)FG[!G`H4V?C7:-^[`Z;T4N<#[LZ:$65
M83@<T>TVA+8L^K#14EQ<N+>EAS)8CF&\7L>1'''^25DS0JF.X&!`1^F[H0SY
M!:U_;_XUEGS70**6&<%07*#DI("^YQ-@A@NA)JBQZID1F"2/&T<.1RZJM+\X
M8D3<D-04RI?"D?N80L9^(WRIM8"O^M3Q94D!??G`(K,NDG:WV_>"F9GW4"6]
M-/#-5(=G$+[0ICU>>=I1_O.5K/*@U$%L;4M!LY?`L.0+DH"`]V7S59RG7K2\
M"UX$3S`S*X`R]7`U3D&(*X69!XBC+L^";TI`[<J#\N.TQ.E`"$,/#4=='A09
M(O'1;T=!I#;.1,V`$M2T1%5&-NASAAS8<Q2=R#%?!4F&4*0$M[@A4**8EH#+
M20=]])!<,>-<'=[#2J#<+6U7SA-)H$\4P.%,]Q(ICNT;AWH"[)P7+%J49/F+
MQO6WSXJH!#Q<B]^)K(M69W$%ZY72A"C'7%A2=[>C-R6M;5(@L$)EZ4ML!W1L
MQZ&[;?^H'`:.>Z/.K>=H#(9(9MNO8G>/"!X]75>;L3YOXF@O./>R5KDUX%B,
MKJRFF2:T.0WP%`V]$/#"^JXO4S_4U"^?]L216KX11Q<%)04X07@AFT6A:#6T
M)AQ=$A3$AW8>=S_5D/R$AA,,J0H<Q@<QK6S%=HHRE+M)N+EL$DR*_?\4QTO"
MU3F*([3>A/$K0M5C]_/$PQ+Y1*0F$?\*+3NZG6BO%;M/H:7'%7]%$-%_4,[`
M*'Y%S.C&<"RDW=`V]\#O]1`M)Z$7C;PU.S:GR\\!;S9.[*'AC40SR>VVOD$U
M"HGK95QT71A8R:P#G'G0%<!T<^)IP8D#;:&46[QLRZPY53G@G(9NUYR:D):3
MON[$$:X71R6!<Q].8!"@M>NT87&;Q1MORL&;_%K`20L4G5/B3X0BF!F]2>NV
M.`B07PLX":$Y7@<B0'OB%``;A(2S71VR>CW@K(3FH!T)86A`)JWG\Z\H;#(S
MUNM!<SXUQ^U8"D/#*JE=EPJ=%=>$YC5J`=Z)'-#AE2K[$:G06'%-:*ZA%AN3
M$SG<X#V;D@.QX%2W*P.5FM#YD>Y`0LL#30M9A(Z;6BFH_`.Z\CD`G284V(G0
MEC!4B-%!.:C4`A8"=)Q.NJP+J>,@K7/"57)=BN&JEX,.ZY>$Z[C+T$<XW?<H
M<JO#O5*FAV*;X+'Z72V:K32B[>QBZ$T=ZWJAO!U(BRUF.HS*G*U/29QVDF7$
M_MKB"M;EU,YX&M[J-5.3`TM8\^LPJFIX3S9W<M^LW(O%%3!E"(1YZU6?:UL!
M'7/"D<Z*/Q)WPBX6\6R3N+`GBVM8-Z?Y$[R4"J&=XR:.@IVFAE&6!%$:^.>U
M?<;W%]>POF'S+9ZCN`[O$@P+E7Y_"94&"Y5N:<WC/$LS+UH&T?,T#L.[."%_
M['#>H7_0U<#JKI3E1`B<1NV4+T"?QVS+;T&'?W=F69U;\DY_NHQX4ZS$L\Q+
M,CL-&=YU!7P):9DQTS4(?;IG\72W%!9K\PD%&5X;T\JA03;B@V^;("F:VBF"
M%<1POAZ8'B*OR8[/K]7V9_8/I6U'Z)GLJ.R<IV$W',"Q_Y;-T33]:3N1ESN.
M062I'6_'.[F+[-R.3[X%G.-@FQW3]`<=YFB&%?^&4N)J+I:LDJ(@)K\ZYR0M
MVP7@Y!';;%Y!K6Z$C&H$B'<'2<![.J>'3[(SP+DZ%GC_Y!4)?0JU:D#`CP+H
M=UA`3!1TN-32L]QW/+H7A&1*"(8%XT6OVCLC![7#N:DX-@SJ'72"GPECQC`X
M+NY4NS9IP#F6)HP@`)5?W+4G+D"@<2+9`_!D5H?&B8+*+^Y@.:<AT.!IUS'H
M5&*7QE1[)+2YFPUX(8'Z5$X9T3O'C>>X]"6NUR0*Y$9OB/$F-HWOE#GIO]?Y
MCIO5]`H5:Z>`U:1>##H^MOLW^(ZD=0-A(6.E4=S$QQ#P@0(G%68Y,<E*3#I)
M_L3G@Z(4!8YY%!'Z<KKM1!)#,^YX\WA\-4^.Q^):SNC;7$_FT,@;P"U<-PC=
MEUI<R>U>G/72R!L>B]808+HY\;1@)A?R,/*QP,&+%-B"&L!Q55SE4W8)7$',
M1&L41RG6:X[+OTH#QJT$'!"DBIE(%C?"T>9!1G9+PV@9O`3+W`L%FSUJ>?#8
ME>YW?4RY+2<`/9'K2Y"M"O<2<2NO@LT\'N"9*WL5[NP46X*.W6`#*FD`8O$,
M.XQ7$^#?XW`Y1R2>@RQ*XZ\12DC_JY<R^3.\4B/0T05-,*.L!,HRF[FBC[,5
M2BI9^"A3BD+?@&O"DB&9&XOYCAR9,TW7")2!KU^[7[0/9+6<1+3&T2M"UR`.
MZ)WR.0#IYW^VBJG;(.IGIN_JI,L.T)PV9.J&]3%)PG7<93>6M\9!,O=*E-U-
M&P=G2>Y^0=6C)&U1?8;>F+"44*;V;N%)>WFVBI/@WZB3C%76M\SA.FYE09K-
MDZ<M,P]SC44]"/R[1:F?!(5`VC-]6!\RAVM8HP5VIRKHI9MA?W/\UW05A\NM
M-\1[QNL.(4-^\)(_4%90Q>(_%?*.HQV7;"^52B_3T[HY'+^Z+4V??KYSRNKB
M7R12.HB>RP2WJRY68\IG%M>69EYUNA`S%.46X;1$>/K5)3[]$I]^B4^_Q*<W
M"\)T/D+]6%R[078A!A/V=O#$'AKN2YI);K?UZ8W!-#RGLR'`='/B::$SMQ'Y
MQ]Q+96`*U'/>*6M\`-66*V4#+K\JU8LOE/7%0=MTGPQ[!W6D?YG;9"?>S&QV
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M%R+Z]4_7'&6U/\FU>RN(E=J$DG7M%,R0EYFZ)%5[<6WI>R(\6U&4__+`;5"\
MAG+RQE:'>TS*UQ;7AH=L0NXR&?JJ3/=GNTV7A*T.TS1'R]L\V65<E3-V+:9U
MES7(M4SEQA;7P%S1G1I>(W54=O6+Q:%PO;!H'"WI^MU>+O!26:0:6%P#AQIW
M:3WR*J@LYE>K9Z)=(#U*7O`YAB[U*(Y>RF>.B!K3>9QY8?WO)-ML%&>_HVR*
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M`$U$I7H..B<4$7;"T_`5#]A(W2,`Z"B=]/B[Y5T!)F&00^NXQVX$Y&^Y?07K
M6:T4-,-"9TO:D8R6Q^UNI1&>3`[*07,H'$/`!6K?9;L7.(;+J'`'8>/%YCZ.
MQ/L3A5:@Z1).\5-REK)$<F#U[(`9PU%/E4!FRW.2.^+#,)(580>9$M![D>R>
M_*<8"JS&%1X/M^@%A?&&2"G+AB%1&YK&0(P?XP@K)YH3'B75N?%>B0!#L4UP
M.@%3+C?N:4_DM<Z-,6J/:1/)A2F,`4V,IV$P0#,U.7,'UYH^@9`FGC6;2_AM
M<Q@$S#%C*:5U^."41;8-S'YA"BF`.;9+59*VPZ<KMMH5X86>'IA#$V"D78M4
MIVUG#.AWVX>#\]7U>*RN^O.(4Z*G=/\`J,BR=7_/'`H#S7;<A:*T)8Q#6VV3
M00[YR*HIX;D&S+4,_6C+.=<4UJ:JLUVN-,FT887`M6K4'**"]E:D1QO06>="
MTVF]#>F%>*:-L,S;`5.Y"9GGH#-WP%%[[!RW[@@"S4R8O;DDS)J4,'MY2)H^
MI5P>DNZ>[&E[)=H/O33%^B"3ARAKB57'P#1;W5SU'-'M-H2Z0,((C]/"P(FO
M7%SH4%)E,"R7!^^:`I3VQA&:5)\O^LM/[.'7`DY-I:N=MOL320$::<<';/XU
M;@`8HQ9PFJ<J8&PIH$/5!9CA0DV&&;,><+ZD,FX<.1PA4"\$_2B)L40MX(1)
M&83EI'#D7KN0L=\(7VHMX+1)=7Q94KAQ%ZR6\@H<J=7]6:0NJN715NK)KR9D
M5E:ZY\"C/ZO2JO17<Q(JV6]9GW39@0R>AOFOL.X;2;B.NPQ]JM"4*.F%>:'P
M.?)74?!G+EKHZ!6@4R?/L.RQ!;><`>)4,'':+*,*>&XE&R-94/>"&.:3VT:@
MS;(D^`--\JR\;.QM-DGL^2N^RT"F+G2R)!<*BOM`5B;'<J0,?2T8F*/+CM>"
M?[:=5J%\+Z1\1Z0(@9V@I/B=R+IH=:!S,S4ARC$7EM2&K2Q];Q-D7HAGTMPG
MB2B_!RA<HF5!!O_@)7^@C,S->'`-MV3QVPJLU:9I>^"YEUT81&N-0)\S&$:S
M[3#6U#J."J\?RQQ.2YJ3SJ@;:+JL;EQCW'E!4L@WC#9YEI(8F3B/LKLXN??\
M/\9/I2%[CT$89*^<!4&I'7-2!CM8))0UX<A]"5&85/J3,\_Q\O<))Z_EMKXO
MV<1ID`4O-8"K?P`"0Z>#^]Y\<#OI3>>_SZ>]T:S7GP_'H]EA:.BY(T.WL7P3
M+\E>:]'!,K&?HJJ@T9VLSGU\/?B+="2G0GO`49L2L+!&84-I[;Y<D9-5=/$I
MW8@Q49J*&#.NV53D=L=.A*[AT\+`(9IJ0(G!-C5FLX>7Z-#[E,3Y9ACY`G\P
MI2QP?"9=Q32_+[WO3KAY&;;:;`HVZJF.+N=<-U[?8`BG-.&>U`..!14`IH2R
MN>]>))LXP3U^\"*O/!#.,O+_SX&/YZJ[(/(B/R#/:A8O0@31L^AYC&;M`0>%
M"E&CN46;B^K$=*^?\-84\D(MTSU?4,NC+KHAN87UJPL`4T)Y)Y#=9Z=/*$*)
M%^+9K+=<!U%`/!'$,2?+<2M5'SHJ50@A'7EIV9R8[!E3HDR`AJ@J=,#K>;;Y
M!^):'DC!$'%K^>D=5G%=?5^";%6OHFXKLBV#!^/*8*]D-BJ2=S?1`-!QY(\I
M^C/'[0]>2-P3[&W+<6\D;EE852!N5PZ[(KP\H10'OAOA*)-U)T(7PN[MV+%0
MK\+WW!DUH"\S&.#(0?GJRL/MIW*)WZ)EU8%FDF!C)`TJ^-5$)["*,VEIY:%?
M0N>A(P6HB3<;*?)_?(Y?WBU10.!\3WX@*+ZOH8A_M;A'SUXXB+*`>7U,*05]
M5R$UI=+[S;YZZ%;/92>8<]YQ$:#;`(;.3A5[U%>FX;?WV>/>YLDKWO<+N#9.
M"@)YV6G:H3G4*=T%GCX8"$P#'R7^"LTV*`F(T\@+@X>8_`?_RNM%RR'NHA_C
MG_D`J;8#Y"&7Q*^!--#AX=\AQ8+2WIO&EF#IE<6%+<%P@*Q_?EHZ_5Z?'T+O
MLM9[3E!Q!\*8RTX+03M<Y68S>K_!G/`B[3-WQ+1B4-P%#)WR%`__Z#-+\^O"
M5]W')8D;>I9O-N$KWJ_TXQAO94J-5D((0A.56X(B'6!"0T.PD50&G?Q;I(UA
MD3-T'[P@O'O-\&0?X!FFEZ:(I&(_>/^*DX)O3+#Y4V@%FLA`;7^H*)CE3SMS
MI-W+.O+68C^N8DO0#`6J,"L;"TMHNW>T?7SX)==4N1>6[Q@)][:,&M!D`TV0
MH]L`1T`GUHNCZ?->AL"$406<4*#-+=V]$0\PL_9["?+&3_?(2VGWX,=%P//]
M>9JE[=8.N^[$L+I'>+)!1";R+$V-#V=<;D"CYT+>=(Z2-2$PB$3A&<T:!,_G
MES>%]H*ZX9L]$G-*=+>-T"PI+*>%HYHW0<LV`9[JKVX=*J)I\_\"4GRRY1TA
MWG3!K0?^"*U.W+?RN,'5(3OY8?G15R\D<Z"&-:/6&OB[KMTM&$=20I.E,[9Z
M6T:3>5R]?5P2+7Z.<&=W/BO6)E"J,OBSJ(K;0VFAM.W:.T%TBF4.<`_NXC",
MOV*KO%MZ!7WF"YO:3:(J^/.DS=`4B03[9#(+R3SQ5W@J&3\-UZ2KY`G,=!C]
M(PACYNT3K\[B&IC'4Q4[@2S:'A/6.P!Q)RM.2-)5%E)'Q1;7P'R9BN!0NF_H
M0[U'/2TF\L&WH'RQM;RJ$2UT"DTLKHWR2JGB*!*MPOB#U?O>@KNQI&^]S9/=
M$^5U6M>[.*E>%^;Y)I4:6EQ;XREK+N#>+6+Q.;A&\3GQDG%29+\N"S9'"5)D
MB=J+&^L\99)2[?#OP"]&S;-[1WI+GNK%__/_`5!+`P04````"`![@0Q'M.[(
MJB@4``"=UP``$0`<`')T='(M,C`Q-3`V,S`N>'-D550)``.)J,M5B:C+575X
M"P`!!"4.```$.0$``.T]77/;.)+O6W7_@>>7S56-K,ARYB:IR6S)LIS1C2WJ
M)":9N9<MF(0D;"A2`Y*V-;_^ND%2X@=(@9(2(VN])#+1#:"[@49WL]'\^1]/
M2]=XH#Q@OO?^K'/^^LR@GNT[S)N_/_MHW;1^.OO'+__QMY__L]7Z_6IR:US[
M=K2D7FC<`<R,4<=X9.'"&/S5&C@L]+GQ*>[+Z)QWSU^?7QKPTUI$/'#(^@>C
M%\VC(#0ZW1^,B]>=-T;GXEWG\EWWM=&[,UHM'">P%W1)C)#P.0U'9$F#%;'I
M^[-%&*[>M=N/CX_GG(4AY:L%X4MHBD)F$S<XM_UE&_M\_6,7:7`ISO+&Y\MK
M.B.1&[X_^S,BKICRF0%$>\$['H:\<<\"-8?UV#WW^1Q`7G?:O]_=3@4%Z1@N
M\[[DH)_NN9O"=]O8?$\"FH)CJQ-N$++`;]IQXP;4K>GW]UOH.-LIJP%F7A`2
MS]Y.HC3IA,3.V[=OVZ(U!?7HG(34J>S\;9O[+FTG8"E6%+3FA*PV6#,2W`N,
MI$&PN_6ZT^IV"B@M$H;5:-#(V7T4TB!%L_W("_DZS]"`VN=S_Z&=-.)HW?QH
M=L0Y;(,JO*05$2_SB`YE<AQHD(#3)WLAA\<6"1N8]T"#4(X2MTFH\0BS`SF.
M:$*43AXE8+8<`1HDX""`<+VB@50THD5"2Q"N>,4@T"(9A=-9Y4+[L0VM6RFL
M.+5W+$S";;$V9\0.6_1IY1*/@`);W\#?&\[YGA<MY9TX(6\C:6T`:@$4Y<S>
MX.U&2A!0YQ'/\T,2@M;\Y6>R6C%OYN-CW&?O<(H6(!CXX^-DJ*BO!&6IKD[_
M[WG.P`M9N![""(""(YX9#)BD!+F9DT-GS&-BOJ#SC-;V4,C\))YCQ'T8F4Y^
M;A=[2#N-`NJ8WB_B-T@O@#X$!BJR!"L!D6%L.U2#!T;9D5L]0#O'_*-(HV^.
MK@>CZ>#ZJG?;&_4'TU\'`VL:\[^B3<[Q"V#S%)A#$Y9OD(T$VXC13[PN\'-,
M0&V'"QI#UW&^`"F70U=1#L:K?'?_=1+,X'IJ]:S!W6!D3<T;<SR8]*RA.9I^
M]$@$9B1:"CGA[(*6"^BR4D#;_@SSQMCV:+S:]'F24H'O_=[TUYM;\[.2D"3`
M<AF]4901=FB('D\RB@]W%MBN'T2<FGQ.//:7&!T.[C%GGLU6Q.W9(7L`(FBB
MZAIAR*7U(Y[PFV[@#W/RH3<:_I_8/49O=&V,)\-1?SCNW1J]OC7\-+2&@Y=\
M$&V9=44"%IBS<8;*HEAD('(Y_'=1#E>]Z5#LD_%D,(4](P1RXCLP9QHMEX2O
MS=F4S3UP_VT"YJTM7#_FS<>^RVS)#E'$DDOGIZ)TIA_O[GJ3/U`^T^&'T?!F
MV.^-+-@A??/CR!J./AAC\W;8/VV5F&-C[J\H#]?HA?P9L14>#44!26'DXGA;
M%,=X@B>^]8=06(/__3@<XS%S8CUPI^\OERQ$9@;`V;XOECOU9%ND#E0JB,[K
MHB#ZYMW=T(K/>)0%'/ZX&P:CTU9(]5#HVU\6ONM0'ES#Q&T6B@.;SBCGU!'-
MT^C^7]0.+7]"';I<R4Z6?;N1R[%3TF^6V?_M5_/V>C"9_MVX'H!^&UJ).3"X
M&4PFPIP#&-"$5_\SZ%N&91KP<'`W/IU3"1L_$\[AD"EML\USN2PNBK+XW)M,
MX'`Y;9_-N@>SBH)^6JZH%TCMK@HH.<.[TL7?`@-L@`KL;@S>RTNWOB:#6_#=
MKL<].&0M6(U3]`7`O8X97]DJ9_AED>$)OB$Z,+(]O&"69TW7^X#^&0&%@P<J
M42BE=CG;WY2-V*LI&$MP6!N#3X.7K6$2@]Z\R9CS6VL^->;SSD5#'+E42@ZX
MNFMAO$K[?LEAD]3V!^-D8_E;Y-Y-I533+I=(R167>Q?&J[B7E\S[U#3)\KOP
M3,[CDD.=8IVX"KH([0]A?F2MCRR/:R'D'"_YS%56SDD"M+T[G'I-0\)<BSZ%
MT>;-4V,LJ:0N2DZU4DC6>!5W;J2]OV3Y2>*N,H'M!I-+J.0N2X.U)XED=9I2
M^%4FI+TPY7(KN=9-;*V3,&M-KI@]-397"B`73<D)KS*ZDFY>-/LED7)'LG,4
MX.3"*#GH<F&<MD3F!7MU[%RFU-3!Y1(J^?*U@?>3\MI'4IV&HNI4R*KDX3>3
ME=$Y24N!^Q<-I751(:V2]]]06A<G:2EPO]M06MT*:97B"`VEU3U)2X'[EPVE
M=5DAK5(,HJ&T+E^RM/9\XRMUJ8[2E53&W5+TXL!7R2?;Y=AKH'/$15!A\W2/
MG5!PLHJ.OPXNCK@.*JRI;CGB<NQU\*+MK:/(KGO$=5!AIW7E.1;'7`<OVI([
MBNPNC[@.*BS`;BFR=/1U\*)MQ/0M:BX86WPHETPIHK1](WL*N;;3G#V9-5W1
M)F=S*1A49//)SDWU62E_+[>JZT'DS"_%=JK?@9_6?$4:0L*83ETBP@9&+H;R
M;8I=8CA9^^6EGK^"6A!+$PRYD!KDBQ0NPYZDMGO[7"ALGPJ?ZE(>8:G=/B_;
M2:IC<E=!$!5.S:4\R%$KB)?MI=0Q^5)!$!5>Q:4\RE`KB!?M)M393I)(\2Y(
MN5"4KU6<+-^&HJD]Y)7BLY=R/UQ%."_\4%?@^86Z>*J.^/)5#67QO.RC7H'G
M777Q5!W\Y3L;RN)YT09`U3TQV<FC""L74,G1K[YA=CI]<EFZ^9MD\GS<6ABY
M0"0%%`IWS_[MY(#_8"'("9T9HL+B.RP3]_XL8,N5BY49Q;.%*(&'=2M;:47*
M?P))YT]+-P7!GFMJ/0K!%;F0#)QVD53&JZ\`"9V(?%%&@W8Z^;/V$>@!AC>E
M)R\CK:AQR7U3:@"%NMH1`NNZ*2&%K7!<<MIII43XM:V?"`U`B<]#PY/6CJTJ
M?!J7G;WU;=%-#0K^U4KQ6OBHU;EH=3OG3X$33ZS!^!N*&HZ?XC4;7UY,5G'D
M%`&'?*,P6&U)UXHQQ7A2Q#9UPR!]TMIVI4IU38G4NKE(T)+?K6T73><@JSJK
M,HDL7OK'(=.0%;%5FD<6<?-7:]M-TYF42MVJS&*#)'X=L"3*%7!5AM]BQ3];
MVPZ:3J!845=E^!0'?QPR=+'.KM+8*9+XU6ST7>6A5921RWD."S726U2"G1\/
MF8&B*LR,'AXZ<GT%8M799'L9;#MI-KG:6M4JJR+%P1_-=$%]?60E-A2Q#A",
MO*ISLTGXWFB?>=37S-[_S!1]235D4B5?S&5;!%I6_+EW'X1<+$MTZM`R_*<:
M>&Q>B@KT[^`9\^;#D"[1]3DS2`+U_BSD$1J?`@K,/>8[EL!S(IY4[/&8Z^)%
M\Q0V`+\2!HVP]0/WHU4Z"(/N@3JC1-X8E(47]OT@+8DBJ,@]S4YVZ<,.)WPM
MF^X,',X=\XW;[HF+=B(TT'L6'H.*$0V''GC@]-8/@MX#N,#8G^5CMKWO9;.Q
M\+JR#<*Y9FZT*=8J:#Z@CZ_'(9M3YS@LZMDVCXAKSL0-A`"_1H$W$(9!$.%0
M0M;FS%K0(?J,Q!U']RZSS=F,XO+,\.G0CK1D5IE?&;%G,O56$;<7PC?9\&,7
MH);T%HB57.*7Z+9:*'U46II+AD&P*Q?$DB%!TA9///ZFP;LP?;ZGA`Z?/7XH
MQ8E<BGQF-@TFU*;L@3HWW%].B4M!`)\(#!T%?9<$`?XMUIXH."(C^5@=:L:G
MW85"!`$91BAC?..E[(3O%H#)[>B>#O<G]Y9Y`CUH1'(&2Y\=/"9K<4/.G'WT
MX,!]Y`QOR6'L&QW\^.+<YNS)F2V-\+X'S?S9YU^`ACY9L9"X64U6:#B8F#A\
M%WX](ZWFZF-QJ^X&U7&/]N:<BK][3RR[+`O/O_W4'0:CXZ+?/?5K?TF8)YM\
MVI([!QSQ\+GTQ#2DJUN*;^,VL[RCRWO*L\=?-8Q&E*!-Q9S8;\3/LU'>7S`Z
M&SQ1&WIY@,-[!F<W+U'7$$\CBL4\IS!@2.?"/9#25PNE$36#Y<KUUS0NFFN*
MRSS6HU\BIQY,<WH6L'V4*,H"ZD13NBER^=QPRI6)V@7YG%0U.EAE1J$:N#[6
MH!6)E]@3RI;W$0_BDS0*%SYG?U&GMT3;+D.>&OA7,Y>.9_J-Q6CF3$90]@BH
M!<O2F0KEV7RV483;QYS%>N(#>N+Y$)R\/4L#@T=SRI^-!."VC<&/.9TN"$=G
M.1/_N4;[PK'\*VI&(2X/)Q\ZVP<Y436@9U8QM@:DF[-X_MMX%YLO0G,FC8\U
M0].'W&L:V)R)E0A3Q)EFXWJW9)6C4@E:3:=^$^JN?"\*<J(!!<;7V6A?%80^
M(NJ38"&FB6];-B:O$`+.7+QX$2%IV$OB8<$QVQ-?1P>N,2DE1V_O'C0R\6X<
M<D<IVC."$G.%+Q4C3T2Z2E:>"K!&M/5=YF&JJ<49<6\B<3QL33D%>O?M0",>
MX*PY88&B@%6@-:(NL\ONF$N#$.Q2'*6@M>K!=%1.53,NZ:!=@)H+:Z,;3:_L
M*:LB?"\TRN(;J@@:T2CU]7?%`KZ+I(@[4/?+:-FS\2K`-<4X#;::,]2+P=7:
M6C#NC`D/LU9?$Z3O@`<B68$Z0OU;_D:6Q70&&<1W0-TM`_,[H.(.B<)YJ`:N
MT=ZL5R?2>*0ZBD9T8H_F+#:^'PEW"@>^O%G'@[XXT](!7P6@D3`^<.)$F$*[
M<8A*BZP:1",ZLJY[FHHEADK40/*RO")24XNA3P1`C3`%8K36\R)E9Q6JRE$-
M_'O(?LBNR,U>&SS9-`C,V4:_IVD?%4M9!5&?%9U]H]L/)":VO%TCQ?,)F(M?
ME8F[QR/W#TIX68ON@-.5(G#5<)[UY!2`]'I?F%,+56I2LU='/6`=<>,=7+?Q
M=\!];TJOY\26*W$W6JQ"RTDA-5)K.=L"F$4".O1B:4WJS!`9J#YD3:%?&O1@
MN^>+NY;3D'8`:J3MDJE:C[X:396`&M*$IXPB5=6@&M$U3EXPBM3N[![*/\]M
M&/$2=K]<AR.XNH^^M?"C@&"^6L1#2KV1'TJ"%;L`-1)"U51E46`%6)THHWQI
MSI)+$WC#)Y>N(6W5RFJX(8Q_(FY$Q\FRS[X=*K?ILTW2G'732XRR/G!Y#>:E
MF'$V[V`'X,$&SU=/"\\>]T)=2615`Z./+9#S.7WO`0MT>/-,,L\UO4>O+8DX
M#[V0@B]79?DTZD$?)NQ9^;YX`>"P;KY]:'3WY8`)#<`AM!=X;Y0^4-<7GY+<
MY*0GT9G2>=$,3:.C8QR)"`5QW3B'I#I#?R>D1E1MYH:OP-!,K+CID6O6,5)?
MG&GUO8\"@$;"^,UWH[&_(%\BB]H+SW?].>8PNW9IB>V$U)*J.^+!42"V>2U-
M4CB-*-I3F<MRUP_OZAMOQEJ?](%Z&"5,+R5+7-$*"(V$*RX-;[P`DXO<UW)J
M=SU83B@B1_CY<DIE$QT\P>G.`NH,GE8,UMF-SV>4*5!8@_B=T%R\F;D3]$"Z
MCNA$U4I$N!&;QB!I#117KFHO!WJ4WVQA5]!Q\+IOWN^_!\<:[!JEGO2)3*37
MC>))8-"GG)XJ!=#1"B[/59:26@&BT2&,-D(VLL@>RIYD#8R^E$S9TRY",B#Z
MTC&(;P05GHZ8)$+<&%-?JBWJE6:.":08]=Y%MPJNOI2GL?V=N[``IQ%%PH91
M42R[`#6G2;H)=P%J3M/`1<]1B:H\J.9T68_455R!>5#=Z:I2BBK`FM-6J0I5
M@#6B31B`I8^=]-!HCX-O5^LM2))Q)'*<DSN4B8\3@4.<6O[Q54OP@$17P=`K
MI61]RT$U"DA\.[(_4[2OJ--[H)S,:<XG>Q8YU$]((^]8Q%JQ*`K6T)6479*T
M:K2;AQZ^)@4K)5.XID1$'9!&M(Q\=.\!P^?K.G)VP&E$45I5Z%??14<@>2]N
M/GJ4!PNV2E]\5U8C4L33B&(S7%">3K]$E[15H]GOK1YSZBU30^,8JK>Z;[50
MU#?1HIAF&.`+K6SN!Z8FW1'^A8:Y!"4S+HES34+:"ZI.JF-U>%A*R2$!QYH[
MNDD!.'%T)KNA_-9,"5JCS1.GT6W6<,4J+^7=[4;(+O-G3\7KP^$3N:'T/:>D
M32/Y;+7+!]]W<#7!04K3NG>4/V!590OX'L"44`:NB]\C0'V5R^XZL)^L-#6]
MIY;8K%-0J5_H.`J3?)[5BOO$7I3$K@:NT4I(BNW"A",;;?D_&'4=K-D%#S/J
M%:\MX.>0\'YHL6SO_ET<+/^O7[$NF7JFJ%GV?I2D44>:I"<0;%;J$H$!3D%Y
M)4N;=5JY/E_Y6$5UFRNTJ:J*I6.9!WS#[.%8$X-%)%'2^W:A$Q_@9\378]AI
M90++;1K-?(*FC+V@4QP`GQ.7W?GX'SPB^`$.C[BV#[_+.:2-436BNP>_04&F
MQ:NFT6KEKD7=4OP$(JE/+=T'62?:.27F[);F"RKFGF8UZ+/7QHR=+U%%1;@2
M\8$N:O%OV%PNU[\+_CLP?!)*)O3/*$YG`=/M$33@C4.$.?.0LP&4H+\>U4>\
MJ9K<,@-K98GS1LLV&'J_,=?/9834@FT=S24)GB_D#%-*;Y;@Q++O*8HM\8S3
M;XCAC#YZ[/FN7!3F)[;/X(F)V^B)QI-LOD98FE&<"2Z__JDN]+QMK=7J]3.H
M):9X(!2(DWQ03IH+EE8^3I/`)J`3;GR.8:Q=:62UJ'61KN>GNNY=1P,.*'>C
M#3>NDWSU]*MHXJ-I$VHC=6S&T!_<WN<?$P866MF5/*23^M/E*+Q(-$%QM\L/
M(PF/S-A"\^;"TL&+_X.GE;CL%)>H0PMVX:XGPI[-??2H(:(VO(C-$63%T5^(
M9NX0]MR0<@_\MJ1@2?I]L%B/'/&=9X,QZUX]?T4!2%9=YKU88/DXW0D)`65M
M>LFZ$5_!*QXW*AA')7(3^-B#QOAJ*2;&BH_YQ5HD]Z%+6816$46C@S8S9[P*
M1)<(G[\KI$YUHQ[T84)^LB9G<P:G@<AC+M6,V`E:EWWPE5=P._[2+_S\?U!+
M`0(>`Q0````(`'N!#$>O]:6&B;<``*[;"``1`!@```````$```"D@0````!R
M='1R+3(P,34P-C,P+GAM;%54!0`#B:C+575X"P`!!"4.```$.0$``%!+`0(>
M`Q0````(`'N!#$</"6G+*`<``,-3```5`!@```````$```"D@=2W``!R='1R
M+3(P,34P-C,P7V-A;"YX;6Q55`4``XFHRU5U>`L``00E#@``!#D!``!02P$"
M'@,4````"`![@0Q'571Z&_$X``"</00`%0`8```````!````I(%+OP``<G1T
M<BTR,#$U,#8S,%]D968N>&UL550%``.)J,M5=7@+``$$)0X```0Y`0``4$L!
M`AX#%`````@`>X$,1WNO>G#.;@``ZR,&`!4`&````````0```*2!B_@``')T
M='(M,C`Q-3`V,S!?;&%B+GAM;%54!0`#B:C+575X"P`!!"4.```$.0$``%!+
M`0(>`Q0````(`'N!#$='[>+B.D4``-95!0`5`!@```````$```"D@:AG`0!R
M='1R+3(P,34P-C,P7W!R92YX;6Q55`4``XFHRU5U>`L``00E#@``!#D!``!0
M2P$"'@,4````"`![@0Q'M.[(JB@4``"=UP``$0`8```````!````I($QK0$`
M<G1T<BTR,#$U,#8S,"YX<V155`4``XFHRU5U>`L``00E#@``!#D!``!02P4&
2``````8`!@`:`@``I,$!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624464827456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Detail Textuals) - Jun. 30, 2015 - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rttr_AndelaGroupIncMember', window );">Andela Group Inc | Corporate management, strategic and financial consulting | General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transaction expense</a></td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="nump">$ 99,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rttr_AndelaGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rttr_AndelaGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rttr_CorporateManagementStrategicAndFinancialConsultingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rttr_CorporateManagementStrategicAndFinancialConsultingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624282201120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 4 &#8211; PROPERTY AND EQUIPMENT</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Property and equipment consists of the following:</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>June 30,</b></font></td>
<td style="text-align: center; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>December 31,</b></font></td>
<td style="text-align: center; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Estimated Life</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>2015</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>2014</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left; width: 861px;">Computers and equipment</td>
<td style="width: 14px;">&#160;</td>
<td style="text-align: center; width: 169px;">5 years</td>
<td style="width: 14px;">&#160;</td>
<td style="text-align: left; width: 14px;">$</td>
<td style="text-align: right; width: 141px;">5,487</td>
<td style="text-align: left; width: 14px;">&#160;</td>
<td style="width: 14px;">&#160;</td>
<td style="text-align: left; width: 14px;">$</td>
<td style="text-align: right; width: 141px;">5,487</td>
<td style="text-align: left; width: 14px;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Furniture and fixtures</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 1pt;">7 years</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">4,270</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">4,270</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">Total property and equipment</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9,757</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9,757</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Accumulated depreciation</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(5,191</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(4,585</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Total property and equipment, net of accumulated depreciation</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">4,566</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">5,172</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: center; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Depreciation expense of approximately $300&#160;and $1,300&#160;was recognized for the three months ended June 30, 2015 and 2014, respectively,&#160;and approximately $600 and $2,500 for the six months ended June 30, 2015 and 2014, respectively&#160;and is classified in general and administrative expense in the accompanying Unaudited Condensed Statements of Operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13-14)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624269437344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Detail Textuals) - Jun. 30, 2015 - 2015 Stock Plan - shares<br></strong></div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rttr_StockPlan2015Member', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum aggregate number of shares of common stock authorized to issue</a></td>
<td class="nump">328,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription', window );">Description of exercise price for stock options</a></td>
<td class="text"><div style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The exercise price for each option is determined by the Board of Directors, but will be (i) in the case of an incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share on the date of grant; and (ii) in the case of a nonstatutory stock option, no less than 100% of the fair market value per share on the date of grant. The options awarded under the Plans shall vest as determined by the Board of Directors but shall not exceed a ten-year period.</div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rttr_StockPlan2015Member', window );">Stock Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rttr_StockPlan2015Member', window );">Incentive stock option | Employee - 10% stockholder | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice', window );">Threshold percentage of fair market value per share on grant date as exercise price of options</a></td>
<td class="nump">110.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rttr_StockPlan2015Member', window );">Incentive stock option | Other employee | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice', window );">Threshold percentage of fair market value per share on grant date as exercise price of options</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rttr_StockPlan2015Member', window );">Nonstatutory stock option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice', window );">Threshold percentage of fair market value per share on grant date as exercise price of options</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the description related to exercise price of options issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents a threshold percentage of fair market value per share on grant date as exercise price of share based awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ThresholdPercentageOfFairMarketValuePerShareOnGrantDateAsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rttr_StockPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rttr_StockPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rttr_IncentiveStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rttr_IncentiveStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rttr_EmployeeHoldTenPercentOwnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rttr_EmployeeHoldTenPercentOwnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rttr_OtherEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rttr_OtherEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rttr_NonstatutoryStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rttr_NonstatutoryStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624279828864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Detail Textuals 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Period of lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals', window );">Minimum monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfIncreaseInAnnualRent', window );">Percentage of increase in annual rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Period of lease agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Minimum annual rent</a></td>
<td class="nump">$ 107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to monthly payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_OperatingLeaseRentExpenseMinimumMonthlyRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PercentageOfIncreaseInAnnualRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage increase in annual rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PercentageOfIncreaseInAnnualRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7661868&amp;loc=d3e34039-112682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624206181776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Detail Textuals 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 02, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_InitialPeriod', window );">Initial period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfAdditionalCashBonus', window );">Additional cash bonus earned as Clinical Trial and Fundraising Bonus or a License Event Bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise price of fully vested options (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,890,824<span></span>
</td>
<td class="nump">1,788,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price per share of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.062<span></span>
</td>
<td class="nump">$ 7.059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AnnualExcessMilestonePayments', window );">Annual excess milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Andrew Ritter and Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of fully vested options</a></td>
<td class="nump">20,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise price of fully vested options (in dollars per share)</a></td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">432,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage of option</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Andrew Ritter and Ira Ritter | Share-based Compensation Award, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of fully vested options</a></td>
<td class="nump">152,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise price of fully vested options (in dollars per share)</a></td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Andrew Ritter and Ira Ritter | Share-based Compensation Award, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of fully vested options</a></td>
<td class="nump">140,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise price of fully vested options (in dollars per share)</a></td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Andrew Ritter and Ira Ritter | Share-based Compensation Award, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise price of fully vested options (in dollars per share)</a></td>
<td class="nump">$ 13.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Non-employee directors | Three years vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">1,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Non-employee directors | One year vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">453,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">453,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_AnnualExcessMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual excess milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_AnnualExcessMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_InitialPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent initial period of stated event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_InitialPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PercentageOfAdditionalCashBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of additional cash bonus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PercentageOfAdditionalCashBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rttr_PresidentAndCsoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rttr_PresidentAndCsoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=rttr_VestingPeriodThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=rttr_VestingPeriodThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=rttr_VestingPeriodOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=rttr_VestingPeriodOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rttr_PresidentAndFormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rttr_PresidentAndFormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rttr_ChiefStrategicOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rttr_ChiefStrategicOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624273014832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Detail Textuals 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">108 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,788,717<span></span>
</td>
<td class="nump">1,890,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,890,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,680,247<span></span>
</td>
<td class="nump">$ 91,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost of nonvested stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of compensation cost expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Executive officers and employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Options to purchase an aggregate common stock no longer considered to be probable of achievement by September 25, 2015</a></td>
<td class="num">(41,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Executive officers and employees | General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 880,000<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Executive Officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,729,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,853,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,853,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_TermOfShareBaseCompensationArrangement', window );">Term of employee share base compensation arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of options expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Minimum | Executive officers and employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Minimum | Executive Officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Maximum | Executive officers and employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Maximum | Executive Officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_TermOfShareBaseCompensationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of share base compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_TermOfShareBaseCompensationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares purchased on the open market during the period for issuance to employees under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rttr_ExecutiveOfficersAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rttr_ExecutiveOfficersAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624282323264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 17, 2015</div></th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">7.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Stock Split<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624205977840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 1) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">8,887,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of preferred stock and preferred stock subject to redemption converted into common stock (in shares)</a></td>
<td class="nump">3,322,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Preferred stock, Annual dividend rate, per share</a></td>
<td class="nump">$ 0.00556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Original issue price per share, per share</a></td>
<td class="nump">0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesATwoPreferredStockMember', window );">Series A-2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,687,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Preferred stock, Annual dividend rate, per share</a></td>
<td class="nump">0.032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Original issue price per share, per share</a></td>
<td class="nump">0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesAThreePreferredStockMember', window );">Series A-3 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,220,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference, per share</a></td>
<td class="nump">0.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Preferred stock, Annual dividend rate, per share</a></td>
<td class="nump">0.04957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Original issue price per share, per share</a></td>
<td class="nump">0.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,658,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference, per share</a></td>
<td class="nump">1.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Preferred stock, Annual dividend rate, per share</a></td>
<td class="nump">$ 0.09524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears', window );">Preferred stock, undeclared dividends in arrears (in dollars)</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Original issue price per share, per share</a></td>
<td class="nump">$ 1.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PurchasePrice', window );">Purchase price, per share</a></td>
<td class="nump">1.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference, per share</a></td>
<td class="nump">1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Preferred stock, Annual dividend rate, per share</a></td>
<td class="nump">0.104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Original issue price per share, per share</a></td>
<td class="nump">1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PurchasePrice', window );">Purchase price, per share</a></td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents price of a single shares purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of cumulative preferred dividends in arrears.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAmountOfPreferredDividendsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePerDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount per share used to calculated dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePerDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(d)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rttr_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesATwoPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rttr_SeriesATwoPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesAThreePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rttr_SeriesAThreePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624282253184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 3&#8201;&#8212;&#8201;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company&#8217;s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2014 included in the Company&#8217;s Form S-1 filed on June 19, 2015 with the SEC. Since the date of such financial statements, there have been no changes to the Company&#8217;s significant accounting policies, other than those detailed below.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Deferred Offering Costs</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Deferred offering costs, which primarily consist of direct, incremental banking, legal and accounting fees relating to a planned public offering of the Company&#8217;s common stock, are capitalized within long term assets. The deferred offering costs were reclassified to additional paid-in capital upon the consummation of the offering on June 29, 2015.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Net Loss Per Share</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company determines basic loss per share and diluted loss per share in accordance with the provisions of ASC 260, &#8220;<i>Earnings per Share</i>.&#8221; Basic net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period. Diluted net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The potentially dilutive stock options issued under the 2015 Stock Plan (described in Note 8) and warrants on the Company&#8217;s common stock (describe in Note 7) were not considered in the computation of diluted net loss per share because they would be anti-dilutive.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">All common share amounts and per share amounts have been adjusted to reflect a 1-for-7.15 reverse stock split of the Company&#8217;s common stock effected on June 17, 2015.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Recent Accounting Pronouncements</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In August&#160;2014, the FASB issued ASU No. 2014-15,&#160;<i>Presentation of Financial Statements&#8201;&#8212;&#8201;Going Concern (Subtopic 205-40)&#8201;&#8212;&#8201;Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i>, which provides guidance regarding management&#8217;s responsibility to assess whether substantial doubt exists regarding the ability to continue as a going concern and requires related footnote disclosures. In connection with preparing financial statements for each annual and interim reporting period, management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). This ASU is effective for the annual period ending after December&#160;15, 2016, and for annual periods and interim periods thereafter. Management is currently evaluating the new guidance and has not determined the impact this standard may have on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624282248080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,194,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of preferred stock and preferred stock subject to redemption converted into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,322,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares sold</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares of common stock sold, per share (in dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Aggregate gross proceeds from sale of common stock</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PaymentsOfUnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PaymentsOfUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents cash outflow from underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PaymentsOfUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624208354688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details 2)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 07, 2013</div></th>
<th class="th"><div>Jul. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.55%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">2.01%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Maturity (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624206306864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 19,658,994<span></span>
</td>
<td class="nump">$ 2,747,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">42,079<span></span>
</td>
<td class="nump">57,115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">19,701,073<span></span>
</td>
<td class="nump">2,804,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">10,331<span></span>
</td>
<td class="nump">10,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,566<span></span>
</td>
<td class="nump">5,172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">19,715,970<span></span>
</td>
<td class="nump">2,963,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,389,443<span></span>
</td>
<td class="nump">1,083,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">972,992<span></span>
</td>
<td class="nump">168,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liablities</a></td>
<td class="nump">1,022<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,363,457<span></span>
</td>
<td class="nump">1,254,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of June 30, 2015; 8,887,500 shares authorized, issued and outstanding as of December 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 25,000,000 shares authorized, 7,788,028 shares issued and outstanding as of June 30, 2015; 50,000,000 shares authorized, 465,378 shares issued and outstanding as of December 31, 2014</a></td>
<td class="nump">7,788<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">39,124,630<span></span>
</td>
<td class="nump">3,399,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(21,779,905)<span></span>
</td>
<td class="num">(17,904,319)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">17,352,513<span></span>
</td>
<td class="num">(14,495,042)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity (Deficit)</a></td>
<td class="nump">$ 19,715,970<span></span>
</td>
<td class="nump">2,963,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember', window );">Preferred stock subject to redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock subject to redemption, $0.001 par value, no shares authorized, issued and outstanding as of June 30, 2015; 16,378,646 shares authorized, 13,399,668 shares issued and outstanding as of December 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,203,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amount of long-term deferred finance costs capitalized at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5879-108316<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624206185216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Detail Textuals 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">126 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">1,890,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,890,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,890,824<span></span>
</td>
<td class="nump">1,788,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price of outstanding options</a></td>
<td class="nump">$ 7.062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.062<span></span>
</td>
<td class="nump">$ 7.059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber', window );">Number of options subject to alternate vesting schedule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options forfeited or exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">36,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Remaining options vesting monthly in equal amounts, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Consultants | Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost', window );">Nonemployee stock based compensation expense</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Consultants | First anniversary of the vesting commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage of option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Consultants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price of outstanding options</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Consultants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price of outstanding options</a></td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents alternated vesting shares during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAlternateVestingScheduleNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with non-employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ShareBasedGoodsAndNonemployeeServicesTransactionAllocatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=rttr_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=rttr_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624282201120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND PRINCIPAL ACTIVITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND PRINCIPAL ACTIVITIES</a></td>
<td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 1&#8201;&#8212;&#8201;ORGANIZATION AND PRINCIPAL ACTIVITIES</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Ritter Pharmaceuticals, Inc. (&#8220;Ritter&#8221; or the &#8220;Company&#8221;) is a Delaware corporation headquartered in Los Angeles, California. The Company was formed as a Nevada limited liability company on March&#160;29, 2004 under the name Ritter Natural Sciences, LLC, and converted into a Delaware corporation on September&#160;16, 2008.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company is advancing human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have a meaningful impact on a patient&#8217;s health. The Company&#8217;s lead compound, RP-G28 is currently under development for the treatment of lactose intolerance. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On June 24, 2015, the Company&#8217;s registration statement on Form&#160;S-1 (File No. 333-202924) relating to its initial public offering of its common stock was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;). The shares began trading on the NASDAQ Capital Market on June 24, 2015.&#160; The initial public offering closed on June 29, 2015, and 4,000,000 shares of common stock were sold at an initial public offering price of $5.00 per share, for aggregate gross proceeds to the Company of $20 million.&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company paid to the underwriters underwriting discounts and commissions of approximately $1.6 million in connection with the offering. In addition, the Company incurred expenses of approximately $1 million in connection with the offering. Thus, the net offering proceeds to the Company, after deducting underwriting discounts and commissions and offering expenses, were approximately $17.4 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6003-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=SL51803626-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624279107552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>WARRANTS (Details) - Jun. 30, 2015 - Seven-year warrants - $ / shares<br></strong></div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at December 31, 2014</a></td>
<td class="nump">418,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ClassOfWarrantOrRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ClassOfWarrantOrRightExercisedExpiredForfeited', window );">Exercised/Expired/ Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at June 30, 2015</a></td>
<td class="nump">418,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ClassOfWarrantOrRightExercisable', window );">Exercisable at June 30, 2015</a></td>
<td class="nump">418,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding at December 31, 2014</a></td>
<td class="nump">$ 9.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited', window );">Exercised/Expired/ Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding at June 30, 2015</a></td>
<td class="nump">$ 9.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable', window );">Exercisable at June 30, 2015</a></td>
<td class="nump">$ 9.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights Exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights exercised/expired/forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedExpiredForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ClassOfWarrantOrRightExercisedExpiredForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of warrants or rights exercised/expired/forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ClassOfWarrantOrRightExercisedExpiredForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ClassOfWarrantOrRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of warrants or rights granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ClassOfWarrantOrRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ClassOfWarrantOrRightNumberOfWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rttr_SevenYearWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rttr_SevenYearWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624206410128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 17, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock Split, Conversion Ratio</a></td>
<td class="nump">7.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Stock Split<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624282799264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>WARRANTS (Detail Textuals) - Seven-year warrants - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock called by warrants</a></td>
<td class="nump">418,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rttr_SevenYearWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rttr_SevenYearWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624282175056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT(Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
<td class="nump">$ 2,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624208258464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_BasisOfPresentationAbstract', window );"><strong>Basis of presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 2&#8201;&#8212;&#8201;BASIS OF PRESENTATION</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. All common share amounts and per share amounts have been adjusted to reflect a 1-for-7.15 reverse stock split of the Company&#8217;s common stock effected on June 17, 2015.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The accompanying interim period unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) and applicable rules and regulations of the SEC regarding interim financial reporting.&#160;&#160;The condensed balance sheet as of June 30, 2015, the condensed&#160;statements of operations for the three and six months ended June 30, 2015 and 2014, and the condensed statements of cash flows for the six months ended June 30, 2015 and 2014, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of its financial position, operating results and cash flows for the periods presented. The condensed balance sheet at December 31, 2014 has been derived from audited financial statements included in Form S-1 filed on June 19, 2015 with the SEC and declared effective on June 24, 2015. The results for the three and six months ended June 30, 2015 are not&#160;necessarily indicative of the results expected for the full fiscal year or any other period.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The accompanying interim period unaudited condensed financial statements and related financial information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Form S-1, filed with the SEC on June 19, 2015.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company currently operates in one business segment focusing on the development and commercialization of RP-G28. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of business or separate business entities.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b><b>&#160;</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Liquidity</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">At June 30, 2015, after&#160;consummation of the Company&#8217;s initial public offering, the Company had working capital of&#160;approximately $17.3 million, an accumulated deficit of&#160;approximately&#160;$21.8 million, and cash of&#160;approximately&#160;$19.7 million.&#160; The&#160;Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable&#160;operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities,&#160;clinical and pre-clinical testing, and commercialization of the Company&#8217;s products will require significant additional financing.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company believes that its existing cash will be sufficient to enable the Company to continue as a going concern for at least the next twelve months. However, the Company will need to secure additional funding in the future, from one or more equity or debt financings, collaborations, or other sources, in order to carry out all of its planned research and development activities. If the Company is unable to obtain additional financing or generate license or product revenue, the lack of liquidity could have a material adverse effect on the Company&#8217;s future prospects.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624208073056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">8,887,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,887,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,887,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares Issued</a></td>
<td class="nump">7,788,028<span></span>
</td>
<td class="nump">465,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">7,788,028<span></span>
</td>
<td class="nump">465,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember', window );">Preferred stock subject to redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock subject to redemption, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock subject to redemption, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,378,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock subject to redemption, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,399,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock subject to redemption, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,399,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (27)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 480<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011957&amp;loc=d3e177068-122764<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.27(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph b<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.27(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph b<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.27(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph b<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624208287376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule Property and equipment</a></td>
<td class="text"><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>June 30,</b></font></td>
<td style="text-align: center; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>December 31,</b></font></td>
<td style="text-align: center; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Estimated Life</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>2015</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>2014</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 861px; text-align: left;">Computers and equipment</td>
<td style="width: 14px;">&#160;</td>
<td style="width: 169px; text-align: center;">5 years</td>
<td style="width: 14px;">&#160;</td>
<td style="width: 14px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">5,487</td>
<td style="width: 14px; text-align: left;">&#160;</td>
<td style="width: 14px;">&#160;</td>
<td style="width: 14px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">5,487</td>
<td style="width: 14px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1pt;">Furniture and fixtures</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 1pt;">7 years</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">4,270</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">4,270</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;">Total property and equipment</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9,757</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9,757</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1pt;">Accumulated depreciation</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(5,191</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(4,585</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 1pt;">Total property and equipment, net of accumulated depreciation</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">4,566</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">5,172</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph b<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624208346176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Aug. 04, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RITTER PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001460702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,792,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624282210912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule summary of the warrants</a></td>
<td class="text"><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>Weighted Average</b></font></td>
<td style="text-align: center; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>Warrants</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>Exercise Price</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 928px;">Outstanding at December 31, 2014</td>
<td style="width: 13px;">&#160;</td>
<td style="width: 13px; text-align: left;">&#160;</td>
<td style="width: 126px; text-align: right;">418,321</td>
<td style="width: 12px; text-align: left;">&#160;</td>
<td style="width: 12px;">&#160;</td>
<td style="width: 12px; text-align: left;">$</td>
<td style="width: 125px; text-align: right;">9.30</td>
<td style="width: 12px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-indent: 10pt;">Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; text-indent: 10pt; padding-bottom: 1pt;">Exercised/Expired/ Forfeited</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 1pt;">Outstanding at June 30, 2015</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">418,321</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">9.30</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="padding-bottom: 2.5pt;">Exercisable at June 30, 2015</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">418,321</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">9.30</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 28<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624208025584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 47,977<span></span>
</td>
<td class="nump">$ 6,315<span></span>
</td>
<td class="nump">$ 79,555<span></span>
</td>
<td class="nump">$ 11,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PatentCosts', window );">Patent costs</a></td>
<td class="nump">50,148<span></span>
</td>
<td class="nump">27,382<span></span>
</td>
<td class="nump">112,423<span></span>
</td>
<td class="nump">64,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,001,706<span></span>
</td>
<td class="nump">352,431<span></span>
</td>
<td class="nump">3,304,152<span></span>
</td>
<td class="nump">597,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">2,099,831<span></span>
</td>
<td class="nump">386,128<span></span>
</td>
<td class="nump">3,496,130<span></span>
</td>
<td class="nump">672,667<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(2,099,831)<span></span>
</td>
<td class="num">(386,128)<span></span>
</td>
<td class="num">(3,496,130)<span></span>
</td>
<td class="num">(672,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income (expense), net</a></td>
<td class="nump">2,101<span></span>
</td>
<td class="num">(4,944)<span></span>
</td>
<td class="nump">4,305<span></span>
</td>
<td class="num">(4,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Total other income (expense)</a></td>
<td class="nump">2,101<span></span>
</td>
<td class="num">(4,944)<span></span>
</td>
<td class="nump">11,396<span></span>
</td>
<td class="num">(4,739)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,097,730)<span></span>
</td>
<td class="num">(391,072)<span></span>
</td>
<td class="num">(3,484,734)<span></span>
</td>
<td class="num">(677,406)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Cumulative preferred stock dividends</a></td>
<td class="nump">178,286<span></span>
</td>
<td class="nump">147,337<span></span>
</td>
<td class="nump">327,569<span></span>
</td>
<td class="nump">294,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionDiscount', window );">Accretion of discount on Series C preferred stock</a></td>
<td class="nump">31,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted', window );">Net loss applicable to common stockholders</a></td>
<td class="num">$ (2,307,481)<span></span>
</td>
<td class="num">$ (538,409)<span></span>
</td>
<td class="num">$ (3,875,586)<span></span>
</td>
<td class="num">$ (972,191)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (4.18)<span></span>
</td>
<td class="num">$ (1.18)<span></span>
</td>
<td class="num">$ (7.62)<span></span>
</td>
<td class="num">$ (2.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">551,912<span></span>
</td>
<td class="nump">456,408<span></span>
</td>
<td class="nump">508,645<span></span>
</td>
<td class="nump">453,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period) and accretion of discount on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PatentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents costs incurred and are directly related to patent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PatentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income recognized by the entity in the period not otherwise specified in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of (1) the carrying amount of the preferred stock in the registrant's balance sheet over (2) the fair value of the consideration transferred to the holders of the preferred stock, during the accounting period, which will be added to net earnings to arrive at net earnings available to common shareholders in the calculation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010884&amp;loc=d3e42851-122695<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624275087680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_WarrantsTextBlock', window );">WARRANTS</a></td>
<td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 7&#8201;&#8212;&#8201;WARRANTS</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">As described in Note 6, in 2014, the Company issued seven-year warrants (&#8220;the Warrants&#8221;) to investors for the purchase of 418,321 shares of the Company&#8217;s common stock at an exercise price of&#8201;$9.30 per share.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company analyzed the Warrants in accordance with ASC Topic 815 to determine whether the Warrants meet the definition of a derivative and, if so, whether the Warrants meet the scope exception that provides for equity classification of derivative instruments issued or held by the reporting entity that are both (1) indexed to its own stock and (2) classified in stockholders&#8217; equity. The Company concluded these Warrants should be classified as equity since they contain no provisions, which would require recognition as a liability.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The following represents a summary of the warrants outstanding at June 30, 2015 and changes during the period then ended:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>Weighted Average</b></font></td>
<td style="text-align: center; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>Warrants</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>Exercise Price</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 928px;">Outstanding at December 31, 2014</td>
<td style="width: 13px;">&#160;</td>
<td style="width: 13px; text-align: left;">&#160;</td>
<td style="width: 126px; text-align: right;">418,321</td>
<td style="width: 12px; text-align: left;">&#160;</td>
<td style="width: 12px;">&#160;</td>
<td style="width: 12px; text-align: left;">$</td>
<td style="width: 125px; text-align: right;">9.30</td>
<td style="width: 12px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-indent: 10pt;">Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; text-indent: 10pt; padding-bottom: 1pt;">Exercised/Expired/ Forfeited</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style:
 solid;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 1pt;">Outstanding at June 30, 2015</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">418,321</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">9.30</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="padding-bottom: 2.5pt;">Exercisable at June 30, 2015</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">418,321</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">9.30</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents disclosure of warrants issued. Warrants outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624282184400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION</a></td>
<td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 6&#8201;&#8212;&#8201;STOCKHOLDERS&#8217; EQUITY (DEFICIT) AND PREFERRED STOCK SUBJECT TO REDEMPTION</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Common Stock</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">As of December 31, 2014, the Company was authorized to issue 50,000,000 shares of common stock with a par value of&#8201;$0.001 per share. The Company amended and restated its Certificate of Incorporation in June 2015 (&#8220;the Amended Certificate&#8221;) and reduced the authorized shares of the Company&#8217;s common stock to 25,000,000 with a par value of $0.001 per share.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Effective June 17, 2015, all common share amounts and per share amounts have been adjusted to reflect a 1-for-7.15 reverse stock split.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Preferred Stock</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company&#8217;s Board of Directors is authorized, subject to any limitations prescribed by law, to provide for the&#160;issuance of the authorized shares of preferred stock in series and to&#160;establish the number of shares to be included in each such series, and to fix the designation, powers, preferences and&#160;rights of the shares of each such series and any qualifications, limitations or restrictions thereon.&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="color: black;">Pursuant to the Amended Certificate, as of June 30, 2015, the Company is authorized to issue 5,000,000 shares of preferred stock, $0.001 par value per share.</font><b><i>&#160;</i></b><font style="color: black;">Prior to the Amended Certificate and as of December 31, 2014, the Company was authorized to issue 7,200,000 shares, 1,687,500 shares, 4,220,464 shares, 7,658,182 shares, and 4,500,000 shares of Series A-1, Series A-2, Series A-3, Series B, and Series C preferred stock, respectively, with a par value of&#8201;$0.001 per share.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="color: black;">Upon the closing of the Company&#8217;s initial public offering, all outstanding shares of convertible preferred stock and preferred stock subject to redemption were converted into an aggregate of 3,322,650 shares of common stock. The following provides material terms and certain historical information regarding the&#160;</font>Series A-1, Series A-2, Series A-3, Series B and Series C Preferred Stock prior to their conversion to common stock:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table align="center" style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; font-size-adjust: none;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><i>Redemption.&#160;</i><font style="color: black;">At any time after five years following the date of the initial issuance of the Series A-3, Series B, or Series C preferred stock, as applicable, and at the option of the holders of a majority of the then outstanding shares of Series A-3, Series B, and Series C preferred stock, voting together as a single class, the Company was required to redeem any outstanding shares that have not been converted by paying cash in an amount per share equal to the liquidation preference of&#8201; $0.62 and $1.30 for the Series A-3 and Series C preferred stock, respectively, and $1.19 per share, plus any accrued but unpaid dividends, for the Series B preferred stock. Given the holders&#8217; redemption option, the Series A-3, Series B, and Series C preferred stock is classified as preferred stock subject to redemption in the accompanying Condensed Balance Sheets.</font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: -0.25in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b></b>&#160;</p>
<table align="center" style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; font-size-adjust: none;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><i>Dividends.&#160;</i><font style="color: black;">The holders of outstanding shares of preferred stock were entitled to receive dividends, when, as and if declared by the Company&#8217;s Board of Directors. The annual dividend rate was $0.00556 per share for the Series A-1 preferred stock, $0.032 per share for the Series A-2 preferred stock, $0.04957 per share for the Series A-3 preferred stock, $0.09524 per share for the Series B preferred stock, and $0.104 for Series C preferred stock (subject to adjustment). The right to receive dividends on shares of Series B preferred stock was cumulative and the dividends accrue to holders of Series B preferred stock whether or not dividends are declared or paid in a calendar year. Undeclared dividends in arrears for the Series B preferred stock was approximately $2 million and $1.7 million as of June 30, 2015 and December 31, 2014, respectively. The right to receive dividends on shares of Series A and Series C preferred stock was not cumulative and no right to such dividends accrued to holders of Series A or Series C preferred stock.</font></td>
</tr>
</table>
<table align="center" style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; font-size-adjust: none;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><i>Liquidations.&#160;</i><font style="color: black;">In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series B and Series C preferred stockholders receive an amount per share equal to the sum of the original purchase price of&#8201;$1.19 plus all cumulative but unpaid dividends for Series B, and $1.30 for Series C. If upon the liquidation, the available assets are insufficient to permit payments to Series B and Series C holders, the entire assets legally available will be distributed in a pro rata basis among the holders in proportion to the full amounts they would otherwise be entitled to receive. Upon the completion of the distribution to the holders of the Series B and Series C preferred stock, the holders of the Series A preferred stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the Company to the holders of all other capital stock by reason of their ownership of such stock, an amount per share equal to the sum of the original issue price per share of&#8201; $0.07, $0.4, and $0.62 for Series A-1, Series A-2, and Series A-3 preferred stock, respectively, plus any accrued but unpaid dividends on the preferred stock. Any remaining assets are distributed pro rata among the preferred and common shareholders.</font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Stock Transactions</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Initial Public Offering</u></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On June 29, 2015, the Company closed its initial public offering, selling 4,000,000 shares of the Company&#8217;s common stock at an initial public offering price of $5.00 per share, for aggregate gross proceeds to the Company of $20 million.&#160; The Company paid to the underwriters underwriting discounts and commissions of approximately $1.6 million in connection with the offering, and approximately $1 million of other expenses in connection with the offering. Effectively prior to the closing of the initial public offering, the Company converted all of its outstanding shares of Series A-1, Series A-2, Series A-3, Series B, and Series C preferred into an aggregate of 3,322,650 shares of the Company&#8217;s common stock.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Series C Financing</u></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="color: black;">In December&#160;2014, the Company issued an aggregate of&#160;</font><font style="color: #231f20;">2,369,228&#160;</font><font style="color: black;">shares of Series C preferred stock, which was later converted into an aggregate of 331,358 shares of the Company&#8217;s common stock, and warrants to purchase an aggregate of 331,358 shares of the Company&#8217;s common stock (the &#8220;Warrants&#8221;), for aggregate gross proceeds of&#8201; $3,081,893 (the &#8220;Series C Financing&#8221;). Each Warrant has a term of seven (7) years and provides for the holder to purchase one share of the Company&#8217;s common stock at a purchase price of&#8201;$9.30 per share of common stock. The Warrants are indexed to the Company&#8217;s own stock and classified within stockholders&#8217; equity pursuant to ASC 815-40. The gross proceeds were allocated to the Series C preferred stock and Warrants on a relative fair value basis, resulting in a value of&#8201;$7.83 for the Series C preferred stock. The allocation of proceeds to the Warrants creates a discount of&#8201;$1.47 in the initial carrying value of the Series C preferred stock, which was recognized as accretion, similar to preferred stock dividends, over the five-year period prior to optional redemption by the holders.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In connection with the Series C Financing, all of the 2014 Notes were converted into shares of Series C preferred stock and Warrants as follows:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; font-size-adjust: none;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="color: black; font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><font style="color: black;">$535,000 unpaid principal plus accrued interest of&#8201; $18,342 on convertible notes converted into&#160;</font>567,529&#160;<font style="color: black;">shares of Series C preferred stock, which was later converted into 79,374 shares of the Company&#8217;s common stock, and 79,374 Warrants</font></td>
</tr>
</table>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; font-size-adjust: none;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="color: black; font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><font style="color: black;">$70,000 unpaid principal plus accrued interest of&#8201; $537 on note payable extinguished and converted into&#160;</font>54,259&#160;<font style="color: black;">shares of Series C preferred stock, which was later converted into 7,589 shares of the Company&#8217;s common stock and 7,589 Warrants</font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Notes with an unpaid principal balance of $535,000 were converted into shares of Series C preferred stock and warrants to purchase shares of common stock at 75% of the price paid by other purchasers of the Series C Financing. The Company recognized additional interest expense of&#8201;$184,445 upon conversion, calculated as the fair value of incremental shares and warrants received by the holders compared to converting the outstanding debt and accrued interest at 100% of the price paid by purchasers of the Series&#160;C Financing. The note with an unpaid principal balance of&#8201;$70,000 was exchanged for shares of Series C preferred stock and warrants to purchase shares of common stock at a price per share equal to the price per share paid by purchasers of the Series C Financing. As such, there was no gain recognized or loss incurred upon extinguishment of the note in 2014.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Prepaid Forward Sale of Preferred Stock</u></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On November&#160;30, 2010, the Company concurrently entered into a Research and Development Agreement &amp; License (&#8220;R&amp;D Agreement&#8221;) and a Put and Call Option Agreement (&#8220;Put/Call&#8221;) with two commonly controlled entities, Kolu Pohaku Technologies, LLC (&#8220;KPT&#8221;) and Kolu Pohaku Management, LLC (&#8220;KPM&#8221;). The agreement was subsequently amended on July&#160;6, 2011, September&#160;30, 2011, February&#160;6, 2012 and November&#160;4, 2013 to increase the funding received by the Company.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>&#160;</i></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Research and Development Agreement &amp; License</i></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The R&amp;D Agreement between the Company and KPM and KPT, a Qualified High Technology Business within the meaning of Hawaii Revised Statutes, called for KPT to make a series of payments to the Company totaling $1,750,000 in exchange for the Company performing research and development activities in Hawaii for the benefit of KPT (referred to herein as the KP Research). The KP Research consisted of the initial phase of research, including the conduct of Phase II clinical trials in Hawaii for RP-G28. Pursuant to the terms of the R&amp;D Agreement, the Company maintained ownership of the results of the Company&#8217;s ongoing research related to RP-G28, but KPT maintained ownership of the results of the KP Research. Inventions, developments and improvements arising out of the KP Research were owned by KPT. Under the terms of the R&amp;D Agreement, the Company would bear any costs involved in obtaining patents for any inventions, developments or improvements resulting from the Research Project. In exchange for the irrevocable, perpetual, exclusive, worldwide right and license to the results of the KP Research, as they are generated under this R&amp;D Agreement, the Company agreed to pay a quarterly royalty payment to KPT of $32,000 commencing March&#160;31, 2015 and continuing through December&#160;31, 2035 or until such time as the KPM Option (as described below) was exercised. On March&#160;26, 2015, the Company exercised the right to put the KPM Option and issued 1,469,994 shares of Series B preferred stock to KPM, resulting in the full satisfaction of the Company&#8217;s obligation to make royalty payments to KPT.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>&#160;</i></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Put and Call Option Agreement</i></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Pursuant to the terms of the KPM Option Agreement, the Company had the right to put 1,469,994 shares of the Company&#8217;s Series B Preferred Stock (&#8220;Series B&#8221;) to KPM and KPM has the option to call the same amount of shares of Series B from the Company at any time after December&#160;31, 2014. The number of shares was determined by dividing the $1,750,000 of payments made by KPT to the Company under the R&amp;D Agreement by the Series B original issue price of&#8201;$1.19. Exercise of the Put/Call results in full satisfaction of the Company&#8217;s obligation to make royalty payments to KPT under the R&amp;D Agreement and KPT&#8217;s right, title and interest in the research conducted pursuant to the R&amp;D Agreement becomes the property of the Company. On March&#160;26, 2015, the Company exercised the right to put the KPM Option and issued 1,469,994 shares of Series B preferred stock to KPM, or the KPM Shares. Pursuant to the terms of the KPM Option Agreement, this resulted in the full satisfaction of the Company&#8217;s obligation to make royalty payments to KPT under the R&amp;D Agreement and also resulted in the termination of the R&amp;D Agreement and all of KPT&#8217;s right, title and interest in and to the KP Research, which rights now belong to the Company.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The R&amp;D Agreement and the Put/Call have been recognized on a combined basis, pursuant to ASC 815-10-15-9, as a fully prepaid forward sale contract on the Company&#8217;s Series B preferred stock. The fully prepaid forward sale contract is a hybrid instrument comprising (1) a debt host instrument and (2) an embedded forward sale contract, requiring the Company to issue 1,469,994 shares of the Company&#8217;s Series&#160;B for no further consideration. Payments received by the Company, totaling $1,750,000, are recognized as preferred stock subject to redemption in the Condensed Balance Sheet as of December 31, 2014. The Company converted these shares into an aggregate of 205,593 shares of the Company&#8217;s common stock upon the closing of the IPO.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Preferred Stock<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section C<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624206074768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 9,757<span></span>
</td>
<td class="nump">$ 9,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(5,191)<span></span>
</td>
<td class="num">(4,585)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net of accumulated depreciation</a></td>
<td class="nump">$ 4,566<span></span>
</td>
<td class="nump">5,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 5,487<span></span>
</td>
<td class="nump">5,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 4,270<span></span>
</td>
<td class="nump">$ 4,270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.14)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624279120304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule assumptions used in the Black-Scholes option-pricing method</a></td>
<td class="text"><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="3" nowrap="nowrap"><font style="font-size: 8pt;"><b>Three months ended June 30,</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="3" nowrap="nowrap"><font style="font-size: 8pt;"><b>Six months ended June 30,</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="width: 439px; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="width: 251px; text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"><font style="font-size: 8pt;"><b>2015</b></font></td>
<td style="width: 32px; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="width: 251px; text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"><font style="font-size: 8pt;"><b>2014</b></font></td>
<td style="width: 31px; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="width: 266px; text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"><font style="font-size: 8pt;"><b>2015</b></font></td>
<td style="width: 31px; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="width: 266px; text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"><font style="font-size: 8pt;"><b>2014</b></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-size: 10pt;" nowrap="nowrap">Expected dividend yield</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">0.00%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">0.00%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">0.00%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">0.00%</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-size: 10pt;" nowrap="nowrap">Expected stock-price volatility</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">65.06% - 67.08%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">55.32% - 62.09%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">51.45% - 67.08%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">55.32% - 62.09%</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-size: 10pt;" nowrap="nowrap">Risk-free interest rate</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">1.79% - 2.07%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">1.54% - 2.67%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">0.77% - 2.07%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">1.49% - 3.04%</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-size: 10pt;" nowrap="nowrap">Term of options</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">10</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">10</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">10</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">10</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-size: 10pt;" nowrap="nowrap">Stock price</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">$5.86</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">$1.17</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">$5.86</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">$1.17</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock', window );">Schedule the prices received from sales to third parties</a></td>
<td class="text"><table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 940px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold;" nowrap="nowrap">Year</td>
<td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold;" nowrap="nowrap">Share Class</td>
<td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold;" nowrap="nowrap">Price per Share</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: center; width: 320px;">2005</td>
<td style="width: 10px;">&#160;</td>
<td style="text-align: center; width: 413px;">Common Stock (a)</td>
<td style="width: 9px;">&#160;</td>
<td style="text-align: center; width: 188px;">$1.79</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;">2006</td>
<td>&#160;</td>
<td style="text-align: center;">Series A-2 Preferred Stock (a)(b)</td>
<td>&#160;</td>
<td style="text-align: center;">$0.40</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: center;">2008 - 2009</td>
<td>&#160;</td>
<td style="text-align: center;">Series A-3 Preferred Stock (b)</td>
<td>&#160;</td>
<td style="text-align: center;">$0.62</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;">2010 - 2013</td>
<td>&#160;</td>
<td style="text-align: center;">Series B Preferred Stock (b)</td>
<td>&#160;</td>
<td style="text-align: center;">$1.19</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: center;">2014</td>
<td>&#160;</td>
<td style="text-align: center;">Series C Preferred Stock (b)</td>
<td>&#160;</td>
<td style="text-align: center;">$1.30</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;">2015</td>
<td>&#160;</td>
<td style="text-align: center;">Common Stock</td>
<td>&#160;</td>
<td style="text-align: center;">$5.00</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;">(a)</td>
<td style="text-align: justify;">After giving effect to the Company&#8217;s conversion from a LLC to a corporation.</td>
</tr>
</table>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;">(b)</td>
<td style="text-align: justify;">Shares of preferred stock were converted into an aggregate of 3,322,650 shares of the Company&#8217;s common stock effective June 29, 2015, after giving effect to the 1-for-7.15 reverse stock of shares of the Company&#8217;s common stock effective June 17, 2015.</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsInstrumentsClassifiedInShareholdersEquityQuantitativeInformationTableTextBlock', window );">Schedule inputs were applied in the Black-Scholes calculations of the OPM</a></td>
<td class="text"><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font style="font-size: 8pt;"><b><br class="apple-interchange-newline" />&#160;</b></font></td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="5" nowrap="nowrap"><font style="font-size: 8pt;"><b>Valuation Date</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="width: 286px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="width: 21px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="width: 244px; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"><font style="font-size: 8pt;"><b>November 7, 2013</b></font></td>
<td style="width: 20px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="width: 183px; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"><font style="font-size: 8pt;"><b>July 31, 2012</b></font></td>
<td style="width: 10px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="width: 254px; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"><font style="font-size: 8pt;"><b>December 31, 2010</b></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td nowrap="nowrap">Volatility</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">58.00%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">61.00%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">61.00%</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td nowrap="nowrap">Risk-free interest rate</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">0.55%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">0.57%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">2.01%</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td nowrap="nowrap">Maturity (years)</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">3</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">4</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">5</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Schedule regarding the Company's stock option grants to the Company's employees and non-employees</a></td>
<td class="text"><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="width: 395px; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="width: 15px; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="width: 240px; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Number of Common</b></font></td>
<td style="width: 15px; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="width: 239px; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Exercise Price</b></font></td>
<td style="width: 14px; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="width: 239px; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Estimated Fair Value</b></font></td>
<td style="width: 14px; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="width: 239px; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Shares Underlying</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>per Common</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>per Share of</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Intrinsic Value</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Grant Date</b></font></td>
<td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Options Granted</b></font></td>
<td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Share</b></font></td>
<td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Common Stock</b></font></td>
<td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Option</b></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: center;">2005</td>
<td>&#160;</td>
<td style="text-align: center;" nowrap="nowrap">58,321</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$0.07</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$1.79</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$1.72</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: center;">2009</td>
<td>&#160;</td>
<td style="text-align: center;" nowrap="nowrap">60,559</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$0.72 - $0.79</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$4.43</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$3.71 - $3.64</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: center;">2011</td>
<td>&#160;</td>
<td style="text-align: center;" nowrap="nowrap">33,846</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$1.00</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$1.00</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$0.00</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: center;">2012</td>
<td>&#160;</td>
<td style="text-align: center;" nowrap="nowrap">60,019</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$1.14</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$1.14</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$0.00</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: center;">2013</td>
<td>&#160;</td>
<td style="text-align: center;" nowrap="nowrap">100,000</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$1.14 - $1.30</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$1.14</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$0.00</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: center;">2014</td>
<td>&#160;</td>
<td style="text-align: center;" nowrap="nowrap">1,626,740</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$5.86- $13.23</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$5.86</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$0.00</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule represents a summary of the options granted to employees and non-employees</a></td>
<td class="text"><table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 1253px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>Options</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>Weighted Average</b></font><br  /><font style="font-size: 8pt;"><b>Exercise Price</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 802px;">Outstanding at December 31, 2014</td>
<td style="width: 13px;">&#160;</td>
<td style="text-align: left; width: 13px;">&#160;</td>
<td style="text-align: right; width: 188px;">1,788,717</td>
<td style="text-align: left; width: 13px;">&#160;</td>
<td style="width: 13px;">&#160;</td>
<td style="text-align: left; width: 12px;">$</td>
<td style="text-align: right; width: 187px;">7.059</td>
<td style="text-align: left; width: 12px;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-indent: 10pt;">Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">103,025</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5.863</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt;">Exercised/ Expired/ Forfeited</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(918</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(1.158</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>Outstanding at June 30, 2015</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,890,824</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">7.062</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt;">Exercisable at June 30, 2015</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">298,437</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">4.563</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Expected to be vested</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,592,387</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">4.563</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<div>&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents schedule of prices received from sales of various classes of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ScheduleOfPricesReceivedFromSalesOfVariousClassesOfStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsInstrumentsClassifiedInShareholdersEquityQuantitativeInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quantitative information about the inputs used in the fair value measurement of financial instruments classified in shareholders' equity. This disclosure may include, but is not limited to, the fair value of the financial instrument classified in shareholders' equity, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (bbb)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsInstrumentsClassifiedInShareholdersEquityQuantitativeInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624477544976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: times new roman,times;" size="2"><b>NOTE 10&#8201;&#8212;&#8201;SUBSEQUENT EVENTS</b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: times new roman,times;" size="2">On July 9, 2015, the Company entered into a lease with Century Park, a California limited partnership, pursuant to which Ritter will lease approximately 2,780 square feet of office space in Los Angeles, California. The lease provides for a term of sixty-one (61) months, commencing on the later of October 1, 2015 or the date of substantial completion of certain tenant improvements provided for under the lease. The Company will pay no rent for the first month of the term and base rent of $9,174 per month for months 2 through 13 of the term, with increasing base rent for each twelve month period thereafter under the term of the lease to a maximum of $10,325.42 per month for months 50 through 61. The base rent payments do not include the Company&#8217;s proportionate share of any operating expenses, including real estate taxes. The Company has the option to extend the term of the lease for one five-year term, provided that the rent would be subject to market adjustment at the beginning of the renewal term.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: times new roman,times;" size="2">Effective July 24, 2015, the Company entered into an&#160;<font style="color: black;">amended Clinical Supply and Cooperation Agreement (the &#8220;Amended Supply Agreement&#8221;) with Ricerche Sperimentali Montale SpA (&#8220;Ricerche&#8221;) and Inalco SpA (collectively, &#8220;RSM&#8221;). The Amended Supply Agreement amends certain terms of the Clinical Supply and Cooperation Agreement, dated December 16, 2009, amended on September 25, 2010 (the &#8220;Existing Supply Agreement&#8221;).</font></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: times new roman,times;" size="2">Under the Existing Supply Agreement, RSM granted Ritter an exclusive worldwide option in a specified field and territory to assignment of all right, title and interest to a purified&#160;Galacto-oligosaccharides product (&#8220;Improved GOS&#8221;), the composition of matter of the Improved GOS and any information relating to the Improved GOS, including certain specified technical information and other intellectual property rights (the &#8220;Improved GOS IP&#8221;). Pursuant to the amended terms, the Company may exercise the option by paying RSM $800,000 within ten days after the effective date of the Amended Supply Agreement. The Company exercised the option on July 30, 2015 and RSM is transferring the Improved GOS IP to the Company. Under the terms of the existing agreement, if a further option payment due in the future is not made, the Company may be required to return the Improved GOS IP to RSM.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: times new roman,times;" size="2">The Amended Supply Agreement also provides that&#160;the Company must pay RSM $400,000 within 10 days following FDA approval of a new drug application for the first product owned or controlled by the Company using Improved GOS as its active pharmaceutical ingredient. In addition, the Company agreed to purchase 350 kilos of Improved GOS for the sum of $250 per kilo for clinical supply of Improved GOS instead of $2,000 per kilo as under the Existing Supply Agreement.&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: times new roman,times;" size="2">In consideration for RSM entering into the Amended Supply Agreement, the Company will issue 100,000 shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Shares&#8221;), to RSM. The Shares are to be issued within 90 days of the effective date of the Amended Supply Agreement pursuant to a stock purchase agreement to be negotiated by the parties in good faith. The stock purchase agreement is to include a lock-up agreement by RSM in favor of the
 Company pursuant to which RSM will not be able to sell the Shares for a period ending on the earlier of (i) the public release by the Company of the final results of its Phase 2b/3 clinical trial of RP-G28 and (ii) the filing of its Form 10-Q with the Securities and Exchange Commission for the fiscal quarter in which the Company receives the results of its Phase 2b/3 clinical trial of RP-G28. The Company has not issued the shares to RSM as of August&#160;</font>4<font style="font-family: times new roman,times;" size="2">, 2015.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624477544976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 8&#8201;&#8212;&#8201;STOCK-BASED COMPENSATION</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Terms of the Company&#8217;s share-based compensation are governed by the Company&#8217;s 2015 Stock Plan, 2009 Stock Plan and 2008 Stock Plan (collectively the &#8220;Plans&#8221;.) The Plans permit the Company to grant non-statutory stock options, incentive stock options and stock purchase rights to the Company&#8217;s employees, outside directors and consultants; however, incentive stock options may only be granted to the Company&#8217;s employees. Beginning June 29, 2015, no awards may be granted under the 2009 Stock Plan or 2008 Stock Plan. &#160;As of&#160;June 30, 2015, the maximum aggregate number of shares of common stock that may be issued is 328,289 under the 2015 Stock Plan. The exercise price for each option is determined by the Board of Directors, but will be (i) in the case of an incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share on the date of grant; and (ii) in the case of a nonstatutory stock option, no less than 100% of the fair market value per share on the date of grant. The options awarded under the Plans shall vest as determined by the Board of Directors but shall not exceed a ten-year period.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>&#160;</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Options Issued to Directors and Employees as Compensation</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Pursuant to the terms of the Plans, from inception to December 31, 2013, the Company has issued options to purchase an aggregate of 206,172 shares to its executive officers and employees of the Company. Of these, 26,163 options were forfeited and 180,009 options remain outstanding as of December 31, 2013. No additional options were granted or forfeited during the six months ended June 30, 2014. The exercise prices of these option grants, as determined by the Company&#8217;s Board of Directors, range from $0.79 to $1.27 per share, and a portion of these vest subject to certain performance conditions described in Note 5. The Company&#8217;s management initially assessed the likelihood of the performance conditions for the options granted to its executive officers to be probable of achievement. In April 2015, certain performance conditions providing for options to purchase an aggregate of 41,958 shares of the Company&#8217;s common stock were no longer considered to be probable of achievement by September&#160;25, 2015.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">In December 2014, the Company granted additional non-qualified 10-year term options to its executive officers to purchase an aggregate of 1,729,766 shares of the Company&#8217;s common stock. Also in 2014, an aggregate of 41,958 options expired and 13,985 options were exercised. The exercise prices of these option grants, as determined by the Company&#8217;s Board of Directors, range from $5.86 to $13.23 per share. No additional options were granted in the six month period ended June 30, 2015. As of June 30, 2015, 1,853,831 options remain outstanding.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company recognized stock based compensation expense for these services within general and administrative expense in the accompanying Unaudited Condensed Statements of Operations of approximately $1.7 million and $88,000 for the six months ended June 30, 2015 and 2014, respectively, and approximately $880,000 and $87,000 for the three months ended June 30, 2015 and 2014, respectively. As of June 30, 2015, there was approximately $2.9 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements. This cost is expected to be recognized over a weighted average period of 1.6 years.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>&#160;</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Options Issued to Nonemployees for Services Received</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">From inception to June 30, 2015, the Company has issued options to its consultants to purchase an aggregate of 106,573 shares of the Company&#8217;s common stock under the Plans. Of these, 69,580 options were forfeited or exercised, and 36,993 options remain outstanding as of June 30, 2015. The exercise prices of the outstanding options, as determined by the Company&#8217;s Board of Directors, range from $0.72 to $1.14 per share. These outstanding options, with the exception of an option to purchase an aggregate of 7,271 shares granted to a consultant, vest 25% upon the first anniversary of the vesting commencement date with the remaining options vesting monthly in equal amounts over 36 months. In March&#160;2011, the Company granted an option to a consultant to purchase an aggregate of 7,271 shares with an exercise price of&#8201;$1.00 which vests 25% on the date of grant with the remaining options vesting monthly in equal amounts over 36 months. The Company recognized stock based compensation expense for these services of approximately $700 and $3,500 for the six months ended June 30, 2015 and 2014, respectively, and approximately $600 and $4,000 for the three months ended June 30, 2015 and 2014, respectively, within research and development expense in the accompanying Unaudited Condensed Statements of Operations.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>&#160;</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Options Valuation</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. If the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company&#8217;s stock options could change significantly. Higher volatility and longer expected lives would result in an increase to stock-based compensation expense to non-employees determined at the date of grant.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Stock-based compensation expense to non-employees affects the Company&#8217;s general and administrative expenses and research and development expenses.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Black-Scholes option-pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards. The assumptions used in the Black-Scholes option-pricing method for the three months and six months ended June 30, 2015 and 2014 are set forth below:</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="3" nowrap="nowrap"><font style="font-size: 8pt;"><b>Three months ended June 30,</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="3" nowrap="nowrap"><font style="font-size: 8pt;"><b>Six months ended June 30,</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; width: 439px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; width: 251px; font-size: 10pt;" nowrap="nowrap"><font style="font-size: 8pt;"><b>2015</b></font></td>
<td style="text-align: center; width: 32px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; width: 251px; font-size: 10pt;" nowrap="nowrap"><font style="font-size: 8pt;"><b>2014</b></font></td>
<td style="text-align: center; width: 31px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; width: 266px; font-size: 10pt;" nowrap="nowrap"><font style="font-size: 8pt;"><b>2015</b></font></td>
<td style="text-align: center; width: 31px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; width: 266px; font-size: 10pt;" nowrap="nowrap"><font style="font-size: 8pt;"><b>2014</b></font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="font-size: 10pt;" nowrap="nowrap">Expected dividend yield</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">0.00%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">0.00%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">0.00%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">0.00%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="font-size: 10pt;" nowrap="nowrap">Expected stock-price volatility</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">65.06% - 67.08%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">55.32% - 62.09%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">51.45% - 67.08%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">55.32% - 62.09%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="font-size: 10pt;" nowrap="nowrap">Risk-free interest rate</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">1.79% - 2.07%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">1.54% - 2.67%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">0.77% - 2.07%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">1.49% - 3.04%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="font-size: 10pt;" nowrap="nowrap">Term of options</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">10</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">10</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">10</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">10</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="font-size: 10pt;" nowrap="nowrap">Stock price</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">$5.86</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">$1.17</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">$5.86</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-size: 10pt;" nowrap="nowrap">$1.17</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><i>Expected dividend.</i>&#160;&#160;&#160;The expected dividend is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on the Company&#8217;s common stock.</td>
</tr>
</table>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><i>Expected volatility.</i>&#160;&#160;&#160;As the Company&#8217;s common stock only recently became publicly traded, the expected volatility is derived from the average historical volatilities of publicly traded companies within the Company&#8217;s industry that the Company considers to be comparable to the Company&#8217;s business over a period approximately equal to the expected term.</td>
</tr>
</table>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><i>Risk-free interest rate.</i>&#160;&#160;&#160;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.</td>
</tr>
</table>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><i>Expected term.</i>&#160;&#160;&#160;The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&#8217;s historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by the SEC. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">In addition to the assumptions used in the Black-Scholes option-pricing model, the Company also estimates a forfeiture rate to calculate the stock-based compensation for the Company&#8217;s equity awards. The Company will continue to use judgment in evaluating the expected volatility, expected terms and forfeiture rates utilized for the Company&#8217;s stock-based compensation calculations on a prospective basis.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>&#160;</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Significant factors, assumptions and methodologies used in determining the estimated fair value of the Company&#8217;s common stock</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company is also required to estimate the fair value of the common stock underlying the Company&#8217;s stock-based awards when performing the fair value calculations using the Black-Scholes option-pricing model. The Company&#8217;s Board of Directors, with the assistance of management, determined the fair value of the Company&#8217;s common stock on each grant date. Option grants are based on the estimated fair value of the Company&#8217;s common stock on the date of grant, which is determined by taking into account several factors, including the following:</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;">the prices at which the Company sold the Company&#8217;s convertible preferred stock and the rights, preferences, and privileges of the convertible preferred stock relative to those of the Company&#8217;s common stock, including the liquidation preferences of the convertible preferred stock;</td>
</tr>
</table>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;">important developments in the Company&#8217;s operations;</td>
</tr>
</table>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;">the Company&#8217;s actual operating results and financial performance;</td>
</tr>
</table>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;">conditions in the Company&#8217;s industry and the economy in general;</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px 0px 0px 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;">stock price performance of comparable public companies;</td>
</tr>
</table>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;">the estimated likelihood of achieving a liquidity event, such as an IPO or an acquisition of the Company, given prevailing market conditions; and</td>
</tr>
</table>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;">the illiquidity of the common stock underlying stock options.</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The table below presents the prices received from sales to third parties of the Company&#8217;s common stock and various classes of the Company&#8217;s preferred stock from inception to date:</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 940px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold;" nowrap="nowrap">Year</td>
<td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold;" nowrap="nowrap">Share Class</td>
<td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold;" nowrap="nowrap">Price per Share</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: center; width: 320px;">2005</td>
<td style="width: 10px;">&#160;</td>
<td style="text-align: center; width: 413px;">Common Stock (a)</td>
<td style="width: 9px;">&#160;</td>
<td style="text-align: center; width: 188px;">$1.79</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;">2006</td>
<td>&#160;</td>
<td style="text-align: center;">Series A-2 Preferred Stock (a)(b)</td>
<td>&#160;</td>
<td style="text-align: center;">$0.40</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: center;">2008 - 2009</td>
<td>&#160;</td>
<td style="text-align: center;">Series A-3 Preferred Stock (b)</td>
<td>&#160;</td>
<td style="text-align: center;">$0.62</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;">2010 - 2013</td>
<td>&#160;</td>
<td style="text-align: center;">Series B Preferred Stock (b)</td>
<td>&#160;</td>
<td style="text-align: center;">$1.19</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: center;">2014</td>
<td>&#160;</td>
<td style="text-align: center;">Series C Preferred Stock (b)</td>
<td>&#160;</td>
<td style="text-align: center;">$1.30</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;">2015</td>
<td>&#160;</td>
<td style="text-align: center;">Common Stock</td>
<td>&#160;</td>
<td style="text-align: center;">$5.00</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;">(a)</td>
<td style="text-align: justify;">After giving effect to the Company&#8217;s conversion from a LLC to a corporation.</td>
</tr>
</table>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;">(b)</td>
<td style="text-align: justify;">Shares of preferred stock were converted into an aggregate of 3,322,650 shares of the Company&#8217;s common stock effective June 29, 2015, after giving effect to the 1-for-7.15 reverse stock of shares of the Company&#8217;s common stock effective June 17, 2015.</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">For options issued from inception to November&#160;7, 2013, in determining the estimated fair value of the Company&#8217;s common stock, the Company&#8217;s Board of Directors, with the assistance of management, used the market approach to estimate the enterprise value of the Company in accordance with the American Institute of Certified Public Accountants (&#8220;AICPA&#8221;) Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the &#8220;AICPA Guide&#8221;) for the three valuation dates of November&#160;7, 2013, July&#160;31, 2012, and December&#160;31, 2010. The Market Approach is one of the three approaches (along with the Income Approach and Asset Approach) used to estimate enterprise and equity value. The market approach employs analysis using comparable companies in determining the value of the entity. Both public and private companies, if publicly available information exists, are considered in the market approach. Two information points commonly available &#8212; company valuation and transaction value &#8212; are used for their respective methodologies. There are a number of different methods within the Market Approach that may be used: the three main methods utilized are: the Guideline Pubic Companies Method; the Guideline Transactions Method; and the Backsolve Method.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Given the early stage of the Company, the Backsolve Method was used to estimate the fair value of the Company&#8217;s securities. This method derives an implied market value of invested capital from a transaction involving a company&#8217;s own securities. The price of a company&#8217;s security that was involved in a recent arms-length transaction is used as a reference point in an allocation of value. The Company first raised additional capital through the sales of the Company&#8217;s LLC units. These units later converted into common shares and preferred shares upon the Company&#8217;s conversion to a corporation. Subsequent to the Company&#8217;s corporation conversion, the Company raised additional capital through the sales of the Company&#8217;s Series A-1, Series A-2, Series A-3, Series B, and Series C preferred shares at the price of&#8201;$0.07, $0.40, $0.62, $1.19, and $1.30, respectively.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company valued LLC units and common stock (after converting to a corporation) from inception through 2009 by reference to the Company&#8217;s sales of units and/or common stock &amp; preferred stock over the period. Beginning in 2010, the Company valued the Company&#8217;s common stock using the Backsolve Method. The Backsolve Method requires considering the rights and preferences of each class of equity and solving for the total market value of invested capital that is consistent with a recent transaction in the Company&#8217;s own securities, considering the rights and preferences of each class of equity. However, management has decided that the liquidation preferences between the Company&#8217;s preferred shares and common shares are immaterial for a pre-revenue company.</p>
<p></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Per the AICPA Guide, the Backsolve Method is generally the most reliable indicator of value of early-stage enterprises with no product revenue or cash flow, if relevant and reliable transactions have occurred in the Company&#8217;s equity securities. This methodology is also prescribed by the AICPA when a valuation is conducted in close proximity to the date of a financing transaction, and when other methodologies are deemed less reliable.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The stage of development of the Company&#8217;s compound was reflected in the Company&#8217;s selection of the term and volatility estimates used in the analysis. The estimate of the term considers the Company&#8217;s existing cash runway and the time to the next potential financing or liquidity event, while the volatility estimate reflects the relative riskiness of the Company&#8217;s equity securities (or asset base) relative to the general stock market.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Management estimated the implied market value of invested capital of the Company by backsolving for the purchase price of the Company&#8217;s preferred shares for one common share through the option-pricing method. The premise of this method is that the transaction implied a market price for a share which in turn implied values for the other classes of equity based on relative claims on equity value, such as liquidation preferences and conversion rights. The application of the backsolve method considering the Company&#8217;s capital structure yielded a total market value of invested capital of approximately $15.5 million, $14.4 million, and $8.9 million, of which approximately $819,000, $870,000, and $670,000 were allocated to the total value of common stock as of the Company&#8217;s three valuation dates of November&#160;7, 2013, July&#160;31, 2012, and December&#160;31, 2010, respectively.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On the three valuation dates of November&#160;7, 2013, July&#160;31, 2012, and December&#160;31, 2010, after estimating the market value of invested capital, the Company allocated it to the various equity classes comprising the subject company&#8217;s capitalization table. This process ultimately results in creating a final estimate of value for the subject company&#8217;s underlying equity interests. While there are many different value allocation methods, these various methods can be grouped into three general categories as defined by the AICPA Guide, one of which is the Option-Pricing Method (OPM).</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company used the OPM to allocate market value of invested capital to the various equity classes and debt comprising the Company&#8217;s capitalization structure. The Company chose the OPM over other acceptable methods due to the complex capital structure, the uncertainty related to market conditions, and the lack of visibility on an imminent exit event. Under the OPM, each equity class is modeled as a call option with a distinct claim on the equity of the Company. The option&#8217;s exercise price is based on the Company&#8217;s total equity value available for each participating equity holder. The characteristics of each equity class determine the equity class&#8217; claim on the total equity value. By constructing a series of options in which the exercise price is set at incremental levels of value, which correspond to the equity value necessary for each level of equity to participate, the Company determined the incremental option value of each series. When multiplied by the percentage of ownership of each equity class participating under that series, the result is the incremental value allocated to each class under that series.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The OPM relies on the Black-Scholes option-pricing model to value the call options on the Company&#8217;s invested capital. The following inputs were applied in the Black-Scholes calculations of the OPM:</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="5" nowrap="nowrap"><font style="font-size: 8pt;"><b>Valuation Date</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="width: 286px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="width: 21px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; width: 244px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>November 7, 2013</b></font></td>
<td style="width: 20px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; width: 183px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>July 31, 2012</b></font></td>
<td style="width: 10px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; width: 254px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>December 31, 2010</b></font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td nowrap="nowrap">Volatility</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">58.00%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">61.00%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">61.00%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td nowrap="nowrap">Risk-free interest rate</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">0.55%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">0.57%</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">2.01%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td nowrap="nowrap">Maturity (years)</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">3</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">4</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">5</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Discounts ranging from 35.8% to 40% were applied for lack of control and lack of marketability for the common stock. The calculation resulted in a fair value for the common stock of&#8201;$1.17, $1.19, and $1.03 per share as of the Company&#8217;s three valuation dates of November&#160;7, 2013, July&#160;31, 2012, and December&#160;31, 2010, respectively.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">For options issued in 2014, given the Company&#8217;s distinct possible exit scenarios of an initial public offering, the Company used the probability weighted expected return method (PWERM) to estimate the fair value of the Company&#8217;s common equity. Under this method, an analysis of future values of a company is performed for several likely liquidity scenarios. The value of the common stock is determined for each scenario at the time of each future liquidity event and discounted back to the present using a risk-adjusted discount rate. The present values of the common stock under each scenario are then weighted based on the probability of each scenario occurring to determine the value for the common stock. The Company&#8217;s management determined the probability weighting of potential liquidity events to be 45% for an initial public offering and 55% for other scenarios, which represents all other likely outcomes for the Company.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Management estimated the implied market value of invested capital of the Company by backsolving for the purchase price of the Company&#8217;s preferred shares for one common share through the use of OPM. The application of the backsolve method considering the Company&#8217;s capital structure yielded a total market value of invested capital of approximately $25.2 million, of which approximately $1.4 million was allocated to the total value of common stock as of the Company&#8217;s valuation date of October&#160;31, 2014.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Given the lack of marketability for the common stock, the Company applied a discount of 21.4% for using the average strike put option approach. This resulted in a probability weighted common share value, after adjustment, of&#8201;$5.86 per share as of valuation date of October&#160;31, 2014.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Stock-based Compensation Summary Tables</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Information regarding the Company&#8217;s stock option grants to the Company&#8217;s employees and non-employees, along with the estimated fair value per share of the underlying common stock, for stock options granted since 2005 is summarized as follows:</p>
<p style="widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center; width: 395px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; width: 15px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; width: 240px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Number of Common</b></font></td>
<td style="text-align: center; width: 15px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; width: 239px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Exercise Price</b></font></td>
<td style="text-align: center; width: 14px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; width: 239px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Estimated Fair Value</b></font></td>
<td style="text-align: center; width: 14px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; width: 239px;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Shares Underlying</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>per Common</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>per Share of</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Intrinsic Value</b></font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Grant Date</b></font></td>
<td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Options Granted</b></font></td>
<td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Share</b></font></td>
<td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Common Stock</b></font></td>
<td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>Option</b></font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: center;">2005</td>
<td>&#160;</td>
<td style="text-align: center;" nowrap="nowrap">58,321</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$0.07</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$1.79</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$1.72</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;">2009</td>
<td>&#160;</td>
<td style="text-align: center;" nowrap="nowrap">60,559</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$0.72 - $0.79</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$4.43</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$3.71 - $3.64</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: center;">2011</td>
<td>&#160;</td>
<td style="text-align: center;" nowrap="nowrap">33,846</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$1.00</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$1.00</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$0.00</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;">2012</td>
<td>&#160;</td>
<td style="text-align: center;" nowrap="nowrap">60,019</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$1.14</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$1.14</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$0.00</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: center;">2013</td>
<td>&#160;</td>
<td style="text-align: center;" nowrap="nowrap">100,000</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$1.14 - $1.30</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$1.14</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$0.00</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;">2014</td>
<td>&#160;</td>
<td style="text-align: center;" nowrap="nowrap">1,626,740</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">$5.86- $13.23</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$5.86</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;">$0.00</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The following represents a summary of the options granted to employees and non-employees outstanding at June 30, 2015 and changes during the period then ended:</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>Options</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;"><b>Weighted Average</b></font><br  /><font style="font-size: 8pt;"><b>Exercise Price</b></font></td>
<td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;"><b>&#160;</b></font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 802px;">Outstanding at December 31, 2014</td>
<td style="width: 13px;">&#160;</td>
<td style="text-align: left; width: 13px;">&#160;</td>
<td style="text-align: right; width: 188px;">1,788,717</td>
<td style="text-align: left; width: 13px;">&#160;</td>
<td style="width: 13px;">&#160;</td>
<td style="text-align: left; width: 12px;">$</td>
<td style="text-align: right; width: 187px;">7.059</td>
<td style="text-align: left; width: 12px;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-indent: 10pt;">Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">103,025</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5.863</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt;">Exercised/ Expired/ Forfeited</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(918</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(1.158</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>Outstanding at June 30, 2015</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,890,824</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">7.062</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt;">Exercisable at June 30, 2015</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">298,437</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">4.563</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Expected to be vested</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,592,387</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">4.563</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624272870512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 9&#8201;&#8212;&#8201;RELATED PARTY TRANSACTIONS</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">A director of the Company is a managing director of Javelin Venture Partners GP, LLC, the general partner of Javelin Venture Partners GP, L.P., which held a significant investment in the Company&#8217;s Series A-1, Series A-2, Series A-3, Series B, and Series C preferred stock that was converted to common stock prior to the Company&#8217;s initial public offering.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Prior to and during his employment with the Company, Mr. Ira Ritter served as CEO of Andela Group Inc., (&#8220;Andela&#8221;) a company he founded in 1987, which is involved in corporate management, strategic and financial consulting. The Company incurred no expenses for services received from Andela during the three months and six months ended June 30, 2015, and approximately $49,000 and $99,000, respectively, during the three months and six months ended June 30, 2014, all of which were classified in general and administrative expenses in the Unaudited Condensed Statements of Operations.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Other than disclosed, the Company has not entered into or been a participant in any transaction in which a related party had or will have a direct or indirect material interest.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph b<br><br><br><br> -Article 3A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624279128144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Deferred Offering Costs</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Deferred offering costs, which primarily consist of direct, incremental banking, legal and accounting fees relating to a planned public offering of the Company&#8217;s common stock, are capitalized within long term assets. The deferred offering costs were reclassified to additional paid-in capital upon the consummation of the offering on June 29, 2015.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Net Loss Per Share</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company determines basic loss per share and diluted loss per share in accordance with the provisions of ASC 260, &#8220;<i>Earnings per Share</i>.&#8221; Basic net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period. Diluted net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The potentially dilutive stock options issued under the 2015 Stock Plan (described in Note 8) and warrants on the Company&#8217;s common stock (describe in Note 7) were not considered in the computation of diluted net loss per share because they would be anti-dilutive.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">All common share amounts and per share amounts have been adjusted to reflect a 1-for-7.15 reverse stock split of the Company&#8217;s common stock effected on June 17, 2015.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Recent Accounting Pronouncements</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In August&#160;2014, the FASB issued ASU No. 2014-15,&#160;<i>Presentation of Financial Statements&#8201;&#8212;&#8201;Going Concern (Subtopic 205-40)&#8201;&#8212;&#8201;Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i>, which provides guidance regarding management&#8217;s responsibility to assess whether substantial doubt exists regarding the ability to continue as a going concern and requires related footnote disclosures. In connection with preparing financial statements for each annual and interim reporting period, management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). This ASU is effective for the annual period ending after December&#160;15, 2016, and for annual periods and interim periods thereafter. Management is currently evaluating the new guidance and has not determined the impact this standard may have on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624208252080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 26, 2015</div></th>
<th class="th"><div>Nov. 30, 2010</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AgreementAxis=rttr_ResearchAndDevelopmentAgreementLicenseMember', window );">Research and Development Agreement &amp; License | Kolu Pohaku Technologies, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems', window );"><strong>Stockholders Deficit And Preferred Stock Subject To Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Payments received for performing research and development activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Payment of quarterly royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AgreementAxis=rttr_ResearchAndDevelopmentAgreementLicenseMember', window );">Research and Development Agreement &amp; License | Kolu Pohaku Management, LLC | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems', window );"><strong>Stockholders Deficit And Preferred Stock Subject To Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued</a></td>
<td class="nump">1,469,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AgreementAxis=rttr_PutAndCallOptionAgreementMember', window );">Put and Call Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems', window );"><strong>Stockholders Deficit And Preferred Stock Subject To Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Aggregate converted shares of the common stock upon the closing of the IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AgreementAxis=rttr_PutAndCallOptionAgreementMember', window );">Put and Call Option Agreement | Kolu Pohaku Technologies, LLC | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems', window );"><strong>Stockholders Deficit And Preferred Stock Subject To Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Payments received for performing research and development activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AgreementAxis=rttr_PutAndCallOptionAgreementMember', window );">Put and Call Option Agreement | Kolu Pohaku Management, LLC | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems', window );"><strong>Stockholders Deficit And Preferred Stock Subject To Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued</a></td>
<td class="nump">1,469,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PreferredStockOriginalIssuePrice', window );">Preferred stock original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PreferredStockOriginalIssuePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represent preferred stock original issue price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PreferredStockOriginalIssuePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_StockholdersDeficitAndPreferredStockSubjectToRedemptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-30)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_AgreementAxis=rttr_ResearchAndDevelopmentAgreementLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_AgreementAxis=rttr_ResearchAndDevelopmentAgreementLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_AgreementPartiesAxis=rttr_KoluPohakuTechnologiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_AgreementPartiesAxis=rttr_KoluPohakuTechnologiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_AgreementPartiesAxis=rttr_KoluPohakuManagementLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_AgreementPartiesAxis=rttr_KoluPohakuManagementLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_AgreementAxis=rttr_PutAndCallOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_AgreementAxis=rttr_PutAndCallOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624269475008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 17, 2015 </div>
<div>Segment</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_BasisOfPresentationAbstract', window );"><strong>Basis of presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock Split, Conversion Ratio</a></td>
<td class="nump">7.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating business segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,779,905)<span></span>
</td>
<td class="num">$ (17,904,319)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,658,994<span></span>
</td>
<td class="nump">$ 2,747,248<span></span>
</td>
<td class="nump">$ 237,591<span></span>
</td>
<td class="nump">$ 448,226<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents carrying value of working capital as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Stock Split<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624200937680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Detail Textuals 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 02, 2014</div></th>
<th class="th"><div>Jun. 29, 2015</div></th>
<th class="th"><div>Apr. 30, 2013</div></th>
<th class="th"><div>Jul. 17, 2012</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>Sep. 25, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net offering proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FdaMeetingBonusOpportunitiesMember', window );">FDA Meeting Bonus Opportunities | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ExecutiveCompensation', window );">Cash bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FdaMeetingBonusOpportunitiesMember', window );">FDA Meeting Bonus Opportunities | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ExecutiveCompensation', window );">Cash bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember', window );">Clinical Trial Funding Commitment Bonus Opportunities | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ExecutiveCompensation', window );">Cash bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember', window );">Clinical Trial Funding Commitment Bonus Opportunities | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ExecutiveCompensation', window );">Cash bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember', window );">Clinical Trial Funding Commitment Bonus Opportunities | General and administrative expense | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AccruedBonusToExecutive', window );">Accrued bonus to executive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember', window );">Clinical Trial Funding Commitment Bonus Opportunities | General and administrative expense | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AccruedBonusToExecutive', window );">Accrued bonus to executive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember', window );">Clinical Trial Funding Commitment Bonus Opportunities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Minimum cash available limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FundraisingBonusOpportunitiesMember', window );">Fundraising Bonus Opportunities | General and administrative expense | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AccruedBonusToExecutive', window );">Accrued bonus to executive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FundraisingBonusOpportunitiesMember', window );">Fundraising Bonus Opportunities | General and administrative expense | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AccruedBonusToExecutive', window );">Accrued bonus to executive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FundraisingBonusOpportunitiesMember', window );">Fundraising Bonus Opportunities | Performance milestone condition one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ExecutiveCompensation', window );">Cash bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_MinimumActualDeploymentOfFundsByThirdParty', window );">Minimum actual deployment of funds by third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FundraisingBonusOpportunitiesMember', window );">Fundraising Bonus Opportunities | Performance milestone condition one | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Minimum cash available limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FundraisingBonusOpportunitiesMember', window );">Fundraising Bonus Opportunities | Performance milestone condition two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_MinimumActualDeploymentOfFundsByThirdParty', window );">Minimum actual deployment of funds by third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FundraisingBonusOpportunitiesMember', window );">Fundraising Bonus Opportunities | Performance milestone condition two | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ExecutiveCompensation', window );">Cash bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FundraisingBonusOpportunitiesMember', window );">Fundraising Bonus Opportunities | Performance milestone condition two | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ExecutiveCompensation', window );">Cash bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FundraisingBonusOpportunitiesMember', window );">Fundraising Bonus Opportunities | Performance milestone condition two | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Minimum cash available limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">453,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">453,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | FDA Meeting Bonus Opportunities | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of stock options expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
<td class="nump">2,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | FDA Meeting Bonus Opportunities | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of stock options expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
<td class="nump">2,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Clinical Trial Funding Commitment Bonus Opportunities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_StockOptionsToVestRatablyOnMonthlyBasis', window );">Stock options to vest ratably on a monthly basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of option vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Clinical Trial Funding Commitment Bonus Opportunities | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of stock options expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Clinical Trial Funding Commitment Bonus Opportunities | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of stock options expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Fundraising Bonus Opportunities | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net offering proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Fundraising Bonus Opportunities | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of stock options expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Fundraising Bonus Opportunities | Performance milestone condition one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of option vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum aggregate number of shares of common stock authorized to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Fundraising Bonus Opportunities | Performance milestone condition two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of option vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum aggregate number of shares of common stock authorized to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Fundraising Bonus Opportunities | Performance milestone condition two | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of stock options expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Fundraising Bonus Opportunities | Performance milestone condition two | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of stock options expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_AccruedBonusToExecutive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of accrued bonus to executive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_AccruedBonusToExecutive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ExecutiveCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents executive compensation payable upon satisfaction of condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ExecutiveCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_MinimumActualDeploymentOfFundsByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents minimum actual deployment of funds by third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_MinimumActualDeploymentOfFundsByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_StockOptionsToVestRatablyOnMonthlyBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of share options vests ratably on a monthly basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_StockOptionsToVestRatablyOnMonthlyBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FdaMeetingBonusOpportunitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FdaMeetingBonusOpportunitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rttr_PresidentAndFormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rttr_PresidentAndFormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rttr_ChiefStrategicOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rttr_ChiefStrategicOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FundraisingBonusOpportunitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FundraisingBonusOpportunitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PerformanceMilestoneTypeAxis=rttr_PerformanceMilestoneConditionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PerformanceMilestoneTypeAxis=rttr_PerformanceMilestoneConditionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PerformanceMilestoneTypeAxis=rttr_PerformanceMilestoneConditionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PerformanceMilestoneTypeAxis=rttr_PerformanceMilestoneConditionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624206442288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details 3) - 6 months ended Jun. 30, 2015 - $ / shares<br></strong></div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Common Shares Underlying Options Granted</a></td>
<td class="nump">103,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise Price per Common Share</a></td>
<td class="nump">$ 5.863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Grant year 2005</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Common Shares Underlying Options Granted</a></td>
<td class="nump">58,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise Price per Common Share</a></td>
<td class="nump">$ 0.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated Fair Value per Share of Common Stock</a></td>
<td class="nump">1.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Intrinsic Value Option</a></td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Grant year 2009</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Common Shares Underlying Options Granted</a></td>
<td class="nump">60,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated Fair Value per Share of Common Stock</a></td>
<td class="nump">$ 4.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Grant year 2009 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise Price per Common Share</a></td>
<td class="nump">0.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Intrinsic Value Option</a></td>
<td class="nump">3.71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Grant year 2009 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise Price per Common Share</a></td>
<td class="nump">0.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Intrinsic Value Option</a></td>
<td class="nump">$ 3.64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Grant year 2011</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Common Shares Underlying Options Granted</a></td>
<td class="nump">33,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise Price per Common Share</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated Fair Value per Share of Common Stock</a></td>
<td class="nump">1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Intrinsic Value Option</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Grant year 2012</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Common Shares Underlying Options Granted</a></td>
<td class="nump">60,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise Price per Common Share</a></td>
<td class="nump">$ 1.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated Fair Value per Share of Common Stock</a></td>
<td class="nump">1.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Intrinsic Value Option</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Grant year 2013</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Common Shares Underlying Options Granted</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated Fair Value per Share of Common Stock</a></td>
<td class="nump">$ 1.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Intrinsic Value Option</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Grant year 2013 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise Price per Common Share</a></td>
<td class="nump">1.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Grant year 2013 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise Price per Common Share</a></td>
<td class="nump">$ 1.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Grant year 2014</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Common Shares Underlying Options Granted</a></td>
<td class="nump">1,626,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated Fair Value per Share of Common Stock</a></td>
<td class="nump">$ 5.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Intrinsic Value Option</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Grant year 2014 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise Price per Common Share</a></td>
<td class="nump">5.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Grant year 2014 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise Price per Common Share</a></td>
<td class="nump">$ 13.23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=rttr_GrantYearTwoThousandFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=rttr_GrantYearTwoThousandFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=rttr_GrantYearTwoThousandNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=rttr_GrantYearTwoThousandNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=rttr_GrantYearTwoThousandElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=rttr_GrantYearTwoThousandElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=rttr_GrantYearTwoThousandTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=rttr_GrantYearTwoThousandTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=rttr_GrantYearTwoThousandThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=rttr_GrantYearTwoThousandThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=rttr_GrantYearTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=rttr_GrantYearTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624206074592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,484,734)<span></span>
</td>
<td class="num">$ (677,406)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">606<span></span>
</td>
<td class="nump">2,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="nump">1,680,247<span></span>
</td>
<td class="nump">91,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">15,036<span></span>
</td>
<td class="num">(41,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">305,846<span></span>
</td>
<td class="nump">32,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">590,796<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="num">(1,676)<span></span>
</td>
<td class="num">(773)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(893,879)<span></span>
</td>
<td class="num">(584,469)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,166)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Commissions and issuance costs of initial public offering</a></td>
<td class="num">(2,194,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares upon closing of initial public offering</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds of borrowing under notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">17,805,625<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash</a></td>
<td class="nump">16,911,746<span></span>
</td>
<td class="num">(210,635)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of period</a></td>
<td class="nump">2,747,248<span></span>
</td>
<td class="nump">448,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of period</a></td>
<td class="nump">19,658,994<span></span>
</td>
<td class="nump">237,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering', window );">Accrual of commissions and issuance costs of the initial public offering</a></td>
<td class="nump">213,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital', window );">Deferred offering costs reclassified to additional paid-in capital</a></td>
<td class="nump">665,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommonStockSubjectToRepurchase', window );">Common stock subject to repurchase</a></td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Cumulative preferred stock dividends</a></td>
<td class="nump">327,569<span></span>
</td>
<td class="nump">$ 294,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Accretion of discount on Series C preferred stock</a></td>
<td class="nump">$ 63,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=rttr_ConversionOfPreferredToCommonStockMember', window );">Conversion of Preferred Stock to Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of all oustanding preferred stock, redeemable preferred stock into common stock</a></td>
<td class="nump">$ 8,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=rttr_ConversionOfRedeemablePreferredStockToCommonStockMember', window );">Conversion of Redeemable Preferred Stock to Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of all oustanding preferred stock, redeemable preferred stock into common stock</a></td>
<td class="nump">$ 16,594,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the value Accrual Of Commissions And Issuance Costs Of The Initial Public Offering in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_AccrualOfCommissionsAndIssuanceCostsOfTheInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_CommonStockSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the value of Common Stock Subject to repurchase in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_CommonStockSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of deferred offering costs reclassified to additional paid-in capital in non cash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 405<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion of the preferred stock redemption discount during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAccretionOfRedemptionDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=rttr_ConversionOfPreferredToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=rttr_ConversionOfPreferredToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=rttr_ConversionOfRedeemablePreferredStockToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=rttr_ConversionOfRedeemablePreferredStockToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624282313808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 5&#8201;&#8212;&#8201;COMMITMENTS AND CONTINGENCIES</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Employment Agreements</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>&#160;</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Michael Step</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>&#160;</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On December&#160;2, 2014, the Company entered into a letter agreement (the &#8220;Step Letter Agreement&#8221;), with Michael Step, the Company&#8217;s current Chief Executive Officer, setting forth the terms of his employment. The Step Letter Agreement provides that Michael Step is entitled to an annual base salary of $360,000 and a total of three grants of options to purchase the Company&#8217;s common stock.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The first two options entitle Michael Step to purchase 646,537 and 73,777 of the Company&#8217;s shares, respectively, for an exercise price of&#8201;$5.86 per share. Each of these options is immediately exercisable in full as of the date of the grant, with 44/48<font style="font-size: 10pt;">ths</font>&#160;of the total number of shares covered by each option subject to a right of repurchase by the Company upon termination of Michael Step&#8217;s employment with the Company for any reason. This right of repurchase will lapse over a period of 44 months, with 1/44<font style="font-size: 10pt;">th</font>&#160;of the total number of shares subject to the right of repurchase lapsing on January&#160;1, 2015 and on the first day of each month thereafter. In addition, the right of repurchase will lapse in its entirety upon a termination of the employment under certain circumstances.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>&#160;</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The third option became exercisable upon the closing of the Company&#8217;s initial public offering on June 29, 2015. Pursuant to the terms of the agreement, the option is exercisable for a total of 103,025 shares of the Company&#8217;s common stock, which, together with the shares subject to the first option, represent 7.5% of the shares of common stock deemed to be outstanding at June 29, 2015 on a fully-diluted basis after giving effect to the number of shares subject to the third option. Seventy-five percent (75%) of the shares subject to the third option are subject to a right of repurchase by the Company upon termination of Michael Step&#8217;s employment for any reason. This right of repurchase will lapse with respect to 1/36<font style="font-size: 10pt;">th</font>&#160;of the total number of shares subject to the right of repurchase on the first day of each month following the date on which the third option first becomes exercisable. In addition, the right of repurchase will lapse in its entirety upon Michael Step&#8217;s termination of employment under certain circumstances.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Under the terms of the agreement, Michael Step will be entitled to receive certain payments in the event his employment is terminated under certain scenarios.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>&#160;</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Andrew Ritter and Ira Ritter</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On September&#160;25, 2013, the Company&#8217;s Board of Directors approved the Executive Compensation Plan (the &#8220;Compensation Plan&#8221;), which was later amended in June 2015, setting forth the compensation to be paid to Andrew Ritter and Ira Ritter, the Company&#8217;s current President and also the Company&#8217;s former Chief Executive Officer, and Chief Strategic Officer (&#8220;CSO&#8221;), respectively, for their contributions to the Company. Pursuant to the amended terms of the Compensation Plan, effective June 29, 2015, the President&#8217;s salary increased to $310,000 per year and the CSO&#8217;s salary is $295,000 per year. The President will also be entitled to receive up to $180,000 payable over a three year period for tuition reimbursement. As of June 30, 2015, the Company accrued $121,000 in tuition reimbursement for the President and recognized such amount in general and administrative expenses in our Unaudited Condensed Statements of Operations in the three and six month periods ending June 30, 2015.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Under the terms of the agreement, both the President and the CSO will be entitled to receive certain payments in the event their employment is terminated under certain scenarios.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Each executive received options to purchase up to 48,951 shares of the Company&#8217;s common stock (each referred to in this section as &#8220;Executive Options&#8221;) pursuant to the 2008 Stock Plan, which will vest based on specific performance conditions, described below.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><i>Cash Bonus and Executive Options Performance Conditions</i></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Pursuant to the amended terms of the Compensation Plan, the Company will review bonus opportunities annually for the President and the CSO based on achievement of specific performance as determined by the Company. The initial target bonus opportunities are 40% and 35% of the base salary for the President and the CSO, respectively.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">In addition, each covered executive is also entitled to the following cash payments and vests in Executive Options upon the satisfaction of the events described below:</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><i>FDA Meeting Bonus Opportunities</i>.&#160;&#160;&#160;In April&#160;2013, each executive received a one-time cash bonus of&#8201;$10,000 for&#160;a milestone associated with&#160;meeting with the FDA regarding RP-G28&#8217;s path to FDA approval. In addition, 2,360 shares of the Executive Options vested and became exercisable as of the grant date of September&#160;25, 2013. The balance of&#160;1,136&#160;shares vests ratably on a monthly basis beginning on September&#160;30, 2013.</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px 0px 0px 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><i>Clinical Trial Funding Commitment Bonus Opportunities</i>.&#160;&#160;&#160;Each executive is entitled to receive a one-time cash bonus of&#8201; $75,000 upon the Company&#8217;s receipt of a commitment by a third party to fund a Phase 2 or later clinical trial; provided, however, that no such bonus may be paid at any time the Company has less than $2,000,000 in available cash. In addition, upon the satisfaction of this milestone, 35% of 10,489 shares of the Executive Options will vest and become exercisable, with the balance of the 10,489 shares vesting in 36 equal monthly installments beginning on the last day of the following month. Each executive satisfied this performance condition on June 29, 2015 and was entitled to receive a bonus of $75,000 accrued and recognized in general and administrative expenses in the accompanying Unaudited Condensed Statements of Operations in the three and six month periods ending June 30, 2015. In addition, 3,671 shares of the Executive Options vested and became exercisable as of June 29, 2015, with the balance of 6,818 shares vests ratably on a monthly basis beginning July 31, 2015.</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px 0px 0px 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><i>Fundraising Bonus Opportunities</i>.&#160;&#160;&#160;Each executive is entitled to receive (i) a one-time cash bonus of&#8201; $50,000 upon the sale of additional equity capital for cash, in one or more closings after July&#160;17, 2012, and/or the actual deployment of funds by a third party for a clinical trial in an aggregate amount in excess&#160;of&#8201; $2,000,000 and (ii) a one-time cash bonus of&#8201; $150,000 upon the sale of additional equity capital for cash, in one or more closings after July&#160;17, 2012 and/or the actual deployment of funds by a third party for a clinical trial in an aggregate amount in excess of $10,000,000 (which such bonus will be reduced by any cash bonus paid under subsection (i)); provided, however, that no bonus under subsection (i) or (ii) may be paid at any time the Company has less than $2,000,000 in available cash. In addition, upon the satisfaction of the milestone described in subsection (i), 35% of 6,993 shares of the Executive Options will vest and become exercisable, with the balance of the 6,993 shares vesting in 36 equal monthly installments beginning on the last day of the following month, and, upon satisfaction of the milestone described in subsection (ii), 35% of 13,986 shares of the Executive Options will vest and become exercisable, with the balance of the 13,986 shares vesting in 36 monthly installments beginning on the last day of the following month. Upon the closing of the initial public offering on June 29, 2015 raising approximately $17.4 million, net of offering costs, each executive was entitled to receive a bonus of $150,000 accrued and recognized in general and administrative expenses in the accompanying Unaudited Condensed Statements of Operations in the three and six month periods ending June 30, 2015. In addition, 4,895 shares of the Executive Options vested and became exercisable as of June 29, 2015, with the balance of 9,091 shares vests ratably on a monthly basis beginning July 31, 2015.</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: -0.25in; margin: 0px 0px 0px 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;&#160;</p>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: justify;"><i>License Event Bonus Opportunities</i>.&#160;&#160;&#160;Each executive is entitled to receive the following bonus payments in connection with the closing of an exclusive license of RP-G28 and/or any future product candidate developed by the Company from time to time during the term of the Compensation Plan by an/or any option to exclusively license such product candidate to a third party (referred to under the Compensation Plan as a &#8220;License Event&#8221;) with a minimum upfront payment to the Company of&#8201; $2,000,000:</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: 'times new roman', times, serif;">o</font></td>
<td style="text-align: justify;">A graduated cash bonus equal to (i) 5% of the Initial Period License Payment (as defined below) up to $5,000,000; (ii) 4% of the Initial Period License Payment in excess of&#8201; $5,000,000 up to $10,000,000; and (iii) 3% of the Initial Period License Payment in excess of $10,000,000. In addition, upon the Company&#8217;s receipt of an Initial Period License Payment of more than $2,000,000, 35% of 45,454 shares of their Executive Options will vest and become exercisable, with the balance of the 45,454 shares vesting in 36 monthly installments beginning on the last day of the following month.</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px 0px 0px 0.75in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: 'times new roman', times, serif;">o</font></td>
<td style="text-align: justify;">A cash bonus equal to 3% of any Annual Excess Milestone Payments (as defined below); provided, however that no such bonus may be paid at any time the Company has less than $1,000,000 in available cash. In addition, upon the Company&#8217;s receipt of an Annual Excess Milestone Payment, 35% of 6,993 shares of their Executive Options will vest and become exercisable, with the balance of the 6,993 shares vesting in 36 monthly installments beginning on the last day of the following month.</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Notwithstanding any of the vesting provisions set forth above, the total potential number of Executive Options that may vest will not exceed 48,951 and the Executive Options will automatically terminate for any options for which a vesting date or performance condition has not been met by September&#160;25, 2015.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">For purposes of the Compensation Plan, the term &#8220;<i>Initial Period License Payment</i>&#8221; means the aggregate amount in cash received by the Company (not including any amount placed in escrow or subject to earn-outs, contingencies or other deferrals or earmarked to pay or reimburse the Company for research and development activities) in respect of the License Event over a 24 month period beginning on the closing date of such License Event (which period is referred to therein as the &#8220;<i>Initial Period</i>&#8221;). The term &#8220;<i>Annual Excess Milestone Payments</i>&#8221; means the amount in cash in excess of&#8201; $2,000,000 (not including any amounts placed in escrow or subject to earn-outs, contingencies or other deferrals) that is received by the Company in respect of any Post-Closing Milestones (as defined below) in each 12-month period beginning on the expiration of the Initial Period. The term &#8220;<i>Post-Closing Milestones</i>&#8221; means any post-closing payouts set forth in the definitive transaction documentation executed in connection with a License Event; provided, however, that such amounts will not include any amounts that are determined by the Board of Directors to comprise all or any portion of any upfront payment made in connection with a License Event and any royalty payment based on product sales.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Compensation Plan provides that in the event that the Company enters into more than one License Event with respect to a single product candidate (i.e., for a separate field of use), then the proceeds of any such additional License Event will be included with the proceeds of the original License Event for purposes of meeting any of the financial thresholds set forth above. Under the terms of the Compensation Plan, receipt by the Company of more than one&#160;<i>bona fide</i>&#160;term sheet for a proposed License Event with respect to RP-G28 will result in the payment of an additional 10% of any cash bonus earned as Clinical Trial and Fundraising Bonus or a License Event Bonus.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">Under the terms of the Compensation Plan, each executive is entitled to receive certain payments in the event their employment is terminated under certain scenarios.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">On December&#160;2, 2014, pursuant to the 2008 stock plan, the Company granted an aggregate of 453,413 options to the President and the CSO to purchase the Company&#8217;s common stock listed as follows:</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;">(i)</td>
<td style="text-align: justify;">20,979 fully vested options with an exercise price of&#8201; $5.86; and</td>
</tr>
</table>
<table style="widows: 1; text-transform: none; margin-top: 0px; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; margin-bottom: 0px; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;">(ii)</td>
<td style="text-align: justify;">432,434 options which vest 25% upon the first anniversary of the vesting commencement date with the remaining options vesting monthly in equal amounts over 36 months with an exercise price equal to $5.86 for the first 152,347 options covered thereby, $9.30 for the next 140,044 options covered thereby, and $13.23 for the remaining balance.</td>
</tr>
</table>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;In addition, all non-employee directors will each be initially entitled to receive an option to acquire 1,398 shares of the Company&#8217;s common stock, which will vest annually over a three-year term from the grant date, and annually thereafter be entitled to receive an option to acquire 979 shares of the Company&#8217;s common stock, each of which will vest one year from the grant date. As of June 30, 2015, no stock based compensation or cash compensation has been granted to the directors under this program.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Leases</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="color: black;">The Company leases office and storage space for its headquarters in California pursuant to a two-year agreement ending September&#160;30, 2015 which calls for a minimum monthly rent of approximately $5,000 and an annual increase of 3%. Rent expense, recognized on a straight-line basis, was approximately $15,000 for each of the three months ended June 30, 2015 and 2014.&#160;</font>The Company recognized approximately $30,000 in each of the six months ended June 30, 2015 and 2014 in rent expense. Rent expense is recorded in general and administrative expenses in the Unaudited Condensed Statements of Operations.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">In July 2015, the Company entered into a new five-year lease agreement for new corporate office space, projected to be effective October 1, 2015, which calls for a minimum lease payment of approximately $107,000 annually.</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b><b>&#160;</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Legal</b></p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company is not currently involved in any legal matters arising in the normal course of business. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 440<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624200230048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Detail Textuals 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 02, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Common Shares Underlying Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Common Shares Underlying Options Granted</a></td>
<td class="nump">453,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Options | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Common Shares Underlying Options Granted</a></td>
<td class="nump">453,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_MinimumActualDeploymentOfFundsByThirdParty', window );">Minimum actual deployment of funds by third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfCashBonusExcessOfMilestonePayments', window );">Percentage of annual excess milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_MinimumActualDeploymentOfFundsByThirdParty', window );">Minimum actual deployment of funds by third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfCashBonusExcessOfMilestonePayments', window );">Percentage of annual excess milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Minimum | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ReceiptOfInitialPeriodLicensePayment', window );">Receipt of Initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Minimum cash available limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Minimum | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_ReceiptOfInitialPeriodLicensePayment', window );">Receipt of Initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Minimum cash available limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Executive Options | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of option vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Common Shares Underlying Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum aggregate number of shares of common stock authorized to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Executive Options | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of option vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Common Shares Underlying Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum aggregate number of shares of common stock authorized to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Executive Options | Graduated Cash Bonus | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of option vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Common Shares Underlying Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum aggregate number of shares of common stock authorized to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Executive Options | Graduated Cash Bonus | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of option vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Common Shares Underlying Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum aggregate number of shares of common stock authorized to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Performance milestone condition one | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfInitialPeriodLicensePayment', window );">Percentage of initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_InitialPeriodLicensePayment', window );">Initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Performance milestone condition one | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfInitialPeriodLicensePayment', window );">Percentage of initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_InitialPeriodLicensePayment', window );">Initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Performance milestone condition two | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfInitialPeriodLicensePayment', window );">Percentage of initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Performance milestone condition two | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfInitialPeriodLicensePayment', window );">Percentage of initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Performance milestone condition two | Minimum | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_InitialPeriodLicensePayment', window );">Initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Performance milestone condition two | Minimum | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_InitialPeriodLicensePayment', window );">Initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Performance milestone condition two | Maximum | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_InitialPeriodLicensePayment', window );">Initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Performance milestone condition two | Maximum | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_InitialPeriodLicensePayment', window );">Initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Performance milestone condition three | Andrew Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfInitialPeriodLicensePayment', window );">Percentage of initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_InitialPeriodLicensePayment', window );">Initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember', window );">License Event Bonus Opportunities | Performance milestone condition three | Ira Ritter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PercentageOfInitialPeriodLicensePayment', window );">Percentage of initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_InitialPeriodLicensePayment', window );">Initial period license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_InitialPeriodLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents initial period license payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_InitialPeriodLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_MinimumActualDeploymentOfFundsByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents minimum actual deployment of funds by third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_MinimumActualDeploymentOfFundsByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PercentageOfCashBonusExcessOfMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of cash bonus percentage in excess of milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PercentageOfCashBonusExcessOfMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PercentageOfInitialPeriodLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of initial period license payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PercentageOfInitialPeriodLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_ReceiptOfInitialPeriodLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents receipt of initial period license payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_ReceiptOfInitialPeriodLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rttr_PresidentAndFormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rttr_PresidentAndFormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rttr_ChiefStrategicOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rttr_ChiefStrategicOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_LicenseEventBonusOpportunitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_TypeOfBonusAwardAxis=rttr_GraduatedCashBonusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_TypeOfBonusAwardAxis=rttr_GraduatedCashBonusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PerformanceMilestoneTypeAxis=rttr_PerformanceMilestoneConditionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PerformanceMilestoneTypeAxis=rttr_PerformanceMilestoneConditionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PerformanceMilestoneTypeAxis=rttr_PerformanceMilestoneConditionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PerformanceMilestoneTypeAxis=rttr_PerformanceMilestoneConditionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PerformanceMilestoneTypeAxis=rttr_PerformanceMilestoneConditionThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PerformanceMilestoneTypeAxis=rttr_PerformanceMilestoneConditionThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.2.0.727</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>220</ContextCount>
  <ElementCount>219</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>77</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/CONDENSEDBALANCESHEETS</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONDENSED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/CONDENSEDBALANCESHEETSParentheticals</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/CONDENSEDSTATEMENTSOFOPERATIONSUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/DisclosureOrganizationAndPrincipalActivities</Role>
      <ShortName>ORGANIZATION AND PRINCIPAL ACTIVITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/DisclosureStockholdersDeficitAndPreferredStockSubjectToRedemption</Role>
      <ShortName>STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/DisclosureWarrants</Role>
      <ShortName>WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>17</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/WARRANTSTables</Role>
      <ShortName>WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureWarrants</ParentRole>
      <Position>18</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/OrganizationAndPrincipalActivitiesDetailTextuals</Role>
      <ShortName>ORGANIZATION AND PRINCIPAL ACTIVITIES (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureOrganizationAndPrincipalActivities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - BASIS OF PRESENTATION (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/BasisOfPresentationDetailTextuals</Role>
      <ShortName>BASIS OF PRESENTATION (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureBasisOfPresentation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesDetailTextuals</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/PROPERTYANDEQUIPMENTDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/PROPERTYANDEQUIPMENTTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - PROPERTY AND EQUIPMENT(Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/PropertyAndEquipmentdetailTextuals</Role>
      <ShortName>PROPERTY AND EQUIPMENT(Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals2</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Detail Textuals 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals3</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Detail Textuals 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/CommitmentsAndContingenciesDetailTextuals4</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Detail Textuals 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals</Role>
      <ShortName>STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureStockholdersDeficitAndPreferredStockSubjectToRedemption</ParentRole>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1</Role>
      <ShortName>STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureStockholdersDeficitAndPreferredStockSubjectToRedemption</ParentRole>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals2</Role>
      <ShortName>STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureStockholdersDeficitAndPreferredStockSubjectToRedemption</ParentRole>
      <Position>32</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals3</Role>
      <ShortName>STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureStockholdersDeficitAndPreferredStockSubjectToRedemption</ParentRole>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals4</Role>
      <ShortName>STOCKHOLDERS' DEFICIT AND PREFERRED STOCK SUBJECT TO REDEMPTION (Detail Textuals 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureStockholdersDeficitAndPreferredStockSubjectToRedemption</ParentRole>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/WARRANTSDetails</Role>
      <ShortName>WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/WARRANTSTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - WARRANTS (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/WarrantsDetailTextuals</Role>
      <ShortName>WARRANTS (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/WARRANTSTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>037 - Disclosure - STOCK-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>038 - Disclosure - STOCK-BASED COMPENSATION (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails1</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>039 - Disclosure - STOCK-BASED COMPENSATION (Parentheticals) (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/StockBasedCompensationParentheticalsDetails1</Role>
      <ShortName>STOCK-BASED COMPENSATION (Parentheticals) (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>040 - Disclosure - STOCK-BASED COMPENSATION (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails2</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>041 - Disclosure - STOCK-BASED COMPENSATION (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails3</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>042 - Disclosure - STOCK-BASED COMPENSATION (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONDetails4</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>043 - Disclosure - STOCK-BASED COMPENSATION (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals</Role>
      <ShortName>STOCK-BASED COMPENSATION (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>044 - Disclosure - STOCK-BASED COMPENSATION (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals1</Role>
      <ShortName>STOCK-BASED COMPENSATION (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>045 - Disclosure - STOCK-BASED COMPENSATION (Detail Textuals 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals2</Role>
      <ShortName>STOCK-BASED COMPENSATION (Detail Textuals 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>046 - Disclosure - STOCK-BASED COMPENSATION (Detail Textuals 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/StockBasedCompensationDetailTextuals3</Role>
      <ShortName>STOCK-BASED COMPENSATION (Detail Textuals 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>047 - Disclosure - RELATED PARTY TRANSACTIONS (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSDetailTextuals</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>048 - Disclosure - SUBSEQUENT EVENTS (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ritterpharmaceuticals.com/role/SubsequentEventsDetailTextuals</Role>
      <ShortName>SUBSEQUENT EVENTS (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ritterpharmaceuticals.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''CONDENSED BALANCE SHEETS'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>rttr-20150630.xml</File>
    <File>rttr-20150630_cal.xml</File>
    <File>rttr-20150630_def.xml</File>
    <File>rttr-20150630_lab.xml</File>
    <File>rttr-20150630_pre.xml</File>
    <File>rttr-20150630.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624279198672">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details 1)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | 2005</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesATwoPreferredStockMember', window );">Series A-2 Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesATwoPreferredStockMember', window );">Series A-2 Preferred Stock | 2006</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesAThreePreferredStockMember', window );">Series A-3 Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesAThreePreferredStockMember', window );">Series A-3 Preferred Stock | 2008 - 2009</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | 2010 - 2013</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock | 2014</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 1.30<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">After giving effect to the Company's conversion from a LLC to a corporation.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Shares of preferred stock were converted into an aggregate of 3,322,676 shares of the Company's common stock effective June 29, 2015, after giving effect to the 1-for-7.15 reverse stock of shares of the Company's common stock effective June 17, 2015.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PeriodOfShareIssueAxis=rttr_YearTwoThousandFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PeriodOfShareIssueAxis=rttr_YearTwoThousandFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesATwoPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rttr_SeriesATwoPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PeriodOfShareIssueAxis=rttr_YearTwoThousandSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PeriodOfShareIssueAxis=rttr_YearTwoThousandSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rttr_SeriesAThreePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rttr_SeriesAThreePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PeriodOfShareIssueAxis=rttr_YearTwoThousandEightToYearTwoThousandNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PeriodOfShareIssueAxis=rttr_YearTwoThousandEightToYearTwoThousandNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PeriodOfShareIssueAxis=rttr_YearTwoThousandTenToYearTwoThousandThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PeriodOfShareIssueAxis=rttr_YearTwoThousandTenToYearTwoThousandThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PeriodOfShareIssueAxis=rttr_YearTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PeriodOfShareIssueAxis=rttr_YearTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140624208272576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND PRINCIPAL ACTIVITIES (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_OrganizationAndPrincipalActivitiesLineItems', window );"><strong>Organization And Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,194,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_OrganizationAndPrincipalActivitiesLineItems', window );"><strong>Organization And Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares sold</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares of common stock sold, per share (in dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Aggregate gross proceeds from sale of common stock</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rttr_PaymentsOfUnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net offering proceeds</a></td>
<td class="nump">$ 17,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_OrganizationAndPrincipalActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_OrganizationAndPrincipalActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rttr_PaymentsOfUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents cash outflow from underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rttr_PaymentsOfUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rttr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
